PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GOLDSMITH, MA; XU, WD; AMARAL, MC; KUCZEK, ES; GREENE, WC				GOLDSMITH, MA; XU, WD; AMARAL, MC; KUCZEK, ES; GREENE, WC			THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-2 RECEPTOR-BETA CHAIN CONTAINS BOTH UNIQUE AND FUNCTIONALLY REDUNDANT SIGNAL-TRANSDUCTION ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; LYMPHOCYTES-T; PROTEIN-KINASE; POINT MUTATION; ACTIVATION; EXPRESSION; ANTIGEN	Binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) triggers a series of intracellular events culminating in lymphocyte proliferation and differentiation. A novel transient assay of signal transduction leading to proliferation is now described which allows the rapid functional assessment of wild type and mutant receptors, including the IL-2R and other members of the cytokine receptor superfamily. This assay has been used to define domains and specific residues within the IL-2R beta intracellular region that contribute to growth signal transduction. In these studies, internal deletion of either the conserved ''Box 1'' or ''Box 2'' proximal cytokine receptor homology segments significantly impaired receptor function. Similarly, mutation of specific key residues within or between Box 1 and Box 2, or deletion of the C-terminal 94 residues of the IL-2R beta chain, impaired growth signaling. In contrast, either replacement of the transmembrane domain with that of the CD4 molecule or internal deletion of the 119 amino acids immediately downstream of Box 2 had no impact on growth signaling competence. These studies thus further define the functional architecture of the intracellular region of IL-2R beta, and reveal specific receptor domains that are dispensable, unique, or functionally redundant.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco	GOLDSMITH, MA (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94141, USA.			Kuczek, Elizabeth/0000-0002-5412-5509	NIAID NIH HHS [AI 07395-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007395] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOLS MO; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FUNG MR, 1991, J IMMUNOL, V147, P1253; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GOLDSMITH MA, 1994, IN PRESS CYTOKINE HD; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; IZUHARA K, 1993, BIOCHEM BIOPH RES CO, V190, P992, DOI 10.1006/bbrc.1993.1147; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; MILLS GB, 1986, J IMMUNOL, V136, P3019; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REED JC, 1987, ONCOGENE, V1, P223; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SHARON M, 1989, J IMMUNOL, V143, P2530; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	48	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14698	14704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182077				2022-12-27	WOS:A1994NM06500062
J	LAVOIE, C; TAM, R; CLARK, M; LEE, H; SONENBERG, N; LASKO, P				LAVOIE, C; TAM, R; CLARK, M; LEE, H; SONENBERG, N; LASKO, P			SUPPRESSION OF A TEMPERATURE-SENSITIVE CDC33 MUTATION OF YEAST BY A MULTICOPY PLASMID EXPRESSING A DROSOPHILA RIBOSOMAL-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING PROTEIN; HIGH-EFFICIENCY TRANSFORMATION; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; ESCHERICHIA-COLI; TRANSLATION INITIATION; 5'-TERMINAL CAP; GENES; CLONING	The Saccharomyces cerevisiae cdc33ts4-2 mutant produces a temperature sensitive allele of the cap-binding subunit of eukaryotic initiation factor-4F (also termed eIF-4E). From a Drosophila cDNA library constructed in a multicopy yeast shuttle vector, a clone was isolated which restored the ability to grow at elevated temperature to cdc33ts4-2 cells. The rescuing Drosophila clone encodes a small ribosomal subunit protein, which we name S15a based on its molecular weight and similarity with the Brassica napus S15a ribosomal protein. Transcription of the Drosophila gene, RpS15a, occurs at all developmental stages and is enhanced during oogenesis. The ribosomal protein gene is capable of suppressing other alleles of cdc33 but not an inactivation mutation, suggesting that suppression is dependent upon the presence of the temperature-sensitive eIF-4E protein. Supporting this, Western blot analysis shows that far more eIF-4E protein is present in cdc33 yeast cells expressing the RpS15a gene than lacking it. Levels of other unrelated proteins are unaffected. We propose therefore that the expression of high levels of the Drosophila S15a ribosomal protein in the cdc33 yeast cells leads to a selective stabilization of the temperature-sensitive eIF-4E protein, which accounts for the suppression phenomenon.	MCGILL UNIV, DEPT BIOL, MONTREAL H3A 1B1, PQ, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 1B1, PQ, CANADA	McGill University; McGill University			Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGERER LM, 1992, DEV BIOL, V149, P27, DOI 10.1016/0012-1606(92)90261-E; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel FM, 1988, MOL REPROD DEV; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BONHAMSMITH PC, 1992, PLANT MOL BIOL, V18, P909, DOI 10.1007/BF00019205; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BURNS DK, 1984, MOL CELL BIOL, V4, P2643, DOI 10.1128/MCB.4.12.2643; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHOOI WY, 1980, BIOCHEMISTRY-US, V19, P3469, DOI 10.1021/bi00556a010; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FRANCOEUR AM, 1985, J IMMUNOL, V135, P2378; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JONES EW, 1991, METHOD ENZYMOL, V194, P428; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P701, DOI 10.1093/nar/13.3.701; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LINDER P, 1990, BIOESSAYS, V12, P519, DOI 10.1002/bies.950121103; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1980, GENETICS, V95, P561; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROEMER T, 1993, MOL CELL BIOL, V13, P4039, DOI 10.1128/MCB.13.7.4039; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; TBONE WM, 1991, J BACTERIOL, V173, P3291; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; [No title captured]	44	28	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14625	14630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182070				2022-12-27	WOS:A1994NM06500051
J	HENDERSON, GB; HUGHES, TR; SAXENA, M				HENDERSON, GB; HUGHES, TR; SAXENA, M			FUNCTIONAL IMPLICATIONS FROM THE EFFECTS OF 1-CHLORO-2,4-DINITROBENZENE AND ETHACRYNIC-ACID ON EFFLUX ROUTES FOR METHOTREXATE AND CHOLATE IN L1210 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-CONJUGATE; ATP-DEPENDENT TRANSPORT; PLASMA-MEMBRANE VESICLES; ORGANIC ANION TRANSPORT; RAT-HEART SARCOLEMMA; HUMAN-ERYTHROCYTES; DINITROPHENYL GLUTATHIONE; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; CYCLIC-AMP	1-Chloro-2,4-dinitrobenzene (CDNB) and ethacrynic acid were examined for the ability to inhibit unidirectional efflux routes in L1210 cells that extrude both methotrexate and cholate (system I) and methotrexate alone (system II). These electrophiles were selected for study because of their known ability to undergo rapid intracellular conversion to glutathione conjugates. CDNB produced typical inhibitor kinetics and was a moderate inhibitor of both system I (IC50 = 4.8 mu m) and system II (IC50 = 7.5 mu m) with methotrexate as the substrate. However, a complex response was observed when cholate was employed as an alternative substrate for system I. Cholate efflux was stimulated initially at low levels of CDNB, but then slowed to a net inhibition as CDNB concentrations exceeded 10 mu m The latter characteristics for CDNB were not observed with ethacrynic acid, which produced a comparable inhibition of efflux system I regardless of the substrate employed (IC50 = 4.6 mu m). Efflux measurements in an L1210/C7 variant which lacks system I confirmed that CDNB stimulates the activity of a substantial and unique efflux activity for cholate (system III). The inhibition of system I and II by CDNB and ethacrynic acid was not reversed by a wash step but required inhibitor removal and subsequent incubation at 37 degrees C. This slow reversal was attributed to a time dependent clearance of inhibitory glutathione conjugates. A correlation between efflux systems for anions and anionic glutathione conjugates was demonstrated further by the ability of prostaglandin A, and indomethacin, two potent inhibitors of methotrexate and cholate efflux, to inhibit the efflux of 2,4-dinitrophenyl-S-glutathione. These results support the hypothesis that efflux systems for methotrexate and cholate in L1210 cells are part of a family of efflux pumps which function in vivo to extrude various anions and anionic glutathione conjugates.			HENDERSON, GB (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA023970] Funding Source: NIH RePORTER; NCI NIH HHS [CA23970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; AKERBOOM TPM, 1992, BIOCHIM BIOPHYS ACTA, V1103, P115, DOI 10.1016/0005-2736(92)90064-S; AWASTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1164, P173, DOI 10.1016/0167-4838(93)90245-M; BOARD PG, 1981, FEBS LETT, V124, P163, DOI 10.1016/0014-5793(81)80127-5; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; BRUNTON LL, 1979, J BIOL CHEM, V254, P9714; CHEER S, 1974, ANAL BIOCHEM, V60, P102, DOI 10.1016/0003-2697(74)90134-1; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HEASLEY LE, 1985, J BIOL CHEM, V260, P1520; HENDERSON GB, 1993, BIOCHIM BIOPHYS ACTA, V1152, P91, DOI 10.1016/0005-2736(93)90235-R; HENDERSON GB, 1988, CANCER RES, V48, P5995; HENDERSON GB, 1990, BIOCHIM BIOPHYS ACTA, V1051, P60, DOI 10.1016/0167-4889(90)90174-C; HENDERSON GB, 1987, J BIOL CHEM, V262, P13571; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON GB, 1991, J BIOL CHEM, V266, P1641; HENDERSON GB, 1992, BIOCHIM BIOPHYS ACTA, V1110, P137, DOI 10.1016/0005-2736(92)90350-U; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1989, FEBS LETT, V246, P177, DOI 10.1016/0014-5793(89)80278-9; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1989, FEBS LETT, V259, P95, DOI 10.1016/0014-5793(89)81503-0; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KONDO T, 1981, BIOCHIM BIOPHYS ACTA, V645, P132, DOI 10.1016/0005-2736(81)90520-4; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LIPMAN BJ, 1990, J BIOL CHEM, V265, P2142; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RINDLER MJ, 1978, J BIOL CHEM, V253, P5431; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCOTT RB, 1990, J LAB CLIN MED, V116, P674; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1991, CANCER RES, V51, P1412; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; WIDDICOMBE JH, 1991, TRENDS BIOCHEM SCI, V16, P474, DOI 10.1016/0968-0004(91)90183-V; ZIMNIAK P, 1993, TRENDS BIOCHEM SCI, V18, P164, DOI 10.1016/0968-0004(93)90106-W	38	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13382	13389						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175768				2022-12-27	WOS:A1994NK18400051
J	KING, JS; FAIRLEY, CF; MORGAN, WF				KING, JS; FAIRLEY, CF; MORGAN, WF			BRIDGING THE GAP - JOINING OF NONHOMOLOGOUS ENDS BY DNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHROMOSOMAL INSTABILITY; ESCHERICHIA-COLI; TRANSFECTED DNA; MAMMALIAN-CELLS; RECOMBINATION; ALPHA; INTEGRATION; GENE	DNA double strand breaks with noncomplementary ends can be joined by mechanisms of nonhomologous recombination. In some systems a DNA end with a 3'protruding single strand (PSS), which does not have a recessed 3'-hydroxyl that can allow for fill-in DNA synthesis, is joined to a blunt end with preservation of the 3'-PSS. It has been proposed that this process occurs via single strand ligation or is facilitated by an alignment protein. We were interested in testing the hypothesis that a DNA polymerase could function as this putative alignment protein. To characterize polymerase activities in this type of reaction, we incubated short double-stranded oligonucleotides that had an excess of one of the strands with an exonuclease-free Klenow fragment of Escherichia coli polymerase I, Tag DNA polymerase from Thermus aquaticus, or an exonuclease-free Stoffel fragment of Tag DNA polymerase. Products were analyzed by using biotinylated oligonucleotides separated by denaturing polyacrylamide gel electrophoresis. To further assess the effect of DNA polymerases on the joining of 3'-PSS ends to blunt ends, we incubated linear plasmid DNA with the polymerases and subjected the DNA to Southern blot and sequence analysis. We determined that these DNA polymerases can use a S'-PSS end as a template after priming off the S'-hydroxyl of a blunt end. This implies that the joining of noncomplementary ends in eukaryotic cells could proceed by a similar mechanism.	UNIV CALIF SAN FRANCISCO,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KING, JS (corresponding author), UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,CAMPUS BOX 0750,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [T32CA009215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09215-12] Funding Source: Medline; NIEHS NIH HHS [5 T32 ES07106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLARK JM, 1991, GENE, V104, P75, DOI 10.1016/0378-1119(91)90467-P; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MORGAN WF, 1988, MOL CELL BIOL, V8, P4204, DOI 10.1128/MCB.8.10.4204; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; WEISS SJ, 1992, J BIOL CHEM, V267, P18520; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOLFF S, 1973, ADV RAD RES, P457; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2	23	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13061	13064						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175727				2022-12-27	WOS:A1994NK18400002
J	HAYSTEAD, CMM; GREGORY, P; SHIRAZI, A; FADDEN, P; MOSSE, C; DENT, P; HAYSTEAD, TAJ				HAYSTEAD, CMM; GREGORY, P; SHIRAZI, A; FADDEN, P; MOSSE, C; DENT, P; HAYSTEAD, TAJ			INSULIN ACTIVATES A NOVEL ADIPOCYTE MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE THAT SHOWS RAPID PHASIC KINETICS AND IS DISTINCT FROM C-RAF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PHEROMONE RESPONSE; MAP KINASE; GROWTH-FACTOR; PHOSPHORYLATION; REQUIREMENT; PATHWAY; HOMOLOG	Treatment of adipocytes with insulin or phorbol 12-myristate 13-acetate (PMA) results in transient activation of mitogen-activated protein kinase kinase (MEK) (T-max = 90 s) and mitogen-activated protein kinase (MAPK) (T-max = 300 s). We have identified a novel insulin-stimulated MEK kinase (I-MEKK) in the 100,000 x g infranatant that shows rapid phasic kinetics that temporally precede that of MEK. Maximal activation of I-MEKK occurs within 20 +/- 5 s (S.D., n = 3) followed by complete inactivation by 30 +/- 10 s (S.D., n = 3). I-MEKK was characterized by anion-exchange and gel filtration chromatography and separated into two distinct activities of similar to 56 kDa that phosphorylated and activated MEK. I-MEKKs did not co-elute on anion exchange with c-Raf or 73-kDa MEK kinase (MEKK), suggesting they are distinct enzymes. Protein phosphatase 2A inactivated both I-MEKKs in vitro and in the intact cell okadaic acid blocked inactivation in the presence of insulin. These results suggest activation of I-MEKK involves phosphorylation on serine or threonine residues. I-MEKK was not activated by PMA, suggesting that in adipocytes the enzyme represents a divergence point between signal transduction pathways mediated by insulin and those activating protein kinase C.			HAYSTEAD, CMM (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1994, IN PRESS BIOCH J; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GEER P, 1993, PROTEIN PHOSPHORYLAT, P31; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HAYSTEAD CMM, 1993, FEBS LETT, V317, P12, DOI 10.1016/0014-5793(93)81481-E; HAYSTEAD TAJ, 1986, BIOCHEM J, V240, P99, DOI 10.1042/bj2400099; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LLOYD ED, 1992, J NEUROCHEM, V59, P1099, DOI 10.1111/j.1471-4159.1992.tb08352.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	36	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12804	12808						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175693				2022-12-27	WOS:A1994NH71600067
J	HOFFMANN, K; SCHNEIDERSCHERZER, E; KLEINKAUF, H; ZOCHER, R				HOFFMANN, K; SCHNEIDERSCHERZER, E; KLEINKAUF, H; ZOCHER, R			PURIFICATION AND CHARACTERIZATION OF EUKARYOTIC ALANINE RACEMASE ACTING AS KEY ENZYME IN CYCLOSPORINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; MULTIENZYME POLYPEPTIDE; PEPTIDE; INACTIVATION; SYNTHETASE; PROTEINS; ISOMERS	A specific alanine racemase, which is a key enzyme in the biosynthesis of the undecapeptide cyclosporin A, was purified to electrophoretic homogeneity from the fungus Tolypocladium niveum. This is the first enzyme of this kind isolated from a eucaryotic organism. The enzyme catalyzes the reversible racemization of alanine and requires pyridoxal phosphate as the exclusive cofactor. K-m values for L- and D-alanine were found to be 38 and 2 mM, respectively. Maximal reaction velocity was observed at 42 degrees C and pH 8.8 for the L to D direction. Molecular mass determinations of the denatured enzyme by SDS-polyacrylamide gel electrophoresis gave a value of 37 kDa, whereas gel filtration calibration studies yielded a value between 120 and 150 kDa, indicating an oligomeric native structure.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,W-1000 BERLIN 10,GERMANY; BIOCHEM GMBH,A-6330 KUFSTEIN SCHAFTENA,AUSTRIA; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Technical University of Berlin; Yale University								ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; ADAMS E, 1972, ENZYMES, V6, P479; BADET B, 1985, BIOCHEMISTRY-US, V24, P1333, DOI 10.1021/bi00327a010; BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; BILLICH A, 1987, J BIOL CHEM, V262, P17258; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOREL JF, 1986, PROG ALLERGY, V38, P9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; KLEINKAUF H, 1991, BIOMED BIOCHIM ACTA, V50, P219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWEN A, 1990, J BIOL CHEM, V265, P11355; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; NAGATA Y, 1985, ANAL BIOCHEM, V150, P238, DOI 10.1016/0003-2697(85)90465-8; OFFENZELLER M, 1993, J BIOL CHEM, V268, P26127; ROISE D, 1984, BIOCHEMISTRY-US, V23, P5195, DOI 10.1021/bi00317a017; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4839; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; Silverman R B, 1988, J Enzyme Inhib, V2, P73, DOI 10.3109/14756368809040714; SODA K, 1986, COENZYMES COFACTOR B, V1, P223; TOYAMA H, 1991, J BIOCHEM-TOKYO, V110, P279, DOI 10.1093/oxfordjournals.jbchem.a123571; VATER J, 1976, BIOCHIM BIOPHYS ACTA, V429, P1062, DOI 10.1016/0005-2744(76)90351-X; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WALSH CT, 1989, J BIOL CHEM, V264, P2393; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005	24	128	133	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12710	12714						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175682				2022-12-27	WOS:A1994NH71600054
J	KUMAR, TKS; SUBBIAH, V; RAMAKRISHNA, T; PANDIT, MW				KUMAR, TKS; SUBBIAH, V; RAMAKRISHNA, T; PANDIT, MW			TRICHLOROACETIC ACID-INDUCED UNFOLDING OF BOVINE PANCREATIC RIBONUCLEASE - EXISTENCE OF MOLTEN GLOBULE-LIKE STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLDING REACTIONS; SMALL PROTEINS; INTERMEDIATE; DENATURATION; MECHANISM; PATHWAY; CHAINS; FORM	The exposure of ribonuclease A to trichloroacetic acid was earlier shown to alter the conformation of the protein resulting in reduced enzymatic activity (Sagar, A.J., Subbiah, V., and Pandit, M.W. (1989) Biochim. Biophys. Acta 995, 144-150). We have studied the structure and enzymatic activity of ribonuclease A treated with trichloroacetic acid over a wide range of acid concentrations (0-40%). The far ultraviolet circular dichroism spectra of ribonuclease A, on exposure to acid concentrations less than 10%, indicated an exceptionally high degree of chiral structure. Exposure of ribonuclease A to acid concentrations between 10 and 30% resulted in the formation of a molecule with significant chiral structure (conventionally assigned to residual secondary structure) but reduced tertiary structure (characteristics very similar to those of molten globule). Increased binding of the hydrophobic probe 1-anilinonaphthalene-8-sulfonate to the enzyme treated with 15-30% acid, as compared with the untreated or completely unfolded protein, supported the existence of a state having characteristics of molten globule. Reversed phase high performance liquid chromatography corroborated the data obtained by circular dichroism as well as 1-anilino-naphthalene-8-sulfonate-binding studies. Beyond acid concentrations of 30%, the ribonuclease is completely denatured. The trichloroacetic acid-induced unfolding is shown to be completely reversible.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)			Kumar, Suresh Thallapuranam/R-5606-2016; Kumar, Dr Suresh/HHZ-2615-2022; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604				ABRAHAM KA, 1963, J REPROD FERTIL, V5, P277, DOI 10.1530/jrf.0.0050277; ABRAHAM KA, 1963, INDIAN J CHEM, V1, P124; AHMAD F, 1979, J MOL BIOL, V131, P607, DOI 10.1016/0022-2836(79)90010-X; ALFRED G, 1971, INDIAN J BIOCHEM BIO, V8, P28; ALFRED G, 1971, INDIAN J BIOCHEM BIO, V8, P35; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AUNE KC, 1967, J BIOL CHEM, V242, P4486; BALDWIN RL, 1991, CHEMTRACTS BIOCH MOL, V2, P379; BRANDTS JF, 1967, J AM CHEM SOC, V89, P4826, DOI 10.1021/ja00995a002; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DENTON JB, 1982, BIOCHEMISTRY-US, V21, P5155, DOI 10.1021/bi00264a008; GAREL JR, 1973, P NATL ACAD SCI USA, V70, P3347, DOI 10.1073/pnas.70.12.3347; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; JAGANNADHAM MV, 1985, FEBS LETT, V188, P326, DOI 10.1016/0014-5793(85)80396-3; JANICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117; KALNITSKY G, 1959, ANN NY ACAD SCI, V31, P542; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LABHARDT AM, 1982, J MOL BIOL, V157, P331, DOI 10.1016/0022-2836(82)90238-8; LATTMAN EE, 1993, P NATL ACAD SCI USA, V90, P439, DOI 10.1073/pnas.90.2.439; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RAO MSN, 1965, INDIAN J BIOCHEM, V2, P47; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; SAGAR AJ, 1983, BIOCHIM BIOPHYS ACTA, V743, P303, DOI 10.1016/0167-4838(83)90386-2; SAGAR AJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P144, DOI 10.1016/0167-4838(89)90073-3; SAGAR AJ, 1972, INDIAN J BIOCHEM BIO, V9, P52; SAGAR KDA, 1969, INDIAN J BIOCH, V6, P161; SCATCHARD G, 1957, J AM CHEM SOC, V79, P12, DOI 10.1021/ja01558a003; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHMID FX, 1979, J MOL BIOL, V133, P285, DOI 10.1016/0022-2836(79)90536-9; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; TANFORD C, 1955, J AM CHEM SOC, V77, P6421, DOI 10.1021/ja01629a003; Tsong T Y, 1970, Biochemistry, V9, P2666, DOI 10.1021/bi00815a015; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0	39	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12620	12625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175671				2022-12-27	WOS:A1994NH71600041
J	YANG, SH; JAYARAM, M				YANG, SH; JAYARAM, M			GENERALITY OF THE SHARED ACTIVE-SITE AMONG YEAST FAMILY SITE-SPECIFIC RECOMBINASES - THE ARG SITE-SPECIFIC RECOMBINASE FOLLOWS THE FLP PARADIGM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGIONAL SIMILARITIES; FUNCTIONAL-ANALYSIS; INTEGRASE FAMILY; DNA; MUTANTS; MUTAGENESIS; MECHANISM; TYROSINE; BINDING	Mutations of the invariant Int family tetrad residues, the RHR triad, and the active site tyrosine, within the Zygosaccharomyces rouxii site-specific recombinase ARg cause the same ''step-arrest'' phenotypes as they do in the Flp recombinase of Saccharomyces cerevisiae. In ''half-site'' recombinations, the ARg recombinase exhibits catalytic complementation between an RHR triad mutant and an active site tyrosine mutant. Strand cutting by R follows the ''trans'' DNA cleavage rule. These results are best explained by the assembly of a functional active site from partial active sites harbored by the ARg monomers. Complementation tests using single and double step-arrest ARg mutants verify critical predictions of the ''shared active site'' model. A wild type monomer paired with an RHR triad-Tyr(358) double mutant is a catalytically inactive combination. Pairwise combinations of a single or a double RHR mutant with R(Y358F) yield comparable levels of catalytic complementation. These results strongly imply conservation of the mechanism of active site assembly and the mode of substrate cleavage within the yeast family site specific recombinases, and perhaps within the larger Int family recombinases.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; Maniatis T., 1982, MOL CLONING; PAN H, 1993, MOL CELL BIOL, V13, P3167; PAN H, 1992, J BIOL CHEM, V267, P12397; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	22	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12789	12796						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175691				2022-12-27	WOS:A1994NH71600065
J	BRANDT, R; LEE, G; TEPLOW, DB; SHALLOWAY, D; ABDELGHANY, M				BRANDT, R; LEE, G; TEPLOW, DB; SHALLOWAY, D; ABDELGHANY, M			DIFFERENTIAL EFFECT OF PHOSPHORYLATION AND SUBSTRATE MODULATION ON TAUS ABILITY TO PROMOTE MICROTUBULE GROWTH AND NUCLEATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUBULIN BINDING DOMAIN; DEPENDENT PHOSPHORYLATION; MEDIATED PHOSPHORYLATION; DYNAMIC INSTABILITY; RAT-BRAIN; SEQUENCE; NEUROFILAMENTS; IDENTIFICATION; LOCALIZATION	The neuronal microtubule associated protein tau promotes microtubule assembly and has been implicated in the development of axonal morphology. To study the effect of phosphorylation and substrate modulation on tau's distinct activities to promote growth of existing microtubules and nucleation of new ones, we phosphorylated bacterially expressed human tau by cAMP-dependent protein kinase in the absence or presence of heparin, an acidic substrate modulator. We found that heparin increased phosphorylation of tau by a factor of more than 2 and produced tau bands with decreased electrophoretic mobility. We demonstrate that phosphorylation of tau in the absence or presence of heparin similarly reduced tau's activity to promote microtubule growth, whereas tau's activity to nucleate free microtubules was suppressed much more after phosphorylation in the presence of heparin. Using recombinant tau fragments we showed that heparin-induced phosphorylation caused a specific shift in electrophoretic mobility indicative of a change in tau's conformation. By aminoterminal sequencing of a tau fragment starting at residue 154 we provide evidence that phosphorylation of serine 156 is responsible for this mobility shift and for the effect on tau's nucleation activity. We conclude that tau's activities to promote growth of existing microtubules and nucleation of new ones are differentially affected by the phosphorylation of specific tau residues. Regulation of the phosphorylation state by substrate modulation may play an important role in regulating tau's function.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BIOPOLYMER LAB,BOSTON,MA 02115; CORNELL UNIV,DIV BIOL SCI,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University			Lee, Gloria/F-5965-2011	Lee, Gloria/0000-0002-8633-1534; Brandt, Roland/0000-0003-0101-1257	NATIONAL CANCER INSTITUTE [R01CA008964] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964] Funding Source: Medline; NIGMS NIH HHS [GM39300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELGHANY M, 1993, J BIOL CHEM, V268, P11976; ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P1761, DOI 10.1073/pnas.86.6.1761; ABDELGHANY M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P349, DOI 10.1016/0167-4889(92)90156-6; ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BRANDT R, 1993, J NEUROCHEM, V61, P997, DOI 10.1111/j.1471-4159.1993.tb03613.x; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1991, J NEUROSCI, V11, P1515; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE G, 1992, J CELL SCI, V102, P227; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LU Q, 1993, J NEUROSCI, V13, P508; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; NESTLER EJ, 1984, PROTEIN PHOSPHORYLAT, P2; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; RACKER E, 1989, JNCI-J NATL CANCER I, V81, P247, DOI 10.1093/jnci/81.4.247; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRINCZEK B, 1990, FEBS LETT, V277, P167, DOI 10.1016/0014-5793(90)80835-7; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WITMAN GB, 1976, P NATL ACAD SCI USA, V73, P4070, DOI 10.1073/pnas.73.11.4070; WRIGHT TC, 1989, HEPARIN CHEM BIOL PR, P295; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	54	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11776	11782						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163474				2022-12-27	WOS:A1994NG37700018
J	MILLAR, DG; SHORE, GC				MILLAR, DG; SHORE, GC			MITOCHONDRIAL MAS70P SIGNAL ANCHOR SEQUENCE - MUTATIONS IN THE TRANSMEMBRANE DOMAIN THAT DISRUPT DIMERIZATION BUT NOT TARGETING OR MEMBRANE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; GOLGI RETENTION; PROTEIN IMPORT; RECEPTOR; OLIGOMERIZATION; ASSOCIATION; HELIX	Mas70p is an integral membrane protein in Saccharomyces cerevisiae that is targeted and inserted into the mitochondrial outer membrane in an N-in-C-cyto orientation by its NH2-terminal 29-amino acid signal anchor sequence. Recently, we demonstrated that the signal anchor was capable of mediating homo-oligomerization of a fusion protein, pOMD29, in the outer membrane in vitro (Millar, D. G., and Shore, G. C. (1992) J. Biol. Chem. 268, 18403-18406). Consistent with this finding, we show here that a synthetic peptide corresponding to the Mas70p signal anchor is capable of independent membrane insertion and dimerization with pOMD29. To further map the oligomerization domain in the signal anchor sequence, a deletion mutant of pOMD29 that lacks amino acids 2-10 was constructed. This protein, pOMD29 Delta 2-10, efficiently participated in dimer formation following import, indicating that dimerization was mediated by the putative membrane spanning segment (amino acids 11-29). This segment is predicted to form an alpha-helix that has an alanine-rich face and contains multiple copies of a pentapeptide dimerization motif that is widespread among members of the receptor tyrosine kinase family. Substitution of the alanine residues in one of these copies with isoleucine, producing a potentially bulkier contact surface, resulted in a protein which was targeted and inserted into the outer membrane but failed to assemble into dimers. Taken together, these results identify a structural feature of the signal anchor transmembrane domain that is important for oligomerization but is not required for targeting and membrane insertion.			MILLAR, DG (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,PQ,CANADA.			Millar, Douglas/0000-0002-8640-7148				BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KEIL P, 1993, J BIOL CHEM, V268, P19177; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; NAKAI M, 1989, J BIOCHEM-TOKYO, V105, P513, DOI 10.1093/oxfordjournals.jbchem.a122698; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SHORE GC, 1992, MEMBRANE BIOGENESIS, P253; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12229	12232						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163528				2022-12-27	WOS:A1994NG37700084
J	MORRIS, L; CANNON, W; CLAVERIEMARTIN, F; AUSTIN, S; BUCK, M				MORRIS, L; CANNON, W; CLAVERIEMARTIN, F; AUSTIN, S; BUCK, M			DNA DISTORTION AND NUCLEATION OF LOCAL DNA UNWINDING WITHIN SIGMA-54 (SIGMA(N)) HOLOENZYME CLOSED PROMOTER COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE-NIFL; BINDING-PROTEIN NTRC; TRANSCRIPTIONAL ACTIVATION; ATPASE ACTIVITY; A-DNA; INVIVO; CONFORMATION; INITIATION; POLYMERASE; MECHANISM	The sigma(N) (sigma54) RNA polymerase holoenzyme has the distinctive property of binding to promoters to form a closed promoter complex, which only isomerizes to the open complex when acted upon by an enhancer binding activator protein. We probed promoter complexes that form between sigma(N) and its holoenzyme with the conformationally sensitive footprinting reagents ortho-copper phenanthroline, potassium permanganate, and diethylpyrocarbonate. Results from these experiments indicate that the contacts sigma(N) makes at the -12 promoter element are necessary to promote a local DNA distortion immediately adjacent to this promoter element when the holoenzyme but not sigma(N) alone binds promoter DNA. Complexes in which this local distortion is not detected are not activatable, and the altered DNA conformation is diminished in the activated complex. We propose that a barrier to open complex formation in the sigma(N) holoenzyme closed complex is at some step or steps after the initial nucleation of DNA strand separation, which is detected as an altered DNA conformation stably maintained within the closed complex. Thus the activator protein may promote a conformational change in the sigma(N) holoenzyme to allow propagation of the altered DNA conformation, probably local unwinding, which we propose is necessary for formation of the melted DNA state, characteristic of the open promoter complex.	UNIV SUSSEX,AFRC,INST PLANT SCI RES,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Sussex; Massachusetts Institute of Technology (MIT)				Claverie-Martin, Felix/0000-0003-2468-3267				AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BUCK M, 1985, NUCLEIC ACIDS RES, V13, P7621, DOI 10.1093/nar/13.21.7621; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CALLADINE CR, 1984, J MOL BIOL, V178, P773, DOI 10.1016/0022-2836(84)90251-1; CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x; CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; CHARLTON W, 1993, MOL MICROBIOL, V7, P1007, DOI 10.1111/j.1365-2958.1993.tb01192.x; CONNER BN, 1984, J MOL BIOL, V174, P663, DOI 10.1016/0022-2836(84)90089-5; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; DRAPER DE, 1993, P NATL ACAD SCI USA, V90, P7429, DOI 10.1073/pnas.90.16.7429; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992; MINCHIN SD, 1989, EMBO J, V8, P3491, DOI 10.1002/j.1460-2075.1989.tb08514.x; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEITZ TA, 1990, Q REV BIOPHYS, V23, P205; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SPASSKY A, 1988, EMBO J, V7, P1871, DOI 10.1002/j.1460-2075.1988.tb03020.x; TRAVERS AA, 1993, PROTEIN DNA INTERACT; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WHITEHALL S, 1992, J MOL BIOL, V225, P591, DOI 10.1016/0022-2836(92)90388-Z; WONG CN, 1992, J BIOL CHEM, V267, P24762	37	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11563	11571						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157688				2022-12-27	WOS:A1994NF96600087
J	YE, Q; WORMAN, HJ				YE, Q; WORMAN, HJ			PRIMARY STRUCTURE-ANALYSIS AND LAMIN-B AND DNA-BINDING OF HUMAN LBR, AN INTEGRAL PROTEIN OF THE NUCLEAR-ENVELOPE INNER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; GENE ENCODES; PORE COMPLEX; RAT-LIVER; RECEPTOR; IDENTIFICATION; PHOSPHORYLATION; FRACTION; PURIFICATION; MITOSIS	We have determined the primary structure of human LBR, an integral protein of the nuclear envelope inner membrane, and examined its interactions with lamin B and DNA. Human LBR is 68% identical to the chicken lamin B receptor and has a basic nucleoplasmic amino-terminal domain of 208 amino acids followed by a hydrophobic domain with eight putative transmembrane segments. The amino-terminal domain contains a Ser-Arg-rich stretch and consensus sites for phosphorylation by protein kinase A and p34cdc2 protein kinase. A fusion protein containing the amino-terminal domain of human LBR is recognized by autoantibodies from patients with primary biliary cirrhosis, and these serum antibodies label the nuclear envelope when examined by immunofluorescence microscopy. The LBR amino-terminal domain precipitates lamin B from nuclear extracts and retards the migration of double-stranded DNA subjected to agarose gel electrophoresis. When immobilized on nitrocellulose, the amino-terminal domain of LBR also associates with DNA, and the stretch between amino acids 71 and 100, which contains the Ser-Arg-rich stretch, is necessary for DNA binding. These results demonstrate that LBR is conserved among vertebrate species and that its nucleoplasmic domain can potentially mediate the interaction of both the nuclear lamina and the chromatin with the inner nuclear membrane.	CUNY MT SINAI SCH MED, DEPT MED, BOX 1269, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; APPELBAUM J, 1990, J BIOL CHEM, V265, P4181; BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CANCE WG, 1992, J EXP CLIN CANC RES, V11, P233; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; COURVALIN JC, 1990, J EXP MED, V172, P961, DOI 10.1084/jem.172.3.961; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FAWCETT DW, 1966, AM J ANAT, V119, P129, DOI 10.1002/aja.1001190108; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HAREL A, 1989, J CELL SCI, V94, P463; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; NICKOWITZ RE, 1994, GASTROENTEROLOGY, V106, P193, DOI 10.1016/S0016-5085(94)95333-3; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; PADAN R, 1990, J BIOL CHEM, V265, P7808; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WORMAN HJ, 1990, J CELL BIOL, V111, P1534	46	209	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11306	11311						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157662				2022-12-27	WOS:A1994NF96600052
J	STENBERG, L; OTOOLE, PW; MESTECKY, J; LINDAHL, G				STENBERG, L; OTOOLE, PW; MESTECKY, J; LINDAHL, G			MOLECULAR CHARACTERIZATION OF PROTEIN SIR, A STREPTOCOCCAL CELL-SURFACE PROTEIN THAT BINDS BOTH IMMUNOGLOBULIN-A AND IMMUNOGLOBULIN-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GROUP-B STREPTOCOCCI; CLOSELY LINKED GENES; IGA-RECEPTOR; NUCLEOTIDE-SEQUENCES; ESCHERICHIA-COLI; CLONING VECTORS; FC-RECEPTOR; IDENTIFICATION; PURIFICATION	Cell surface proteins that bind to the Fc part of immunoglobulin (Ig) A and/or IgG are expressed by many strains of the group A Streptococcus, an important human pathogen. Two extensively characterized proteins in this group of molecules are protein Arp that preferentially binds IgA and protein H that binds IgG. In addition, recent work has shown that many group A strep streptococcal strains express a novel type of Fc-binding protein, designated protein Sir, that binds both IgA and IgG. Protein Sir22, the molecule expressed by a strain of serotype M22, has now been purified and characterized after expression of the cloned gene in Escherichia coli. Dot-blot analysis with a large number of purified monoclonal Igs showed that protein Sir22 reacted with 19 out of 20 IgA proteins and with 19 out of 24 IgG proteins. The affinity constants for the reactions between protein Sir22 and Ig were determined to be 7.0 x 10(8) M(-1) for serum IgA, 2.4 x 10(8) M(-1) for secretory IgA, and 7.8 x 10(8) M(-1) for IgG. Inhibition experiments showed that the bindings of IgA and IgG to protein Sir22 were mutually exclusive, indicating shared or contiguous binding sites. Analysis of the sequence of the sir22 gene indicated a gene product with 365 amino acid residues, including a 41-residue signal peptide. The processed form of the protein, 324 residues, has a calculated M(r) of 37,186. Deletion analysis of the sir22 gene showed that a 156-residue NH2-terminal fragment of protein Sir22 retained the ability to bind both IgA and IgG. The overall organization of protein Sir22 is similar to that of the IgA-binding protein Arp and the IgG-binding protein H. All three of these proteins are members of the M protein family and have a central repeat region of the C type.	LUND UNIV,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	Lund University; University of Alabama System; University of Alabama Birmingham			O'Toole, Paul W/G-1593-2012	O'Toole, Paul W/0000-0001-5377-0824	NIDDK NIH HHS [DK-28537] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028537] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERSTROM B, 1991, MOL IMMUNOL, V28, P349, DOI 10.1016/0161-5890(91)90147-C; AKERSTROM B, 1992, J IMMUNOL, V148, P3238; AKERSTROM B, 1994, IN PRESS MOL IMMUNOL; AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; AKESSON P, 1994, IN PRESS BIOCH J; ANRAKU Y, 1967, J BIOL CHEM, V242, P2561; BESSEN DE, 1992, INFECT IMMUN, V60, P124, DOI 10.1128/IAI.60.1.124-135.1992; BJORCK L, 1984, J IMMUNOL, V133, P969; BOYLE MDP, 1990, BACTERIAL IMMUNOGLOB, V1; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FISCHETTI VA, 1984, J EXP MED, V159, P1083, DOI 10.1084/jem.159.4.1083; FORSGREN A, 1966, J IMMUNOL, V97, P822; FRICK IM, 1994, IN PRESS MOL MICROBI; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GOMI H, 1990, J IMMUNOL, V144, P4046; HAANES EJ, 1992, J BACTERIOL, V174, P4967, DOI 10.1128/JB.174.15.4967-4976.1992; HEATH DG, 1989, P NATL ACAD SCI USA, V86, P4741, DOI 10.1073/pnas.86.12.4741; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; HEDEN LO, 1993, J GEN MICROBIOL, V139, P2067, DOI 10.1099/00221287-139-9-2067; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; JEPPSON H, 1992, FEMS MICROBIOL LETT, V92, P139, DOI 10.1016/0378-1097(92)90502-F; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; LINDAHL G, 1989, MOL GEN GENET, V216, P372, DOI 10.1007/BF00334378; LINDAHL G, 1990, EPIDEMIOL INFECT, V105, P87, DOI 10.1017/S0950268800047683; LINDAHL G, 1991, GENETICS AND MOLECULAR BIOLOGY OF STREPTOCOCCI, LACTOCOCCI, AND ENTEROCOCCI, P155; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESTECKY J, 1985, METHOD ENZYMOL, V116, P37; MICHAELSEN TE, 1977, J BIOL CHEM, V252, P883; MISRA TK, 1985, GENE, V34, P263, DOI 10.1016/0378-1119(85)90135-0; MYHRE EB, 1983, INFECT IMMUN, V40, P29, DOI 10.1128/IAI.40.1.29-34.1983; OTOOLE P, 1992, P NATL ACAD SCI USA, V89, P8661, DOI 10.1073/pnas.89.18.8661; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RAEDER R, 1992, J CLIN MICROBIOL, V30, P3074, DOI 10.1128/JCM.30.12.3074-3081.1992; RETNONINGRUM DS, 1993, J IMMUNOL, V150, P2332; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STENBERG L, 1992, MOL MICROBIOL, V6, P1185, DOI 10.1111/j.1365-2958.1992.tb01557.x; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANLOGHEM E, 1982, SCAND J IMMUNOL, V15, P275; WHATMORE AM, 1994, MOL MICROBIOL, V11, P363, DOI 10.1111/j.1365-2958.1994.tb00316.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13458	13464						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175778				2022-12-27	WOS:A1994NK18400061
J	WU, XR; LIN, JH; WALZ, T; HANER, M; YU, J; AEBI, UL; SUN, TT				WU, XR; LIN, JH; WALZ, T; HANER, M; YU, J; AEBI, UL; SUN, TT			MAMMALIAN UROPLAKINS - A GROUP OF HIGHLY CONSERVED UROTHELIAL DIFFERENTIATION-RELATED MEMBRANE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT URINARY-BLADDER; TRANSITIONAL EPITHELIAL-CELLS; EXPANSION-CONTRACTION CYCLE; LUMINAL MEMBRANE; 3-DIMENSIONAL STRUCTURE; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; PLASMA-MEMBRANE; CD9 ANTIGEN; SURFACE	The asymmetric unit membrane (AUM) forms the apical plaques of mammalian urothelium and is believed to play a role in strengthening the urothelial apical surface thus preventing the cells from rupturing during bladder distention. We have shown previously that purified bovine AUMs contain four major integral membrane proteins: the uroplakins Ia (27 kDa), Ib (28 kDa), II (15 kDa), and III (47 kDa). This contradicts some previous reports indicating that some of these proteins are absent in AUMs of several species. Using an improved procedure, we isolated AUMs from, in addition to cattle, eight mammalian species (human, monkey, sheep, pig, dog, rabbit, rat, and mouse). The AUMs of these species appear morphologically similar bearing crystalline patches of 12-nm protein particles with a center-to center spacing of 16.5 nm. Using antibodies raised against synthetic oligopeptides or individual bovine uroplakins, we established by immunoblotting that the four uroplakins are present in AUMs of all these species. The DNA-deduced amino acid sequences of bovine and mouse uroplakin II revealed 83% identity. These results indicate that uroplakins Ia, Ib, II, and m are the major protein components of probably all mammalian urothelial plaques, and that the sequence and three-dimensional structure of uroplakin molecules are highly conserved during mammalian evolution.	NYU, SCH MED, RONALD O PERELMAN DEPT DERMATOL, EPITHELIAL BIOL UNIT, NEW YORK, NY 10016 USA; NYU, KAPLAN COMPREHENS CANC CTR, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; UNIV BASEL, BIOCTR, MAURICE E MULLER INST HIGH RESOLUT ELECTRON M, CH-4056 BASEL, SWITZERLAND	New York University; New York University; University of Basel			Sun, Tung-Tien/J-4425-2015; 郑, 征/C-8514-2011	Sun, Tung-Tien/0000-0002-6841-1063; Walz, Thomas/0000-0003-2606-2835; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047529, R01DK039753] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39749] Funding Source: Medline; NIDDK NIH HHS [DK47529, DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBI U, 1973, Journal of Supramolecular Structure, V1, P498, DOI 10.1002/jss.400010606; AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRISSON A, 1983, J MOL BIOL, V166, P21, DOI 10.1016/S0022-2836(83)80048-5; CARUTHERS JS, 1977, J CELL BIOL, V73, P382, DOI 10.1083/jcb.73.2.382; CHLAPOWSKI FJ, 1972, J CELL BIOL, V53, P92, DOI 10.1083/jcb.53.1.92; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FIRTH JA, 1973, J ANAT, V116, P31; HICKS RM, 1970, J CELL BIOL, V45, P542, DOI 10.1083/jcb.45.3.542; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; HOTTA H, 1988, CANCER RES, V48, P2955; KALLIN B, 1991, MOL CELL BIOL, V11, P5338, DOI 10.1128/MCB.11.10.5338; KNUTTON S, 1976, J CELL SCI, V22, P355; KOSS LG, 1969, LAB INVEST, V21, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JH, 1994, J BIOL CHEM, V269, P1775; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MINSKY BD, 1978, J CELL BIOL, V77, P685, DOI 10.1083/jcb.77.3.685; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; PARSONS CL, 1980, SCIENCE, V208, P605, DOI 10.1126/science.6154316; PAULI BU, 1983, PATHOLOGY BLADDER CA, P42; PORTER KR, 1963, INTRO FINE STRUCTURE; ROBERTSON JD, 1980, J CELL BIOL, V86, P514, DOI 10.1083/jcb.86.2.514; RUGGIERI MR, 1992, J UROLOGY, V148, P173, DOI 10.1016/S0022-5347(17)36547-3; RYAN AM, 1993, MAMM GENOME, V4, P656, DOI 10.1007/BF00360903; SAMBROOK J, 1989, MOLCLONING LABORATOR; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIKAS SN, 1986, CELL TISSUE RES, V246, P109; SARIKAS SN, 1989, CELL TISSUE RES, V258, P393; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SEVERS NJ, 1979, J ULTRA MOL STRUCT R, V69, P279, DOI 10.1016/S0022-5320(79)90117-5; STAEHELIN LA, 1972, J CELL BIOL, V53, P73, DOI 10.1083/jcb.53.1.73; STUBBS CD, 1979, BIOCHIM BIOPHYS ACTA, V558, P58, DOI 10.1016/0005-2736(79)90315-8; STUBBS CD, 1975, BIOCHEM SOC T, V3, P759, DOI 10.1042/bst0030759; SURYA B, 1990, J CELL SCI, V97, P419; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TAYLOR KA, 1984, J ULTRA MOL STRUCT R, V87, P23, DOI 10.1016/S0022-5320(84)90113-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERGARA J, 1974, J CELL BIOL, V61, P83, DOI 10.1083/jcb.61.1.83; WALKER BE, 1960, J ULTRA MOL STRUCT R, V3, P345, DOI 10.1016/S0022-5320(60)90014-9; WARREN RC, 1970, NATURE, V227, P280, DOI 10.1038/227280b0; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU J, 1994, IN PRESS J CELL BIOL	52	243	265	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13716	13724						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175808				2022-12-27	WOS:A1994NK18400096
J	BRANDT, U; URIBE, S; SCHAGGER, H; TRUMPOWER, BL				BRANDT, U; URIBE, S; SCHAGGER, H; TRUMPOWER, BL			ISOLATION AND CHARACTERIZATION OF QCR10, THE NUCLEAR GENE ENCODING THE 8.5-KDA SUBUNIT-10 OF THE SACCHAROMYCES-CEREVISIAE CYTOCHROME BC(1), COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We have cloned and sequenced QCR10, the nuclear gene encoding an 8.5-kDa protein proposed to be a subunit of the cytochrome bc(1) complex of Saccharomyces cerevisiae. QCR10 includes a 231-base pair open reading frame capable of encoding a protein of 77 amino acids with a predicted molecular mass of 8492 Da. The codons for the amino-terminal methionine and alanine are separated from the remainder of the open reading frame by a 63-base pair intron that contains 5'-donor, 3'-acceptor, and TACTAAC sequences known to be necessary for splicing. The deduced amino acid sequence of the 8.5-kDa yeast protein is 28% identical to that of the 6.4-kDa subunit 11 from the bovine heart cytochrome be, complex, and the predicted secondary structures of the two proteins are very similar. Deletion of the chromosomal copy of QCR10 did not affect the growth of yeast on nonfermentable carbon sources. However, deletion of QCR10 synergistically contributes to the temperature-dependent phenotype resulting from deletion of QCR6, the gene for subunit 6 of the cytochrome bc(1) complex. In addition, ubiquinol-cytochrome c oxidoreductase activity was reduced 40% in mitochondrial membranes from the QCR10 deletion strain, and the Rieske iron-sulfur protein was lost when the cytochrome bc(1) complex lacking the 8.5-kDa protein was purified. We conclude that the 8.5-kDa protein encoded by QCR10 is a subunit of the yeast cytochrome bc(1) complex and that the presence of this subunit during assembly is required for stable association of the iron-sulfur protein with the complex.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV FRANKFURT KLINIKUM, ZENTRUM BIOL CHEM, D-60596 FRANKFURT, GERMANY	Dartmouth College; Goethe University Frankfurt; Goethe University Frankfurt Hospital			Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BRANDT U, 1993, J BIOL CHEM, V268, P8387; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; GEIER BM, 1992, EUR J BIOCHEM, V208, P375, DOI 10.1111/j.1432-1033.1992.tb17197.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRECO DA, 1989, CURRENT PROTOCOLS MO; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; YANG MJ, 1994, J BIOL CHEM, V269, P1270; YANG XH, 1986, J BIOL CHEM, V261, P2282; ZHOU C, 1990, BIOTECHNIQUES, V8, P172; 1991, PROGRAM MANUAL GCG P	32	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12947	12953						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175712				2022-12-27	WOS:A1994NH71600087
J	ERNST, F; HOFFSCHULTE, HK; THOMEKROMER, B; SWIDERSKY, UE; WERNER, PK; MULLER, M				ERNST, F; HOFFSCHULTE, HK; THOMEKROMER, B; SWIDERSKY, UE; WERNER, PK; MULLER, M			PRECURSOR-SPECIFIC REQUIREMENTS FOR SECA, SECB, AND DELTA-MU(H+) DURING PROTEIN EXPORT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We compare translocation into inside-out plasma membrane vesicles (INV) of the in vitro synthesized outer membrane proteins LamB and OmpA and the periplasmic protein Skp of Escherichia coli and demonstrate a precursor-specific dependence on the export factors SecA, SecB, and the proton-motive force (Delta mu(H+)). A partial reduction in soluble SecA caused a 50% decrease in translocation of preLamB. In contrast, removal of INV-bound SecA by urea extraction was required to see a decrease in translocation of preOmpA and preSkp, with 8% of preSkp still being translocated into ureatreated INV. Translocation of the three precursors into INV showed a corresponding differential sensitivity toward dissipation of Delta mu(H+) following removal of the F-1- ATPase from the INV. While depletion of both F-1 and SecA or simply lowering of the reaction temperature resulted in an inhibition of complete transmembrane translocation, it interfered less severely with signal sequence cleavage, indicating the formation of translocation intermediates under these conditions. The relative amounts of intermediate obtained were also different for the three preproteins correlating a low requirement for SecA and Delta mu(H+) with a facilitated initiation of translocation. Whereas preSkp was translocated independently of SecB, preLamB was not even targeted to the INV in its absence. Functional targeting of preOmpA required the presence of SecB during incubation of the precursor with INV and not during its synthesis. SecB, exogenously added during the period of synthesis, did not prevent the formation of translocation-incompetent preLamB. The latter results are consistent with an important targeting function of SecB, which so far has mostly been described as a molecular chaperone. The findings are discussed with respect to current models of bacterial protein export usually derived from the analysis of a single precursor.	UNIV MUNICH, INST PHYS BIOCHEM, D-80366 MUNICH, GERMANY	University of Munich								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALTMAN E, 1991, EMBO J, V10, P239, DOI 10.1002/j.1460-2075.1991.tb07943.x; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DECOCK H, 1992, MOL MICROBIOL, V6, P599; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; ITO K, 1992, MOL MICROBIOL, V6, P2423; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1990, J BIOENERG BIOMEMBR, V22, P337, DOI 10.1007/BF00763171; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1987, EMBO J, V6, P3855, DOI 10.1002/j.1460-2075.1987.tb02723.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; SWIDERSKY UE, 1992, EUR J BIOCHEM, V207, P803, DOI 10.1111/j.1432-1033.1992.tb17111.x; TANI K, 1989, J BIOL CHEM, V264, P18582; THOME BM, 1990, FEBS LETT, V269, P113, DOI 10.1016/0014-5793(90)81132-8; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA H, 1989, J BIOL CHEM, V264, P1723	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12840	12845						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175698				2022-12-27	WOS:A1994NH71600072
J	FLICK, KE; GONZALEZ, L; HARRISON, CJ; NELSON, HCM				FLICK, KE; GONZALEZ, L; HARRISON, CJ; NELSON, HCM			YEAST HEAT-SHOCK TRANSCRIPTION FACTOR CONTAINS A FLEXIBLE LINKER BETWEEN THE DNA-BINDING AND TRIMERIZATION DOMAINS - IMPLICATIONS FOR DNA-BINDING BY TRIMERIC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								All heat shock transcription factors (HSFs) share two regions of homology, identified as the DNA binding and trimerization regions. The DNA binding region consists of two parts, an 89-amino-acid minimal DNA-binding domain and an additional 21 amino acids which are not necessary for specific DNA binding of a monomeric DNA-binding domain. These 21 amino acids may act as a flexible linker between the DNA-binding and trimerization domains. Saccharomyces cerevisiae HSF has an additional 52 amino acids between the proposed flexible linker and the trimerization domain. Deletion of this unique region has no effect on the structural integrity or essential in vivo functions of HSF. To investigate the role of the 21-amino-acid proposed linker a series of internal deletions was created in fragments containing the DNA-binding and trimerization domains. The deletions have no effect on the structural integrity of the protein as assayed by circular dichroism spectroscopy. However, alterations of the linker do affect affinity of trimeric HSF binding to its target DNA In addition, deletion of part or all of the proposed linker from full-length yeast HSF, an essential protein, disrupts growth of yeast.	UNIV CALIF BERKELEY, DEPT MOLEC & CELLULAR BIOL, DIV BIOCHEM & MOLEC BIOL, STANLEY DONNER ASU, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Gonzalez, Lino/E-4102-2012	Gonzalez, Lino/0000-0003-3817-6450	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R01GM044086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44086, GM-07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P409; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GUBLER M, 1991, EMBO J, V10, P951, DOI 10.1002/j.1460-2075.1991.tb08029.x; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Maxam A M, 1980, Methods Enzymol, V65, P499; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; OERTELBUCHHEIT P, 1993, J MOL BIOL, V229, P1, DOI 10.1006/jmbi.1993.1001; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RADFORD SE, 1989, J BIOL CHEM, V264, P767; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; RYE HS, 1993, J BIOL CHEM, V268, P25229; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SAXENA VP, 1971, P NATL ACAD SCI USA, V68, P969, DOI 10.1073/pnas.68.5.969; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHEN H, 1991, J BIOL CHEM, V266, P11335; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VUISTER GW, 1994, BIOCHEMISTRY-US, V33, P10, DOI 10.1021/bi00167a002; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	35	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12475	12481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175654				2022-12-27	WOS:A1994NH71600019
J	KELLEHER, DJ; GILMORE, R				KELLEHER, DJ; GILMORE, R			THE SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE IS A PROTEIN COMPLEX COMPOSED OF WBP1P, SWP1P, AND 4 ADDITIONAL POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Asparagine linked glycosylation of proteins in the lumen of the endoplasmic reticulum is catalyzed by the oligosaccharyltransferase. Previously, the mammalian oligosaccharyltransferase was shown to co-purify with a protein complex consisting of three integral membrane proteins: ribophorin I and ribophorin II and a nonglycosylated 48-kDa polypeptide designated OST48. Here, we describe the purification of the oligosaccharyltransferase from Saccharomyces cerevisiae. The yeast oligosaccharyltransferase complex is composed of six subunits (alpha, beta, gamma, delta, epsilon, and zeta). The alpha subunit of the yeast oligosaccharyltransferase complex is a heterogeneously glycosylated protein with three glycoforms of 64, 62, and 60 kDa that contain, respectively, four, three, and two asparagine-linked oligosaccharide chains. The beta and delta subunits were shown to correspond to the 45-kDa Wbp1 glycoprotein and the 30-kDa Swp1 protein, respectively. The Wbp1 and Swp1 proteins were previously shown to be essential for asparagine-linked glycosylation in vivo. The nonglycosylated gamma, epsilon, and zeta subunits have apparent molecular masses of 34, 16, and 9 kDa. Homology between the yeast and mammalian oligosaccharyltransferase complexes first became evident when the 48-kDa subunit of the mammalian enzyme was found to be 25% identical in sequence with the Wbp1 protein. Here we present an alignment between the Swp1 protein and the carboxyl-terminal half of human ribophorin II that reveals that these two proteins are related gene products.			KELLEHER, DJ (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA.				NIGMS NIH HHS [GM 43768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMARCOSTESEC A, 1984, J CELL BIOL, V99, P2247, DOI 10.1083/jcb.99.6.2247; BADET J, 1988, CARBOHYD RES, V178, P49, DOI 10.1016/0008-6215(88)80101-0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HARLOW E, 1988, ANTIBODIES LABORATOR; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; Smith EL, 1940, P NATL ACAD SCI USA, V26, P272, DOI 10.1073/pnas.26.4.272; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; Steele J C Jr, 1978, Methods Enzymol, V48, P11; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; Turco SJ, 1977, P NATL ACAD SCI USA, V74, P4410; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	32	90	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12908	12917						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175708				2022-12-27	WOS:A1994NH71600082
J	LAPPI, DA; YING, WB; BARTHELEMY, I; MARTINEAU, D; PRIETO, I; BENATTI, L; SORIA, M; BAIRD, A				LAPPI, DA; YING, WB; BARTHELEMY, I; MARTINEAU, D; PRIETO, I; BENATTI, L; SORIA, M; BAIRD, A			EXPRESSION AND ACTIVITIES OF A RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR-SAPORIN FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								A fusion protein containing the full-length sequences of the mitogen, basic fibroblast growth factor (FGF-2), and the ribosome inactivating protein, saporin (SAP), has been expressed in E. coli. As expected, it binds with high affinity to heparin-Sepharose like FGF-2 and can displace the binding of radiolabeled FGF-2 to its high affinity receptor. In contrast, the fusion protein only has much lower ribosome-inactivating activity than free saporin, although full ribosome-inactivating protein activity can be generated by proteolytic removal of the FGF-2 moiety. Cytotoxicity experiments with B16-F10 mouse melanoma cells establish that the fusion protein is active as a chemical conjugate against these intact cells. Presumably these cells have the ability to activate the SAP component of the fusion protein through an intracellular metabolism of the fusion protein. Because we also show the fusion protein has tumor growth inhibition properties and antimetastatic activity in in vivo models of melanoma, the findings support the hypothesis that FGF-based ligand-mediated cytotoxicity can serve to target cytotoxic agents in vivo.	FARMITALIA CARLO ERBA LTD, I-20014 NERVIANO, ITALY; IST SCI SAN RAFFAELE, DIPARTIMENTO BIOTECNOL, I-20132 MILAN, ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	LAPPI, DA (corresponding author), WHITTIER INST DIABET & ENDOCRINOL, DEPT MOLEC & CELLULAR GROWTH BIOL, LA JOLLA, CA 92037 USA.			Lappi, Douglas/0000-0003-4239-7387; Baird, Andrew/0000-0003-0027-9905	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18811] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BARRA D, 1991, BIOTECHNOL APPL BIOC, V13, P48; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Battey, 1986, BASIC METHODS MOL BI; BEATTIE GM, 1991, J CLIN ENDOCR METAB, V73, P93, DOI 10.1210/jcem-73-1-93; BEATTIE GM, 1990, DIABETES, V39, P1002, DOI 10.2337/diabetes.39.8.1002; BEITZ JG, 1992, CANCER RES, V52, P227; BENARDI MA, 1992, INT J CANCER S, V7, P73; BIRO S, 1992, CIRC RES, V71, P640, DOI 10.1161/01.RES.71.3.640; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3065, DOI 10.1073/pnas.89.7.3065; CASE JP, 1989, P NATL ACAD SCI USA, V86, P287, DOI 10.1073/pnas.86.1.287; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DAVID T, 1992, J CELL PHYSIOL, V153, P483, DOI 10.1002/jcp.1041530307; ESCH F, 1992, ANAL BIOCHEM, V136, P39; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; GOLDIN A, 1985, INVEST NEW DRUG, V3, P3; GRISWOLD DP, 1972, CANCER CHEMOTH REP 2, V3, P315; Hill G J 2nd, 1971, J Surg Oncol, V3, P1, DOI 10.1002/jso.2930030104; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JEAN LFL, 1993, PROTEIN ENG, V6, P305, DOI 10.1093/protein/6.3.305; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KELLEY VE, 1988, P NATL ACAD SCI USA, V85, P3980, DOI 10.1073/pnas.85.11.3980; KIYOKAWA T, 1991, ANN NY ACAD SCI, V636, P331, DOI 10.1111/j.1749-6632.1991.tb33463.x; KREITMAN RJ, 1990, P NATL ACAD SCI USA, V87, P8291, DOI 10.1073/pnas.87.21.8291; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LAPPI DA, 1993, ANAL BIOCHEM, V212, P446, DOI 10.1006/abio.1993.1353; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; LAPPI DA, 1991, J CELL PHYSIOL, V147, P17, DOI 10.1002/jcp.1041470104; LAPPI DA, 1991, PROG GROWTH FACTOR R, V2, P223; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LORBERBOUMGALSKI H, 1988, J BIOL CHEM, V263, P18650; LORBERBOUMGALSKI H, 1989, P NATL ACAD SCI USA, V86, P1008, DOI 10.1073/pnas.86.3.1008; MARAS B, 1990, BIOCHEM INT, V21, P831; MERWIN JR, 1992, CANCER RES, V52, P4995; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MURATA J, 1989, JPN J CANCER RES, V80, P866, DOI 10.1111/j.1349-7006.1989.tb01728.x; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; MURPHY JR, 1987, BIOCHEM SOC SYMP, P9; OELTMANN TN, 1991, FASEB J, V5, P2334, DOI 10.1096/fasebj.5.10.1676688; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; OHARE M, 1990, FEBS LETT, V273, P200, DOI 10.1016/0014-5793(90)81084-2; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PRIETO I, 1991, ANN NY ACAD SCI, V638, P434, DOI 10.1111/j.1749-6632.1991.tb49062.x; SANTORO MG, 1977, CANCER RES, V37, P3774; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; Soria M R, 1992, Targeted Diagn Ther, V7, P193; STIRPE F, 1983, BIOCHEM J, V216, P617, DOI 10.1042/bj2160617; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; UCKUN FM, 1993, LEUKEMIA, V7, P341; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WALICKE PA, 1991, J NEUROSCI, V11, P2249; WILEY RG, 1991, BRAIN RES, V562, P149, DOI 10.1016/0006-8993(91)91199-B	61	54	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12552	12558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175664				2022-12-27	WOS:A1994NH71600031
J	POST, PL; TRYBUS, KM; TAYLOR, DL				POST, PL; TRYBUS, KM; TAYLOR, DL			A GENETICALLY-ENGINEERED, PROTEIN-BASED OPTICAL BIOSENSOR OF MYOSIN-II REGULATORY LIGHT-CHAIN PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Myosin II is an important motor in the contraction of smooth and striated muscle as well as in a variety of nonmuscle cell motile events including cytokinesis, cortical contractions during migration of fibroblasts, and capping of receptors. Phosphorylation of the 20-kDa light chain by myosin light chain kinase is part of the regulation of smooth muscle and mammalian nonmuscle myosin II. We designed, characterized, and tested the use of a protein-based optical biosensor to monitor this phosphorylation ''switch.'' A regulatory light chain was genetically engineered to contain a single cysteine at amino acid position 18. The mutant light chain (Cys(18).LC(20)), reacted with the fluorophore acrylodan, responded to phosphorylation of serine 19 with a fluorescence emission quenching of 60% and a 28-nm red-shift. When the acrylodan-labeled mutant light chain (AC-Cys(18).LC(20)) was exchanged into turkey gizzard myosin II, it exhibited a 25% fluorescence emission quenching and a 10-nm red-shift upon phosphorylation of serine 19. The myosin II optical biosensor exhibited nearly control levels of the rate of phosphorylation, K(+)ATPase activity, and in vitro motility. The acrylodan-labeled light chain was exchanged into the A-bands of chicken pectoralis myofibrils in situ to demonstrate the localization and activity of the biosensor in a highly ordered contractile system. Fluorometry and quantitative fluorescence microscopic imaging experiments demonstrated that AC-Cys(18). LC(20) exchanged myofibrils expressed a phosphorylation-dependent fluorescence change. Labeled light chains were also incorporated into stress fibers of living fibroblasts and smooth muscle cells. This general approach of combining molecular biology and fluorescence spectroscopy to create novel protein-based optical biosensors should provide valuable tools for investigations with model systems and solution studies and ultimately yield important information about temporal-spatial chemical and molecular changes in live cells.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA	Carnegie Mellon University; Brandeis University	POST, PL (corresponding author), CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, PITTSBURGH, PA 15213 USA.			Taylor, D. Lansing/0000-0001-6947-1343	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032461, R01AR032461] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline; NIAMS NIH HHS [AR32461] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; BENNETT JP, 1988, J CELL BIOL, V107, P2623, DOI 10.1083/jcb.107.6.2623; BOWMAN BF, 1990, BIOPHYS J, V57, pA152; CLARK ID, 1988, ARCH BIOCHEM BIOPHYS, V260, P595, DOI 10.1016/0003-9861(88)90486-9; COLE HA, 1985, FEBS LETT, V180, P165, DOI 10.1016/0014-5793(85)81064-4; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; GIULIANO KA, 1990, CELL MOTIL CYTOSKEL, V16, P14, DOI 10.1002/cm.970160104; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HAHN KM, 1990, J BIOL CHEM, V265, P20335; HAHN KM, 1993, FLUORESCENT LUMINESC, P349; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1985, J BIOL CHEM, V260, P27; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; KOLEGA J, 1993, MOL BIOL CELL, V4, P819, DOI 10.1091/mbc.4.8.819; Kolega J., 1993, Bioimaging, V1, P136, DOI 10.1002/1361-6374(199309)1:3<136::AID-BIO2>3.3.CO;2-4; KOLEGA J, 1991, J CELL BIOL, V114, P993, DOI 10.1083/jcb.114.5.993; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; MARSH DJ, 1980, BIOCHEMISTRY-US, V19, P774, DOI 10.1021/bi00545a025; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RAJASEKHARAN KN, 1991, ARCH BIOCHEM BIOPHYS, V288, P584, DOI 10.1016/0003-9861(91)90240-J; REID SW, 1993, ARCH BIOCHEM BIOPHYS, V302, P31, DOI 10.1006/abbi.1993.1176; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; STAFFORD WF, 1983, BIOPHYS J, V41, pA93; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAYLOR DL, 1980, NATURE, V284, P405, DOI 10.1038/284405a0; TAYLOR DL, 1992, AM SCI, V80, P322; TAYLOR DL, 1978, P NATL ACAD SCI USA, V75, P857, DOI 10.1073/pnas.75.2.857; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; [No title captured]	47	44	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12880	12887						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175704				2022-12-27	WOS:A1994NH71600078
J	TANG, MS; PAO, A; ZHANG, XS				TANG, MS; PAO, A; ZHANG, XS			REPAIR OF BENZO(A)PYRENE DIOL EPOXIDE-INDUCED AND UV-INDUCED DNA-DAMAGE IN DIHYDROFOLATE-REDUCTASE AND ADENINE PHOSPHORIBOSYLTRANSFERASE GENES OF CHO CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DIPLOID HUMAN FIBROBLASTS; MAMMALIAN-CELLS; TRANSCRIBED STRAND; LINEAR DICHROISM; EXCISION REPAIR; N-METHYLPURINES; DHFR GENE; HPRT GENE; BENZO<A>PYRENE	Using Uvr proteins we have quantified benzo(a)pyrene diol epoxide (BPDE)-DNA adduct formation and repair at the dihydrofolate reductase (DHFR) and adenine phosphoribosyltransferase (APRT) genes in two Chinese hamster ovary cell lines: B-11 cells, which are 50-fold amplified for DHFR, and AT3-2 cells, which are diploid for DHFR. We have found that: 1) BPDE-DNA adduct formation in different regions of the DHFR gene is proportional to the concentration of BPDE. 2) There is no significant difference in the repair of BPDE-DNA adducts between the coding and noncoding regions in either amplified or nonamplified DHFR gene domains. 3) Repair in the nonamplified DHFR gene is more efficient (30-40%) than in the amplified DHFR genes. 4) There are no significant differences of repair in the transcribed or nontranscribed strands of the DHFR gene. 5) BPDE-DNA adduct formation and repair in the APRT gene in B-11 and AT3-2 cells are the same. These results contrast those for the repair of cyclobutane pyrimidine dimers, which occurs preferentially in the transcribed strand of the DHFR gene and in which gene amplification appears to play no role,			TANG, MS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV SCI PK RES,SMITHVILLE,TX 78957, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03124] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELAND FA, 1989, PATHOBIOLOGY NEOPLAS, P57; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; CAROTHERS AM, 1991, P NATL ACAD SCI USA, V88, P5749, DOI 10.1073/pnas.88.13.5749; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; COHN SM, 1984, P NATL ACAD SCI-BIOL, V81, P4828, DOI 10.1073/pnas.81.15.4828; Friedberg E C, 1980, Methods Enzymol, V65, P191; GEACINTOV NE, 1978, BIOCHEMISTRY-US, V17, P5256, DOI 10.1021/bi00617a027; HARVEY RG, 1981, ACCOUNTS CHEM RES, V14, P218, DOI 10.1021/ar00067a004; HARVEY RG, 1988, ACCOUNTS CHEM RES, V21, P66, DOI 10.1021/ar00146a004; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; MACLEOD MC, 1982, CARCINOGENESIS, V3, P1031, DOI 10.1093/carcin/3.9.1031; MACLEOD MC, 1988, MUTAT RES, V199, P243, DOI 10.1016/0027-5107(88)90252-7; Maniatis T., 1982, MOL CLONING; MELCHIOR W B JR, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P175; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MENICHINI P, 1991, MUTAT RES, V251, P143, DOI 10.1016/0027-5107(91)90224-C; PELKONEN O, 1982, PHARMACOL REV, V34, P189; ROSS J, 1985, ANAL BIOCHEM, V144, P212, DOI 10.1016/0003-2697(85)90108-3; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SCICCHITANO DA, 1990, MUTAT RES, V233, P31, DOI 10.1016/0027-5107(90)90148-W; SEEBERG E, 1983, MUTAT RES, V112, P139, DOI 10.1016/0167-8817(83)90036-6; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1989, J BIOL CHEM, V264, P14455; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; UNDEMAN O, 1983, CANCER RES, V43, P1851; VRIELING H, 1992, MUTAT RES, V274, P147, DOI 10.1016/0921-8777(92)90061-7; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; WASSERMANN K, 1990, J BIOL CHEM, V265, P13906; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; YANG LL, 1982, MUTAT RES, V94, P435, DOI 10.1016/0027-5107(82)90306-2	35	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12749	12754						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175687				2022-12-27	WOS:A1994NH71600059
J	LEE, WS; KANAI, Y; WELLS, RG; HEDIGER, MA				LEE, WS; KANAI, Y; WELLS, RG; HEDIGER, MA			THE HIGH-AFFINITY NA+/GLUCOSE COTRANSPORTER - REEVALUATION OF FUNCTION AND DISTRIBUTION OF EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-GLUCOSE COTRANSPORTER; RABBIT SMALL-INTESTINE; RAT-KIDNEY; ESCHERICHIA-COLI; SUGAR-TRANSPORT; CLONING; CDNA; LOCALIZATION; SIMILARITY; EPITHELIUM	We report the primary structure, functional characterization, and tissue distribution of the high affinity Na+/glucose cotransporter SGLT1 from rat kidney. Rat SGLT1 (665 amino acid residues) is 86-87% identical to SGLT1 from rabbit, pig, and human. High stringency Northern analysis demonstrated that SGLT1 is strongly expressed in small intestine and at lower levels in kidney, liver, and lung. In situ hybridization performed on kidney sections revealed that SGLT1 is predominantly present in S3 segments of the proximal tubule. In small intestine, SGLT1 message was located in cells of the lower two-thirds of intestinal villi. Expression of rat SGLT1 in Xenopus oocytes resulted in a large Na+-dependent uptake of [C-14]-alpha-methyl-D-glucopyranoside (alpha MeGlc). Overall, the transport characteristics were similar to those of rabbit SGLT1. High affinity Na+/glucose cotransport in membrane vesicles was previously shown to be coupled to the cotransport of two Na+ ions (Turner, R. J., and Moran, A. (1982) J. Membr. Biol. 70, 37-45). Previous kinetic analysis of rat and rabbit SGLT1, however, demonstrated between second and first order dependence of sugar uptake on extracellular Na+ concentration, suggesting the existence of Na+-binding sites with different affinities. Here, we directly compared the initial rates of the alpha MeGlc uptake with alpha MeGlc induced inward currents as an indicator of the Na+ flux. This analysis clearly revealed a Na+ to glucose coupling ratio of 2:1. In summary, our data provide important insights into the function and tissue distribution of the high affinity Na+/glucose cotransporter SGLT1 and clarify its role in the reabsorption mechanism of D-glucose in the kidney.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,CTR STUDY KIDNEY DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University				Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043632, R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43171, DK-43632] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARFUSS DW, 1981, AM J PHYSIOL, V240, pF322; BASSET G, 1988, BIOCHIM BIOPHYS ACTA, V942, P11, DOI 10.1016/0005-2736(88)90269-6; BROWN D, 1990, P NATL ACAD SCI USA, V87, P7457, DOI 10.1073/pnas.87.19.7457; BURANT CF, 1994, J CLIN INVEST, V93, P578, DOI 10.1172/JCI117010; CRAMER SC, 1992, DIABETES, V41, P766, DOI 10.2337/diabetes.41.6.766; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HWANG ES, 1991, BIOCHEM BIOPH RES CO, V181, P1208, DOI 10.1016/0006-291X(91)92067-T; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; KINTER WB, 1965, J CELL BIOL, V25, P19, DOI 10.1083/jcb.25.2.19; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; KONG CT, 1993, J BIOL CHEM, V268, P1509; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEE WS, 1993, ENDOCRINOLOGY, V132, P2136, DOI 10.1210/en.132.5.2136; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; SABOLIC I, 1992, AM J PHYSIOL, V262, pF217, DOI 10.1152/ajprenal.1992.262.2.F217; SAUMON G, 1990, BIOCHIM BIOPHYS ACTA, V1023, P313, DOI 10.1016/0005-2736(90)90121-4; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; THORENS B, 1990, AM J PHYSIOL, V259, pC279; THORENS B, 1990, AM J PHYSIOL, V259, pC286; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; TURNER RJ, 1985, ANN NY ACAD SCI, V456, P10, DOI 10.1111/j.1749-6632.1985.tb14839.x; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406, DOI 10.1152/ajprenal.1982.242.4.F406; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	40	232	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12032	12039						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163506				2022-12-27	WOS:A1994NG37700056
J	LIM, BL; WILLIS, AC; REID, KBM; LU, JH; LAURSEN, SB; JENSENIUS, JC; HOLMSKOV, U				LIM, BL; WILLIS, AC; REID, KBM; LU, JH; LAURSEN, SB; JENSENIUS, JC; HOLMSKOV, U			PRIMARY STRUCTURE OF BOVINE COLLECTIN-43 (CL-43) - COMPARISON WITH CONGLUTININ AND LUNG SURFACTANT PROTEIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; MANNOSE-BINDING PROTEIN; APOPROTEIN; LECTINS; LIVER	Collectin-43 (CL-43) is a bovine serum protein that is composed of subunits of three identical chains, each of which contains a collagen region and a C-type carbohydrate recognition domain; thus, CL-43 belongs to the collectins (group III of the C type lectins). We have derived the complete primary sequence of CL-43 using partial protein sequencing, cDNA cloning, and reverse transcription-polymerase chain reaction techniques. The primary sequence of CL-43 shows that it contains an N-terminal region of 28 residues, followed by a collagenous domain of 38 repeats of Gly-Xaa-Yaa and then a C-terminal section of 159 residues, containing a short ''neck'' region and the carbohydrate recognition domain with the conserved residues found in all C-type lectins. The amino acid sequence of CL-43 showed 74% identity to bovine conglutinin and 70% identity to bovine lung surfactant protein D (SP-D), but the collagen region is considerably shorter than the 57 Gly-Xaa-Yaa triplets found in conglutinin and SP-D. Northern blot analysis showed that CL-43 was only synthesized in bovine liver, with no detectable signal in a variety of other bovine tissues, including lung. No cross-hybridizing signals were detected in mRNA from sheep, human, rat, or mouse liver. Since CL-43 and conglutinin have only been detected in members of bovidae, it is probable that an ancestral gene of these two proteins was first derived from a SP-D-like gene, and that this ancestral gene duplicated during evolution.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; AARHUS UNIV,INST MED MICROBIOL,DEPT IMMUNOL,DK-8000 AARHUS,DENMARK	University of Oxford; Aarhus University			Holmskov, Uffe/AAA-3056-2022; Lim, Boon Leong/D-3104-2009	Holmskov, Uffe/0000-0002-2391-9445; Lim, Boon Leong/0000-0002-2720-2353				BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; Bordet J., 1906, ANN I PASTEUR PARIS, V20, P467; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; CROUCH E, 1993, J BIOL CHEM, V268, P2976; DAVIS AE, 1984, BIOCHEMISTRY-US, V23, P2139, DOI 10.1021/bi00305a006; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FRIISCHRISTIANSEN P, 1990, SCAND J IMMUNOL, V31, P453, DOI 10.1111/j.1365-3083.1990.tb02792.x; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; HIRANI S, 1985, J IMMUNOL, V134, P1105; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LACHMANN PJ, 1968, J IMMUNOL, V100, P691; LEE YM, 1991, J BIOL CHEM, V266, P2715; LIM BL, 1993, IMMUNOLOGY, V78, P159; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; LU JH, 1993, BIOCHEM J, V292, P157, DOI 10.1042/bj2920157; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1991, Complement and Inflammation, V8, P188; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; MIYAMURA K, 1994, IN PRESS BIOCH J; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V191, P335, DOI 10.1006/bbrc.1993.1222; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; USHIJIMA H, 1992, JPN J CANCER RES, V83, P58; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WHITE RT, 1985, NATURE, V317, P261	33	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11820	11824						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163480				2022-12-27	WOS:A1994NG37700025
J	KATO, K; HASEGAWA, K; GOTO, S; INAGUMA, Y				KATO, K; HASEGAWA, K; GOTO, S; INAGUMA, Y			DISSOCIATION AS A RESULT OF PHOSPHORYLATION OF AN AGGREGATED FORM OF THE SMALL STRESS PROTEIN, HSP27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TUMOR-NECROSIS-FACTOR; EHRLICH ASCITES TUMOR; ALPHA-B-CRYSTALLIN; RODENT CELLS; OKADAIC ACID; EXPRESSION; IDENTIFICATION; INTERLEUKIN-1; KINASE	We have found that the small stress protein, hsp27, exists in extracts of U251 MG human glioma cells in two forms: a large or aggregated form (L-hsp27, 300-400 kDa) and a small or dissociated form (S-hsp27, <70 kDa), as indicated by centrifugation on sucrose density gradients. Dissociation of L-hsp27 to S-hsp27 was enhanced by incubation of cells with phorbol 12-myristate-13 acetate, interleukin-1alpha, tumor necrosis factor alpha, or okadaic acid, all of which are known to enhance or mimic the effects of phosphorylation of hsp27 without stimulation of its synthesis. Exposure of cells to chemical stressors, namely, NaAsO2 and CdCl2, also enhanced the dissociation of L-hsp27. hsp27 that had been labeled with [P-32]H3PO4 in U251 MG cells was detected mostly in fractions that contained S-hsp27, and the incorporation of radioactivity to S-hsp27 was enhanced under conditions that stimulated the dissociation of L-hsp27. L-hsp27 present in the (NH4)2SO4 fraction (0-50% saturation) of cell extracts were dissociated to P-32-labeled hsp27 when incubated in the presence of [gamma-P-32]ATP and Mg. These results indicate that the molecular configuration of hsp27 in cells is determined in part by phosphorylation and dephosphorylation of this protein by protein kinase(s) and phosphatase(s) and, moreover, that the rapid dissociation of the aggregated form of hsp27 by phosphorylation might be involved in a cellular defense mechanism for protection against stress.			KATO, K (corresponding author), AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN.							ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNDORF R, 1992, BIOCHIM BIOPHYS ACTA, V1136, P203, DOI 10.1016/0167-4889(92)90258-D; BEYSTEAD TAJ, 1989, NATURE, V337, P78; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1992, J BIOL CHEM, V267, P1846; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; KASAHARA K, 1993, EUR J BIOCHEM, V213, P1101, DOI 10.1111/j.1432-1033.1993.tb17859.x; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1992, J BIOL CHEM, V267, P7718; KIM YJ, 1983, J CELL BIOL, V96, P393, DOI 10.1083/jcb.96.2.393; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; ROYAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHOU M, 1993, J BIOL CHEM, V268, P325	28	218	221	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11274	11278						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157658				2022-12-27	WOS:A1994NF96600047
J	WEBER, J; WILKEMOUNTS, S; GRELL, E; SENIOR, AE				WEBER, J; WILKEMOUNTS, S; GRELL, E; SENIOR, AE			TRYPTOPHAN FLUORESCENCE PROVIDES A DIRECT PROBE OF NUCLEOTIDE-BINDING IN THE NONCATALYTIC SITES OF ESCHERICHIA-COLI F(1)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART F1-ATPASE; PROTON ADENOSINE-TRIPHOSPHATASE; BETA-SUBUNIT; CATALYTIC SITES; OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL F1-ATPASE; ADENINE-NUCLEOTIDES; ENERGY-TRANSFER; ATP HYDROLYSIS; MUTANT STRAINS	Tryptophan fluorescence was investigated as a tool to study the noncatalytic nucleotide-binding sites of Escherichia coli F1-ATPase. Site-directed mutagenesis, affinity labeling, and lin-benzo-ATP binding studies had shown that residues alphaR365 and betaY354 are located close to the base moiety of bound nucleotide; here, we mutagenized each to tryptophan. The new tryptophans gave a fluorescence signal indicating an environment of high (alphaW365) or intermediate (betaW354) polarity in unoccupied sites. AlphaW365 fluorescence was completely quenched by binding of ATP or ADP, providing a direct, specific probe of noncatalytic site nucleotide occupancy. Using this signal, we measured binding parameters for ATP and ADP, showed that nucleotide binding was magnesium-dependent, and showed that GTP and ITP did bind to some extent, but AMP, GDP, and EDP did not. It was possible to follow initial rates of MgATP hydrolysis and noncatalytic site binding under identical conditions; the results indicated that occupancy of noncatalytic sites was not required for catalysis. Fluorescence from betaW354 was quenched completely by lin-benzo-ATP, but only slightly by ATP or ADP. Probably, residue beta354 is not as closely juxtaposed to the adenine ring of bound ATP and ADP as is residue alpha365. With either alphaW365 or betaW354 as donor and catalytic site-bound lin-benzo-ADP as acceptor, no fluorescence resonance energy transfer was detected, indicating that the distance between noncatalytic and catalytic sites is greater-than-or-equal-to 27 angstrom.	MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT 70, GERMANY	Max Planck Society	WEBER, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LEONARD NJ, 1978, BIOCHEMISTRY-US, V17, P3677, DOI 10.1021/bi00611a001; LEONARD NJ, 1976, J AM CHEM SOC, V98, P3987, DOI 10.1021/ja00429a040; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; PAGAN J, 1990, FEBS LETT, V273, P147, DOI 10.1016/0014-5793(90)81071-U; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3728; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; RAO R, 1988, J BIOL CHEM, V263, P5569; RAO R, 1988, J BIOL CHEM, V263, P15957; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SMITH RA, 1985, BIOCHEMISTRY-US, V24, P4490, DOI 10.1021/bi00337a034; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; VANDEYAR M, 1988, GENE, V65, P125; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	54	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11261	11268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157656				2022-12-27	WOS:A1994NF96600045
J	BEDOWS, E; NORTON, SE; HUTH, JR; SUGANUMA, N; BOIME, I; RUDDON, RW				BEDOWS, E; NORTON, SE; HUTH, JR; SUGANUMA, N; BOIME, I; RUDDON, RW			MISFOLDED HUMAN CHORIONIC-GONADOTROPIN BETA-SUBUNITS ARE SECRETED FROM TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; PROTEIN-DEGRADATION; HEMAGGLUTININ; FORM; KINETICS; HORMONE; INVITRO; DIMER	There are six intramolecular disulfide (S-S) bonds that form during intracellular folding of the human chorionic gonadotropin (hCG)-beta subunit. Site-directed mutagenesis of every pair of Cys residues involved in the formation of each S-S bond was used to examine the roles that S-S bonds play in beta subunit folding and secretion. Tryptic maps of secreted hCG-beta showed that only one S-S bond formed in all S-S bond mutants that failed to fold from the earliest detectable beta folding intermediate, p beta 1, into a second major intermediate, p beta 2 (C34A-C88A, C38-C57A or C9A-C90A mutants), whereas all 5 remaining S-S bonds formed in mutants when p beta 1 --> p beta 2 conversion occurred (C23A-C72A, C93A-C100A, or C26A-C110A mutants). Nonreducing SDS-polyacrylamide gel electrophoresis showed that beta multimers were secreted from cells expressing S-S bond mutations where the folding of p beta 1 --> p beta 2 was blocked. However, for mutations where p beta 1 --> p beta 2 conversion was efficient, beta monomers rather than multimers were secreted. For all cell lines studied, secreted hCG-beta migrated as monomeric beta during reducing SDS-polyacrylamide gel electrophoresis, indicating that hCG-beta multimers formed via intermolecular cross-linking of unpaired thiols. Tryptic maps of hCG-beta isolated from mutants lacking the 34-88 bond, where >80% turnover occurs, showed that only the 38-57 S-S bond formed. beta Subunits lacking the 9-90 linkage also have only S-S bond 38-57 formed, but <10% turnover of C9A-C90A hcg-beta occurs. Thus, subtle conformational differences between partially folded or misfolded beta subunits may determine whether hCG-beta is degraded, or undergoes intracellular translocation and secretion.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Washington University (WUSTL); Washington University (WUSTL); University of Nebraska System; University of Nebraska Medical Center					FIC NIH HHS [1F05TW-04124] Funding Source: Medline; NCI NIH HHS [CA32949] Funding Source: Medline; NICHD NIH HHS [HD23398] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [F05TW004124] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, J BIOL CHEM, V265, P312; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MCGUIRE MC, 1989, P NATL ACAD SCI USA, V86, P953, DOI 10.1073/pnas.86.3.953; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERS BP, 1984, J BIOL CHEM, V259, P5123; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; YON JM, 1991, BIOL CELL, V71, P17, DOI 10.1016/0248-4900(91)90047-Q; YOUNG J, 1993, J BIOL CHEM, V268, P19810	36	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10574	10580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144645				2022-12-27	WOS:A1994NF01700059
J	FIORELLA, PD; NAPOLI, JL				FIORELLA, PD; NAPOLI, JL			MICROSOMAL RETINOIC ACID METABOLISM - EFFECTS OF CELLULAR RETINOIC ACID-BINDING PROTEIN (TYPE-I) AND C18-HYDROXYLATION AS AN INITIAL STEP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; INVIVO METABOLISM; DIFFERENTIAL EXPRESSION; 13-CIS-RETINOIC ACID; ESCHERICHIA-COLI; RECEPTOR-ALPHA; RAT-LIVER; INVITRO; BETA; IDENTIFICATION	This report extends our observation that cellular retinoic acid-binding protein type I (CRABP) serves as substrate for retinoic acid metabolism by testis microsomes. Retinoic acid bound to excess CRABP was metabolized at 70% of the unbound retinoic acid rate with testis microsomes and at the same rates as unbound retinoic acid with kidney and lung microsomes. Chromatography of testis, lung, kidney, and liver microsomal incubations provided two sets of metabolites each, P1 and P2. The composition of P2 was characteristic of the individual tissue. CRABP had modest quantitative affects on P2 composition, but did not affect P2 qualitatively. Retinoids bound to CRABP, isolated from a testis microsomal incubation, consisted of 50% retinoic acid, 32% P1 and 17% P2, suggesting that CRABP may bind retinoic acid metabolites in vivo. The effect of CRABP on the rate of metabolism was retinoid specific. Two major components of P2, 4-hydroxy-retinoic acid and 4-oxo-retinoic acid, when bound to CRABP were metabolized slowly if at all, by testis microsomes, in contrast to CRABP-bound retinoic acid which had an elimination t(1/2) of 40 min. Unbound retinoic acid, 4-hydroxy-retinoic acid, and 4-oxo-retinoic acid had elimination t(1/2) values of 35, 40, and 9 min, respectively. Reduced metabolism of CRABP-bound C4-derivatized retinoids suggests pathways of retinoic acid metabolism besides the one initiated by C4-hydroxylation, This was corroborated by identification of 18-hydrexy-retinoic acid as a testis, lung, and liver microsomal retinoic acid metabolite. Ketoconazole inhibited the metabolism by testis microsomes of free and CRABP-bound retinoic acid with IC50 values of 2 and 0.7 mu M, respectively, denoting catalysis by cytochrome P-450. These results indicate that cloistering retinoic acid in CRABP, while permitting metabolism, may operate throughout CRABP-expressing tissues as a mechanism of controlling the concentrations of free retinoic acid.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36870] Funding Source: Medline; NIEHS NIH HHS [ES09505] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; COWAN SW, 1993, MOL BIOL, V230, P1225; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; DUNAGIN PE, 1965, SCIENCE, V148, P86, DOI 10.1126/science.148.3666.86; ERIKSSON U, 1987, J CELL PHYSIOL, V133, P482, DOI 10.1002/jcp.1041330308; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FROLIK CA, 1980, J BIOL CHEM, V255, P8057; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; HANNI R, 1977, HELV CHIM ACTA, V60, P881, DOI 10.1002/hlca.19770600317; HANNI R, 1976, HELV CHIM ACTA, V59, P2221, DOI 10.1002/hlca.19760590636; HAQ RU, 1992, J LIPID RES, V33, P381; HARNISH DC, 1990, DIFFERENTIATION, V45, P103, DOI 10.1111/j.1432-0436.1990.tb00463.x; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LI E, 1991, J BIOL CHEM, V266, P3622; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; MARTINI R, 1993, ARCH BIOCHEM BIOPHYS, V303, P57, DOI 10.1006/abbi.1993.1255; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; MCCORMICK AM, 1983, BIOCHEMISTRY-US, V22, P3933, DOI 10.1021/bi00285a032; MORRISSKAY G, 1992, CANCER SURV, V14, P181; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAPOLI JL, 1982, BIOCHEMISTRY-US, V21, P1942, DOI 10.1021/bi00537a038; NAPOLI JL, 1981, BIOCHIM BIOPHYS ACTA, V666, P165, DOI 10.1016/0005-2760(81)90102-8; ONG DE, 1982, J BIOL CHEM, V257, P13385; ONG DE, 1978, J BIOL CHEM, V253, P4551; ONG DE, 1988, J BIOL CHEM, V263, P5789; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SANI BP, 1978, BIOCHEM J, V173, P643, DOI 10.1042/bj1730643; SOPRANO DR, 1993, J NUTR, V123, P367, DOI 10.1093/jn/123.suppl_2.367; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SWART P, 1993, J CLIN ENDOCR METAB, V77, P98, DOI 10.1210/jc.77.1.98; Vanden Bossche H, 1988, Skin Pharmacol, V1, P176; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; WILLIAMS JB, 1987, ANAL BIOCHEM, V160, P267, DOI 10.1016/0003-2697(87)90046-7; WILLIAMS JB, 1987, BIOCHEM PHARMACOL, V36, P1386, DOI 10.1016/0006-2952(87)90102-X; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WINSTON JH, 1989, THESIS SW MED SCH DA; YOST RW, 1988, J BIOL CHEM, V263, P18693; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	55	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10538	10544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144640				2022-12-27	WOS:A1994NF01700054
J	HURME, R; NAMORK, E; NURMIAHOLASSILA, EL; RHEN, M				HURME, R; NAMORK, E; NURMIAHOLASSILA, EL; RHEN, M			INTERMEDIATE FILAMENT-LIKE NETWORK FORMED IN-VITRO BY A BACTERIAL COILED-COIL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE TROPOMYOSIN; TYPHIMURIUM VIRULENCE PLASMID; KERATIN-LIKE PROTEINS; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; DNA-BINDING; EPITHELIAL-CELLS; LEUCINE ZIPPER; CROSS-LINKING; ALPHA	The TlpA protein encoded by the virulence plasmid of Salmonella enterica is an alpha-helical 371-amino acid protein possessing characteristics similar to eukaryotic coiled coil proteins (Koski, P., Saarilahti, H., Sukupolvi, S., Taira, S., Rikkonen, P., Osterlund, K., Hurme, R., and Rhen, M. (1992) J. Biol. Chem. 267, 12258-12265). In this paper we have investigated inter- and intramolecular associations and the morphology of structures formed by TlpA. Dynamics and temperature stability of TlpA dimers were studied by examining the feasibility and conditions in which TlpA would form an artificial heterodimer with its truncated derivative. Formation of heterodimers, bridged by Cu2+-catalyzed air oxidation of adjacent Cys residues, showed that TlpA dimers are dynamic chain exchanging structures at 37 degrees C, whereas they were nonexchanging at room temperature or on ice. Chemical cross-linking suggested higher order interaction between TlpA dimers. Electron microscopy studies revealed two levels of TlpA organization in vitro: thin filaments and rods, 2-5 nm in diameter, and a higher ordered filament network consisting of tonofilament-like formations with a diameter of 8-15 nm. Electron microscopy of thin-sectioned Escherichia coli overproducing TlpA showed an extraordinary intracellular assembly of proteinacious lamellae with a striated appearance and a 38-nm periodicity. This study describes for the first time a bacterial protein capable of organizing itself into an ordered and suspectedly dynamic intermediate filament-like architecture.	NATL INST PUBL HLTH,N-0462 OSLO 4,NORWAY; UNIV HELSINKI,DEPT ELECTRON MICROSCOPY,SF-00014 HELSINKI,FINLAND	University of Helsinki	HURME, R (corresponding author), UNIV HELSINKI,DEPT BIOCHEM,POB 5,UNIONINKATU 35,SF-00014 HELSINKI,FINLAND.							ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMOFONSECA M, 1990, ELECTRON MICROSC REV, V3, P115, DOI 10.1016/0892-0354(90)90017-M; CERIN H, 1989, MICROB PATHOGENESIS, V7, P85, DOI 10.1016/0882-4010(89)90028-4; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COWGILL RW, 1974, BIOCHEMISTRY-US, V13, P2467, DOI 10.1021/bi00709a002; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGEL AM, 1992, EMBO J, V11, P4369, DOI 10.1002/j.1460-2075.1992.tb05537.x; FINLAY BB, 1991, J CELL SCI, V99, P283; FISCHETTI VA, 1991, SCI AM, V264, P32; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Gibson T. J., 1984, THESIS CAMBRIDGE U C; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GOLDMAN AE, 1986, P NATL ACAD SCI USA, V83, P3839, DOI 10.1073/pnas.83.11.3839; GRACEFFA P, 1989, BIOCHEMISTRY-US, V28, P1282, DOI 10.1021/bi00429a050; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KOSKI P, 1992, J BIOL CHEM, V267, P12258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MILLER RK, 1993, J CELL BIOL, V122, P123, DOI 10.1083/jcb.122.1.123; NAMORK E, 1982, ULTRAMICROSCOPY, V7, P321, DOI 10.1016/0304-3991(82)90257-1; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; RHEN M, 1988, FEMS MICROBIOL LETT, V52, P145; RHEN M, 1986, J BACTERIOL, V168, P1234, DOI 10.1128/jb.168.3.1234-1242.1986; RHEN M, 1992, VIRULENCE FACTORS SA, P103; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS C, 1986, J BIOL CHEM, V261, P2774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; THOMAS CM, 1990, GENE, V89, P29, DOI 10.1016/0378-1119(90)90202-3; TINGE SA, 1990, J BACTERIOL, V172, P5266, DOI 10.1128/jb.172.9.5266-5277.1990; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZACKROFF RV, 1984, J CELL BIOL, V98, P1231, DOI 10.1083/jcb.98.4.1231	72	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10675	10682						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144657				2022-12-27	WOS:A1994NF01700073
J	LUO, XN; MOOKERJEE, B; FERRARI, A; MISTRY, S; ATWEH, GF				LUO, XN; MOOKERJEE, B; FERRARI, A; MISTRY, S; ATWEH, GF			REGULATION OF PHOSPHOPROTEIN P18 IN LEUKEMIC-CELLS - CELL-CYCLE-REGULATED PHOSPHORYLATION BY P34(CDC2) KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; LYMPHOCYTES-T; EXPRESSION; CDC2; GENE; STATHMIN; ELECTROPHORESIS; IDENTIFICATION; PURIFICATION; CONSERVATION	p18 is a phosphoprotein that is expressed at very high levels in leukemic cells, at moderately high levels in proliferating normal lymphocytes, and at low levels in quiescent lymphocytes. Induction of terminal differentiation of leukemic cells in culture results in a decrease in cellular proliferation. These phenotypic changes are associated with rapid phosphorylation of p18, followed by a more gradual decrease in the level of its mRNA expression. More than 12 different phosphorylation products of p18 have been identified in different cells by high resolution two-dimensional polyacrylamide gel electrophoresis. Previous studies have suggested that p18 may be a substrate for protein kinase C in some cellular processes and protein kinase A in others. In this report, we show that the phosphorylation of p18 increases as cells progress toward the G2-M phases of the cell cycle in proliferating leukemic cells. We have examined the hypothesis that the putative role of p18 in cellular proliferation may be mediated by its involvement in the p34(cdc2) kinase signal transduction pathway. We have produced recombinant p18 in bacterial cells and shown that it can be phosphorylated in vitro by purified p34(cdc2) kinase with a stoichiometry of 0.86 mol of PO4/mol of substrate. We have used site-directed mutagenesis to demonstrate that the site of p34(cdc2) phosphorylation is the serine at position 38. This same site has previously been shown to be phosphorylated in vivo in bovine brain along with another serine at position 25. The observation that p18 gets phosphorylated in the G2-M phases of the cell cycle and the demonstration that p18 is phosphorylated efficiently by p34(cdc2) kinase in vitro at a residue that is also phosphorylated in vivo support the hypothesis that p18 may be a physiologic substrate for p34(cdc2) kinase in vivo. We have also examined the effect of inhibiting the expression of p18 on cell cycle progression. These experiments demonstrated that antisense inhibition of the expression of p18 in K562 erythroleukemia cells is associated with a decrease in cellular proliferation and accumulation of cells in the G2-M phases of the cycle. The implications of these findings to the proposed role of p18 in the regulation of cellular proliferation are discussed.	MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNDTJOVIN DJ, 1977, J HISTOCHEM CYTOCHEM, V25, P585, DOI 10.1177/25.7.70450; ATWEH GF, 1988, MOL CELL BIOL, V8, P5047, DOI 10.1128/MCB.8.11.5047; BRICKNER HE, 1991, J BIOL CHEM, V266, P15363; COOPER HL, 1989, J IMMUNOL, V143, P956; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DOYE V, 1989, J BIOL CHEM, V264, P12134; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GHOSH PK, 1993, ONCOGENE, V8, P2869; GOBINDA S, 1990, BIOTECHNIQUES, V8, P404; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LOKEN MR, 1980, CYTOMETRY, V1, P136, DOI 10.1002/cyto.990010208; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO XN, 1991, J BIOL CHEM, V266, P21004; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; TOUTANT M, 1987, DEV BIOL, V124, P370, DOI 10.1016/0012-1606(87)90489-1; Vindelov L, 1990, Methods Cell Biol, V33, P127; WANG YK, 1993, J BIOL CHEM, V268, P14269; ZHU XX, 1989, J BIOL CHEM, V264, P14556	38	104	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10312	10318						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144611				2022-12-27	WOS:A1994NF01700023
J	SCHRODER, B; REINHARDTMAELICKE, S; SCHRATTENHOLZ, A; MCLANE, KE; KRETSCHMER, A; CONTITRONCONI, BM; MAELICKE, A				SCHRODER, B; REINHARDTMAELICKE, S; SCHRATTENHOLZ, A; MCLANE, KE; KRETSCHMER, A; CONTITRONCONI, BM; MAELICKE, A			MONOCLONAL-ANTIBODIES FK1 AND WF6 DEFINE 2 NEIGHBORING LIGAND-BINDING SITES ON TORPEDO ACETYLCHOLINE-RECEPTOR ALPHA-POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; H-3 CHLORPROMAZINE; AMINO-ACIDS; SYNTHETIC PEPTIDES; DELTA-SUBUNIT; NONCOMPETITIVE BLOCKERS; MOLECULAR-BIOLOGY; SOLID-PHASE; ION CHANNEL; BUNGAROTOXIN	Previous studies have identified the sequence region flanking the invariant vicinal cysteinyl residues at positions 192 and 193 of the nicotinic acetylcholine receptor alpha-subunit as containing major elements of the binding site for acetylcholine and its agonists and antagonists, including antibody WF6 (Conti-Tronconi, B. M., Diethelm, B. M., Wu, X., Tang, F., Bertazzon, T., Schroder, B., Reinhardt-Maelicke, A., and Maelicke, A (1991) Biochemistry 30, 2575-2584). Recently we have shown that the sequence region flanking lysine alpha 125 contains elements of the binding site for physostigmine and related ligands, including antibody FK1 (Schrattenholz, A., Godovac-Zimmerman, J., Schafer, H.-J., Albuquerque, E. X, and Maelicke, A. (1993) Eur. J. Biochem. 216, 671-677). Here we report the identification by enzyme-linked immunosorbent assay techniques, employing fragments of the Torpedo nicotinic acetylcholine receptor alpha-subunit N-terminal region and a panel of synthetic peptides matching in sequence preselected portions of this subunit, of the sequence regions alpha 118-145 and alpha 181-216 as contributing to the FK1 epitope. Of the synthetic peptides employed, alpha 118-137 displayed the highest affinity of FK1 binding. Binding of FK1 and WF6 to single residue-substituted analogs of the sequence alpha 181-200 indicated that the two antibodies have different attachment point patterns within this sequence region. These results, and those of ligand competition studies, suggest that the binding sites for FK1 and physostigmine, and those of WF6 and acetylcholine, are within the same general region of the receptor's three-dimensional structure. The sites neighbor each other, with limited overlap in the case of occupation by high molecular weight ligands.	UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108; BAYER AG,ZENT FORSCH,D-51375 LEVERKUSEN,GERMANY	University of Minnesota System; University of Minnesota Twin Cities; Bayer AG	SCHRODER, B (corresponding author), UNIV MAINZ,SCH MED,INST PHYSIOL CHEM & PATHOBIOCHEM,MOLEC NEUROBIOL LAB,DUESBERGWEG 6,D-55099 MAINZ,GERMANY.				NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695] Funding Source: NIH RePORTER; NIDA NIH HHS [5P01-DA05695] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ARONHEIM A, 1988, J BIOL CHEM, V263, P9933; BARNARD EA, 1990, TRENDS PHARMACOL SCI, V11, P500, DOI 10.1016/0165-6147(90)90051-9; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; Catty D., 1989, ANTIBODIES PRACTICAL, VII, P97; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; CONTITRONCONI BM, 1982, SCIENCE, V218, P1277; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DENNIS M, 1986, FEBS LETT, V207, P2443; DUGUID JR, 1980, P NATL ACAD SCI USA, V77, P4509; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8608, DOI 10.1021/bi00084a031; FELS G, 1986, J BIOL CHEM, V261, P5746; FRIGUET B, 1983, J IMMUNOL METHODS, V60, P351, DOI 10.1016/0022-1759(83)90292-2; GALZI JL, 1990, J BIOL CHEM, V265, P1043; GERSHONI JM, 1987, P NATL ACAD SCI USA, V84, P4318, DOI 10.1073/pnas.84.12.4318; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x; GUAN C, 1987, GENE, V67, P21; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; KAO PN, 1984, J BIOL CHEM, V259, P1662; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGENBUCHCACHAT J, 1988, BIOCHEMISTRY-US, V27, P2337, DOI 10.1021/bi00407a015; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; MAELICKE A, 1993, ANN NY ACAD SCI, V681, P140, DOI 10.1111/j.1749-6632.1993.tb22880.x; MAELICKE A, 1992, RECEPTOR SUBUNITS CO, P119; MAELICKE A, 1989, NATO ASI SERR H, V32, P221; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCLANE KE, 1992, J RECEPTOR RES, V12, P299, DOI 10.3109/10799899209074798; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; OBERTHUR W, 1988, J PROTEIN CHEM, V7, P141, DOI 10.1007/BF01025243; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; OHANA B, 1990, BIOCHEMISTRY-US, V29, P6409, DOI 10.1021/bi00479a011; OHANA B, 1991, BIOCHEM BIOPH RES CO, V179, P648, DOI 10.1016/0006-291X(91)91421-8; OKONJO KO, 1991, EUR J BIOCHEM, V200, P671, DOI 10.1111/j.1432-1033.1991.tb16231.x; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PEREIRA EFR, 1993, J PHARMACOL EXP THER, V265, P1474; PEREIRA EFR, 1993, J RECEPTOR RES, V13, P413, DOI 10.3109/10799899309073670; PLUMER R, 1984, FEBS LETT, V178, P204, DOI 10.1016/0014-5793(84)80601-8; RALSTON S, 1987, BIOCHEMISTRY-US, V26, P3261, DOI 10.1021/bi00386a004; REINHARDT S, 1984, FEBS LETT, V173, P217, DOI 10.1016/0014-5793(84)81050-9; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SCHRATTENHOLZ A, 1993, J RECEPTOR RES, V13, P393, DOI 10.3109/10799899309073669; SCHRATTENHOLZ A, 1993, EUR J BIOCHEM, V216, P671, DOI 10.1111/j.1432-1033.1993.tb18187.x; SHAW KP, 1985, MOL PHARMACOL, V28, P527; SMART L, 1984, FEBS LETT, V178, P64, DOI 10.1016/0014-5793(84)81241-7; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1981, NATURE, V292, P862, DOI 10.1038/292862a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; WAHLSTEN JL, 1993, J RECEPTOR RES, V13, P989, DOI 10.3109/10799899309073705; WATTERS D, 1983, BIOCHEMISTRY-US, V22, P1811, DOI 10.1021/bi00277a011; WHITING P, 1991, MOL PHARMACOL, V40, P463; WILSON PT, 1988, BIOCHEMISTRY-US, V27, P6667, DOI 10.1021/bi00418a004	62	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10407	10416						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144624				2022-12-27	WOS:A1994NF01700036
J	RAYMOND, JR; ARTHUR, JM; CASANAS, SJ; OLSEN, CL; GETTYS, TW; MORTENSEN, RM				RAYMOND, JR; ARTHUR, JM; CASANAS, SJ; OLSEN, CL; GETTYS, TW; MORTENSEN, RM			ALPHA(2A) ADRENERGIC-RECEPTORS INHIBIT CAMP ACCUMULATION IN EMBRYONIC STEM-CELLS WHICH LACK G(I-ALPHA-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-AMP ACCUMULATION; DISTINCT G-PROTEINS; ADENYLATE-CYCLASE; SUBTYPES; GI2; ACTIVATION; MUTANT; PHOSPHOLIPASE-A2; DIFFERENTIATION; IDENTIFICATION	alpha(2A) adrenergic receptors are thought to inhibit adenylyl cyclase primarily through G(i alpha 2). We tested the requirement for G(i alpha 2) to inhibit cAMP accumulation by stable expression of alpha(2A) adrenergic receptors in mouse embryonic stem cells. Host lines consisted of wild-type CCE cells, and CCE cells with targeted disruption of the G(i alpha 2) gene by two-stage homologous recombination (Mortensen, R. M., Zubiuar, M., Neer, E. J., and Seidman, J. G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7036-7040; Mortensen, R. M., Conner, D. A., Chao, S., Geisterfer-Lowrance, A. A., and Seidman, J. G. (1992) Mol. Cell. Biol. 12, 2391-2395). Knockouts were confirmed by Northern blot and immunoblot. We studied three clones derived from wild-type CCE cells (2, 6, and 8) expressing 450 +/- 50, 3000 +/- 120, and 150 +/- 20 fmol of receptor/mg of protein, respectively, and two G(i alpha 2)-null clones (7 and 18) expressing 2100 +/- 250 and 300 +/- 40 fmol of receptor/mg of protein. The specific agonist UK14304 caused an inhibition of cAMP accumulation in clones 2,6 and 8 (58 +/- 16%, 62 +/- 7%, and 52 +/- 12%) and in clones 7 (47 +/- 3%) and 18 (40 +/- 5%), but not in nontransfected CCE cells. IC50 values were similar for all clones (approximate to 200 nM). The effect was attenuated by pertussis toxin and the antagonist rauwolscine. These studies show that expression of G(i alpha 2) is not required for alpha(2A) adrenergic receptors to inhibit cAMP accumulation.	VET AFFAIRS MED CTR, DEPT MED, DURHAM, NC 27710 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; BRIGHAM & WOMENS HOSP, DIV ENDOCRINOL & HYPERTENS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical University of South Carolina; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	RAYMOND, JR (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3459, DURHAM, NC 27710 USA.		Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Arthur, John/0000-0003-4342-4762	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42486] Funding Source: Medline; NIGMS NIH HHS [GM49122] Funding Source: Medline; NINDS NIH HHS [NS30927] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUZIC E, 1992, J BIOL CHEM, V267, P9844; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GOETZL EJ, 1994, J BIOL CHEM, V269, P809; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LAW SF, 1993, J BIOL CHEM, V268, P10721; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; POBINER BF, 1991, MOL PHARMACOL, V40, P157; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SUKI WN, 1987, FEBS LETT, V220, P187, DOI 10.1016/0014-5793(87)80900-6; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; THOMAS R, 1991, METHOD ENZYMOL, V195, P280; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	40	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13073	13075						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175730				2022-12-27	WOS:A1994NK18400005
J	GAO, WY; AGBARIA, R; DRISCOLL, JS; MITSUYA, H				GAO, WY; AGBARIA, R; DRISCOLL, JS; MITSUYA, H			DIVERGENT ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITY AND ANABOLIC PHOSPHORYLATION OF 2',3'-DIDEOXYNUCLEOSIDE ANALOGS IN RESTING AND ACTIVATED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDINE KINASE-1; REVERSE-TRANSCRIPTASE; REPLICATION; TYPE-1; DNA; (-)-2'-DEOXY-3'-THIACYTIDINE; 3'-AZIDO-3'-DEOXYTHYMIDINE; 2',3'-DIDEOXYADENOSINE; 2',3'-DIDEOXYINOSINE; DIDEOXYNUCLEOSIDES	The mechanism of divergent anti-human immunodeficiency virus type I (HIV-I) activity of various 2',3'-dideoxynucleoside analogs (ddNs) in peripheral blood mononuclear cells (PBM) was studied. We demonstrate that the in vitro anti-EW-l activity of various ddNs varies profoundly and that the divergent antiviral activity is related to the extent of anabolic phosphorylation of each ddN and its counterpart 2' deoxynucleoside (dN). We also show that certain ddNs cause a reduction of their counterpart dNTP formation in PBM in the following order: 2',3'-dideoxycytidine (ddC) >> 2',3'-didehydro-2',3'-dideoxythymidine (d4T), 3'-thia-2',3'-dideoxycytidine (3TC), 2'3'-dideoxyinosine (ddI), 2',3'-dideoxyguanosine (ddG) > 3'-azido-2',3'-dideoxythymidine (AZT) > 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ara-ddA). Based on the phosphorylation profiles, anti-HIV-1 ddNs can be classified into two groups: (i) cell-activation-dependent ddNs such as AZT and d4T that are preferentially phosphorylated, yield higher ratios of ddNTP/dNTP, and exert more potent anti-HIV-1 activity in activated cells than in resting cells; and (ii) cell-activation-independent ddNs including ddI (and 2',3'-dideoxyadenosine), F-ara-ddA, ddG, ddC, and 3TC that produce higher ratios of ddNTP/dNTP and exert more potent anti-HIV-1 activity in resting cells. These data should provide a basis for the elucidation of the mechanism of the divergent antiretroviral activity of ddNs.	NCI,MED BRANCH,EXPTL RETROVIROL SECT,BETHESDA,MD 20892; NCI,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHANG CN, 1992, J BIOL CHEM, V267, P22414; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HARTMAN NR, 1991, MOL PHARMACOL, V40, P118; JACKSON RC, 1989, INHIBITORS RIBONUCLE, P127; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163; MARQUEZ VE, 1987, BIOCHEM PHARMACOL, V36, P2719, DOI 10.1016/0006-2952(87)90254-1; MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015; MASOOD R, 1990, MOL PHARMACOL, V37, P590; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933; RUXRUNGTHAM K, 1993, 9 INT AIDS C BERL; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; STARNES MC, 1987, J BIOL CHEM, V262, P988; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; YARCHOAN R, 1991, BLOOD, V78, P859; YARCHOAN R, 1993, J INFECT DIS, V168, P810; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	31	217	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12633	12638						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175673				2022-12-27	WOS:A1994NH71600043
J	JIMENEZ, SA; VARGA, J; OLSEN, A; LI, LY; DIAZ, A; HERHAL, J; KOCH, J				JIMENEZ, SA; VARGA, J; OLSEN, A; LI, LY; DIAZ, A; HERHAL, J; KOCH, J			FUNCTIONAL-ANALYSIS OF HUMAN ALPHA-1(I) PROCOLLAGEN GENE PROMOTER - DIFFERENTIAL ACTIVITY IN COLLAGEN-PRODUCING AND COLLAGEN-NONPRODUCING CELLS AND RESPONSE TO TRANSFORMING GROWTH-FACTOR BETA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; NUCLEAR FACTOR-I; CHICK-EMBRYO FIBROBLASTS; PROGRESSIVE SYSTEMIC-SCLEROSIS; 1ST INTRON CONTRIBUTE; ROUS-SARCOMA VIRUS; DNA-BINDING FACTOR; TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; EXTRACELLULAR-MATRIX	To gain a further understanding of the regulation of human type I collagen gene expression under physiologic and pathologic conditions, we characterized 5.3 kilobase pairs (kb) of the human alpha 1(I) procollagen gene promoter. A series of deletion constructs containing portions of the alpha 1(I) procollagen 5'-flanking region (with end points from -5.3 kb to -84 base pairs (bp)) ligated to the chloramphenicol acetyltransferase (CAT) reporter gene were transiently transfected into NIH/3T3 cells. Maximal CAT activity was observed with constructs having 5' end points from -804 to -174 bp. A further 5' deletion to -84 bp caused a marked reduction in CAT activity. Cells transfected with plasmids containing longer 5'-flanking fragments of the al(I) procollagen gene (-2.3 or -5.3 kb) showed reduced CAT activity compared with the -804 bp construct. The activity of the al(I) procollagen promoter was much lower in cells that do not normally express type I collagen (HeLa cells) compared with collagen-producing NIH/3T3 cells. The CAT activity of deletion constructs containing longer 5' regions than -84 bp was increased by approximate to 2-fold in NIH/3T3 cells treated with transforming growth factor beta 1 (TGF beta 1). Electrophoretic mobility shift assays indicated that protein-DNA complex formation with a probe corresponding to the -170 to -80 bp fragment of the alpha 1(I) procollagen promoter was markedly enhanced in nuclear extracts prepared from TGF beta 1 treated fibroblasts as compared with untreated fibroblasts. The DNA binding activity stimulated by TGF beta 1 was specific for an Spl-like sequence at positions -164 to -142 bp in the promoter. These results demonstrate that 1) there are both positive and negative cis-acting regulatory elements in the human al(I) procollagen promoter, 2) these regulatory regions function differently in collagen-producing and -nonproducing cells, 3) the alpha 1(I) procollagen promoter contains TGF beta 1-responsive sequences located between -174 and -84 bp from the transcription start site, and 4) TGF beta 1 caused marked stimulation of the DNA binding activity of a nuclear factor interacting with an Sp1-like binding site located within a region encompassing -164 to -142 bp of the alpha 1(I) procollagen promoter.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,INST MOLEC MED,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University	JIMENEZ, SA (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,RM 509,BLUEMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.			Jimenez, Sergio/0000-0001-5213-1203	NIADDK NIH HHS [AM 19106] Funding Source: Medline; NIAMS NIH HHS [AR 42309] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BORUNDAARMENDAR.J, 1990, FASEB J, V4, P215; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CACERES J, 1990, ONCOGENE, V5, P59; CHOJKIER M, 1988, HEPATOLOGY, V8, P808, DOI 10.1002/hep.1840080419; CHU ML, 1985, J BIOL CHEM, V260, P2315; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DEWET W, 1987, J BIOL CHEM, V262, P16032; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; HATA RI, 1977, P NATL ACAD SCI USA, V74, P2933, DOI 10.1073/pnas.74.7.2933; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JIMENEZ SA, 1986, J BIOL CHEM, V261, P657; JIMENEZ SA, 1986, BIOCHEM J, V237, P837, DOI 10.1042/bj2370837; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; Liska Deann J., 1992, Gene Expression, V2, P379; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERLINO GT, 1983, J BIOL CHEM, V258, P41; MOEN RC, 1979, J BIOL CHEM, V254, P3526; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NEHLS MC, 1991, BIOCHEM BIOPH RES CO, V177, P538; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; OHTA A, 1987, ARTHRITIS RHEUM, V30, P404, DOI 10.1002/art.1780300407; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PETERKOFSKY B, 1986, J BIOL CHEM, V261, P6818; PIERCE RA, 1987, J BIOL CHEM, V262, P1652; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAGHOW R, 1989, J CLIN INVEST, V84, P1836, DOI 10.1172/JCI114369; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J, 1989, MOL CLONING LABORATO; SANDMEYER S, 1979, J BIOL CHEM, V254, P4950; SANDMEYER S, 1981, CANCER RES, V41, P830; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT A, 1984, J BIOL CHEM, V259, P7411; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TOLSTOSHEV P, 1981, J BIOL CHEM, V256, P9672; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X	67	151	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12684	12691						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175678				2022-12-27	WOS:A1994NH71600050
J	SU, XL; CHEN, FL; HOKIN, LE				SU, XL; CHEN, FL; HOKIN, LE			CLONING AND EXPRESSION OF A NOVEL, HIGHLY TRUNCATED PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C CDNA FROM EMBRYOS OF THE BRINE SHRIMP, ARTEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCE; ISOZYMES; BRAIN	A novel, highly truncated form of a cDNA encoding Artemia phosphoinositide-specific phospholipase C (PLC), designated PLC-beta(x), was isolated from a brine shrimp cDNA library. The full-length cDNA is of the beta-type, it is 2855 base pairs long, and it contains an open reading frame encoding 489 amino acids. The deduced amino acid sequence of PLC-beta(x) cDNA shows novel features. It lacks several hundred amino acids at the 5' end, as compared to PLC-beta s in the higher species. It contains conserved domains X and Y, but domain X is highly truncated at the 5' end (only 14-25 conserved amino acids as compared to about 150 amino acids in the higher eukaryotic organisms). Northern blot hybridization showed that the PLC-beta(x) cDNA corresponds to a 4.4-kilobase mRNA. Northern blot hybridization with a cDNA probe from the 5' end and PCR performed upstream from domain Y showed that PLC-beta(x) is not a cloning artifact due to fusion of an unrelated clone into the coding region of the PLC-beta homologue. A functional PLC and new protein bands on SDS-PAGE were observed after subcloning full-length PLC-beta(x) cDNA, as well as a fragment containing the conserved regions, into expression plasmid vectors and transfecting into Escherichia coli. 1 mM lithium markedly stimulated expression in E. coli.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL16318] Funding Source: Medline; NIGMS NIH HHS [GM33850] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033850] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P491; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; GERFEN CR, 1988, P NATL ACAD SCI USA, V85, P3208, DOI 10.1073/pnas.85.9.3208; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P1083; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MICHELL RH, 1982, CELL CALCIUM, V3, P429, DOI 10.1016/0143-4160(82)90028-8; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X	26	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12925	12931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175710				2022-12-27	WOS:A1994NH71600084
J	TOGEL, M; MOSSIER, B; FUCHS, K; SIEGHART, W				TOGEL, M; MOSSIER, B; FUCHS, K; SIEGHART, W			GAMMA-AMINOBUTYRIC ACID(A) RECEPTORS DISPLAYING ASSOCIATION OF GAMMA(3)-SUBUNITS WITH BETA(2/3) AND DIFFERENT ALPHA-SUBUNITS EXHIBIT UNIQUE PHARMACOLOGICAL PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BENZODIAZEPINE RECEPTOR; RAT-BRAIN; GABA(A) RECEPTORS; MESSENGER-RNAS; ALPHA-1-SUBUNIT; ANTAGONIST; AGONIST	Two polyclonal antibodies were raised against the gamma(3)-subunit of gamma-aminobutyric acid(A) (GABA(A)) receptors. These antibodies were able to precipitate GABA(A) receptors from brain membrane extracts, and the precipitated receptors exhibited benzodiazepine binding properties that were dramatically different from those of receptors precipitated by anti-gamma(2) antibodies. The anti-gamma(3) antibodies were used for immunopurification of GABA(A) receptors containing gamma(3)-subunits. Western blot analysis of the immunopurified GABA(A) receptors indicated that the gamma(3)-subunit exhibits an apparent molecular mass of 43-46 kDa. Furthermore, in addition to gamma(3)-subunits, beta(2/3)-, alpha(1)-, alpha(2)-, alpha(3)-, alpha(4)-, and alpha(6)-subunits could be detected in immunoaffinity column eluates from total brain and cerebellum, respectively. These data indicate that gamma(3)-subunits can combine with most alpha-subunits to form a multiplicity of GABA(A) receptors with distinct pharmacology.	UNIV VIENNA,PSYCHIAT CLIN,DEPT BIOCHEM PSYCHIAT,A-1090 VIENNA,AUSTRIA	University of Vienna			Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				BENKE D, 1991, J BIOL CHEM, V266, P4478; BUCHSTALLER A, 1991, NEUROSCI LETT, V129, P237, DOI 10.1016/0304-3940(91)90470-E; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DREXLER G, 1986, J IMMUNOL METHODS, V95, P117, DOI 10.1016/0022-1759(86)90325-X; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FUCHS K, 1989, NEUROSCI LETT, V97, P329, DOI 10.1016/0304-3940(89)90619-8; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KERN W, 1994, J NEUROCHEM, V62, P764; KHAN ZU, 1993, J NEUROCHEM, V60, P961, DOI 10.1111/j.1471-4159.1993.tb03243.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MOHLER H, 1981, NATURE, V294, P763, DOI 10.1038/294763a0; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SIEGHART W, 1993, J NEUROCHEM, V60, P93, DOI 10.1111/j.1471-4159.1993.tb05826.x; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SIEGHART W, 1992, CELL SIGNAL, V4, P231, DOI 10.1016/0898-6568(92)90062-D; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISDEN W, 1992, J NEUROSCI, V12, P1040; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	26	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12993	12998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175718				2022-12-27	WOS:A1994NH71600094
J	RISTIMAKI, A; GARFINKEL, S; WESSENDORF, J; MACIAG, T; HLA, T				RISTIMAKI, A; GARFINKEL, S; WESSENDORF, J; MACIAG, T; HLA, T			INDUCTION OF CYCLOOXYGENASE-2 BY INTERLEUKIN-1-ALPHA - EVIDENCE FOR POSTTRANSCRIPTIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; II PHOSPHOLIPASE-A2; COMPLEMENTARY-DNA; ENDOTHELIAL-CELLS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; G/H SYNTHASE; CDNA CLONING; H SYNTHASE	Prostanoids, produced by diverse cell types, modulate a variety of pathophysiological processes. The rate of prostanoid synthesis is determined, in part, by the levels of prostanoid-synthetic enzymes, such as cyclooxygenase (Cox), a rate-limiting enzyme in the conversion of arachidonic acid to prostanoids. While two Cox genes have been identified, Cox-2 is unique because it is highly induced in response to cell activation processes including inflammation. We have studied the effect of interleukin-1 alpha (IL-1 alpha), a proinflammatory cytokine that facilitates its actions in part by inducing the synthesis of prostanoids, on the expression of Cox-2 in a human cell line (ECV304) and demonstrated that IL-1 alpha induces a sustained increase in the expression of the Cox-2 mRNA as well as the functional enzyme. Three mechanistically distinct inhibitors of translation stimulated the expression of the Cox-2 mRNA and potentiated the effect of IL-1 alpha. Furthermore, IL-1 alpha induced rapid but transient activation of Cox-2 transcription and, in the absence of transcription, prolonged the half-life of the Cox-2 mRNA Together, these data suggest that post-transcriptional mechanisms are important in the sustained induction of the Cox-2 mRNA and that IL-1 alpha may increase the stability of the Cox-2 transcript.	AMER RED CROSS, DEPT MOLEC BIOL, HOLLAND LAB, ROCKVILLE, MD 20855 USA	American Red Cross			Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	FIC NIH HHS [FO5 TWO4963] Funding Source: Medline; NHLBI NIH HHS [HL49094, HL35627] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004963] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL049094] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; APPLEBY SB, 1994, IN PRESS BIOCH J; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HLA T, 1993, ANN NY ACAD SCI, V696, P197; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; JONES DA, 1993, J BIOL CHEM, V268, P9049; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN LL, 1992, J BIOL CHEM, V267, P23451; LYONSGIORDANO B, 1993, EXP CELL RES, V206, P58, DOI 10.1006/excr.1993.1120; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OKA S, 1991, J BIOL CHEM, V266, P9956; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; RISTIMAKI A, 1992, PROSTAG LEUKOTR ESS, V47, P93, DOI 10.1016/0952-3278(92)90143-7; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P43; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; XIE W, 1991, P NATL ACAD SCI USA, V88, P2892; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	49	431	436	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11769	11775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163473				2022-12-27	WOS:A1994NG37700017
J	COVER, TL; TUMMURU, MKR; CAO, P; THOMPSON, SA; BLASER, MJ				COVER, TL; TUMMURU, MKR; CAO, P; THOMPSON, SA; BLASER, MJ			DIVERGENCE OF GENETIC SEQUENCES FOR THE VACUOLATING CYTOTOXIN AMONG HELICOBACTER-PYLORI STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARCESCENS SERINE PROTEASE; TRANSFER RNA-SYNTHETASE; OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; RICKETTSIA-RICKETTSII; CAMPYLOBACTER-PYLORI; IGA PROTEASE; PRECURSOR; UREASE; TOXIN	Approximately 50% of Helicobacter pylori isolates produce a cytotoxin in vitro that induces vacuolation of eukaryotic cells. Screening a lambda ZapII library of H. pylori 60190 chromosomal fragments permitted the identification of a 3864-base pair (bp) open reading frame (vacA) that encoded the vacuolating cytotoxin, and a greater than or equal to 567-bp upstream gene that was homologous to Escherichia coli cysteinyl-tRNA synthetase. The sequence data suggest that a 33-amino-acid leader sequence and a C-terminal peptide are cleaved from a 139-kDa protoxin to yield the mature 87-kDa cytotoxin. The vacA gene product contains a C-terminal motif that is present in several other bacterial proteins that undergo C-terminal cleavage, including IgA proteases of Haemophilus influenzae and Neisseria gonorrhoeae. Isogenic H. pylori mutants with insertional mutation of the vacA gene lacked vacuolating cytotoxin activity and failed to produce the 87-kDa protein. Southern analysis of naturally occurring tox(-) H. pylori strains with vacA probes indicated the presence of hybridizing bands, but both Southern analysis and polymerase chain reaction studies suggested that the vacA sequences of tox(-) strains differed from those of tox(+) strains. Sequence analysis of a 1541-bp region of polymerase chain reaction-amplified vacA from tox(-) strain 87-203 indicated 64.8% amino acid identity with the corresponding region from tox(+) strain 60190. Thus, sequence divergence in vacA genes may explain the lack of functionally active cytotoxin production by some H. pylori isolates.	VANDERBILT UNIV, SCH MED, DEPT MICROBIOL, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	COVER, TL (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MED, DIV INFECT DIS, MED CTR N A3310, NASHVILLE, TN 37232 USA.		Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X; Thompson, Stuart/0000-0002-0457-6926	NCI NIH HHS [R01 CA58834] Funding Source: Medline; NIDDK NIH HHS [R29 DK45293-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045293] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; AVALOS J, 1991, FEBS LETT, V286, P176, DOI 10.1016/0014-5793(91)80968-9; BENZ I, 1992, MOL MICROBIOL, V6, P1539, DOI 10.1111/j.1365-2958.1992.tb00875.x; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; CARL M, 1990, P NATL ACAD SCI USA, V87, P8237, DOI 10.1073/pnas.87.21.8237; CORREA P, 1992, CANCER RES, V52, P6735; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; COVER TL, 1993, INFECT IMMUN, V61, P5008, DOI 10.1128/IAI.61.12.5008-5012.1993; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FOXALL PA, 1992, J CLIN MICROBIOL, V30, P739, DOI 10.1128/JCM.30.3.739-741.1992; GILMORE RD, 1989, MOL MICROBIOL, V3, P1579, DOI 10.1111/j.1365-2958.1989.tb00143.x; GILMORE RD, 1991, MOL MICROBIOL, V5, P2361, DOI 10.1111/j.1365-2958.1991.tb02082.x; GOOSSENS H, 1992, MED MICROBIOL LETT, V1, P153; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Maniatis T, 1989, MOL CLONING; MIYAZAKI H, 1989, J BACTERIOL, V171, P6566, DOI 10.1128/jb.171.12.6566-6572.1989; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; POLLOCK MR, 1962, NATURE, V194, P446, DOI 10.1038/194446a0; POULSEN K, 1989, INFECT IMMUN, V57, P3097, DOI 10.1128/IAI.57.10.3097-3105.1989; SANGER F, 1977, P NATL ACAD SCI USA, V71, P1342; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SHIKATA S, 1992, J BIOCHEM-TOKYO, V111, P627, DOI 10.1093/oxfordjournals.jbchem.a123809; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; SUERBAUM S, 1993, J BACTERIOL, V175, P3278, DOI 10.1128/jb.175.11.3278-3288.1993; TEE W, 1993, GASTROENTEROLOGY, V104, pA789; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986	40	429	456	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10566	10573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144644				2022-12-27	WOS:A1994NF01700058
J	DOLCE, V; IACOBAZZI, V; PALMIERI, F; WALKER, JE				DOLCE, V; IACOBAZZI, V; PALMIERI, F; WALKER, JE			THE SEQUENCES OF HUMAN AND BOVINE GENES OF THE PHOSPHATE CARRIER FROM MITOCHONDRIA CONTAIN EVIDENCE OF ALTERNATIVELY SPLICED FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP TRANSLOCASE; COMPLEMENTARY-DNA SEQUENCE; BROWN FAT MITOCHONDRIA; UNCOUPLING PROTEIN; HEART-MITOCHONDRIA; STRUCTURAL RELATIONSHIP; TRANSPORT PROTEIN; CDNA; SYNTHASE; CLONING	The sequences of the human and bovine genes for the phosphate carrier from the inner membranes of mitochondria have been determined. The genes have similar structures and each is divided into nine exons. In both genes, two exons, named IIIA and IIIB, are closely related, and they appear to be alternatively spliced. The human exon IIIB sequence is found in a published human heart cDNA sequence, and bovine exon IIIA forms part of a published bovine heart cDNA sequence. By further examination of the human heart cDNA library, sequences arising from both alternatively spliced forms of the phosphate carrier have been characterized. Both forms were also found in several bovine tissues, but the ratios of expression of the two forms varied. The form containing exon IIIA was expressed most highly in bovine heart and liver, less highly in brain and kidney, and only in low amounts in lung. The opposite hierarchy was found for the form containing exon IIIB; it was most highly expressed in lung and least in heart and liver. The alternative splicing mechanism affects amino acids 4-45 of the mature phosphate carrier protein, which is believed to form one of six transmembrane segments of the phosphate carrier and to emerge into a large extramembranous loop. The alternative splicing mechanism changes 13 and 11 amino acids in the human and bovine carrier proteins, respectively. As the function of this region of the phosphate carrier is not known, the effects of the changes on carrier function are not understood at present.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV BARI,DEPT PHARMACOBIOL,BIOCHEM & MOLEC BIOL LAB,I-70125 BARI,ITALY	MRC Laboratory Molecular Biology; Universita degli Studi di Bari Aldo Moro			Iacobazzi, Vito/A-6106-2016	Iacobazzi, Vito/0000-0002-0470-2056; Dolce, Vincenza/0000-0003-2966-4866; Walker, John/0000-0001-7929-2162				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAPOBIANCO L, 1991, BIOCHEMISTRY-US, V30, P4963, DOI 10.1021/bi00234a018; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; Dolce V, 1991, DNA Seq, V2, P133, DOI 10.3109/10425179109039683; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; Iacobazzi V, 1992, DNA Seq, V3, P79, DOI 10.3109/10425179209034000; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P493, DOI 10.1007/BF01108406; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; RUNSWICK MJ, 1994, IN PRESS DNA SEQUENC; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P4731, DOI 10.1093/nar/10.15.4731; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALKER JE, 1987, BIOCHEMISTRY-US, V26, P8613, DOI 10.1021/bi00400a018; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WALKER JE, 1987, CHEM SCRIPTA, V27B, P97; ZARA V, 1992, J BIOL CHEM, V267, P12077	42	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10451	10460						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144629				2022-12-27	WOS:A1994NF01700042
J	DREVET, JR; SKEIKY, YAW; IATROU, K				DREVET, JR; SKEIKY, YAW; IATROU, K			GATA-TYPE ZINC-FINGER MOTIF-CONTAINING SEQUENCES AND CHORION GENE-TRANSCRIPTION FACTORS OF THE SILKWORM BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIGENE FAMILY; DEVELOPMENTAL REGULATION; SILKMOTH; DNA; EXPRESSION; DROSOPHILA; PROTEIN; EVOLUTION; PROMOTER; ENCODES	To characterize a DNA-binding protein, BCFI, which regulates the expression of silkmoth chorion genes through binding to gene promoter elements identical to those recognized by the GATA family of transcription factors, we have carried out polymerase chain reaction amplifications of Bombyx mori genomic DNA using degenerate primers derived from the conserved DNA binding domain of mammalian GATA factors. Two single copy genes, BmGATA alpha and BmGATA beta, were identified, which encode sequences containing GATA-type zinc finger motifs. The BmGATA beta gene is expressed in follicular and Bm5 tissue culture cells, the two cell types that contain BCFI. No BmGATA alpha gene transcripts were detectable in the tissues that were tested. Upon overexpression in Escherichia coli, a peptide encompassing the BmGATA beta zinc finger motif was able to bind specifically to the BCFI recognition motif of the chorion gene promoters. A polyclonal antibody directed against the zinc finger domain of BmGATA beta was also used in gel retardation assays to confirm that factor BCFI is indeed encoded by the BmGATA beta gene. Conceptual translation of a complete cDNA clone encoding the BmGATA beta protein revealed that this protein has a size similar to that of an immunoreactive protein, presumably BCFI, which is present in follicular cell extracts.	UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA	University of Calgary			Drevet, Joël/W-2692-2019	Drevet, Joël/0000-0003-3077-6558				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BALTZ R, 1992, PLANT J, V2, P713, DOI 10.1046/j.1365-313X.1992.t01-13-00999.x; BOCK SC, 1982, P NATL ACAD SCI-BIOL, V79, P1032, DOI 10.1073/pnas.79.4.1032; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BURKE WD, 1986, J MOL BIOL, V190, P343, DOI 10.1016/0022-2836(86)90006-9; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; EICKBUSH TH, 1982, CELL, V19, P633; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HARLOW E, 1988, ANTIBODIES LABORATOR; HIBNER BL, 1988, DEV BIOL, V125, P423, DOI 10.1016/0012-1606(88)90223-0; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IATROU K, 1980, CELL, V20, P659, DOI 10.1016/0092-8674(80)90312-8; IATROU K, 1982, J MOL BIOL, V157, P417, DOI 10.1016/0022-2836(82)90469-7; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; IATROU K, 1984, P NATL ACAD SCI-BIOL, V81, P4452, DOI 10.1073/pnas.81.14.4452; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JONES CW, 1980, CELL, V22, P855; Kafatos F.C, 1977, Results Probl Cell Differ, V8, P45; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; MITSIALIS SA, 1987, P NATL ACAD SCI USA, V84, P7987, DOI 10.1073/pnas.84.22.7987; ORKIN SH, 1992, BLOOD, V80, P575; RODAKIS GC, 1982, P NATL ACAD SCI-BIOL, V79, P3551, DOI 10.1073/pnas.79.11.3551; RODAKIS GC, 1984, J MOL EVOL, V20, P265, DOI 10.1007/BF02104732; RODAKIS GC, 1982, MOL CELL BIOL, V2, P554, DOI 10.1128/MCB.2.5.554; SKEIKY YAW, 1987, J BIOL CHEM, V262, P6628; SKEIKY YAW, 1991, J MOL BIOL, V218, P517, DOI 10.1016/0022-2836(91)90698-6; SKEIKY YAW, 1990, J MOL BIOL, V213, P53, DOI 10.1016/S0022-2836(05)80121-4; SKEIKY YAW, 1991, MOL CELL BIOL, V11, P1954, DOI 10.1128/MCB.11.4.1954; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; SPOEREL N, 1986, J MOL BIOL, V190, P23, DOI 10.1016/0022-2836(86)90072-0; SWEVERS L, 1992, DEV BIOL, V150, P12, DOI 10.1016/0012-1606(92)90003-Y; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	41	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10660	10667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144656				2022-12-27	WOS:A1994NF01700071
J	HAJNOCZKY, G; LIN, C; THOMAS, AP				HAJNOCZKY, G; LIN, C; THOMAS, AP			LUMINAL COMMUNICATION BETWEEN INTRACELLULAR CALCIUM STORES MODULATED BY GTP AND THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CA2+ RELEASE; PERMEABILIZED HEPATOCYTES; GUANINE-NUCLEOTIDES; CELL-LINE; TRISPHOSPHATE; FEEDBACK; MOBILIZATION	The activation properties of inositol 1,4,5-trisphosphate (InsP(3)) sensitive Ca2+ stores in permeabilized and intact hepatocytes were investigated by monitoring Mn2+ quench of fura-2 compartmentalized within these stores, as Mn2+ passed through InsP(3)-activated channels in a retrograde manner. In cells permeabilized in suspension the InsP(3)-sensitive pool size was dependent on InsP(3) dose, and there was a large unresponsive compartment. By contrast, essentially all of the compartmentalized dye was accessible following activation of a small fraction of the InsP(3) receptors in carefully permeabilized attached cells. After loading the cytosol of intact hepatocytes with Mn2+, both submaximal and maximal vasopressin doses caused complete quench of the entire intracellular pool of compartmentalized fura-2. Vasopressin-induced Mn2+ quench occurred in a stepwise manner at doses that gave cytosolic Ca2+ oscillations, reflecting periodic opening of intracellular Ca2+ channels. Pretreatment with thapsigargin to eliminate feedback effects of Ca2+ fluxes converted the steps to a continuous quench. The data suggest that Ca2+ stores in attached permeabilized and intact hepatocytes are luminally connected, making the entire store accessible to InsP(3). In cells permeabilized in suspension, GTP increased InsP(3)-sensitive pool size, and this effect was inhibited by cytochalasin B. GTP did not change the initial rate of Mn2+ quench but increased the proportion of slowly accessible stores in the InsP(3)-sensitive compartment, apparently by recruitment of InsP(3)-insensitive stores. Preincubation on ice or with cytoskeletal inhibitors dissociated slowly accessible compartments from the InsP(3)-sensitive stores in both intact and subsequently permeabilized attached hepatocytes. Addition of GTP to permeabilized cells reversed this disruption of store continuity. It is suggested that GTP- and cytoskeleton-dependent luminal communication between Ca2+ stores is an important determinant of function, which could modulate the availability of Ca2+ for release.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA07215, AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BORLE AB, 1982, J MEMBRANE BIOL, V68, P37, DOI 10.1007/BF01872252; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; COMERFORD JG, 1989, BIOCHEM J, V258, P823, DOI 10.1042/bj2580823; COMERFORD JG, 1991, BIOCHEM J, V280, P335, DOI 10.1042/bj2800335; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; DOWNEY GP, 1991, J CELL BIOL, V114, P1179, DOI 10.1083/jcb.114.6.1179; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KACHAR B, 1988, J CELL BIOL, V106, P1545, DOI 10.1083/jcb.106.5.1545; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; KWAN CY, 1990, J BIOL CHEM, V265, P678; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PAYNE R, 1988, PHILOS T ROY SOC B, V320, P359, DOI 10.1098/rstb.1988.0082; PRENTKI M, 1985, J BIOL CHEM, V260, P9185; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; UEDA T, 1986, J BIOL CHEM, V261, P3184; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	50	78	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10280	10287						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144609				2022-12-27	WOS:A1994NF01700019
J	HANASAKI, K; VARKI, A; STAMENKOVIC, I; BEVILACQUA, MP				HANASAKI, K; VARKI, A; STAMENKOVIC, I; BEVILACQUA, MP			CYTOKINE-INDUCED BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE IN HUMAN ENDOTHELIAL-CELLS MEDIATES ALPHA-2,6-SIALYLATION OF ADHESION MOLECULES AND CD22 LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; SIALIC-ACID; LINKED OLIGOSACCHARIDES; LEUKOCYTE ADHESION; ALPHA-1-ACID GLYCOPROTEIN; LIQUID-CHROMATOGRAPHY; RAT-LIVER; SIALYLTRANSFERASE; INFLAMMATION; EXPRESSION	Sialic acids decorating blood and cell surface proteins can play important roles in various biological processes. The inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1, as well as bacterial lipopolysaccharide, can activate vascular endothelium, increasing expression of several surface glycoproteins. Here we show that treatment of cultured human endothelial cells (HEC) with TNF-alpha, interleukin-1, or lipopolysaccharide causes increased expression of the enzyme beta-galactoside alpha-2,6-sialyltransferase (alpha 2-6STN). TNF-alpha was most effective, inducing a 3.5-fold enhancement of cell-associated sialyltransferase activity by 72 h. In addition, activated HEC secreted a large portion of the induced sialyltransferase activity into the medium. Analysis of labeled HEC showed both a relative and an absolute increase of alpha 2,6-linked sialic acid on N-linked oligosaccharides after TNF-alpha stimulation. This coincided with increased expression of endothelial glycoproteins bearing N-linked glycans with alpha 2,6-linked sialic acid detected by the lectin Sambucus nigra agglutinin. The cytokine-inducible endothelial cell adhesion molecules E-selectin, ICAM-1, and VCAM-1 are among these glycoprotein substrates for alpha 2-6STN. These changes also correlated with a substantial increase in binding sites for CD22 beta, a mammalian lectin known to recognize oligosaccharides carrying multiple copies of alpha 2,6-linked sialic acid. Northern analysis revealed increased levels of mRNA encoding alpha 2-6STN. Thus, activation of endothelial cells during in flammatory and immunological processes may induce alpha 2-6STN, which can participate in sialylation of other activation-dependent molecules.	UNIV CALIF SAN DIEGO,CTR CANC,DIV CELLULAR & MOLEC MED,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02129	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Massachusetts General Hospital					NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINVOSS HG, 1992, J CELL BIOL, V119, P483, DOI 10.1083/jcb.119.2.483; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1993, J IMMUNOL, V150, P4715; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; ENGEL P, 1993, J IMMUNOL, V150, P4719; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; GILLARD BK, 1990, ARCH BIOCHEM BIOPHYS, V279, P122, DOI 10.1016/0003-9861(90)90471-A; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAYES BK, 1993, J BIOL CHEM, V268, P16139; JAMIESON JC, 1987, COMP BIOCHEM PHYS B, V87, P11, DOI 10.1016/0305-0491(87)90463-9; JAMIESON JC, 1983, CAN J BIOCHEM CELL B, V61, P1041, DOI 10.1139/o83-133; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; NILSSON B, 1979, J BIOL CHEM, V254, P4545; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SILVER HKB, 1979, CANCER RES, V39, P5036; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WOLOSKI BMRNJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P185, DOI 10.1016/0167-4889(86)90087-X; WOLOSKI BMRNJ, 1985, BIOCHEM BIOPH RES CO, V130, P30, DOI 10.1016/0006-291X(85)90377-8	56	121	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10637	10643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144653				2022-12-27	WOS:A1994NF01700068
J	BOHNI, R; HEMMI, S; AGUET, M				BOHNI, R; HEMMI, S; AGUET, M			SIGNALING STEPS INVOLVING THE CYTOPLASMIC DOMAIN OF THE INTERFERON-GAMMA RECEPTOR ALPHA-SUBUNIT ARE NOT SPECIES-SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; ACCESSORY FACTOR; EXPRESSION; ANTIGEN; CDNA; DNA; PHOSPHORYLATION; PURIFICATION; SENSITIVITY	The ligand binding chain of the interferon-gamma receptor (IFN-gamma R) is a unique cell surface protein which has no similarities to other cytokine receptors. Expression of this receptor chain (alpha-subunit) is not sufficient to mediate responsiveness to IFN-gamma. We and others have shown that IFN-gamma-mediated signal transduction requires a species-specific interaction of the extracellular portion of the known IFN-gamma receptor alpha-chain with an additional receptor subunit that was cloned recently and designated IFN-gamma R beta-chain or accessory factor 1. Here, we investigated whether this tight species barrier also ap plies to signaling events mediated by the cytoplasmic receptor domain. A cell line derived from embryos that lack the IFN-gamma R alpha-subunit was reconstituted with a hybrid mouse-human alpha-subunit that consisted of an extracellular murine and transmembrane and cytoplasmic human domains. The experiments reported herein showed that in mouse cells, the human intracellular domain of the hybrid IFN-gamma R alpha-subunit was fully functional and that, therefore, signaling steps involving this domain are not species-specific.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND	University of Zurich								AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BASU M, 1989, J INTERFERON RES, V9, P551, DOI 10.1089/jir.1989.9.551; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFANO F, 1990, J BIOL CHEM, V265, P4064; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11176; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HERSHEY GKK, 1990, J BIOL CHEM, V265, P17868; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAO C, 1990, J IMMUNOL, V145, P4257; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P139; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	53	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14541	14545						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182061				2022-12-27	WOS:A1994NM06500038
J	HALL, ET; YAN, JP; MELANCON, P; KUCHTA, RD				HALL, ET; YAN, JP; MELANCON, P; KUCHTA, RD			3'-AZIDO-3'-DEOXYTHYMIDINE POTENTLY INHIBITS PROTEIN GLYCOSYLATION - A NOVEL MECHANISM FOR AZT CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROUGH ENDOPLASMIC-RETICULUM; HAMSTER OVARY CELLS; N-LINKED GLYCANS; GOLGI-APPARATUS; RAT-LIVER; INFECTED CELLS; TRANSPORT; MEMBRANE; INVITRO; ACETYLGLUCOSAMINE	3'-Azido-3'-deoxythymidine (AZT) is one of the primary chemotherapeutic agents used in the treatment of human immunodeficiency virus (HIV) infection. Unfortunately, AZT therapy is accompanied by severe side effects. Using Golgi-enriched membrane fractions, we have determined that 3'-azido-3'-deoxythymidine monophosphate, the primary AZT metabolite in treated cells, potently inhibits protein glycosylation. This inhibition results from direct competition with several pyrimidine-sugars for transport into Golgi membranes. This potential mechanism of cytotoxicity does not involve 3'-azido-3'-deoxythymidine triphosphate, the AZT metabolite most likely responsible for its antiviral effects; thus, it may be possible to develop novel therapeutic strategies that prevent inhibition of glycosylation without affecting the anti-HIV properties of AZT.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albein A. D., 1987, ANNU REV BIOCHEM, V56, P497; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CALVARUSO G, 1986, LIFE SCI, V39, P2221, DOI 10.1016/0024-3205(86)90400-5; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAPASSO JM, 1984, BIOCHIM BIOPHYS ACTA, V777, P133, DOI 10.1016/0005-2736(84)90505-4; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FARAJ A, 1993, P ANN M AM ASS CANCE, V34, pA2111; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; Hauschka P V, 1973, Methods Cell Biol, V7, P361; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KEPPLER DOR, 1977, CANCER RES, V37, P911; KORNFELD S, 1966, EXP CELL RES, V41, P592, DOI 10.1016/S0014-4827(66)80109-X; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; OATES JA, 1989, NEW ENGL J MED, V321, P726; OLOFSSON S, 1988, VIROLOGY, V166, P440, DOI 10.1016/0042-6822(88)90515-6; OLOFSSON S, 1993, ARCH VIROL, V128, P241, DOI 10.1007/BF01309437; PEREZ M, 1985, J BIOL CHEM, V260, P4671; READING CL, 1978, J BIOL CHEM, V253, P5600; SOMMADOSSI JP, 1988, ANTIMICROB AGENTS CH, V32, P997, DOI 10.1128/AAC.32.7.997; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006	30	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14355	14358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182037				2022-12-27	WOS:A1994NM06500008
J	HARTONG, R; WANG, NS; KUROKAWA, R; LAZAR, MA; GLASS, CK; APRILETTI, JW; DILLMANN, WH				HARTONG, R; WANG, NS; KUROKAWA, R; LAZAR, MA; GLASS, CK; APRILETTI, JW; DILLMANN, WH			DELINEATION OF 3 DIFFERENT THYROID HORMONE-RESPONSE ELEMENTS IN PROMOTER OF RAT SARCOPLASMIC-RETICULUM CA2+-ATPASE GENE - DEMONSTRATION THAT RETINOID-X RECEPTOR BINDS 5' TO THYROID-HORMONE RECEPTOR IN RESPONSE ELEMENT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Thyroid hormone (3,5,3'-triiodothyronine) positively regulates transcription of the sarcoplasmic reticulum Ca(2+)ATPase gene in rat heart, and sequences within 559 nucleotides upstream from the transcription start site confer thyroid hormone responsiveness upon a reporter gene. In the present study, three thyroid hormone-response elements (TREs) are identified between nucleotides -485 and -190. Each TRE is active in transient transfection assays and specifically binds 3,5,3'-triiodothyronine receptors (TRs) alpha 1 and beta 1 alone and in combination with retinoid X receptors (RXRs) alpha and beta. TRE 1 is a direct repeat of two half-sites separated by four nucleotides; TREs 2 and 3 are inverted palindromes of two half-sites separated by four and six nucleotides, respectively. Methylation interference analysis of TRE 1 showed binding of a TR alpha 1 monomer to the 3' half-site, whereas the heterodimer contacts both half-sites. Subsequent studies employed TR beta and RXR alpha mutants in which their P-boxes were replaced with the P-box of the glucocorticoid receptor. Bandshifts of wild type and mutant proteins with either wild type TRE 1 or a mutant version, in which the 5' half-site was converted to a glucocorticoid response element half-site, demonstrated preferential binding of RXR to the 5' half-site and of TR to the 3' half-site of TRE 1.	UNIV PENN, SCH MED, DEPT MED, DIV ENDOCRINE, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco	HARTONG, R (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, 200 W ARBOR DR 8412, SAN DIEGO, CA 92103 USA.		Glass, Christopher/AAI-3933-2021; Lazar, Mitchell A/AAF-3738-2019	Glass, Christopher/0000-0003-4344-3592; 	NATIONAL CANCER INSTITUTE [R01CA052599] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER; NCI NIH HHS [NCI RO1 CA52599] Funding Source: Medline; NHLBI NIH HHS [HL 25022] Funding Source: Medline; NIDDK NIH HHS [DK 43806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURK SE, 1989, J BIOL CHEM, V264, P18561; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; GEBALLE AP, 1986, CELL, V46, P865, DOI 10.1016/0092-8674(86)90068-1; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANGER GA, 1992, FASEB J, V6, P893, DOI 10.1096/fasebj.6.3.1310947; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MORGAN JP, 1991, AM HEART J, V121, P961, DOI 10.1016/0002-8703(91)90227-9; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; OJAMAA K, 1992, AM J PHYSIOL, V263, pE534, DOI 10.1152/ajpendo.1992.263.3.E534; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	67	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13021	13029						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175722				2022-12-27	WOS:A1994NH71600098
J	MOSS, JB; MCQUINN, TC; SCHWARTZ, RJ				MOSS, JB; MCQUINN, TC; SCHWARTZ, RJ			THE AVIAN CARDIAC ALPHA-ACTIN PROMOTER IS REGULATED THROUGH A PAIR OF COMPLEX ELEMENTS COMPOSED OF E-BOXES AND SERUM RESPONSE ELEMENTS THAT BIND BOTH POSITIVE-ACTING AND NEGATIVE-ACTING FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MUSCLE-SPECIFIC TRANSCRIPTION; DNA-BINDING; GENE-EXPRESSION; ACTIVATION; MYOD1; SITES; SEQUENCE; ENHANCER; CELLS	The chicken alpha-cardiac actin is one of the earliest contractile protein genes selectively expressed during embryonic skeletal and cardiac muscle differentiation. Cardiac actin promoter elements were examined in these two sarcomeric cell types. A portion of the alpha-cardiac actin promoter responsible for striated muscle specificity has been delineated (1, 2) and shown to contain four serum response elements (SRE). Previously, SRE3 was shown to be part of a complex element in cojunction with a functional E box (2), and we now show that SRE4 is also part of an upstream SRE E box cis-element complex. The SREs function similarly, but the E boxes have dissimilar properties within and between striated muscle types. The SRES-E1 box binds myogenic basic helix-loop-helix factors and is required for cardiac actin trans-activation in primary muscle cell cultures but functions as a negative regulatory element in cardiac muscle cells. The SRE4-E2 box, on the other hand, fails to bind basic helix-loop-helix (bHLH) factors, is negative acting in skeletal muscle cells, and is positive acting in cardiac myocytes. A DNA binding factor similar to HF1a (3) was identified that interacts specifically with the SRE4-E2 box. This study shows that the avian cardiac actin promoter elements are differentially used between skeletal and cardiac striated muscle cell lineages.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [R01 HL38401, P01 HL49953] Funding Source: Medline; NICHD NIH HHS [5P30-HD27823] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038401, P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BLANK RS, 1992, J BIOL CHEM, V267, P984; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHANG KS, 1985, NUCLEIC ACIDS RES, V13, P1223, DOI 10.1093/nar/13.4.1223; CHIEN K, 1993, J CELL BIOCH D S, V17; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MOLENTKIN JD, 1993, J BIOL CHEM, V268, P2602; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WEYDERT A, 1987, CELL, V49, P121, DOI 10.1016/0092-8674(87)90762-8; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	58	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12731	12740						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175685				2022-12-27	WOS:A1994NH71600057
J	QIAN, YM; BLASKOVICH, MA; SALEEM, M; SEONG, CM; WATHEN, SP; HAMILTON, AD; SEBTI, SM				QIAN, YM; BLASKOVICH, MA; SALEEM, M; SEONG, CM; WATHEN, SP; HAMILTON, AD; SEBTI, SM			DESIGN AND STRUCTURAL REQUIREMENTS OF POTENT PEPTIDOMIMETIC INHIBITORS OF P21(RAS) FARNESYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN FARNESYLTRANSFERASE; TETRAPEPTIDE INHIBITORS; RAS; P21RAS; FARNESYL; TRANSFORMATION; TRANSFERASE; TERMINUS; MEMBRANE	Cysteine farnesylation of the ras oncogene product, p21(ras), on its carboxyl terminal CA(1)A(2)X box (C = cysteine, A = aliphatic, and X = methionine or serine) is required for its transforming activity. p21(ras) farnesyltransferase (FTase), the enzyme responsible for this important posttranslational modification can be inhibited by simple CA(1)A(2)X peptides. We have synthesized a family of CA(1)A(2)X peptidomimetics where the central 2 aliphatic amino acids are replaced by a variety of spacer groups with different shapes and conformational characteristics to investigate the structural requirements of these inhibitors. The biological activities of CA(1)A(2)X peptidomimetics, where the dipeptide ''A(1)A(2)'' is replaced by 3- or 4-ami nomethylbenzoic acid (AMBA) and 3- or 4-aminobenzoic acid (ABA), are evaluated in a p21(ras) FTase inhibitory assay. Peptidomimetics Cys-4-ABA-Met and Cys-3-AMBA-Met contain spacers that provide good distance correspondence of the carboxylate and ammonium separation with that of the parent K-B p21(ras) tetrapeptide, Cys-Val-Ile-Met, and are as potent FTase inhibitors (IC50 values of 50 and 100 nM, respectively). In contrast, replacing the central dipeptide with 4-AMBA reduced FTase inhibitory activity by 17-fold whereas replacement by 3-ABA reduces inhibitory activity of the pep- tidomimetics by 43-fold. Cys-4-ABA-Met (IC50 = 50 nM) is 128 times more potent as a p21(ras) FTase inhibitor than Cys-3-ABA-Met (IC50 = 6400 nM), yet these two peptidomimetics differ only in the substitution pattern around the phenyl ring. These results coupled with computer modeling studies demonstrate that the interaction between FTase and the peptidomimetics requires precise structural and conformational characteristics; in particular, correct positioning of the Cys and Met must be respected. Furthermore, Cys-3-AMBA-Met and Cys-4-ABA-Met are true inhibitors of p21(ras) FTase since they are not farnesylated by this enzyme, in contrast to Cys-Val-Ile-Met, which inhibits the enzyme by acting as alternative substrate. Computer modeling studies of the potent FTase inhibitor Cys-4-ABA-Met show that a folded conformation, where the thiol and carboxylate groups are close, is not possible. Therefore a beta-turn conformation that would result in the simultaneous coordination of the Cys-thiol and Met-carboxylate to zinc ion is not important for inhibition of p21(ras) FTase, as previously suggested.	UNIV PITTSBURGH,FAC ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NIGAM M, 1993, J BIOL CHEM, V268, P20695; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	27	109	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12410	12413						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175645				2022-12-27	WOS:A1994NH71600008
J	SRINIVASAN, M; BEGUM, N				SRINIVASAN, M; BEGUM, N			REGULATION OF PROTEIN PHOSPHATASE-1 AND PHOSPHATASE-2A ACTIVITIES BY INSULIN DURING MYOGENESIS IN RAT SKELETAL-MUSCLE CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								In this study, we examined protein phosphatase 1 (PP-1) and protein phosphatase 2A (PP-2A) activities during various stages of myogenesis and their regulation by insulin in rat skeletal muscle cells. Protein phosphatase activities were measured using P-32-labeled phosphorylase alpha, glycogen synthase, and phosphorylase kinase as substrates. Spontaneous PP-1 activity increased progressively in cultures from 2 to 5 days, PP-2A activities remained constant in days 2-4 cultures and increased sharply on day 5. Most of the times in culture, a significant proportion (approximate to 65%) of PP-1 was in a form that could be activated by trypsin. Insulin stimulated PP-1 activity (40-80% increase over basal) in a time (t(1/2) approximate to 5 min)- and dose (EC(50) approximate to 0.1 nM)-dependent manner. Insulin activation of PP-1 was accompanied by a corresponding inhibition in PP-2A activity. The effects of insulin on PP-1 and PP-2A were differentiation dependent and were observed only in cells at fusion (day 5) and post-fusion. The insulin's effect on PP-1 correlated with the gradual appearance of PP-1 G subunit in cells at fusion. Immunoprecipitation of PP-1 from P-32-labeled cells with an antibody directed against the site 1 sequence of rabbit skeletal muscle PP-1G detected a 160-kDa protein, phosphorylation of which was significantly increased by insulin. This correlated well with the increase observed in immunoprecipitated PP-1G activity. Treatment of cells with a cAMP agonist (SpcAMP) completely blocked activation of PP-1 by insulin and diminished insulin-stimulated phosphorylation of the 160-kDa protein. The likely identity of the 160-kDa band as the regulatory subunit of PP-1 was confirmed by assay of PP-1 activity in the immunoprecipitates and by competition studies with the site 1 peptide against which the antibody was made. From these studies, we conclude that insulin activates PP-1 in L6 cells by increasing the phosphorylation of its regulatory subunit.	WINTHROP UNIV HOSP, DIABET RES LAB, MINEOLA, NY 11501 USA; SUNY STONY BROOK, SCH MED, STONY BROOK, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								AVRUCH J, 1976, J BIOL CHEM, V251, P1511; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1985, CURR TOP CELL REGUL, V27, P23; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRUPPUSO PA, 1987, BIOCHEM BIOPH RES CO, V148, P1174, DOI 10.1016/S0006-291X(87)80256-5; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INOUE G, 1993, J BIOL CHEM, V268, P5272; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIM SJ, 1992, J BIOL CHEM, V267, P15140; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PERISIC O, 1983, J BIOL CHEM, V258, P9589; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SEALS JR, 1979, J BIOL CHEM, V254, P6991; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YU KT, 1984, J BIOL CHEM, V259, P5277; ZHANG JN, 1989, J BIOL CHEM, V264, P17513	47	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12514	12520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175660				2022-12-27	WOS:A1994NH71600025
J	WAX, SD; ROSENFIELD, CL; TAUBMAN, MB				WAX, SD; ROSENFIELD, CL; TAUBMAN, MB			IDENTIFICATION OF A NOVEL GROWTH FACTOR-RESPONSIVE GENE IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; CULTURED MOUSE CELLS; MYC MESSENGER-RNA; ANGIOTENSIN-II; PROTEIN-SYNTHESIS; ARTERIAL INJURY; C-FOS; EXPRESSION; INDUCTION; SEQUENCE	We have employed differential screening of a rat aortic smooth muscle cell cDNA library to isolate a cDNA clone, SM-20, whose nucleotide and deduced amino acid sequences are distinct from those reported previously. SM-20 encodes an mRNA of approximate to 2.5-3.0 kilobase pairs which is present at low levels in quiescent vascular smooth muscle cells. SM-20 levels increase within 1 h of treatment with growth agonists (serum, platelet-derived growth factor, angiotensin II), isoproterenol, and forskolin. Cycloheximide induces high levels of SM-20 mRNA and superinduces it in the presence of serum, suggesting that the increase in SM-20 mRNA levels is not dependent on protein synthesis and is part of the primary response to growth agonists. SM-20 is expressed at high levels in tissues and cells derived from muscle (smooth, skeletal, and cardiac) and nerve (brain, PC12 cells) and is not expressed in 3T3 fibroblasts or rat 6 fibroblasts. SM-20 encodes a new member of the immediate early gene family and is unusual in that it is expressed in vascular smooth muscle, but not in fibroblasts.	CUNY MT SINAI SCH MED,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,DIV CARDIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL43302] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CAMPBELL GR, 1987, VASCULAR SMOOTH MUSC, V1, P39; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND D W, 1989, New Biologist, V1, P121; CLOWES AW, 1983, LAB INVEST, V49, P327; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FENG P, 1993, J BIOL CHEM, V268, P9387; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guyton AC, 1986, TXB MED PHYSL; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE RMKW, 1983, BLOOD VESSELS, V20, P72; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MARMUR JD, 1992, CIRCULATION, V86, P53; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OWENS GK, 1985, CIRC RES, V56, P525, DOI 10.1161/01.RES.56.4.525; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; Schneider C, 1991, CURR OPIN CELL BIOL, V3, P276, DOI 10.1016/0955-0674(91)90152-O; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	50	80	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13041	13047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175725				2022-12-27	WOS:A1994NH71600101
J	WAUGH, DS; SAUER, RT				WAUGH, DS; SAUER, RT			A NOVEL CLASS OF FOKI RESTRICTION-ENDONUCLEASE MUTANTS THAT CLEAVE HEMI-METHYLATED SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCES; MODIFICATION SYSTEM; ECORI ENDONUCLEASE; ESCHERICHIA-COLI; RECOGNITION; TRANSFORMATION; EXPRESSION; DOMAINS; PLASMID	A genetic screen was used to identify amino acid substitutions that enable the FokI restriction endonuclease to cleave DNA in cells that express the cognate methyltransferase activity. Missense mutations that give rise to this phenotype were isolated at eight different positions (G188K, P196S, T343I, S388N, S395F, E407K, E410K, D421N), clustered in two regions of the polypeptide sequence of FokI. Two of the mutant endonucleases (P196S and D421N) were purified to homogeneity and analyzed in detail. Both mutants cleave FokI target sites (5'-GGATG-3') in a manner similar to the wild-type enzyme. Neither mutant cleaved noncanonical sequences, but both efficiently cleaved DNA substrates containing hemi-methylated FokI sites. This class of mutations has not been observed with other restriction enzymes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NIGMS NIH HHS [GM-13909] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013909] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKMAN K, 1978, CELL, V13, P65, DOI 10.1016/0092-8674(78)90138-1; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COHEN SN, 1977, J BACTERIOL, V132, P734, DOI 10.1128/JB.132.2.734-737.1977; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KITA K, 1989, J BIOL CHEM, V264, P5751; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; LOONEY MC, 1989, GENE, V80, P193, DOI 10.1016/0378-1119(89)90284-9; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MESELSON M, 1968, NATURE, V217, P1110, DOI 10.1038/2171110a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGISAKI H, 1981, GENE, V16, P73; SZYBALSKI W, 1985, GENE, V40, P169, DOI 10.1016/0378-1119(85)90039-3; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	23	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12298	12303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163534				2022-12-27	WOS:A1994NG37700094
J	EGERTON, M; SAMELSON, LE				EGERTON, M; SAMELSON, LE			BIOCHEMICAL-CHARACTERIZATION OF VALOSIN-CONTAINING PROTEIN, A PROTEIN-TYROSINE KINASE SUBSTRATE IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ZETA-CHAIN; ANTIGEN RECEPTOR; T-CELLS; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; ACTIVATION; PHOSPHORYLATION; YEAST; GENE; CD4	Engagement of the T cell antigen receptor (TCR) leads to activation of multiple tyrosine kinases and rapid tyrosine phosphorylation of intracellular protein substrates. A number of these substrates have been identified and they include TCR subunits, phospholipase C-gamma1, p95vav, and ezrin. In a recent study we have demonstrated that VCP (valosin-containing protein) becomes tyrosine phosphorylated upon TCR cross-linking. Analysis of the predicted amino acid sequence of this protein indicates that it is a member of a family of oligomeric proteins containing duplicated domains with predicted ATPase activity. In the current study we determine the site of tyrosine phosphorylation in VCP, demonstrate that murine VCP indeed is an oligomeric ATPase, and show that the tyrosine phosphorylation of the protein has no effect on VCP ATPase activity. Recent evidence suggests that VCP associates with clathrin. A possible role of tyrosine phosphorylation in regulating this protein-protein interaction is discussed.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; EGERTON M, 1992, J IMMUNOL, V149, P1847; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HSI ED, 1989, J BIOL CHEM, V264, P10836; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; QIAN DP, 1993, J BIOL CHEM, V268, P4488; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Sober HA, 1970, HDB BIOCH; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1973, J IMMUNOL METHODS, V2, P293, DOI 10.1016/0022-1759(73)90055-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	46	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11435	11441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157674				2022-12-27	WOS:A1994NF96600068
J	PARSEK, MR; YE, RW; PUN, P; CHAKRABARTY, AM				PARSEK, MR; YE, RW; PUN, P; CHAKRABARTY, AM			CRITICAL NUCLEOTIDES IN THE INTERACTION OF A LYSR-TYPE REGULATOR WITH ITS TARGET PROMOTER REGION - CATBC PROMOTER ACTIVATION BY CATR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RPOA; PSEUDOMONAS-PUTIDA; BINDING-SITE; TRANSCRIPTIONAL ACTIVATOR; GEL-ELECTROPHORESIS; RNA-POLYMERASE; DNA; PROTEIN; MUTATIONS; SEQUENCE	We have used site-directed mutagenesis to analyze the importance of nucleotides in the catBC promoter region for the binding of CatR, a member of the LysR family of DNA-binding proteins and for the in vivo activation of the catBC operon. The binding affinity of CatR for its binding site in the catBC promoter region was shown to increase about 2.2-fold in the presence of the inducer, cis,cis-muconate. Nucleotides were targeted for mutagenesis on the basis of previous footprinting data and sequence analysis of CatR binding sites. Critical nucleotides for CatR binding were found within an imperfect inverted repeat. Previous studies have indicated that the LysR family of DNA-binding proteins shares a consensus T-N-11-A binding motif (Goethals, K., Van Montagu, M., and Holsters, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1646-1650), but the CatR binding site sequence has located within the imperfect inverted repeat a G-N-11-A instead of the predicted T. Mutagenesis of the G to a T resulted in an increase in both the binding of CatR to the catBC promoter and in the in vivo activation. Nucleotides within the -35 and -10 regions of the catBC promoter were found to be important for promoter activity but not for CatR binding.	UNIV ILLINOIS, COLL MED,DEPT MICROBIOL & IMMUNOL,M-C 790,BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004050] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04050-07] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDRICH TL, 1989, MOL GEN GENET, V218, P266, DOI 10.1007/BF00331277; ALDRICH TL, 1988, J BACTERIOL, V170, P1297, DOI 10.1128/jb.170.3.1297-1304.1988; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERLY KA, 1991, J BACTERIOL, V173, P3547, DOI 10.1128/jb.173.11.3547-3553.1991; CHANG M, 1990, NUCLEIC ACIDS RES, V18, P979, DOI 10.1093/nar/18.4.979; COCO WM, 1993, J BACTERIOL, V175, P417, DOI 10.1128/JB.175.2.417-427.1993; FARINHA MA, 1990, J BACTERIOL, V172, P3496, DOI 10.1128/jb.172.6.3496-3499.1990; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAO J, 1991, EMBO J, V10, P4137, DOI 10.1002/j.1460-2075.1991.tb04991.x; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; GUSSIN GN, 1992, J BACTERIOL, V174, P5156, DOI 10.1128/JB.174.15.5156-5160.1992; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HUANG JZ, 1991, J BIOL CHEM, V266, P10830; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Maniatis T, 1989, MOL CLONING; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Miller J. H, 1972, EXPT MOL GENETICS; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARSEK MR, 1992, J BACTERIOL, V174, P7798, DOI 10.1128/JB.174.23.7798-7806.1992; PARSEK MR, 1994, METH MOL G, V3, P273; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; ROGOWSKY PM, 1987, J BACTERIOL, V169, P5101, DOI 10.1128/jb.169.11.5101-5112.1987; ROTHMEL RK, 1991, J BACTERIOL, V173, P4717, DOI 10.1128/jb.173.15.4717-4724.1991; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1989, J BACTERIOL, V171, P837, DOI 10.1128/jb.171.2.837-846.1989; Stanier R Y, 1973, Adv Microb Physiol, V9, P89; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THOMAS MS, 1991, MOL MICROBIOL, V5, P2719, DOI 10.1111/j.1365-2958.1991.tb01980.x; VIERA J, 1988, METHOD ENZYMOL, V153, P3; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; WEK RC, 1988, J MOL BIOL, V203, P643, DOI 10.1016/0022-2836(88)90199-4; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; WHEELIS ML, 1972, J BACTERIOL, V109, P790, DOI 10.1128/JB.109.2.790-795.1972; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11279	11284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157659				2022-12-27	WOS:A1994NF96600048
J	PAK, CC; KRUMBIEGEL, M; BLUMENTHAL, R; RAVIV, Y				PAK, CC; KRUMBIEGEL, M; BLUMENTHAL, R; RAVIV, Y			DETECTION OF INFLUENZA HEMAGGLUTININ INTERACTION WITH BIOLOGICAL-MEMBRANES BY PHOTOSENSITIZED ACTIVATION OF [I-125] IODONAPHTHYLAZIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; HUMAN-ERYTHROCYTE-MEMBRANE; RED-BLOOD-CELL; FUSION ACTIVITY; VIRUS HEMAGGLUTININ; 5-IODONAPHTHYL 1-AZIDE; AMPHIPHILIC COMPOUNDS; ANION PERMEABILITY; DISULFIDE BONDS; PROTEINS	Fusion of influenza virus with cells is triggered by a pH-dependent conformational change in the viral envelope protein, hemagglutinin, which results in exposure of the fusion peptide and its insertion into the target membrane. We have investigated the association of hemagglutinin with erythrocyte membranes by photosensitized labeling with [I-125]iodonaphthylazide. This technique relies on the collisional energy transfer from a photosensitizing chromophore to [I-125]iodonaphthylazide, which selectively labels proteins in the vicinity of the chromophore. Incubation of influenza virus with erythrocyte membranes containing chromophore and [I-125]iodonaphthylazide results in labeling of hemagglutinin under fusogenic conditions (pH 5 and 37 degrees C). We also examined photosensitized labeling of hemagglutinin upon incubation of the X31 strain of influenza virus with labeled erythrocyte membranes in a pre-fusion state (pH 5 and 4 degrees C). There was little hemagglutinin labeling under these conditions, although incubation of bromelain-cleaved hemagglutinin, which lacks the transmembrane region, resulted in rapid labeling. Hemagglutinin was also labeled by [I-125]iodonaphthylazide photosensitized by a fluorescent substrate transported through the erythrocyte band 3 sialoglycoprotein. Hemagglutinin labeling decreased after an initial rapid rise, suggesting that the fusion site is close to the sialoglycoprotein and that [I-125]iodonaphthylazide photosensitized labeling may be used to assay protein movement during fusion.	NCI, MEMBRANE STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA; NIDDK, CELL BIOL & GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AROETI B, 1991, J BIOL CHEM, V266, P15845; BAYLEY H, 1980, BIOCHEMISTRY-US, V19, P3883, DOI 10.1021/bi00558a001; BERCOVICI T, 1978, BIOCHEMISTRY-US, V17, P1484, DOI 10.1021/bi00601a020; BOSSART W, 1973, VIROLOGY, V55, P295, DOI 10.1016/S0042-6822(73)81034-7; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CORBETT JD, 1993, J CLIN INVEST, V91, P208, DOI 10.1172/JCI116172; COUSIN JL, 1979, J MEMBRANE BIOL, V46, P125, DOI 10.1007/BF01961377; COUSIN JL, 1982, BIOCHIM BIOPHYS ACTA, V687, P147, DOI 10.1016/0005-2736(82)90540-5; DOMS RW, 1985, J BIOL CHEM, V260, P2973; EIDELMAN O, 1983, J MEMBRANE BIOL, V71, P141, DOI 10.1007/BF01870682; EIDELMAN O, 1980, ANAL BIOCHEM, V106, P335, DOI 10.1016/0003-2697(80)90529-1; FIDGEN KJ, 1981, J VIROL METHODS, V3, P271, DOI 10.1016/0166-0934(81)90064-1; FRANK A, 1983, BIOCHEMISTRY-US, V22, P5647, DOI 10.1021/bi00293a029; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; Gitler C, 1980, Ann N Y Acad Sci, V346, P199, DOI 10.1111/j.1749-6632.1980.tb22100.x; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GOTTESMAN MM, 1992, DRUG RESISTANCE BIOC, P46; HARTER C, 1989, J BIOL CHEM, V264, P6459; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; KAHANE I, 1978, SCIENCE, V201, P351, DOI 10.1126/science.663661; KAPLAN D, 1991, EXP CELL RES, V195, P137, DOI 10.1016/0014-4827(91)90509-S; KARLISH SJD, 1977, NATURE, V269, P716; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; LOWY RJ, 1993, J CELL BIOCHEM, V16, P131; LOYTER A, 1988, METHOD BIOCHEM ANAL, V33, P129; MATAYOSHI ED, 1991, BIOCHEMISTRY-US, V30, P3527, DOI 10.1021/bi00228a025; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; PAK CC, 1994, J GEN VIROL, V75, P395, DOI 10.1099/0022-1317-75-2-395; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RAVIV Y, 1984, BIOCHEMISTRY-US, V23, P503, DOI 10.1021/bi00298a016; RAVIV Y, 1989, BIOCHEMISTRY-US, V28, P1313, DOI 10.1021/bi00429a055; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RAVIV Y, 1987, P NATL ACAD SCI USA, V84, P6103, DOI 10.1073/pnas.84.17.6103; ROSENWALD AG, 1991, J BIOL CHEM, V266, P9814; SIDMAN CL, 1980, MOL IMMUNOL, V17, P1575, DOI 10.1016/0161-5890(80)90183-2; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WYATT K, 1992, BIOCHIM BIOPHYS ACTA, V1103, P327, DOI 10.1016/0005-2736(92)90104-T; YOSHIMURA A, 1985, EXP CELL RES, V160, P126, DOI 10.1016/0014-4827(85)90242-3	47	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14614	14619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182068				2022-12-27	WOS:A1994NM06500049
J	KIMATA, Y; KOHNO, K				KIMATA, Y; KOHNO, K			ELONGATION-FACTOR-2 MUTANTS DEFICIENT IN DIPHTHAMIDE FORMATION SHOW TEMPERATURE-SENSITIVE CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN-RESISTANT MUTANTS; MR 100,000 SUBSTRATE; PROTEIN KINASE-III; DIPHTHERIA-TOXIN; SACCHAROMYCES-CEREVISIAE; BIOSYNTHESIS; METHYLTRANSFERASE; IDENTIFICATION; EXPRESSION; RECEPTOR	Protein synthesis elongation factor 2 (EF-2) from eukaryotes contains an unusual modified histidine residue, termed diphthamide. Diphthamide has been shown to be a site of ADP-ribosylation by bacterial toxins, but its function remains obscure. We expressed mutant genes of EF-2 with substitutions of 19 other amino acids for His-699, which is modified to diphthamide, in yeast cells and found that they can be classified into three groups. In the first group (Group 1), replacement of His-699 by the basic amino acid Arg or Lys showed not only loss of EF 2 activity but also inhibitory effects on the growth of cells co-expressing wild-type EF-2. In the second group (Group 2), replacement with Gly, Pro, Ser, or Asp resulted in nonfunctional EF-2, but it did not affect the growth of cells co-expressing wild-type EF-2. In the third group (Group 3), replacement by one of the other 13 amino acids resulted in a functional EF-2. In the Group 3 mutants, EF-2 was not ribosylated by diphtheria toxin, indicating that the mutant EF-2s did not form diphthamide. However, the viable cells grew more slowly than cells expressing wild-type EF-2 and showed temperature sensitivities. This result suggests that diphthamide may confer heat resistance on EF-2, although it still may be active without diphthamide at a normal temperature.	NARA INST SCI & TECHNOL, MARA 63001, JAPAN; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	Nara Institute of Science & Technology; Osaka University			Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				CHEN JYC, 1988, J BIOL CHEM, V263, P11692; FOLEY BT, 1992, SOMAT CELL MOLEC GEN, V18, P227, DOI 10.1007/BF01233859; GILL DM, 1969, J EXP MED, V129, P1, DOI 10.1084/jem.129.1.1; HONJO T, 1968, J BIOL CHEM, V243, P3553; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KESSEL M, 1980, NATURE, V287, P250, DOI 10.1038/287250a0; KIMATA Y, 1993, BIOCHEM BIOPH RES CO, V191, P1145, DOI 10.1006/bbrc.1993.1336; KIMATA Y, 1991, Cell Structure and Function, V16, P566; KOHNO K, 1987, EXP CELL RES, V172, P54, DOI 10.1016/0014-4827(87)90092-9; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; KOHNO K, 1987, J BIOL CHEM, V262, P12298; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; MOEHRING JM, 1979, SOMAT CELL GENET, V5, P453, DOI 10.1007/BF01538880; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MOEHRING JM, 1980, P NATL ACAD SCI-BIOL, V77, P1010, DOI 10.1073/pnas.77.2.1010; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SIKORSKI RS, 1989, GENETICS, V122, P19; VANNESS BG, 1980, J BIOL CHEM, V255, P710	28	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13497	13501						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175783				2022-12-27	WOS:A1994NK18400066
J	LAMORTE, VJ; THORBURN, J; ABSHER, D; SPIEGEL, A; BROWN, JH; CHIEN, KR; FERAMISCO, JR; KNOWLTON, KU				LAMORTE, VJ; THORBURN, J; ABSHER, D; SPIEGEL, A; BROWN, JH; CHIEN, KR; FERAMISCO, JR; KNOWLTON, KU			G(G)-DEPENDENT AND RES-DEPENDENT PATHWAYS MEDIATE HYPERTROPHY OF NEONATAL RAT VENTRICULAR MYOCYTES FOLLOWING ALPHA(1)-ADRENERGIC STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MYOSIN LIGHT CHAIN-2; PROTEIN-KINASE-C; ALPHA-ADRENERGIC STIMULATION; CARDIAC GENE-TRANSCRIPTION; MYOCARDIAL-CELLS; PHOSPHOLIPASE-C; TRISPHOSPHATE FORMATION; ADENYLYL CYCLASE; GQ FAMILY	alpha(1),-Adrenergic agonists activate a hypertrophic response in cultured neonatal ventricular myocytes, which include an increase in cell size, organization of contractile proteins into sarcomeric units, and the induction of the atrial natriuretic factor (ANF) gene. Previous findings have supported a role for ras in this signaling pathway. Utilizing microinjection techniques to deliver affinity-purified neutralizing antibodies to G alpha(q,11) into cultured ventricular myocytes, the current studies demonstrate a functional requirement for the heterotrimeric G protein, G(q), in the alpha(1)-adrenergic induction of the ANF gene, changes in cell size, organization of myofilaments, and phosphoinositide hydrolysis. Expression of a constitutively active mutant of G alpha(q) leads to the expression of ANF protein in these cells. Taken together, these data suggest that G(q)-dependent pathways are necessary and sufficient to activate defined features of the hypertrophic response. In attempts to further delineate the relative roles of ras and G(q) in this pathway, we found that G alpha(q) is required for alpha(1)-adrenergic phosphoinositide hydrolysis, though ras does not appear to be necessary for this response. In addition, we coexpressed an inhibitory ras mutant, along with the constitutively active G alpha(q). Expression of ANF protein stimulated by the G alpha(q) mutant was not inhibited. Thus, both ras- and G(q)-dependent pathways are necessary to fully transduce defined features of alpha(1)-adrenergic-stimulated hypertrophy of neonatal cardiac ventricular myocytes, but activated G(q) may be able to induce ANF expression independent of inhibitory ras.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; THEODORE GILDRED CANC CTR, LA JOLLA, CA 92093 USA; AMER HEART ASSOC, BUGHER FDN CTR MOLEC BIOL, LA JOLLA, CA 92093 USA; NIDDK, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02618, HL46345] Funding Source: Medline; NIGMS NIH HHS [GM36927] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ARGENTIN S, 1985, J BIOL CHEM, V260, P4568; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE HR, 1988, J BIOL CHEM, V263, P7352; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; WU DQ, 1992, J BIOL CHEM, V267, P25798; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50	41	170	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13490	13496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175782				2022-12-27	WOS:A1994NK18400065
J	NISHIZAWA, M; YASUHARA, T; NAKAI, T; FUJIKI, Y; OHASHI, A				NISHIZAWA, M; YASUHARA, T; NAKAI, T; FUJIKI, Y; OHASHI, A			MOLECULAR-CLONING OF THE AMINOPEPTIDASE-Y GENE OF SACCHAROMYCES-CEREVISIAE - SEQUENCE-ANALYSIS AND GENE DISRUPTION OF A NEW AMINOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE YSCB; AMINO-ACIDS; YEAST; PROPEPTIDE; ACTIVATION; LOCALIZATION; MATURATION; CATALYSTS; PRECURSOR; CLEAVAGE	A yeast genomic DNA encoding a new vacuolar aminopeptidase, aminopeptidase Y, was isolated by using a cDNA fragment obtained by screening the lambda gt11 yeast cDNA library with anti-aminopeptidase Y antibody. The DNA sequence encodes 537 amino acids. The ''mature'' protein, whose NH2-terminal sequence was determined previously by analysis of the purified enzyme, consists of 481 amino acids, and the calculated molecular weight (52,900) coincides with the value obtained by SDS-polyacrylamide gel electrophoresis of the enzyme after removal of sugar chains, 53 kDa. The 56-residue preprosequence was divided into two parts by putative processing sites for signal peptidase and conversion to the mature form; the 21-residue presequence has a hydrophobic stretch which may function as the signal sequence for transit through the endoplasmic reticulum, and the 35-residue prosequence (4013 Da) accounts for the 4-kDa difference between proaminopeptidase Y in the vacuolar proteases-deleted ABYS1 mutant and wild-type mature enzyme. The aminopeptidase Y gene was localized on chromosome II by genetic mapping. A deletion mutant was constructed by disrupting the aminopeptidase Y gene. Vacuolar aminopeptidase activities toward Ala-4-methylcoumaryl-7-amide (MCA) and Lys-MCA were 13 and 20% of wild-type, and those in the presence of Co2+ were 2.2 and 2.8%, respectively. Mutant cells showed no ability to hydrolyze Lys-Ala-MCA to Lys and Ala-MCA although vacuolar carboxypeptidase Y activity was similar to that in wild-type cells.	MEIJI INST HLTH SCI,ODAWARA 250,JAPAN									AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; CHANG YH, 1989, J BIOL CHEM, V264, P6979; FREY J, 1978, BIOCHIM BIOPHYS ACTA, V527, P31, DOI 10.1016/0005-2744(78)90253-X; GARCIAALVAREZ N, 1991, EUR J BIOCHEM, V202, P993, DOI 10.1111/j.1432-1033.1991.tb16461.x; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HIRSCH HH, 1992, EUR J BIOCHEM, V203, P641, DOI 10.1111/j.1432-1033.1992.tb16594.x; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; NEBES VL, 1991, J BIOL CHEM, V266, P22851; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; PARODI AJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P1, DOI 10.1016/0304-4157(79)90006-6; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RIORDAN JF, 1984, METHOD ENZYMAT AN, V5, P44; Rothstein R., 1985, DNA CLONING, VII, P45; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YASUHARA T, 1994, J BIOL CHEM, V269, P13644	30	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13651	13655						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175800				2022-12-27	WOS:A1994NK18400086
J	SMITH, AG; SANTANA, MA; WALLACECOOK, ADM; ROPER, JM; LABBEBOIS, R				SMITH, AG; SANTANA, MA; WALLACECOOK, ADM; ROPER, JM; LABBEBOIS, R			ISOLATION OF A CDNA-ENCODING CHLOROPLAST FERROCHELATASE FROM ARABIDOPSIS-THALIANA BY FUNCTIONAL COMPLEMENTATION OF A YEAST MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; PRECURSOR PROTEINS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; GENE DISRUPTION; MITOCHONDRIA; EXPRESSION; PURIFICATION	Ferrochelatase catalyzes the insertion of ferrous iron into protoporphyrin IX to form protoheme. It is located in the mitochondria in all eukaryotes and is also found in plastids in plants. Although it has been purified from animals and microorganisms, and genes for it isolated and characterized, very little is known about plant ferrochelatases. We have isolated a cDNA for ferrochelatase from the higher plant Arabidopsis thaliana by functional complementation of a mutant of Saccharomyces cerevisiae defective in this enzyme. The cDNA encodes a protein of 52 kDa, which has 25-35% sequence similarity to ferrochelatases from other organisms. There is an N-terminal extension of about 65 residues, which is almost certainly the chloroplast transit peptide, since the precursor protein, transcribed and translated in vitro, is efficiently imported and processed to the mature size by isolated pea chloroplasts. In contrast, the precursor was not processed by mitochondrial processing peptidase activity, nor could import into isolated yeast mitochondria be demonstrated conclusively, although, presumably, in the rescued yeast mutant, at least some of the Arabidopsis ferrochelatase must be present in the mitochondria. A single transcript the same size as the cDNA was detected in both Arabidopsis leaves and roots, although the amount of message was greater in the photosynthetic tissue. Southern analysis suggests that there is a single gene for chloroplast ferrochelatase in Arabidopsis.	UNIV PARIS 07,INST JACQUES MONOD,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite	SMITH, AG (corresponding author), UNIV CAMBRIDGE,DEPT PLANT SCI,DOWNING ST,CAMBRIDGE CB2 3EA,ENGLAND.			Smith, Alison Gail/0000-0001-6511-5704	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BOUTRY M, 1987, NATURE, V328, P340, DOI 10.1038/328340a0; BOWLER C, 1989, P NATL ACAD SCI USA, V86, P3237, DOI 10.1073/pnas.86.9.3237; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DELAUNEY AJ, 1990, MOL GEN GENET, V221, P299, DOI 10.1007/BF00259392; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GOLDIN BR, 1969, BIOCHIM BIOPHYS ACTA, V171, P321, DOI 10.1016/0005-2744(69)90165-X; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HENIKOFF S, 1981, NATURE, V289, P33, DOI 10.1038/289033a0; HIRT H, 1991, P NATL ACAD SCI USA, V88, P1636, DOI 10.1073/pnas.88.5.1636; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES OTG, 1968, BIOCHEM J, V107, P113, DOI 10.1042/bj1070113; KARR SR, 1988, BIOCHEM J, V254, P799, DOI 10.1042/bj2540799; KRONSTAD JW, 1989, GENE, V79, P97, DOI 10.1016/0378-1119(89)90095-4; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; MINET M, 1992, PLANT J, V2, P417; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MORGENTHALER JJ, 1975, ARCH BIOCHEM BIOPHYS, V168, P289, DOI 10.1016/0003-9861(75)90253-2; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; PFALLER R, 1989, J BIOL CHEM, V264, P34; PORRA RJ, 1968, BIOCHEM J, V108, P343, DOI 10.1042/bj1080343; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; Sambrook J, 1989, MOL CLONING LABORATO; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; THOMPSON WF, 1983, PLANTA, V158, P487, DOI 10.1007/BF00397240; VANCAMP W, 1990, P NATL ACAD SCI USA, V87, P9903, DOI 10.1073/pnas.87.24.9903; VOLLAND C, 1988, J BIOL CHEM, V263, P8294; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WHELAN J, 1990, PLANT MOL BIOL, V14, P977, DOI 10.1007/BF00019394; WHELAN J, 1991, PLANT MOL BIOL, V16, P283, DOI 10.1007/BF00020559; WITTY M, 1993, PLANT PHYSIOL, V103, P139, DOI 10.1104/pp.103.1.139; ZHU D, 1992, GENETICS, V131, P803	55	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13405	13413						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175771				2022-12-27	WOS:A1994NK18400054
J	WAKABAYASHI, S; BERTRAND, B; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M				WAKABAYASHI, S; BERTRAND, B; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M			MUTATION OF CALMODULIN-BINDING SITE RENDERS THE NA+/H+ EXCHANGER (NHE1) HIGHLY H+-SENSITIVE AND CA2+ REGULATION-DEFECTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; GROWTH-FACTOR; MOLECULAR-CLONING; HUMAN-FIBROBLASTS; ALPHA-THROMBIN; OKADAIC ACID; KINASE-C; ANTIPORTER; ACTIVATION; EXPRESSION	The ubiquitous plasma membrane Na+/H+ exchanger (NHE1) is rapidly activated in response to various extracellular signals. To understand how the intracellular Ca2+ is involved in this activation process, we investigated the effect of Ca2+ ionophore ionomycin on activity of the wild-type or mutant NHE1 expressed in the exchanger deficient fibroblasts (PS120). In wild-type transfectants, a short (up to 1 min) incubation with ionomycin induced a significant alkaline shift (similar to 0.2 pH unit) in the intracellular pH (pH(i)) dependence of the rate of 5-(N-ethyl-N-isopropyl) amiloride-sensitive Na-22(+) uptake, without changes in the cell volume and phosphorylation state of NHE1. Mutations that prevented calmodulin (CaM) binding to a high affinity binding region (region A, amino acids 636-656) rendered NHE1 constitutively active by inducing a similar alkaline shift in pH(i) dependence of Na+/H+ exchange. These same mutations abolished the ionomycin-induced NHE1 activation. These data suggest that CaM-binding region A functions as an ''autoinhibitory domain'' and that Ca2+/CaM activates NHE1 by binding to region A and thus abolishing its inhibitory effect. Furthermore, we found that a short stimulation with thrombin and ionomycin had apparently no additive effects on the alkaline shift in the pH(i) dependence of Na+/H+ exchange and that deletion of region A also abolished such an alkaline shift induced by a short thrombin stimulation, The results strongly suggest that the early thrombin response and the ionomycin response share the same activation mechanism. Based on these data and the results shown in the accompanying paper (Bertrand, B., Wakabayashi, S., Ikeda, T, Pouyssegur, J., and Shigekawa, M. (1994) J. Biol. Chem. 269, 13703-13709), we propose that CaM is one of the major ''signal transducers'' that mediate distinct extracellular signals to the ''pH(i) sensor'' of NHE1.	UNIV NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	WAKABAYASHI, S (corresponding author), NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN.							ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GRINSTEIN S, 1987, J GEN PHYSIOL, V89, P185, DOI 10.1085/jgp.89.2.185; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENDEY B, 1989, J BIOL CHEM, V264, P19540; HUANG CL, 1987, J BIOL CHEM, V262, P14134; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; KIMURA M, 1990, J BIOL CHEM, V265, P21068; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WOLL E, 1993, FEBS LETT, V322, P261, DOI 10.1016/0014-5793(93)81583-L	34	228	231	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13710	13715						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175807				2022-12-27	WOS:A1994NK18400095
J	DASILVA, CP; EMMRICH, F; GUSE, AH				DASILVA, CP; EMMRICH, F; GUSE, AH			ADRIAMYCIN INHIBITS INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE ACTIVITY IN-VITRO AND BLOCKS FORMATION OF INOSITOL 1,3,4,5-TETRAKISPHOSPHATE IN STIMULATED JURKAT T-LYMPHOCYTES - DOES INOSITOL 1,3,4,5-TETRAKISPHOSPHATE PLAY A ROLE IN CA2+-ENTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIPID-PEROXIDATION; CA-2+ INFLUX; HL-60 CELLS; TETRAKISPHOSPHATE; POLYPHOSPHATES; ACTIVATION; TRISPHOSPHATE; MEMBRANE	Effects of the cytostatic drug adriamycin on inositol polyphosphate metabolism were analyzed in a human T-cell line (Jurkat) using a recently developed anion-exchange high performance liquid chromatography/ post-column complexometric dye system. Treatment of intact T-cells with adriamycin prior to stimulation with an anti-CD3 monoclonal antibody induced a dose- and time-dependent decrease in the intracellular level of inositol 1,3,4,5-tetrakisphosphate (complete inhibition after 2 h at 10 mu M adriamycin) and an increase in the level of inositol 1,3,4-trisphosphate without significantly changing the levels of other inositol phosphates. A marked inhibition of the inositol 1,4,5-trisphosphate 3-kinase activity and a slight activation of the inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity were observed in cytosolic extracts in the presence of adriamycin, providing an explanation for the drug-induced metabolic effect. Adriamycin thus seems to be an extremely valuable tool for further dissecting inositol polyphosphate metabolism, as well as signaling pathways. Along these lines, we observed that adriamycin did not change the free cytosolic Ca2+ concentration of Jurkat T-lymphocytes and, in particular, did not modulate Ca2+ influx upon T-cell receptor stimulation. We conclude that (i) inositol phosphate signaling pathways constitute an as yet undescribed target for the action of adriamycin and that (ii) an increase of inositol 1,3,4,5-tetrakisphosphate is not necessary for sustained Ca2+-entry in stimulated T-cells.	UNIV ERLANGEN NURNBERG,MAX PLANCK SOC,INST CLIN IMMUNOL,CLIN RES UNIT RHEUMATOL IMMUNOL,D-91054 ERLANGEN,GERMANY; UNIV COIMBRA,DEPT CHEM,P-3049 COIMBRA,PORTUGAL; UNIV COIMBRA,CTR CELL BIOL,P-3049 COIMBRA,PORTUGAL	Max Planck Society; University of Erlangen Nuremberg; Universidade de Coimbra; Universidade de Coimbra								BALLA T, 1991, J BIOL CHEM, V266, P24719; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONADONNA G, 1988, HDB MED ONCOLOGY, P335; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; GAMBETTA RA, 1989, TUMORI, V75, P358, DOI 10.1177/030089168907500411; GREENE RF, 1983, CANCER RES, V43, P3417; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; GUSE AH, 1992, J CHROMATOGR, V593, P157, DOI 10.1016/0021-9673(92)80281-X; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; GUSE AH, 1991, J BIOL CHEM, V266, P24498; HILL TD, 1989, J CELL PHYSIOL, V140, P403, DOI 10.1002/jcp.1041400227; IMBODEN JB, 1987, BIOCHEM J, V247, P695, DOI 10.1042/bj2470695; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KING WG, 1989, J BIOL CHEM, V264, P6070; LANZI C, 1988, BIOCHEM PHARMACOL, V37, P3497, DOI 10.1016/0006-2952(88)90702-2; LANZI C, 1991, INT J CANCER, V47, P136, DOI 10.1002/ijc.2910470124; LEAR L, 1992, BIOCHEM PHARMACOL, V44, P747, DOI 10.1016/0006-2952(92)90412-C; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MAYR GW, 1990, METHODS INOSITIDE RE, P83; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MURPHREE SA, 1981, BIOCHIM BIOPHYS ACTA, V649, P317, DOI 10.1016/0005-2736(81)90421-1; Neidle S., 1983, MOL ASPECTS ANTICANC, P35; PITTET D, 1989, J BIOL CHEM, V264, P18489; PITTET D, 1989, J BIOL CHEM, V264, P7251; POSADA J, 1989, CANCER RES, V49, P6634; SCHOBITZ B, 1991, EUR J BIOCHEM, V199, P257, DOI 10.1111/j.1432-1033.1991.tb16118.x; SIM SS, 1990, J BIOL CHEM, V265, P10367; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113	36	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12521	12526						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175661				2022-12-27	WOS:A1994NH71600026
J	NARAYAN, S; WIDEN, SG; BEARD, WA; WILSON, SH				NARAYAN, S; WIDEN, SG; BEARD, WA; WILSON, SH			RNA-POLYMERASE-II TRANSCRIPTION .2. RATE OF PROMOTER CLEARANCE IS ENHANCED BY A PURIFIED ACTIVATING TRANSCRIPTION FACTOR CAMP RESPONSE ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL PREINITIATION COMPLEX; GENE-TRANSCRIPTION; DNA-BINDING; FACTOR CREB; PHOSPHORYLATION; INITIATION; MECHANISM; PURIFICATION; REPRESSOR; TARGETS	The core promoter of the human DNA beta-polymerase (beta-pol) gene is regulated by proteins binding at 3 GC boxes and the single activating transcription factor/ cAMP response element (ATF/CRE) centered at -45; the central 8 residues of this ATF/CRE match the ATF/CRE consensus sequence, TGACGTCA. Previously, we purified a beta-pol promoter ATF/CRE-binding protein (named palindrome-binding protein or PBP) from bovine testes and found that this protein is a beta-pol promoter transcriptional activator in vitro using a HeLa nuclear extract transcription system (Widen, S. G., and Wilson, S. H. (1991) Biochemistry 30, 6296-6305). In this study, we determined the mechanism of in vitro transcriptional activation by this purified PBP. We used a PBP-depleted HeLa nuclear extract transcription system with an artificial promoter containing a solitary activator element corresponding to the entire 22-nucleotide beta-pol promoter ATF/CRE-binding site. Kinetic analyses of the 180-nucleotide run-off product formation indicated that stimulation of transcriptional activity by PBP was due entirely to an increase in the rate constant for promoter clearance. Thus, under our conditions, the purified PBP had no effect on the rate of closed preinitiation complex formation or for the closed complex to open complex transition. Instead, the rate of productive initiation leading to the 180-nucleotide transcript was stimulated by PBP. We found that the rate of closed preinitiation complex formation was not in rapid equilibrium with promoter and RNA polymerase II, in contrast to the model with prokaryotic RNA polymerase transcription. The results also indicated that PBP binding to the ATF/ CRE is required for the stimulation of promoter clearance. These studies define the kinetic mechanism of a purified ATF/CRE-binding protein in stimulation of the in vitro transcription of a designed mammalian promoter.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; ENGLANDER EW, 1992, NUCLEIC ACIDS RES, V20, P5527, DOI 10.1093/nar/20.21.5527; ENGLANDER EW, 1991, NUCLEIC ACIDS RES, V19, P3369, DOI 10.1093/nar/19.12.3369; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HERSHBERGER PA, 1991, J MOL BIOL, V222, P479, DOI 10.1016/0022-2836(91)90491-N; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SUGDEN B, 1973, J BIOL CHEM, V218, P3777; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEIBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	36	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12755	12763						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175688				2022-12-27	WOS:A1994NH71600060
J	DEVULAPALLE, KS; MOOSER, G				DEVULAPALLE, KS; MOOSER, G			SUBSITE SPECIFICITY OF THE ACTIVE-SITE OF GLUCOSYLTRANSFERASES FROM STREPTOCOCCUS-SOBRINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GLUCAN-BINDING; GENE; INHIBITION; MUTANS; GALACTOSIDASE; GLUCOSIDASE; MECHANISM; PEPTIDE; ENZYME	Oral bacterial glucosyltransferases use sucrose as a substrate in synthesis of either alpha-1,3 water-insoluble glucans (GTF-I) or alpha-1,6 water-soluble glucans (GTF-S). The binding specificity of the glucosyl and fructosyl subsites of the sucrose-binding site was examined to identify ligands that bind exclusively to each subsite. Such compounds can be used as reporter ligands to localize the subsite binding of any reversible or irreversible active site inhibitor. In examining potential subsite-specific ligands, binding affinity to GTF-I was consistently stronger than binding to GTF-S. Fructose was found to be a moderate GTF inhibitor, but free glucose, alpha-methylglucoside, and glucose epimers were very weak inhibitors. In contrast, glucose transition-state analogues, D-glucano-1,5-lactone, 1-deoxynojirimycin (dNJ), and most N-alkyl derivatives of dNJ were moderate to strong inhibitors; in particular N-methyl-dNJ was found to be the strongest GTF inhibitor identified to date. Multiple inhibitor kinetic analysis established nonexclusive binding of fructose and dNJ at the respective subsites. Binding of fructose and N-alkyl-dNJ derivatives was, to a small degree, partially exclusive. Fructose and dNJ were used as reporter ligands to localize the subsite specificity of two test inhibitors: a reversible inhibitor, Zn2+, and an irreversible inhibitor, diethyl pyrocarbonate (DEP). Zn2+ paired with dNJ in multiple inhibitor kinetic analysis showed no competition between the inhibitors, while Zn2+ paired with fructose decreased ligand affinity 7-fold, establishing Zn2+ binding exclusively at the fructose subsite. Analogous experiments adapted to the irreversible inhibitor DEP indicated that it reacts at both subsites or induces a protein conformational change at one subsite that alters ligand binding at the adjacent subsite.	UNIV SO CALIF,SCH DENT,DEPT BASIC SCI,BIOCHEM SECT,LOS ANGELES,CA 90089	University of Southern California					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003739, R37DE003739] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE03739] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABO H, 1991, J BACTERIOL, V173, P989, DOI 10.1128/jb.173.3.989-996.1991; ANGYAL SJ, 1979, ASYMMETRY CARBOHYDRA, P15; CHIDA N, 1992, CARBOHYD RES, V237, P185, DOI 10.1016/S0008-6215(92)84242-K; Cleland W W, 1979, Methods Enzymol, V63, P103; DONSIMONI R, 1988, ENZYME, V39, P78; FERRETTI JJ, 1987, J BACTERIOL, V169, P4271, DOI 10.1128/jb.169.9.4271-4278.1987; FERSHT A, 1977, ENZYME STRUCTURE MEC, P244; FLEET GWJ, 1985, TETRAHEDRON LETT, V26, P5073, DOI 10.1016/S0040-4039(01)80856-X; FLEET GWJ, 1985, J CHEM SOC CHEM COMM, V13, P841; FU D, 1988, CARBOHYD RES, V93, P97; GIBBONS RJ, 1975, ANNU REV MED, V26, P121, DOI 10.1146/annurev.me.26.020175.001005; GILMORE KS, 1990, INFECT IMMUN, V58, P2452, DOI 10.1128/IAI.58.8.2452-2458.1990; GROVER AK, 1977, BIOCHIM BIOPHYS ACTA, V482, P109, DOI 10.1016/0005-2744(77)90359-X; HANOZET G, 1981, J BIOL CHEM, V256, P3703; HEHRE EJ, 1977, BIOCHEMISTRY-US, V16, P1780, DOI 10.1021/bi00628a003; HONDA O, 1990, J GEN MICROBIOL, V136, P2099, DOI 10.1099/00221287-136-10-2099; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LEGLER G, 1984, CARBOHYD RES, V128, P61, DOI 10.1016/0008-6215(84)85084-3; LEGLER G, 1986, CARBOHYD RES, V155, P119, DOI 10.1016/S0008-6215(00)90138-1; LEHMANN J, 1977, CARBOHYD RES, V58, P73, DOI 10.1016/S0008-6215(00)83405-9; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; MOOSER G, 1989, BIOCHEMISTRY-US, V28, P443, DOI 10.1021/bi00428a006; MOOSER G, 1991, J BIOL CHEM, V266, P8916; MOOSER G, 1988, INFECT IMMUN, V56, P880, DOI 10.1128/IAI.56.4.880-884.1988; MOOSER G, 1985, J BIOL CHEM, V260, P6907; Mooser G., 1992, ENZYMES, P187; NEWBRUN E, 1983, ARCH ORAL BIOL, V28, P531, DOI 10.1016/0003-9969(83)90186-3; SEGEL IH, 1975, ENZYME KINETICS, P481; SHIROZA T, 1987, J BACTERIOL, V169, P4263, DOI 10.1128/jb.169.9.4263-4270.1987; UEDA S, 1988, GENE, V69, P101, DOI 10.1016/0378-1119(88)90382-4	30	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11967	11971						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163499				2022-12-27	WOS:A1994NG37700047
J	RIDDICK, DS; HUANG, Y; HARPER, PA; OKEY, AB				RIDDICK, DS; HUANG, Y; HARPER, PA; OKEY, AB			2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN VERSUS 3-METHYLCHOLANTHRENE - COMPARATIVE-STUDIES OF AH RECEPTOR-BINDING, TRANSFORMATION, AND INDUCTION OF CYP1A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; MOUSE HEPATOMA-CELLS; RESPONSIVE TRANSCRIPTIONAL ENHANCER; PROTEIN-DNA INTERACTIONS; POLYCYCLIC AROMATIC-COMPOUNDS; DIOXIN-RECEPTOR; GENE-EXPRESSION; MESSENGER-RNA; INVITRO TRANSFORMATION; CULTURE LINES	Halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons such as 3-methylcholanthrene (MC) cause transcriptional activation of the CYP1A1 gene via their interaction with the aromatic hydrocarbon (Ah) receptor. Direct radioligand binding and competitive binding studies demonstrated that the cytosolic Ah receptor from the mouse hepatoma cell line Hepa-1 bound TCDD with an affinity similar to 3-4-fold greater than that for MC. However, TCDD was similar to 1,000-fold more potent than MC as an inducer of CYP1A1-mediated aryl hydrocarbon hydroxylase activity in cultured Hepa-1 cells as assessed at 14 h following exposure to inducer. To understand the basis for this quantitative discrepancy between Ah receptor binding affinity and CYP1A1 induction potency, we systematically compared TCDD and MC for their abilities to activate sequential events in the CYP1A1 induction mechanism that occur subsequent to initial binding to the cytosolic Ah receptor. Using a gel retardation assay, TCDD and MC were shown to be equipotent in causing in vitro transformation of the cytosolic Ah receptor to its DNA-binding form. In addition, the transformed Ah receptor bound to a specific dioxin-responsive enhancer sequence with the same apparent affinity when MC was the ligand as when TCDD was the ligand. At an early time point (i.e. 2 h) in the CYP1A1 induction process, TCDD was only similar to 4-25-fold more potent than MC in stimulating the nuclear uptake of the ligand-Ah receptor complex, and the two ligands displayed a relatively small difference (greater than or equal to 10-fold) in CYP1A1 mRNA induction potency. When assessed at 4 h following ligand treatment, TCDD was only similar to 10-fold more potent than MC as an aryl hydrocarbon hydroxylase inducer, suggesting a time-dependent reduction in the potency of MC in intact cells. Exposure of Hepa-1 cells to MC over a 16-h time course resulted in an increased ability of these cells to convert [H-3]MC to alkali-extractable metabolites. Our data are consistent with the idea that TCDD and MC display relatively small differences in their intrinsic abilities to activate Ah receptor-mediated events. The reduced biological potency of MC observed in intact cells and whole animals is at least partially due to the more rapid metabolic inactivation of this ligand compared with the poorly metabolized TCDD. By extension, the extraordinary toxicity of TCDD may not be explained solely by its high affinity for the cytosolic Ah receptor.	UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ON,CANADA; HOSP SICK CHILDREN,RES INST,DIV CLIN PHARMACOL & TOXICOL,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								AITIO A, 1974, RES COMMUN CHEM PATH, V9, P701; ASTROFF B, 1989, TOXICOLOGY, V59, P285, DOI 10.1016/0300-483X(89)90198-4; BANK PA, 1992, EUR J PHARM-ENVIRON, V228, P85, DOI 10.1016/0926-6917(92)90016-6; BERGHARD A, 1992, CARCINOGENESIS, V13, P651, DOI 10.1093/carcin/13.4.651; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P682; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNCE NJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P384, DOI 10.1016/0003-9861(88)90044-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOU M, 1990, CARCINOGENESIS, V11, P1691, DOI 10.1093/carcin/11.10.1691; CRESSIE NAC, 1981, BIOMETRICS, V37, P235, DOI 10.2307/2530414; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DENISON MS, 1991, ARCH BIOCHEM BIOPHYS, V284, P158, DOI 10.1016/0003-9861(91)90278-Q; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1986, EUR J BIOCHEM, V155, P223, DOI 10.1111/j.1432-1033.1986.tb09480.x; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DUNN RT, 1993, BIOCHEM PHARMACOL, V45, P1121, DOI 10.1016/0006-2952(93)90257-W; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GASIEWICZ TA, 1991, MOL PHARMACOL, V40, P607; GASIEWICZ TA, 1991, BIOCHEMISTRY-US, V30, P2909, DOI 10.1021/bi00225a026; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GUENTHNER TM, 1977, J BIOL CHEM, V252, P8981; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HARPER PA, 1992, MOL PHARMACOL, V42, P603; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HARRIS M, 1990, TOXICOL APPL PHARM, V105, P243, DOI 10.1016/0041-008X(90)90186-X; HO D, 1983, MOL PHARMACOL, V23, P198; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISRAEL DI, 1983, J BIOL CHEM, V258, P390; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JAISWAL AK, 1985, BIOCHEM PHARMACOL, V34, P2721, DOI 10.1016/0006-2952(85)90573-8; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KIMURAS, 1984, J BIOL CHEM, V259, P10705; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MAHON MJ, 1992, ARCH BIOCHEM BIOPHYS, V297, P1, DOI 10.1016/0003-9861(92)90633-8; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V292, P250, DOI 10.1016/0003-9861(92)90076-9; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1968, J BIOL CHEM, V243, P6242; NEBERT DW, 1970, MOL PHARMACOL, V6, P293; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; NIWA A, 1975, MOL PHARMACOL, V11, P399; OKEY AB, 1980, J BIOL CHEM, V255, P1415; OKEY AB, 1979, J BIOL CHEM, V254, P1636; OKEY AB, 1982, EUR J BIOCHEM, V127, P39, DOI 10.1111/j.1432-1033.1982.tb06834.x; OKEY AB, 1984, CANCER RES, V44, P1426; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PASCO DS, 1993, J BIOL CHEM, V268, P1053; PIPER W N, 1973, Environmental Health Perspectives, V5, P241, DOI 10.2307/3428134; POLAND A, 1975, MOL PHARMACOL, V11, P389; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1974, MOL PHARMACOL, V10, P349; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND AP, 1974, J BIOL CHEM, V249, P5599; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; PROKIPCAK RD, 1991, CAN J PHYSIOL PHARM, V69, P1204, DOI 10.1139/y91-176; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROSE JQ, 1976, TOXICOL APPL PHARM, V36, P209, DOI 10.1016/0041-008X(76)90001-6; ROSENGREN R, 1992, CHEM RES TOXICOL, V5, P376, DOI 10.1021/tx00027a009; RUCCI G, 1988, ARCH BIOCHEM BIOPHYS, V265, P197, DOI 10.1016/0003-9861(88)90385-2; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Sambrook J, 1989, MOL CLONING LABORATO; SANTOSTEFANO M, 1992, ARCH BIOCHEM BIOPHYS, V297, P73, DOI 10.1016/0003-9861(92)90642-A; TIERNEY B, 1980, ARCH BIOCHEM BIOPHYS, V200, P513, DOI 10.1016/0003-9861(80)90383-5; Titus DE, 1991, PROMEGA PROTOCOLS AP; TSUI HW, 1981, CAN J PHYSIOL PHARM, V59, P927, DOI 10.1139/y81-143; TUKEY RH, 1981, J BIOL CHEM, V256, P6969; TUKEY RH, 1982, CELL, V31, P275, DOI 10.1016/0092-8674(82)90427-5; Vinopal J H, 1973, Arch Environ Contam Toxicol, V1, P122; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; XU LC, 1990, BIOCHEM PHARMACOL, V40, P1399; ZYTKOVICZ TH, 1982, CANCER RES, V42, P4387	78	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12118	12128						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163516				2022-12-27	WOS:A1994NG37700068
J	CAPPS, GG; ZUNIGA, MC				CAPPS, GG; ZUNIGA, MC			CLASS-I HISTOCOMPATIBILITY MOLECULE ASSOCIATION WITH PHOSPHORYLATED CALNEXIN - IMPLICATIONS FOR RATES OF INTRACELLULAR-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSPLANTATION ANTIGENS; PEPTIDE BINDING; VIRAL PEPTIDES; CELL-SURFACE; T-CELLS; COMPLEX; PROTEIN; BETA-2-MICROGLOBULIN; CHAPERONE	Recent studies have shown that the endoplasmic reticulum (ER)-resident protein, calnexin, associates with class I major histocompatibility complex (MHC) molecules early in their biosynthesis. It has been suggested that calnexin participates in the assembly of class I MHC molecules or in the retention within the ER of unassembled class I molecules. We have examined the role of phosphorylation of calnexin in its association with mouse class I MHC molecules. We show that phosphocalnexin associates with H-2L(d) and H-2D(b) molecules but not with H-2K(b) and H-2D(d) molecules, although calnexin-H2K(b) association can be demonstrated. These observations are interesting in light of the fact that H-2K(b) and H-2D(d) molecules are transported out of the ER more rapidly than are H-2L(d) and H-2D(b) molecules. H-2L(d) and H-2D(b) molecules differ in amino acid sequence only in their membrane-distal alpha1 and alpha2 domains. Nevertheless, the affinity of phosphocalnexin for H-2L(d) is greater than its affinity for H-2D(b). Furthermore, H-2D(b) becomes endoglycosidase H-resistant more slowly in cells in which it associates with phosphocalnexin than in cells in which it does not. Ca2+ ionophore A23187 prevents association of phosphocalnexin with H-2L(d) molecules in vivo but does not cause the disruption of phosphocalnexin-H-2L(d) complexes after they have formed. A23187 does not prevent assembly of H-2L(d)-beta2-microglobulin (beta2-m) heterodimers. Furthermore, phosphocalnexin is found associated with H-2L(d) molecules regardless of their state of assembly with beta2-m and antigenic peptide. These results suggest that phosphocalnexin association with class I MHC molecules does not play a role in assembly of the class I MHC-beta2-m-peptide complex nor in preventing release of unassembled class I molecules from the ER but may otherwise influence their rate of transport through the ER.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,DEPT BIOL,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BURKE T, 1989, MOL IMMUNOL, V26, P1095, DOI 10.1016/0161-5890(89)90053-9; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAPPS GG, 1993, J BIOL CHEM, V268, P21263; CAPPS GG, 1990, BIOTECHNIQUES, V8, P62; CAPPS GG, 1993, J IMMUNOL, V151, P159; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; DAVID W, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JONES PP, 1980, SELECTED METHODS CEL, P398; KAARIAINEN L, 1984, ANNU REV MICROBIOL, V38, P91, DOI 10.1146/annurev.mi.38.100184.000515; KLEIN J, 1986, NATURAL HIST MAJOR H, P609; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MILNER RE, 1991, J BIOL CHEM, V266, P7155; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER KC, 1992, J IMMUNOL, V149, P3580; PARKER KC, 1992, J IMMUNOL, V149, P1896; PULLEN JK, 1992, J IMMUNOL, V148, P953; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROCK KL, 1992, P NATL ACAD SCI USA, V89, P8918, DOI 10.1073/pnas.89.19.8918; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; WADA I, 1991, J BIOL CHEM, V266, P19599; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZUNIGA MC, 1983, CELL, V34, P535, DOI 10.1016/0092-8674(83)90386-0; ZUNIGA MC, 1986, J CELL BIOL, V102, P1, DOI 10.1083/jcb.102.1.1	44	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11634	11639						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157696				2022-12-27	WOS:A1994NF96600098
J	KENNEDY, SP; WEED, SA; FORGET, BG; MORROW, JS				KENNEDY, SP; WEED, SA; FORGET, BG; MORROW, JS			A PARTIAL STRUCTURAL REPEAT FORMS THE HETERODIMER SELF-ASSOCIATION SITE OF ALL BETA-SPECTRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; FUNCTIONAL DOMAINS; MEMBRANE-PROTEINS; IDENTIFICATION; CYTOSKELETON; OLIGOMERS; CDNA; ELLIPTOCYTOSIS; PEPTIDES; SEQUENCE	The self-polymerization of alphabeta-spectrin heterodimers to form tetramers and higher oligomers is central to its role as a membrane stabilizer and organizer. Mutations near the amino terminus of alphaISIGMA1-spectrin or the COOH terminus of betaISIGMA1-spectrin often lead to profound impairment of heterodimer polymerization and to hemolytic disease of varying severity. Previous studies using an 80-kDa univalent fragment of alphaISIGMA1-spectrin have established that the amino-terminal segment of alphaISIGMA1-spectrin mediates the association of the alpha subunit with either intact heterodimers or with isolated beta-spectrin (betaISIMGA1). However, the nature of the self-association site in beta-spectrin has remained unclear. In the present study, native beta-spectrin and recombinant beta-spectrin peptides representing COOH-terminal portions of two alternative transcripts of the gene on chromosome 2 (betaISIGMA1 or ''erythrocyte'' spectrin and betaISIGMA2 or ''muscle'' spectrin), and one transcript of the gene on chromosome 14 (betaIISIGMA1 or ''beta(G)-fodrin'') have been examined for their ability to bind either intact alphabeta-spectrin or the alphaI-spectrin 80-kDa univalent fragment. Deletion of the nonhomologous beta-spectrin sequence downstream of repeat 17 (spectrin domain III) had no discernible effect on binding. Truncations proximal to codon 2085 of betaISIGMA1-spectrin demonstrated a precipitous loss of activity, accounted for by a loss of both binding affinity and capacity. Further truncations to repeat 16 (codon 1979) restored binding activity to levels approximating that of the intact molecule. Repeat 16/17 and 17/16 chimeras displayed reduced binding activity. Collectively, these data indicate that the beta-subunit self-association site is highly sensitive to conformation, involves widespread interactions within the 17th repeat unit, is largely independent of sequences in domain III, and can be recreated by the deletion of all residues distal to the COOH end (codon 1979) of the 16th and presumably other spectrin sequence repeat units. All beta-spectrins appear to use this binding motif, regardless of the nature of the nonhomologous sequence in domain III.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Weed, Scott/0000-0001-7033-9999				CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P248, DOI 10.1002/cm.970120406; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; KENNEDY S P, 1991, Journal of Cell Biology, V115, p42A; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, IN PRESS FASEB J; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Maniatis T., 1982, MOL CLONING; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; MORROW JS, 1981, J SUPRAMOL STR CELL, V17, P275, DOI 10.1002/jsscb.380170308; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; PALEK J, 1992, BLOOD, V80, P308; SPEICHER DW, 1983, J BIOL CHEM, V258, P4931; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; TSE WT, 1991, BLOOD, V78, P517; WEAVER DC, 1984, J BIOL CHEM, V259, P6170; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINKELMANN JC, 1988, BLOOD, V72, P328; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YURCHENCO PD, 1982, J BIOL CHEM, V257, P9102	39	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11400	11408						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157672				2022-12-27	WOS:A1994NF96600064
J	KUMAR, S; MATSUZAKI, T; YOSHIDA, Y; NODA, M				KUMAR, S; MATSUZAKI, T; YOSHIDA, Y; NODA, M			MOLECULAR-CLONING AND BIOLOGICAL-ACTIVITY OF A NOVEL DEVELOPMENTALLY-REGULATED GENE ENCODING A PROTEIN WITH BETA-TRANSDUCIN-LIKE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN NEURO-BLASTOMA; GAMMA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; ADENYLYL CYCLASE; SHOWS HOMOLOGY; CELL-LINE; EXPRESSION; IDENTIFICATION; STIMULATION	In the developing mammalian central nervous system, neural precursor cells show a tightly regulated inverse relationship between cell proliferation and differentiation. The molecular mechanisms which control the interrelationship between these two events are poorly understood. To approach this problem, we previously identified several novel genes which are most prominently expressed in the early embryonic brain. Further cloning and sequencing of one such gene, Nedd1, revealed that it can encode a protein with a M(r) of 71,000, the amino-terminal half of which shares significant structural similarity with the beta-subunit of heterotrimeric GTP-binding proteins. Nedd1 mRNA is strongly expressed in early embryonic brain, but it can be detected at low levels in a number of adult tissues as well as cell lines and is up-regulated in an embryonal carcinoma cell line upon retinoic acid-induced differentiation. Ectopic expression of Nedd1 gene by means of eukaryotic vectors in various cell lines resulted in varying degrees of growth suppression. The strongest effects were evident in differentiation-competent neuroblastoma-derived cell lines. Our results suggest that the Nedd1 gene may play a role in the differentiation-coupled growth arrest in neuronal cells.			KUMAR, S (corresponding author), JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN.		Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814				AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CATTANEO E, 1991, TRENDS NEUROSCI, V14, P338, DOI 10.1016/0166-2236(91)90158-Q; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FISCHER PB, 1982, P NATL ACAD SCI USA, V79, P3527; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAFFREY EV, 1976, IN VITRO, V12, P144; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIS W, 1989, ABHANDL MATH PHYS KO, V26, P313; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JAKOB H, 1973, ANN INST PASTEUR MIC, VB124, P269; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KITANI H, 1991, IN VITRO CELL DEV B, V27, P615; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LEFKOWITZ RJ, 1992, NATURE, V358, P372, DOI 10.1038/358372a0; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; Sambrook J, 1989, MOL CLONING LABORATO; SAZUKA T, 1992, BIOCHIM BIOPHYS ACTA, V1132, P240, DOI 10.1016/0167-4781(92)90156-T; SCHLOSS JA, 1990, MOL GEN GENET, V221, P443, DOI 10.1007/BF00259410; SEKIGUCHI M, 1979, JPN J EXP MED, V49, P67; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SUGIMOTO T, 1984, J NATL CANCER I, V73, P51; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	58	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11318	11326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157664				2022-12-27	WOS:A1994NF96600054
J	CLARK, DP; DURELL, S; MALOY, WL; ZASLOFF, M				CLARK, DP; DURELL, S; MALOY, WL; ZASLOFF, M			RANALEXIN - A NOVEL ANTIMICROBIAL PEPTIDE FROM BULLFROG (RANA-CATESBEIANA) SKIN, STRUCTURALLY RELATED TO THE BACTERIAL ANTIBIOTIC, POLYMYXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANTIBACTERIAL PEPTIDES; FROG-SKIN; BOVINE NEUTROPHILS; AMPHIBIAN SKIN; PIG INTESTINE; IMMUNITY; CDNA; DERMORPHIN; PRECURSOR	Antimicrobial peptides comprise a diverse class of molecules used in host defense by plants, insects, and animals. In this study we have isolated a novel antimicrobial peptide from the skin of the bullfrog, Rana catesbeiana. This 20 amino acid peptide, which we have termed Ranalexin, has the amino acid sequence: NH2-Phe-Leu-Gly-Gly-Leu-Ile-Lys-Ile-Val-Pro-Ala-Met-Ile- Cys-Ala-Val-Thr-Lys-Lys-Cys-COOH, and it contains a single intramolecular disulfide bond which forms a heptapeptide ring within the molecule. Structurally, Ranalexin resembles the bacterial antibiotic, polymyxin, which contains a similar heptapeptide ring. We have also cloned the cDNA for Ranalexin from a metamorphic R. catesbeiana tadpole cDNA library. Based on the cDNA sequence, it appears that Ranalexin is initially synthesized as a propeptide with a putative signal sequence and an acidic amino acid-rich region at its amino-terminal end. Interestingly, the putative signal sequence of the Ranalexin cDNA is strikingly similar to the signal sequence of opioid peptide precursors isolated from the skin of the South American frogs Phyllomedusa sauvagei and Phyllomedusa bicolor. Northern blot analysis and in situ hybridization experiments demonstrated that Ranalexin mRNA is first expressed in R. catesbeiana skin at metamorphosis and continues to be expressed into adulthood.	MAGAININ PHARMACEUT INC,MAGAININ RES INST,PLYMOUTH MEETING,PA 19462; HOSP UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19104; NCI,MATH BIOL LAB,BETHESDA,MD 20892	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AINSWORTH GC, 1947, NATURE, V160, P263, DOI 10.1038/160263a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTECZKO I, 1970, ZOOL POLONIAE, V20, P189; BENEDICT RG, 1947, J BACTERIOL, V54, P24; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CEVIKBAS A, 1978, TOXICON, V16, P195, DOI 10.1016/0041-0101(78)90038-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Helff OM, 1941, J MORPHOL, V68, P303, DOI 10.1002/jmor.1050680206; JONES DE, 1992, J BIOL CHEM, V267, P23216; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; KREIL G, 1984, CURR TOP CELL REGUL, V24, P261; KURIHARA T, 1972, YAKUGA ZASSHI, V92, P129, DOI 10.1248/yakushi1947.92.2_129; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOORE KS, 1991, J BIOL CHEM, V266, P19851; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; MORRIS HR, 1988, TRENDS BIOTECHNOL, V6, P140, DOI 10.1016/0167-7799(88)90083-2; NAKAJIMA K, 1967, CHEM PHARM BULL, V15, P1219; Nakajima T, 1989, Adv Exp Med Biol, V247A, P215; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SIANSLY PG, 1947, B J HOPKINS HOSP, V81, P43; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; TEUBER M, 1970, Z NATURFORSCH PT B, VB 25, P117, DOI 10.1515/znb-1970-0137; VOGLER K, 1964, EXPERIENTIA, V20, P365, DOI 10.1007/BF02147959; VOGLER K, 1960, HELV CHIM ACTA, V43, P1751, DOI 10.1002/hlca.19600430638; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	52	200	214	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10849	10855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144672				2022-12-27	WOS:A1994NF01700097
J	DAUM, G; REGENASS, S; SAP, J; SCHLESSINGER, J; FISCHER, EH				DAUM, G; REGENASS, S; SAP, J; SCHLESSINGER, J; FISCHER, EH			MULTIPLE FORMS OF THE HUMAN TYROSINE PHOSPHATASE RPTP-ALPHA - ISOZYMES AND DIFFERENCES IN GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROCELLULOSE SHEETS; CLONING; FAMILY; DROSOPHILA; EXPRESSION; TRANSFORMATION; CLEAVAGE; PROTEINS; DOMAINS; MEMBER	Among all the receptor-linked protein-tyrosine-phosphatase RPTP alpha clones described from mammalian tissues, one differed in that it encoded a 9-amino-acid insert 3 residues upstream from the transmembrane segment (Kaplan, R, Morse, B., Huebner, K, Croce, C., Howk, R. Ravera, M., Ricca, G., Jaye, M., and Schlessinger, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7000-7004). Using the polymerase chain reaction technique, simultaneous expression of both isoforms was demonstrated in human T-cell and vascular smooth muscle libraries, as well as in the A431 human epidermal cancer cell Line. Following transient expression in COS-1 cells, each isoform gave rise to two proteins of 100 and 130 kDa, respectively. Endoglycosidase treatment showed that the 100-kDa species corresponded to a molecule exclusively glycosylated on N-residues, whereas the 130-kDa species contained both, N- and O-linked carbohydrates. Pulse-chase experiments demonstrated that the smaller RPTP alpha protein is a precursor of the larger one. A high affinity antibody was generated that recognizes the immature protein only; however, both proteins can be detected by Western blot analysis after a simple chemical hydrolysis. Following Superose 12 chromatography, the 100- and 130-kDa species of RPTP alpha emerged as 200- and 340-kDa proteins, respectively. Both species exhibited similar enzymatic activities as determined with a peptide substrate in immunoprecipitates.	UNIV WASHINGTON,DEPT PATHOL SM30,SEATTLE,WA 98195; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Washington; University of Washington Seattle; New York University	DAUM, G (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM SJ70,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK000709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK0709] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAUM G, 1991, J BIOL CHEM, V266, P12211; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HATHCOCK KS, 1993, IMMUNOL RES, V12, P21, DOI 10.1007/BF02918366; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAN XH, 1993, J BIOL CHEM, V268, P6835; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	35	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10524	10528						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144638				2022-12-27	WOS:A1994NF01700052
J	RYE, KA; BARTER, PJ				RYE, KA; BARTER, PJ			THE INFLUENCE OF APOLIPOPROTEINS ON THE STRUCTURE AND FUNCTION OF SPHEROIDAL, RECONSTITUTED HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; A-II PARTICLES; CHOLESTEROL ACYLTRANSFERASE; EGG PHOSPHATIDYLCHOLINE; RICH LIPOPROTEINS; CONVERSION FACTOR; INVITRO; TRIGLYCERIDE; PROTEIN; SURFACE	This study investigates the influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins (rHDL). Spheroidal rHDL containing apolipoprotein (apo) A-I, (A-I)rHDL, were prepared by incubating discoidal rHDL with low density lipoproteins and lecithin:cholesterol acyltransferase. Spheroidal rHDL containing apoA-II, (A-II)rHDL, were prepared by displacing apoA-I from (A-I)rHDL with apoA-II. When the (A-I)rHDL were subjected to agarose gel electrophoresis, their migration was retarded relative to native HDL. The (A-II)rHDL migrated slower than either the (A-I)rHDL or native HDL. Spectroscopic studies showed that the packing order of the rHDL phospholipids was independent of apolipoprotein composition and that the polarity, or hydration, of the lipid-water interface of the (A-I)rHDL was greater than that of the (A-II)rHDL. When the rHDL were incubated with very low density lipoproteins (VLDL) and cholesteryl ester transfer protein, comparable amounts of cholesteryl ester (CE) were transferred from (A-I)rHDL and (A-II)rHDL to VLDL, The transfer of triglyceride (TG) from VLDL to (A-I)rHDL and (A-II)rHDL was also comparable. Similar results were obtained when Intralipid was substituted for VLDL. It is concluded that (i) apolipoproteins influence the surface charge of spheroidal rHDL, (ii) the hydration of the lipid-water interface of (A-I)rHDL is greater than that of (A-II)rHDL and (ii) cholesteryl ester transfer protein-mediated transfers of CE and TG between spheroidal rHDL and TG-rich particles are independent of rHDL apolipoprotein composition.	UNIV ADELAIDE,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA	University of Adelaide								ATMEH RF, 1983, BIOCHIM BIOPHYS ACTA, V751, P175, DOI 10.1016/0005-2760(83)90172-8; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P294, DOI 10.1016/0005-2760(90)90529-7; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BEKAERT ED, 1991, J LIPID RES, V32, P1587; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BENYASHAR V, 1991, CHEM PHYS LIPIDS, V60, P1, DOI 10.1016/0009-3084(91)90009-Z; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; HOPKINS GJ, 1980, METABOLISM, V29, P546, DOI 10.1016/0026-0495(80)90080-3; HOPKINS GJ, 1989, ATHEROSCLEROSIS, V75, P73, DOI 10.1016/0021-9150(89)90209-8; JAMES RW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P292, DOI 10.1016/0005-2760(89)90343-3; JAMES RW, 1988, J LIPID RES, V29, P1557; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; KILSDONK EPC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P205, DOI 10.1016/0005-2760(90)90121-D; KINOSHITA M, 1993, J LIPID RES, V34, P261; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MOWRI HO, 1992, J LIPID RES, V33, P1269; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PIRAN U, 1979, J LIPID RES, V20, P1040; RADER DJ, 1991, J LIPID RES, V32, P1849; RAJARAM OV, 1985, BIOCHIM BIOPHYS ACTA, V835, P41, DOI 10.1016/0005-2760(85)90028-1; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; SATA T, 1972, J LIPID RES, V13, P757; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; STUART WD, 1992, BIOCHEMISTRY-US, V31, P8552, DOI 10.1021/bi00151a024; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; VANTORNOUT P, 1981, BIOCHIM BIOPHYS ACTA, V663, P630, DOI 10.1016/0005-2760(81)90073-4; WEINBERG RB, 1982, ATHEROSCLEROSIS, V44, P141, DOI 10.1016/0021-9150(82)90109-5	39	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10298	10303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144610				2022-12-27	WOS:A1994NF01700021
J	BUTT, E; ABEL, K; KRIEGER, M; PALM, D; HOPPE, V; HOPPE, J; WALTER, U				BUTT, E; ABEL, K; KRIEGER, M; PALM, D; HOPPE, V; HOPPE, J; WALTER, U			CAMP-DEPENDENT AND CGMP-DEPENDENT PROTEIN-KINASE PHOSPHORYLATION SITES OF THE FOCAL ADHESION VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) IN-VITRO AND IN INTACT HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATED PHOSPHOPROTEIN; SUBSTRATE-SPECIFICITY; RABBIT CEREBELLUM; CELL-EXTRACTS; INHIBITION; SEQUENCES; ACTIVATOR; DARPP-32	The vasodilator-stimulated phosphoprotein (VASP) is a major substrate for cAMP-dependent- (cAK) and cGMP-dependent protein kinase (cGK) in human platelets and other cardiovascular cells. To identify the VASP phosphorylation sites, purified VASP was phosphorylated by either protein kinase and subjected to trypsin, V8 and Lys-C proteolysis, The phosphorylated proteolytic fragments obtained were separated by reversed phase high performance liquid chromatography. Sequence analysis of the phosphorylated peptides and P-32 measurement of the released P-32-labeled amino acids revealed three phosphorylation sites: a serine 1-containing site (LRKVSXQEEA), a serine 2-containing site (HIERRVSNAG), and a threonine-containing site (MNAVLARRRKATQVGE). Additional experiments with purified VASP demonstrated that both cAK and cGK phosphorylated serine 2 rapidly and the threonine residue slowly, whereas cGK phosphorylated the serine 1 residue more rapidly than the cAK. These differences in the phosphorylation rates of VASP by the two protein kinases were also observed with synthetic peptides corresponding to the sequences of the three identified phosphorylation sites. These experiments also established the synthetic peptide serine 1 as one of the best in vitro cGK substrates and the serine 2-containing site as the site responsible for the phosphorylation-induced mobility shift of VASP in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Experiments with P-32-labeled platelets provided evidence that VASP is phosphorylated at the same three identified sites also in intact cells and that selective activation of cAK or cGK primarily increased the phosphorylation of both serine 2 and serine 1 but not threonine. Our results demonstrated overlapping substrate specificities of cAK and cGK in vitro and in intact cells. However, important quantitative and qualitative differences between cAK- and cGK-mediated phosphorylation of the focal adhesion protein VASP in human platelets were also observed, suggesting distinct functions of the two types of cyclic nucleotide-mediated VASP phosphorylation.	BIOZENTRUM WURZBURG, D-97074 WURZBURG, GERMANY	University of Wurzburg	BUTT, E (corresponding author), UNIV WURZBURG, MED KLIN, BIOCHEM & PATHOBIOCHEM KLIN, JOSEF SCHNEIDER STR 2, D-97080 WURZBURG, GERMANY.		Walter, ulrich/W-2478-2017; Krieger, Marco/AAE-8611-2020	Walter, ulrich/0000-0001-6784-2307; 				AITKEN A, 1981, J BIOL CHEM, V256, P3501; ASWAD DW, 1981, J BIOL CHEM, V256, P3494; BOWEN R, 1991, J CARDIOVASC PHARM, V17, P424, DOI 10.1097/00005344-199103000-00011; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT K, 1992, 8TH INT C 2ND MESS P; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GLASS DB, 1990, PEPT PROT PHOSPH, P209; GUMBINER BM, 1992, CURR OPIN CELL BIOL, V4, P757; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HALBRUGGE M, 1992, CELL SIGNAL, V4, P189, DOI 10.1016/0898-6568(92)90082-J; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HOPPE J, 1981, EUR J BIOCHEM, V117, P585; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; NOLTE C, 1991, J BIOL CHEM, V266, P14808; NOLTE C, 1991, BIOCHEM PHARMACOL, V42, P253, DOI 10.1016/0006-2952(91)90711-D; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; WALAAS SI, 1983, NATURE, V301, P69; WALDMANN R, 1986, EUR J BIOCHEM, V158, P203, DOI 10.1111/j.1432-1033.1986.tb09739.x; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; WALTER U, 1980, J BIOL CHEM, V255, P3757; WILLIGEN GV, 1991, BIOCHEM J, V273, P115; ZEILIG CE, 1981, J BIOL CHEM, V256, P994; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	39	388	400	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14509	14517						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182057				2022-12-27	WOS:A1994NM06500033
J	AZZI, L; MEIJER, L; OSTVOLD, AC; LEW, J; WANG, JH				AZZI, L; MEIJER, L; OSTVOLD, AC; LEW, J; WANG, JH			PURIFICATION OF A 15-KDA CDK4-BINDING AND CDK5-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; MOBILITY-GROUP PROTEINS; CELL-CYCLE REGULATION; XENOPUS CDC2 PROTEIN; CASEIN KINASE-II; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; HMG-I; HISTONE-H1 KINASE	Yeasts p13(suc1)/p18(CKS) and their human homologues, p9(CKShs1)/p9(CKShs2), strongly interact with p34(cdc2) and p34(cdk2). While attempting to purify the starfish oocyte p13(suc1) homologue, we discovered a 15-kDa protein crossreactive with anti-p9(CRShs2)/anti-p13(suc1) antibodies. p15(cdk-BP)-Sepharose binds an anti-PSTAIRE cross-reactive protein of 33 kDa when loaded with starfish oocyte extracts. The p15(cdk-BP)-bound ''PSTAIRE signal'' is part of a 250-kDa complex distinct from p34(cdc2)/cyclin B. p15(cdk-BP)-Sepharose beads retain a kinase phosphorylating HMG I/Y, P1, and myelin basic protein (among 24 substrates tested). Major cdc2 kinase substrates are not phosphorylated by the p15(cdk-BP)-bound kinase. Phosphopeptide maps of P1 phosphorylated by the p15(cdk-BP)-bound kinase, p34(cdc2)/cyclin B, p33(cdk5)/p25, and casein kinase 2 showed that these kinases phosphorylate P1 on different sites. Phosphopeptide maps of P1 phosphorylated by the p15(cdk-BP)-bound starfish kinase and p15(cdk-BP)-bound human p34(cdh4)/cyclin D are largely coincident. To investigate the nature of the p15(cdk-BP)-bound kinase, extracts of mammalian tissues and cells were loaded on p9(CKShs1)- and p15(cdk-BP)-Sepharose and the bound proteins were analyzed using specific anti-cdk antibodies. cdc2 and cdk2 bind to p9(CKShs1)-Sepharose, but not to p15(cdk-BP). cdk4 and cdk5 bind to p15(cdk-BP)-Sepharose, but not to p9(CKShs1)-Sepharose. We conclude that p15(cdk-BP) specifically binds the cdk4/cyclin D and cdk5 kinases and, along with p13(suc1) and p9(CKShs), may be part of a larger family of cdk-binding proteins.	CNRS,BIOL STN,F-29682 ROSCOFF,FRANCE; UNIV OSLO,NEUROCHEM LAB,N-0317 OSLO 3,NORWAY; UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA	Centre National de la Recherche Scientifique (CNRS); University of Oslo; University of Calgary								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BARATTE B, 1992, ANTICANCER RES, V12, P873; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KIDD VJ, 1992, MOL CARCINOGEN, V5, P95, DOI 10.1002/mc.2940050203; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13384; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; MAELANDSMO GM, 1989, EUR J BIOCHEM, V184, P529, DOI 10.1111/j.1432-1033.1989.tb15046.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; MEIJER L, 1986, CAH BIOL MAR, V25, P457; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OKUDA T, 1992, ONCOGENE, V7, P2249; OSTVOLD AC, 1985, EUR J BIOCHEM, V153, P469, DOI 10.1111/j.1432-1033.1985.tb09325.x; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERANO M, 1993, NATURE, V366, P704; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALAAS SI, 1989, FEBS LETT, V258, P106, DOI 10.1016/0014-5793(89)81626-6; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406	84	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13279	13288						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175758				2022-12-27	WOS:A1994NK18400037
J	BENHAR, I; WANG, QC; FITZGERALD, D; PASTAN, I				BENHAR, I; WANG, QC; FITZGERALD, D; PASTAN, I			PSEUDOMONAS EXOTOXIN-A MUTANTS - REPLACEMENT OF SURFACE-EXPOSED RESIDUES IN DOMAIN-III WITH CYSTEINE RESIDUES THAT CAN BE MODIFIED WITH POLYETHYLENE-GLYCOL IN A SITE-SPECIFIC MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT INTERLEUKIN-2; DIPHTHERIA-TOXIN; ACTIVE-SITE; ESCHERICHIA-COLI; ANIMAL TOXICITY; AERUGINOSA; PROTEIN; MUTAGENESIS; NAD; EXPRESSION	Pseudomonas exotoxin A (PE) is composed of three structural and functional domains. Domain Ia is responsible for cell recognition, domain II for translocation of PE across the cell membrane, and domain III for ADP-ribosylation of elongation factor 2. To investigate the role of the amino acids exposed on the surface of domain III, we replaced 15 of these, generating 29 different mutants at positions 412, 416, 418, 490, 513, 516, 522, 551, 576, 590, 599, 604, 606, 607 and 608. Ah but one mutant retained substantial ADP-ribosylation and cytotoxic activities. Modification of proteins with monomethoxypolyethylene glycol (mPEG) prolongs their circulation in the blood stream and reduces their immunogenicity. Unlike PEGylated enzymes acting on small molecule substrates, PEGylated toxins may lose those functions that are based on macromolecular interactions. Therefore, we selectively PEGylated mutant PEs at positions 490, 513, 516, 522, 604, and 606. Most PEs modified by a 5-kDa mPEG via a disulfide or a thioether bond retained high cytotoxic activity. However, when a 20-kDa mPEG was used there was a decrease in cytotoxic activity with the disulfide-bonded molecules being more active. Positions 522 and 604 are good sites for PEGylation, but 490 is not. We also found that PEGylation of PE 522C prolonged its in vivo circulation time in mice.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Benhar, Itai/0000-0002-0824-7177				ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3065, DOI 10.1073/pnas.89.7.3065; CARROL SF, 1988, MOL MICROBIOL, V262, P293; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHILDS CE, 1975, MICROCHEM J, V20, P190, DOI 10.1016/0026-265X(75)90038-7; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; DREBORG S, 1990, CRIT REV THER DRUG, V6, P315; GOODSON RJ, 1990, BIO-TECHNOL, V8, P343, DOI 10.1038/nbt0490-343; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERSHFIELD MS, 1991, P NATL ACAD SCI USA, V88, P7185, DOI 10.1073/pnas.88.16.7185; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1989, J BIOL CHEM, V264, P15953; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KATRE NV, 1987, P NATL ACAD SCI USA, V84, P1487, DOI 10.1073/pnas.84.6.1487; KITAMURA K, 1990, BIOCHEM BIOPH RES CO, V171, P1387, DOI 10.1016/0006-291X(90)90839-F; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUAN CT, 1994, J BIOL CHEM, V269, P7610; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LISI PJ, 1982, J APPL BIOCHEM, V4, P19; LORY S, 1980, INFECT IMMUN, V28, P494; LUCAK M, 1988, BIOCHEMISTRY-US, V27, P7629; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SIMS GEC, 1980, ANAL BIOCHEM, V107, P60, DOI 10.1016/0003-2697(80)90492-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; WANG QC, 1993, CANCER RES, V53, P4588; WOZNIAK DJ, 1988, P NATL ACAD SCI USA, V85, P8880, DOI 10.1073/pnas.85.23.8880; ZIMMERMAN RJ, 1989, CANCER RES, V49, P6521	44	41	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13398	13404						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175770				2022-12-27	WOS:A1994NK18400053
J	KONG, GH; PENN, R; BENOVIC, JL				KONG, GH; PENN, R; BENOVIC, JL			A BETA-ADRENERGIC-RECEPTOR KINASE DOMINANT-NEGATIVE MUTANT ATTENUATES DESENSITIZATION OF THE BETA(2)-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; BETA-2-ADRENERGIC RECEPTOR; HOMOLOGOUS DESENSITIZATION; PHOSPHORYLATION SITES; S49-LYMPHOMA CELLS; ADENYLATE-CYCLASE; AGONIST; TRANSLOCATION; EXPRESSION; MECHANISM	The beta-adrenergic receptor kinase (beta ARK) specifically phosphorylates the activated form of the beta(2)-adrenergic receptor (beta(2)AR) and related G protein-coupled receptors. To further elucidate the role of beta ARK in receptor desensitization, we generated a beta ARK dominant negative mutant by converting an invariant lysine residue in the protein kinase catalytic domain to an arginine. Expressed and purified beta ARK-K220R was able to inhibit wild type beta ARK phosphorylation of the beta(2)AR in vitro. When stably transfected into human bronchial epithelial BEAS-2B cells, beta ARK-K220R promoted a >2-fold increase in p-agonist-stimulated cAMP production without affecting beta(2)AR sequestration. In contrast, beta ARK-K220R had no effect on the desensitization of the prostaglandin E, receptor response in BEAS-2B cells. These findings directly demonstrate a role for beta ARK in desensitization of the beta(2)AR in intact cells and establish the potential utility of using dominant negative mutants to elucidate the substrate specificity of G protein-coupled receptor kinases.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KE Y, 1988, DIFFERENTIATION, V38, P60, DOI 10.1111/j.1432-0436.1988.tb00592.x; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAYOR F, 1987, J BIOL CHEM, V262, P6468; OHNO S, 1990, J BIOL CHEM, V265, P6296; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P397; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990	37	181	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13084	13087						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175732				2022-12-27	WOS:A1994NK18400008
J	MORGAN, JW; REDDY, GS; USKOKOVIC, MR; MAY, BK; OMDAHL, JL; MAIZEL, AL; SHARMA, S				MORGAN, JW; REDDY, GS; USKOKOVIC, MR; MAY, BK; OMDAHL, JL; MAIZEL, AL; SHARMA, S			FUNCTIONAL BLOCK FOR 1-ALPHA,25-DIHYDROXYVITAMIN D-3-MEDIATED GENE-REGULATION IN HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR VIRUS; CELL GROWTH-FACTOR; MYELOID-LEUKEMIA CELLS; NORMAL HUMAN-MONOCYTES; 1,25-DIHYDROXYVITAMIN D3; VITAMIN-D; RECEPTOR EXPRESSION; RENAL METABOLISM; LINE U-937; DIFFERENTIATION	Elements necessary for the steroid hormone 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25-(OH)(2)D-3) to induce a biological response include the presence of specific intracellular receptors (vitamin D-3 receptors (VDR)) and modulation of gene expression via hormone-activated receptor binding to regulatory regions of target genes. These parameters were examined in normal and Epstein-Barr virus-immortalized human B cells and compared with 1 alpha,25-(OH)(2)D-3-responsive cells of the T and monocytic lineages. Although resting tonsillar B cells did not express VDR mRNA, activation of these cells with interleukin-4 induced VDR in the absence of exogenously supplemented 1 alpha,25-(OH)(2)D-3. As indicators of hormone-mediated gene regulation we analyzed modulation of CD23, a common B cell/monocyte surface antigen, and 28-hydroxylase. 1 alpha,25-(OH)(2)D-3 inhibited CD23 expression in U937 cells, yet failed to modulate CD23 expression in B cells. Furthermore, 1 alpha,25-(OH)(2)D-3 induced 24-hydroxylase mRNA expression and metabolic activity in both U937 cells and lectin-activated T cells, yet failed to induce 24-hydroxylase mRNA or its metabolic activity in B cells. These findings suggest that although human B lymphocytes can express VDR mRNA and protein, they exhibit a functional block for vitamin D dependent gene regulation.	BROWN UNIV,ROGER WILLIAMS CANC MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908; BROWN UNIV,WOMEN & INFANTS HOSP,DEPT PEDIAT,PROVIDENCE,RI 02905; HOFFMANN LA ROCHE INC,DEPT CHEM,NUTLEY,NJ 07110; UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87102	Brown University; Roger Williams Medical Center; Brown University; Women & Infants Hospital Rhode Island; Roche Holding; University of New Mexico			Morgan, James/N-8104-2018; Morgan, James/GRO-2905-2022	Morgan, James/0000-0002-8920-1065	NCI NIH HHS [CA54763, CA45418, CA55910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054763, U10CA045418, R01CA055910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; AMENTO E P, 1987, Steroids, V49, P55, DOI 10.1016/0039-128X(87)90079-1; ARNAOUT MA, 1990, BLOOD, V75, P1037; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN TA, 1990, J BIOL CHEM, V265, P10025; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHEN WC, 1987, CLIN EXP IMMUNOL, V69, P639; CLARK JW, 1993, BIOORG MED CHEM LETT, V3, P1873, DOI 10.1016/S0960-894X(00)80123-7; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FARGEAS C, 1990, J IMMUNOL, V145, P4053; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; GENDELMAN HE, 1990, J EXP MED, V172, P1433, DOI 10.1084/jem.172.5.1433; HAHN CN, 1993, CYTOGENET CELL GENET, V62, P192, DOI 10.1159/000133473; HEWISON M, 1989, IMMUNOLOGY, V68, P247; IHO S, 1986, J IMMUNOL, V136, P4427; JONES G, 1984, BIOCHEMISTRY-US, V23, P3749, DOI 10.1021/bi00311a028; KASONO K, 1993, BONE MINER, V21, P179, DOI 10.1016/S0169-6009(08)80229-2; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KIZAKI M, 1991, BLOOD, V77, P1238; LACEY DL, 1993, J CELL BIOCHEM, V53, P122, DOI 10.1002/jcb.240530205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; MAIZEL AL, 1983, P NATL ACAD SCI-BIOL, V80, P5047, DOI 10.1073/pnas.80.16.5047; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; MAYUMI M, 1988, CLIN EXP IMMUNOL, V71, P202; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEZZETTI G, 1984, LIFE SCI, V34, P2185, DOI 10.1016/0024-3205(84)90319-9; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MORGAN J, 1989, J VIROL, V63, P3190, DOI 10.1128/JVI.63.7.3190-3194.1989; MULLER K, 1991, IMMUNOPHARMACOLOGY, V21, P121, DOI 10.1016/0162-3109(91)90015-Q; NEMERE I, 1991, MOL CELL ENDOCRINOL, V80, pC165, DOI 10.1016/0303-7207(91)90132-C; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NUNN JD, 1986, IMMUNOLOGY, V59, P479; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PEACOCK M, 1982, VITAMIN D CHEM BIOCH, P83; PIKE JW, 1984, J BIOL CHEM, V259, P1167; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; PIKE JW, 1985, VITAMIN D CHEM BIOCH, P97; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; PROVVEDINI DM, 1986, J IMMUNOL, V136, P2734; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; PROVVEDINI DM, 1986, BONE, V7, P23; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; REINHARDT TA, 1989, J BIOL CHEM, V264, P15917; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54; RIGBY WFC, 1987, J CLIN INVEST, V79, P1659, DOI 10.1172/JCI113004; ROSMARIN AG, 1989, BLOOD, V73, P131; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIOZAWA S, 1987, INT J IMMUNOPHARMACO, V9, P719, DOI 10.1016/0192-0561(87)90043-9; SUGDEN B, 1983, J VIROL, V46, P800, DOI 10.1128/JVI.46.3.800-807.1983; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; UENO K, 1992, BIOCHEM BIOPH RES CO, V189, P1521, DOI 10.1016/0006-291X(92)90248-J; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YU XP, 1991, J BIOL CHEM, V266, P7588	69	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13437	13443						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175775				2022-12-27	WOS:A1994NK18400058
J	MUKHOPADHYAY, CK; CHATTERJEE, IB				MUKHOPADHYAY, CK; CHATTERJEE, IB			NADPH-INITIATED CYTOCHROME P450-MEDIATED FREE METAL ION-INDEPENDENT OXIDATIVE DAMAGE OF MICROSOMAL PROTEINS - EXCLUSIVE PREVENTION BY ASCORBIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE; OXYGEN RADICALS; COVALENT MODIFICATION; CATALYZED OXIDATION; LIPID-PEROXIDATION; LIVER-MICROSOMES; DEGRADATION; TURNOVER; INACTIVATION; CONSEQUENCES	In this paper we demonstrate that NADPH-initiated oxidative damage of microsomal proteins occurs in the absence of free metal ions and that this protein oxidation is mediated by cytochrome P450 (cyt P450). Oxidized proteins are rapidly degraded by proteases. Ascorbate (AH(2)) specifically inhibits free metal ion-independent cyt P450-mediated protein oxidation and thereby prevents subsequent proteolytic degradation. Other scavengers of reactive oxygen species including superoxide dismutase, catalase, and glutathione are ineffective. This is in variance with free metal ion-catalyzed protein oxidation, which is accelerated by AH(2), and inhibited by catalase. Oxidative damage of proteins has been assessed by the production of carbonyl groups, bi-tyrosine formation, and tryptophan loss. The mechanism of protein oxidation has been studied using a reconstituted system comprised of purified NADPH-cyt P450 reductase, cyt P450, and isolated microsomal proteins as well as model polypeptides, e.g. poly L-proline and poly-L-lysine. Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O-2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O-2(radical-anion). It is proposed that cyt P450 Fe3+.O-2(radical-anion) abstracts hydrogen from amino acid side chains leading to the production of carbonyl derivatives. Tentatively, AH(2) prevents protein oxidation by interacting with cyt P450 Fe3+.O-2(radical-anion).	UNIV COLL SCI CALCUTTA, DEPT BIOCHEM, CALCUTTA 700019, INDIA	University of Calcutta								AMICI A, 1989, J BIOL CHEM, V264, P3341; BIELSKI BHJ, 1975, ANN NY ACAD SCI, V258, P231, DOI 10.1111/j.1749-6632.1975.tb29283.x; CHAKRABARTY S, 1992, MOL CELL BIOCHEM, V111, P41; CHAKRABARTY S, 1993, IN PRESS FREE RADICA; CHAPMAN ML, 1989, J RHEUMATOL, V16, P15; CLEMETSON CAB, 1989, VITAMIN C, V2, P213; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; FARBER JM, 1982, FED PROC, V41, P865; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GARLAND D, 1986, ARCH BIOCHEM BIOPHYS, V251, P771, DOI 10.1016/0003-9861(86)90389-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Masters B, 1967, METHOD ENZYMOL, V10, P565; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINOTTI G, 1992, ARCH BIOCHEM BIOPHYS, V297, P189, DOI 10.1016/0003-9861(92)90661-F; MURPHY ME, 1989, BIOCHEM J, V260, P359, DOI 10.1042/bj2600359; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1984, MOL BASIS AGING, P235; OMURA T, 1964, J BIOL CHEM, V239, P2370; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PALAMANDA JR, 1992, ARCH BIOCHEM BIOPHYS, V293, P103, DOI 10.1016/0003-9861(92)90371-3; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROSEMAN JE, 1987, J BIOL CHEM, V260, P12600; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; VANDERHO.TA, 1974, J BIOL CHEM, V249, P6302; ZANNONI VG, 1982, ADV CHEM SER, P349	42	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13390	13397						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175769				2022-12-27	WOS:A1994NK18400052
J	TURINA, P; CAPALDI, RA				TURINA, P; CAPALDI, RA			ATP HYDROLYSIS-DRIVEN STRUCTURAL-CHANGES IN THE GAMMA-SUBUNIT OF ESCHERICHIA-COLI ATPASE MONITORED BY FLUORESCENCE FROM PROBES BOUND AT INTRODUCED CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; CATALYTIC SITES; CRYOELECTRON MICROSCOPY; ELEMENTARY STEPS; RATE CONSTANTS; F1 ATPASE; F1-ATPASE; SYNTHASE; NUCLEOTIDE	Four mutants of the Escherichia coli F(1)ATPase, gamma S8-C, gamma T106-C, gamma S179-C, and gamma V286-C, which have a cysteine introduced at different sites in the gamma-subunit by site-directed mutagenesis, were reacted with the fluorescent reagent N-(4-7-(diethylamino)4-methylcoumarin-3-yl)-maleimide (CM) under conditions that selectively label the introduced Cys residue. With each mutant the effect of nucleotide binding on the fluorescence of the probe has been monitored. The results obtained with the mutants gamma S8-C and gamma T106-C are similar. In both cases, there was a spectral shift and change in fluorescence intensity on adding AMP.PNP or ATP to enzyme emptied of nucleotide from catalytic sites, while no change in the fluorescence spectrum was observed upon adding ADP. The fluorescence spectral changes obtained with ATP were transient and involved an initial rapid fluorescence enhancement followed by a subsequent fluorescence quenching. The kinetics of these ATP-induced fluorescence changes and the kinetics of ATP hydrolysis as monitored by the rates of ATP binding and of Pi formation were the same under conditions of unisite catalysis, indicating that the conformational changes in the gamma-subunit being measured by the fluorescent probe are driven by ATP hydrolysis in catalytic sites. No nucleotide-dependent fluorescence changes were observed with CM bound at a Cys at position 179. Nucleotide-dependent changes in fluorescence were seen with CM bound at position 286, but these appear to reflect structural changes due to binding of ADP or ATP in noncatalytic sites. The fluorescence changes observed in mutants gamma S8-C and gamma T106-C were not seen in subunit epsilon free E. coli F(1)ATPase, although such enzyme preparations are highly active ATPases. We conclude that the structural changes monitored by the fluorescent probe are a part of the conformational coupling, whereby catalytic site events are linked to proton channeling.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon			Turina, Paola/P-9342-2015; Turina, Paola/GYJ-0656-2022	Turina, Paola/0000-0001-9174-511X; 	PHS HHS [LH 24236] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, IN PRESS TRENDS BIOC; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; CUNNINGHAMD, 1988, J BIOL CHEM, V263, P18850; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; LABAHN A, 1990, FEBS LETT, V271, P116, DOI 10.1016/0014-5793(90)80385-V; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MASUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SIPPEL TO, 1981, J HISTOCHEM CYTOCHEM, V29, P1377, DOI 10.1177/29.12.7320496; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; TANG CL, 1994, J BIOL CHEM, V269, P4467; TURINA P, 1993, J BIOL CHEM, V268, P6978; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WILKENS S, 1994, HOPPESYELERS Z BIOL, V375, P43; WISE JG, 1981, J BIOL CHEM, V256, P383; WOOD JM, 1987, J BIOL CHEM, V262, P2180; [No title captured]	44	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13465	13471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175779				2022-12-27	WOS:A1994NK18400062
J	BROWN, MP; SHAIKH, N; BRENOWITZ, M; BRAND, L				BROWN, MP; SHAIKH, N; BRENOWITZ, M; BRAND, L			THE ALLOSTERIC INTERACTION BETWEEN D-GALACTOSE AND THE ESCHERICHIA-COLI GALACTOSE REPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL REPRESSOR; TRYPTOPHYL FLUORESCENCE; CONFORMATIONAL CHANGE; OPERON PROMOTERS; BINDING PROTEIN; LAC REPRESSOR; 2 PROMOTERS; L-ARABINOSE; OPERATOR; DNA	The Escherichia cell galactose repressor protein (GalR) inhibits transcription of the gal operon upon binding to two operator sites (1-7).This DNA binding activity is inhibited when D-galactose or D-fucose binds to GalR (8-14). Fluorescence spectroscopy was used to characterize the single tryptophan of GalR and to investigate the interaction between galactose and GalR. Fluorescence quenching experiments place both tryptophan residues of the GalR dimer in similar, solvent-exposed locations. Galactose is shown to enhance the intrinsic tryptophan fluorescence of GalR, the source of which is not explained by a change in decay times, but is due to an increase in the pre exponential factor of the longest of the three fluorescence decay times. It is shown that the beta-anomer of D-galactose is the likely form that binds to GalR. An increase in pH from 6.3 to 9.5 causes the equilibrium association constant (K-a) describing the galactose-GalR interaction to decrease 10-fold. The interaction is cooperative below pH 9.5, Over the pH range of 6.3 to 9.5, the tryptophan solvent exposure of GalR increases. Galactose binding also induces an increase in exposure. These results, and others presented in this paper, show that both pH and galactose cause global alterations in the structure of GalR.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine			FACS, Nina S. Naidu MD/W-8049-2019		NIGMS NIH HHS [GM07231, GM11632, GM39929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039929, R29GM039929, R01GM011632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1966, J BACTERIOL, V92, P601, DOI 10.1128/JB.92.3.601-608.1966; ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ADHYA S, 1989, ANNU REV GENET, V23, P207; BOOS W, 1972, J BIOL CHEM, V247, P917; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BROCHON JC, 1977, BIOCHEM BIOPH RES CO, V79, P1261, DOI 10.1016/0006-291X(77)91142-1; BUTTIN G, 1963, J MOL BIOL, V7, P164, DOI 10.1016/S0022-2836(63)80044-3; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; Contino P B, 1991, J Fluoresc, V1, P5, DOI 10.1007/BF00865253; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DILAURO R, 1979, NATURE, V279, P494, DOI 10.1038/279494a0; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GARDNER JA, 1990, J BIOL CHEM, V265, P21061; GASTON K, 1988, BIOCHEM J, V253, P809, DOI 10.1042/bj2530809; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HSIEH M, 1994, IN PRESS J BIOL CHEM, V269; IRANI M, 1989, J BACTERIOL, V171, P1623, DOI 10.1128/jb.171.3.1623-1630.1989; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KALCKAR HM, 1959, P NATL ACAD SCI USA, V45, P1776, DOI 10.1073/pnas.45.12.1776; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MAJUMDAR A, 1989, J MOL BIOL, V208, P217, DOI 10.1016/0022-2836(89)90383-5; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MAJUMDAR A, 1987, J BIOL CHEM, V262, P13258; MCGOWAN, 1974, BIOCHEMISTRY-US, V13, P993; MILLER DM, 1983, J BIOL CHEM, V258, P3665; NAKANISHI S, 1973, P NATL ACAD SCI USA, V70, P334, DOI 10.1073/pnas.70.2.334; PARKS JS, 1971, P NATL ACAD SCI USA, V68, P1891, DOI 10.1073/pnas.68.8.1891; PARSONS RG, 1974, J BIOL CHEM, V249, P3602; Pigman W., 1972, CARBOHYDRATES CHEM A, V1, P165; PONNAMBALAM S, 1986, J BIOL CHEM, V261, P6043; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4369, DOI 10.1021/bi00518a021; SAEDLER H, 1968, MOL GEN GENET, V102, P79, DOI 10.1007/BF00341872; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WARTELL RM, 1988, NUCLEIC ACIDS RES, V16, P11531, DOI 10.1093/nar/16.24.11531; WU PG, 1991, P NATL ACAD SCI USA, V88, P9355, DOI 10.1073/pnas.88.20.9355	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12600	12605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175668				2022-12-27	WOS:A1994NH71600038
J	CANCELA, ML; WILLIAMSON, MK; PRICE, PA				CANCELA, ML; WILLIAMSON, MK; PRICE, PA			THE PUTATIVE RGD-DEPENDENT CELL-ADHESION ACTIVITY OF MATRIX GLA PROTEIN IS DUE TO HIGHER MOLECULAR-WEIGHT CONTAMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MESSENGER-RNA; BONE; CARBOXYLASE; GENE; CDNA; RAT	This study was carried out to further characterize the RGD-dependent cell adhesion activity which was previously observed in the vitamin K-dependent matrix Gla protein (MGP) (Loeser, R. F., and Wallin, R. (1992) J. Biol. Chem. 267, 9459-9462). We have found that this cell adhesion activity can be completely removed from the 10-kDa MGP by gel filtration over Sephacryl S-800-HR. The higher molecular weight contaminants removed by the gel filtration step display potent cell adhesion activity. The additional evidence previously adduced in support of the putative cell adhesion activity of MGP is that heat decarboxylation of the vitamin K-dependent gamma-carboxyglutamate residues in MGP abolished the adhesion activity. The heat decarboxylation conditions used, however, appear to cause other chemical changes in proteins in addition to decarboxylation, as evidenced by the fact that the cell adhesion activity of fibronectin, which is not a vitamin K-dependent protein, is also destroyed by this procedure. The present evidence that the putative cell adhesion activity of MGP is caused by contaminating higher molecular weight cell adhesion proteins accounts for two apparent anomalies in the previously reported cell adhesion activity of MGP, the failure of antibodies raised against a synthetic peptide corresponding to the C-terminal 19 residues of bovine MGP to inhibit the cell adhesion activity of the intact, 79-residue bovine protein, and the potent inhibition of the cell adhesion activity of MGP by a synthetic peptide containing an RGD sequence, even though MGP does not contain this sequence.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Cancela, M. Leonor/F-4665-2012	Cancela, M. Leonor/0000-0003-3114-6662	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 25921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; CANCELA L, 1990, J BIOL CHEM, V265, P15040; CANCELA ML, 1992, ENDOCRINOLOGY, V130, P102, DOI 10.1210/en.130.1.102; CHEN L, 1990, ONCOGENE, V5, P1391; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FRASER JD, 1988, J BIOL CHEM, V263, P11033; HALE JE, 1991, J BIOL CHEM, V266, P21145; HALE JE, 1988, J BIOL CHEM, V263, P5820; IKEDA T, 1991, J BONE MINER RES, V6, P1013; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LOESER RF, 1993, ARTHRITIS RHEUM, V36, P1103, DOI 10.1002/art.1780360811; LOESER RF, 1992, J BIOL CHEM, V267, P9459; OTAWARA Y, 1986, J BIOL CHEM, V261, P828; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; RANNELS SR, 1993, AM J PHYSIOL, V265, pL270, DOI 10.1152/ajplung.1993.265.3.L270; RICE JS, 1994, IN PRESS J BONE MINE; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193	20	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12185	12189						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163523				2022-12-27	WOS:A1994NG37700078
J	SCHLOSSMANN, J; DIETMEIER, K; PFANNER, N; NEUPERT, W				SCHLOSSMANN, J; DIETMEIER, K; PFANNER, N; NEUPERT, W			SPECIFIC RECOGNITION OF MITOCHONDRIAL PREPROTEINS BY THE CYTOSOLIC DOMAIN OF THE IMPORT RECEPTOR MOM72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PRECURSOR PROTEINS; ADP/ATP CARRIER; OUTER-MEMBRANE; YEAST MITOCHONDRIA; GENE; IDENTIFICATION; TRANSLOCATION	The import receptor MOM72 constitutes part of the protein translocation machinery of the outer mitochondrial membrane, the receptor general insertion pore complex. The protein contains a membrane anchor at the NH2 terminus and a large cytosolic domain. In yeast and Neurospora crassa the cytosolic domain comprises about 570-580 amino acid residues. The cytosolic domain of yeast MOM72 was purified after expression in Escherichia coli as a homogeneous monomeric protein. It can recognize precursor proteins as demonstrated by its ability to compete for binding and import into the mitochondria and to physically interact with preproteins. A subset of preproteins including the ADP/ATP carrier and the phosphate carrier interact with very high affinity, precursors that are known to be targeted via MOM72. Thus, the cytosolic domain of MOM72 plays a critical function in the recognition of preproteins by directly binding to precursor proteins and thereby facilitating their targeting to mitochondria.	UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016; Pfanner, Nikolaus/AAV-7878-2021	Schlossmann, Jens/0000-0002-2550-6839; 				BAKER KP, 1990, NATURE, V348, P6025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1990, NATURE, V348, P605; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARKNESS TAA, 1994, GENETICS, V136, P107; HARKNESS TAA, 1994, IN PRESS J CELL BIOL, V124; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; INIS MA, 1988, SCIENCE, V86, P8432; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAHLKE K, 1991, THESIS U MUNICH; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	52	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11893	11901						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163488				2022-12-27	WOS:A1994NG37700036
J	SIMMACO, M; MIGNOGNA, G; BARRA, D; BOSSA, F				SIMMACO, M; MIGNOGNA, G; BARRA, D; BOSSA, F			ANTIMICROBIAL PEPTIDES FROM SKIN SECRETIONS OF RANA-ESCULENTA - MOLECULAR-CLONING OF CDNAS ENCODING ESCULENTIN AND BREVININS AND ISOLATION OF NEW ACTIVE PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-BACTERIAL PROTEINS; XENOPUS-LAEVIS; BOMBINA-VARIEGATA; INSECT IMMUNITY; SEQUENCE; PRECURSORS; FAMILY	Three cytolytic peptides, termed brevinin-1E, brevinin-2E, and esculentin, were isolated from skin secretions of the European frog Rana esculenta (Simmaco, M., Mignogna, G., Barra, D., and Bossa, F. (1993) FEBS Lett. 324, 159-161). Nucleotide sequence analysis of cDNAs coding for the corresponding precursors revealed that in all of them a single copy of the sequence of the mature peptide is present preceded by a dibasic cleavage site and followed by a stop codon. The signal peptides of these precursors show a clear homology to the corresponding region of the precursor of dermorphin, a neuropeptide occurring in the skin of amphibians of the subfamily Phyllomedusinae. Ten new peptides, ranging in size from 24 to 46 residues, all possessing an intramolecular disulfide bridge located at the carboxyl-terminal end, were isolated from skin secretions of R. esculenta. These peptides can be grouped into four subfamilies on the basis of their distinctive structural and/or functional properties. All of these new peptides have antimicrobial and/or hemolytic activities typical for the respective subfamily. In addition, we demonstrate that esculentin-1 also inhibits the growth of Pseudomonas aeruginosa, Candida albicans, and Saccharomyces cerevisiae.	UNIV ROMA LA SAPIENZA, DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR BIOL MOLEC, I-00185 ROME, ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Barra, Donatella/D-1236-2011; Simmaco, Maurizio/AAC-2870-2019; Mignogna, Giuseppina/A-2126-2010	Simmaco, Maurizio/0000-0003-4164-1472; Mignogna, Giuseppina/0000-0001-9238-132X				Arrand J., 1985, NUCLEIC ACID HYBRIDI, P17; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; HORIKAWA R, 1985, FED PROC, V44, P695; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINN JP, 1992, PSEUDOMONAS : MOLECULAR BIOLOGY AND BIOTECHNOLOGY, P154; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1990, FEBS LETT, V262, P353, DOI 10.1016/0014-5793(90)80227-A; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; RICHTER K, 1986, J BIOL CHEM, V261, P3676; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STONE DJM, 1992, J CHEM SOC P1, V1, P3173; TERRY AS, 1988, J BIOL CHEM, V263, P5745; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	26	213	231	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11956	11961						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163497				2022-12-27	WOS:A1994NG37700045
J	EWART, GD; CANNELL, D; COX, GB; HOWELLS, AJ				EWART, GD; CANNELL, D; COX, GB; HOWELLS, AJ			MUTATIONAL ANALYSIS OF THE TRAFFIC ATPASE (ABC) TRANSPORTERS INVOLVED IN UPTAKE OF EYE PIGMENT PRECURSORS IN DROSOPHILA-MELANOGASTER - IMPLICATIONS FOR STRUCTURE-FUNCTION-RELATIONSHIPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PERIPLASMIC PERMEASES; RESISTANT HUMAN-CELLS; MULTIDRUG RESISTANCE; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; P-GLYCOPROTEIN; WHITE LOCUS; CHLORIDE CHANNEL; GENE; DNA	The white, brown, and scarlet genes of Drosophila melanogaster encode three proteins that belong to the Traffic ATPase superfamily of transmembrane permeases and are involved in the transport of guanine and tryptophan (precursors of the red and brown eye pigments). We have determined the nucleotide sequences of two mutant white alleles (w(co2) and w(Bwx)) that cause reduced red pigmentation but have no effect on brown pigmentation. In w(co2) the effect is only observed when interacting with the bw(6) allele or a newly isolated allele (bW(T50)). These alleles of the brown gene were cloned and sequenced. In w(co2) the codon for glycine 588 is changed to encode serine; in w(Bwx) the triplet ATC encoding isoleucine 581 is deleted; asparagine 638 is changed to threonine in bW(6), and glycine 578 is changed to aspartate in bW(T50). NO Other relevant changes to the gene structures were detected. P-element-mediated germline transduction was used to construct a fly strain containing a white gene with a mutation of the nucleotide binding domain. Such flies had white eyes, indicating that the mutated white gene was unable to support either guanine or tryptophan transport. The implications of these mutations are discussed in terms of a model of the Drosophila pigment precursor transport system.	AUSTRALIAN NATL UNIV,FAC SCI,DIV BIOCHEM & MOLEC BIOL,CANBERRA 2600,AUSTRALIA	Australian National University	EWART, GD (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,POB 4,CANBERRA 2600,AUSTRALIA.							AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COX GB, 1989, J BACTERIOL, V171, P1531, DOI 10.1128/jb.171.3.1531-1534.1989; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; FARMER JL, 1977, HEREDITY, V39, P297, DOI 10.1038/hdy.1977.70; FARMER JL, 1986, DROSOPHILA INFO SERV, V63, P50; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOWETT T, 1986, DROSOPHILA PRACTICAL, P278; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; LINDSAY DL, 1968, PUBLICATION, V627; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PEPLING M, 1990, NUCLEIC ACIDS RES, V18, P1633, DOI 10.1093/nar/18.6.1633; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; SULLIVAN DT, 1980, BIOCHEM GENET, V18, P1109, DOI 10.1007/BF00484342; SULLIVAN DT, 1979, BIOCHEM GENET, V17, P565, DOI 10.1007/BF00498891; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; SUMMERS KM, 1982, ADV INSECT PHYSIOL, V16, P119, DOI 10.1016/S0065-2806(08)60153-8; TEARLE RG, 1989, GENETICS, V122, P595; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBB DC, 1992, J BIOL CHEM, V267, P24661; ZACHAR Z, 1982, CELL, V30, P529, DOI 10.1016/0092-8674(82)90250-1	47	143	148	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10370	10377						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144619				2022-12-27	WOS:A1994NF01700031
J	VERES, Z; KIM, IY; SCHOLZ, TD; STADTMAN, TC				VERES, Z; KIM, IY; SCHOLZ, TD; STADTMAN, TC			SELENOPHOSPHATE SYNTHETASE - ENZYME PROPERTIES AND CATALYTIC REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE PHOSPHATE DIKINASE; SELD GENE-PRODUCT; ESCHERICHIA-COLI; SELENIUM METABOLISM; TRANSFER-RNAS; NUCLEOSIDE; MUTANT; 5-METHYLAMINOMETHYL-2-SELENOURIDINE; INTERMEDIATE; GENISTEIN	Selenophosphate synthetase, the product of the selD gene, produces the biologically active selenium donor compound, monoselenophosphate, from ATP and selenide. Isolation of the enzyme and characterization of some of its physical and catalytic properties are described. Magnesium ion and a monovalent cation, K+, NH4+ , or Rb+, are required for catalytic activity. Polyphosphates and other common nucleotide triphosphates do not replace ATP as substrate. The stoichiometry of the catalytic reaction (Reaction 1) was established using P-31 NMR, anaerobic molecular sieve chromatography, and radiochemical labeling procedures. ATP + selenide + H2O --> selenophosphate + P-i + AMP In the absence of selenide, ATP is converted completely to AMP and orthophosphate upon prolonged incubation with elevated levels of enzyme. AMP is a competitive inhibitor of ATP, K-i = 170 mu m, whereas selenophosphate and orthophosphate are weak inhibitors indicating a multistep reaction. Attempts to obtain direct evidence for a postulated enzyme-pyrophosphate intermediate using several experimental approaches are described. No exchange of [C-14]AMP with ATP could be detected after the enzyme was freed of traces of contaminating adenylate kinase by chromatography on phenyl-Sepharose.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; HUNGARIAN ACAD SCI,CENT RES INST CHEM,H-1025 BUDAPEST,HUNGARY; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Iowa				Scholz, Thomas/0000-0003-0759-2486				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; Bock A, 1988, Biofactors, V1, P245; Boyer Paul D., 1942, JOUR BIOL CHEM, V146, P673; BUTLERRANSOHOFF JE, 1988, BIOCHEMISTRY-US, V27, P4777, DOI 10.1021/bi00413a029; CARROLL LJ, 1989, J AM CHEM SOC, V111, P5965, DOI 10.1021/ja00197a081; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CHING WM, 1985, P NATL ACAD SCI USA, V82, P347, DOI 10.1073/pnas.82.2.347; CHING WM, 1982, P NATL ACAD SCI-BIOL, V79, P374, DOI 10.1073/pnas.79.2.374; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; GLASS RS, 1993, BIOCHEMISTRY-US, V32, P12555, DOI 10.1021/bi00210a001; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HUANG JM, 1992, J BIOL CHEM, V267, P15511; KIM IY, 1992, J BIOL CHEM, V267, P19650; KIM IY, 1993, J BIOL CHEM, V268, P27020; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; MILNER Y, 1978, J BIOL CHEM, V253, P878; MILNER Y, 1976, J BIOL CHEM, V251, P7920; PHILLIPS NFB, 1986, BIOCHEMISTRY-US, V25, P1644, DOI 10.1021/bi00355a030; REUBEN J, 1971, J BIOL CHEM, V246, P6227; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THRALL SH, 1993, BIOCHEMISTRY-US, V32, P1803, DOI 10.1021/bi00058a014; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WITTWER AJ, 1984, BIOCHEMISTRY-US, V23, P4650, DOI 10.1021/bi00315a021	32	118	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10597	10603						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144648				2022-12-27	WOS:A1994NF01700062
J	JAYANTHI, LD; RAMAMOORTHY, S; MAHESH, VB; LEIBACH, FH; GANAPATHY, V				JAYANTHI, LD; RAMAMOORTHY, S; MAHESH, VB; LEIBACH, FH; GANAPATHY, V			CALMODULIN-DEPENDENT REGULATION OF THE CATALYTIC FUNCTION OF THE HUMAN SEROTONIN TRANSPORTER IN PLACENTAL CHORIOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; PROTEIN-KINASE-C; 5-HYDROXYTRYPTAMINE TRANSPORTER; PARTIAL-PURIFICATION; RAT-BRAIN; LINE; ANTAGONISTS; EXPRESSION; INHIBITION; MODULATION	We investigated the involvement of calmodulin-dependent cellular processes in the regulation of the human serotonin transporter in placental choriocarcinoma cells. Treatment of JAR and BeWo cells with the selective calmodulin antagonist 1,3-dihydro-1-[1-((4-methyl-4H,6H-pyrrolo[1,2-alpha] [4,1]-benzoxapin-4-yl)-methyl)-4-piperindinyl]-2H-benzimidazol-2-one (CGS93-43B (CGS)) for 1 h decreased the imipramine-sensitive serotonin transport activity markedly. The inhibitory effect was specific and was reproducible with other calmodulin antagonists. The basal serotonin transport activity as well as the activity that was stimulated by cholera toxin were inhibited to a similar extent. The CGS-induced inhibition was accompanied by a decrease in the maximal velocity and in the affinities of the transporter for Na+ and Cl- and an increase in the affinity for serotonin. There was, however, no change in the Na+/Cl-/serotonin stoichiometry. The inhibition of the transport activity induced by the treatment of intact cells with CGS was observable in plasma membrane vesicles isolated hom these cells. Treatment with CGS had no effect on steady state levels of the serotonin transporter mRNAs nor on the transporter density in the plasma membrane. We conclude that the serotonin transporter is regulated by calmodulin-dependent processes in human placental choriocarcinoma cells involving posttranslational modification, most likely phosphorylation/dephosphorylation, of the transporter protein.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027487] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 27487] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BIESSEN EAL, 1990, BIOCHEMISTRY-US, V29, P3349, DOI 10.1021/bi00465a029; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; BRANDSCH M, 1994, IN PRESS BIOCH BIOPH; COOL DR, 1991, J BIOL CHEM, V266, P15750; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; FOGUET M, 1993, EMBO J, V12, P903, DOI 10.1002/j.1460-2075.1993.tb05731.x; FORSTNER GG, 1968, BIOCHEM J, V106, P381, DOI 10.1042/bj1060381; GANAPATHY V, 1989, J PHARMACOL EXP THER, V251, P9; GONZALEZHEYDRICH J, 1990, J CLIN PSYCHIAT, V51, P5; GRAHAM D, 1992, BIOCHEM J, V286, P801, DOI 10.1042/bj2860801; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; PRASAD PD, 1994, IN PRESS PLACENTA; RAMAMOORTHY S, 1992, PEDIATR RES, V32, P125, DOI 10.1203/00006450-199207000-00024; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1992, BIOCHEM J, V286, P89, DOI 10.1042/bj2860089; RAMAMOORTHY S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P181, DOI 10.1016/0167-4889(92)90255-A; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1189, DOI 10.1152/ajpcell.1992.262.5.C1189; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SCHATZMAN RC, 1981, BIOCHEM BIOPH RES CO, V98, P669, DOI 10.1016/0006-291X(81)91166-9; TANAKA T, 1982, MOL PHARMACOL, V22, P408; TURNER RJ, 1983, J MEMBRANE BIOL, V76, P1, DOI 10.1007/BF01871450; WALL SC, 1993, MOL PHARMACOL, V43, P264	33	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14424	14429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182048				2022-12-27	WOS:A1994NM06500021
J	JUNTTIBERGGREN, L; CIVELEK, VN; BERGGREN, PO; SCHULTZ, V; CORKEY, BE; TORNHEIM, K				JUNTTIBERGGREN, L; CIVELEK, VN; BERGGREN, PO; SCHULTZ, V; CORKEY, BE; TORNHEIM, K			GLUCOSE-STIMULATED INCREASE IN CYTOPLASMIC PH PRECEDES INCREASE IN FREE CA2+ IN PANCREATIC BETA-CELLS - A POSSIBLE ROLE FOR PYRUVATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; INDUCED INSULIN RELEASE; ACYL-COA ESTERS; INTRACELLULAR PH; AMMONIA PRODUCTION; EUKARYOTIC CELLS; ISLET CELLS; MALONYL-COA; B-CELLS; SECRETION	The temporal relationship of glucose-induced increases in cytoplasmic pH (pH(i)) and cytoplasmic free Ca2+ was studied in single mouse pancreatic beta cells and suspensions of clonal beta-cells (HIT). In both preparations of cells the increase in pH(i) preceded the cytoplasmic free Ca2+ increase. Therefore the alkalinization cannot be a consequence of the Ca2+ influx. A potential metabolic mechanism for the increase in pH(i), involving stimulation of pyruvate transport and oxidation, was demonstrated in a model system of liver mitochondria incubated with pyruvate, ATP, and hexokinase to which glucose was then added to initiate ATP use. The involvement of this mechanism in beta-cells is suggested by the observation that the alkalinization was prevented in most cells by incubation with 3-hydroxycyanocinnamate, a mitochondrial pyruvate transport inhibitor. On the other hand, the inhibited cells exhibited normal Ca2+ responses to glucose stimulation. This indicates that neither pyruvate metabolism nor the alkalinization is of critical importance for the Ca2+ signal, though pyruvate oxidation or its metabolites may be important in downstream regulation of secretion.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; KAROLINSKA INST,KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT ENDOCRINOL,S-10401 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118	Boston University; Karolinska Institutet; Karolinska University Hospital; Boston University			Civelek, Vildan Nur/D-7097-2014; Corkey, Barbara/E-7712-2015	Civelek, Vildan Nur/0000-0002-2942-6609; Berggren, Per-Olof/0000-0001-8991-413X; Tornheim, Keith/0000-0002-6235-5128; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK031559, P30DK046200, R01DK035914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46200, DK-35914, DK-31559] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAGON JJ, 1980, FEBS LETT, V117, pK56, DOI 10.1016/0014-5793(80)80570-9; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; ASHCROFT SJH, 1981, ISLETS LANGERHANS BI, P117; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; BUKOWIECKI L, 1979, BIOCHIM BIOPHYS ACTA, V583, P370, DOI 10.1016/0304-4165(79)90461-6; CORKEY BE, 1982, J BIOL CHEM, V257, P9668; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; DELEERS M, 1983, FEBS LETT, V154, P97, DOI 10.1016/0014-5793(83)80882-5; FREINKEL N, 1974, J CLIN INVEST, V54, P1179, DOI 10.1172/JCI107861; GRAPENGIESSER E, 1989, BIOCHIM BIOPHYS ACTA, V1014, P219, DOI 10.1016/0167-4889(89)90215-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3340; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HUTTON JC, 1979, BIOCHEM J, V184, P291, DOI 10.1042/bj1840291; JUNTTIBERGGREN L, 1992, BIOCHEM J, V287, P59, DOI 10.1042/bj2870059; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; KAIBARA M, 1988, J PHYSIOL-LONDON, V403, P621, DOI 10.1113/jphysiol.1988.sp017268; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KRZANOWSKI JJ, 1971, DIABETES, V20, P598, DOI 10.2337/diab.20.9.598; KUSHMERICK MJ, 1983, BIOCH EXERCISE, P50; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; LINDSTROM P, 1986, BIOCHEM J, V239, P199, DOI 10.1042/bj2390199; LONGO EA, 1991, J BIOL CHEM, V266, P9314; LOWENSTE.J, 1971, SCIENCE, V171, P397, DOI 10.1126/science.171.3969.397; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; MAHOWALD TA, 1962, J BIOL CHEM, V237, P1535; MALAISSE WJ, 1980, LIFE SCI, V26, P1367, DOI 10.1016/0024-3205(80)90038-7; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1981, METABOLISM, V30, P527, DOI 10.1016/0026-0495(81)90191-8; MALAISSE WJ, 1981, ISLETS LANGERHANS BI, P149; MARYNISSEN G, 1992, BIOCHEM MED METAB B, V48, P127, DOI 10.1016/0885-4505(92)90057-6; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; PACE CS, 1986, METABOLISM, V35, P176, DOI 10.1016/0026-0495(86)90120-4; PACE CS, 1983, AM J PHYSIOL, V244, pE3, DOI 10.1152/ajpendo.1983.244.1.E3; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SCHULTZ V, 1978, J BIOL CHEM, V253, P1938; SCHULTZ V, 1976, J BIOL CHEM, V251, P485; TAKAHASHI KI, 1993, J GEN PHYSIOL, V101, P695, DOI 10.1085/jgp.101.5.695; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; UI M, 1966, BIOCHIM BIOPHYS ACTA, V124, P310, DOI 10.1016/0304-4165(66)90194-2	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14391	14395						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182044				2022-12-27	WOS:A1994NM06500016
J	UMAR, A; BOYER, JC; THOMAS, DC; NGUYEN, DC; RISINGER, JI; BOYD, J; IONOV, Y; PERUCHO, M; KUNKEL, TA				UMAR, A; BOYER, JC; THOMAS, DC; NGUYEN, DC; RISINGER, JI; BOYD, J; IONOV, Y; PERUCHO, M; KUNKEL, TA			DEFECTIVE MISMATCH REPAIR IN EXTRACTS OF COLORECTAL AND ENDOMETRIAL CANCER CELL-LINES EXHIBITING MICROSATELLITE INSTABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARCINOMA; ESTABLISHMENT; MUTATIONS	A replication error (RER(+)) phenotype, characterized by somatic instability in simple repeated sequences, is associated with several types of cancer. To determine if a defect in DNA replication fidelity or repair of replication errors might explain this instability, we compared both processes in cell-free extracts from RER(+) endometrial and colorectal cancer cell lines to RER(-) cell lines. SV40 origin-dependent replication of a microsatellite sequence is highly accurate in cell extracts regardless of their RER phenotype. However, extracts from RER(+) cell lines are defective in mismatch repair, while extracts of RER(-) cell lines are not. Lack of repair was observed when the signal (a nick) for strand specific repair was either 3' or 5' to the mispair. One colorectal cancer cell line contained deletions in both alleles of the putative mismatch repair gene hMSH2, and one endometrial cancer cell line contained a 4-base pair duplication in one hMSH2 allele. No hMSH2 mutation was detected in the other allele or in the other five RER(+) cell lines. Repair was readily detected when each of the defective extracts was mixed with a repair-proficient extract, demonstrating that no trans-acting inhibitor is present. Attempts to complement the repair deficiencies by mixing two different defective extracts identified three combinations that restored repair. The data suggest that: (i) defective repair is associated with colorectal and endometrial cancer and, by extrapolation, with other types of cancer; (ii) mutations in the hMSH2 gene, and possibly other genes, result in defective mismatch repair; (iii) the defect(s) in these lines likely involves pre-incision events or the excision step, but not the incision, polymerization, or ligation steps; and (iv) at least four functional complementation groups for mismatch repair may be involved in human cancer.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; NIEHS,MOLEC CARCINOGENESIS LAB,GYNECOL PATHOBIOL SECT,RES TRIANGLE PK,NC 27709; CALIF INST BIOL RES,LA JOLLA,CA 92037	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Perucho, Manuel/0000-0002-2169-2662				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOYD J, 1991, MOL CARCINOGEN, V4, P189, DOI 10.1002/mc.2940040305; BRATTAIN MG, 1981, CANCER RES, V41, P1751; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; DEXTER DL, 1979, CANCER RES, V39, P1020; DREWINKO B, 1976, CANCER RES, V36, P467; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Morisawa T, 1987, J JPN SOC CLIN CYTOL, V26, P433; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PUCK TT, 1956, J EXP MED, V103, P273, DOI 10.1084/jem.103.2.273; RISINGER JI, 1993, CANCER RES, V53, P5100; RISINGER JI, 1994, IN PRESS NAT GENET, V6; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SHIBATA D, 1994, NAT GENET, V6, P278; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; STRAND M, 1993, NATURE, V365, P273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	38	326	332	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14367	14370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182040				2022-12-27	WOS:A1994NM06500011
J	YANG, EY; HUESTIS, WH				YANG, EY; HUESTIS, WH			OXIDATIVE INTERACTIONS BETWEEN THE ERYTHROCYTE-MEMBRANE AND PHOSPHATIDYLCHOLINE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; LOW-PH ASSOCIATION; VITAMIN-E; LIPID-PEROXIDATION; CROSS-LINKING; HEMOGLOBIN; PROTEINS; SUPEROXIDE; MECHANISM; TRANSGLUTAMINASES	Sonicated unilamellar phosphatidylcholine vesicles induce hemoglobin oxidation in erythrocytes and resealed membrane fragments (buds) at pH 5.5. No such oxidation was observed in vesicle-bud mixtures at pH 7.4, in cells or buds suspended in pH 5.5 buffer, or in cells incubated with multilamellar lipid vesicles at pH 5.5. In buds, vesicle-induced hemoglobin oxidation was accompanied by lipid peroxidation and formation of covalent high molecular weight protein aggregates. The causative relationships among the oxidative events were examined using selective antioxidants and membrane fragments in which the cytoplasmic domain of band 3 was cleaved. Protein cross-linking and lipid peroxidation were found to be independent events, but both were found only in concert with heme oxidation. Further, vesicle-induced hemoglobin oxidation was found to be correlated with quasi-stable adsorption of intact vesicles to cells; intercalation of foreign lipid into the cell bilayer was not required. The inability of multilamellar vesicles to induce these low pH oxidative effects suggests a steric Limitation on this cell-vesicle association. The results suggest that membrane component reorganization and patching induced by low pH may enhance vesicle adsorption, which in turn initiates oxidative damage.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL 23787] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023787] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES GFL, 1974, J BIOL CHEM, V249, P634; ARVINTE T, 1989, BIOCHIM BIOPHYS ACTA, V981, P51, DOI 10.1016/0005-2736(89)90081-3; ARVINTE T, 1989, BIOCHIM BIOPHYS ACTA, V981, P61, DOI 10.1016/0005-2736(89)90082-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BIABER B, 1977, J LAB CLIN MED, V85, P235; BOSSI L, 1975, BIOCHIM BIOPHYS ACTA, V375, P477, DOI 10.1016/0005-2736(75)90364-8; BURTON GW, 1983, ARCH BIOCHEM BIOPHYS, V221, P281, DOI 10.1016/0003-9861(83)90145-5; BUTIKOFER P, 1989, BLOOD, V74, P1481; CALVEZ JY, 1988, BIOCHEMISTRY-US, V27, P5666, DOI 10.1021/bi00415a041; CLASTER S, 1984, BLOOD, V64, P1079; CLASTER S, 1987, J LAB CLIN MED, V109, P201; COAKLEY WT, 1978, BIOCHIM BIOPHYS ACTA, V512, P318, DOI 10.1016/0005-2736(78)90256-0; CRICHTON RR, 1979, CIBA F S, V65, P57; Davies P J, 1988, Adv Exp Med Biol, V250, P391; DILLARD CJ, 1982, ARCH BIOCHEM BIOPHYS, V216, P204, DOI 10.1016/0003-9861(82)90205-3; DORMANDY TL, 1971, BRIT J HAEMATOL, V20, P457, DOI 10.1111/j.1365-2141.1971.tb07060.x; FLYNN TP, 1983, J CLIN INVEST, V71, P1215, DOI 10.1172/JCI110870; FLYNN TP, 1981, PROG CLIN BIOL RES, V91, P231; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEBBEL RP, 1984, BLOOD, V64, P733; HERSCHBERGER LA, 1982, LIPIDS, V17, P686, DOI 10.1007/BF02534652; HUISMAN THJ, 1986, METHODS HEMATOLOGY, V15; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; JAIN MK, 1980, INTRO BIOL MEMBRANES, P72; JOHNSON GJ, 1979, NEW ENGL J MED, V301, P522, DOI 10.1056/NEJM197909063011004; KIMELBERG HK, 1976, MOL CELL BIOCHEM, V10, P171, DOI 10.1007/BF01731688; KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546; KWEI GY, 1985, NUTR REP INT, V32, P179; LABRAKE CC, 1992, J BIOL CHEM, V267, P16703; LITOV RE, 1981, TOXICOL APPL PHARM, V59, P96, DOI 10.1016/0041-008X(81)90456-7; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LUBIN B, 1982, PEDIATR RES, V16, P928, DOI 10.1203/00006450-198211000-00005; MACDONALD VW, 1983, J LAB CLIN MED, V102, P762; MACHLIN LJ, 1980, VITAMIN E; MANNOJI M, 1985, SCAND J HAEMATOL, V35, P257; MCCAY PB, 1971, LIPIDS, V6, P297, DOI 10.1007/BF02531819; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MISRA HP, 1972, J BIOL CHEM, V247, P6960; PALEK J, 1979, SEMIN HEMATOL, V14, P75; PAPAHADJOPOULOS D, 1973, Biochimica et Biophysica Acta, V330, P8, DOI 10.1016/0005-2736(73)90280-0; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PRYOR W A, 1976, FREE RADICALS BIOLOG, P1; Riggs A., 1981, Methods in Enzymology, V76, P5; SALIN ML, 1975, J CLIN INVEST, V56, P1319, DOI 10.1172/JCI108208; SEVANIAN A, 1982, LIPIDS, V17, P269, DOI 10.1007/BF02534941; SHAKLAI N, 1978, ISRAEL J MED SCI, V14, P1152; SHVIRO Y, 1982, BIOCHIM BIOPHYS ACTA, V687, P63, DOI 10.1016/0005-2736(82)90170-5; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SNYDER LM, 1983, BRIT J HAEMATOL, V53, P379, DOI 10.1111/j.1365-2141.1983.tb02038.x; Steck T L, 1974, Methods Enzymol, V31, P172; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; Stokes J, 1971, BRIT J HAEMATOL, V20, P95; SZEBENI J, 1988, BIOCHEMISTRY-US, V27, P6425, DOI 10.1021/bi00417a034; SZEBENI J, 1985, BIOCHEMISTRY-US, V24, P2827, DOI 10.1021/bi00333a003; SZEBENI J, 1984, BIOCHEM J, V220, P685, DOI 10.1042/bj2200685; TAPPEL AL, 1972, ANN NY ACAD SCI, V203, P12, DOI 10.1111/j.1749-6632.1972.tb27851.x; Tappel AL, 1980, FREE RADICALS BIOL, P1; VANHEMMEN JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P743, DOI 10.1016/0003-9861(77)90556-2; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WEISS SJ, 1980, J BIOL CHEM, V255, P9912; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486; [No title captured]	72	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14518	14524						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182058				2022-12-27	WOS:A1994NM06500034
J	BERANGER, F; CADWALLADER, K; PORFIRI, E; POWERS, S; EVANS, T; DEGUNZBURG, J; HANCOCK, JF				BERANGER, F; CADWALLADER, K; PORFIRI, E; POWERS, S; EVANS, T; DEGUNZBURG, J; HANCOCK, JF			DETERMINATION OF STRUCTURAL REQUIREMENTS FOR THE INTERACTION OF RAB6 WITH RABGDI AND RAB GERANYLGERANYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; PROTEIN; GTPASE; METHYLATION; BINDING; PROTEOLYSIS; GAP	The importance of geranylgeranylation to the interaction of Rab proteins with RabGDI was investigated with a set of Rab6 mutants post-translationally modified by all known C-terminal lipid combinations. Rab6 proteins geranylgeranylated on CXC or CC motifs were found to be significantly better substrates for membrane extraction by RabGDI than either Rab6 proteins geranylgeranylated on CAAL motifs or Rab6 proteins that were farnesylated and palmitoylated. The methylation status of the CXC motif did not significantly affect interaction of wild type Rab6 with RabGDI. Rab6 protein sequences required for RabGDI interaction were then identified. Consistent with the significant homology between RabGDI and the Rab escort protein, a subunit of Rab geranylgeranyltransferase (RabGGTase), we show that there is an overlap between RabG motifs required for RabGDI binding and RabGGTase processing. The effector domain, loop3/beta 3 and the hypervariable region of RabG are all required for RabGDI binding, whereas loop3/beta 3 and the hypervariable region but not the effector domain are required for efficient processing of RabG by RabGGTase. Interestingly, however, loop3/beta 3 of RabG when introduced into H-Ras is sufficient to allow some in vivo processing of a C-terminal CSC motif.	ONYX PHARMACEUT,RICHMOND,CA 94806; INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Beranger, Florence/R-7581-2019	Hancock, John/0000-0003-0542-4710; Powers, Scott/0000-0003-2769-1932				ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; GIANNAKOUROS T, 1993, LIPID MODIFICATIONS; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEABRA MC, 1992, J BIOL CHEM, V70, P1049; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WEI C, 1992, ONCOGENE, V7, P467; WILSON AL, 1993, J BIOL CHEM, V268, P14561; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	38	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13637	13643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175798				2022-12-27	WOS:A1994NK18400084
J	KINDMAN, LA; KIM, S; MCDONALD, TV; GARDNER, P				KINDMAN, LA; KIM, S; MCDONALD, TV; GARDNER, P			CHARACTERIZATION OF A NOVEL INTRACELLULAR SPHINGOLIPID-GATED CA2+-PERMEABLE CHANNEL FROM RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; SPHINGOSINE; RELEASE; DERIVATIVES; BINDING	Sphingolipids stimulate the release of Ca2+ from intracellular stores. However, the mechanism by which this process occurs has not been characterized. Through single-channel recording from microsomes incorporated into planar lipid bilayers, we describe a novel channel that gates Ba2+ in response to sphingosyl-phosphorylcholine. The channel is both ligand-gated and voltage-modulated. Maximal open probability is observed between -10 and -20 mV and has a relatively high conductance (160 picosiemens with 53 mM Ba2+). We also observe that Ca2+ efflux from permeabilized rat basephilic leukemia cells is not antagonized by heparin, La3+, Ni2+, nifedipine, or Omega-conotoxin GVIa. The sphingolipid-gated Ca2+-permeable channel is therefore a new member of the Ca2+-permeable, ligand-gated channel family.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University	KINDMAN, LA (corresponding author), DUKE UNIV,MED CTR,DIV CARDIOVASC MED,BOX 3547,DURHAM,NC 27710, USA.				NHLBI NIH HHS [NHLBI K11-HL02361, NHLBI K11-HL02397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002361, K11HL002397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DIXON DA, 1989, J BIOL CHEM, V264, P13612; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; FUJINO Y, 1968, BIOCHEM J, V109, P310, DOI 10.1042/bj1090310; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	23	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13088	13091						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175733				2022-12-27	WOS:A1994NK18400009
J	BOUSSAC, A; RUTHERFORD, AW				BOUSSAC, A; RUTHERFORD, AW			ELECTRON-TRANSFER EVENTS IN CHLORIDE-DEPLETED PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; PHOTOSYNTHETIC WATER OXIDATION; S3 EPR SIGNAL; D1 POLYPEPTIDE; ENZYME; STATE; TYROSINE; EVOLUTION; CALCIUM; SYSTEM	Cl- and Ca2+ are obligatory cofactors in photosystem II (PS-II), the oxygen-evolving enzyme of plants. The electron transfer events in Cl--depleted PS-II were investigated by using continuous wave (cw) and pulsed EPR, and the results were compared with those obtained in untreated and Ca2+-depleted PS-II. In Cl--depleted PS II, the S-1 to S-2 transition is not accompanied by the appearance of the S-2 manganese signal in both cw and field-swept echo experiments. In the S-3 state, the cw experiment reveals the presence of a radical signal, and the field-swept echo experiment reveals the presence of a manganese signal similar to that observed in the S-2 state in Cl--reconstituted PS-II. A relaxation enhancement study of the oxidized tyrosine D indicates that a relaxation enhancement occurs only in the S-2 to S-3 transition and not in the S-1 to S-2 transition. The results are interpreted by the following preferred model. In Cl--depleted PS-II, the S-1 to S-2 transition corresponds to the oxidation of a component other than the manganese cluster, possibly an amino acid, and the S-2 to S-3 transition corresponds to the oxidation of the manganese complex. This oxidation sequence is the opposite of that observed in Ca2+-depleted PS-II. and may be due to a modulation by chloride of the relative redox potentials of the mangenese cluster and a nearby oxidizable amino acid. An alternative model involving manganese oxidation that is invisible in the S-1 to S-2 transition but that becomes visible on S-3 formation cannot be ruled out, although it is considered less likely.			BOUSSAC, A (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,SERV BIOENERGET,CNRS,UNITE RECH ASSOCIEE 1290,F-91191 GIF SUR YVETTE,FRANCE.		Rutherford, Alfred W/A-7831-2019	Rutherford, Alfred W/0000-0002-3124-154X				BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BAUMGARTEN M, 1990, BIOCHEMISTRY-US, V29, P10814, DOI 10.1021/bi00500a014; BOUSSAC A, 1990, FEBS LETT, V277, P69, DOI 10.1016/0014-5793(90)80811-V; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P1224, DOI 10.1021/bi00119a036; BOUSSAC A, 1989, BIOCHEMISTRY-US, V28, P8984, DOI 10.1021/bi00449a005; BOUSSAC A, 1988, BIOCHEMISTRY-US, V27, P3476, DOI 10.1021/bi00409a052; BOUSSAC A, 1990, NATURE, V347, P303, DOI 10.1038/347303a0; BOUSSAC A, 1985, BIOCHIM BIOPHYS ACTA, V808, P231, DOI 10.1016/0005-2728(85)90004-0; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P7441, DOI 10.1021/bi00148a003; BOUSSAC A, 1993, RES PHOTOSYNTHESIS, V1, P235; COLEMAN WJ, 1990, PHOTOSYNTH RES, V23, P1, DOI 10.1007/BF00030059; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEGROOT A, 1986, BIOCHIM BIOPHYS ACTA, V848, P8, DOI 10.1016/0005-2728(86)90154-4; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; HOMANN PH, 1986, BIOCHIM BIOPHYS ACTA, V850, P10, DOI 10.1016/0005-2728(86)90003-4; HOMANN PH, 1987, J BIOENERG BIOMEMBR, V19, P105, DOI 10.1007/BF00762720; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V851, P193, DOI 10.1016/0005-2728(86)90125-8; RUTHERFORD AW, 1991, NEW J CHEM, V15, P491; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; RUTHERFORD AW, 1992, RES PHOTOSYNTHESIS, V2, P21; RUTHERFORD AW, 1992, TOPICS PHOTOSYNTHESI, V11, P179; STYRING S, 1988, BIOCHIM BIOPHYS ACTA, V933, P378, DOI 10.1016/0005-2728(88)90046-1; STYRING S, 1987, BIOCHEMISTRY-US, V26, P2401, DOI 10.1021/bi00383a001; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; ZIMMERMANN JL, 1993, BIOCHEMISTRY-US, V32, P4831, DOI 10.1021/bi00069a019	31	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12462	12467						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175652				2022-12-27	WOS:A1994NH71600017
J	IMMENSCHUH, S; NAGAE, Y; SATOH, H; BAUMANN, H; MULLEREBERHARD, U				IMMENSCHUH, S; NAGAE, Y; SATOH, H; BAUMANN, H; MULLEREBERHARD, U			THE RAT AND HUMAN HEMOPEXIN GENES CONTAIN AN IDENTICAL INTERLEUKIN-6 RESPONSE ELEMENT THAT IS NOT A TARGET OF CAAT ENHANCER-BINDING PROTEIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Hemopexin (Hx) is an abundant acute-phase protein (APP) that binds heme with high affinity. In rat hepatic cells, the transcription rate of the Hx gene is increased by interleukin (IL)-1 and IL-6. To investigate the cis-acting regulatory elements (REs) responsive to these hormones, chloramphenicol acetyltransferase constructs of rat and human Hx gene sequences were tested in transiently transfected hepatoma cells. An IL-6-RE was identified in the promoter of both rat and human Hx genes, the function of which was dependent on the core sequence (CCGGGAA) common in other APP genes. The previously characterized Hx A element mediated a relatively minor cytokine response as compared with the Hx IL-6-RE. The human Hx A element, in contrast to the rat and human Hx IL-6-REs, was strongly trans activated by cotransfected CAAT enhancer-binding proteins (C/EBP)-beta and -delta. The rat gene homolog of the human Hx A element was inactive as a cytokine RE and was minimally trans-activated by C/EBP isoforms. Results of electrophoretic mobility shift assays indicated that the Hx IL-6-RE is a binding site for the IL-6-inducible nuclear protein IL-6 RE-BP, which also binds to the conserved IL-6-REs of other APP genes and is distinct from C/EBP beta.	CORNELL UNIV, COLL MED, DEPT PEDIAT, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA	Cornell University; Cornell University; Cornell University; Roswell Park Cancer Institute			Immenschuh, Stephan/AAM-9181-2020	Immenschuh, Stephan/0000-0003-3722-5791	NCI NIH HHS [CA 26122] Funding Source: Medline; NIDDK NIH HHS [DK 30664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Aldred A.R., 1993, ACUTE PHASE PROTEINS, V1st ed., P21; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; BALLA G, 1991, LAB INVEST, V64, P648; BARNARD ML, 1993, BIOCHEM BIOPH RES CO, V192, P82, DOI 10.1006/bbrc.1993.1384; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1993, J BIOL CHEM, V268, P25311; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fey G H, 1990, Prog Liver Dis, V9, P89; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOJ A, 1985, ACUTE PHASE RESPONSE, P00145; KUSHNER I, 1972, J LAB CLIN MED, V80, P18; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI XX, 1991, J BIOL CHEM, V266, P15192; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MORRONE G, 1988, J BIOL CHEM, V263, P12554; Muller- Eberhard U, 1974, STRUCTURE FUNCTION P, V1, ppp; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; NAGAE Y, 1992, BIOCHEM BIOPH RES CO, V185, P420, DOI 10.1016/S0006-291X(05)81002-2; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; POLI V, 1989, NUCLEIC ACIDS RES, V17, P9351; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SATOH H, 1994, IN PRESS J BIOL CHEM; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965	58	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12654	12661						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175675				2022-12-27	WOS:A1994NH71600046
J	SWIFT, GH; ROSE, SD; MACDONALD, RJ				SWIFT, GH; ROSE, SD; MACDONALD, RJ			AN ELEMENT OF THE ELASTASE-I ENHANCER IS AN OVERLAPPING BIPARTITE BINDING-SITE ACTIVATED BY A HETEROMERIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; PANCREATIC ACINAR-CELLS; GENE-EXPRESSION; TRANSGENIC MICE; REGULATORY ELEMENT; ENDOTHELIAL-CELLS; TRANSFECTED CELLS; 2 DOMAINS; TRANSCRIPTION; PROMOTER	The B element of the elastase I transcriptional enhancer is active in both exocrine and endocrine cells of the pancreas. Cell transfection experiments revealed that in an acinar cell line the active sequence of the element is more extensive than in an endocrine cell line. Electrophoretic mobility shift assays identified three major complexes (designated C, M, and L) from acinar cell. nuclear extracts bound to the element. The C complex appears to be responsible for the activity of the element in acinar cells because its binding site, determined by methylation interference and mobility shift competition experiments, matches the critical sequence identified by cell transfection analysis of mutated B elements. The DNA sequence requirements for formation of the C complex is the sum of those for the M and L complexes. Methylation interference experiments indicated that the sensitivity of the C complex to guanine methylation also was the sum of that of the M and L complexes. Diagonal electrophoretic mobility shift assays confirmed that L is a component of complex C. However, the M complex which we identified as GATA-4, is not part of the C complex, because the C complex was neither competed by GATA-binding sites nor supershifted by anti-GATA-4 antiserum. Both the C and L complexes are specific to the pancreatic acinar cell line.			SWIFT, GH (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		MacDonald, Ray/AAA-1290-2022		NIADDK NIH HHS [AM27430] Funding Source: Medline; NIGMS NIH HHS [GM31689] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DUBASP, 1988, NUCLEIC ACIDS RES, V16, P1251; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONOWICZ ES, 1980, J IMMUNOL, V125, P976; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HENNEY CS, 1971, J IMMUNOL, V107, P1558; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE ME, 1991, J BIOL CHEM, V266, P16188; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; ORKIN SH, 1992, BLOOD, V80, P575; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; RUTTER WJ, 1968, J CELL PHYSIOL, V72, P1, DOI 10.1002/jcp.1040720403; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	32	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12809	12815						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175694				2022-12-27	WOS:A1994NH71600068
J	WILCOX, MD; SCHEY, KL; DINGUS, J; MEHTA, ND; TATUM, BS; HALUSHKA, M; FINCH, JW; HILDEBRANDT, JD				WILCOX, MD; SCHEY, KL; DINGUS, J; MEHTA, ND; TATUM, BS; HALUSHKA, M; FINCH, JW; HILDEBRANDT, JD			ANALYSIS OF G-PROTEIN GAMMA-SUBUNIT HETEROGENEITY USING MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; C-TERMINAL CYSTEINE; ADENYLYL CYCLASE; BETA-SUBUNIT; BRAIN; DIVERSITY; NS; NI; TRANSDUCTION; PURIFICATION	The diversity of the gamma subunits in bovine brain G protein preparations was investigated using matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Analysis of these G protein mixtures revealed art least four gamma subunit masses by the following four criteria. 1) The measured masses were in the same mass range as the predicted molecular weights of gamma isoforms. 2) The masses were reproducible between the same or different preparations of G proteins. 3) The masses were independent of the matrix used for MALDI analysis. 4) The masses comigrated with the gamma subunit, as part of the heterotrimer, the beta gamma dimer, or the separated gamma subunit. These measured masses were compared with those calculated from cDNA sequences of known bovine brain gamma isoforms with the addition of plausible post-translationmodifications. The mass of each spectral peak was consistent with the calculated mass for only one of four known bovine brain gamma subunit isoforms, but the data suggest modifications of the gamma subunits in addition to those already known or suspected at their carboxyl termini. Besides these four major masses, several additional, less resolved spectral peaks were observed whose measured masses did not correlate with any known gamma subunit or plausible modification. MALDI mass spectrometry promises to be a powerful technique for the analysis of the diversity of the gamma subunit in G proteins and for the characterization of their post-translational modifications.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT,CHARLESTON,SC 29425	Medical University of South Carolina				Halushka, Marc/0000-0002-7112-7389	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILMAN AG, 1989, JAMA-J AM MED ASSOC, V262, P1819, DOI 10.1001/jama.262.13.1819; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; HURLEY JB, 1980, BIOCHEM BIOPH RES CO, V92, P505, DOI 10.1016/0006-291X(80)90362-9; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KATADA T, 1987, J BIOL CHEM, V262, P11897; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12508	12513						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175659				2022-12-27	WOS:A1994NH71600024
J	HAYASHI, S; JAIN, S; CHU, RY; ALVARES, K; XU, B; ERFURTH, F; USUDA, N; RAO, MS; REDDY, SK; NOGUCHI, T; REDDY, JK; YELDANDI, AV				HAYASHI, S; JAIN, S; CHU, RY; ALVARES, K; XU, B; ERFURTH, F; USUDA, N; RAO, MS; REDDY, SK; NOGUCHI, T; REDDY, JK; YELDANDI, AV			AMPHIBIAN ALLANTOINASE - MOLECULAR-CLONING, TISSUE DISTRIBUTION, AND FUNCTIONAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT URATE OXIDASE; POLYACRYLAMIDE GELS; LIVER PEROXISOMES; URIC-ACID; PROTEINS; GENE; EVOLUTION; PURIFICATION; DEGRADATION; RNA	The chain of enzymes necessary to convert uric acid to its metabolic products urea and glyoxylic acid in vertebrates is truncated through the successive loss of allantoicase, allantoinase, and urate oxidase during phylogenetic evolution. Previous studies have assigned the localization of both mate oxidase and allantoinase to the peroxisome in the amphibian liver. This study reports the cloning of a cDNA encoding bullfrog (Rana catesbeiana) allantoinase, an enzyme that converts allantoin to allantoic acid. The cDNA is 2112 base pairs in length containing a 1449-base pair open reading frame which corresponds to a 483-residue protein (53,296 Da). Structural analysis of the deduced protein suggested two potential transmembrane segments and the presence of a putative mitochondrial localization sequence in the amino terminus. Immunocytochemical analysis revealed that allantoinase is localized to mitochondria and not to peroxisomes. On Northern blotting, a single mRNA species was detected in the liver and kidney of frog but not in other tissues; this distribution was confirmed by immunoblotting. The hepatic- and renal- specific expression of allantoinase coincides with the distribution of urate oxidase in these tissues in the frog. The allantoinase expressed in Saccharomyces cerevisiae and in Spodoptera frugiperda (Sf9) insect cells exhibits catalytic activity and is antigenically identical to the native frog enzyme.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; KYUSHU DENT COLL, DEPT BIOCHEM, KITAKYUSHU 803, JAPAN	Northwestern University; Kyushu Dental University				Alvares, Keith/0000-0003-3710-4367; jain, sanjay/0000-0003-2804-127X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARES K, 1992, P NATL ACAD SCI USA, V89, P4908, DOI 10.1073/pnas.89.11.4908; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BUCKHOLZ RG, 1991, YEAST, V7, P913, DOI 10.1002/yea.320070903; Campbell J., 1991, EXPT METABOLIC ANIMA, V4th ed., P277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRIEDMAN TB, 1985, COMP BIOCHEM PHYS B, V81, P653, DOI 10.1016/0305-0491(85)90381-5; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAYASHI S, 1989, J BIOL CHEM, V264, P3211; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; KEILIN J, 1959, BIOL REV, V34, P265, DOI 10.1111/j.1469-185X.1959.tb01447.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NOGUCHI T, 1986, J BIOL CHEM, V261, P4221; NOGUCHI T, 1982, J BIOCHEM-TOKYO, V92, P525, DOI 10.1093/oxfordjournals.jbchem.a133960; REDDY PG, 1988, P NATL ACAD SCI USA, V85, P9081, DOI 10.1073/pnas.85.23.9081; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENBERG DR, 1989, MOL ENDOCRINOL, V3, P805, DOI 10.1210/mend-3-5-805; SCOTT PJ, 1969, ANN NY ACAD SCI, V168, P244, DOI 10.1111/j.1749-6632.1969.tb43113.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P27; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUDA N, 1988, LAB INVEST, V58, P100; USUDA N, 1994, IN PRESS J CELL SCI; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; WANG XD, 1991, GENE, V97, P223, DOI 10.1016/0378-1119(91)90055-G; WU X, 1992, J MOL EVOL, V34, P178; YELDANDI AV, 1991, GENE, V109, P281, DOI 10.1016/0378-1119(91)90622-I	32	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12269	12276						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163532				2022-12-27	WOS:A1994NG37700090
J	SOLER, C; BEGUINOT, L; CARPENTER, G				SOLER, C; BEGUINOT, L; CARPENTER, G			INDIVIDUAL EPIDERMAL GROWTH-FACTOR RECEPTOR AUTOPHOSPHORYLATION SITES DO NOT STRINGENTLY DEFINE ASSOCIATION MOTIFS FOR SEVERAL SH2-CONTAINING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; POINT MUTATION; EGF-RECEPTOR; SH2 DOMAINS; PHOSPHORYLATION; TYROSINE; BINDING; GAP	To determine whether individual autophosphorylation sites in the epidermal growth factor (EGF) receptor define specific interaction sites for the in vivo association of signal transduction proteins that contain src homology 2 (SH2) domains, the capacity of wild-type and mutant EGF receptors to associate with several SH2 domain containing proteins has been assayed. Mutants in eluded receptors with single autophosphorylation site mutations at each of five autophosphorylation sites and receptors in which multiple autophosphorylation sites were removed by point mutation or deletion of carboxyl-terminal residues. Receptor association, as measured by coimmunoprecipitation, has been determined for phospholipase C-gamma 1, the ras GTPase-activating protein, the p85 subunit of phosphatidylinositol 3-kinase, and the src homology and collagen protein. In contrast to data obtained with single autophosphorylation site mutants of other receptor tyrosine kinases, none of the EGF receptor single site mutants was dramatically impaired in its capacity to associate with any of these SH2-containing proteins. However, association was completely abrogated when all five autophosphorylation sites were mutated or removed by deletion. These results indicate that individual autophosphorylation sites in the EGF receptor are not stringently required for the recognition and association of different SH2-containing substrates. Thus, EGF receptor autophosphorylation sites seem to be flexible and/or compensatory in their capacity to mediate association with these four SH2-containing substrates.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; HOSP SAN RAFFAELE, CNR, INST NEUROSCI & BIOIMMAGINI, I-20132 MILAN, ITALY	Vanderbilt University; Vanderbilt University; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Soler, Concepció/L-1185-2014	Soler, Concepció/0000-0001-6502-5012	NATIONAL CANCER INSTITUTE [P01CA043720, R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720, CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HELIN K, 1991, ONCOGENE, V6, P825; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAGNI M, 1991, BIOCHEM J, V277, P305, DOI 10.1042/bj2770305; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCNAMARA DJ, 1993, INT J PEPT PROT RES, V42, P240; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SUH PG, 1988, J BIOL CHEM, V263, P14497; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	100	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12320	12324						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163537				2022-12-27	WOS:A1994NG37700097
J	WU, K; FREGIEN, N; CARRAWAY, KL				WU, K; FREGIEN, N; CARRAWAY, KL			MOLECULAR-CLONING AND SEQUENCING OF THE MUCIN SUBUNIT OF A HETERODIMERIC, BIFUNCTIONAL CELL-SURFACE GLYCOPROTEIN COMPLEX OF ASCITES RAT MAMMARY ADENOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALOMUCIN COMPLEX; INTESTINAL MUCIN; EPISIALIN; PRECURSOR; CONTAINS; REGION; CDNAS; RICH	Ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma contain abundant amounts of a heterodimeric cell surface glycoprotein complex composed of a mucin subunit ASGP-1 (ascites sialoglycoprotein-1) and a transmembrane subunit (ASGP-2). Previous studies showed that the complex is synthesized from a single polypeptide encoded by a 9 kb transcript. The sequence of the transmembrane subunit was obtained from a 5-kilobase (kb) cDNA isolated from a plasmid library (Sheng, Z., Wu, K., Carraway, K. L., and Fregien, N. (1992) J. Biol. Chem. 267, 16341-16346). Completion of the sequence of this cDNA revealed the C-terminal domain of ASGP-1, which is rich in serine and threonine but contains no typical mucin type repeats. The remainder of the sequence of ASGP-1 and the 9-kb transcript was obtained by two 5'-RACE (rapid amplification of cDNA ends) steps and primer extension analysis. These results revealed that the 5' half of the 9-kb transcript contains a short B'-noncoding region and encodes a signal sequence, a short nonrepeat region, and a repeat domain containing 11 repeats. Nine of these repeats are found in tandem, but the two end repeats are separated from the others by short unique sequences. The repeats vary from 117-124 amino acids and are 70-90% identical to a consensus sequence. Overall, the sequence predicts that ASGP-1 contains 2172 amino acids (M(r) 224,190), 43% of which are serine and threonine. We propose that the complex of this mucin and its transmembrane subunit, which contains growth factor-modulating activity, may play an important role in tumor progression.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami; University of Miami					NATIONAL CANCER INSTITUTE [R01CA052498, P30CA014395] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14395, CA 52498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CARRAWAY KL, 1992, J CELL SCI, V103, P299; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HUGGINS JW, 1980, CANCER RES, V40, P1873; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MORIARTY J, 1990, CANCER RES, V50, P6800; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; XU G, 1992, BIOCH BIPHYS RES COM, V183, P921; XU GQ, 1992, J BIOL CHEM, V267, P5401	31	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11950	11955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163496				2022-12-27	WOS:A1994NG37700044
J	KOZYAVKIN, SA; KRAH, R; GELLERT, M; STETTER, KO; LAKE, JA; SLESAREV, AI				KOZYAVKIN, SA; KRAH, R; GELLERT, M; STETTER, KO; LAKE, JA; SLESAREV, AI			A REVERSE GYRASE WITH AN UNUSUAL STRUCTURE - A TYPE-I DNA TOPOISOMERASE FROM THE HYPERTHERMOPHILE METHANOPYRUS-KANDLERI IS A 2-SUBUNIT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ESCHERICHIA-COLI; DESULFUROCOCCUS-AMYLOLYTICUS; SUPERHELICAL TURNS; CLEAVAGE REACTION; SUPERCOILED DNA; ATPASE ACTIVITY; NALIDIXIC-ACID; GENE-PRODUCT; DUPLEX DNA	Reverse gyrase, an ATP-dependent topoisomerase that positively supercoils DNA, has been purified to near-homogeneity from the hyperthermophile Methanopyrus kandleri. It migrates on SDS-polyacrylamide gel electrophoresis as two principal bands with apparent molecular masses of 150 and 50 kDa. Both proteins remain associated throughout all chromatographic steps. Transfer of a radioactive phosphate from DNA to the 50-kDa protein and gel retardation experiments indicate that this protein forms the covalent complex with DNA. A blot overlay assay identifies the 150-kDa protein as the potential ATPase. This is the first evidence that a reverse gyrase can be a topoisomerase consisting of two protomers. In analogy with the DNA gyrase A subunit (DNA breakage and reunion activity) and the B subunit (ATPase), the 50- and 150-kDa components of Mka reverse gyrase have been designated the A and B subunits, respectively. Methanopyrus reverse gyrase changes DNA linking number in steps of one and its A subunit covalently binds to the 5'-DNA phosphoryl group. It nicks DNA at sites that predominantly have a cytosine at the -4-position. The same rule was derived previously for monomeric reverse gyrase from sulfur-metabolizing hyperthermophiles and for topoisomerase I from mesophilic bacteria. Based on these results, Mka reverse gyrase is classified as belonging to group A of type I topoisomerases. The structural diversity of type I group A topoisomerases parallels the diversity of type II enzymes and suggests the evolution of an essential function by gene fusion.	UNIV REGENSBURG, W-8400 REGENSBURG, GERMANY; UNIV CALIF LOS ANGELES, INST MICROBIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of Regensburg; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	KOZYAVKIN, SA (corresponding author), NIDDKD, MOLEC BIOL LAB, BLDG 5, RM 238, BETHESDA, MD 20892 USA.			Kozyavkin, Sergei/0000-0001-5605-5113				ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; AGHAAMIRI K, 1993, NUCLEIC ACIDS RES, V21, P1491, DOI 10.1093/nar/21.6.1491; ANDERA L, 1993, FEMS MICROBIOL LETT, V110, P107, DOI 10.1111/j.1574-6968.1993.tb06303.x; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; BAUER WR, 1990, CHROMOSOMES EUKARYOT, V1, P87; BONCHOSMOLOVSKAIA EA, 1986, DOKL AKAD NAUK SSSR+, V290, P1259; BONCHOSMOLOVSKAYA EA, 1988, MICROBIOLOGY+, V57, P78; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P346, DOI 10.1016/S0723-2020(11)80308-5; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DEAN FB, 1985, J BIOL CHEM, V260, P4984; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DELATOUR CB, 1991, J BACTERIOL, V173, P3921, DOI 10.1128/JB.173.12.3921-3923.1991; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DOOLITTLE WF, 1992, BIOCHEM SOC SYMP, P1; FELSENFELD G, 1977, ORG EXPRESSION EUKAR, P157; Forterre P, 1992, Biochem Soc Symp, V58, P99; FORTERRE P, 1992, BIOSYSTEMS, V28, P15, DOI 10.1016/0303-2647(92)90004-I; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; Kandler O, 1992, Biochem Soc Symp, V58, P195; KIKUCHI A, 1986, SYST APPL MICROBIOL, V7, P72, DOI 10.1016/S0723-2020(86)80126-6; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; Kikuchi A, 1990, DNA TOPOLOGY ITS BIO, P285; KIM RA, 1992, J BIOL CHEM, V267, P17178; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KORNBERG A, 1992, DNA REPLICATION, P379; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Kristjansson Jakob K., 1992, P1; KURR M, 1991, ARCH MICROBIOL, V156, P239, DOI 10.1007/BF00262992; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LEE MP, 1989, J BIOL CHEM, V264, P13510; LIU LF, 1979, J BIOL CHEM, V254, P1082; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYUBCHENKO YL, 1988, NUCLEIC ACIDS RES, V16, P3269, DOI 10.1093/nar/16.8.3269; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; ORR E, 1982, J BACTERIOL, V151, P524, DOI 10.1128/JB.151.1.524-527.1982; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEASHOLTZ AF, 1983, J BIOL CHEM, V258, P1221; SEGERER A, 1985, NATURE, V313, P787, DOI 10.1038/313787a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SLESAREV A I, 1988, Biopolimery i Kletka, V4, P119; SLESAREV AI, 1994, J BIOL CHEM, V269, P3295; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1986, SYST APPL MICROBIOL, V7, P393; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TABASSUM R, 1992, J BACTERIOL, V174, P7890, DOI 10.1128/JB.174.24.7890-7895.1992; TSE YC, 1980, J BIOL CHEM, V255, P5560; TU J, 1982, J MOL EVOL, V18, P109, DOI 10.1007/BF01810829; van Holde K.E., 1988, CHROMATIN; VOLOSHIN ON, 1989, FEBS LETT, V243, P377, DOI 10.1016/0014-5793(89)80165-6; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; Wang J C, 1985, Harvey Lect, V81, P93; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1987, NATL CANCER I MONOGR, V4, P3; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	90	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11081	11089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157633				2022-12-27	WOS:A1994NF96600020
J	MORI, H; HASHIRAMOTO, M; CLARK, AE; YANG, J; MURAOKA, A; TAMORI, Y; KASUGA, M; HOLMAN, GD				MORI, H; HASHIRAMOTO, M; CLARK, AE; YANG, J; MURAOKA, A; TAMORI, Y; KASUGA, M; HOLMAN, GD			SUBSTITUTION OF TYROSINE-293 OF GLUT1 LOCKS THE TRANSPORTER INTO AN OUTWARD FACING CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; BINDING; MUTAGENESIS; SYSTEM	Tyrosines 292 and 293 in the mammalian glucose transporter GLUT1 have been substituted by either isoleucine or phenylalanine. Chinese hamster ovary clones that were transfected with Tyr-292 --> Ile, Tyr-292 --> Phe, Tyr-293 --> Ile, and Tyr-293 --> Phe constructs of GLUT1 were shown, by Western blotting and cell surface carbohydrate labeling, to have expression levels that were comparable with the wild type. The V(max) for 2-deoxy-D-glucose transport was markedly reduced only as a result of the Tyr-293 --> Ile mutation. The ability of the Tyr-293 --> Ile mutated GLUT1 to bind the exofacial ligand 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis-(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA) and the endofacial ligand cytochalasin B were assessed by photolabeling procedures. The ability to bind the bis-mannose compound was unimpaired, whereas the ability to bind cytochalasin B was totally abolished, and the level of labeling was lower than in the nontransfected clone. Affinities of the wild-type and Tyr-293 --> Ile GLUT1 for D-glucose, the exofacial ligands (ATB-BMPA and 4,6-O-ethylidene-D-glucose), and the endofacial ligand (cytochalasin B) were assessed by the ability of these agents to displace the radioactive ATB-BMPA photolabel. These data indicated that the Tyr-293 --> Ile substitution produced no change in the affinity for D-glucose, a relatively small enhancement in the affinity for exofacial ligands, but a large almost-equal-to 300-fold reduction in affinity for cytochalasin B, suggesting that the mutated GLUT1 is locked in an outward facing conformation. The observation that the Tyr-293 --> Ile mutant transporter can bind nontransported C4 and C6 substituted hexose analogues but cannot catalyze transport is interpreted as indicating that Tyr-293 is involved in closing the exofacial site around C4 and C6 of D-glucose in the transport catalysis process.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 1,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN; UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	Kobe University; University of Bath				Holman, Geoffrey/0000-0001-7045-1358				APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BARNETT JEG, 1973, BIOCHEM J, V135, P539, DOI 10.1042/bj1350539; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; DEZIEL M, 1984, BIOCHIM BIOPHYS ACTA, V772, P403, DOI 10.1016/0005-2736(84)90157-3; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HENDERSON PJF, 1990, RES MICROBIOL, V14, P316; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; HOLMAN GD, 1982, BIOCHIM BIOPHYS ACTA, V685, P78, DOI 10.1016/0005-2736(82)90037-2; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P227; SCHURMANN A, 1993, BIOCHEM J, V290, P497, DOI 10.1042/bj2900497; Stein WD, 1986, TRANSPORT DIFFUSION, P231; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; WADZINSKI BE, 1988, BIOCHEM J, V255, P983, DOI 10.1042/bj2550983; WELLNER M, 1992, FEBS LETT, V309, P293, DOI 10.1016/0014-5793(92)80792-F	27	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11578	11583						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157690				2022-12-27	WOS:A1994NF96600089
J	STOKES, DL; LACAPERE, JJ				STOKES, DL; LACAPERE, JJ			CONFORMATION OF CA2+-ATPASE IN 2 CRYSTAL FORMS - EFFECTS OF CA2+, THAPSIGARIN, ADENOSINE 5'-(BETA,GAMMA-METHYLENE)TRIPHOSPHATE), AND CHROMIUM(III)-ATP ON CRYSTALLIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CALCIUM-PUMP; ACTIVE-SITE; CA-2+,MG-2+-ADENOSINE TRIPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; ELECTRON-MICROSCOPY; SULFHYDRYL-GROUPS; TRYPTIC CLEAVAGE; TRANSPORT ATPASE; CROSS-LINKING	The structure of Ca2+-ATPase has been studied by electron microscopy of two different crystal forms: one tubular form induced by vanadate in native sarcoplasmic reticulum (SR) membranes and another multilamellar form grown from detergent-solubilized SR. To determine the conformation of Ca2+-ATPase within each crystal form, the respective effects of Ca2+, thapsigargin, adenosine 5'-(beta,gamma-methylene)triphosphate) (AMP-PCP), and chromium(III) (Cr-ATP) on crystallization have been studied. Vanadate-induced tubes were prevented from forming by micromolar Ca2+, but if preformed in the absence of Ca2+, millimolar Ca2+ was required to disrupt these crystals. Thapsigargin promoted tube formation even in the presence of 10 mM Ca2+. Neither AMP-PCP nor Cr-ATP prevented tube formation, and the Ca2+ sensitivity of tube formation from Cr-ATP-inhibited SR was identical to controls. Multilamellar crystals required at least 0.2 mM Ca2+ and were prevented from forming by thapsigargin, AMP-PCP, or Cr-ATP. It is concluded that helical tubes are composed of the Ca2+-free, dephosphorylated conformation (E), and the nucleotide-bound conformation (E.ATP) is also tolerated. In contrast, multilamellar crystals are composed of the Ca2+-bound conformation (E.Ca2) and do not tolerate nucleotide binding. Thus, comparison of structures obtained from the two crystal forms should reveal physiologically relevant conformational differences.	CENS, DEPT BIOL CELLULAIRE & MOLEC, CNRS, URA 1290, F-91190 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS)	STOKES, DL (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT MOLEC PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040997] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40997] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BISHOP JE, 1988, BIOCHEMISTRY-US, V27, P5233, DOI 10.1021/bi00414a043; BLASIE JK, 1985, BIOPHYS J, V48, P9, DOI 10.1016/S0006-3495(85)83756-5; BUHLE EL, 1983, J ULTRA MOL STRUCT R, V85, P186, DOI 10.1016/S0022-5320(83)90106-5; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CASTELLANI L, 1989, J CELL BIOL, V108, P511, DOI 10.1083/jcb.108.2.511; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; COAN C, 1986, J BIOL CHEM, V261, P394; COAN CR, 1977, J BIOL CHEM, V252, P3044; CSERMELY P, 1985, EUR J BIOCHEM, V150, P455, DOI 10.1111/j.1432-1033.1985.tb09043.x; CSERMELY P, 1987, BIOCHEM J, V241, P663, DOI 10.1042/bj2410663; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUX L, 1985, J BIOL CHEM, V260, P3454; DUX L, 1983, J BIOL CHEM, V258, P1896; DUX L, 1985, J BIOL CHEM, V260, P1730; DUX L, 1987, J BIOL CHEM, V262, P6439; DUX L, 1983, J BIOL CHEM, V258, P2599; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; GRYCZYNSKI I, 1989, BIOCHEMISTRY-US, V28, P3490, DOI 10.1021/bi00434a051; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P1049, DOI 10.1021/bi00353a015; IMAMURA Y, 1984, J BIOCHEM, V95, P1305, DOI 10.1093/oxfordjournals.jbchem.a134736; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JORGEGARCIA I, 1988, ARCH BIOCHEM BIOPHYS, V265, P82, DOI 10.1016/0003-9861(88)90373-6; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEWIS SM, 1986, BIOCHEMISTRY-US, V25, P4615, DOI 10.1021/bi00364a024; LUND S, 1989, J BIOL CHEM, V264, P4907; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MARTONOSI AN, 1990, FEBS LETT, V268, P365, DOI 10.1016/0014-5793(90)81287-X; MAURER A, 1984, J BIOENERG BIOMEMBR, V16, P491, DOI 10.1007/BF00743241; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MESZAROS LG, 1992, BIOCHEMISTRY-US, V31, P1195, DOI 10.1021/bi00119a032; MOLNAR E, 1990, BIOCHIM BIOPHYS ACTA, V1023, P147, DOI 10.1016/0005-2736(90)90410-P; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1978, J BIOL CHEM, V253, P385; NAKAMOTO RK, 1986, FEBS LETT, V194, P258, DOI 10.1016/0014-5793(86)80096-5; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PIKULA S, 1988, J BIOL CHEM, V263, P5277; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; STOKES DL, 1990, J MOL BIOL, V213, P529, DOI 10.1016/S0022-2836(05)80213-X; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TAYLOR KA, 1988, J BIOL CHEM, V263, P5287; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VARGA S, 1985, EUR J BIOCHEM, V148, P119, DOI 10.1111/j.1432-1033.1985.tb08815.x; VARGA S, 1987, BIOCHIM BIOPHYS ACTA, V896, P187, DOI 10.1016/0005-2736(87)90179-9; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; WATANABE T, 1982, J BIOL CHEM, V257, P1510; YASUOKAYABE K, 1983, J BIOCHEM-TOKYO, V94, P665, DOI 10.1093/oxfordjournals.jbchem.a134406	65	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11606	11613						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157694				2022-12-27	WOS:A1994NF96600094
J	FELDMAN, GM; PETRICOIN, EF; DAVID, M; LARNER, AC; FINBLOOM, DS				FELDMAN, GM; PETRICOIN, EF; DAVID, M; LARNER, AC; FINBLOOM, DS			CYTOKINES THAT ASSOCIATE WITH THE SIGNAL TRANSDUCER GP130 ACTIVATE THE INTERFERON-INDUCED TRANSCRIPTION FACTOR P91 BY TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; DNA-BINDING PROTEIN; FC-GAMMA RECEPTOR; ONCOSTATIN-M; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; RESPONSE ELEMENTS; IFN-GAMMA; CELLS; ALPHA	Interleukin-6, leukemia inhibitory factor, and oncostatin M exert a broad range of similar biological activities through association of their receptors with the signal-transducing component gp130. Although it is known that these cytokines trigger rapid tyrosine phosphorylation of a common set of cellular proteins as well as induction of several of the same early response genes, the mechanisms by which these genes are activated is not well understood. In this report, we show that interleukin-6 leukemia inhibitory factor, and oncostatin M stimulate the assembly of protein complexes that recognize conserved sequences within the enhancers of two genes (interferon regulatory factor 1 and Fc gamma receptor type I) that are rapidly activated by these cytokines. These enhancers are known to be required for transcriptional induction of these genes by interferon-gamma. Assembly of the DNA-binding protein complexes occurs within minutes after ligand addition and depends upon tyrosine phosphorylation. These complexes contain the p91 transcription factor, which is tyrosine-phosphorylated in response to these cytokines. An additional tyrosine-phosphorylated protein of 93 kDa can be coimmunoprecipitated with antibodies against p91. These findings further expand the network of cytokines known to activate p91 and, in addition, support the concept that sets of tyrosine-phosphorylated proteins may be responsible for the cytokine-regulated expression of early response genes.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENECH PD, 1992, J EXP MED, V176, P1115, DOI 10.1084/jem.176.4.1115; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GROVE RI, 1991, J BIOL CHEM, V266, P18194; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1993, J BIOL CHEM, V268, P9092; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUHL S, 1993, BLOOD, V82, P2641; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEARS DW, 1990, J IMMUNOL, V144, P371; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	51	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10747	10752						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144663				2022-12-27	WOS:A1994NF01700083
J	HOU, CF; GILBERT, RL; BARBER, DL				HOU, CF; GILBERT, RL; BARBER, DL			SUBTYPE-SPECIFIC SIGNALING MECHANISMS OF SOMATOSTATIN RECEPTORS SSTR1 AND SSTR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; BINDING PROTEINS; TUMOR-CELLS; INHIBITION; CLONING; BRAIN; ACTIVATION; CALCIUM	Somatostatin regulates diverse cellular effecters, including adenylyl cyclase, ion channels, and ion exchangers. We expressed two somatostatin receptor subtypes, SSTR1 and SSTR2, stably in mouse fibroblast Ltk(-) cells and transiently in human embryonic kidney HEK293 cells to investigate subtype-specific pharmacological and functional properties. The effects of GTP gamma S and pertussis toxin on [I-125-Tyr(11)]somatostatin-14 binding indicated that SSTR2 may couple exclusively to pertussis toxin sensitive G proteins, whereas SSTR1 may couple to both pertussis-sensitive and -insensitive G proteins. When expressed either stably or transiently, both receptor subtypes mediated somatostatin inhibition of cAMP accumulation by a pertussis toxin-sensitive mechanism. In contrast, only SSTR1 mediated somatostatin inhibition of Na+-H+ exchange activity, and this action was insensitive to pertussis toxin. We generated two chimeric receptors by replacing sequential residues of SSTR2 with cognate sequences of SSTR1 to identify molecular determinants unique to SSTR1 that may confer coupling to the exchanger. SSTCR4 included a SSTR1 segment encompassing determinants within the fifth and sixth hydrophobic domains and the entire third cytoplasmic loop, while SSTCRS5 contained a SSTR1 segment spanning the second through sixth hydrophobic domains, including both second and third cytoplasmic loops. Although both chimeric receptors mediated somatostatin inhibition of cAMP accumulation, only SSTCR5 mediated the inhibition of Na+-H+ exchange activity, and this effect was pertussis-insensitive. These findings demonstrate both pharmacological and functional differences between SSTR1 and SSTR2. The ability of SSTR1 to selectively attenuate Na+-H+ exchange activity requires determinants outside the third cytoplasmic domain.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM47413] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; GANZ MB, 1990, J BIOL CHEM, V265, P8989; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH BD, 1985, J BIOL CHEM, V260, P3138; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LI XJ, 1992, J BIOL CHEM, V267, P21307; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MURRAYWHELAN R, 1992, J BIOL CHEM, V267, P2960; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRNAD J, 1993, BIOCHEM BIOPH RES CO, V191, P968, DOI 10.1006/bbrc.1993.1312; TALLENT M, 1992, MOL PHARMACOL, V41, P452; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	40	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10357	10362						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144617				2022-12-27	WOS:A1994NF01700029
J	SASAOKA, T; DRAZNIN, B; LEITNER, JW; LANGLOIS, WJ; OLEFSKY, JM				SASAOKA, T; DRAZNIN, B; LEITNER, JW; LANGLOIS, WJ; OLEFSKY, JM			SHC IS THE PREDOMINANT SIGNALING MOLECULE COUPLING INSULIN-RECEPTORS TO ACTIVATION OF GUANINE-NUCLEOTIDE RELEASING-FACTOR AND P21(RAS)-GTP FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; RAS P21; PROTEIN; TRANSDUCTION; STIMULATION; ASSOCIATION; EXPRESSION; ONCOGENES; DOMAIN; GROWTH	Insulin stimulates tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and She in Rat1 fibroblasts overexpressing wild type insulin receptors. We investigated the relative role of IRS-1 and She in insulin activation of guanine nucleotide releasing factor (GNRF) and p21(ras)-GTP formation. The time course of insulin stimulated tyrosine phosphorylation of IRS-1 was rapid, whereas She phosphorylation was relatively slow. Growth factor receptor bound protein-2 (Grb2) associated with IRS-1 rapidly and gradually dissociated after 5 min, whereas Grb2 association with She was slower and reached a maximum at 10 min after insulin stimulation. Thus, the kinetics of Grb2 association with IRS-1 and She corresponded closely to the time course of tyrosine phosphorylation of IRS-1 and Shc, respectively. Importantly, 3-13-fold more Grb2 was associated with Shc than with IRS-1. In addition, the kinetics of insulin-stimulated GNRF activity and p21(ras)-GTP formation corresponded more closely to the time course of She phosphorylation than to the kinetics of IRS-1 phosphorylation. Furthermore, immunoprecipitation of She proteins from cell lysates of insulin-stimulated cells removed 67% of the GNRF activity, whereas precipitation of IRS-1 had a negligible effect on GNRF activity. Thus, although both IRS-1 and She associate with Grb2, the current results indicate that She plays a more important role than IRS-1 in insulin stimulation of GNRF activity and subsequent p21(ras)-GTP formation.	UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	39	186	187	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10734	10738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144662				2022-12-27	WOS:A1994NF01700081
J	BROWN, LJ; MACDONALD, MJ; LEHN, DA; MORAN, SM				BROWN, LJ; MACDONALD, MJ; LEHN, DA; MORAN, SM			SEQUENCE OF RAT MITOCHONDRIAL GLYCEROL-3-PHOSPHATE DEHYDROGENASE CDNA - EVIDENCE FOR EF-HAND CALCIUM-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCEROL-PHOSPHATE DEHYDROGENASE; AMINO-ACID-SEQUENCES; GLYCEROPHOSPHATE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; PANCREATIC-ISLETS; INSULIN-SECRETION; L-3-GLYCEROPHOSPHATE DEHYDROGENASE; MODULATED PROTEINS; THYROID-HORMONE; BETA-CELLS	The FAD-dependent, mitochondrial glycerol-3-phosphate dehydrogenase (EC 1.1.99.5) is an essential component of the glycerol phosphate shuttle and is abundant in the pancreatic insulin cell, skeletal muscle, and brain. Although DNA clones for this enzyme and its homologues have been isolated from bacteria and yeast, it has never been cloned from a higher eukaryote. We have cloned and sequenced cDNAs encoding the rat mitochondrial glycerol-3-phosphate dehydrogenase. The longest cDNA (2337 base pairs) encodes a deduced protein of 727 amino acids that shows strong homology to the yeast and bacterial FAD-dependent glycerol phosphate dehydrogenases. The amino terminus of the purified mature protein was sequenced and shows identity with the deduced amino acid sequence beginning with residue 43. The 42 preceding amino acids are consistent with a mitochondrial leader peptide. A highly conserved FAD binding domain and conserved regions possibly involved with glycerol phosphate binding are present. An unexpected finding was the homology of the deduced protein to calmodulin. Analysis of the deduced protein sequence shows a region near the carboxyl terminus containing two sequences homologous to ''EF-hand'' calcium-binding domains that are not present in the shorter yeast and bacterial homologues. The second of these domains appears to have features compatible with considerable affinity for calcium, whereas the first does not. The finding of a potential calcium-binding region is consistent with the known enhancement by calcium of the mammalian enzyme activity at low substrate concentrations and the lack of a requirement for calmodulin. This is the first report of EF-hands in a metabolic enzyme or in a mitochondrial protein.	UNIV WISCONSIN,CTR CHILDRENS DIABET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK042176, R01DK028348] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28348, DK42176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSTIN D, 1991, J BACTERIOL, V173, P101, DOI 10.1128/jb.173.1.101-107.1991; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BUCHER T, 1958, ANGEW CHEM INT EDIT, V70, P552, DOI 10.1002/ange.19580701707; CAVENER DR, 1991, MOL BIOL EVOL, V8, P194; CHEN C, 1979, THESIS U N DAKOTA; CLAY VJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P112, DOI 10.1016/S0005-2728(89)80208-7; COLE ES, 1978, J BIOL CHEM, V253, P7952; COLE ST, 1988, J BACTERIOL, V170, P2448, DOI 10.1128/jb.170.6.2448-2456.1988; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; DAWSON AP, 1969, BIOCHEM J, V111, P27, DOI 10.1042/bj1110027; ESTABROOK RW, 1958, J BIOL CHEM, V233, P1014; FISHER AB, 1973, BIOCHEMISTRY-US, V12, P1438, DOI 10.1021/bi00731a026; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; GARONE L, 1991, ARCH BIOCHEM BIOPHYS, V291, P89, DOI 10.1016/0003-9861(91)90108-U; GARRIB A, 1988, J BIOL CHEM, V263, P19821; GARRIB A, 1986, J BIOL CHEM, V261, P8042; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; HANSFORD RG, 1967, BIOCHEM BIOPH RES CO, V27, P686, DOI 10.1016/S0006-291X(67)80090-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLMBERG C, 1990, J GEN MICROBIOL, V136, P2367, DOI 10.1099/00221287-136-12-2367; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE E, 1979, NATURE, V279, P677, DOI 10.1038/279677a0; LEE YP, 1965, J BIOL CHEM, V240, P1427; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1990, CANCER RES, V50, P7203; MACDONALD MJ, 1983, J CLIN ENDOCR METAB, V57, P662, DOI 10.1210/jcem-57-3-662; MACDONALD MJ, 1979, HORM METAB RES, V14, P678; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MATSCHINSKY FM, 1986, J BIOL CHEM, V261, P14057; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELNICK MB, 1993, BIOCHIM BIOPHYS ACTA, V1171, P334, DOI 10.1016/0167-4781(93)90079-S; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; OSTENSON CG, 1993, DIABETOLOGIA, V36, P722, DOI 10.1007/BF00401142; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; ROENNOW B, 1993, YEAST, V9, P1121; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SHAW MA, 1982, ANN HUM GENET, V46, P11, DOI 10.1111/j.1469-1809.1982.tb00690.x; TAYLOR VJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P49, DOI 10.1016/0005-2728(86)90247-1; WERNETTE ME, 1981, J BIOL CHEM, V256, P2767; WOLHRAB H, 1977, BIOCHIM BIOPHYS ACTA, V462, P102	45	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14363	14366						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182039				2022-12-27	WOS:A1994NM06500010
J	LI, GP; BARBIERI, MA; COLOMBO, MI; STAHL, PD				LI, GP; BARBIERI, MA; COLOMBO, MI; STAHL, PD			STRUCTURAL FEATURES OF THE GTP-BINDING DEFECTIVE RAB5 MUTANTS REQUIRED FOR THEIR INHIBITORY ACTIVITY ON ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE TARGET PROTEIN; NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN; EFFECTOR DOMAIN; MEMBRANE ASSOCIATION; MUTATIONAL ANALYSIS; H-RAS; MUTAGENESIS; ENDOSOMES; INTERACTS	Rab5 is a Ras-like small GTPase that regulates early events of endocytosis. Previous work indicates that two GTP-binding defective Rab5 mutants (Rab5:S34N and Rab5:N133I) are dominant inhibitors of endocytosis. In this report, we have initiated experiments to address the structural features necessary for the inhibitory activity of these two Rab5 mutants. Second-site mutations were introduced into Rab5:S34N and Rab5:N133I, respectively, and the resulting double mutants were expressed in cultured BHK-21 cells via a Sindbis virus expression vector. Endocytic activity of the cells was monitored by following the uptake of a fluid-phase endocytic marker (horseradish peroxidase). The effects of the Rab5 mutants on endosome fusion in vitro were also examined. Truncation of the C-terminal isoprenylation motif CCSN abolished the inhibitory activity of both Rab5:S34N and Rab5:N133I. The same held true when the secondary mutation was a substitution mutation (F57S) in the effector domain. Another substitution mutation in this region (I53A) had no effect on the inhibitory activity of either Rab5:S34N or Rab5:N133I. The final mutation (R81A) was created immediately downstream of the second GTP binding motif (WDTAGQER), i.e. in the loop 4 region based on the structural model of Pas. This mutation greatly decreased the isoprenylation of Rab5:N133I and its inhibitory activity on endocytosis. It is believed that Rab5 function requires protein-protein interactions with Rab5-specific regulators and effecters. Some of these interactions are disrupted by Rab5:S34N and Rab5:N133I. By analogy to Ras, both Rab5:S34N and Rab5:N133I are likely to sequester a Rab5-specific guanine nucleotide exchange factor. This interaction requires the effector domain Phe(57) residue and C-terminal isoprenylation of Rab5.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Stahl, Philip/D-6315-2012; Li, Guangpu/GRS-5397-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42259-19] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AUSUBEL FM, 1981, CURRENT PROTOCOLS MO; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHUNG HH, 1993, P NATL ACAD SCI USA, V90, P10145, DOI 10.1073/pnas.90.21.10145; DIAZ R, 1988, J BIOL CHEM, V263, P6093; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HANN CS, 1992, P NATL ACAD SCI USA, V89, P2679; HWANG YW, 1993, J BIOL CHEM, V268, P24692; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI GP, 1993, J BIOL CHEM, V268, P24475; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	49	98	99	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14631	14635						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182071				2022-12-27	WOS:A1994NM06500052
J	SARDANA, VV; WOLFGANG, JA; VELOSKI, CA; LONG, WJ; LEGROW, K; WOLANSKI, B; EMINI, EA; LAFEMINA, RL				SARDANA, VV; WOLFGANG, JA; VELOSKI, CA; LONG, WJ; LEGROW, K; WOLANSKI, B; EMINI, EA; LAFEMINA, RL			PEPTIDE SUBSTRATE CLEAVAGE SPECIFICITY OF THE HUMAN CYTOMEGALOVIRUS PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IDENTIFICATION; GENE; PROTEINASE; EXPRESSION; SEQUENCE; PRODUCT; FRAME; SITES; DNA	The human cytomegalovirus UL80 gene encodes an 80-kDa precursor polyprotein whose N-terminal 256-amino acid domain is a protease. This enzyme cleaves a specific peptide bond that results in its own release from the precursor, as well as a peptide bond near the C terminus of the viral assembly protein. The latter cleavage is apparently required for encapsidation of the viral genomic DNA and maturation of the viral capsid. A series of peptide substrates, representing the assembly protein cleavage site, was used to study the enzyme's substrate requirements and specificity. It was found that efficient cleavage minimally required the amino acid residues spanning the P4 to P4' positions. Substitution at any of these residues adversely affected the reaction. Conservation of the hydrophobic residues at P3 and P4 was essential. In addition, cleavage of a peptide representing the protease domain release site was reduced almost 100-fold relative to cleavage of the assembly protein maturation site peptide substrate.			SARDANA, VV (corresponding author), MERCK SHARP & DOHME LTD, RES LABS, DEPT ANTIVIRAL RES, WP16-206, West Point, PA 19486 USA.							AHMED AK, 1975, J BIOL CHEM, V250, P8477; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; LAFEMINA RL, 1983, J GEN VIROL, V64, P373, DOI 10.1099/0022-1317-64-2-373; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PRESTON VG, 1992, VIROLOGY, V186, P87, DOI 10.1016/0042-6822(92)90063-U; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	11	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14337	14340						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182034				2022-12-27	WOS:A1994NM06500003
J	WORLEY, JF; MCINTYRE, MS; SPENCER, B; MERTZ, RJ; ROE, MW; DUKES, ID				WORLEY, JF; MCINTYRE, MS; SPENCER, B; MERTZ, RJ; ROE, MW; DUKES, ID			ENDOPLASMIC-RETICULUM CALCIUM STORE REGULATES MEMBRANE-POTENTIAL IN MOUSE ISLET BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC B-CELLS; THAPSIGARGIN; INFLUX; INHIBITION	Glucose stimulation of islet beta-cell insulin secretion is initiated by membrane depolarization and an elevation in intracellular free calcium concentration ([Ca2+](i)) from a combination of influx through depolarization-activated Ca2+ channels and intracellular Ca2+ store release. Prevention of Ca2+ store refilling with thapsigargin produced a sustained depolarization, leading to enhanced Ca2+ influx and an elevation in [Ca2+](i) in 12 mM glucose. Depletion of intracellular Ca2+ stores by external EGTA reduced [Ca2+](i) and also caused a long lasting depolarization. In single beta-cells, external EGTA activated an inward current, the voltage range and kinetic properties of which differed from those of voltage-dependent Ca2+ channels. A novel pathway thus exists in beta-cells by which depletion of endoplasmic reticulum Ca2+ stores results in the activation of an inward current that, by inducing depolarization, facilitates Ca2+ influx through voltage-gated Ca2+ channels. The physiological relevance of this pathway in the control of beta cell function is indicated by the stimulation of insulin secretion by thapsigargin.	GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Atwater I, 1980, Horm Metab Res Suppl, VSuppl 10, P100; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON IM, 1992, BIOCHEM J, V288, P457, DOI 10.1042/bj2880457; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROE MW, 1994, AM J PHYSL, V266; ROE MW, 1993, BIOPHYS J, V64, P126; ROE MW, 1993, DIABETES, V42, P77; ROSSI JP, 1989, BIOCHIM BIOPHYS ACTA, V943, P175; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SMOLEN P, 1992, J MEMBRANE BIOL, V127, P9; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	28	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14359	14362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182038				2022-12-27	WOS:A1994NM06500009
J	ZEINDLEBERHART, E; JUNGBLUT, PR; OTTO, A; RABES, HM				ZEINDLEBERHART, E; JUNGBLUT, PR; OTTO, A; RABES, HM			IDENTIFICATION OF TUMOR-ASSOCIATED PROTEIN VARIANTS DURING RAT HEPATOCARCINOGENESIS - ALDOSE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; TWO-DIMENSIONAL ELECTROPHORESIS; 2-DIMENSIONAL ELECTROPHORESIS; TISSUE PROTEINS; CELL-FRACTIONS; ALDEHYDE REDUCTASES; LIVER; PURIFICATION; SUPERFAMILY; RESOLUTION	Tumor-associated protein variants were detected by two-dimensional gel electrophoresis (2-DE) in soluble proteins from chemically induced rat hepatomas and transformed rat liver cell lines. Among them, a series of 8 protein variants was found localized at similar sites in 2-DE gels (33-35 kDa, with different pI values). We characterized four of them. In situ peptide mapping with limited proteolysis disclosed a significant relationship between these four individual protein spots. Their different position in 2-DE gels might be due to posttranslational modifications: one of the variants was phosphorylated, three others were modified by glycosylation. The most prominent tumor-associated protein variant of this series (spot 17) was further studied by amino acid analysis and internal amino acid microsequencing. It became evident that this variant is identical to aldose reductase (EC 1.1.1.21). This enzyme of the sorbitol pathway is expressed in the liver during embryogenesis, but is absent in adult rat liver. Our results suggest that it is reexpressed and functionally active during liver carcinogenesis.	UNIV MUNICH, INST PATHOL, D-80338 MUNICH, GERMANY; TECHNOL CTR TELTOW, WITTMANN INST TECHNOL & ANAL BIOMOLEC, D-14513 TELTOW, GERMANY; MAX DELBRUCK CTR MOLEC MED, INST MOLEC MED, D-13125 BERLIN, GERMANY	University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Jungblut, Peter R/A-1576-2011					ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0; BANNASCH P, 1980, BIOCHIM BIOPHYS ACTA, V605, P217, DOI 10.1016/0304-419X(80)90005-0; BARTELS D, 1991, EMBO J, V10, P1037, DOI 10.1002/j.1460-2075.1991.tb08042.x; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CARPER DA, 1989, EXP EYE RES, V49, P377, DOI 10.1016/0014-4835(89)90048-1; CELIS JE, 1991, ELECTROPHORESIS, V12, P765, DOI 10.1002/elps.1150121103; CLEMENTS RS, 1969, BIOCHEM BIOPH RES CO, V37, P347, DOI 10.1016/0006-291X(69)90741-4; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROMLISH JA, 1983, J BIOL CHEM, V258, P3416; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P94; ECKERSKORN C, 1990, ELECTROPHORESIS, V11, P554, DOI 10.1002/elps.1150110705; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GAYNES BI, 1989, COMP BIOCHEM PHYS B, V92, P685, DOI 10.1016/0305-0491(89)90250-2; GRAHAM CA, 1988, ELECTROPHORESIS, V9, P343, DOI 10.1002/elps.1150090711; HAYMAN S, 1965, J BIOL CHEM, V240, P877; HERS HG, 1960, BIOCHIM BIOPHYS ACTA, V37, P127, DOI 10.1016/0006-3002(60)90086-X; HERS HG, 1960, BIOCHIM BIOPHYS ACTA, V37, P120, DOI 10.1016/0006-3002(60)90085-8; JAIN S, 1991, LEC RAT NEW MODEL HE, P335; JEFFERY J, 1983, P NATL ACAD SCI-BIOL, V80, P901, DOI 10.1073/pnas.80.4.901; JUNGBLUT P, 1990, ELECTROPHORESIS, V11, P581, DOI 10.1002/elps.1150110709; JUNGBLUT P, 1992, J PROTEIN CHEM, V11, P603, DOI 10.1007/BF01024960; JUNGBLUT P, 1994, IN PRESS ELECTROPHOR; KADOFUKU T, 1985, J CHROMATOGR, V343, P51, DOI 10.1016/S0378-4347(00)84567-3; KAPITANY RA, 1973, ANAL BIOCHEM, V56, P361, DOI 10.1016/0003-2697(73)90202-9; KERLER R, 1988, J CANCER RES CLIN, V114, P113, DOI 10.1007/BF00417823; KERN TS, 1982, HISTOCHEM J, V14, P507, DOI 10.1007/BF01011860; KLEE GG, 1987, TUMOR MARKERS TUMOR, P2; KLOSE J, 1984, CLIN CHEM, V30, P2014; KLOSE J, 1975, HUMANGENETIK, V26, P231; KLOSE J, 1983, MODERN METHODS PROTE, P49; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; LEVINE GA, 1978, J BIOL CHEM, V253, P5985; MAYES PA, 1990, HARPERS BIOCH, P189; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; NISHIMURA C, 1988, BIOCHEM BIOPH RES CO, V153, P1051, DOI 10.1016/S0006-291X(88)81335-4; NISHIMURA C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P171, DOI 10.1016/0167-4838(91)99006-E; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHTA M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P395, DOI 10.1016/0167-4838(91)90162-S; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PETRASH JM, 1991, ELECTROPHORESIS, V12, P84, DOI 10.1002/elps.1150120116; RABES HM, 1989, FALK SYMP, V51, P305; RABES HM, 1986, CANCER RES, V46, P645; RABES HM, 1979, CANCER RES, V39, P1298; RASMUSSEN HH, 1991, ELECTROPHORESIS, V12, P873, DOI 10.1002/elps.1150121107; SAMANTA BK, 1984, EXPERIENTIA, V40, P1420, DOI 10.1007/BF01951922; SELL S, 1987, HUMAN TUMOR MARKERS, P301; SRIVASTAVA SK, 1985, BIOCHIM BIOPHYS ACTA, V840, P334, DOI 10.1016/0304-4165(85)90213-2; SRIVASTAVA SK, 1984, BIOCHIM BIOPHYS ACTA, V800, P220, DOI 10.1016/0304-4165(84)90399-4; TAKAMI H, 1979, CANCER RES, V39, P2096; TAKAMI H, 1979, CANCER RES, V39, P507; TULSIANI DRP, 1977, J BIOL CHEM, V252, P2545; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; WIRTH PJ, 1990, JPN J CANCER RES, V81, P477, DOI 10.1111/j.1349-7006.1990.tb02594.x; WIRTH PJ, 1986, CANCER RES, V46, P400; WIRTH PJ, 1987, CANCER RES, V47, P2839; WIRTH PJ, 1991, LEC RAT NEW MODEL HE, P185; WU BC, 1979, CANCER RES, V39, P116; ZEINDLEBERHART E, 1987, HUM GENET, V77, P371, DOI 10.1007/BF00291429; ZEINDLEBERHART E, 1992, CARCINOGENESIS, V13, P1177, DOI 10.1093/carcin/13.7.1177	63	54	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14589	14594						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182065				2022-12-27	WOS:A1994NM06500045
J	BERTRAND, B; WAKABAYASHI, S; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M				BERTRAND, B; WAKABAYASHI, S; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M			THE NA+/H+ EXCHANGER ISOFORM-1 (NHE1) IS A NOVEL MEMBER OF THE CALMODULIN-BINDING PROTEINS - IDENTIFICATION AND CHARACTERIZATION OF CALMODULIN-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; LIGHT CHAIN KINASE; GROWTH-FACTORS; HUMAN-FIBROBLASTS; CA-2+ PUMP; MOLECULAR-CLONING; ALPHA-THROMBIN; CYTOPLASMIC PH; OKADAIC ACID; ACTIVATION	The Na+/H+ exchange activity (NHE1 human isoform) is rapidly activated in response to growth factors and hyperosmotic stress. To get insight into the mechanism of NHE1 activation, we studied the direct interaction of a ubiquitous Ca2+-dependent regulatory factor, calmodulin (CaM) with NHE1. Binding experiments with CaM-Sepharose, as well as fluorescence measurements with dansylated CaM, revealed that the NHE1 cytoplasmic domain strongly binds CaM in a Ca2+-dependent manner. Fusion protein analysis with deletion mutants provided evidence for high (K-d similar to 20 nM) and intermediate (K-d similar to 350 nM) affinity CaM-binding sites located in neighboring regions of NHE1 (amino acids 636-656 and 657-700). To assess a regulatory role of CaM-binding sites, several cDNAs having deletion and point mutations in the high affinity site were generated and expressed in the exchanger-deficient fibroblast cell line PS120. Deletion and point mutations of positively charged residues of the high affinity CaM-binding site resulted in up to 50 and 80% reductions of cytoplasmic alkalinization caused by growth factors (alpha-thrombin, etc.) and 100 mM sucrose, respectively. In these mutants, the reduction in alkalinization was apparently in proportion to that of the CaM-binding ability. These results suggest that binding of Ca2+/CaM to the high affinity site is involved at least partly in the activation of NHE1 in response to different extracellular signals.	UNIV NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	BERTRAND, B (corresponding author), NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN.							ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1986, NAPLUS HPLUS EXCHANG; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2598; GNEGY ME, 1993, ANN REV PHARM TOXICO, V32, P45; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1988, NAPLUS HPLUS EXCHANG; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HENDEY B, 1989, J BIOL CHEM, V264, P19540; JAMES P, 1988, J BIOL CHEM, V263, P2905; KIMURA M, 1990, J BIOL CHEM, V265, P21068; LADANT D, 1988, J BIOL CHEM, V263, P2612; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MEECH RW, 1977, J PHYSIOL-LONDON, V265, P867, DOI 10.1113/jphysiol.1977.sp011749; MITSUHASHI T, 1988, J BIOL CHEM, V263, P8790; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; MULDOON LL, 1985, AM J PHYSIOL, V249, pC140, DOI 10.1152/ajpcell.1985.249.1.C140; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; ZIEGELSTEIN RC, 1992, SCIENCE, V258, P656, DOI 10.1126/science.1329207	47	298	302	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13703	13709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175806				2022-12-27	WOS:A1994NK18400094
J	KOZARSKY, KF; MCKINLEY, DR; AUSTIN, LL; RAPER, SE; STRATFORDPERRICAUDET, LD; WILSON, JM				KOZARSKY, KF; MCKINLEY, DR; AUSTIN, LL; RAPER, SE; STRATFORDPERRICAUDET, LD; WILSON, JM			IN-VIVO CORRECTION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR DEFICIENCY IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT WITH RECOMBINANT ADENOVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED GENE-TRANSFER; LIVER-TRANSPLANTATION; WHHL-RABBIT; INVIVO; EXPRESSION; ATHEROSCLEROSIS; IMPROVEMENT; HEPATOCYTES; THERAPY	A rabbit animal model of the human disease familial hypercholesterolemia (FH), which is the result of low density lipoprotein (LDL) receptor deficiency, was used to develop an in vivo approach to gene therapy based on recombinant adenoviruses. Recombinant, replication-defective adenoviruses expressing the lacZ gene under the control of different promoters were infused into the portal circulation of New Zealand White (NZW) rabbits. Expression of lacZ could be obtained in virtually all hepatocytes within 3 days post infusion, but was undetectable by 3 weeks. This was not associated with liver pathology, An LDL receptor expressing adenovirus was constructed using the most active promoter and was infused into the portal vein of rabbits deficient in LDL receptor. Analysis of liver tissues harvested 3 days after virus infusion demonstrated human LDL receptor protein in the majority of hepatocytes that exceeded the levels found in human liver by at least 10-fold. Transgene expression was stable for 7-10 days and diminished to undetectable levels within 3 weeks. Infusion of LDL receptor expressing virus led to substantial reductions in serum cholesterol that returned to base line within 3 weeks; this acute reduction in serum cholesterol was associated with accumulations of lipid in hepatocytes. The development of neutralizing antibodies to the recombinant adenovirus markedly diminished the effectiveness of a second dose. These studies illustrate the advantages of recombinant adenoviruses for the treatment of liver metabolic diseases and define issues, such as viral genome instability and blocking immune response, that need to be overcome before the promise of this technology can be fully realized.	UNIV PENN,WISTAR INST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT SURG,PHILADELPHIA,PA 19104; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				BARR E, 1994, GENE THER, V1, P51; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; ENGELHARDT JF, 1994, IN PRESS P NATL ACAD; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GROSSMAN M, 1992, HUM GENE THER, V3, P501, DOI 10.1089/hum.1992.3.5-501; GROSSMAN M, 1993, J LAB CLIN MED, V121, P472; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HIERHOLZER JC, 1978, J CLIN MICROBIOL, V7, P499; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; NICOLAU C, 1987, METHOD ENZYMOL, V149, P157; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROESSLER BJ, 1993, J CLIN INVEST, V92, P1085, DOI 10.1172/JCI116614; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STARZL TE, 1984, LANCET, V1, P1382; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Strauss SE, 1984, ADENOVIRUSES, P451; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WILSON JM, 1992, HUM GENE THER, V3, P179, DOI 10.1089/hum.1992.3.2-179; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1991, J BIOL CHEM, V266, P14338; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YANG Y, 1994, IN PRESS P NATL ACAD; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	34	275	294	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13695	13702						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175805				2022-12-27	WOS:A1994NK18400093
J	LUJAN, HD; MOWATT, MR; HELMAN, LJ; NASH, TE				LUJAN, HD; MOWATT, MR; HELMAN, LJ; NASH, TE			INSULIN-LIKE GROWTH-FACTORS STIMULATE GROWTH AND L-CYSTEINE UPTAKE BY THE INTESTINAL PARASITE GIARDIA-LAMBLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANNOSE 6-PHOSPHATE RECEPTOR; COHN FRACTION-IV; II IGF-II; HUMAN-PLASMA; GASTROINTESTINAL-TRACT; PROTEIN; IDENTIFICATION; PURIFICATION; ANTIBODIES; PEPTIDES	Giardia lamblia, a parasitic protozoan responsible for diarrhea and malabsorption in humans, grows axeni- cally only in media that contain serum and a high concentration of L-cysteine. During our attempts to grow Giardia in the absence of serum, we found that: (a) human insulin-like growth factors (especially IGF-II), but not insulin, promote the growth and L-cysteine uptake by G. lamblia trophozoites; (b) the growth stimulation was inhibited by alpha IR3, an anti-type 1 IGF receptor monoclonal antibody, but an anti-type 2 IGF receptor antibody had no effect; and (c) IGFs act on Giardia through a type 1 IGF receptor-like protein, which can bind IGF-II with higher affinity than IGF-I, and most likely possesses intrinsic phosphotyrosine kinase activity.	NCI,PEDIAT BRANCH,MOLEC GENET SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LUJAN, HD (corresponding author), NIAID,PARASIT DIS LAB,9000 ROCKVILLE PIKE,BLDG 4,RM B1-31,BETHESDA,MD 20892, USA.							ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; [Anonymous], 1991, INSULIN LIKE GROWTH; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BLUM WF, 1986, ACTA ENDOCRINOL-COP, V111, P271, DOI 10.1530/acta.0.1110271; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DUNCAN M D, 1991, Gastroenterology, V100, pA638; DURONIO V, 1988, RECEPTOR BIOCH MET B, V12, P3; GILLIN FD, 1982, MOL CELL BIOL, V2, P369, DOI 10.1128/MCB.2.4.369; HARI J, 1987, EMBO J, V6, P3367, DOI 10.1002/j.1460-2075.1987.tb02658.x; HEIDE K, 1960, PLASMA PROTEINS, P545; HEINZERIAN P, 1991, ENDOCRINOLOGY, V129, P1769, DOI 10.1210/endo-129-4-1769; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P65; JAFFE D L, 1990, Gastroenterology, V98, pA659; KATO H, 1993, J BIOL CHEM, V268, P2655; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTERIO TJ, 1987, PHYSIOL BEHAV, V40, P755, DOI 10.1016/0031-9384(87)90279-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUJAN HD, 1994, IN PRESS J EUK MICRO; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; NOLAN CM, 1987, J CELL BIOCHEM, V35, P137, DOI 10.1002/jcb.240350207; OH Y, 1993, GROWTH REGULAT, V3, P113; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PARKES JL, 1986, BIOCHEM BIOPH RES CO, V134, P427, DOI 10.1016/0006-291X(86)90581-4; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; READ LC, 1991, MODERN CONCEPTS INSU, P225; ROSENZWEIG SA, 1990, J BIOL CHEM, V265, P18030; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STRACZEK J, 1990, J CHROMATOGR-BIOMED, V532, P237, DOI 10.1016/S0378-4347(00)83775-5; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; TONG PY, 1988, J BIOL CHEM, V263, P2585; VANDENBRANDE JL, 1990, ACTA ENDOCRINOL-COP, V122, P683, DOI 10.1530/acta.0.1220683; WIEDER SC, 1983, J PARASITOL, V69, P1181, DOI 10.2307/3280897; ZUMKELLER W, 1992, J PEDIATR GASTR NUTR, V15, P357, DOI 10.1097/00005176-199211000-00001	39	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13069	13072						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175729				2022-12-27	WOS:A1994NK18400004
J	MIDURA, RJ; EVANKO, SP; HASCALL, VC				MIDURA, RJ; EVANKO, SP; HASCALL, VC			PARATHYROID-HORMONE STIMULATES HYALURONAN SYNTHESIS IN AN OSTEOBLAST-LIKE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; ISOLATED BONE-CELLS; CYCLIC-AMP; UMR 106-01; BIOCHEMICAL-CHARACTERIZATION; COLLAGEN-SYNTHESIS; EMBRYONIC CHICKEN; CULTURE SYSTEM; CALCIUM; PROTEOGLYCANS	An osteoblast-like cell line (UMR 106-01 BSP), cloned from a transplantable osteosarcoma, was cultured in the presence of parathyroid hormone (PTH1-34) and metabolically labeled with [S-35]sulfate, [H-3]glucosamine, and [H-3]tyrosine to determine proteoglycan, glycoconjugate, and protein synthesis, respectively. The synthesis of secreted proteins was substantially increased by PTH treatment. However, the synthesis of bone sialoprotein and proteoglycans was, at best, only moderately stimulated by PTH. Hyaluronan (HA) synthesis was dramatically stimulated by PTH in this cell line. A 5-6-fold increase in HA production was observed using 10(-8) M PTH, and even a 50% increase was detected using 10(-10) M PTH. The PTH-induced stimulation of HA synthesis was rapid and transient, reaching a maximum level (similar to 560 pmol of HA disaccharide equivalents/h/10(6) cells at 10(-8) M PTH) by 4-7 h after hormone exposure and returning to control levels by 12-15 h after the initial treatment. Lastly, the majority of this HA synthesis stimulated by PTH required only a short exposure (<90 min) to the hormone. These data suggest (i) that normal osteoblasts (or a sub-population of preosteoblasts) probably synthesize HA in response to PTH treatment, and (ii) that this PTH-induced synthesis of HA most likely involves some signal transduction mechanism(s).	NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BERESFORD JM, 1984, METAB BONE DIS RELAT, V5, P335; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo-116-1-234; COCHRAN DL, 1987, CALCIFIED TISSUE INT, V41, P79, DOI 10.1007/BF02555249; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; DICKSON IR, 1993, BIOCHIM BIOPHYS ACTA, V1181, P15, DOI 10.1016/0925-4439(93)90084-E; DONAHUE HJ, 1988, J BIOL CHEM, V263, P13522; DUNLAY R, 1990, CALCIUM REGUL BONE M, V10, P24; DZIAK R, 1975, ENDOCRINOLOGY, V97, P1281, DOI 10.1210/endo-97-5-1281; EANES ED, 1992, GLYCOBIOLOGY, V2, P571, DOI 10.1093/glycob/2.6.571; FARNDALE RW, 1988, BIOCHEM J, V252, P263, DOI 10.1042/bj2520263; FELDMAN RS, 1980, ENDOCRINOLOGY, V107, P1137, DOI 10.1210/endo-107-4-1137; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; JONES SJ, 1976, CELL TISSUE RES, V169, P449; JONGEN JWJM, 1993, J CELL PHYSIOL, V155, P36, DOI 10.1002/jcp.1041550106; KARPF DB, 1990, CALCIUM REGUL BONE M, V10, P15; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1986, DEV BIOL, V114, P519, DOI 10.1016/0012-1606(86)90215-0; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; LAURENT TC, 1986, FUNCTIONS PROTEOGLYC, P9; LORENZO JA, 1983, J CLIN INVEST, V72, P1924, DOI 10.1172/JCI111156; LUBEN RA, 1974, ENDOCRINOLOGY, V94, P737, DOI 10.1210/endo-94-3-737; LUBEN RA, 1976, ENDOCRINOLOGY, V98, P413, DOI 10.1210/endo-98-2-413; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARTIN TJ, 1979, CLIN ORTHOP RELAT R, P247; MARTIN TJ, 1985, CHEM BIOL MINERALIZE, P311; MARTIN TJ, 1987, CLIN ENDOCRINOLOGY C, P1; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; MERRITT BS, 1992, J CELL PHYSIOL, V152, P520, DOI 10.1002/jcp.1041520311; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MILLER SS, 1976, SCIENCE, V192, P1340, DOI 10.1126/science.1273593; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; PASCHALAKIS P, 1993, BIOCHIM BIOPHYS ACTA, V1158, P129, DOI 10.1016/0304-4165(93)90006-T; PECK WA, 1977, ENDOCRINOLOGY, V100, P1357, DOI 10.1210/endo-100-5-1357; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; RIZZOLI RE, 1983, ENDOCRINOLOGY, V113, P1832, DOI 10.1210/endo-113-5-1832; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SEVERSON AR, 1983, EXP CELL BIOL, V51, P70; SEVERSON AR, 1973, ENDOCRINOLOGY, V92, P1282, DOI 10.1210/endo-92-4-1282; SILVE CM, 1982, J CELL BIOL, V94, P379, DOI 10.1083/jcb.94.2.379; TURLEY EA, 1989, CIBA F SYMP, V143, P121; UNDERWOOD JCE, 1979, EUR J CANCER, V15, P1151, DOI 10.1016/0014-2964(79)90131-2; WONG GL, 1977, SCIENCE, V197, P663, DOI 10.1126/science.195343; WONG GL, 1984, J BIOL CHEM, V259, P4019; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	61	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13200	13206						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175749				2022-12-27	WOS:A1994NK18400026
J	ONDA, M; KUDO, S; FUKUDA, M				ONDA, M; KUDO, S; FUKUDA, M			GENOMIC ORGANIZATION OF GLYCOPHORIN-A GENE FAMILY REVEALED BY YEAST ARTIFICIAL CHROMOSOMES CONTAINING HUMAN GENOMIC DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HOMINOID PRIMATES; B-GENES; IDENTIFICATION; SEQUENCE; POLYMORPHISMS; POLYMERASE; CLONES; CDNA; STA	Human glycophorins A, B, and E are members of the glycophorin gene family located at chromosome 4, band q31. These genes were apparently generated by two successive gene duplications, and the following evolutionary pathway was proposed based on the genomic sequences. First, the ancestral gene was duplicated, and one of the duplicated genes evolved directly into the GPA gene. Another duplicated gene acquired a 3' sequence from the precursor genomic segment and was then duplicated to yield glycophorin B and E genes (Onda, M., Kudo, S., Rearden, A., Mattei, M.-G. and Fukuda, M. (1993) Proc. Natl. Acad. Sci. USA 90, 7220-7224). Although the above hypothesis was proposed, it has been difficult to provide solid evidence for this, because no genomic clones studied encompass two members of the gene family. In this study we isolated several yeast artificial chromosome (YAC) clones encoding the entire region or a portion of this gene locus. The physical gene mapping was carried out by testing the presence of specific sequences using a polymerase chain reaction. Moreover, the YAC clones were digested by rare cutting restriction enzymes, and the resultant large DNA fragments were separated by pulse-field electrophoresis. Southern blot analyses of those DNA fragments were carried out using various probes encoding specific portions of glycophorin genes, The results obtained revealed that the distance between glycophorin A and B genes is almost the same as that between glycophorin B and E genes. Moreover, it was shown that no precursor genomic sequence was present in the sequences downstream from the GPB or GPE gene, suggesting that the duplication of glycophorin B/E progenitor gene was made through unequal crossing over homologous recombination. These combined results suggest that two duplication events took place tandemly to produce these three members of the glycophorin gene family.	LA JOLLA CANC RES FDN,CANC RES CTR,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R37CA033000, R01CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CARTRON JP, 1992, PROTEIN BLOOD GROUP, P101; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; COOK PJL, 1981, ANN HUM GENET, V45, P39, DOI 10.1111/j.1469-1809.1981.tb00304.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUKUDA M, 1993, SEMIN HEMATOL, V30, P138; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; HUANG CH, 1991, J BIOL CHEM, V266, P23306; HUANG CH, 1993, J BIOL CHEM, V268, P4945; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LU WM, 1990, BIOCHEM GENET, V28, P399, DOI 10.1007/BF02401428; MAEDA N, 1986, P NATL ACAD SCI USA, V83, P7395, DOI 10.1073/pnas.83.19.7395; MANIATITIS T, 1982, MOL CLONING LABORATO; ONDA M, 1993, P NATL ACAD SCI USA, V90, P7220, DOI 10.1073/pnas.90.15.7220; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; REARDEN A, 1990, BIOCHEM GENET, V28, P209, DOI 10.1007/BF00561338; REARDEN A, 1993, J BIOL CHEM, V268, P2260; REARDEN A, 1990, J BIOL CHEM, V265, P9259; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TATE CG, 1989, BIOCHEM J, V263, P993, DOI 10.1042/bj2630993; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; WASNIOWSKA K, 1977, BIOCHEM BIOPH RES CO, V76, P385	31	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13013	13020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175721				2022-12-27	WOS:A1994NH71600097
J	RAMPERSAUD, A; HARLOCKER, SL; INOUYE, M				RAMPERSAUD, A; HARLOCKER, SL; INOUYE, M			THE OMPR PROTEIN OF ESCHERICHIA-COLI BINDS TO SITES IN THE OMPF PROMOTER REGION IN A HIERARCHICAL MANNER DETERMINED BY ITS DEGREE OF PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SIGNAL TRANSDUCTION; 2 REGULATORY COMPONENTS; DNA-BINDING; ACTIVATOR PROTEIN; TRANSCRIPTIONAL ACTIVATION; POSITIVE REGULATOR; GENETIC-ANALYSIS; ENVZ; OSMOREGULATION; EXPRESSION	In Escherichia coli the ompF gene encodes a major outer membrane porin protein that is differentially regulated by the OmpR protein. OmpR acts as a positive as well as a negative regulator of ompF expression by binding to DNA sequences in the ompF promoter region. The DNA binding activity of OmpR is itself regulated by phosphorylation through the kinase protein EnvZ. Phosphorylation is believed to change the function of OmpR from an activator to a repressor molecule. By using purified OmpR and various regions of the ompF promoter we show that phosphorylation causes binding of OmpR to a DNA region between the -40 to -100 region of the ompF promoter previously shown to be important for ompF expression. As the amount of OmpR phosphate increases, a binding site located at a further upstream -360 to -380 region was occupied. This latter site has been reported to be important for ompF repression. Fur ther experiments indicate that the -70 to -100 region is a high affinity site, while the -45 to -60 and -360 to -380 regions are low affinity sites. We also provide evidence that OmpR binding at the -360 to -380 region requires previous binding at downstream sequences, which is indicative of long range interactions between OmpR molecules. We intrepret our results in terms of a model for ompF regulation involving hierarchical binding by phosphorylated OmpR and potential DNA looping.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; OHIO STATE UNIV,DEPT PATHOL,COLUMBUS,OH 43210	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; HALL MN, 1979, J BACTERIOL, V140, P342, DOI 10.1128/JB.140.2.342-350.1979; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IKENAKA K, 1988, MOL GEN GENET, V211, P538, DOI 10.1007/BF00425713; JO YL, 1986, J BIOL CHEM, V261, P5252; KANAMARU K, 1990, J BIOCHEM-TOKYO, V108, P483, DOI 10.1093/oxfordjournals.jbchem.a123225; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MIZUNO T, 1988, J BIOL CHEM, V263, P1008; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NORIOKA S, 1986, J BIOL CHEM, V261, P7113; OSTROW KA, 1986, J BACTERIOL, V168, P736; RAMAKRISHNAN G, 1985, J BACTERIOL, V163, P82, DOI 10.1128/JB.163.1.82-87.1985; RAMPERSAUD A, 1989, J BIOL CHEM, V264, P18693; RAMPERSAUD A, 1991, J BACTERIOL, V173, P6882, DOI 10.1128/jb.173.21.6882-6888.1991; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; TOKISHITA S, 1990, J BIOCHEM-TOKYO, V108, P488, DOI 10.1093/oxfordjournals.jbchem.a123226; TSUI P, 1988, J BACTERIOL, V170, P4950, DOI 10.1128/jb.170.10.4950-4953.1988; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VANALPHEN W, 1977, J BACTERIOL, V131, P623	37	79	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12559	12566						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175665				2022-12-27	WOS:A1994NH71600032
J	BLUML, K; MUTSCHLER, E; WESS, J				BLUML, K; MUTSCHLER, E; WESS, J			FUNCTIONAL-ROLE OF A CYTOPLASMIC AROMATIC AMINO-ACID IN MUSCARINIC RECEPTOR-MEDIATED ACTIVATION OF PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; PHOSPHATIDYLINOSITOL HYDROLYSIS; INTRACELLULAR LOOP; DOMAINS; GS; SUBTYPES; SELECTIVITY; IDENTIFICATION	The N-terminal portion of the third intracellular loop (i3) of muscarinic acetylcholine and other G protein-coupled receptors has been shown to largely determine the G protein coupling profile of a given receptor subtype. Using the rat m3 muscarinic receptor as a model system, we have recently demonstrated that a tyrosine residue (Tyr-254), located at the beginning of the i3 domain, is critically involved in muscarinic receptor-mediated stimulation of phosphatidylinositol (PI) hydrolysis (Bluml, K., Mutschler, E., and Wess, J. (1994) J. Biol. Chem. 269, 402-405). This study was designed to investigate the functional role of this amino acid in further molecular detail. Replacement of Tyr-254 (rat m3 receptor) with alanine or exchange of its position with Ile-253 virtually abolished receptor-mediated stimulation of PI hydrolysis studied in transfected COS-7 cells. In contrast, substitution of Tyr-254 by other aromatic residues such as phenylalanine or tryptophan resulted in mutant receptors that behaved functionally similar to the wild type m3 receptor. Introduction of Tyr-254 into the corresponding position (Ser-210) of the m2 muscarinic receptor (which is only poorly coupled to PI turnover) did not result in an enhanced PI response. However, ''reinsertion'' of Tyr-254 into a functionally inactive chimeric m3/m2 muscarinic receptor (containing m2 receptor sequence at the N terminus of the i3 loop) yielded a mutant receptor that was able to stimulate PI hydrolysis to a similar maximum extent as the wild type m3 receptor. Taken together, our data provide strong evidence that muscarinic receptor-mediated stimulation of PI metabolism is critically dependent on the presence and proper positioning of an aromatic residue at the beginning of the i3 loop.	NIDDKD,BIOORGAN CHEM LAB,BLDG 8A,RM B1A-09,BETHESDA,MD 20892; UNIV FRANKFURT,DEPT PHARMACOL,D-60053 FRANKFURT,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Goethe University Frankfurt								ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P402; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CONKLIN RB, 1993, NATURE, V363, P274; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; Higuchi R., 1989, PCR TECHNOLOGY, P61; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; VOSS T, 1993, J BIOL CHEM, V268, P4637; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1990, MOL PHARMACOL, V38, P872; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1990, J BIOL CHEM, V265, P6219	36	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11537	11541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157684				2022-12-27	WOS:A1994NF96600083
J	FERTALA, A; SIERON, AL; HOJIMA, Y; GANGULY, A; PROCKOP, DJ				FERTALA, A; SIERON, AL; HOJIMA, Y; GANGULY, A; PROCKOP, DJ			SELF-ASSEMBLY INTO FIBRILS OF COLLAGEN-II BY ENZYMATIC CLEAVAGE OF RECOMBINANT PROCOLLAGEN-II - LAG PERIOD, CRITICAL CONCENTRATION, AND MORPHOLOGY OF FIBRILS DIFFER FROM COLLAGEN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; ALPHA-1(I) CHAIN; THERMAL-STABILITY; PC-COLLAGEN; INVITRO; GENE; COPOLYMERIZATION; PROTEINASE; MECHANISM; POLYMERIZATION	A recently developed recombinant system for synthesis of human procollagen II by stably transfected host cells was used to prepare adequate amounts of protein to study the self-assembly of collagen II into fibrils. The procollagen II was cleaved to pCcollagen II by procollagen N-proteinase (EC 3.4.24.14), the pCcollagen II was chromatographically purified, and the pCcollagen Il was then used as a substrate to generate collagen II fibrils by cleavage with procollagen C-proteinase. The kinetics for assembly of collagen II fibrils were similar to those observed previously for the self-assembly of collagen I in that a distinct lag phase was observed followed by a sigmoidal propagation phase. However, under the same experimental conditions, the lag time for assembly of collagen II fibrils was 5-6-fold longer, and the propagation rate for collagen II fibrils was about 30-fold lower than for collagen I fibrils. The relatively long lag time for the assembly of collagen II into fibrils made it possible to demonstrate that most of the conversion of pCcollagen II to collagen II occurred in the solution phase. The critical concentration at 37-degrees-C for collagen II was about 50-fold greater than the critical concentration for collagen I. The Gibbs free energy change for the assembly of collagen II into fibrils was -40 kJ/mol, a value that was about 14 kJ/mol less than the free energy change for collagen I and about the same as the free energy change for the homotrimer of collagen I. Dark-field light microscopy and negative-staining electron microscopy demonstrated that the collagen II fibrils were thin and formed network-like structures. The results demonstrated, therefore, that the structural information of the monomer is sufficient to explain the characteristically small diameters and arcade-like geometry of collagen II fibrils found in cartilage and other tissues.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University			Sieron, Aleksander L/G-1700-2013	Sieron, Aleksander L./0000-0002-3894-9508	NIAMS NIH HHS [AR-38188, AR-39740] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188, P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1990, MATRIX, V10, P279, DOI 10.1016/S0934-8832(11)80182-4; ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; BACHINGER HP, 1990, MATRIX, V10, P331; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BOISTELLE R, 1988, J CRYST GROWTH, V90, P14, DOI 10.1016/0022-0248(88)90294-1; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P2201, DOI 10.1002/bip.360281212; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; CHU ML, 1992, EXTRACELLULAR MATRIX, P149; COMPER WD, 1977, BIOPOLYMERS, V16, P2113, DOI 10.1002/bip.1977.360161004; COOPER A, 1970, BIOCHEM J, V118, P355, DOI 10.1042/bj1180355; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; ELIMA K, 1987, NUCLEIC ACIDS RES, V15, P9499, DOI 10.1093/nar/15.22.9499; FARBER S, 1986, INT J BIOL MACROMOL, V8, P37, DOI 10.1016/0141-8130(86)90069-3; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; FRIEDEN C, 1989, TRENDS BIOCHEM SCI, V14, P283, DOI 10.1016/0968-0004(89)90065-0; GELMAN RA, 1979, J BIOL CHEM, V254, P180; GROSS J, 1958, J BIOL CHEM, V233, P355; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLMES DF, 1986, INT J BIOL MACROMOL, V8, P161, DOI 10.1016/0141-8130(86)90020-6; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; LAW MF, 1983, MOL CELL BIOL, V3, P2110, DOI 10.1128/MCB.3.11.2110; LEE SL, 1983, COLLAGEN REL RES, V3, P89; LEIBOVICH SJ, 1970, BIOCHIM BIOPHYS ACTA, V214, P445, DOI 10.1016/0005-2795(70)90303-X; MCBRIDE DJ, 1992, MATRIX, V12, P256; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; NA GC, 1986, BIOCHEMISTRY-US, V25, P958, DOI 10.1021/bi00353a003; NA GC, 1986, J BIOL CHEM, V261, P2290; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; OOSAWA F, 1975, THERMODYNAMICS POLYM, P25; PELTONEN L, 1980, P NATL ACAD SCI-BIOL, V77, P162, DOI 10.1073/pnas.77.1.162; Piez K.A., 1976, BIOCH COLLAGENS, P1; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PROCKOP DJ, 1993, IN PRESS BIOL EXTRAC; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; ROMANIC AM, 1992, J BIOL CHEM, V267, P22265; Sambrook J, 1989, MOL CLONING LABORATO; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2207, DOI 10.1093/nar/13.7.2207; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SIERON AL, 1993, J BIOL CHEM, V268, P21232; SILVER FH, 1979, BIOPOLYMERS, V18, P2523, DOI 10.1002/bip.1979.360181011; SILVER FH, 1982, COLLAGEN REL RES, V3, P219; STOKER NG, 1985, NUCLEIC ACIDS RES, V13, P4613, DOI 10.1093/nar/13.13.4613; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; Veis A, 1988, COLLAGEN, V1, P113; WESTON RB, 1992, J BIOL CHEM, V267, P9093; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WOOD GC, 1960, BIOCHEM J, V75, P598, DOI 10.1042/bj0750598	57	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11584	11589						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157691				2022-12-27	WOS:A1994NF96600090
J	SHI, GP; WEBB, AC; FOSTER, KE; KNOLL, JHM; LEMERE, CA; MUNGER, JS; CHAPMAN, HA				SHI, GP; WEBB, AC; FOSTER, KE; KNOLL, JHM; LEMERE, CA; MUNGER, JS; CHAPMAN, HA			HUMAN CATHEPSIN-S - CHROMOSOMAL LOCALIZATION, GENE STRUCTURE, AND TISSUE DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; CYSTEINE PROTEINASES; MOLECULAR-CLONING; EXPRESSION; DNA; PROMOTER; ORGANIZATION; CONSERVATION; ASSIGNMENT; MARKERS	The human lysosomal cysteine proteinases, cathepsins H, L, and B, have been mapped to chromosomes 15, 9, and 8, respectively, and the genomic structures of cathepsins L and B have been determined. We report here the chromosomal localization and partial gene structure for a recently sequenced human cysteine proteinase, cathepsin S. A 20-kilobase pair genomic clone of the human cathepsin S gene was isolated from a human fibroblast genomic library and used to map the human cathepsin S gene to chromosome 1q21 by fluorescence in situ hybridization. This clone contains exons 1 through 5, introns 1 through 4, part of intron 5, and >7 kilobase pairs of the 5'-flanking sequence. The gene structure of human cathepsin S is similar to that of cathepsin L through the first 5 exons, except that cathepsin S introns are substantially larger. Sequencing of the 5'-flanking region revealed, similar to human cathepsin B, no classical TATA or CAAT box. In contrast to cathepsin B, cathepsin S contains only two SP1 and at least 18 AP1 binding sites that potentially could be involved in regulation of the gene. This 5'-flanking region also contains CA microsatellites. The presence of AP1 sites and CA microsatellites suggest that cathepsin S can be specifically regulated. Results of Northern blotting using probes for human cathepsins B, L, and S are consistent with this hypothesis; only cathepsin S shows a restricted tissue distribution, with highest levels in spleen, heart, and lung. In addition, immunostaining of lung tissue demonstrated detectable cathepsin S only in lung macrophages. The high level of expression in the spleen and in phagocytes suggests that cathepsin S may have a specific function in immunity, perhaps related to antigen processing.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,PHYSIOL PROGRAM,BOSTON,MA 02115; WELLESLEY COLL,DEPT BIOL SCI,WELLESLEY,MA 02181; CHILDRENS HOSP MED CTR,DIV GENET,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Wellesley College; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital			Webb, Andrew C/GOK-1601-2022	Munger, John/0000-0002-9679-2983; Knoll, Joan/0000-0001-6691-1710				ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BONHAM K, 1993, ONCOGENE, V8, P1973; BOUYON C, 1989, CYTOGENET CELL GENET, V51, P966; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; DELIC J, 1991, BIOCHEM BIOPH RES CO, V180, P1273, DOI 10.1016/S0006-291X(05)81333-6; FAN YS, 1989, CYTOGENET CELL GENET, V51, P996; FONG D, 1992, HUM GENET, V89, P10, DOI 10.1007/BF00207033; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAMADA H, 1984, MOL CELL BIOL, V4, P2610, DOI 10.1128/MCB.4.12.2610; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KINGSTON RE, 1987, CURRENT PROTOCOLS MO, V1; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KNOLL JHM, 1993, HUM MOL GENET, V2, P183, DOI 10.1093/hmg/2.2.183; LITT M, 1989, AM J HUM GENET, V44, P397; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; QIAN F, 1989, CANCER RES, V49, P4870; QIAN F, 1990, INT J BIOCHEM, V22, P1457, DOI 10.1016/0020-711X(90)90237-W; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; Sambrook J, 1989, MOL CLONING LABORATO; SAMIA JA, 1990, GENOMICS, V6, P159, DOI 10.1016/0888-7543(90)90461-3; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SHI GP, 1992, J BIOL CHEM, V267, P7258; SLOANE BF, 1991, BIOMED BIOCHIM ACTA, V50, P549; SMEETS HJM, 1989, HUM GENET, V83, P245, DOI 10.1007/BF00285165; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WANG X, 1987, CYTOGENET CELL GENET, V46, P710; WEBER JL, 1989, AM J HUM GENET, V44, P388; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; XIN XQ, 1992, ARCH BIOCHEM BIOPHYS, V299, P334, DOI 10.1016/0003-9861(92)90283-3; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	44	173	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11530	11536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157683				2022-12-27	WOS:A1994NF96600082
J	WURST, H; KORNBERG, A				WURST, H; KORNBERG, A			A SOLUBLE EXOPOLYPHOSPHATASE OF SACCHAROMYCES-CEREVISIAE - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; POLYPHOSPHATE; VACUOLES; ENZYMES	A soluble polyphosphatase of Saccharomyces cerevisiae, purified to apparent homogeneity, is monomeric with a molecular mass of 40 kDa. It acts as an exoenzyme in a processive mode releasing orthophosphate residues from long polyphosphate chains until pyrophosphate is reached. Polyphosphates of all the lengths examined are used as substrates with a preference for those of about 250 residues. These are degraded with a k(cat)/K(m) near the limit for diffusion-controlled reactions. At 37-degrees-C, the enzyme releases about 500 phosphate residues/s. It does not act on pyrophosphate, ATP, or the cyclic form of tripolyphosphate. For optimal activity the enzyme requires magnesium, manganese, or cobalt.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; ANDREEVA NA, 1993, YEAST, V9, P127, DOI 10.1002/yea.320090204; BEAUVOIT B, 1989, FEBS LETT, V252, P17, DOI 10.1016/0014-5793(89)80882-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; DURR M, 1979, ARCH MICROBIOL, V121, P169, DOI 10.1007/BF00689982; FELTER S, 1973, BIOCHIMIE, V55, P245, DOI 10.1016/S0300-9084(73)80122-1; FELTER S, 1970, B SOC CHIM BIOL, V52, P433; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; HANES CS, 1949, NATURE, V164, P1107, DOI 10.1038/1641107a0; JACOBSON L, 1982, BIOCHEM J, V201, P473, DOI 10.1042/bj2010473; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEN P, 1958, BIOCHEM Z, V330, P455; LANGEN P, 1962, ACIDES RIBONUCLEIQUE, P603; LUSBY EW, 1980, MOL GEN GENET, V178, P69, DOI 10.1007/BF00267214; MATSUHASHL MICHIO, 1963, ZEIT PHYSIOL CHEM, V333, P28; MATTENHEIMER H, 1951, BIOCHEM Z, V322, P36; SCHUDDEMAT J, 1989, BIOCHIM BIOPHYS ACTA, V1010, P191, DOI 10.1016/0167-4889(89)90160-2; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WIEMKEN A, 1974, ARCH MICROBIOL, V101, P45, DOI 10.1007/BF00455924	23	139	140	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10996	11001						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157625				2022-12-27	WOS:A1994NF96600008
J	BANERJEE, A; DHOORE, A; ENGELBORGHS, Y				BANERJEE, A; DHOORE, A; ENGELBORGHS, Y			INTERACTION OF DESACETAMIDOCOLCHICINE, A FAST BINDING ANALOG OF COLCHICINE WITH ISOTYPICALLY PURE TUBULIN DIMERS ALPHA-BETA(II), ALPHA-BETA(III) AND ALPHA-BETA(IV)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE STOPPED FLOW; BETA-TUBULIN; BOVINE BRAIN; B-RING; MONOCLONAL-ANTIBODY; KINETICS; COMPLEX; ISOTYPE; AFFINITY; 2-METHOXY-5-(2'	Desacetamidocolchicine (DAAC) is a colchicine analogue that lacks the acetamido side chain in the ring-B of colchicine. Unlike colchicine, it binds to tubulin very quickly, and yet it has powerful antimitotic properties. It has been demonstrated that the beta-tubulin isoforms differ significantly in their interactions with colchicine. In an effort to understand the role of the ring-B of colchicine, we have studied the interaction of DAAC with purified beta-tubulin isoforms. The association was studied fluorometrically using a stopped-now instrument under pseudo-first order conditions in the presence of a large excess of drug. The observed pseudo-first-order rate constants increased in a nonlinear way with the drug concentration, indicating that the binding of DAAC to tubulin isoforms occur in two steps as is true for the binding of colchicine to tubulin (Garland, D. L. (1978) Biochemistry 17, 4266-4272), [GRAPHICS] where the first step is a fast reversible binding and the second step is a slow conformational change leading to the formation of the stable complex (T.DAAC)*. Kinetic analysis shows that the tubulin isoforms exhibit very little differences in their K-1 values, which are 5794 +/- 670, 7109 +/- 1800, and 8993 +/- 1780 M(-1) for alpha beta(II), alpha beta(III), and alpha beta(IV), respectively. The k(2) values for alpha beta(II), alpha beta(III), and alpha beta(IV) are 0.67 +/- 0.05, 0.05 +/- 0.006, and 0.59 +/- 0.07 s(-1), respectively. The apparent on-rate constants (k(on,app) = K(1)k(2)) for alpha beta(II), alpha beta(III), and alpha beta(IV) are 3907 +/- 530, 376 +/- 80, and 5305 +/- 1200 M(-1) s(-1), respectively. The off-rate constants as measured by the loss of fluorescence of drug-tubulin complexes in the presence of a large excess of podophyllotoxin are 6.3 x 10(-4), 5.2 x 10(-4), and 5.7 x 10(-4) s(-1), respectively, for alpha beta(II), alpha beta(III), and alpha beta(IV). The affinity constants as determined by Scatchard analyses are 2.5 x 10(6), 1.5 x 10(6), and 4 x 10(6) M(-1) for alpha beta(II), alpha beta(III), and alpha beta(IV), respectively. The results indicate that the colchicine-binding domain on the alpha beta(III) isoform may differ from that of alpha beta(II) or alpha beta(IV) isoforms in a small region that might accommodate the ring-B of colchicine; and furthermore, this region is much less flexible in alpha beta(III) than in alpha beta(II) or alpha beta(IV) isoforms.	KATHOLIC UNIV LEUVEN, CHEM & BIOL DYNAM LAB, B-3001 LOUVAIN, BELGIUM	KU Leuven	BANERJEE, A (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.				NCI NIH HHS [CA 26376, CA 59711] Funding Source: Medline; NIGMS NIH HHS [GM 23476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026376, R29CA059711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU JM, 1991, BIOCHEMISTRY-US, V30, P3777, DOI 10.1021/bi00229a027; ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; ARAI T, 1975, ANAL BIOCHEM, V69, P443, DOI 10.1016/0003-2697(75)90146-3; BANE S, 1984, J BIOL CHEM, V259, P7391; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1987, FEBS LETT, V219, P103, DOI 10.1016/0014-5793(87)81199-7; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BANERJEE A, 1987, BIOCHIM BIOPHYS ACTA, V913, P138, DOI 10.1016/0167-4838(87)90322-0; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; CHOUDHURY GG, 1983, FEBS LETT, V161, P55, DOI 10.1016/0014-5793(83)80729-7; DETRICH HW, 1981, BIOCHEMISTRY-US, V20, P5999, DOI 10.1021/bi00524a012; DIAZ JF, 1991, J BIOL CHEM, V266, P2890; Dustin P., 1978, MICROTUBULES; ENGELBORGHS Y, 1987, J BIOL CHEM, V262, P5204; ENGELBORGHS Y, 1986, ANN NY ACAD SCI, V466, P709, DOI 10.1111/j.1749-6632.1986.tb38453.x; ENGELBORGHS Y, 1993, J BIOL CHEM, V268, P107; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P1; LAMBEIR A, 1981, J BIOL CHEM, V256, P3279; MAITY SN, 1987, FEBS LETT, V218, P102, DOI 10.1016/0014-5793(87)81027-X; MUKHOPADHYAY K, 1990, BIOCHEMISTRY-US, V29, P6845, DOI 10.1021/bi00481a013; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; PYLES EA, 1993, BIOCHEMISTRY-US, V32, P2329, DOI 10.1021/bi00060a026; RAY K, 1981, J BIOL CHEM, V256, P6241; RAY K, 1984, EUR J BIOCHEM, V142, P577, DOI 10.1111/j.1432-1033.1984.tb08325.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMITT H, 1976, J MOL BIOL, V102, P743, DOI 10.1016/0022-2836(76)90289-8; SERRANO L, 1984, J BIOL CHEM, V259, P6607; SHERLINE P, 1975, J BIOL CHEM, V250, P5481; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WILSON L, 1966, BIOCHEMISTRY-US, V5, P2463, DOI 10.1021/bi00871a042; Wilson L., 1973, ADV CELL MOLECULAR B, V3, P21; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	41	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10324	10329						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144613				2022-12-27	WOS:A1994NF01700025
J	GOWDA, DC; JACKSON, CM; HENSLEY, P; DAVIDSON, EA				GOWDA, DC; JACKSON, CM; HENSLEY, P; DAVIDSON, EA			FACTOR X-ACTIVATING GLYCOPROTEIN OF RUSSELLS VIPER VENOM - POLYPEPTIDE COMPOSITION AND CHARACTERIZATION OF THE CARBOHYDRATE MOIETIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; AFFINITY-CHROMATOGRAPHY; OLIGOSACCHARIDES; ENZYME; FRACTIONATION; GLYCOPEPTIDES; COAGULATION; PROTEINS	There is contradictory information regarding the molecular weight and polypeptide chain composition of RVV-X, a glycoprotein in Russell's viper venom that is capable of activating factor X to Xa. We show that RVV-X is a 92,880-Da glycoprotein. It consists of three disulfide-linked polypeptide chains, one heavy chain (alpha-chain, M(r) 57,600) and two light chains (beta- and gamma-chains, M(r) 19,400 and 16,400, respectively). The two light chains seen on SDS-polyacrylamide gel electrophoresis under reducing conditions are two distinct components of the molecule, rather than a heterogeneous mixture of a single chain as previously reported (Takeya, H., Nishida, S., Miyata, T., Kawada, S., Saisaka, Y., Morita, T., and Iwanaga, S. (1992) J. Biol. Chem. 267, 14109-14117). The following evidence supports this conclusion. (i) The two light chains of RVV-X are present in equal proportion. (ii) The estimated molecular weight of an alpha(1) beta(1) gamma(1)-structure closely matches the molecular weight determined by matrix-assisted laser desorption mass spectrometry. (iii) The amino acid compositions and NH2-terminal sequences of the beta- and gamma-chains are different. (iv) Although both the beta- and gamma-chains contain one N-linked oligosaccharide chain each, they are glycosylated differentially. RVV-X contains six N-linked oligosaccharides, four in the alpha-chain and one in each of the beta- and gamma-chains. The carbohydrate structures are different from those known for other snake venom glycoproteins, and they resemble closely those in various mammalian glycoproteins. The majority of the oligosaccharides are complex bi-, tri-, and tetraantennary structures, with a small proportion of multiantennary and high mannose-type structures. Two notable structural features of RVV-X oligosaccharides are as follows. (i) Sialic acid residues are linked to beta-galactosyl residues solely by alpha 2,3-linkages, and (ii) bisecting N-acetylglucosamine residues are present in the majority of the oligosaccharides.	AMER RED CROSS, DETROIT, MI 48232 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	American Red Cross; GlaxoSmithKline	GOWDA, DC (corresponding author), GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.		Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420; Gowda, Channe/0000-0002-6860-5108	NCRR NIH HHS [1-P41-RR05351-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMPHLETT GW, 1982, BIOCHEMISTRY-US, V21, P125, DOI 10.1021/bi00530a022; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; Furie B.C., 1976, Methods Enzymol, V45, P191; Gowda D. Channe, 1992, Glycobiology, V2, P475; GOWDA DC, 1992, MOL IMMUNOL, V29, P335, DOI 10.1016/0161-5890(92)90020-X; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARADA H, 1987, ANAL BIOCHEM, V164, P374, DOI 10.1016/0003-2697(87)90507-0; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1943; NOSE M, 1990, J IMMUNOL, V145, P910; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; PIERCECRETEL A, 1984, EUR J BIOCHEM, V139, P337, DOI 10.1111/j.1432-1033.1984.tb08012.x; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SIEFTER S, 1950, ARCH BIOCH, V25, P191; Stocker K., 1990, P97; TAKEYA H, 1992, J BIOL CHEM, V267, P14109; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; WEINBERGER SR, 1992, AM LAB SHELTON CONN, P54; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WILLIAMS WJ, 1962, BIOCHEM J, V84, P52, DOI 10.1042/bj0840052; YAMASHITA K, 1983, CANCER RES, V43, P4691; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YORK WS, 1984, METHOD ENZYMOL, V118, P3; YOSHIMA H, 1980, J BIOL CHEM, V255, P9713	33	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10644	10650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144654				2022-12-27	WOS:A1994NF01700069
J	RANDAZZO, PA; KAHN, RA				RANDAZZO, PA; KAHN, RA			GTP HYDROLYSIS BY ADP-RIBOSYLATION FACTOR IS DEPENDENT ON BOTH AN ADP-RIBOSYLATION FACTOR GTPASE-ACTIVATING PROTEIN AND ACID PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAS GTPASE; BINDING-PROTEIN; ENDOSOME FUSION; CHOLERA-TOXIN; GENE; COFACTOR; ENCODES; DOMAIN; TRANSPORT	ADP-ribosylation factor (ARF) is a 21-kDa GTP binding protein that regulates eukaryotic membrane traffic. Both the binding and hydrolysis of GTP by ARF have been shown to be necessary for this function. However, purified mammalian ARF lacks intrinsic GTPase activity (<0.0015 min(-1)). We document the presence, in bovine brain extracts, of a protein with the predicted properties for an ARF GTPase activating protein (ARF GAP). This activity was highly dependent on phospholipids. An acid phospholipid fraction from bovine brain (containing primarily phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol 4-phosphate, phosphatidylinositol, and phosphatidylserine) had no effect on intrinsic GTPase activity of purified ARF but increased the ARF GAP activity of bovine brain homogenates about 8-fold. This dependence on acid phospholipids was retained after >100-fold purification of ARF GAP, making it, likely, an inherent property of this reaction. PIP2 alone stimulated ARF GAP activity up to 30-fold with a half-maxmal effect at 100-300 mu M but had no effect on the GTPase rate of ARF alone. Phosphatidylinositol 4-phosphate was also active but had only 50% of the maximal effect and twice the EC(50) of PIP2. Phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol, and diacylglycerol either alone or in the presence of ARF GAP do not stimulate ARF GTPase activity. ARF proteins have been identified recently as regulators of phospholipase D. The product of the phospholipase D reaction, phosphatidic acid, stimulated ARF GAP approximately 5-fold and reduced the PIP2 concentration needed for GAP stimulation about 6-fold. The substrate of phospholipase D, phosphatidylcholine, inhibited ARF GAP activity, but this inhibition seen with phosphatidylcholine was partially reversed by phosphatidic acid. A feedback loop for the coordinate regulation of phospholipase D and ARF activities is proposed.			RANDAZZO, PA (corresponding author), NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1993, GTPASES BIOL, P529; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MORITZ A, 1992, J BIOL CHEM, V267, P7207; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; ROSENWALD AG, 1994, IN PRESS GTPASE CONT; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZHANG CJ, 1994, IN PRESS J CELL BIOL	45	179	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10758	10763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144664				2022-12-27	WOS:A1994NF01700085
J	TAVARES, P; RAVI, N; MOURA, JJG; LEGALL, J; HUANG, YH; CROUSE, BR; JOHNSON, MK; HUYNH, BH; MOURA, I				TAVARES, P; RAVI, N; MOURA, JJG; LEGALL, J; HUANG, YH; CROUSE, BR; JOHNSON, MK; HUYNH, BH; MOURA, I			SPECTROSCOPIC PROPERTIES OF DESULFOFERRODOXIN FROM DESULFOVIBRIO-DESULFURICANS (ATCC-27774)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; RESONANCE RAMAN-SPECTRA; BLUE COPPER PROTEINS; MOSSBAUER-SPECTROSCOPY; RUBREDOXIN; DESULFOREDOXIN; HILDENBOROUGH; PURIFICATION; ENVIRONMENT; CYTOCHROME	Desulfoferrodoxin, a non-heme iron protein, was purified previously from extracts of Desulfovibrio desulfuricans (ATCC 27774) (Moura, I., Tavares, P., Moura, J. J. G., Ravi, N., Huynh, B. H., Liu, M.-Y., and LeGall, J. (1990) J. Biol. Chem. 265, 21596-21602). The as-isolated protein displays a pink color (pink form) and contains two mononuclear iron sites in different oxidation states: a ferric site (center I) with a distorted tetrahedral sulfur coordination similar to that found in desulforedoxin from Desulfovibrio gigas and a ferrous site (center II) octahedrally coordinated with predominantly nitrogen/ oxygen-containing ligands. A new form of desulfoferrodoxin which displays a gray color (gray form) has now been purified. Optical, electron paramagnetic resonance (EPR), and Mossbauer data of the gray desulfoferrodoxin indicate that both iron centers are in the high-spin ferric states. In addition to the EPR signals originating from center I at g = 7.7, 5.7, 4.1, and 1.8, the gray form of desulfoferrodoxin exhibits a signal atg = 4.3 and a shoulder at g = 9.6, indicating a high-spin ferric state with E/D approximate to 1/3 for the oxidized center II. Redox titrations of the gray form of the protein monitored by optical spectroscopy indicate midpoint potentials of +4 +/- 10 and +240 +/- 10 mV for centers I and II, respectively. Mossbauer spectra of the gray form of the protein are consistent with the EPR finding that both centers are high-spin ferric and can be analyzed in terms of the EPR-determined spin Hamiltonian parameters. The Mossbauer parameters for both the ferric and ferrous forms of center II are indicative of a mononuclear high spin iron site with octahedral coordination and predominantly nitrogen/oxygen-containing ligands. Resonance Raman studies confirm the structural similarity of center I and the distorted tetrahedral FeS4 center in desulforedoxin and provide evidence for one or two cysteinyl-S ligands for center II. On the basis of the resonance Raman results, the 635 nm absorption band that is responsible for the gray color of the oxidized protein is assigned to a cysteinyl-S --> Fe(III) charge transfer transition localized on center II. The novel properties and possible function of center II are discussed in relation to those of mononuclear iron centers in other enzymes.	UNIV GEORGIA,DEPT CHEM,ATHENS,GA 30602; UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; Universidade Nova de Lisboa; Emory University; Universidade Nova de Lisboa; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			Tavares, Pedro/B-3654-2008; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Tavares, Pedro/0000-0002-7398-2661; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295, R01GM041482, R01GM033806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33806, GM-41482, GM-47295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; BLAIR DF, 1985, J AM CHEM SOC, V107, P5755, DOI 10.1021/ja00306a025; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; CZERNUSZEWICZ RS, 1986, INORG CHEM, V25, P696, DOI 10.1021/ic00225a022; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; FU WG, 1992, J BIOL CHEM, V267, P15502; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; JIN HY, 1993, J AM CHEM SOC, V115, P5290, DOI 10.1021/ja00065a048; KENT TA, 1987, INORG CHEM, V26, P1402, DOI 10.1021/ic00256a014; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kretchmar S A, 1988, Biol Met, V1, P26, DOI 10.1007/BF01128014; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; LIU MC, 1981, J BIOL CHEM, V256, P3159; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; MOORE S, 1963, METHOD ENZYMOL, V46, P41; MOURA I, 1977, BIOCHEM BIOPH RES CO, V75, P1037, DOI 10.1016/0006-291X(77)91486-3; MOURA I, 1980, J BIOL CHEM, V255, P2493; MOURA I, 1990, J BIOL CHEM, V265, P21596; NELSON MJ, 1991, J AM CHEM SOC, V113, P7072, DOI 10.1021/ja00018a074; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; QUE L, 1983, COORDIN CHEM REV, V50, P73, DOI 10.1016/0010-8545(83)85027-9; Que L, 1988, BIOL APPLICATIONS RA, P491; ROTTMAN GA, 1989, J AM CHEM SOC, V111, P8613, DOI 10.1021/ja00205a009; SHELNUTT JA, 1979, P NATL ACAD SCI USA, V76, P3865, DOI 10.1073/pnas.76.8.3865; Spiro T. G., 1988, BIOL APPLICATIONS RA, P523; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4466; YACHANDRA VK, 1983, J AM CHEM SOC, V105, P6455, DOI 10.1021/ja00359a015; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023	28	89	90	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10504	10510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144635				2022-12-27	WOS:A1994NF01700049
J	WOOTAN, MG; STORCH, J				WOOTAN, MG; STORCH, J			REGULATION OF FLUORESCENT FATTY-ACID TRANSFER FROM ADIPOCYTE AND HEART FATTY-ACID-BINDING PROTEINS BY ACCEPTOR MEMBRANE LIPID-COMPOSITION AND STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNILAMELLAR VESICLES; RAT-HEART; 3-DIMENSIONAL STRUCTURE; MAGNETIC-RESONANCE; BILAYER-MEMBRANES; MODEL MEMBRANES; MESSENGER-RNAS; LIVER; CHOLESTEROL; CARDIOLIPIN	Adipocyte and heart fatty acid binding proteins (A-FABP and H-FABP) are closely related members of the FABP family. Unlike the more distantly related liver FABP, these FABP have been proposed to transfer free fatty acids to model membranes by a collisional mechanism (Wootan, M. G., Bernlohr, D.A,, and Storch, J. (1993) Biochemistry 32, 8622-8627; Kim, H. K., and Storch, J. (1992) J. Biol. Chen. 267, 20051-20056). Collisional transfer requires that the acceptor membranes interact with FABP during the transfer process. We, therefore, examined whether the acceptor membrane structure and lipid composition regulate the rate of anthroyloxy-labeled palmitate (2AP) transfer from A- and H-FABP, using a fluorescence resonance energy transfer assay. The results showed that 2AP transfer from A and H-FABP was more rapid to acceptor vesicles containing acidic phospholipids and was slower to positively charged membranes. In addition, the rate of 2AP transfer from A- and H-FABP was enhanced by unsaturation of the phosphatidylcholine acyl chains and was slowed by the presence of cholesterol or sphingomyelin in the acceptor membranes. These latter changes were small but of a similar magnitude and together suggest that fatty acid transfer from A- and H-FABP was slower to membranes of greater lipid order. Since transfer by an aqueous diffusion mechanism would be unaffected by acceptor membrane properties, these studies strengthen the hypothesis that free fatty acid transfer from A- and H-FABP to membranes occurs via a collisional mechanism.	RUTGERS STATE UNIV, COOK COLL, DEPT NUTR SCI, NEW BRUNSWICK, NJ 08903 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Rutgers State University New Brunswick; Harvard University; Harvard T.H. Chan School of Public Health				Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389, DK38389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRINI PR, 1984, BIOCHEMISTRY-US, V23, P6452, DOI 10.1021/bi00321a027; BAR LK, 1987, BIOCHEMISTRY-US, V26, P5460, DOI 10.1021/bi00391a037; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLOCH K, 1985, BIOCH LIPIDS MEMBRAN, P1; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; BRECHER P, 1984, J BIOL CHEM, V259, P3395; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; DAEL HV, 1982, BIOCHEM BIOPH RES CO, V104, P173; DECUYPER M, 1984, COLLOID SURFACE, V10, P313, DOI 10.1016/0166-6622(84)80032-3; EASTMAN SJ, 1989, BIOCHIM BIOPHYS ACTA, V981, P178, DOI 10.1016/0005-2736(89)90026-6; Gomori G, 1942, J LAB CLIN MED, V27, P955; GRINSTEAD GF, 1983, BIOCHIM BIOPHYS ACTA, V751, P41, DOI 10.1016/0005-2760(83)90255-2; Huang C, 1974, Methods Enzymol, V32, P485; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; IOANNOU P V, 1979, Progress in Lipid Research, V17, P279, DOI 10.1016/0079-6832(79)90010-7; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; KUTCHAI H, 1983, BIOCHIM BIOPHYS ACTA, V736, P137, DOI 10.1016/0005-2736(83)90277-8; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LEE A G, 1975, Progress in Biophysics and Molecular Biology, V29, P3; LEE AG, 1972, BIOCHIM BIOPHYS ACTA, V255, P43, DOI 10.1016/0005-2736(72)90006-5; LEVINE YK, 1972, BIOCHEMISTRY-US, V11, P1416, DOI 10.1021/bi00758a014; LIS LJ, 1982, BIOPHYS J, V37, P667; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; POWELL GL, 1985, BIOCHEMISTRY-US, V24, P2902, DOI 10.1021/bi00333a013; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SAID B, 1984, J BIOL CHEM, V259, P1155; SALSBURY NJ, 1970, T FARADAY SOC, V66, P1554, DOI 10.1039/tf9706601554; SANKARAM MB, 1989, BIOCHIM BIOPHYS ACTA, V980, P389, DOI 10.1016/0005-2736(89)90331-3; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SHEETZ MP, 1972, BIOCHEMISTRY-US, V11, P4573, DOI 10.1021/bi00774a024; SQUIER TC, 1991, BIOPHYS J, V59, P654, DOI 10.1016/S0006-3495(91)82281-0; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEELEY CC, 1985, BIOCH LIPIDS MEMBRAN, P371; TANFORD C, 1961, PHYSICAL CHEM MACROM, P346; THILO L, 1977, BIOCHIM BIOPHYS ACTA, V469, P326, DOI 10.1016/0005-2736(77)90168-7; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XU ZH, 1991, J BIOL CHEM, V266, P14367; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	57	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10517	10523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144637				2022-12-27	WOS:A1994NF01700051
J	ZHANG, WG; GUSTAFSON, TA; RUTTER, WJ; JOHNSON, JD				ZHANG, WG; GUSTAFSON, TA; RUTTER, WJ; JOHNSON, JD			POSITIVELY CHARGED SIDE-CHAINS IN THE INSULIN-LIKE GROWTH-FACTOR-I C-REGIONS AND D-REGIONS DETERMINE RECEPTOR-BINDING SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR	Human insulin-like growth factor-1 (hIGF-1) contains seven positively charged residues in the A-, C-, and D-regions that are not present in similar positions in insulin. To determine whether these residues contribute to receptor binding specificity for the insulin-like growth factor-1 receptor (IGF-1R) relative to the insulin receptor (IR) we examined the binding of hIGF-1 analogs in which these residues have been replaced with either alanine or the corresponding residue of insulin. To improve expression and facilitate purification we employed insulin-like growth factor (IGF-1) analogs modified with an N-terminal 8 amino acid epitope. This additional epitope did not alter receptor binding specificity. Alanine substitution for the positively charged residues in the C- and D-regions of IGF-1 led to 15- and 10-fold losses, respectively, in binding potency for the human IGF-1R, but they increased the potency of binding to the human IR 29 and 6-fold, respectively. In contrast, substitution of the positively charged side chains in the A-region with the corresponding uncharged residues of insulin had little effect on binding to either receptor. These data suggest that the positive charges in the C- and D-regions of IGF-1 contribute significantly to the binding preference of the IGF-1R for IGF-1. In complementary experiments using chimeric receptors we have also shown that the IGF-1 receptor elements required to discriminate in favor of the positive charges in the C- and D-regions are contained in the N-terminal 283 amino acids of the alpha-subunit. Insulin receptor elements that discriminate against these charges are within the N-terminal 225 amino acids of its alpha-subunit.	UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT PHYSIOL,BALTIMORE,MD 21201	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [DK37661, DK44093] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; CARA JF, 1990, J BIOL CHEM, V265, P17820; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANKEL AD, 1992, P NATL ACAD SCI USA, V89, P11653, DOI 10.1073/pnas.89.24.11653; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RUTTER W, 1991, MODERN CONCEPTS INSU, P541; SCHAFFER L, 1993, J BIOL CHEM, V268, P3044; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	20	42	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10609	10613						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144650				2022-12-27	WOS:A1994NF01700064
J	CHATURVEDI, MM; LAPUSHIN, R; AGGARWAL, BB				CHATURVEDI, MM; LAPUSHIN, R; AGGARWAL, BB			TUMOR-NECROSIS-FACTOR AND LYMPHOTOXIN - QUALITATIVE AND QUANTITATIVE DIFFERENCES IN THE MEDIATION OF EARLY AND LATE CELLULAR-RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COLONY-STIMULATING FACTOR; ENHANCER BINDING-PROTEIN; HUMAN-ENDOTHELIAL CELLS; FACTOR-ALPHA; FACTOR-BETA; MOLECULAR-CLONING; FACTOR RECEPTOR; FACTOR TNF; HUMAN-FIBROBLASTS	Tumor necrosis factor (TNF) is a 17-kDa protein produced by monocytes and a wide variety of other cell types in response to endotoxin and other cytokines. In contrast, lymphotoxin (LT) is a 25-kDa glycoprotein produced only by lymphocytes activated by mitogens. These two cytokines are 28% identical in their amino acid sequences. As they have common cell surface receptors, it is generally assumed that all cellular responses mediated through TNF are also mediated by LT and vice versa. In this report we tested this assumption, comparing the effect of TNF and LT on mediation of early (activation of the transcription factor NF-kappa B) and late (reduction of nitro blue tetrazolium, NBT) cellular responses in the human myelomonoblastic leukemic cell line ML-1a. Both qualitative and quantitative differences were found. LT was found to display 5-10 times more potent antiproliferative effects against murine fibroblasts than TNF. However, in ML-1a cells at concentrations wherein TNF activated NF-kappa B, LT did not. Higher concentrations (1,000-10,000 fold) of LT could activate NF-kappa B, but the activated complex was short lived (less than 1 h versus greater than 6 h when activated by TNF) and required longer treatment (15 min versus less than 5 min). TNF induced NBT-reducing activity in a dose-dependent manner, whereas LT was essentially inactive. Since both TNF and LT have been shown to bind to a common receptor, we tested whether the TNF-induced effects could be blocked by LT. LT inhibited both the early and late TNF-mediated cellular responses. By using receptor-blocking antibodies we found that both p60 and p80 forms of TNF receptors were functional for NBT-reducing activity, but TNF-dependent NF-kappa B activation required only the p60 receptor. Furthermore, we found that both TNF and LT bound with higher affinity to the p80 than to the p60 receptor. Thus, our overall results indicate that there are qualitative and quantitative differences in the action of TNF and LT, and these could be noted quite early in their signaling.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; AIYER RA, 1990, LYMPHOKINE RES, V9, P333; AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; ANDREWS JS, 1990, J IMMUNOL, V144, P2582; ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BERAN M, 1987, BLOOD, V69, P721; BRACH MA, 1990, FEBS LETT, V263, P349, DOI 10.1016/0014-5793(90)81411-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUDY VC, 1987, J IMMUNOL, V138, P4298; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BUCK C, 1989, LEUKEMIA, V4, P431; CICCO NA, 1990, BLOOD, V75, P2049; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEUEL TF, 1992, HUMAN CYTOKINES HDB, P300; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOWER SK, 1992, HUMAN CYTOKINES HDB, P46; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASS PE, 1985, J BIOL CHEM, V260, P2214; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; HIGUCHI M, 1994, J IMMUNOL, V152, P4017; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAMIJO R, 1990, J IMMUNOL, V144, P1311; KAPP A, 1989, J INVEST DERMATOL, V92, P348, DOI 10.1111/1523-1747.ep12277174; KOEFFLER HP, 1987, BLOOD, V70, P55; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LEE SH, 1984, J IMMUNOL, V133, P1083; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MANTOVANI L, 1990, FEBS LETT, V270, P152, DOI 10.1016/0014-5793(90)81256-N; MATSUBARA N, 1990, PATHOBIOLOGY, V58, P168, DOI 10.1159/000163578; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUNOZFERNANDEZ MA, 1993, BIOCHEM BIOPH RES CO, V194, P319, DOI 10.1006/bbrc.1993.1822; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OSTER W, 1987, BLOOD, V70, P1700; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORTER A G, 1990, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V64, P193, DOI 10.1016/0378-1097(90)90609-T; RUDDLE NH, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P1; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAMAL B, 1990, LEUKEMIA RES, V14, P575, DOI 10.1016/0145-2126(90)90010-7; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHWALB DM, 1993, J BIOL CHEM, V268, P9949; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; SHALABY MR, 1986, J IMMUNOL, V136, P2335; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; Vilcek J, 1992, TUMOR NECROSIS FACTO, P1; VILCEK J, 1992, TUMOR NECROSIS FACTO, P269; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	89	130	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14575	14583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182064				2022-12-27	WOS:A1994NM06500043
J	CUOZZO, JW; SAHAGIAN, GG				CUOZZO, JW; SAHAGIAN, GG			LYSINE IS A COMMON DETERMINANT FOR MANNOSE PHOSPHORYLATION OF LYSOSOMAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHATE RECEPTOR; ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; CATHEPSIN-L; RECOGNITION; SECRETION; OLIGOSACCHARIDES; FIBROBLASTS; PROTEASE	The phosphorylation of lysosomal enzymes on high mannose residues is the first step in the targeting of these enzymes to lysosomes in a wide range of mammalian cells. Phosphorylated lysosomal enzymes bind to mannose 6-phosphate receptors, which divert them from the secretory pathway and direct them toward the lysosome. We have been investigating the basis for the specific recognition of lysosomal enzymes by UDP-Glc-NAc:lysosomal enzyme GlcNAc-1-phosphotransferase by using the precursor form of the lysosomal cysteine protease, cathepsin L, as a model lysosomal enzyme in an in vitro assay for mannose phosphorylation. Cathepsin L was found to be phosphorylated in vitro with the same efficiency as other lysosomal enzymes and to contain a conformationally sensitive protein signal that is recognized by phosphotransferase. Biochemical modification of lysine residues on cathepsin L with sulfo-N-hydroxysuccinimide acetate prevented the enzyme from being phosphorylated, indicating that lysine is an important component of the signal. The modification itself did not cause any major conformational changes in cathepsin L. When the same modification was performed on a number of other lysosomal enzymes, phosphorylation was also inhibited. Thus, we conclude that lysine residues are important features of lysosomal enzyme phosphotransferase recognition sites in general, and we discuss the implications of this finding in the ongoing efforts to define the phosphotransferase recognition site.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Tufts University; Tufts University				Cuozzo, John/0000-0002-6229-0395	NIDDK NIH HHS [DK36632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CUATRECASAS P, 1972, BIOCHEMISTRY-US, V11, P2291, DOI 10.1021/bi00762a013; DISTLER J, 1979, P NATL ACAD SCI USA, V76, P4235, DOI 10.1073/pnas.76.9.4235; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GAL S, 1986, J BIOL CHEM, V261, P1760; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, IN PRESS ARCH BIOCH	22	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14490	14496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182054				2022-12-27	WOS:A1994NM06500030
J	KONDA, Y; GANTZ, I; DELVALLE, J; SHIMOTO, Y; MIWA, H; YAMADA, T				KONDA, Y; GANTZ, I; DELVALLE, J; SHIMOTO, Y; MIWA, H; YAMADA, T			INTERACTION OF DUAL INTRACELLULAR SIGNALING PATHWAYS ACTIVATED BY THE MELANOCORTIN-3 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; INOSITOL PHOSPHATES; ADENYLYL CYCLASE; ALPHA-MSH; L-CELLS; CALCIUM; STIMULATION; HYDROLYSIS; CAMP	We undertook these studies to explore the intracellular signaling mechanisms activated by a newly described human brain melanocortin receptor (hMC3R). Hepa cells transfected with the hMC3R gene responded to stimulation with alpha-melanocyte stimulation hormone (alpha-MSH) and adrenocorticotropic hormone (ACTH) with dose-dependent increases in cellular content of cyclic 3',5'-adenosine monophosphate (cAMP) reaching a maximum of over 1500% of control cells at the 10(-8) M dose (EC(50) = 10(-11) M). In contrast, the production of [H-3]inositol phosphates in cells prelabeled with myo [2-H-3]inositol exhibited a biphasic dose-response curve with increases as high as 155% of basal at 10-(11) M alpha-MSH or ACTH, but beyond that a dose dependent decrease was observed. The inhibitory component of the dose-re sponse curve could be abolished by pretreatment of transfected cells with the cAMP antagonist (Rp)-adenosine 3',5'-monophosphorothioate (Rp-cAMP) or the pro tein kinase A inhibitor H-89. Increases in intracellular calcium induced in transfected cells by alpha-MSH in doses ranging from 10(-11) to 10(-7) M could not be observed unless the cells were pretreated with H-89. By replacing the third intracytoplasmic loop of the canine H2-histamine receptor with that of hMC3R the biphasic characteristic of agonist-induced production of [H-3]inositol phosphates was conferred to the chimeric receptor. These data indicate that the hMC3R is coupled to both cAMP and inositol phospholipid/Ca2+-mediated post-receptor signaling systems and that the latter response is regulated by protein kinase A activity.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT SURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, P30DK034933, R01DK033500] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK33500, R01DK34306, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BROWN NA, 1990, J BIOL CHEM, V265, P13181; BUFFEY J, 1992, J ENDOCRINOL, V133, P333, DOI 10.1677/joe.0.1330333; CANNON JG, 1986, J IMMUNOL, V137, P2232; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLARK D, 1978, NATURE, V273, P163, DOI 10.1038/273163a0; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DEGANI H, 1991, P NATL ACAD SCI USA, V88, P1506, DOI 10.1073/pnas.88.4.1506; DELVALLE J, 1992, AM J PHYSIOL, V263, pG967; DELVALLE J, 1992, AM J PHYSIOL, V262, pG420, DOI 10.1152/ajpgi.1992.262.3.G420; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; FARESE RV, 1986, BIOCHEM BIOPH RES CO, V135, P742, DOI 10.1016/0006-291X(86)90991-5; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; ILAN AB, 1992, PROSTAGLANDINS, V43, P31, DOI 10.1016/0090-6980(92)90062-X; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RHEE SG, 1993, ADV SEC MESS PHOSPH, V28, P57; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TATRO JB, 1993, METHODS NEUROSCIENCE, V11, P87; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WALKER JM, 1980, SCIENCE, V210, P1247, DOI 10.1126/science.6254152; WOODCOCK EA, 1989, MOL CELL ENDOCRINOL, V63, P247, DOI 10.1016/0303-7207(89)90101-9; WREGGETT KA, 1987, BIOCHEM J, V245, P655, DOI 10.1042/bj2450655	32	125	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13162	13166						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175743				2022-12-27	WOS:A1994NK18400020
J	LEE, HB; XU, L; MEISSNER, G				LEE, HB; XU, L; MEISSNER, G			RECONSTITUTION OF THE SKELETAL-MUSCLE RYANODINE RECEPTOR-CA2+ RELEASE CHANNEL PROTEIN COMPLEX INTO PROTEOLIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CA-2+ RELEASE; EXPRESSION; ACTIVATION; DIGESTION; JUNCTION; TRIAD; FORMS; CDNA	The 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid-solubilized 30 S ryanodine receptor (RyR)/Ca2+ release channel complex from rabbit skeletal muscle, purified by density gradient centrifugation, was reconstituted with an excess of phospholipid into proteoliposomes by removal of the detergent by dialysis. Reconstituted proteoliposomes were concentrated by centrifugation, frozen and thawed, and sonicated. [H-3]Ryanodine binding measurements indicated close to 50% recovery of calculated binding activity following reconstitution of the purified RyR and dynamic light scattering measurements a mean vesicle diameter of similar to 150 nm. Using these values, a functional RyR was estimated to be present in only a small fraction (<15%) of the reconstituted vesicles. SDS-polyacrylamide gel electrophoresis of trypsin-treated proteoliposomes revealed that about four-fifths of the reconstituted 30 S complex was readily accessible to proteolytic attack. Vesicle(45)Ca(2+) flux and fusion of proteoliposomes with planar lipid bilayers showed that the reconstituted channel complex could be activated by Ca2+ and ATP, inhibited by Mg2+ and ruthenium red, and modified by ryanodine, similarly as observed for native sarcoplasmic reticulum vesicles. These results suggest that the method described here results in the reconstitution of a functional channel and thus provides the opportunity to study the structure and function of the sarcoplasmic reticulum Ca2+ release channel under well defined conditions.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIAMS NIH HHS [AR 18687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P2743; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CORBETT AM, 1985, J MEMBRANE BIOL, V86, P267, DOI 10.1007/BF01870606; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; HILKERT R, 1992, ARCH BIOCHEM BIOPHYS, V292, P1, DOI 10.1016/0003-9861(92)90043-V; Hoult J.R.S., METHODS ENZYMOLOGY, P443, DOI [10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(67)10072-4]; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LINDSAY ARG, 1991, BIOCHIM BIOPHYS ACTA, V1064, P89, DOI 10.1016/0005-2736(91)90415-5; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PICK U, 1981, ARCH BIOCHEM BIOPHYS, V212, P186, DOI 10.1016/0003-9861(81)90358-1; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TRIMM JL, 1988, J BIOL CHEM, V263, P17443; XU L, 1993, J GEN PHYSIOL, V101, P207, DOI 10.1085/jgp.101.2.207; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	33	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13305	13312						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175760				2022-12-27	WOS:A1994NK18400040
J	ZHOU, ZX; SAR, M; SIMENTAL, JA; LANE, MV; WILSON, EM				ZHOU, ZX; SAR, M; SIMENTAL, JA; LANE, MV; WILSON, EM			LIGAND-DEPENDENT BIPARTITE NUCLEAR TARGETING SIGNAL IN THE HUMAN ANDROGEN RECEPTOR - REQUIREMENT FOR THE DNA-BINDING DOMAIN AND MODULATION BY NH2-TERMINAL AND CARBOXYL-TERMINAL SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN C-MYC; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTORS; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; LOCATION SIGNAL; IMMUNOCYTOCHEMICAL LOCALIZATION; T-ANTIGEN; TRANSPORT	The amino acid sequence requirements for androgen-dependent androgen receptor nuclear import were determined by immunostaining transiently expressed full-length wild type and mutant human androgen receptors (AR) in monkey kidney COS cells and measuring transcriptional activity by cotransfection with a luciferase reporter vector in monkey kidney CV1 cells. Mutagenesis studies revealed a bipartite nuclear targeting sequence in the DNA binding and hinge regions at amino acids 617-633, consisting of two clusters of basic amino acids separated by 10 amino acids, RKCYEAGMTLGAR-KLKK. In a series of deletion mutants, AR NH2-terminal fragments (residues 1-639 through 1-723) displayed constitutive nuclear import, and transcriptional activity was similar to that of the ligand-activated full-length wild type AR. In contrast, nuclear import and transcriptional activation were inhibited by sequence extensions into the steroid-binding domain (1-771). Constitutive nuclear import was regained in part by NH2-terminal deletions of full-length AR. Expression of AR/pyruvate kinase chimeras defined a sequence required for pre dominant nuclear localization as residues 580-661, comprised of the second zinc finger region of the DNA-binding domain, the 17-amino-acid putative targeting sequence, and 28 residues of flanking carboxyl-terminal sequence. These studies suggest that the bipartite nuclear targeting sequence of AR includes flanking sequence and is modulated by interactions between the NH2- and carboxyl-terminal regions.	UNIV N CAROLINA,REPROD BIOL LAB,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, P30HD018968, R37HD016910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16910, P30-HD18968] Funding Source: Medline; NINDS NIH HHS [NS17479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6462; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUSMANN DA, 1990, ENDOCRINOLOGY, V126, P2359, DOI 10.1210/endo-126-5-2359; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; ONATE SA, 1991, MOL ENDOCRINOL, V5, P1993, DOI 10.1210/mend-5-12-1993; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SAR M, 1990, ENDOCRINOLOGY, V127, P3180, DOI 10.1210/endo-127-6-3180; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; WONG CI, 1993, J BIOL CHEM, V268, P19004; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249	61	252	276	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13115	13123						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175737				2022-12-27	WOS:A1994NK18400013
J	BOCCACCIO, C; GAUDINO, G; GAMBAROTTA, G; GALIMI, F; COMOGLIO, PM				BOCCACCIO, C; GAUDINO, G; GAMBAROTTA, G; GALIMI, F; COMOGLIO, PM			HEPATOCYTE GROWTH-FACTOR (HGF) RECEPTOR EXPRESSION IS INDUCIBLE AND IS PART OF THE DELAYED-EARLY RESPONSE TO HGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; PROTEIN-KINASE-C; TYROSINE KINASE; MET PROTOONCOGENE; MOLECULAR-CLONING; EPITHELIAL-CELLS; OWN RECEPTOR; ONCOGENE; GENE; ACTIVATION	The c-MET proto oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), also known as scatter factor, a potent mitogen and motogen for epithelial cells. The level of the HGF receptor expressed by epithelial cells varies in different growth conditions, being lower in growth arrested confluent monolayers and higher in growing sparse cells. The amount of HGF receptor mRNA increases from 3- to 5-fold after stimulation of confluent monolayers by serum and up to 10-fold after stimulation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA). An increased level of the receptor mRNA was also observed after cell stimulation with nanomolar concentration of HGF itself. The effect was transient, dose, and time dependent. Transcription of a reporter gene under control of the cloned 297 base pair c-MET promoter was also stimulated by serum, TPA, or HGF. The accumulation of specific mRNA is followed by appearance of the HGF receptor precursor protein, which is further processed to the receptor mature form. After HGF stimulation, HGF receptor expression follows c-FOS and c-JUN induction with a peak similar to 4 h. Pretreatment with the protein synthesis inhibitor puromycin strongly reduced the response to HGF, while cycloheximide alone increased the level of the receptor mRNA These data show that c-MET behaves as a delayed early-response gene and suggest that the HGF response is autoamplified by inducing the specific receptor.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY	University of Turin			Boccaccio, Carla/AHE-7875-2022; Gambarotta, Giovanna/I-8473-2012; Galimi, Francesco/J-4238-2012	Boccaccio, Carla/0000-0003-2620-9083; Gambarotta, Giovanna/0000-0002-8380-5925; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BJORGE JD, 1987, J BIOL CHEM, V262, P6615; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; DIRENZO MF, 1993, ONCOGENE, V8, P219; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EARP HS, 1986, J BIOL CHEM, V261, P4777; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; GAMBAROTTA G, 1993, J BIOL CHEM, V269, P12852; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO T, 1993, BIOCHEM BIOPH RES CO, V190, P870, DOI 10.1006/bbrc.1993.1129; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEVY JR, 1992, J BIOL CHEM, V267, P25289; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LUND LR, 1991, J BIOL CHEM, V266, P5177; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SEKI T, 1991, GENE, V102, P213; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	63	148	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12846	12851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175699				2022-12-27	WOS:A1994NH71600073
J	LIAO, JK				LIAO, JK			INHIBITION OF G(I) PROTEINS BY LOW-DENSITY-LIPOPROTEIN ATTENUATES BRADYKININ-STIMULATED RELEASE OF ENDOTHELIAL-DERIVED NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE CORONARY-ARTERIES; PHOSPHOLIPASE-C ACTIVITY; VASCULAR SMOOTH-MUSCLE; DEPENDENT RELAXATION; RELAXING FACTOR; ALPHA-SUBUNITS; ERYTHROCYTE-MEMBRANE; ESCHERICHIA-COLI; RABBIT AORTA; CELLS	The mechanism(s) by which low density lipoprotein (LDL) attenuates the release of endothelial-derived nitric oxide (EDNO) is not known but may involve inhibition of membrane signal transduction. To test this hypothesis, we treated bovine aortic endothelial cells with LDL (0-500 mu g/ml, 72 h) to determine its effect on G proteins (G(i) and G(q)) which are known to couple the bradykinin receptor to EDNO release. Bradykinin-stimulated EDNO release was measured by perfusion bioassay and showed a maximal 56% decrease which was unaffected by cotreatment with pertussis toxin (PTX, 100 ng/ml, 16 h). Although radioligand binding studies and Western blotting did not detect any significant changes in the amount of bradykinin receptor, alpha(i2), alpha(i3), and alpha(q), both agonist-stimulated GTPase activity and phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis were reduced by LDL treatment (77 and 70%, respectively). When G(i) and G(q) function in LDL-treated membranes were assessed by PTX and COOH-terminal antisera to alpha(i2) (P4), alpha(i3) (JL14), and alpha(q) (Q17), only the Q17 antisera caused a further reduction in GTPase activity and PIP2 hydrolysis while treatment with PTX alone or in combination with the P4 and JL14 antisera had no further inhibitory effect. These results suggest that LDL attenuates EDNO release by preferentially inhibiting the function of G(i).	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	LIAO, JK (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,221 LONGWOOD AVE,LMRC-307,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; BARNETT JV, 1989, J BIOL CHEM, V264, P10779; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BOROCHOV H, 1979, BIOCHEMISTRY-US, V18, P251, DOI 10.1021/bi00569a002; BOSSALER C, 1987, J CLIN INVEST, V79, P179; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; CUSHING DJ, 1990, J PHARMACOL EXP THER, V254, P28; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALEB ML, 1981, J BIOL CHEM, V256, P1051; MELCHIOR DL, 1979, J BIOL CHEM, V254, P8744; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIGG EA, 1979, BIOCHEMISTRY-US, V18, P3457, DOI 10.1021/bi00583a004; RUBALCAV.B, 1973, J BIOL CHEM, V248, P3831; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SHIMOKAWA H, 1989, CIRC RES, V65, P740, DOI 10.1161/01.RES.65.3.740; SHIMOKAWA H, 1991, CIRCULATION, V83, P652, DOI 10.1161/01.CIR.83.2.652; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SNEDDON JM, 1988, P NATL ACAD SCI USA, V85, P2800, DOI 10.1073/pnas.85.8.2800; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TOMITA T, 1990, CIRC RES, V66, P18, DOI 10.1161/01.RES.66.1.18; WU DQ, 1992, J BIOL CHEM, V267, P1811; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1	42	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12987	12992						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175717				2022-12-27	WOS:A1994NH71600093
J	PLANK, C; OBERHAUSER, B; MECHTLER, K; KOCH, C; WAGNER, E				PLANK, C; OBERHAUSER, B; MECHTLER, K; KOCH, C; WAGNER, E			THE INFLUENCE OF ENDOSOME-DISRUPTIVE PEPTIDES ON GENE-TRANSFER USING SYNTHETIC VIRUS-LIKE GENE-TRANSFER SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; POLYLYSINE DNA COMPLEXES; UNILAMELLAR VESICLES; AMPHIPATHIC PEPTIDE; ANIMAL-CELLS; FUSION; PH; DELIVERY; BINDING; ADENOVIRUS	The process by which viruses destabilize endosomal membranes in an acidification dependent manner has been mimicked with synthetic peptides that are able to disrupt liposomes, erythrocytes, or endosomes of cultured cells. Peptides containing the 20 amino-terminal amino acid sequence of influenza virus hemagglutinin as well as acidic derivatives showed erythrocyte lysis activity only when peptides were elongated by an amphipathic helix or by carboxyl-terminal dimerization. Interestingly, peptides consisting of the 23 amino-terminal amino acids of influenza virus hemagglutinin were also active in erythrocyte lysis. When peptides were in corporated into DNA complexes that utilize a receptor-mediated endocytosis pathway for uptake into cultured cells, either by ionic interaction with positively charged polylysine-DNA complexes or by a streptavidin-biotin bridge, a strong correlation between pH-specific erythrocyte disruption activity and gene transfer was observed. A high-level expression of luciferase or interleukin-2 was obtained with optimized gene transfer complexes in human melanoma cells and several cell lines.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Wagner, Ernst/A-7435-2012; Mechtler, Karl/AAF-2717-2019; Plank, Christian/F-9628-2011; Wagner, Ernst/ABB-5976-2020	Wagner, Ernst/0000-0001-8413-0934; Mechtler, Karl/0000-0002-3392-9946; Wagner, Ernst/0000-0001-8413-0934; Plank, Christian/0000-0002-6072-4903				ALOUF JE, 1989, EUR J BIOCHEM, V183, P381, DOI 10.1111/j.1432-1033.1989.tb14939.x; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; ATHERTON E, 1979, BIOORG CHEM, V8, P351, DOI 10.1016/0045-2068(79)90062-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FRANCHINI G, 1989, SCIENCE, V244, P694; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACFARLANE RD, 1980, J AM CHEM SOC, V102, P875, DOI 10.1021/ja00522a088; MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871; MURATA M, 1992, BIOCHEMISTRY-US, V31, P1986, DOI 10.1021/bi00122a013; MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; PARENTE RA, 1988, J BIOL CHEM, V263, P4724; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Prchla E., 1993, Molecular Biology of the Cell, V4, p435A; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6257, DOI 10.1021/bi00478a021; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1991, BIOCONJUGATE CHEM, V2, P226, DOI 10.1021/bc00010a006; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WAKELAM MJO, 1988, CURRENT TOPICS MEMBR, V32, P87; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WU GY, 1987, J BIOL CHEM, V262, P4429; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	53	592	670	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12918	12924						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175709				2022-12-27	WOS:A1994NH71600083
J	TESSLER, S; ROCKWELL, P; HICKLIN, D; COHEN, T; LEVI, BZ; WITTE, L; LEMISCHKA, IR; NEUFELD, G				TESSLER, S; ROCKWELL, P; HICKLIN, D; COHEN, T; LEVI, BZ; WITTE, L; LEMISCHKA, IR; NEUFELD, G			HEPARIN MODULATES THE INTERACTION OF VEGF(165) WITH SOLUBLE AND CELL-ASSOCIATED FLK-1 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; HEMATOPOIETIC STEM; BINDING; MITOGEN; FAMILY; IDENTIFICATION; ANGIOGENESIS; EXPRESSION	The 165-amino acid form of vascular endothelial growth factor (VEGF(165)) is a mitogen for vascular endothelial cells and a potent angiogenic factor. Expression of a chimeric receptor containing the extracellular domain of the flk-1 receptor fused to the transmembrane and intracellular domains of the human c-fms receptor in NIH-3T3 cells, resulted in the appearance of high affinity binding sites for I-125-VEGF(165) on transfected cells. The binding of I-125-VEGF(165) to the flk-1/fms chimeric receptor of the transfected cells as well as the VEGF(165)-induced autophosphorylation of the chimeric receptors were inhibited in the presence of low concentrations of heparin (1-10 mu g/ml). In contrast, similar concentrations of heparin potentiated the binding of I-125-VEGF(165) to the endogenous VEGF receptors of the transfected cells, indicating that to some extent, the effect of heparin on I-125-VEGF(165) binding is receptor type-dependent. A soluble fusion protein containing the extracellular domain of flk-1 fused to alkaline phosphatase (flk-1/SEAP) was used to study the effects of heparin on the binding of I-125-VEGF(165) to flk-1 in a cell-free environment. The fusion protein specifically inhibited VEGF(165)-induced proliferation of vascular endothelial cells, but bound I-125-VEGF(165) inefficiently in the absence of heparin. Addition of low concentrations of heparin or heparan sulfate (0.1-1 mu g/ml) resulted in a strong potentiation of I-125-VEGF(165) binding, whereas higher heparin or heparan sulfate concentrations inhibited the binding. The effect of heparin on the binding of I-125-VEGF(165) to flk-1/SEAP could not be mimicked by desulfated heparin or by chondroitin sulfate. Both bFGF and aFGF inhibited the binding when low concentrations of heparin were added to the binding reaction. However, higher concentrations of heparin abolished the inhibition, indicating that the inhibition is probably caused by competition for available heparin. Taken as a whole, these results indicate that heparin like molecules regulate the binding of VEGF(165) to its receptors in complex ways which depend on the heparin binding properties of VEGF(165) on the specific VEGF receptor type involved, and on the amount and composition of heparin-like molecules that are present on the cell surface of VEGF receptor containing cells.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; IMCLONE SYST INC,NEW YORK,NY 10014	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Princeton University; Eli Lilly			Neufeld, Gera/F-1524-2019					BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; CHARNOCKJONES SD, 1993, BIOL REPROD, V48, P1120; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WILKS JW, 1991, INT J RADIAT BIOL, V60, P73, DOI 10.1080/09553009114551581; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	36	171	187	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12456	12461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175651				2022-12-27	WOS:A1994NH71600016
J	ARUNACHALAM, U; MASSEY, V				ARUNACHALAM, U; MASSEY, V			STUDIES ON THE OXIDATIVE HALF-REACTION OF P-HYDROXYPHENYLACETATE 3-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; CONTAINING MONO-OXYGENASE; PHENOL HYDROXYLASE; INTERMEDIATE; DERIVATIVES; TEMPERATURE	The oxidative half-reaction of the two-protein enzyme, p-hydroxyphenylacetate 3-hydroxylase from Pseudomonas putida, has been studied by absorbance stopped-flow techniques. The formation of three flavin-oxygen intermediates, the anionic and protonated forms of the flavin hydroperoxide (intermediates I and I*) and the hydroxyflavin (intermediate III), was observed during the course of the oxygen reaction with the reduced flavoprotein-coupling protein complex. The flavin hydroperoxide, which is formed in a second-order reaction with oxygen, is in rapid equilibrium with the aromatic substrate, p-hydroxyphenylacetate. Due to this rapid equilibrium, p-hydroxyphenylacetate effectively competes with other ligands, such as p-chlorophenylacetate and p-aminophenylacetate and proceeds through the hydroxylation pathway. Furthermore, dehydration of intermediate III is subjected to severe inhibition in the presence of excess p-hydroxyphenylacetate, similar to the observations made with phenol hydroxylase. A reaction mechanism for the oxidative half-reaction in the presence of the aromatic substrate, p-hydroxyphenylacetate, is proposed.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUNACHALAM U, 1994, J BIOL CHEM, V269, P150; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; BEATY NB, 1981, J BIOL CHEM, V256, P4619; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRISSETTE P, 1987, FLAVINS FLAVOPROTEIN, P573; DAGLEY S, 1982, FLAVINS FLAVOPROTEIN, P311; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; HASTINGS JW, 1973, P NATL ACAD SCI USA, V70, P3468, DOI 10.1073/pnas.70.12.3468; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; POWLOWSKI J, 1990, J BIOL CHEM, V265, P4969; RYERSON CC, 1982, BIOCHEMISTRY-US, V21, P2644, DOI 10.1021/bi00540a011; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; TAYLOR MG, 1991, J BIOL CHEM, V266, P8291; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VERVOORT J, 1992, EUR J BIOCHEM, V206, P479, DOI 10.1111/j.1432-1033.1992.tb16950.x	22	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11795	11801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163477				2022-12-27	WOS:A1994NG37700021
J	RAJU, RVS; KALRA, J; SHARMA, RK				RAJU, RVS; KALRA, J; SHARMA, RK			PURIFICATION AND PROPERTIES OF BOVINE SPLEEN N-MYRISTOYL-COA PROTEIN-N-MYRISTOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID; TRANSFERASE; PEPTIDE; IDENTIFICATION; MYRISTYLATION; ACYLATION; TISSUES; BINDING; VIRUS; FORMS	Myristoyl-CoA:protein N-myristoyltransferase (NMT) catalyzes the addition of myristate to the amino-terminal glycine residue of a number of eukaryotic proteins. In this report, a simple and rapid purification as well as the properties of this enzyme from bovine spleen is described. Using combination of ammonium sulfate precipitation, chromatography on SP-Sepharose fast flow, phenyl-Sepharose CL BB, DEAE-Sepharose CL-6B, and Superose 12 (HR/30) gel filtration fast protein liquid chromatography, the enzyme was purified 1475-fold with a high yield. Under native conditions, the enzyme exhibited an apparent molecular mass of 58 kDa, whereas under denaturing conditions the enzyme represented an apparent molecular mass of 50 kDa, suggesting that spleen NMT is a monomeric protein. The NMT activity could be greatly activated to severalfold with the use of Tris-HC1 buffer. Kinetic properties indicated that spleen NMT had an apparent low K-m for pp60(src) and myristoylated alanine-rich C kinase substrate as compared with cAMP-dependent protein kinase and the M2 gene segment of reovirus type 3-derived peptides, Bovine spleen NMT was potently inhibited in a concentration-dependent manner by NIP71 (a bovine brain NMT inhibitory protein) with a half-maximal inhibition of 0.816 mu g/ml. Results of this study along with the existing knowledge on NMT indicate that the activity of enzyme resides in a single polypeptide chain of molecular mass between 50 and 68 M)a.	UNIV SASKATCHEWAN,ROYAL UNIV HOSP,COLL MED,DEPT PATHOL,SASKATOON S7N 0W0,SK,CANADA; UNIV SASKATCHEWAN,ROYAL UNIV HOSP,COLL MED,SASKATOON CANC CTR,SASKATOON S7N 0W0,SK,CANADA	University of Saskatchewan; University of Saskatchewan								AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CAMMACK R, 1971, BIOCHEM BIOPH RES CO, V44, P8, DOI 10.1016/S0006-291X(71)80151-1; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; DAVIS KA, 1969, BIOCHEMISTRY-US, V8, P3355, DOI 10.1021/bi00836a033; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GORDON JA, 1972, BIOCHEMISTRY-US, V11, P1862, DOI 10.1021/bi00760a021; Hatefi Y, 1974, Methods Enzymol, V31, P770; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HOLTZER A, 1960, BIOCHIM BIOPHYS ACTA, V42, P453, DOI 10.1016/0006-3002(60)90823-4; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; KING MJ, 1993, BIOCHEM BIOPH RES CO, V196, P665, DOI 10.1006/bbrc.1993.2301; KING MJ, 1993, BIOCHIM BIOPHYS ACTA, V1165, P259, DOI 10.1016/0005-2760(93)90134-U; KING MJ, 1992, MOL CELL BIOCHEM, V113, P77; KING MJ, 1993, BIOCHEM J, V291, P635, DOI 10.1042/bj2910635; LEAMMLI UK, 1970, NATURE, V227, P680, DOI DOI 10.1038/227680A0; MCILHINNEY RAJ, 1989, BIOCHEM J, V263, P387, DOI 10.1042/bj2630387; MCILHINNEY RAJ, 1990, J NEUROCHEM, V54, P110, DOI 10.1111/j.1471-4159.1990.tb13289.x; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; PAIGE LA, 1989, ANAL BIOCHEM, V181, P254, DOI 10.1016/0003-2697(89)90239-X; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234; SWARUP G, 1983, J BIOL CHEM, V258, P341; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WOLFF J, 1962, J BIOL CHEM, V237, P230	35	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12080	12083						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163512				2022-12-27	WOS:A1994NG37700062
J	SAHLIN, M; LASSMANN, G; POTSCH, S; SLABY, A; SJOBERG, BM; GRASLUND, A				SAHLIN, M; LASSMANN, G; POTSCH, S; SLABY, A; SJOBERG, BM; GRASLUND, A			TRYPTOPHAN RADICALS FORMED BY IRON/OXYGEN REACTION WITH ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE PROTEIN R2 MUTANT Y122F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME-C PEROXIDASE; IDENTIFICATION; COMPOUND; SUBUNIT; SITE	The active state of the small subunit, protein R2, of ribonucleotide reductase is formed by the reaction of apoprotein with Fe2+ and O-2, whereby the diferric site and a stable phenoxy free radical on a tyrosyl residue (Tyr(122)) is formed. The corresponding reaction was studied in the mutant Y122F R2. It leads to a normal iron site, but the reduction equivalent from Tyr(122) now has to be supplied from elsewhere. EPR spectroscopy shows formation of several paramagnetic species on different time scales. Using apoprotein with deuterium-labeled tryptophan residues, at least two species could be assigned to tryptophan free radicals. This is the first EPR observation of relatively stable protein-linked tryptophan radicals at room temperature and at 77 K. These tryptophan radicals may be involved as redox intermediates in long range electron transfer within the protein structure.	UNIV STOCKHOLM, DEPT BIOPHYS, ARRHENIUS LAB, S-10691 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY; TECH UNIV BERLIN, MAX VOLMER INST BIOPHYS & PHYS CHEM, D-10623 BERLIN, GERMANY	Stockholm University; Stockholm University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Technical University of Berlin				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1993, J INORG BIOCHEM, V51, P6; FLOSSMANN W, 1978, RADIAT RES, V73, P75, DOI 10.2307/3574574; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HELLWEGE KH, 1979, LANDOLTBORNSTEIN C2, V9, P8; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; LAM KY, 1993, J CHEM SOC DALTON, P2797, DOI 10.1039/dt9930002797; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; LING JS, 1994, J BIOL CHEM, V269, P5595; MOTTLEY C, 1989, BIOL MAGN RESON, V8, P521; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025	25	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11699	11702						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163466				2022-12-27	WOS:A1994NG37700007
J	TAMURA, M; HARRIS, TM; PHILLIPS, D; BLAIR, IA; WANG, YF; HELLERQVIST, CG; LAM, SK; INAGAMI, T				TAMURA, M; HARRIS, TM; PHILLIPS, D; BLAIR, IA; WANG, YF; HELLERQVIST, CG; LAM, SK; INAGAMI, T			IDENTIFICATION OF 2 CARDIAC-GLYCOSIDES AS NA+-PUMP INHIBITORS IN RAT URINE AND DIET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIGITALIS-LIKE-FACTOR; VOLUME-EXPANDED HOG; ENDOGENOUS NA+,K+-ATPASE INHIBITOR; OUABAIN-LIKE COMPOUND; HUMAN PLASMA; K+-ATPASE; HYPERTENSION; SODIUM; DIGOXIN; SEARCH	Endogenous Na+-pump specific inhibitors are present in the plasma, urine, and tissues of humans and animals. To date, the source of these inhibitors has not been rigorously defined. In the present study, large amounts of several Na+-pump specific inhibitors have been demonstrated to exist in the urine of rats raised on a regular chow diet and tap water. Ah of the inhibitor levels have been found to increase 1.5-8-fold by the surgical preparation of reduced renal mass (RRM) and one kidney, one clip (IK, IC) hypertension. These urinary inhibitors, however, except for the ouabain-like inhibitor which eluted from a high performance liquid chromatography C-18 column at the same retention time as [H-3]ouabain, disappeared within a week after switching the diet from regular diet (number 5001, PMI Feeds, Inc.) to pure synthetic diet (number 5755). The urinary level of the ouabain-like inhibitor decreased to only one-half of the level in the control rat raised on a regular diet. Two of these inhibitors were purified from both urine and diet by a combination of Amberlite XAD-2 adsorption chromatography, reverse phase low pressure liquid chromatography, and several high performance liquid chromatographies. Reverse phase high performance liquid chromatography, liquid secondary ion and gas-liquid mass spectrometries, and proton nuclear magnetic resonance spectroscopy identified these inhibitors as a stereoisomer of convalloside, probably neoconvalloside, and a mono-rhamnoside of periplogenin or its stereoisomer These cardiac glycosides exhibited inhibitory potencies comparable to ouabain against ouabain-displacement from Na+,K+-ATPase and against Rb-86 uptake into human erythrocytes, and they also exhibited cross-reactivity to anti-ouabain antibodies and anti-digoxin antibodies. These results clearly demonstrate that the principal source of most of the inhibitors in rat urine is the diet. The results suggest that the ouabain-like inhibitor may be derived from an endogenous origin.	VANDERBILT UNIV,SCH MED,DEPT CHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	TAMURA, M (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.		LAM, SAU KUEN/B-7407-2010; Blair, Ian A/B-3320-2010	Tamura, Masaaki/0000-0003-4863-3379	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, P50HL014192] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14192, HL 35323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAUSTEIN MP, 1991, HYPERTENSION S3, V18, P184; BRIGGS MH, 1970, STEROID BIOCH PHARM, P265; BUCKALEW VM, 1990, HYPERTENSION PATHOPH; DIAMANDIS EP, 1985, CLIN BIOCHEM, V18, P48, DOI 10.1016/S0009-9120(85)80023-0; GOTO A, 1992, PHARMACOL REV, V44, P377; GOTO A, 1988, BIOCHEM BIOPH RES CO, V154, P847, DOI 10.1016/0006-291X(88)90217-3; GOTO A, 1990, BIOCHEM BIOPH RES CO, V173, P1093, DOI 10.1016/S0006-291X(05)80898-8; HABER E, 1987, HYPERTENSION, V9, P315, DOI 10.1161/01.HYP.9.4.315; HADDY FJ, 1990, CARDIOVASC DRUG THER, V4, P343, DOI 10.1007/BF02603174; HADDY FJ, 1983, FED PROC, V42, P2673; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HUOT SJ, 1983, AM J NEPHROL, V3, P92, DOI 10.1159/000166698; JURENITSCH J, 1982, J CHROMATOGR, V240, P125, DOI 10.1016/S0021-9673(01)84013-9; KELLY RA, 1986, AM J PHYSIOL, V251, pH205, DOI 10.1152/ajpheart.1986.251.1.H205; KITANO S, 1993, THER RES, V14, P201; KLODOS I, 1975, ANAL BIOCHEM, V67, P397, DOI 10.1016/0003-2697(75)90311-5; KOMISSARENKO NF, 1986, KHIM PRIR SOEDIN, V2, P201; Lichtstein D., 1992, Journal of Basic and Clinical Physiology and Pharmacology, V3, P269; LUDENS JH, 1992, HYPERTENSION, V19, P721, DOI 10.1161/01.HYP.19.6.721; MATHEWS WR, 1991, HYPERTENSION, V17, P930, DOI 10.1161/01.HYP.17.6.930; NARUSE K, 1994, HYPERTENSION S1, V23, P102; PAMNANI M, 1981, HYPERTENSION, V3, P96, DOI 10.1161/01.HYP.3.6_Pt_2.II-96; TAMURA M, 1987, J HYPERTENS, V5, P219, DOI 10.1097/00004872-198704000-00014; TAMURA M, 1985, J BIOL CHEM, V260, P9672; TAMURA M, 1993, EUR J BIOCHEM, V211, P317, DOI 10.1111/j.1432-1033.1993.tb19901.x; TAMURA M, 1988, BIOCHEMISTRY-US, V27, P4244, DOI 10.1021/bi00412a007; TAMURA M, 1987, BIOCHEMISTRY-US, V26, P2797, DOI 10.1021/bi00384a022; TAMURA M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P15, DOI 10.1016/0304-4165(93)90073-H; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P189	29	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11972	11979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163500				2022-12-27	WOS:A1994NG37700048
J	WANG, X; WURTELE, ES; KELLER, G; MCKEAN, AL; NIKOLAU, BJ				WANG, X; WURTELE, ES; KELLER, G; MCKEAN, AL; NIKOLAU, BJ			MOLECULAR-CLONING OF CDNAS AND GENES-CODING FOR BETA-METHYLCROTONYL-COA CARBOXYLASE OF TOMATO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; BIOTIN-DEPENDENT ENZYMES; COENZYME-A CARBOXYLASE; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; PYRUVATE-CARBOXYLASE; MESSENGER-RNA; OXALOACETATE DECARBOXYLASE; NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS	Tomato cDNA and genomic clones were isolated by using as a probe a cDNA clone that had originally been identified by its ability to direct the synthesis of a biotin-containing polypeptide in Escherichia coli. The nucleotide sequences of the newly isolated cDNAs indicate that they are clones of a single mRNA molecule. However, one of the cDNA clones contains an insertion of a sequence which we identified as an unspliced intron. The amino acid sequence deduced from the nucleotide sequence of the cDNAs showed similarity to regions of previously sequenced biotin enzymes, indicating that the isolated cDNAs code for a biotin-containing protein. Portions of the cDNAs were expressed in E. coli as glutathione S-transferase or beta-galactosidase fusion proteins. Each fusion protein was purified and used to immunize rabbits. The resulting antisera recognized a 78-kDa biotin containing polypeptide in tomato leaf extracts. In addition, both antisera specifically inhibited beta-methylcrotonyl-CoA carboxylase activity in extracts from tomato leaves. These characterizations have identified the isolated tomato cDNAs and genes as coding for the 78-kDa biotin subunit of beta-methylcrotonyl-CoA carboxylase. Comparison of the deduced amino acid sequence of the biotin subunit of beta-methylcrotonyl-CoA carboxylase with other biotin enzymes suggest that this subunit contains the biotin carboxylase and biotin carboxyl carrier domains.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011; IOWA STATE UNIV,DEPT BOT,AMES,IA 50011	Iowa State University; Iowa State University				Wurtele, Eve/0000-0003-1552-9495				ALBAN C, 1993, PLANT PHYSIOL, V102, P957, DOI 10.1104/pp.102.3.957; ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; ALI ST, 1990, BIOCHEM J, V271, P139, DOI 10.1042/bj2710139; APITZCASTRO R, 1970, EUR J BIOCHEM, V16, P71, DOI 10.1111/j.1432-1033.1970.tb01055.x; BAI DH, 1989, EUR J BIOCHEM, V182, P239, DOI 10.1111/j.1432-1033.1989.tb14823.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, J BIOL CHEM, V264, P12680; CHEN Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P103, DOI 10.1006/abbi.1993.1398; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLINS ME, 1987, FEMS MICROBIOL LETT, V43, P53; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DAKSHINAMURTI K, 1985, ANN NY ACAD SCI, V447, P1; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DIEZ TA, IN PRESS ARCH BIOCH; FALL RR, 1977, BIOCHEMISTRY-US, V16, P4000, DOI 10.1021/bi00637a010; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREYTAG SO, 1984, J BIOL CHEM, V259, P2831; Genbauffe F S, 1991, DNA Seq, V2, P19, DOI 10.3109/10425179109008435; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HAMMOND RW, 1984, J BIOL CHEM, V259, P9883; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFFMAN NE, 1987, NUCLEIC ACIDS RES, V15, P3928, DOI 10.1093/nar/15.9.3928; HUNT AG, 1987, PLANT MOL BIOL, V8, P23, DOI 10.1007/BF00016431; KING GJ, 1988, PLANT MOL BIOL, V10, P401, DOI 10.1007/BF00014946; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KONDO H, 1991, P NATL ACAD SCI USA, V88, P9730, DOI 10.1073/pnas.88.21.9730; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1986, P NATL ACAD SCI USA, V83, P4864, DOI 10.1073/pnas.83.13.4864; LAMHONWAH AM, 1989, NUCLEIC ACIDS RES, V17, P4396, DOI 10.1093/nar/17.11.4396; LAU EP, 1979, P NATL ACAD SCI USA, V76, P214, DOI 10.1073/pnas.76.1.214; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; LIM F, 1988, J BIOL CHEM, V263, P11493; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LOPEZCASSILAS F, 1988, P NATL ACAD SCI USA, V85, P5785; MILDVAN AS, 1991, STUDY ENZYMES, V2, P105; MOSS J, 1971, ADV ENZYMOL RAMB, V35, P321; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P3982, DOI 10.1093/nar/17.10.3982; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; NIKOLAU BJ, 1984, ARCH BIOCHEM BIOPHYS, V235, P555, DOI 10.1016/0003-9861(84)90229-7; NIKOLAU BJ, 1985, ANAL BIOCHEM, V149, P448, DOI 10.1016/0003-2697(85)90596-2; NIKOLAU BJ, 1984, PLANT PHYSIOL, V75, P895, DOI 10.1104/pp.75.4.895; NIKOLAU BJ, 1987, METABOLISM STRUCTURE, P517; NIKOLAU BJ, 1993, BIOCH MOL BIOL MEMBR, P138; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; POST LE, 1990, J BIOL CHEM, V265, P7742; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAKAI T, 1987, FEBS LETT, V212, P98, DOI 10.1016/0014-5793(87)81564-8; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WOEHLKE G, 1992, J BIOL CHEM, V267, P22798; WOOD HG, 1985, ANN NY ACAD SCI, V447, P1, DOI 10.1111/j.1749-6632.1985.tb18422.x; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; WURTELE ES, 1992, PLANT PHYSIOL, V99, P1699, DOI 10.1104/pp.99.4.1699; WURTELE ES, 1990, ARCH BIOCHEM BIOPHYS, V278, P179, DOI 10.1016/0003-9861(90)90246-U; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P1766, DOI 10.1073/pnas.90.5.1766	71	23	23	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11760	11768						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163472				2022-12-27	WOS:A1994NG37700016
J	CZAR, MJ; OWENSGRILLO, JK; DITTMAR, KD; HUTCHISON, KA; ZACHAREK, AM; LEACH, KL; DEIBEL, MR; PRATT, WB				CZAR, MJ; OWENSGRILLO, JK; DITTMAR, KD; HUTCHISON, KA; ZACHAREK, AM; LEACH, KL; DEIBEL, MR; PRATT, WB			CHARACTERIZATION OF THE PROTEIN-PROTEIN INTERACTIONS DETERMINING THE HEAT-SHOCK PROTEIN (HSP90-CENTER-DOT-HSP70-CENTER-DOT-HSP56) HETEROCOMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COMPLEXES; CELL GLUCOCORTICOID RECEPTOR; ROUS-SARCOMA VIRUS; PROGESTERONE-RECEPTOR; 59-KILODALTON PROTEIN; POLYCLONAL ANTIBODY; HSP90; RECONSTITUTION; TRANSFORMATION; MOLYBDATE	We have reported previously that the three heat shock proteins hsp56, hsp70, and hsp90 exist together in a heterocomplex in human lymphocyte cytosol (Sanchez, E. R., Faber, L. E., Henzel, W. J., and Pratt, W. B. (1990) Biochemistry 29, 5145-5152). All three of these proteins also exist in the native glucocorticoid receptor heterocomplex isolated from WCL2 cell cytosol and we have recently shown that the three heat shock proteins are present when immunopurified mouse glucocorticoid receptor is reconstituted into a heterocomplex by rabbit reticulocyte lysate (Hutchison, K. A., Scherrer, L. C., Czar, M. J., Ning, Y., Sanchez, E. R., Leach, K. L., Deibel, M. R., Jr., and Pratt, W. B. (1993) Biochemistry 32,3953-3957). In this work, we show that highly purified mouse hsp90 binds in a reversible equilibrium to immunopurified rabbit hsp56, but hsp56 does not bind to purified mouse hsp70. In contrast to the equilibrium binding of hsp90 to hsp56, purified hsp90 binds poorly or not at all to purified hsp70 unless a third factor from reticulocyte lysate is present to permit complex formation. This hsp70-hsp90 complex-forming factor is heat-labile, and in the presence of this factor and ATP, a heat shock protein heterocomplex can be reconstituted from purified mouse hsp90 and hsp70 and rabbit hsp56 that is present in the factor preparation. Our data are consistent with a model in which hsp56 and hsp70 bind to different sites on hsp90 but do not interact with each other. The presence of hsp56 in the heat shock protein heterocomplex is not stabilized by molybdate but hsp56 is stabilized if the glucocorticoid receptor is present in addition to hsp90 and hsp70.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6448 MED SCI BLDG 1,ANN ARBOR,MI 48109; UPJOHN CO,DEPT CELL BIOL & BIOCHEM,KALAMAZOO,MI 49001	University of Michigan System; University of Michigan; Pfizer					NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIS MN, 1992, EUR J BIOCHEM, V204, P75, DOI 10.1111/j.1432-1033.1992.tb16607.x; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; LEACH KL, 1979, J BIOL CHEM, V254, P1884; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; NADEAU K, 1993, J BIOL CHEM, V268, P1479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YEM AW, 1992, J BIOL CHEM, V267, P2868	43	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11155	11161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157642				2022-12-27	WOS:A1994NF96600030
J	LIU, MS; JIRIK, FR; LEBOEUF, RC; HENDERSON, H; CASTELLANI, LW; LUSIS, AJ; MA, YH; FORSYTHE, IJ; ZHANG, HF; KIRK, E; BRUNZELL, JD; HAYDEN, MR				LIU, MS; JIRIK, FR; LEBOEUF, RC; HENDERSON, H; CASTELLANI, LW; LUSIS, AJ; MA, YH; FORSYTHE, IJ; ZHANG, HF; KIRK, E; BRUNZELL, JD; HAYDEN, MR			ALTERATION OF LIPID PROFILES IN PLASMA OF TRANSGENIC MICE EXPRESSING HUMAN LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ADIPOSE-TISSUE; GENETIC-FACTORS; FATTY-ACIDS; MOUSE; ATHEROSCLEROSIS; CHOLESTEROL; BEZAFIBRATE; DEFICIENCY; ENHANCER	Lipoprotein lipase (LPL) is a key enzyme required for the hydrolysis of triglyceride-rich particles. To assess the effects of increased plasma LPL on lipoprotein levels, transgenic mice expressing human LPL (hLPL) were produced. Abundant hLPL transcripts were detected in RNA from different tissues of transgenic mice which resulted in an increase in post-heparin plasma LPL activity of approximately 154%. On rodent chow (p = 0.01) and after a 16-h fast (p = 0.001), plasma triglycerides in transgenic mice were decreased by approximately 50% as compared to littermate controls. Gel filtration chromatography showed a 2-3-fold decrease in very low density lipoprotein triglycerides and cholesterol enrichment of low density lipoprotein. Transgenic mice maintained on a high carbohydrate diet exhibited a 78% (p = 0.03) lowering of low density lipoprotein and very low density lipoprotein cholesterol levels, in addition to a 68% (p = 0.01) lowering of total to high density lipoprotein cholesterol (TC/HDL-C) ratios compared to controls. The distribution of apoA-I and A-II were similar in the transgenics and their non-transgenic littermates, while the apoE distribution was mildly altered in the plasma from the transgenic mice. These data demonstrate that moderate increases in total LPL activity are associated with significant changes in lipoprotein levels and altered composition of lipoprotein particles.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V6T 1Z4, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CAPE TOWN, DEPT CHEM PATHOL, RONDEBOSCH 7700, SOUTH AFRICA	University of British Columbia; University of British Columbia; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Cape Town			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL042333, R37HL042488, R01HL042488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42488, HL42333] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; DUERDEN JM, 1988, BIOCHEM J, V255, P929, DOI 10.1042/bj2550929; EISENBERG S, 1984, J CLIN INVEST, V74, P470, DOI 10.1172/JCI111444; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; HOGAN B, 1986, MANIPULATING MOUSE E; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JIAO S, 1990, J LIPID RES, V31, P467; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; LEBOEUF RC, 1993, J NUTR, V123, P547, DOI 10.1093/jn/123.3.547; LEBOEUF RC, 1994, J LIPID RES, V35, P121; LEBOEUF RC, 1990, J LIPID RES, V31, P91; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MAGILL P, 1982, EUR J CLIN INVEST, V12, P113, DOI 10.1111/j.1365-2362.1982.tb00947.x; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MIESENBOCK G, 1993, J CLIN INVEST, V91, P448, DOI 10.1172/JCI116222; Mikkelsen Thomas R., 1992, Transgenic Research, V1, P164, DOI 10.1007/BF02522534; NIKKILA EA, 1978, ATHEROSCLEROSIS, V29, P497, DOI 10.1016/0021-9150(78)90178-8; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; PETERSON J, 1992, J LIPID RES, V33, P1165; REISER S, 1987, METABOLIC EFFECTS DI, P83; SCHWARTZ RS, 1981, J CLIN INVEST, V67, P1425, DOI 10.1172/JCI110171; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVASTAVA RAK, 1992, BIOCHIM BIOPHYS ACTA, V1125, P251, DOI 10.1016/0005-2760(92)90053-X; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; TSUTSUMI K, 1993, J CLIN INVEST, V92, P411, DOI 10.1172/JCI116582; VESSBY B, 1980, ATHEROSCLEROSIS, V37, P257, DOI 10.1016/0021-9150(80)90011-8; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	43	63	68	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11417	11424						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157673				2022-12-27	WOS:A1994NF96600066
J	LYON, M; DEAKIN, JA; GALLAGHER, JT				LYON, M; DEAKIN, JA; GALLAGHER, JT			LIVER HEPARAN-SULFATE STRUCTURE - A NOVEL MOLECULAR DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONATE 2-SULFATE RESIDUES; GLOMERULAR-BASEMENT-MEMBRANE; PROTEIN-LINKAGE REGION; RAT-LIVER; BINDING SEQUENCE; GROWTH-FACTOR; PROTEOGLYCANS; CELLS; POLYSACCHARIDES; IDENTIFICATION	The structure of rat liver heparan sulfate (HS) has been investigated using a combination of (a) chain scission with specific reagents, (b) disaccharide compositional analysis, and (c) end-referenced sequence analysis of the proximal, protein-linked region of the chain. This study reveals that the liver synthesizes a highly sulfated HS species (1.34 sulfates/disaccharide), particularly high in N-sulfation (60%) and 2-O-sulfate content (36%). Approximately half of the latter is found in trisulfated disaccharides, i.e. IdceA(2-OSO3)alpha1-4GlcNSO3(6-OSO3). End-referencing methodology established the existence of an extended, unmodified heparan (GlcUAbeta1-4GlcNAc) sequence, 8-11 disaccharides in length, attached to the linkage tetrasaccharide, similar to that found in a number of other HS species. Directly following this is a mixed HexUA1-4GlcNR(6-OSO3) (where GlcNR represents alpha-D-glucosamine with an unspecified N-substituent)-containing sequence of variable length, culminating in the appearance of the first IdceA(2-OSO3) residue approximately 20 disaccharides from the linkage region, i.e. approximately 40% along the length of the chain. The distal 60% of the polysaccharide is highly sulfated (approximately 2 sulfates/disaccharide) and mainly comprises three heparin-like domains, highly enriched in IdceA(2-OSO3) residues. Overall, liver HS qualifies as an extreme member of the HS family, with a considerable proportion of heparin-like structure asymmetrically concentrated to the distal part of the chain.	UNIV MANCHESTER, CHRISTIE HOSP, DEPT MED ONCOL, MANCHESTER M20 9BX, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	LYON, M (corresponding author), CANCER RES CAMPAIGN, WILMSLOW RD, MANCHESTER M20 9BX, ENGLAND.			Lyon, Malcolm/0000-0001-9575-6879				AKASAKI M, 1975, FEBS LETT, V59, P100, DOI 10.1016/0014-5793(75)80350-4; BAME KJ, 1991, J BIOL CHEM, V266, P12461; CIFONELL.JA, 1968, CARBOHYD RES, V8, P233, DOI 10.1016/S0008-6215(00)80159-7; CIFONELLI JA, 1977, BIOCHEMISTRY-US, V16, P2137, DOI 10.1021/bi00629a014; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; FRANSSON LA, 1989, HEPARIN, P115; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1988, BIOCHEM J, V250, P719, DOI 10.1042/bj2500719; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1989, HEPARIN, P135; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNECHT J, 1967, J BIOL CHEM, V242, P4652; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U., 1989, HEPARIN, P159; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LINKER A, 1975, BIOCHIM BIOPHYS ACTA, V385, P324, DOI 10.1016/0304-4165(75)90360-8; LORIES V, 1992, J BIOL CHEM, V267, P1116; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1987, BIOCHEM J, V242, P493, DOI 10.1042/bj2420493; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MALMSTROM A, 1975, BIOCHEM J, V151, P477; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OLDBERG A, 1977, BIOCHEM J, V164, P75, DOI 10.1042/bj1640075; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TURNBULL JE, 1988, BIOCHEM J, V251, P597, DOI 10.1042/bj2510597; WALKER A, 1994, J BIOL CHEM, V269, P931; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; YAMADA SH, 1993, J BIOL CHEM, V268, P4780	46	231	238	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11208	11215						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157650				2022-12-27	WOS:A1994NF96600038
J	RODEN, L; ANANTH, S; CAMPBELL, P; MANZELLA, S; MEEZAN, E				RODEN, L; ANANTH, S; CAMPBELL, P; MANZELLA, S; MEEZAN, E			XYLOSYL TRANSFER TO AN ENDOGENOUS RENAL ACCEPTOR - PURIFICATION OF THE TRANSFERASE AND THE ACCEPTOR AND THEIR IDENTIFICATION AS GLYCOGENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE GLYCOGENIN; PROTEIN; BIOSYNTHESIS; INITIATION; BIOGENESIS; PRIMER	A xylosyltransferase in rat kidney, tentatively identified as glycogenin (Meezan, E., Ananth, S., Manzella, S., Campbell, P., Siegal, S., Pillion, D. J., and Roden, L. (1994) J. Biol. Chem. 269,11503-11508), was purified by a procedure in which affinity chromatography on UDP-glucuronic acid-agarose was a particularly useful step. The purified material was nearly homogeneous, as shown by SDS-polyacrylamide gel electrophoresis and silver staining, and had an electrophoretic mobility corresponding to a M(r) of 32,000. The purified enzyme possessed both glucosyl- and xylosyltransferase activity, and incubation with UDP-[H-3]xylose or UDP-[H-3]glucose yielded a single macromolecular product, which had the same electrophoretic mobility as the major silver-stained component. These results indicate that the kidney transferase was indeed glycogenin and that it was functionally analogous to the larger glycogenin species previously isolated from rabbit muscle. Further examination of the properties of the rat kidney enzyme showed, i.a., that it was inhibited strongly by cytidine 5'-diphosphate. This effect was used to advantage in an alternative purification procedure, which was applied to beef kidney and involved adsorption of the enzyme to UDP-glucuronic acid-agarose and subsequent elution with cytidine 5'-diphosphate. In contrast to glycogenin, glycogen synthase did not catalyze transfer from UDP-xylose, and it is suggested that the incorporation of xylose into glycogen observed by other investigators was due to glycogenin-catalyzed xylosyl transfer and subsequent chain elongation by glycogen synthase.	UNIV ALABAMA,DEPT PHARMACOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIDCR NIH HHS [DE 08252] Funding Source: Medline; NIDDK NIH HHS [DK 39877] Funding Source: Medline; NINDS NIH HHS [NS 27353] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027353] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTTINEN H, 1978, BIOCHEM J, V175, P737, DOI 10.1042/bj1750737; BLUMENFELD ML, 1985, J BIOL CHEM, V260, P1560; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CAO YJ, 1993, J BIOL CHEM, V268, P14687; GREBNER EE, 1966, BIOCHEM BIOPH RES CO, V22, P672, DOI 10.1016/0006-291X(66)90199-9; GREBNER EE, 1966, ARCH BIOCHEM BIOPHYS, V116, P391, DOI 10.1016/0003-9861(66)90045-2; KIMURA JH, 1978, ARCH BIOCHEM BIOPHYS, V191, P687, DOI 10.1016/0003-9861(78)90408-3; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MYLLYLA R, 1977, BIOCHIM BIOPHYS ACTA, V480, P113, DOI 10.1016/0005-2744(77)90326-6; PARK JT, 1949, J BIOL CHEM, V181, P149; PARTRIDGE SM, 1949, NATURE, V164, P443, DOI 10.1038/164443a0; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	22	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11509	11513						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157680				2022-12-27	WOS:A1994NF96600079
J	SOLIS, D; FEIZI, T; YUEN, CT; LAWSON, AM; HARRISON, RA; LOVELESS, RW				SOLIS, D; FEIZI, T; YUEN, CT; LAWSON, AM; HARRISON, RA; LOVELESS, RW			DIFFERENTIAL RECOGNITION BY CONGLUTININ AND MANNAN-BINDING PROTEIN OF N-GLYCANS PRESENTED ON NEOGLYCOLIPIDS AND GLYCOPROTEINS WITH SPECIAL REFERENCE TO COMPLEMENT GLYCOPROTEIN C3 AND RIBONUCLEASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE PROBES NEOGLYCOLIPIDS; 3RD COMPONENT; STRUCTURAL-ANALYSIS; CONFORMATIONAL-CHANGES; BOVINE SERUM; MANNOSE; C-3; CHAINS; LECTIN; EXTENT	Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains. Several conclusions can be drawn. First, the interaction of conglutinin is profoundly influenced by the state of the protein moiety of the a chain in the vicinity of the glycosylation site Asn-917. Second, the binding to the C3-derived glycoprotein iC3b appears to be exclusively mediated through the Man8 or Man9 oligosaccharide on the a chain; there is no evidence for other N-linked oligosaccharides on C3 that are uniquely bound by conglutinin. Third, although conglutinin shows a more restricted binding relative to mannan-binding protein toward the oligosaccharides free of protein, it has a broader binding pattern toward the oligosaccharides as presented on C3-derived glycoproteins. From these and additional observations with RNase B, which contains high mannose-type oligosaccharides at Asn-34, it is clear that the protein moieties of these glycoproteins markedly influence the presentation of the oligosaccharides such that biological specificity is mediated by the commonly occurring high mannose-type oligosaccharides in the context of specific carrier proteins.	MRC, MOLEC IMMUNOPATHOL UNIT, CAMBRIDGE CB2 2QH, ENGLAND; MRC, CLIN RES CTR, CLIN MASS SPECT SECT, HARROW HA1 3UJ, MIDDX, ENGLAND	Medical Research Council Clinical Trials Unit	SOLIS, D (corresponding author), MRC, CLIN RES CTR, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND.		Solís, Dolores/E-5992-2015	Solís, Dolores/0000-0002-8148-1875; Feizi, Ten/0000-0001-6495-0329; Harrison, Richard Alexander/0000-0002-2408-6043				BARNUM SR, 1990, YEAR IMMUNOLOGY 1989, P208; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BROWN EJ, 1982, J IMMUNOL, V128, P860; CARVER JP, 1993, PURE APPL CHEM, V65, P763, DOI 10.1351/pac199365040763; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DAVIS AE, 1981, FEBS LETT, V134, P147, DOI 10.1016/0014-5793(81)80588-1; DAVIS AE, 1984, J IMMUNOL, V132, P1960; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; EDGE CJ, 1993, BIOCHEM SOC T, V21, P452; HARRISON RA, 1979, MOL IMMUNOL, V16, P767, DOI 10.1016/0161-5890(79)90154-8; HARRISON RA, 1980, MOL IMMUNOL, V17, P9, DOI 10.1016/0161-5890(80)90119-4; HASE S, 1985, J BIOCHEM-TOKYO, V98, P863, DOI 10.1093/oxfordjournals.jbchem.a135366; HIRANI S, 1985, J IMMUNOL, V134, P1105; HIRANI S, 1986, BIOCHEM J, V233, P613, DOI 10.1042/bj2330613; Holmskov U, 1993, Behring Inst Mitt, P224; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1981, MOL IMMUNOL, V18, P331, DOI 10.1016/0161-5890(81)90057-2; KAWASAKI N, 1985, J BIOCHEM-TOKYO, V98, P1309, DOI 10.1093/oxfordjournals.jbchem.a135398; LACHMANN PJ, 1962, IMMUNOLOGY, V5, P687; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; LEON MA, 1964, SCIENCE, V143, P1327, DOI 10.1126/science.143.3612.1327; LINSCOTT WD, 1978, J IMMUNOL, V121, P658; LOVELESS RW, 1989, BIOCHEM J, V258, P109, DOI 10.1042/bj2580109; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; LU JH, 1993, BIOCHEM J, V292, P157, DOI 10.1042/bj2920157; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; NILSSON B, 1985, SCAND J IMMUNOL, V22, P703, DOI 10.1111/j.1365-3083.1985.tb01933.x; NILSSON B, 1992, BIOCHEM J, V282, P715, DOI 10.1042/bj2820715; SANCHEZCORRAL P, 1989, J IMMUNOL METHODS, V122, P105, DOI 10.1016/0022-1759(89)90340-2; SOLIS D, 1987, EUR J BIOCHEM, V165, P131, DOI 10.1111/j.1432-1033.1987.tb11203.x; SOLIS D, 1993, EUR J BIOCHEM, V214, P677, DOI 10.1111/j.1432-1033.1993.tb17968.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TACK BF, 1979, BIOCHEMISTRY-US, V18, P1497, DOI 10.1021/bi00575a017; TAYLOR ME, 1987, BIOCHIM BIOPHYS ACTA, V915, P60, DOI 10.1016/0167-4838(87)90125-7; TOMANA M, 1985, MOL IMMUNOL, V22, P107, DOI 10.1016/S0161-5890(85)80004-3; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILLIAMS DB, 1984, J BIOL CHEM, V259, P5105; YOUNG NM, 1987, BIOCHEM BIOPH RES CO, V143, P645, DOI 10.1016/0006-291X(87)91402-1	40	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11555	11562						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157687				2022-12-27	WOS:A1994NF96600086
J	CURNUTTE, JT; ERICKSON, RW; DING, JB; BADWEY, JA				CURNUTTE, JT; ERICKSON, RW; DING, JB; BADWEY, JA			RECIPROCAL INTERACTIONS BETWEEN PROTEIN-KINASE-C AND COMPONENTS OF THE NADPH OXIDASE COMPLEX MAY REGULATE SUPEROXIDE PRODUCTION BY NEUTROPHILS STIMULATED WITH A PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PLASMA-MEMBRANE; OKADAIC ACID; RABBIT NEUTROPHILS; MYRISTATE ACETATE; CYTOCHALASIN-B; ACTIVATION; PHOSPHORYLATION; CALCIUM	The 47-kDa subunit of the NADPH oxidase system (p47-phox) of neutrophils undergoes an association with proteins in the Triton X-100-insoluble fraction upon stimulation of the cells with 4 beta-phorbol 12-myristate 13-acetate. This fraction contains the assembled oxidase that catalyzes the generation of superoxide by stimulated cells. In this paper, we report that the addition of an inhibitor of protein kinases (1-(5-isoquinolinylsulfonyl-2-methylpiperazine) to neutrophils that are already stimulated results in the dissociation of p47-phox from this fraction. Antagonists of type 1 and 2A protein phosphatases (calyculin A, okadaic acid) prevented this phenomenon. In contrast, norokadanone, an inactive analog of okadaic acid, did not affect this response. These observations are correlated with previous studies on the phosphorylation of p47-phox and superoxide release. In addition, we show that protein kinase C (PKC) also undergoes an extensive redistribution to the Triton X-100-insoluble fraction in 4 beta-phorbol 12-myristate 13-acetate-stimulated cells, the extent of which is diminished significantly in neutrophils from chronic granulomatous disease patients who lack either p47-phox or cytochrome b(558). These studies strongly indicate that PKC and type 1 and/or 2A protein phosphatases are involved in a continuous phosphorylation reaction that maintains the oxidase in the assembled/active state. Moreover, components of the oxidase may target and facilitate the translocation of PKC to a cellular site in close apposition to the oxidase.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Scripps Research Institute; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023323, R01AI028342, R01AI024838] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28342, AI-24838, AI23323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BAZZI MD, 1992, J BIOL CHEM, V267, P22891; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2; DING JB, 1993, BLOOD, V82, P940; DING JB, 1992, J BIOL CHEM, V267, P6442; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMEYER JE, 1979, BLOOD, V54, P35; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LU DJ, 1992, AM J PHYSIOL, V262, pC39; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; NAUSEEF WM, 1990, BLOOD, V76, P2622; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERRY DK, 1992, J IMMUNOL, V149, P2749; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROBINSON JM, 1985, J CELL BIOL, V101, P1052, DOI 10.1083/jcb.101.3.1052; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1990, J BIOL CHEM, V265, P8475; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; STEVENSON KB, 1989, BLOOD, V74, P2136; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WHITE JR, 1984, J BIOL CHEM, V259, P8605; WHITE JR, 1983, J BIOL CHEM, V258, P4041; WOLF M, 1986, J BIOL CHEM, V261, P3327; WOLFSON M, 1985, J IMMUNOL, V135, P2057; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	57	102	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10813	10819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144669				2022-12-27	WOS:A1994NF01700093
J	STEWART, MJ; COX, G; REIFELMILLER, A; KIM, SY; WESTBROOK, CA; LEIBOWITZ, DS				STEWART, MJ; COX, G; REIFELMILLER, A; KIM, SY; WESTBROOK, CA; LEIBOWITZ, DS			A NOVEL TRANSCRIPTIONAL SUPPRESSOR LOCATED WITHIN A DOWNSTREAM INTRON OF THE BCR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; HYBRID MESSENGER-RNA; ABL TYROSINE KINASE; CLUSTER REGION BCR; BETA-GLOBIN; CHRONIC PHASE; BLAST CRISIS; CML PATIENTS; C-ABL	A reciprocal translocation between chromosomes 9 and 22 creates the Philadelphia (Ph(1)) chromosome in chronic myelogenous leukemia. This translocation results in the fusion of the ABL and the BCR genes to form a BCR/ABL fusion gene, the product of which has a greatly increased protein tyrosine kinase activity in comparison with the normal ABL protein. The chromosome 22 translocation breakpoints are concentrated within a 5.8-kilobase region named the major breakpoint cluster region (Mbcr). Gel mobility shift and DNase I footprinting assays have defined binding sites for three proteins, BIF 1-3 (BCR intron factors 1-3), lying within a 427-base pair fragment of the Mbcr. This 427-base pair fragment functions as a transcriptional silencer with both the BCR as well as a heterologous promoter. The silencing is position- and orientation-independent. The transcriptional effects are greatest in chronic myelogenous leukemia cells, decreased in HeLa and B-cells, and absent in T-lymphocytes. Gel mobility shift assays show a corresponding difference in pattern when the T-lymphocyte nuclear extract is compared with other cell Lines. The Mbcr appears to contain a novel group of transcriptional silencers that share a common binding motif with a recently described suppresser in the mouse Adh-1 gene.	INDIANA UNIV, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT MOLEC & MED GENET, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, VET ADM MED CTR, INDIANAPOLIS, IN 46202 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Chicago								AMOUYAL M, 1991, BIOCHIMIE, V73, P1261, DOI 10.1016/0300-9084(91)90086-G; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BEDI A, 1993, BLOOD, V81, P2898; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BERNARDS A, 1987, MOL CELL BIOL, V12, P721; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHEN XR, 1992, ONCOGENE, V7, P1805; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREAZEN O, 1988, BLOOD, V71, P797; DYCK JA, 1989, BRIT J HAEMATOL, V72, P64, DOI 10.1111/j.1365-2141.1989.tb07653.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISENBERG A, 1988, LEUKEMIA, V2, P642; ENVER T, 1991, DEV BIOL, V148, P129, DOI 10.1016/0012-1606(91)90323-U; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FUTAKI M, 1992, LEUKEMIA RES, V16, P1071, DOI 10.1016/0145-2126(92)90045-9; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOLDMAN JM, 1990, LEUKEMIA, V4, P163; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSSMAN A, 1989, AM J HUM GENET, V45, P729; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; INOKUCHI K, 1991, LEUKEMIA RES, V15, P1067, DOI 10.1016/0145-2126(91)90113-8; INOKUCHI K, 1991, BLOOD, V78, P3125; JAUBERT J, 1990, BRIT J HAEMATOL, V74, P30, DOI 10.1111/j.1365-2141.1990.tb02534.x; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; JIANG XY, 1990, BLOOD, V76, P597; KEATING A, 1991, EXP HEMATOL, V19, P539; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEIBOWITZ D, 1989, CANCER INVEST, V7, P195, DOI 10.3109/07357908909038285; LEIBOWITZ D, 1991, GENE CHROMOSOME CANC, V3, P308, DOI 10.1002/gcc.2870030410; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEY TJ, 1991, BLOOD, V77, P1146; LIN ZH, 1993, J BIOL CHEM, V268, P10260; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLS KI, 1988, BLOOD, V72, P1237; MILLS KI, 1991, BLOOD, V78, P1155; MOON AM, 1991, BLOOD, V77, P2272; MORGAN GJ, 1990, BRIT J HAEMATOL, V76, P33, DOI 10.1111/j.1365-2141.1990.tb07833.x; MORRIS SW, 1990, BLOOD, V75, P2035; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OGAWA H, 1989, LEUKEMIA, V3, P492; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; POPENOE DW, 1986, BLOOD, V68, P1123; PRZEPIORKA D, 1988, CANCER GENET CYTOGEN, V36, P117, DOI 10.1016/0165-4608(88)90081-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SCHAEFERREGO K, 1987, BLOOD, V70, P448; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHTALRID M, 1988, BLOOD, V72, P485; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAMATOYANNOPOULOS G, 1991, SCIENCE, V252, P383, DOI 10.1126/science.2017679; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; TIEN HF, 1990, BRIT J HAEMATOL, V75, P469, DOI 10.1111/j.1365-2141.1990.tb07784.x; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WITTE ON, 1993, CANCER RES, V53, P485; WOOD J, 1990, MASTER DRAWINGS, V28, P3; ZHU QS, 1990, ONCOGENE, V5, P885	94	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10820	10829						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144670				2022-12-27	WOS:A1994NF01700094
J	NARANDA, T; STRONG, WB; MENAYA, J; FABBRI, BJ; HERSHEY, JWB				NARANDA, T; STRONG, WB; MENAYA, J; FABBRI, BJ; HERSHEY, JWB			2 STRUCTURAL DOMAINS OF INITIATION-FACTOR EIF-4B ARE INVOLVED IN BINDING TO RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; MAMMALIAN PROTEIN-SYNTHESIS; MESSENGER-RNA; TRANSLATION; RECOGNITION; EXPRESSION; MECHANISM; CONSENSUS; MUTATIONS; SEQUENCE	Translation initiation factor eIF-4B promotes the binding of mRNA to 40 S preinitiation complexes and together with eIF-4A possesses RNA helicase activity. To elucidate structural features involved in its function, a series of internal and C-terminal deletions, as well as point mutations, were constructed in the eIF-4B cDNA The mutated cDNAs were expressed in transiently transfected COS-1 cells, and mutant forms of the factor were overproduced up to about 25-fold over endogenous eIF-4B levels. Inhibition of dihydrofolate reductase (DHFR) synthesis by high levels of eIF-4B variants was determined in vivo, and the binding of the eIF-4B forms to biotinylated RNA was measured in vitro. The results indicate that the N-terminal region containing the RNA binding motif with its RNP1 and RNP2 consensus elements is sufficient for inhibition of DHFR synthesis. Deletion of the RNP1 sequence abrogates RNA binding, but amino acid substitutions at conserved residues do not always inhibit RNA binding. Deletion of the DRYG domain near the middle of eIF-4B results in inhibition of RNA binding, but not of DHFR synthesis. Up to 164 residues of the C terminus are not required for RNA binding, but removal of 226 or more residues completely inhibits RNA binding, perhaps by the loss of two arginine-rich regions. The results suggest that both the RNA recognition motif and the arginine-rich region are required for stable RNA binding but that both are not necessary for in vivo inhibition of protein synthesis.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, T32GM007377, F32GM014311] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07377, GM14311, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENNE R, 1978, J BIOL CHEM, V253, P3078; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J, 1989, MOL CLONING LABORATO; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8	31	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14465	14472						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182051				2022-12-27	WOS:A1994NM06500027
J	QUINN, PG				QUINN, PG			INHIBITION BY INSULIN OF PROTEIN-KINASE A-INDUCED TRANSCRIPTION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE - MEDIATION BY THE ACTIVATION DOMAIN OF CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) AND FACTORS BOUND TO THE TATA BOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIHORMONAL REGULATION; MESSENGER-RNA; GTP GENE; EXPRESSION; IDENTIFICATION; INDUCTION; PROMOTER; ISOFORMS; SEQUENCE; UNIT	The minimal promoter/transcription factor requirements for induction of phosphoenolpyruvate carboxykinase (PEPCK) transcription by cAMP-activated protein kinase A (PKA) and inhibition of this induction by insulin were investigated. H4 hepatoma cells were treated with or without insulin following cotransfection with chloramphenicol acetyltransferase reporter genes and expression vectors coding for the cAMP response element-binding protein (CREB) activation domain fused to the GAL4 DNA binding domain (CRG) and the catalytic subunit of PRA. Mutation of the PEPCK CRE to a GAL4 binding site (G4-PEPCK) within the fully responsive PEPCK promoter (-600/+69) made induction by PKA dependent upon cotransfection of CRG and this induction by CRG + PKA was inhibited by insulin. Mutation of the insulin regulatory sequence (Delta IRS-G4-PEPCK) did not prevent induction by cAMP or inhibition by insulin. Fusion of GAL4 binding sites to the PEPCK TATA region (-40/+1, G4-PT) allowed induction by CRG + PKA and inhibition by insulin. However, inhibition by insulin was not observed when the CREB activation domain in CRG was replaced with the activation domain of VP16 (G4-VP16) or when the PEPCK TATA region was replaced with TATA regions from other genes. Our results indicate that the minimal requirements for induction of PEPCK by PKA and inhibition by insulin include: 1) the CREB activation domain, 2) the PEPCK TATA sequence, and 3) insulin-responsive hepatoma cells. These data suggest that specific factors interacting with both the PEPCB TATA region and the CREB activation domain are required for insulin inhibition of PKA-induced transcription.			QUINN, PG (corresponding author), PENN STATE UNIV, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA.				NIDDK NIH HHS [DK43871] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043871] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1985, J BIOL CHEM, V260, P748; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CHU DTW, 1988, J BIOL CHEM, V263, P13007; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MAURER RA, 1989, J BIOL CHEM, V264, P6870; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SASAKI K, 1984, J BIOL CHEM, V259, P5242; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484	24	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14375	14378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182041				2022-12-27	WOS:A1994NM06500013
J	BRAUNHUT, SJ; MOSES, MA				BRAUNHUT, SJ; MOSES, MA			RETINOIDS MODULATE ENDOTHELIAL-CELL PRODUCTION OF MATRIX-DEGRADING PROTEASES AND TISSUE INHIBITORS OF METALLOPROTEINASES (TIMP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE INHIBITOR; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; IV COLLAGENASE; CDNA CLONING; EXPRESSION; SECRETION; PROTEINS; ACID; NEOVASCULARIZATION	We have previously reported that vitamin A inhibits the growth of capillary endothelial cells (EC) (Braunhut, S. J., and Palomares, M. (1991) Microvasc. Res. 41, 47-62). In this study, we have analyzed the effect of retinoids on the production and activity of enzymes involved in the proteolytic degradation of extracellular matrix (ECM) by EC. Substrate gel electrophoresis (zymography) revealed several major matrix metalloproteinases (MMP), of similar to 98-96, 72-68, and 46-45 kDa, whose activities were altered in their amounts in the conditioned media (CM) of EC following retinol or retinoic acid treatment when compared to amounts detected in CM of control cells. All of these gelatinases were inactivated by 1,10-phenanthroline, indicating that they were MMPs. MMP inhibitors (MMPI) were also present in these CM and were separated by gel filtration. Four distinct peaks of MMPIs were detected in the CM of EC. Chromatographic profiles indicated that an similar to 27-kDa MMPI was specifically increased in the CM of retinol-treated cells, whereas a 22-18.5-kDa MMPI was increased in CM derived from retinoic acid treated cells. The MMPI synthesized by retinol-treated EC was immunologically related to tis sue inhibitor of metalloproteinases, type 1 (TIMP-1), and the MMPI produced by retinoic acid-treated cells was related to TIMP-2, as indicated by biosynthetic labeling and immunoprecipitation studies as well as Western blot analysis. Therefore, retinol and retinoic acid treatment of EC differentially affects the types and activity of MMPs and MMPIs produced by the cells, distinct changes which are both correlated with growth inhibition.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	BRAUNHUT, SJ (corresponding author), HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115, USA.				NCI NIH HHS [CA46776] Funding Source: Medline; NEI NIH HHS [EY06047, EY06726] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046776] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY006726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APODACA G, 1990, CANCER RES, V50, P2322; AUDETTE M, 1983, CANCER DETECT PREV, V6, P497; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BRAUNHUT SJ, 1989, J CELL BIOL, V108, P2467, DOI 10.1083/jcb.108.6.2467; BRAUNHUT SJ, 1991, MICROVASC RES, V41, P47, DOI 10.1016/0026-2862(91)90007-X; BRAUNHUT SJ, 1991, J CELL BIOCHH, V15, pA247; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COTTAM DW, 1992, INVEST OPHTH VIS SCI, V33, P1923; DAMORE PA, 1988, ENDOTHELIAL CELLS, V2, P13; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Goodman DS, 1984, RETINOIDS, V2, P2; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JOHNSONWINT B, 1980, ANAL BIOCHEM, V104, P175, DOI 10.1016/0003-2697(80)90295-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS DB, 1992, BIOTECHNIQUES, V12, P902; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MOSCATELLI D, 1980, CELL, V20, P343, DOI 10.1016/0092-8674(80)90620-0; MOSES MA, 1992, J CELL BIOL, V119, P475, DOI 10.1083/jcb.119.2.475; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; MURRAY JB, 1986, J BIOL CHEM, V261, P4154; PAIGE K, 1991, IN VITRO CELL DEV B, V27, P151; RUNDHAUG J, 1987, CANCER RES, V47, P5637; SHERMAN MI, 1986, RETINOIDS CELL DIFFE, P161; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; WAHRENDORF J, 1986, AM J EPIDEMIOL, V123, P544, DOI 10.1093/oxfordjournals.aje.a114269; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	50	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13472	13479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175780				2022-12-27	WOS:A1994NK18400063
J	KULKARNI, MS; SHERMAN, F				KULKARNI, MS; SHERMAN, F			NAT2, AN ESSENTIAL GENE ENCODING METHIONINE N-ALPHA-ACETYLTRANSFERASE IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ACETYLTRANSFERASE; MESSENGER-RNA; MUTANTS; IDENTIFICATION; ACETYLATION; PROTEINS; SEQUENCE; INVIVO; ACTIN; AMINOPEPTIDASE	N-alpha-Acetylation is catalyzed by N-alpha-acetyltransferases, which transfer acetyl groups from acetyl coenzyme A to the N termini of most eukaryotic proteins co-translationally. NAT1 and ARD1 from the yeast Saccharomyces cerevisiae (Mullen, J. R., Kayne, P. S., Moerschell, R. P, Tsunasawa, S., Gribskov, M., Colavito-Shepanski, M., Grunstein, M., Sherman, F., and Sternglanz, R. (1989) EMBO J. 8, 2067-2075) were previously shown to encode the major N-alpha-acetyltransferase, which act on certain proteins having serine, glycine, and alanine but not methionine termini (Sherman, F., Moerschell, R. P., Tsuna sawa, S., and Sternglanz, R. (1993) in Methods in Protein Sequence Analysis (Imahori, K., and Sakiyama, F., eds) pp. 173-181, Plenum Publishing Corp., New York). We have identified a second gene, NAT2, that may correspend to the N-alpha-acetyltransferase acting on a subset of proteins having methionine termini. Crude extracts of a series of heat-sensitive mutants (Ts(-)) were screened for acetylation of a 24-amino acid synthetic peptide Met-Asn-Asn- in vitro. One mutant, nat2-1, out of 115 strains examined, lacked acetyltransferase activity, and the mutation co segregated as a single gene with the heat-sensitive phenotype. The nat2-1 mutants were deficient in the ability to acetylate Met-Asn-Asn- and Met-Glu-Arg-peptides but were able to N-alpha-acetylate Ser-Glu-Phe- and Ser-Tyr-Ser- peptides in vitro. The NAT2 wild-type gene was cloned by complementation of the nat2-1 mutant, and the DNA sequence revealed an open reading frame of 288 amino acids. Gene disruption demonstrated that NAT2 is an essential gene, and hybridization analysis indicated that it is located on chromosome VII. Furthermore, there was limited, but significant identities between the yeast N-alpha-acetyltransferases Nat1, Ard1, Nat2, and Mak3, although no common motifs could be identified. We propose that NAT2 encodes the major N-alpha-acetyl-transferase acting on certain proteins with only methionine termini, and that N-alpha-acetylation of some of these proteins is essential for viability.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREW C, 1976, MOL GEN GENET, V144, P29, DOI 10.1007/BF00277300; BERGER EM, 1981, BIOCHEM GENET, V19, P321, DOI 10.1007/BF00504277; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1991, J BIOL CHEM, V266, P16825; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FABIAN GR, 1987, J BACTERIOL, V169, P1571, DOI 10.1128/jb.169.4.1571-1578.1987; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HERSHKO A, 1984, P NATL ACAD SCI USA, V81, P7051; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LINK AJ, 1991, GENETICS, V127, P681; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOOPENN WF, 1977, BIOCHEMISTRY-US, V16, P4872, DOI 10.1021/bi00641a019; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NICHOLS BP, 1979, P NATL ACAD SCI USA, V76, P5244, DOI 10.1073/pnas.76.10.5244; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMACHANDRAN J, 1967, ADV ENZYMOL RAMB, V29, P391; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SHERMAN F, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P173; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERMAN F, 1992, J PROTEIN CHEM, V11, P380; SIDDIG MAM, 1980, J MOL BIOL, V137, P125, DOI 10.1016/0022-2836(80)90320-4; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOKOLIK CW, 1992, J BIOL CHEM, V267, P1067; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; SYMTH DG, 1979, NATURE, V279, P252; SYMTH DG, 1980, NATURE, V288, P613; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; THRASH C, 1984, J BIOL CHEM, V259, P1375; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WERTMAN KF, 1992, GENETICS, V132, P337; WINEY M, 1988, GENETICS, V118, P609; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1010, DOI 10.1021/bi00218a018; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1017, DOI 10.1021/bi00218a019	59	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13141	13147						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175741				2022-12-27	WOS:A1994NK18400017
J	HOFFSCHUTE, HK; DREES, B; MULLER, M				HOFFSCHUTE, HK; DREES, B; MULLER, M			IDENTIFICATION OF A SOLUBLE SECA/SECB COMPLEX BY MEANS OF A SUBFRACTIONATED CELL-FREE EXPORT SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We have reconstituted the cell-free synthesis of the Escherichia coli precursor protein LamB from partially purified subfractions of an E. coli cell extract. PreLamB synthesized in this manner is translocated into salt-extracted plasma membrane vesicles only in the presence of SecA/SecB- or SecB-containing preparations of the E. coli cytosol. The most active preparations obtained upon purification were those containing a soluble SecA/ SecB complex. Complex formation between SecA and SecB was verified by co-sedimentation and co-immunoprecipitation. When preLamB was synthesized in the presence of this material, a considerable amount of precursor was recovered from a soluble ternary complex consisting of preLamB, SecA, and SecB. Our results suggest that a soluble SecA/SecB complex participates in the export of preLamB and that this complex is functionally equivalent to a previously described 12 S (7 S) export factor (Muller, M., and Blobel, G. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 7737-7741; Watanabe, M., and Blobel, G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2728-2732).	UNIV MUNICH, INST PHYS BIOCHEM, D-80336 MUNICH, GERMANY	University of Munich								AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DECOCK H, 1992, MOL MICROBIOL, V6, P599; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; ERNST F, 1994, J BIOL CHEM, V269, P12840; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GELLER BL, 1991, MOL MICROBIOL, V5, P2093, DOI 10.1111/j.1365-2958.1991.tb02138.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1992, MOL MICROBIOL, V6, P2423; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KUMAMOTO CA, 1990, J BIOENERG BIOMEMBR, V22, P337, DOI 10.1007/BF00763171; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7737, DOI 10.1073/pnas.81.24.7737; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; TROSCHEL D, 1990, J CELL BIOL, V111, P87, DOI 10.1083/jcb.111.1.87; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	45	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12833	12839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175697				2022-12-27	WOS:A1994NH71600071
J	DHANASEKARAN, N; PRASAD, MVVSV; WADSWORTH, SJ; DERMOTT, JM; VANROSSUM, G				DHANASEKARAN, N; PRASAD, MVVSV; WADSWORTH, SJ; DERMOTT, JM; VANROSSUM, G			PROTEIN-KINASE C-DEPENDENT AND C-INDEPENDENT ACTIVATION OF NA+/H+ EXCHANGER BY G-ALPHA(12) CLASS OF G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; CYTOPLASMIC PH; CELLS; RECEPTORS; LYMPHOCYTES; SEQUENCE; CYCLASE; CLONING	Constitutively activated mutants of the G alpha(12) class of G proteins, G alpha(12)(Q229L) and G alpha(13)(Q226L), were transiently expressed in COS-1 cells, and the activity of amiloride-sensitive Na+/H+ exchanger was measured. The expression of either G alpha(12)(Q229L) or G alpha(13)(Q226L) increased the basal activity of the amiloride sensitive exchanger by 2-5 fold. Regulation of this activation by other G protein signaling pathways was investigated by the transient expression of constitutively activated G protein mutants of G alpha(s)(Q227L), G alpha(i2)(Q205L), and G alpha(q)(Q209L) in COS-1 cells. Only G alpha(q) showed a similar activation of the exchanger. chronic treatment of the transfected cells with 4 beta-phorbol 12-myristate 13-acetate to deplete the endogenous protein kinase C completely inhibited the activation of the antiporter by G alpha(12)(Q229L), whereas activation by G alpha(13)(Q226L) remained unaffected. These results indicated that both G alpha(12) and G alpha(13) can activate Na+/H+ exchanger by two distinct signaling pathways. G alpha(12) activation of the exchanger was dependent on protein kinase C pathway, whereas G alpha(13) activation was not. These studies define the involvement of G alpha(12) class of G proteins, for which no function has been assigned yet, in the activation of Na+/H+ exchanger.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	DHANASEKARAN, N (corresponding author), TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA.				NCI NIH HHS [NCI 5-P30-CA 12227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPERN R, 1985, PHYSIOL REV, V70, P79; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BORON WF, 1977, AM J PHYSIOL, V233, pC61, DOI 10.1152/ajpcell.1977.233.3.C61; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DHANASEKARAN N, 1991, J CELL BIOCHEM, V47, P352, DOI 10.1002/jcb.240470409; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LIM K, 1989, BIOTECHNIQUES, V7, P576; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LITTLE JR, 1964, ANAL BIOCHEM, V7, P87, DOI 10.1016/0003-2697(64)90122-8; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; RENNER EL, 1989, AM J PHYSIOL, V256, pG44, DOI 10.1152/ajpgi.1989.256.1.G44; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Sambrook J, 1989, MOL CLONING LABORATO; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SIFFERT W, 1990, J BIOL CHEM, V265, P15441; SIFFERT W, 1988, TRENDS BIOCHEM SCI, V13, P148, DOI 10.1016/0968-0004(88)90074-6; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1992, J BIOL CHEM, V267, P9340; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	41	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11802	11806						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163478				2022-12-27	WOS:A1994NG37700022
J	MANDON, E; KEMPNER, ES; ISHIHARA, M; HIRSCHBERG, CB				MANDON, E; KEMPNER, ES; ISHIHARA, M; HIRSCHBERG, CB			A MONOMERIC PROTEIN IN THE GOLGI MEMBRANE CATALYZES BOTH N-DEACETYLATION AND N-SULFATION OF HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; RADIATION-INACTIVATION; RAT-LIVER; TARGET ANALYSIS; MOLECULAR-SIZE; CELL-SURFACE; SULFOTRANSFERASE; PROTEOGLYCANS; RECEPTOR; BINDING	Recent studies have shown that the rat liver heparan sulfate N-deacetylase/N-sulfotransferase is a glycoprotein encoded by a single polypeptide chain of 882 amino acids. Using radiation inactivation analyses, we have now determined that in rat liver Golgi vesicles the target size for the N-deacetylase is 88 +/- 14 kDa, whereas that of the N-sulfotransferase is 92 +/- 8 kDa. These results, together with previous biochemical and molecular cloning approaches, demonstrate that 1) in rat Liver Golgi membranes there exists only one population of molecules expressing both activities, 2) the active protein in the Golgi membrane functions as a monomer, and 3) there is no evidence that a large independent protein acts as a regulator of either activity.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA; NIAMSD, PHYS BIOL LAB, BETHESDA, MD 20892 USA; GLYCOMED INC, ALAMEDA, CA 94501 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)				Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM34396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1991, J BIOL CHEM, V266, P12461; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BOLGER GT, 1989, MOL PHARMACOL, V36, P327; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Burchell B, 1981, Methods Enzymol, V77, P188; CAREY DJ, 1981, J BIOL CHEM, V256, P989; FLEISCHER B, 1993, BIOCHEMISTRY-US, V32, P2076, DOI 10.1021/bi00059a027; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KORNFELD SA, 1992, J BIOL CLIN, V267, P11645; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; MATERN H, 1982, J BIOL CHEM, V257, P7422; MCINTYRE JO, 1985, ANAL BIOCHEM, V147, P468, DOI 10.1016/0003-2697(85)90300-8; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OTT S, 1988, J BIOL CHEM, V263, P10524; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHWARZ JK, 1984, J BIOL CHEM, V259, P354; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; TYRELL DJ, 1993, J BIOL CHEM, V268, P4684; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11729	11733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163470				2022-12-27	WOS:A1994NG37700012
J	QUADRI, LEN; SAILER, M; ROY, KL; VEDERAS, JC; STILES, ME				QUADRI, LEN; SAILER, M; ROY, KL; VEDERAS, JC; STILES, ME			CHEMICAL AND GENETIC-CHARACTERIZATION OF BACTERIOCINS PRODUCED BY CARNOBACTERIUM-PISCICOLA LV17B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEDIOCOCCUS-ACIDILACTICI; ESCHERICHIA-COLI; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; EXPRESSION; CLONING; SEQUENCES; DNA; LACTOBACILLUS; PURIFICATION	Carnobacteriocins BM1 and B2 are thermostable class II bacteriocins produced by Carnobacterium piscicola LV17B. These bacteriocins were purified by a three-step procedure that included hydrophobic interaction, size exclusion, and reversed-phase high performance liquid chromatography. The purified peptides and fragments derived by enzymatic digestion were analyzed by Edman degradation, amino acid analysis, and mass spectrometry. An oxidized form of carnobacteriocin BM1 (carnobacteriocin B1) was also purified and characterized. Probes synthesized using information from the N-terminal amino acid sequences for the purified bacteriocins were used to locate structural genes for the carnobacteriocins. A 1.9-kilobase (kb) HindIII fragment from a 61-kb plasmid (pCP40) containing the carnobacteriocin B2 structural gene and a 4.0-kb EcoRI-PstI genomic fragment containing the carnobacteriocin BM1 structural gene were cloned and fully or partially sequenced, respectively. Expression of the chromosomal bacteriocin and its immunity function requires the presence of the 61-kb plasmid. The results indicate that both bacteriocins are synthesized as prebacteriocins. Post-translational cleavage of an 18-amino acid N-terminal extension at a Gly-Gly (positions -2 and -1) site takes place in each prepeptide to yield the mature 43-amino acid carnobacteriocin BM1 (molecular mass 4524.6) and the mature 48-amino acid carnobacteriocin B2 (molecular mass 4969.9). These two peptides showed significant amino acid homology to each other and with those class II bacteriocins which contain the YGNGV amino acid motif near the N terminus.	UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2P5, AB, CANADA; UNIV ALBERTA, DEPT FOOD SCI & NUTR, EDMONTON T6G 2P5, AB, CANADA; UNIV ALBERTA, DEPT MICROBIOL, EDMONTON T6G 2P5, AB, CANADA	University of Alberta; University of Alberta; University of Alberta				Vederas, John/0000-0002-2996-0326				AHN C, 1992, J APPL BACTERIOL, V73, P217, DOI 10.1111/j.1365-2672.1992.tb02981.x; AHN C, 1990, APPL ENVIRON MICROB, V56, P2503, DOI 10.1128/AEM.56.8.2503-2510.1990; DELVESBROUGHTON J, 1990, FOOD TECHNOL-CHICAGO, V44, P100; DOI RH, 1986, MICROBIOL REV, V50, P227, DOI 10.1128/MMBR.50.3.227-243.1986; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HECHARD Y, 1992, J GEN MICROBIOL, V138, P2725, DOI 10.1099/00221287-138-12-2725; HENDERSON JT, 1992, ARCH BIOCHEM BIOPHYS, V295, P5, DOI 10.1016/0003-9861(92)90480-K; HOLCK A, 1992, J GEN MICROBIOL, V138, P2715, DOI 10.1099/00221287-138-12-2715; Jung G, 1991, NISIN NOVEL LANTIBIO; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KOIVULA T, 1991, APPL ENVIRON MICROB, V57, P333, DOI 10.1128/AEM.57.2.333-340.1991; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOZANO JCN, 1992, J GEN MICROBIOL, V138, P1985, DOI 10.1099/00221287-138-9-1985; MARUGG JD, 1992, APPL ENVIRON MICROB, V58, P2360, DOI 10.1128/AEM.58.8.2360-2367.1992; MCMULLEN LM, 1993, INT J FOOD MICROBIOL, V18, P1, DOI 10.1016/0168-1605(93)90002-X; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MURIANA PM, 1991, J BACTERIOL, V173, P1779, DOI 10.1128/jb.173.5.1779-1788.1991; SAILER M, 1993, BIOCHEMISTRY-US, V32, P310, DOI 10.1021/bi00052a039; Sambrook J, 1989, MOL CLONING LABORATO; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; TICHACZEK PS, 1992, SYST APPL MICROBIOL, V15, P460, DOI 10.1016/S0723-2020(11)80223-7; VANBELKUM MJ, 1992, APPL ENVIRON MICROB, V58, P572, DOI 10.1128/AEM.58.2.572-577.1992; VANBELKUM MJ, 1991, APPL ENVIRON MICROB, V57, P492, DOI 10.1128/AEM.57.2.492-498.1991; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VANDERVOSSEN JMBM, 1987, APPL ENVIRON MICROB, V53, P2452, DOI 10.1128/AEM.53.10.2452-2457.1987; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WOROBO RW, 1994, IN PRESS MICROBIOLOG, V140	35	198	205	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12204	12211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163526				2022-12-27	WOS:A1994NG37700081
J	KAZANIETZ, MG; BUSTELO, XR; BARBACID, M; KOLCH, W; MISCHAK, H; WONG, G; PETTIT, GR; BRUNS, JD; BLUMBERG, PM				KAZANIETZ, MG; BUSTELO, XR; BARBACID, M; KOLCH, W; MISCHAK, H; WONG, G; PETTIT, GR; BRUNS, JD; BLUMBERG, PM			ZINC-FINGER DOMAINS AND PHORBOL ESTER PHARMACOPHORE - ANALYSIS OF BINDING TO MUTATED FORM OF PROTEIN KINASE-C-TAU AND THE VAV AND C-RAF PROTOONCOGENE PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY DOMAIN; MOUSE-BRAIN; ACTIVATION; DIACYLGLYCEROL; RECEPTOR; GENE; ZETA; PHOSPHORYLATION; PHOSPHOLIPIDS; INHIBITORS	The phorbol ester binding domain consists of a cysteine-rich region with a postulated consensus sequence for binding that includes 15 amino acids (Ahmed, S., Kozma, R., Lee, J., Monfries, C., Harden, N., and Lim, L. (1991) Biochem. J. 280,233-241). In PKC zeta, the only PKC isoform lacking phorbol ester binding, this region differs in a single residue from the consensus (proline in position 11 of the motif). Restoration of this proline by site-directed mutagenesis of PKC zeta does not restore binding of either [H-3]phorbol 12,13-dibutyrate or of the ultrapotent ligand [H-3]bryostatin 1, suggesting that even a low affinity ligand interaction is absent. In addition, the vav and c-raf proto-oncogene products, proteins that possess cysteine-rich regions with high homology to PKC isozymes and other phorbol ester receptors, are unable to bind any of these ligands. Instead, all of these cysteine-rich regions bind zinc. Our results suggest that other amino acids besides those postulated for the consensus must be necessary for ligand binding and argue against direct modulation of PKC zeta, Vav, and c-Raf by phorbol esters.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; GSF MUNICH,INST CLIN MOLEC BIOL & TUMOR GENET,HAEMATOLOGIKUM,W-8000 MUNICH 70,GERMANY; NIDDKD,NEUROSCI LAB,BETHESDA,MD 20892; ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Bristol-Myers Squibb; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Arizona State University; Arizona State University-Tempe			Kolch, Walter/ABF-2102-2021; Mischak, Harald/E-8685-2011; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ASHENDEL CL, 1983, CANCER RES, V43, P4333; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEWIN NE, 1991, CANCER COMMUN, V3, P67, DOI 10.3727/095535491820873506; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARKEY NA, 1985, CANCER RES, V45, P19; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SOZERI O, 1992, ONCOGENE, V7, P2259; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197	33	115	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11590	11594						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157692				2022-12-27	WOS:A1994NF96600091
J	HUANG, CH; REID, ME; BLUMENFELD, OO				HUANG, CH; REID, ME; BLUMENFELD, OO			REMODELING OF THE TRANSMEMBRANE SEGMENT IN HUMAN GLYCOPHORIN BY ABERRANT RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANES; AMINO-ACID SEQUENCE; BLOOD-GROUP; MOLECULAR ANALYSIS; GENE CONVERSION; HEREDITARY ELLIPTOCYTOSIS; NUCLEOTIDE-SEQUENCE; BETA-THALASSEMIA; SITE SELECTION; CELL MEMBRANE	This paper describes the identification in S-s-U-erythrocytes of a novel glycophorin (GP), He(P-2), with structural variations in both its extracellular and transmembrane domains, In the exon II-intron 2 region, a sequence transfer from GPA to GPB, probably via the mechanism of gene conversion, was associated with the induction of multiple untemplated nucleotide replacements. These changes defined the sequence for the He epitope while concomitantly abolishing GPB-associated N antigenicity. Moreover, the GPHe(P-2) gene carries two splice site mutations that coordinately affect the processing of exon V coding for the transmembrane segment. The C --> G transversion at the 3' end of exon V created a cryptic acceptor splice site, whereas the G --> T transversion at the +5 position of intron 5 altered the consensus of the donor splice site. Transcript sequencing revealed that neither site was utilized in the splicing of GPHe(P-2) pre-mRNA Rather, complete skipping of exon V and subsequent joining of exon IV to exon VI caused a shift in the open reading frame, which remodeled GPHe(P-2) with an elongated new hydrophobic sequence for membrane anchoring. As a result, GPHe(P-2) does not display the S and U epitopes although it still contains an intact linear sequence for the two antigens. These findings illustrate how exon and intron sequences concertedly determine the specificity of in vivo splice site selection. In addition, they pinpoint the conformational dependence of the S, s, and U antigens and the importance of the hinge region for their presentation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	HUANG, CH (corresponding author), NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016389] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 16389] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATWEH GF, 1987, BLOOD, V70, P147; BLANCHARD D, 1987, J BIOL CHEM, V262, P5808; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; DAHR W, 1980, H-S Z PHYSIOL CHEM, V361, P895, DOI 10.1515/bchm2.1980.361.1.895; DAHR W, 1984, EUR J BIOCHEM, V141, P51, DOI 10.1111/j.1432-1033.1984.tb08155.x; DAHR W, 1986, RECENT ADV BLOOD GRO, V19, P23; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURTHMAYR H, 1981, P NATL ACAD SCI-BIOL, V78, P631, DOI 10.1073/pnas.78.1.631; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; Goossens M, 1981, Methods Enzymol, V76, P805; GOTODA T, 1991, J BIOL CHEM, V266, P24757; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; HUANG CH, 1988, P NATL ACAD SCI USA, V85, P9640, DOI 10.1073/pnas.85.24.9640; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1991, BLOOD, V77, P381; HUANG CH, 1992, BLOOD, V80, P2379; HUANG CH, 1992, J BIOL CHEM, V267, P3336; HUANG CH, 1992, BLOOD, V80, P257; HUANG CH, 1991, BLOOD, V77, P1813; HUANG CH, 1991, J BIOL CHEM, V266, P7248; HUANG CH, 1991, J BIOL CHEM, V266, P23306; HUANG CH, 1993, J BIOL CHEM, V268, P4945; HUANG CH, 1993, J BIOL CHEM, V268, P25902; HUANG CH, 1992, BLOOD S, V80, pA274; HUANG CH, 1986, CHIN BIOCH J, V2, P9; JOHE KK, 1989, J BIOL CHEM, V264, P17486; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; KUIVANIEMI H, 1990, J BIOL CHEM, V265, P12067; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LOWE RF, 1972, HUM HERED, V22, P344, DOI 10.1159/000152509; LU YQ, 1987, BLOOD, V69, P618; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; Maniatis T., 1982, MOL CLONING; MARCHESI VT, 1979, SEMIN HEMATOL, V16, P3; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P119; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RACE RR, 1975, BLOOD GROUPS MAN, P92; RAHUEL C, 1991, AM J HEMATOL, V37, P57, DOI 10.1002/ajh.2830370115; REARDEN A, 1990, J BIOL CHEM, V265, P9259; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TATE CG, 1989, BIOCHEM J, V263, P993, DOI 10.1042/bj2630993; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; WEIL D, 1988, J BIOL CHEM, V263, P8561; YOON SH, 1991, J BIOL CHEM, V266, P8490	71	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10804	10812						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144668				2022-12-27	WOS:A1994NF01700092
J	AIYAR, SE; HELMANN, JD; DEHASETH, PL				AIYAR, SE; HELMANN, JD; DEHASETH, PL			A MISMATCH BUBBLE IN DOUBLE-STRANDED DNA SUFFICES TO DIRECT PRECISE TRANSCRIPTION INITIATION BY ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-70 SUBUNIT; PROMOTER DNA; T7 DNA; HOLOENZYME; MECHANISM; BINDING; COMPLEXES; SPECIFICITY; RECOGNITION; TERMINATION	Formation of a transcription-competent ''open'' complex: between Escherichia coli RNA polymerase and a promoter, where base pairing is disrupted over a region of 12 base pairs including the start site of transcription, is a complex process involving at least three steps: recognition of specific DNA sequences, a conformational change in RNA polymerase, and DNA melting. By using synthetic constructs devoid of promoter-specific sequences, we show here that a mismatch bubble of 12 base pairs suffices to direct transcription initiation in divergent directions from its edges, reflecting the absence of polarity determinants for RNA polymerase binding. Bubble transcription is obtained with both core polymerase and holoenzyme, but efficient formation of heparin-resistant initiation complexes requires the a (specificity) factor. Based on these results it is likely that the a factor blocks access of the heparin to a site on the holoenzyme.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; CORNELL UNIV, MICROBIOL SECT, ITHACA, NY 14853 USA	Case Western Reserve University; Cornell University				Helmann, John/0000-0002-3832-3249	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808, R01GM047446] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703] Funding Source: Medline; NIGMS NIH HHS [GM 47446, GM 31808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAMBERLIN MJ, 1976, COLD SPRING HARBOR M; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRAY CP, 1978, P NATL ACAD SCI USA, V75, P50, DOI 10.1073/pnas.75.1.50; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERSHBERGER PA, 1991, J MOL BIOL, V222, P479, DOI 10.1016/0022-2836(91)90491-N; HINKLE DC, 1972, J MOL BIOL, V70, P197, DOI 10.1016/0022-2836(72)90533-5; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; LEIRMO S, 1990, NUCLEIC ACIDS MOL BI, V4, P123; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MELANCON P, 1983, BIOCHEMISTRY-US, V22, P5169, DOI 10.1021/bi00291a017; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TRIPATARA A, 1993, J MOL BIOL, V233, P349, DOI 10.1006/jmbi.1993.1516; VOGT V, 1969, NATURE, V223, P854, DOI 10.1038/223854a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; WARNE SE, 1993, BIOCHEMISTRY-US, V32, P6134, DOI 10.1021/bi00075a003	35	32	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13179	13184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175746				2022-12-27	WOS:A1994NK18400023
J	NGUYEN, T; RUSHMORE, TH; PICKETT, CB				NGUYEN, T; RUSHMORE, TH; PICKETT, CB			TRANSCRIPTIONAL REGULATION OF A RAT-LIVER GLUTATHIONE-S-TRANSFERASE YA SUBUNIT GENE - ANALYSIS OF THE ANTIOXIDANT RESPONSE ELEMENT AND ITS ACTIVATION BY THE PHORBOL ESTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING INDUCIBLE EXPRESSION; PLANAR AROMATIC-COMPOUNDS; AH RECEPTOR COMPLEX; PHENOLIC ANTIOXIDANTS; OXIDATIVE STRESS; BASAL LEVEL; JUN GENE; IDENTIFICATION; PROTEIN; DIOXIN	Using transfection and gel retardation assays, we have characterized further the antioxidant response element (ARE) found in the 5'-flanking region of the rat glutathione S-transferase Ya subunit gene. The ARE core sequence (5-GTGACAAAGC-3') is sufficient for transcriptional activation of the Ya subunit gene by metabolizable planar aromatic compounds, phenolic antioxidants, and hydrogen peroxide. When the ARE sequence is ligated to a chloramphenicol acetyltransferase reporter gene and transfected into HepG2 cells, chloramphenicol acetyltransferase activity is modestly inducible by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). Since the ARE is responsive to TPA and shows some sequence similarity to an AP-1-binding site (Jun/Fos recognition motif), we have explored whether members of the Jun/Fos family of transcription factors might bind to the ARE. Using in vitro synthesized Jun and Fos, binding to the ARE could not be detected, whereas Jun/Fos binding to a classical AP-1-binding site, a TPA response element (TRE) from the human collagenase gene, could be demonstrated by gel retardation assays. If the 2 A nucleotides underlined in the ARE core sequence (5'-GTGACAAAGC-3') are changed to TC, the ARE sequence (ARE-TRE) becomes a high-affinity AP-1-binding site and retains xenobiotic inducibility. Removal of the -GC- dinucleotide at the 3'-end of the ARE or the ARE-TRE eliminates xenobiotic inducibility. However, the ARE-TRE construct without the -GC- dinucleotide is still a high-affinity AP-1 site and responsive to TPA. Taken together, our data suggest that the ARE is not a high-affinity binding site for the Jun/Fos heterodimer. Functionally, however, an AP-1-binding site can resemble an ARE in its response to various xenobiotics if a 3'-GC- dinucleotide is present.	MERCK FROSST CANADA INC, MERCK FROSST CTR THERAPEUT RES, DEPT MOLEC BIOL, POINTE CLAIRE H9R 4P8, PQ, CANADA	Merck & Company								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DANIEL V, 1988, NUCLEIC ACIDS RES, V16, P351, DOI 10.1093/nar/16.1.351; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; LI Y, 1992, J BIOL CHEM, V267, P15097; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; NEUBOLD LA, 1989, MOL CELL BIOL, V9, P2378; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1991, METHOD ENZYMOL, V206, P409; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147	39	144	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13656	13662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175801				2022-12-27	WOS:A1994NK18400087
J	PALLEROS, DR; SHI, L; REID, KL; FINK, AL				PALLEROS, DR; SHI, L; REID, KL; FINK, AL			HSP70-PROTEIN COMPLEXES - COMPLEX STABILITY AND CONFORMATION OF BOUND SUBSTRATE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; HEAT-SHOCK PROTEIN; STAPHYLOCOCCAL NUCLEASE; UNFOLDED PROTEINS; PEPTIDE-BINDING; ATPASE ACTIVITY; DNAK; CHAPERONE; CELLS; MUTANT	The presence of bound substrate protein increases the thermostability of hsp70 molecular chaperones (heat shock proteins of molecular mass 70 kDa). Complexes between hsp70 and unfolded substrate proteins were isolated by size-exclusion high performance liquid chromatography. The isolated complexes were observed to dissociate at a significant rate even in the absence of ATP. The presence of ADP caused a substantial increase in the stability of the complex. Both ADP and inorganic phosphate were found to inhibit the ATP-induced dissociation of complex. ADP was also observed to increase both the rate of complex formation and its stability as a function of temperature, suggesting an important regu latory role for nucleotides during heat shock. Circular dichroism and fluorescence studies of the complex between DnaK and a thermally unstable mutant of staphylococcal nuclease indicate that the bound substrate protein is significantly unfolded. A model for the hsp70 cycle of complex formation and dissociation, which accounts for the regulatory role of nucleotides, is proposed.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz					NIGMS NIH HHS [GM45316] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P8945, DOI 10.1021/bi00101a005; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; IKEGUCHI M, 1989, INT J PEPT PROT RES, V33, P289; JANIN J, 1990, J BIOL CHEM, V265, P16027; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LITTLEWOOD TD, 1987, J CELL SCI, V88, P65; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PARK K, 1993, PROTEIN SCI, V2, P325; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID SL, 1985, J BIOL CHEM, V260, P57; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	49	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13107	13114						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175736				2022-12-27	WOS:A1994NK18400012
J	WOLFE, CL; LOU, YC; HOPPER, AK; MARTIN, NC				WOLFE, CL; LOU, YC; HOPPER, AK; MARTIN, NC			INTERPLAY OF HETEROGENEOUS TRANSCRIPTIONAL START SITES AND TRANSLATIONAL SELECTION OF AUGS DICTATE THE PRODUCTION OF MITOCHONDRIAL AND CYTOSOLIC NUCLEAR TRANSFER-RNA NUCLEOTIDYLTRANSFERASE FROM THE SAME GENE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; CYTOPLASMIC TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY-STRUCTURE; INITIATOR REGION; SEQUENCE; PROTEINS; ENCODES; EXTENSION	ATP (CTP):tRNA nucleotidyltransferase catalyzes the addition of the CCA end to tRNAs. In yeast, nucleotidyltransferase is encoded by the CCA1 gene and is localized to three cellular compartments: mitochondria, nucleus, and cytosol. There are three in-frame ATGs near the 5' end of the CCA1 open reading frame. Primer extension experiments show multiple transcription initiation sites upstream of ATG1 and between ATG1 and ATG2. Fractionation of cells carrying a CCA1-COXIV fusion gene demonstrates that all three in frame AUGs are used as sites of initiation of translation. Therefore, both transcription of CCA1 mRNA with heterogeneous 5' ends and translation from downstream AUGs in CCA1 mRNAs play a role in the synthesis of three nucleotidyltransferase isozymes. Protein initiating from AUG1 is required for mitochondrial protein synthesis and, like many other proteins targeted to mitochondria, it is processed at the amino terminus upon import into the organelle. The shorter proteins arising from AUG2 and AUG3 provide nuclear/cytosol activity.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292; PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT BIOL CHEM,HERSHEY,PA 17033	University of Louisville; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIGMS NIH HHS [GM42454] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042454] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; BACH ML, 1979, P NATL ACAD SCI USA, V76, P386, DOI 10.1073/pnas.76.1.386; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHEN JY, 1990, J BIOL CHEM, V265, P16221; CHIU MI, 1992, GENETICS, V132, P987; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIGAN AM, 1987, GENE, V59, P1; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P450; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; ELLIS SR, 1987, P NATL ACAD SCI USA, V84, P5172, DOI 10.1073/pnas.84.15.5172; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; ELLIS SR, 1989, MOL CELL BIOL, V9, P1611, DOI 10.1128/MCB.9.4.1611; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOPPER AK, 1992, MOL CELLULAR BIOL YE, V2, P110; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; LI JM, 1989, J CELL BIOL, V109, P1411, DOI 10.1083/jcb.109.4.1411; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MORALES MJ, 1992, P NATL ACAD SCI USA, V89, P9875, DOI 10.1073/pnas.89.20.9875; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; ODA T, 1990, J BIOL CHEM, V265, P7513; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; ROSSET R, 1965, BIOCHIM BIOPHYS ACTA, V108, P376, DOI 10.1016/0005-2787(65)90030-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF RB, 1981, PRACTICAL METHODS ME, P81; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1974, METHODS YEAST GENETI, P62; SHERMAN F, 1982, MOL BIOL YEAST SACCH, P301; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SOLARI A, 1982, NUCLEIC ACIDS RES, V10, P4397, DOI 10.1093/nar/10.14.4397; TRIEZENBERG SJ, 1993, CURRENT PROTOCOLS MO, V2; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WESOLOWSKI M, 1979, MOL GEN GENET, V170, P261, DOI 10.1007/BF00267059; WU M, 1987, J BIOL CHEM, V262, P12275	53	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13361	13366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175766				2022-12-27	WOS:A1994NK18400048
J	DECOTTIGNIES, A; KOLACZKOWSKI, M; BALZI, E; GOFFEAU, A				DECOTTIGNIES, A; KOLACZKOWSKI, M; BALZI, E; GOFFEAU, A			SOLUBILIZATION AND CHARACTERIZATION OF THE OVEREXPRESSED PDR5 MULTIDRUG-RESISTANCE NUCLEOTIDE TRIPHOSPHATASE OF YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								A 160-kDa plasma membrane protein of the yeast Saccharomyces cerevisiae was overexpressed by mutating the PDR1 or the PDR3 transcription factor gene. The protein is the membrane-bound ATP binding cassette transporter PDR5 (Balzi, E., Wang, M., Leterme, S., Van Dyck, L., and Goffeau, A. (1994) J. Biol. Chem. 269, 2206-2214). PDR5 was solubilized with n-dodecyl-beta-D-maltoside and separated from the PMA1 plasma membrane H+-ATPase by glycerol gradient centrifugation. The PDR5 protein hydrolyzes nucleoside diphosphates and triphosphates. This activity is sensitive to low concentrations of vanadate, of oligomycin, and of a variety of hydrophobic compounds. Many of these properties liken PDR5 to the purified mammalian P-glycoprotein responsible for multidrug resistance.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain								ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1986, METHOD ENZYMOL, V125, P558; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORSTPAUWELS GWFH, 1977, BIOCHIM BIOPHYS ACTA, V466, P488, DOI 10.1016/0005-2736(77)90341-8; COLSON AM, 1974, MOL GEN GENET, V135, P309, DOI 10.1007/BF00271146; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DEXTER D, 1994, GENETICS, V136, P505; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DUFOUR JP, 1980, EUR J BIOCHEM, V105, P145, DOI 10.1111/j.1432-1033.1980.tb04484.x; DUFOUR JP, 1980, J BIOL CHEM, V255, P5735; DULLEY JR, 1975, ANAL BIOCHEM, V67, P91, DOI 10.1016/0003-2697(75)90275-4; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUERINEAU M, 1974, BIOCHEM BIOPH RES CO, V61, P462, DOI 10.1016/0006-291X(74)90979-6; HAMADA H, 1988, CANCER RES, V48, P4926; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPERT G, 1990, GENETICS, V125, P13; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1980, J BIOL CHEM, V255, P9852; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; VAI M, 1991, J BIOL CHEM, V266, P12242; VANBREUSEGHEM NP, 1962, BIOCHEM PHARMACOL, V11, P813; Vanden Bossche H, 1985, Curr Top Med Mycol, V1, P313; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WILLSKY GR, 1979, J BIOL CHEM, V254, P3326; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061	55	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12797	12803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175692				2022-12-27	WOS:A1994NH71600066
J	HANNON, GE; HANNON, GJ; MARONEY, PA; NILSEN, TW				HANNON, GE; HANNON, GJ; MARONEY, PA; NILSEN, TW			TRANSCRIPTION OF A NEMATODE U1 SMALL NUCLEAR-RNA IN-VITRO - 3'-END FORMATION REQUIRES CIS-ACTING ELEMENTS WITHIN THE CODING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							3' END-FORMATION; SPLICED LEADER RNA; INITIATION; EXPRESSION; PROMOTER	We have used block-substitution mutagenesis and in vitro transcription assays to identify cis-acting DNA sequence elements important for initiation and 3'-end formation of a U1 small nuclear RNA (snRNA) in the parasitic nematode Ascaris lumbricoides. Efficient initiation of synthesis by RNA polymerase II requires a compact element centered similar to 50 base pairs upstream of the transcriptional start site. Surprisingly, 3'-end formation of U1 snRNAs synthesized in vitro is solely dependent upon elements within the U1 coding sequence. In all other systems studied thus far, 3'-end formation of U snRNAs requires signals present in the 3'-flanking region. We also show that sequence elements that direct 3'-end formation of the A. lumbricoides trans-spliced leader RNA function when RNA synthesis is initiated from the U1 promoter. These results indicate that 3'-end formation of U snRNAs in nematodes is mechanistically distinct from the analogous process in higher eukaryotes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Hannon, Gregory/AAB-3568-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28799] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; CILIBERTO G, 1986, EMBO J, V11, P2931; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DEVEGVAR HEN, 1986, CELL, V47, P259; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PARRY HD, 1989, NUCLEIC ACIDS RES, V17, P3633, DOI 10.1093/nar/17.10.3633; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; SHAMBAUGH JD, IN PRESS MOL BIOCH P; SOUTHGATE C, 1989, EMBO J, V8, P539, DOI 10.1002/j.1460-2075.1989.tb03408.x; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WENDELBURG BJ, 1992, MOL CELL BIOL, V12, P4132, DOI 10.1128/MCB.12.9.4132	20	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12387	12390						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175641				2022-12-27	WOS:A1994NH71600002
J	HORREVOETS, AJG; SMILDE, A; DEVRIES, C; PANNEKOEK, H				HORREVOETS, AJG; SMILDE, A; DEVRIES, C; PANNEKOEK, H			THE SPECIFIC ROLES OF FINGER AND KRINGLE-2 DOMAINS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR DURING IN-VITRO FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROMETHYL KETONE; ONE-CHAIN; BINDING; FRAGMENTS; PURIFICATION; DEGRADATION; EXPRESSION; DELETION; CLONING; LYSINE	The specific roles of the finger (F) and kringle 2 (K2) domains of tissue-type plasminogen activator (t-PA) were quantified with regard to fibrin binding and kinetic parameters for plasminogen activation by employing domain-deletion variants. On an intact fibrin clot, active site-blocked I-125-t-pA has a dissociation constant (K-d) of 0.36 +/- 0.08 mu M and a single binding site per fibrin monomer (n = 1.1 +/- 0.1). Deletion of the K2 domain results in a 3-fold increase of the K-d (1.1 +/- 0.2 mu M) and a 2-fold increase of the binding sites per fibrin monomer (n = 2.0 +/- 0.3). Deletion of the F domain results in nonsaturable binding with high K-d (3.2 +/- 0.6 mu M). These results indicate that the high affinity binding of t-PA to intact fibrin is the resultant of the cooperation of two low affinity binding sites assembled on intact t-PA. Furthermore, fibrin clot lysis experiments were performed, using polymerized fibrin and plasminogen. Enzymatic activity of t-PA (variants) was assessed by following the decrease in turbidity of the polymerized fibrin. Intact recombinant t-PA exhibited a Michaelis constant for plasminogen activation (K-m) of 37 +/- 2 nM. Deletion of either the K2 or F domain results in an increase of the K-m for plasminogen of 4- and 16-fold, respectively. We interpret these kinetic parameters in terms of the ternary complex model: binding of t-PA to fibrin, mediated simultaneously by both the F and K2 domain, is essential for a correct orientation of the enzyme on the fibrin polymer to yield the optimal. ''K-m-driven'' stimulation of fibrin on the activation of plasminogen. The different potencies of various deletion mutants in a plasma clot are explained by decreased affinity of the enzymes both for fibrin and for the substrate plasminogen.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM K1159,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam								BECKMANN R, 1988, J BIOL CHEM, V263, P7176; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BURCK PJ, 1990, J BIOL CHEM, V265, P5170; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; DEVRIES C, 1991, THROMB HAEMOSTASIS, V65, P280; EHRLICH HJ, 1990, J BIOL CHEM, V265, P1021; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KEYT BA, 1992, ANAL BIOCHEM, V206, P73, DOI 10.1016/S0003-2697(05)80013-2; KRAUSE J, 1989, FIBRINOLYSIS, V3, P85, DOI 10.1016/0268-9499(89)90036-2; LAU HK, 1979, J BIOL CHEM, V254, P8751; LEWIS ML, 1991, THROMB RES, V64, P223, DOI 10.1016/0049-3848(91)90121-C; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191	36	51	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12639	12644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175674				2022-12-27	WOS:A1994NH71600044
J	SHIMBA, S; REDDY, R				SHIMBA, S; REDDY, R			PURIFICATION OF HUMAN U6 SMALL NUCLEAR-RNA CAPPING ENZYME - EVIDENCE FOR A COMMON CAPPING ENZYME FOR GAMMA-MONOMETHYL-CAPPED SMALL RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNA; POLYMERASE-III; SEQUENCE; RIBONUCLEOPROTEIN; IDENTIFICATION; TRANSCRIPTION; CELLS; N6-METHYLADENOSINE; ANTIBODIES; PHOSPHATE	To understand the mechanism of gamma-monomethyl (meppp) cap formation, we attempted to identify and purify the U6 small nuclear RNA capping enzyme. Although more than one protein was cross-linked to U6, 7SK, B2, or plant U3 RNA, only one protein of approximately 130 kDa was common to all four meppp-capped RNAs; 5 S RNA, which is an uncapped RNA, was not cross-linked to this protein. In addition to specific cross-linking with meppp-capped RNAs, an similar to 130-kDa protein was also cross-linked to H-3-labeled AdoMet. We purified the capping enzyme from a HeLa cell S-100 extract by several successive chromatographic steps, and an similar to 130-kDa protein was purified along with the capping activity. The capping activity and the similar to 130-kDa protein also cosedimented on a glycerol gradient. The purified enzyme catalyzed meppp cap formation of U6, 7SK, B2, and plant U3 RNA, and this enzyme is probably responsible for the capping of multiple RNAs in vivo. The capping activity is distinct from U6 snRNA N-6-adenosine methyltransferase, and this is the first methyltransferase to be purified that methylates gamma-phosphate residues in RNAs.			SHIMBA, S (corresponding author), BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [GM 38320] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038320] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANAANI D, 1979, NUCLEIC ACIDS RES, V6, P2879, DOI 10.1093/nar/6.8.2879; DIMOCK K, 1977, BIOCHEMISTRY-US, V16, P471, DOI 10.1021/bi00622a021; ELICEIRI GL, 1980, J CELL PHYSIOL, V102, P199, DOI 10.1002/jcp.1041020211; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GRONING K, 1991, MOL CELL BIOL, V11, P2026; GUPTA S, 1990, J BIOL CHEM, V265, P9491; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; KLEINSCHMIDT AM, 1990, P NATL ACAD SCI USA, V87, P1283, DOI 10.1073/pnas.87.4.1283; LIU MH, 1992, NUCLEIC ACIDS RES, V20, P4299, DOI 10.1093/nar/20.16.4299; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; NICHOLS JL, 1981, PLANT SCI LETT, V21, P75, DOI 10.1016/0304-4211(81)90071-7; REDDY R, 1974, J BIOL CHEM, V249, P6486; REDDY R, 1992, PHARMACOL THERAPEUT, V54, P249, DOI 10.1016/0163-7258(92)90002-H; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SHIMBA S, 1992, J BIOL CHEM, V267, P13772; SHUMYATSKY G, 1993, NUCLEIC ACIDS RES, V21, P4756, DOI 10.1093/nar/21.20.4756; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V18, P6347, DOI 10.1093/nar/18.21.6347; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SKUZESKI JM, 1984, J BIOL CHEM, V259, P8345; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; WEIL PA, 1979, J BIOL CHEM, V254, P6163	26	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12419	12423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175647				2022-12-27	WOS:A1994NH71600010
J	UNSON, CG; WU, CR; FITZPATRICK, KJ; MERRIFIELD, RB				UNSON, CG; WU, CR; FITZPATRICK, KJ; MERRIFIELD, RB			MULTIPLE-SITE REPLACEMENT ANALOGS OF GLUCAGON - A MOLECULAR-BASIS FOR ANTAGONIST DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; CONFORMATIONAL CONSIDERATIONS; RECEPTOR-BINDING	Extensive structure activity analysis has allowed us to identify specific residues in the glucagon sequence that are responsible for either receptor recognition or signal transduction. For instance, we have demonstrated that aspartic acid 9 and histidine 1 are essential for activation, and that an ionic interaction between the negative carboxylate and the protonated imidazole may contribute to the activation reaction at the molecular level. In the absence of the carboxylic group at position 9, aspartic 21 or aspartic 15 might furnish distal electrostatic effects to maintain partial agonism. Further investigation established that each of the 4 serine residues in the hormone play distinct roles. Serine 8 provides an important determinant of binding. Whereas neither serines 2, 11, nor 16 are required for receptor recognition. We have shown that serine 16 is essential for signal transduction and thus have identified it to be the third residue in glucagon to participate in a putative catalytic triad to gether with aspartic 9 and histidine 1, in the transduction of the glucagon response. In this work, we utilized insights into the functional significance of particular residues in the peptide appropriated from our structure-function assignments, as the basis of a molecular approach for the design of active-site directed antagonists of glucagon. The importance as well as the accuracy of our findings are confirmed by the synthesis of a series of improved glucagon antagonists based on replacements at positions 1, 9, 11, 16, and 21. The inhibition index, (I/A)(50) of our best antagonist des-His(1)[Nle(9)-Ala(11)-Ala(16)]glucagon amide, has been improved 10 fold over the previous best glucagon inhibitor.			UNSON, CG (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 24039] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREU D, 1987, EUR J BIOCHEM, V64, P585; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Barany G, 1979, PEPTIDES           A, V2, P1; HRUBY VJ, 1986, BIOPOLYMERS, V25, pS135; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KRSTENANSKY JL, 1986, J AM CHEM SOC, V108, P1696, DOI 10.1021/ja00267a053; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MERRIFIELD RB, 1987, PEPTIDES 1986, P517; MERRIFIELD RB, 1993, 1992 PEPT P CHIN PEP, P251; POHL SL, 1976, METHODS RECEPTOR R 1, P160; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; UNGER RH, 1976, DIABETES, V25, P136, DOI 10.2337/diab.25.2.136; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; UNSON CG, 1989, J BIOL CHEM, V264, P789; UNSON CG, 1990, PEPTIDES CHEM STRUCT, P203; UNSON CG, 1994, IN PRESS 13TH P AM P; UNSON CG, 1991, 21ST PEPT 1990 P EUR, P729; WRIGHT DE, 1979, J BIOL CHEM, V254, P268	21	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12548	12551						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175663				2022-12-27	WOS:A1994NH71600030
J	YAMASAKI, S; BAUMEISTER, A; BLASI, J; LINK, E; CORNILLE, F; ROQUES, B; FYKSE, EM; SUDHOF, TC; JAHN, R; NIEMANN, H; BINZ, T				YAMASAKI, S; BAUMEISTER, A; BLASI, J; LINK, E; CORNILLE, F; ROQUES, B; FYKSE, EM; SUDHOF, TC; JAHN, R; NIEMANN, H; BINZ, T			CLEAVAGE OF MEMBERS OF THE SYNAPTOBREVIN/VAMP FAMILY BY TYPE-D AND TYPE-F BOTULINAL NEUROTOXINS AND TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; SECRETORY PATHWAY; RAT-BRAIN; EXOCYTOSIS; BINDING; SYNAPTOTAGMIN; GLYCOPROTEIN; SYNAPTOSOMES; PURIFICATION	Tetanus toxin (TeTx) and the various forms of botulinal neurotoxins (BoNT/A to BoNT/G) potently inhibit neurotransmission by means of their L chains which selectively proteolyze synaptic proteins such as synaptobrevin (TeTx, BoNT/B, BoNT/F), SNAP-25 (BoNT/A), and syntaxin (BoNT/C1). Here we show that BoNT/D cleaves rat synaptobrevin 1 and 2 in toxified synaptosomes and in isolated vesicles. In contrast, synaptobrevin 1, as generated by in vitro translation, is only a poor substrate for BoNT/D, whereas this species is cleaved by BoNT/F with similar potency. Cleavage by BoNT/D occurs at the peptide bond Lys(59)-Leu(60) which is adjacent to the BoNT/F cleavage site (Gln(58)-Lys(59)) and again differs from the site hydrolyzed by TeTx and BoNT/B (Gln(76)Phe(77)). Cellubrevin, a recently discovered isoform expressed outside the nervous system, is efficiently cleaved by ah three toxins examined. For further characterization of the substrate requirements of BoNT/D, we tested amino- and carboxyl-terminal deletion mutants of synaptobrevin 2 as well as synthetic peptides. Shorter peptides containing up to 15 amino acids on either side of the cleavage site were not cleaved, and a peptide extending from Arg(47) to Thr(116) was a poor substrate for all three toxins tested. However, cleavability was restored when the peptide is further extended at the NH2 terminus (Thr(27)-Thr(116)) demonstrating that NH2 terminally located sequences of synaptobrevin which are distal from the respective cleavage sites are required for proteolysis. To further examine the isoform specificity, several mutants of rat synaptobrevin 2 were generated in which individual amino acids were replaced with those found in rat synaptobrevin 1. We show that a Met(46) to Ile(46) substitution drastically diminishes cleavability by BoNT/D and that the presence of Val(76) instead of Gln(76) dictates the reduced cleavability of synaptobrevin isoforms by TeTx.	FED RES CTR VIRUS DIS ANIM,DEPT MICROBIOL,D-72001 TUBINGEN,GERMANY; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV PARIS 05,UNITE PHARMACOCHIM MOLEC,F-75270 PARIS 06,FRANCE; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; UDICE-French Research Universities; Universite Paris Cite; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Blasi, Juan/K-7943-2014	Blasi, Juan/0000-0002-0482-9444; Jahn, Reinhard/0000-0003-1542-3498				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JAHN R, 1994, IN PRESS ANN REV NEU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MAYER T, 1988, J BIOL CHEM, V263, P14956; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIYAZAKI S, 1977, INFECT IMMUN, V17, P395, DOI 10.1128/IAI.17.2.395-401.1977; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; OHISHI I, 1974, APPL MICROBIOL, V28, P923, DOI 10.1128/AEM.28.6.923-928.1974; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROQUES BR, 1993, IN PRESS PHARM REV, V45; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; [No title captured]	41	227	246	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12764	12772						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175689				2022-12-27	WOS:A1994NH71600061
J	FERREIRAPEREIRA, A; ALVESFERREIRA, M; DECARVALHOALVES, PC				FERREIRAPEREIRA, A; ALVESFERREIRA, M; DECARVALHOALVES, PC			P-NITROPHENYLPHOSPHATASE ACTIVITY OF PLASMA-MEMBRANE H+-ATPASE FROM YEAST - IMPLICATIONS FOR THE REGULATION OF THE CATALYTIC CYCLE BY H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; ENERGY TRANSDUCTION; ION-TRANSPORT; HYDROLYSIS; PHOSPHATE; SITES; IDENTIFICATION; MECHANISM; EXCHANGE; CLEAVAGE	The H+-ATPase from Schizosaccharomyces pombe belongs to the group of transport ATPases which displays two main conformational states, E(1) and E(2) (P-type ATPase). In this report, we show that, as in the case of other P-type ATPases, the purified enzyme exhibits a p-nitrophenylphosphatase activity which can be completely inhibited by vanadate. In aqueous medium, p-nitrophenylphosphate hydrolysis proceeds at only 0.5% of the rate of ATP hydrolysis, and both activities can be stimulated 3- to 4-fold by decreasing the pH from 7.5 to 6.5. Addition of the organic solvent dimethyl sulfoxide (10-40%), which has been shown to favor the E(2) conformation, stimulates the p-nitrophenylphosphatase activity but inhibits the ATPase activity. At pH 7.5, the K-m for p-nitrophenyl phosphate decreases when dimethyl sulfoxide is present. In the presence of 30% (v/v) dimethyl sulfoxide, the phosphatase activity can be inhibited by ATP (K-i 300 mu M) or by P-i (K-i 1 mM). The H+-ATPase incorporated into lipo somes retains pNPPase activity, but it does not support H+ transport. Gel electrophoresis reveals that the pattern of H+-ATPase cleavage by trypsin changes when vanadate, Me(2)SO, or both compounds are present in the medium, regardless of the pH used during trypsinization. We propose that p-nitrophenyl phosphate is hydrolyzed by a H+-ATPase conformation distinct from that which hydrolyzes ATP, most probably an E(2)-like form. We also suggest that, in addition to the E(1)-E(2) transition, the enzyme activity can be regulated by protons at another step of the catalytic cycle.			FERREIRAPEREIRA, A (corresponding author), FED UNIV RIO DE JANEIRO,ICB CCS,DEPT BIOQUIM MED,CIDADE UNIV,BR-21941590 RIO JANEIRO,BRAZIL.		Ferreira-Pereira, Antonio/A-2910-2011; Ferreira, Marcelo/C-2770-2014	Ferreira-Pereira, Antonio/0000-0002-0474-8388; 				ADDISON R, 1982, J BIOL CHEM, V257, P421; AMORY A, 1982, J BIOL CHEM, V257, P2509; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ASANO S, 1992, J BIOL CHEM, V267, P6590; BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BLANPAIN JP, 1986, THESIS U CATHOLIQUE; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; CARIDE AJ, 1982, BIOCHIM BIOPHYS ACTA, V689, P421, DOI 10.1016/0005-2736(82)90298-X; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1987, FEBS LETT, V212, P323, DOI 10.1016/0014-5793(87)81369-8; DUFOUR JP, 1978, J BIOL CHEM, V253, P7026; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; INESI G, 1971, SCIENCE, V171, P901, DOI 10.1126/science.171.3974.901; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; MORJANA NA, 1989, BIOCHIM BIOPHYS ACTA, V985, P19, DOI 10.1016/0005-2736(89)90097-7; Penefsky H S, 1979, Methods Enzymol, V56, P527; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; ROBINSON JD, 1983, BIOCHIM BIOPHYS ACTA, V731, P406, DOI 10.1016/0005-2736(83)90035-4; SCARPA A, 1992, ANN NY ACAD SCI, V671; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9	27	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12074	12079						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163511				2022-12-27	WOS:A1994NG37700061
J	MIZUTA, M; INAGAKI, N; NEMOTO, Y; MATSUKURA, S; TAKAHASHI, M; SEINO, S				MIZUTA, M; INAGAKI, N; NEMOTO, Y; MATSUKURA, S; TAKAHASHI, M; SEINO, S			SYNAPTOTAGMIN-III IS A NOVEL ISOFORM OF RAT SYNAPTOTAGMIN EXPRESSED IN ENDOCRINE AND NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; TISSUE; P65	Synaptotagmin (p65), an integral membrane protein of synaptic vesicles, is thought to be involved in calcium-dependent exocytosis of synaptic vesicles. Here, we report the cloning and tissue distribution of a novel isoform of synaptotagmin, designated synaptotagmin III. The cDNA clones encoding synaptotagmin In have been isolated from a rat brain cDNA library Rat synaptotagmin III is a protein of 588 amino acids having 40.5, 38.3, and 64.0% identity with rat synaptotagmin I, rat synaptotagmin II, and o-p65-C, a third synaptotagmin isoform of marine ray Discopyge ommata, respectively. The region of the two internal repeats homologous to the regulatory domain (C-2 domain) of protein kinase C is highly conserved among synaptotagmin I, II, and III. RNA blotting studies reveal that synaptotagmin III mRNA is expressed in brain, various endocrine tissues, and hormone-secreting clonal cells, These results suggest that rat synaptotagmin III is a mammalian homolog of o-p65-C and is involved in Ca2+-dependent exocytosis of secretory vesicles in endocrine cells, as well as in neurons.	CHIBA UNIV,CTR BIOMED SCI,SCH MED,DIV MOLEC MED,CHUO KU,CHIBA 260,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA 194,TOKYO,JAPAN; MIYAZAKI MED COLL,DEPT INTERNAL MED 3,MIYAZAKI 88916,JAPAN	Chiba University; University of Miyazaki				Inagaki, Nobuya/0000-0001-8261-2593				BELL RM, 1991, J BIOL CHEM, V266, P4661; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Sambrook J, 1989, MOL CLONING LABORATO; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	26	143	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11675	11678						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163462				2022-12-27	WOS:A1994NG37700001
J	WU, GY; ZHAN, PL; SZE, LL; ROSENBERG, AR; WU, CH				WU, GY; ZHAN, PL; SZE, LL; ROSENBERG, AR; WU, CH			INCORPORATION OF ADENOVIRUS INTO A LIGAND-BASED DNA CARRIER SYSTEM RESULTS IN RETENTION OF ORIGINAL RECEPTOR SPECIFICITY AND ENHANCES TARGETED GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEDIATED ENDOCYTOSIS; CELLS; DELIVERY; RELEASE; TYPE-5; EMBRYO; MARKER	Adenovirus type 5 was modified by coupling an asialoglycoprotein-polylysine conjugate to the virus by reactions that activate carbohydrate residues. Wild-type virus modified in this manner had greatly decreased infectivity toward normally susceptible HeLa S3, (asialoglycoprotein receptor (-)) and SK Hep1 (asialoglycoprotein receptor (-)) cels leaving 91 and 86% viable, respectively, after 48 h. However, with Huh 7 (asialoglycoprotein receptor (+)) cells, modified virus retained its infectivity leaving only 19% of cells viable under identical conditions. Modified virus was complexed to DNA in the form of a plasmid, pSVHBVsurf, containing the gene for hepatitis B surface antigen as a marker of gene expression. Huh 7, receptor (+), cells treated with modified wild type, and modified replication-defective dl312 virus complexed to DNA raised antigen levels by approximately 13- and 30-fold, respectively, compared with asialoglycoprotein-polylysine DNA complex alone. Competition with a large excess of an asialoglycoprotein blocked the enhancement by more than 95%. Using a beta-galactosidase marker gene, the number of cells transfected by modified virus was found to be 200-fold higher than complex alone. Yet, specificity was retained exclusively for asialoglycoprotein receptor-bearing cells. These data indicate that adenovirus can be chemically modified by coupling ligands resulting in targeted gene expression dictated specifically by receptor recognition of the attached ligand.	HOP NECKER ENFANTS MALAD,FAC MED,INSERM,U370,F-75730 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	WU, GY (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL HEPATOL,RM AM-044,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.				NIDDK NIH HHS [NIDDK DK-42182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CURIEL DT, 1992, AM J RESP CELL MOL, V6, P247, DOI 10.1165/ajrcmb/6.3.247; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; GRAYSTON JT, 1958, J INFECT DIS, V103, P86, DOI 10.1093/infdis/103.1.86; GREEN M, 1963, VIROLOGY, V20, P199, DOI 10.1016/0042-6822(63)90157-0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HENNACHE B, 1977, BIOCHEM J, V166, P237, DOI 10.1042/bj1660237; HUEBNER RJ, 1954, NEW ENGL J MED, V251, P1077, DOI 10.1056/NEJM195412302512701; HUGHES G, 1948, J CHEM SOC FARADAY T, V44, P941; ISHIBASHI M, 1974, VIROLOGY, V58, P345, DOI 10.1016/0042-6822(74)90070-1; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; LANE CF, 1975, SYNTHESIS-STUTTGART, V3, P135; LAWRENCE WILLIAM C., 1967, J VIROL, V1, P851; LIANG TJ, 1993, J CLIN INVEST, V91, P1241, DOI 10.1172/JCI116287; MICHAEL SI, 1993, J BIOL CHEM, V268, P6866; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PEREIRA HG, 1963, VIROLOGY, V20, P613, DOI 10.1016/0042-6822(63)90286-1; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Precious B., 1985, VIROLOGY PRACTICAL A, P193; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SETH P, 1984, MOL CELL BIOL, V4, P1528, DOI 10.1128/MCB.4.8.1528; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621	30	89	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11542	11546						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157685				2022-12-27	WOS:A1994NF96600084
J	APPLEGATE, D; FENG, W; GREEN, RS; TAUBMAN, MB				APPLEGATE, D; FENG, W; GREEN, RS; TAUBMAN, MB			CLONING AND EXPRESSION OF A NOVEL ACIDIC CALPONIN ISOFORM FROM RAT AORTIC VASCULAR SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAINS; NONMUSCLE CALDESMON; THIN-FILAMENTS; MESSENGER-RNA; PHOSPHORYLATION; ACTIN; CELLS; SEQUENCE; PROTEIN; FIBROBLASTS	The actin-binding protein calponin has been implicated in the regulation of smooth muscle contraction. We have isolated cDNA clones encoding a novel acidic calponin isoform from rat aortic vascular smooth muscle cells. The initial 273 residues of the deduced 330 amino acid polypeptide (M(r) 36,377) are highly homologous to basic smooth muscle calponin isoforms, but the remaining 57 residues at the carboxyl terminus comprise a unique and strongly acidic domain. The sequence of the acidic domain shows high homology (93.3% identity) to the partial sequence of HUMXT01244, an unidentified human hippocampal gene product (Adams, M., Dubnick, M., Kerlavgne, A. R., Moreno, R., Kelly, J. M., Utterback, T. R., Nagle, J. W., Fields, C., and Venter, J. C. (1992) Nature 355, 632-634). Transcripts encoding acidic calponin are expressed in cultured rat aortic vascular smooth muscle cells and in non-muscle and smooth muscle tissues of adult rat. Based on its calculated M(r) and the tissue distribution of its expression, acidic calponin is an excellent candidate for a previously detected non-muscle calponin homolog (Takeuchi, K., Takahashi, It., Abe, M., Nishida, W, Hiwada, K., Nabeya, T, and Maruyama, It. (1991) J. Biochem. (Tokyo) 109, 311-316). Like basic calponin isoforms, acidic calponin synthesized in a bacterial expression system bound F-actin. However, unlike basic calponin, the acidic isoform did not interact with Ca2+/calmodulin, indicating a functional distinction between the muscle and non-muscle forms.	CUNY MT SINAI SCH MED,DEPT MED,MED MOLEC BIOL UNIT,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	APPLEGATE, D (corresponding author), CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,BOX 1218,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040154] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43302] Funding Source: Medline; NIDDK NIH HHS [DK-40154] Funding Source: Medline; NIGMS NIH HHS [GM-41373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DRAEGER A, 1991, FEBS LETT, V291, P24, DOI 10.1016/0014-5793(91)81095-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GILMAN M, 1987, CURRENT PROTOCOLS MO, V1; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KAWASAKI ES, 1992, PCR TECHNOLOGY, P89; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; MAKUCH R, 1991, BIOCHEM J, V280, P31; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1991, BIOCHEM J, V279, P1; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; NISHIDA W, 1991, BIOCHEM INT, V23, P663; OWENS GK, 1987, VASCULAR SMOOTH MUSC, V1, P57; PEARLSTONE JR, 1987, J BIOL CHEM, V262, P5985; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THWEATT R, 1992, BIOCHEM BIOPH RES CO, V187, P1, DOI 10.1016/S0006-291X(05)81449-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVO P, 1980, BLOOD VESSELS, V17, P110; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	43	120	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10683	10690						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144658				2022-12-27	WOS:A1994NF01700074
J	LEUNG, S; ODONNELL, ME; MARTINEZ, A; PALFREY, HC				LEUNG, S; ODONNELL, ME; MARTINEZ, A; PALFREY, HC			REGULATION BY NERVE GROWTH-FACTOR AND PROTEIN-PHOSPHORYLATION OF NA/K/2CL COTRANSPORT AND CELL-VOLUME IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORT; PHEOCHROMOCYTOMA CELLS; OKADAIC ACID; NA+/K+/CL COTRANSPORT; EPITHELIAL TISSUES; BUMETANIDE BINDING; AVIAN ERYTHROCYTES; TRANSPORT; KINASE; STIMULATION	PC12 cells possess a bumetanide sensitive Na/K/2Cl cotransport system similar to that found in other cell types. Between 10-15% of the total Rb-86 influx in these cells is mediated by this pathway under normal conditions. The cotransporter has affinities of 16.5 mM for Na-o and 0.7 mM for K-o, is absolutely dependent on Cl-o and is loop diuretic inhibitable (benzmetanide > bumetanide > piretanide > furosemide). The cotransporter can be activated (up to 8-fold) by cell shrinkage or (up to 4-fold) by treatment with the protein phosphatase inhibitors okadaic acid (EC(50) similar to 650 nM) or calyculin A (EC(50) similar to 8 nM). Cell shrinkage is followed by a bumetanide-sensitive regulatory volume increase as determined in cell sizing experiments. Calyculin A rapidly elevates normal cell volume in a diuretic-inhibitable manner. Cotransport activity and cell volume are also increased by nerve growth factor (NGF) treatment. The effect of NGF on cotransport rate is biphasic, with an initial rapid similar to 2.5-fold increase followed by a prolonged plateau, and is blocked by pretreatment of the cells with K252a (IC50 similar to 30 nM). By contrast, agents that raise cAMP or phorbol esters lead to an inhibition of cotransport, indicating that the NGF effect is not mediated by stimulation of either cAMP dependent protein kinase or protein kinase C. Long term NGF treatment (>2 days) leads to neurite formation and a maintained similar to 2-fold increase in cotransport activity. Bumetanide treatment does not affect the ability of cells to extend neurites, nor is the growth rate of cells in normal medium affected by the diuretic. These results suggest that the cotransport system in PC12 cells is acutely regulated by protein phosphorylation and dephosphorylation as well as cell shrinkage and that cotransport activity may be up-regulated during neuronotypic differentiation.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; LAWRENCE LIVERMORE NATL LAB, DEPT HUMAN PHYSIOL, DAVIS, CA 95616 USA	University of Chicago; United States Department of Energy (DOE); Lawrence Livermore National Laboratory								ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; ALVAREZLEEFMANS FJ, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P109; AMSLER K, 1985, J CELL PHYSIOL, V123, P257, DOI 10.1002/jcp.1041230216; BALLANYI K, 1988, RENAL PHYSIOL BIOCH, V11, P142; BARBACID M, 1993, ONCOGENE, V8, P2033; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOONSTRA J, 1981, EXP CELL RES, V131, P452, DOI 10.1016/0014-4827(81)90255-X; CHANDLER CE, 1985, J CELL PHYSIOL, V125, P367, DOI 10.1002/jcp.1041250303; CHASSANDE O, 1988, EUR J BIOCHEM, V171, P425, DOI 10.1111/j.1432-1033.1988.tb13807.x; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DELPIRE E, 1991, ARCH INT PHYSIOL BIO, V99, P71, DOI 10.3109/13813459109145906; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, IN PRESS J BIOL CHEM; GARGUS JJ, 1980, J MEMBRANE BIOL, V52, P245, DOI 10.1007/BF01869193; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HEGDE RS, 1992, J MEMBRANE BIOL, V126, P27; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAYME DW, 1981, P NATL ACAD SCI-BIOL, V78, P1057, DOI 10.1073/pnas.78.2.1057; JOHNSON JH, 1982, BIOCHEM BIOPH RES CO, V109, P100, DOI 10.1016/0006-291X(82)91571-6; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN JD, 1993, J MEMBRANE BIOL, V132, P243; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORT JJ, 1989, J CELL PHYSIOL, V141, P181, DOI 10.1002/jcp.1041410126; KREGENOW FM, 1981, ANNU REV PHYSIOL, V43, P493, DOI 10.1146/annurev.ph.43.030181.002425; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MCGUIRE JC, 1979, J BIOL CHEM, V254, P3362; MCROBERTS JA, 1983, J BIOL CHEM, V258, P2320; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; ODONNELL ME, 1993, AM J PHYSIOL, V264, pC1316, DOI 10.1152/ajpcell.1993.264.5.C1316; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; Palfrey H C, 1981, Ann N Y Acad Sci, V372, P291, DOI 10.1111/j.1749-6632.1981.tb15482.x; Palfrey H. Clive, 1992, Cellular Physiology and Biochemistry, V2, P293; PALFREY HC, 1980, AM J PHYSIOL, V238, pC139, DOI 10.1152/ajpcell.1980.238.3.C139; PALFREY HC, 1993, AM J PHYSIOL, V264, pC1270, DOI 10.1152/ajpcell.1993.264.5.C1270; PALFREY HC, 1993, CELL MOL BIOL VOLUME, P129; PARIS S, 1986, J BIOL CHEM, V261, P6177; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RUSSELL JM, 1990, REGULATION K TRANSPO; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; STRANGE K, 1993, CELL MOL BIOL VOLUME; TAPLEY P, 1992, ONCOGENE, V7, P371; TAS PWL, 1987, BIOCHIM BIOPHYS ACTA, V903, P411, DOI 10.1016/0005-2736(87)90047-2; TORCHIA J, 1992, J BIOL CHEM, V267, P25444	53	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10581	10589						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144646				2022-12-27	WOS:A1994NF01700060
J	NAKAGAWA, Y; KOSUGI, H; MIYAJIMA, A; ARAI, K; YOKOTA, T				NAKAGAWA, Y; KOSUGI, H; MIYAJIMA, A; ARAI, K; YOKOTA, T			STRUCTURE OF THE GENE ENCODING THE ALPHA-SUBUNIT OF THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR - IMPLICATIONS FOR THE EVOLUTION OF THE CYTOKINE RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; Y-PSEUDOAUTOSOMAL REGION; HUMAN GROWTH-HORMONE; BETA-CHAIN GENE; TRANSCRIPTION FACTOR; EXTRACELLULAR DOMAIN; EXPRESSION CLONING; MOLECULAR-CLONING; CELL-LINE; ORGANIZATION	The receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) is composed of at least two subunits, alpha and beta. In addition to the conserved cysteine residues and a ''WSxWS'' motif, the extracellular segments of both subunits have domains that are structurally related to a fibronectin type III domain. This structure is conserved in all members of the cytokine receptor superfamily. We isolated and characterized genomic DNA clones containing the entire coding sequences of the alpha subunit of the human GM-CSF receptor (hGMR alpha). The gene spans approximately 44 kilobases and has 13 exons. The major transcription initiation site was determined to be 195 base pairs upstream of the translation initiation site. The putative promoter region lacks a typical TATA motif and an Sp1 binding site, but contains a purine-rich stretch about 30 base pairs upstream of the transcription initiation site. This stretch is also found in the human interleukin 2 receptor gamma subunit and granulocyte colony-stimulating factor receptor genes. We compared the exon-intron organization of the hGMR alpha gene with other members of the cytokine receptor superfamily and found the genomic organizations to be remarkably well conserved. On the basis of these observations, we propose a model for evolution of this gene family.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yokota, Takashi/F-6021-2011; Yokota, Takashi/J-8483-2015					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN DM, 1992, J BIOL CHEM, V267, P15842; GOUGH NM, 1990, NATURE, V345, P734, DOI 10.1038/345734a0; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IMAMURA F, 1994, IN PRESS DNA CELL BI; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREMER E, 1993, BLOOD, V82, P22, DOI 10.1182/blood.V82.1.22.bloodjournal82122; KURATA H, 1993, IN PRESS SIGNAL TRAN; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCLACHLAN AD, 1987, COLD SPRING HARB SYM, V52, P411, DOI 10.1101/SQB.1987.052.01.048; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILATOVICH A, 1992, AM J HUM GENET, V51, P4; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; OGAWA M, 1993, BLOOD, V81, P2844; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; RAPPOLD G, 1992, GENOMICS, V14, P455, DOI 10.1016/S0888-7543(05)80241-1; SAMBOROK J, 1989, MOL CLONING LABORATO; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SETO Y, 1992, J IMMUNOL, V148, P259; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SHEN Y, 1992, CYTOGENET CELL GENET, V61, P175, DOI 10.1159/000133401; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STEWART CB, 1993, CURR BIOL, V3, P158, DOI 10.1016/0960-9822(93)90259-Q; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINKELMANN JC, 1990, BLOOD, V76, P24; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014	64	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10905	10912						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144676				2022-12-27	WOS:A1994NF01700105
J	WANG, JT; MUELLER, KL; GROSSMAN, L				WANG, JT; MUELLER, KL; GROSSMAN, L			A MUTATIONAL STUDY OF THE C-TERMINAL ZINC-FINGER MOTIF OF THE ESCHERICHIA-COLI UVRA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; SITE-SPECIFIC MUTAGENESIS; TRANSCRIPTION FACTOR; GLUCOCORTICOID RECEPTOR; BINDING DOMAINS; DNA-BINDING; RNA GENE; COMPLEX; EXCINUCLEASE; RECOGNITION	The cysteine 763 residue in the C-terminal zinc-finger region of Escherichia coli UvrA protein was subjected to random mutagenesis, and the results suggested that the UvrA mutants with a small amino acid (Ser, Ala, or Gly) substituting for the cysteine 763 were almost as active as the wild-type in supporting nucleotide excision repair, but its replacement with a large, bulky amino acid (Tyr, Trp, or Phe) rendered the mutants inactive. The C763F mutant UvrA protein was purified for further characterization, and it was found this mutant UvrA protein lost its DNA binding (single-stranded or double-stranded DNA) activity and those other activities dependent on DNA binding, such as formation of damage-specific UvrA(2)B complexes and the supercoiling reaction. However, this mutant protein retained vigorous ATPase activity and was capable of negatively complementing the wild-type UvrA in JM109 strain. The purified C763F mutant UvrA protein contains a single zinc ion/molecule, half that of the wild-type. It appears that the C763F mutation destabilizes the zinc-anchored structure in the C-terminal zinc finger region, and as a result, the C763F mutant UvrA protein lost its ability to bind DNA.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21218	Johns Hopkins University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031110, R01GM022846, R37GM022846] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03819] Funding Source: Medline; NIGMS NIH HHS [GM 22846, GM 31110] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; FRIEDBERG EC, 1985, DNA REPAIR, P248; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1973, J MOL BIOL, V80, P545; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REDEMANN N, 1988, NATURE, V332, P90, DOI 10.1038/332090a0; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1991, J BIOL CHEM, V266, P7609; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; WANG JT, 1993, J BIOL CHEM, V268, P5323; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	35	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10771	10775						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144665				2022-12-27	WOS:A1994NF01700087
J	WIECKOWSKI, EU; WNEK, AP; MCCLANE, BA				WIECKOWSKI, EU; WNEK, AP; MCCLANE, BA			EVIDENCE THAT AN APPROXIMATE-TO-50-KDA MAMMALIAN PLASMA-MEMBRANE PROTEIN WITH RECEPTOR-LIKE PROPERTIES MEDIATES THE AMPHIPHILICITY OF SPECIFICALLY BOUND CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; VERO CELLS; A ENTEROTOXIN; ALPHA-TOXIN; PERMEABILITY; BINDING; COMPLEX; CYTOTOXICITY; DAMAGE; ASSAY	Previous studies suggest that Clostridium perfringens enterotoxin (CPE) inserts into mammalian membranes. Using Triton X-114 phase separation analysis and charge-shift electrophoresis, this study demonstrates that CPE exhibits the amphiphilicity required for membrane insertion, but this behavior develops only after exposure of CPE to membranes. This effect does not require proteolytic or covalent CPE modifications or formation of a previously reported 160-kDa CPE-containing complex. A novel 90-kDa CPE containing complex with amphiphilic properties was detected in intestinal brush-border membranes and in CPE-sensitive, but not CPE-insensitive, cell lines using nondenaturing Triton X-100 electrophoresis. Immunoprecipitation analysis suggested that the 90-kDa complex is composed of CPE and a 45-50-kDa membrane protein. Since the 90-kDa complex is formed only in cells that bind and respond to CPE, these results are consistent with the 45-50-kDa protein mediating CPE amphiphilicity and serving as a functional CPE receptor. A four-step model for CPE action is proposed. 1) CPE binds to the 45-50-kDa protein to form a 90-kDa complex. 2) The 90-kDa complex undergoes some physical change corresponding to insertion or a conformational change. 3) The 90-kDa complex and a 70-kDa membrane protein interact to form a 160-kDa complex. 4) Formation of the 160-kDa complex leads to permeability alterations.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019844, R01AI019844] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19844-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; BHAKDI S, 1986, MICROB PATHOGENESIS, V1, P5, DOI 10.1016/0882-4010(86)90027-6; BHAKDI S, 1977, BIOCHIM BIOPHYS ACTA, V470, P35, DOI 10.1016/0005-2736(77)90059-1; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BHAKDI S, 1988, BACTERIAL PROTEIN TO, P71; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CZECZULIN JR, 1993, INFECT IMMUN, V61, P3429, DOI 10.1128/IAI.61.8.3429-3439.1993; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GRANUM PE, 1985, J FOOD BIOCHEM, V9, P137, DOI 10.1111/j.1745-4514.1985.tb00344.x; GRANUM PE, 1985, ACTA PATH MICRO IM B, V93, P41; GRANUM PE, 1986, 2ND P EUR WORKSH BAC, P327; HANNA PC, 1991, MOL MICROBIOL, V5, P225, DOI 10.1111/j.1365-2958.1991.tb01843.x; HANNA PC, 1991, J BIOL CHEM, V266, P11037; HANNA PC, 1992, INFECT IMMUN, V60, P2110, DOI 10.1128/IAI.60.5.2110-2114.1992; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HELENIUS A, 1977, P NATL ACAD SCI USA, V74, P529, DOI 10.1073/pnas.74.2.529; HORIGUCHI Y, 1985, FEMS MICROBIOL LETT, V28, P131; HULKOWER KI, 1989, J CELL PHYSIOL, V140, P498, DOI 10.1002/jcp.1041400314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSHUS IH, 1989, INFECT IMMUN, V57, P1873, DOI 10.1128/IAI.57.7.1873-1878.1989; MATSUDA M, 1986, BIOCHEM BIOPH RES CO, V141, P704, DOI 10.1016/S0006-291X(86)80229-7; MCCLANE BA, 1988, MICROB PATHOGENESIS, V4, P317, DOI 10.1016/0882-4010(88)90059-9; MCCLANE BA, 1990, INFECT IMMUN, V58, P3109, DOI 10.1128/IAI.58.9.3109-3115.1990; MCCLANE BA, 1984, BIOCHIM BIOPHYS ACTA, V777, P99, DOI 10.1016/0005-2736(84)90501-7; MCCLANE BA, 1988, J BIOL CHEM, V263, P2423; MCCLANE BA, 1994, TOXICOLOGY, V87, P43, DOI 10.1016/0300-483X(94)90154-6; McDonel J. L., 1986, Pharmacology of bacterial toxins, P477; MCDONEL JL, 1979, BIOCHEM BIOPH RES CO, V87, P497, DOI 10.1016/0006-291X(79)91823-0; MCDONEL JL, 1988, METHOD ENZYMOL, V165, P94; MCDONEL JL, 1980, BIOCHEMISTRY-US, V19, P4801, DOI 10.1021/bi00562a014; MENESTRINA G, 1992, FEMS MICROBIOL IMMUN, V105, P19; ROLFE RD, 1993, CLIN INFECT DIS, V16, pS219, DOI 10.1093/clinids/16.Supplement_4.S219; SALINOVICH O, 1982, BIOCHIM BIOPHYS ACTA, V707, P147, DOI 10.1016/0167-4838(82)90408-3; SIGRIST H, 1975, BIOCHIM BIOPHYS ACTA, V406, P433, DOI 10.1016/0005-2736(75)90022-X; SUGII S, 1988, FEMS MICROBIOL LETT, V52, P85; SUGIMOTO N, 1988, BIOCHEM BIOPH RES CO, V156, P551, DOI 10.1016/S0006-291X(88)80877-5; THELESTAM M, 1975, INFECT IMMUN, V12, P225, DOI 10.1128/IAI.12.2.225-232.1975; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; WNEK AP, 1986, MICROB PATHOGENESIS, V1, P89, DOI 10.1016/0882-4010(86)90035-5; WNEK AP, 1983, BIOCHEM BIOPH RES CO, V112, P1099, DOI 10.1016/0006-291X(83)91731-X; WNEK AP, 1989, INFECT IMMUN, V57, P574, DOI 10.1128/IAI.57.2.574-581.1989; WNEK AP, 1985, INFECT IMMUN, V50, P442, DOI 10.1128/IAI.50.2.442-448.1985	45	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10838	10848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144671				2022-12-27	WOS:A1994NF01700096
J	PEJLER, G; MACCARANA, M				PEJLER, G; MACCARANA, M			INTERACTION OF HEPARIN WITH RAT MAST-CELL PROTEASE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSIN-LIKE PROTEINASE; SERINE PROTEASES; HUMAN-SKIN; BINDING; CHYMASE; GLYCOSAMINOGLYCANS; PROTEOGLYCAN; ANTITHROMBIN; SULFATE; OLIGOSACCHARIDES	Heparin is a sulfated glycosaminoglycan, synthesized by connective tissue-type mast cells. Rat mast cell protease 1 (RMCP-1), a chymotrypsin-like serine protease expressed specifically by connective tissue-type mast cells, is recovered in a macromolecular complex with heparin proteoglycan. The heparin.RMCP-1 complexes are stored in the secretory granules of the cells and are released following mast cell activation. We showed previously that dissociation of RMCP-1 from heparin resulted in loss of protease activity, as measured by its ability to inactivate thrombin. In the present report the binding of heparin to RMCP-1 was characterized. Affinity chromatography on heparin-Sepharose showed that RMCP-1 displayed high affinity for heparin, with similar to 1.2 M NaCl being required for elution of RMCP-1 from the affinity matrix, The structural requirements for the binding of heparin to RMCP-1 were investigated. Heparan sulfate, chondroitin sulfate, and dermatan sulfate, three glycosaminoglycans structurally related to heparin, were greater than or equal to 80-fold less effective in binding to RMCP-1 than heparin. The 2-O-sulfate, 6-O-sulfate, and N-sulfate groups in heparin were all shown to contribute in the binding. The minimal heparin sequence required for binding to RMCP-1 was found in a 14-saccharide fraction. 14-Saccharide species, obtained after separation by anion exchange chromatography, showed continuously increased binding with increasing anionic charge densities. The 16-18-saccharides were the smallest heparin oligosaccharides capable of accelerating the inactivation of thrombin by RMCP-1.	BIOMED CTR, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN		PEJLER, G (corresponding author), BIOMED CTR, DEPT VET MED CHEM, POB 575, S-75123 UPPSALA, SWEDEN.		maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921				BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; DANISHEF.V, 1965, BIOCHIM BIOPHYS ACTA, V101, P37; EKRE HPT, 1986, INT J IMMUNOPHARMACO, V8, P277, DOI 10.1016/0192-0561(86)90109-8; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; GERVASONI JE, 1986, J IMMUNOL, V136, P285; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; KATUNUMA N, 1988, J CELL BIOCHEM, V38, P291, DOI 10.1002/jcb.240380408; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LANE DA, 1987, J BIOL CHEM, V262, P16343; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NELSON DS, 1963, LANCET, V2, P175; OGAMO A, 1985, BIOCHIM BIOPHYS ACTA, V841, P30; OLIVECRONA T, 1989, HEPARIN, P335; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1988, J BIOL CHEM, V263, P5197; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1989, HEPARIN CHEM BIOL PR, P257; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405	44	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14451	14456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182050				2022-12-27	WOS:A1994NM06500025
J	BARKOCYGALLAGHER, GA; CANNON, JG; BASSFORD, PJ				BARKOCYGALLAGHER, GA; CANNON, JG; BASSFORD, PJ			BETA-TURN FORMATION IN THE PROCESSING REGION IS IMPORTANT FOR EFFICIENT MATURATION OF ESCHERICHIA-COLI MALTOSE-BINDING PROTEIN BY SIGNAL PEPTIDASE-I IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; CLEAVAGE SITE; DIRECTED MUTAGENESIS; SUPPRESSOR MUTATIONS; SEQUENCE; EXPORT; SECRETION; MEMBRANE; LACTAMASE; INVIVO	Signal peptidase I (also called leader peptidase) is the endopeptidase that removes the signal peptides of most secreted proteins during or after translocation in Escherichia coli. Precursor recognition is contingent in part on the presence of small, uncharged residues in the -3 and -1 positions relative to the cleavage site, and may also depend on the structure of the processing region. Most precursor processing regions include residues likely to form a beta-turn. Mutations were introduced into the processing region of maltose binding protein (MBP) that altered the prediction of beta-turn formation in this region. MBP species with a decreased probability of beta-turn formation were processed slowly or not at all, whereas MBP species with an increased probability of beta-turn formation were processed efficiently. Mutations altering the prediction of beta-turn formation in the MBP processing region were also made in cis to a proline in the +1 position. Cleavage at the normal processing site is blocked by proline in the +1 position; this MBP species, MBP27-P, inhibits processing of other proteins by signal peptidase I. Decreasing the probability of beta-turn formation in the processing region of MBP27-P eliminated the inhibition of signal peptidase I, and these MBP27-P derivatives remained unprocessed, suggesting that the formation of a beta-turn in the MBP processing region was necessary for recognition by signal peptidase I. Increasing the probability of beta-turn formation in cis to proline at +1 in MBP did not alter recognition of the protein by the processing enzyme. The results presented here are consistent with the hypothesis that the efficiency of recognition and processing by signal peptidase I is increased by the formation of a beta-turn in the processing region of the MBP signal peptide.	UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017292] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID AI17292] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1991, J CELL BIOCHEM, V46, P321, DOI 10.1002/jcb.240460407; BANKAITIS VA, 1984, J BIOL CHEM, V259, P2193; BANKAITIS VA, 1984, CELL, V37, P243, DOI 10.1016/0092-8674(84)90320-9; BARKOCYGALLAGHER GA, 1992, J BIOL CHEM, V267, P1231; BASSFORD PJ, 1990, J BIOENERG BIOMEMBR, V22, P401, DOI 10.1007/BF00763175; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLIER DN, 1990, J BACTERIOL, V172, P6875, DOI 10.1128/jb.172.12.6875-6884.1990; COLLIER DN, 1989, J BACTERIOL, V171, P4640, DOI 10.1128/jb.171.9.4640-4647.1989; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DEV IK, 1990, J BIOENERG BIOMEMBR, V22, P271, DOI 10.1007/BF00763168; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; EMR SD, 1982, J BIOL CHEM, V257, P5852; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; IINO T, 1988, J BIOL CHEM, V263, P19077; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; KADONAGA JT, 1985, J BIOL CHEM, V260, P6192; KENDALL DA, 1990, BIOPOLYMERS, V29, P139, DOI 10.1002/bip.360290119; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KUHN A, 1985, J BIOL CHEM, V260, P5914; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOTHWEHR SF, 1990, BIOESSAYS, V12, P479, DOI 10.1002/bies.950121005; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PLUCKTHUN A, 1988, J BIOL CHEM, V263, P14315; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RASMUSSEN BA, 1985, J BACTERIOL, V164, P665, DOI 10.1128/JB.164.2.665-673.1985; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	40	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13609	13613						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175796				2022-12-27	WOS:A1994NK18400080
J	GABUZDA, D; BUSCIGLIO, J; CHEN, LB; MATSUDAIRA, P; YANKNER, BA				GABUZDA, D; BUSCIGLIO, J; CHEN, LB; MATSUDAIRA, P; YANKNER, BA			INHIBITION OF ENERGY-METABOLISM ALTERS THE PROCESSING OF AMYLOID PRECURSOR PROTEIN AND INDUCES A POTENTIALLY AMYLOIDOGENIC DERIVATIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; NEXIN-II; DEGRADATION; IDENTIFICATION; CLEAVAGE; PEPTIDE; DOMAIN	The cellular mechanisms which lead to the generation and pathological deposition of beta amyloid in Alzheimer's disease are unknown. In this report we describe the proteolytic processing of the amyloid precursor protein (APP) to an 11.5-kDa COOH-terminal derivative which contains the full-length beta amyloid sequence. This processing step normally occurs at low levels in parallel with APP maturation in the secretory pathway. Inhibition of oxidative energy metabolism by sodium azide or the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone increased the proteolysis of APP to the 11.5-kDa derivative by about 80-fold with accumulation of this APP derivative in the Golgi complex. Agents which inhibit protein transport in the secretory pathway, including monensin and brefeldin A, also increased the production of the 11.5-kDa derivative. Inhibition of APP maturation demonstrated that the 11.5-kDa derivative could be produced by proteolysis of immature APP. These results demonstrate that APP processing to potentially amyloidogenic COOH-terminal derivatives occurs in either the endoplasmic reticulum or Golgi complex and can be modulated by the state of cellular energy metabolism. Deficits in oxidative energy metabolism have recently been found in the cerebral cortex of patients with Alzheimer's disease. These findings raise the possibility that energy-related metabolic stress may lead to altered metabolism of APP and contribute to amyloidosis in Alzheimer's disease.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School			Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG009229] Funding Source: NIH RePORTER; NIA NIH HHS [AG09229] Funding Source: Medline; NINDS NIH HHS [NS30352] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1992, NATURE, V359, P325; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOPS J, 1992, J BIOL CHEM, V267, P16022; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MUTISYA EM, 1993, ABSTR NEUR, V19, P1474; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PERSSON R, 1992, J BIOL CHEM, V267, P2760; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOODS CM, 1985, CELL, V40, P959, DOI 10.1016/0092-8674(85)90356-3; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	46	322	335	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13623	13628						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175797				2022-12-27	WOS:A1994NK18400082
J	RUBINCHIK, S; PARRIS, W; GOLD, M				RUBINCHIK, S; PARRIS, W; GOLD, M			THE IN-VITRO ENDONUCLEASE ACTIVITY OF GENE-PRODUCT-A, THE LARGE SUBUNIT OF THE BACTERIOPHAGE-LAMBDA TERMINASE, AND ITS RELATIONSHIP TO THE ENDONUCLEASE ACTIVITY OF THE HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; COHESIVE END SITE; ESCHERICHIA-COLI; COS DNA; BINDING; PROTEIN; OVERPRODUCTION; MUTATIONS; MECHANISM; SEQUENCES	The reaction requirements and kinetic properties of the in vitro endonuclease activity of the bacteriophage lambda terminase and its large subunit, gene product (gp) A, have been analyzed. Optimal cleavage reaction activity for both proteins requires Mg2+, a pH between 8.5 and 9.0, and is enhanced by ATP or ATP analogs. Under these conditions both terminase and gpA generate aberrant nicks in and around cosN. Optimal nicking specificity of terminase is observed under conditions of 50-100 mM salt, 5 mM spermidine, 1.5 mM ATP, and a pH between 7.0 and 7.5. Specific activity of terminase is greatly reduced under these conditions, and gpA is completely inactive at all protein concentrations tested. Under optimal reaction conditions, gpA endonuclease activity differs from that of the holoenzyme in that it can only be detected at high concentrations, is strongly protein concentration-dependent, and can not be stimulated by the Escherichia coli protein integration host factor. Addition of purified gpNu1 partially, but not completely, minimized these differences, suggesting that the role of gpNu1 in the holoenzyme is to modulate the basal endonuclease of gpA.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA	University of Toronto								BAEZA I, 1987, BIOCHEMISTRY-US, V26, P6380; BEAR SE, 1984, J VIROL, V52, P966, DOI 10.1128/JVI.52.3.966-972.1984; BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BECKER A, 1978, P NATL ACAD SCI USA, V75, P4199, DOI 10.1073/pnas.75.9.4199; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DAVIDSON A, 1991, J BACTERIOL, V173, P5086, DOI 10.1128/jb.173.16.5086-5096.1991; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; GOLD M, 1983, J BIOL CHEM, V258, P4619; GOLD M, 1986, NUCLEIC ACIDS RES, V14, P9797, DOI 10.1093/nar/14.24.9797; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KEELER CL, 1987, THESIS U MARYLAND BA; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; Maxam A M, 1980, Methods Enzymol, V65, P499; MIWA T, 1983, GENE, V24, P199; MIWA T, 1982, GENE, V20, P265; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PARRIS W, 1994, J BIOL CHEM, V269, P13564; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; Sambrook J, 1989, MOL CLONING LABORATO; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SHINDER G, 1989, NUCLEIC ACIDS RES, V17, P2005, DOI 10.1093/nar/17.5.2005; SHINDER G, 1989, THESIS U TORONTO; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WILLIS RC, 1992, THESIS U TORONTO; XIN W, 1993, J MOL BIOL, V230, P505, DOI 10.1006/jmbi.1993.1167; XIN W, 1993, J MOL BIOL, V230, P492, DOI 10.1006/jmbi.1993.1166; XU S, 1989, THESIS U IOWA; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	38	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13575	13585						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175793				2022-12-27	WOS:A1994NK18400076
J	SCHWARTZ, ML; KATAGI, C; BRUCE, J; SCHLAEPFER, WW				SCHWARTZ, ML; KATAGI, C; BRUCE, J; SCHLAEPFER, WW			BRAIN-SPECIFIC ENHANCEMENT OF THE MOUSE NEUROFILAMENT HEAVY GENE PROMOTER IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-M; MESSENGER-RNA; EXPRESSION; PROTEINS; TRANSCRIPTION; PHOSPHORYLATION; SUBUNITS; INTERACT; REVEALS; BOX	We have investigated the DNA elements responsible for transcription from the proximal portion of the mouse neurofilament heavy gene (NF-H) promoter by in vitro transcription using extracts from expressing (brain) and non-expressing (liver) tissues. We have found that constructs containing 5' region from -1314 to -115 exhibit a 3-5-fold higher level of NF-H promoter activity, relative to the adenovirus major late promoter (pML), in brain versus liver extracts. Deletion to -85 lowers the level of brain transcription by 2-fold, while deletion from -65 through -31 reduces transcription by 5-fold to a relatively strong (10% of pML) basal level. Basal level expression is observed in all deletions transcribed with liver extract. Deletion to -24 (TATA-less) abolishes promoter activity with both extracts. Deletion of the -115 to -65 region from a larger construct reduces transcription in brain extracts to basal levels, suggesting that this region contains the elements necessary for the brain specific enhancement of promoter function. Mutation of a palindromic sequence within this region abolishes brain specific enhanced promoter activity. This loss of enhanced transcriptional activity is correlated with the loss of a shifted band in gel shift assays. Our studies suggest that the sequence (-106)GGGGAG-GAGG-(15 bp)-CCTCCTCCCC(-72) (where bp = base pairs) is important in brain-specific enhancement of transcription from the mouse NF-H promoter.			SCHWARTZ, ML (corresponding author), UNIV PENN,SCH MED,DIV NEUROPATHOL,435 JOHNSON PAVILION,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064, R01NS015722] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS15722, T32 NS07064] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ELDER GA, 1992, MOL BRAIN RES, V15, P85, DOI 10.1016/0169-328X(92)90155-5; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HIGUCHI H, 1992, BIOCHEM BIOPH RES CO, V189, P1553, DOI 10.1016/0006-291X(92)90253-H; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; LEE VMY, 1992, MOL BRAIN RES, V15, P76, DOI 10.1016/0169-328X(92)90154-4; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PLEASURE SJ, 1990, J NEUROSCI, V10, P2428; REEBEN M, 1993, BIOCHEM BIOPH RES CO, V192, P465, DOI 10.1006/bbrc.1993.1438; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; THHOREY I, 1993, MOL CELL BIOL, V13, P6742; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAMASAKI H, 1992, LAB INVEST, V66, P734; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P4555; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	36	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13444	13450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175776				2022-12-27	WOS:A1994NK18400059
J	HERBST, JJ; OPRESKO, LK; WALSH, BJ; LAUFFENBURGER, DA; WILEY, HS				HERBST, JJ; OPRESKO, LK; WALSH, BJ; LAUFFENBURGER, DA; WILEY, HS			REGULATION OF POSTENDOCYTIC TRAFFICKING OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR THROUGH ENDOSOMAL RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Little is known about the regulation of EGF receptor (EGF-R) trafficking following endocytosis. We investigated this by using a series of EGF-R with altered cytoplasmic tails and comparing their ability to undergo recycling and lysosomal targeting in both the occupied and empty state. We found that 2-3% of empty EGF-R are internalized each minute, but rapidly recycle (t(1/2) approximately 5 min). This constitutive internalization and recycling of empty receptors was independent of cytoplasmic receptor sequences. Occupied EGF-R, in contrast, displayed a much slower rate of recycling (t(1/2) between 10-23 min) due to retention within recycling endosomes. Endosomal retention of different EGF-R correlated with lysosomal targeting of EGF. Intrinsic receptor tyrosine kinase activity had no discernible effect on postendocytic trafficking of EGF. Although sequences within the cytoplasmic tail of the EGF-R appear to be required for occupancy-dependent endosomal retention, they are distinct from those required for ligand-induced endocytosis. Our studies indicate that intracellular trafficking of the EGF-R is regulated by endosomal components that preferentially recognize occupied receptors. Down-regulation of the EGF-R thus involves two distinct regulatory processes: one at the level of internalization and one at the level of recycling.	UNIV UTAH, MED CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA; UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Wiley, Steven/0000-0003-0232-6867				AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN JW, 1986, BIOCHEM SOC SYMP, P97; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HARLOW E, 1988, ABTIBODIES LABORATOR; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1990, J BIOL CHEM, V265, P20517; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; ONODA T, 1990, DRUG EXP CLIN RES, V16, P249; OPRESKO L, 1980, CELL, V22, P47, DOI 10.1016/0092-8674(80)90153-1; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; THIES RS, 1990, J BIOL CHEM, V265, P10132; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILEY HS, 1985, CURR TOP MEMBR TRANS, V24, P369; WILEY HS, 1985, J BIOL CHEM, V260, P5290; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033	64	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12865	12873						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175702				2022-12-27	WOS:A1994NH71600076
J	YEN, PM; IKEDA, M; WILCOX, EC; BRUBAKER, JH; SPANJAARD, RA; SUGAWARA, A; CHIN, WW				YEN, PM; IKEDA, M; WILCOX, EC; BRUBAKER, JH; SPANJAARD, RA; SUGAWARA, A; CHIN, WW			HALF-SITE ARRANGEMENT OF HYBRID GLUCOCORTICOID AND THYROID-HORMONE RESPONSE ELEMENTS SPECIFIES THYROID-HORMONE RECEPTOR COMPLEX BINDING TO DNA AND TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; AUXILIARY PROTEIN; NUCLEAR RECEPTORS; ENHANCES BINDING; ACID RECEPTORS; LIGAND-BINDING; AMINO-ACIDS; RXR-BETA; GENE; HETERODIMERIZATION	Thyroid hormone receptors bind to thyroid hormone response elements (TREs) as heterodimers with 3,5,3'-L-triiodothyronine (T-3) receptor auxiliary protein (TRAP) and retinoid X receptors (RXRs). Currently, it is not known whether TR/TRAP or TR/RXR heterodimers need to bind to both TRE half-sites and whether there is a preferred orientation for TR/RXR heterodimer binding to TREs or transcriptional activation. Accordingly, we created a mutant TR alpha (TR-P box) by changing 3 amino acids in the P box region of the first zinc finger of the DNA-binding domain to that of the glucocorticoid receptor (GR), and we examined wild-type TR alpha and TR-P box complex binding to hybrid response elements containing TRE and glucocorticoid receptor element (GRE) half sites arranged as a direct repeat with a four-nucleotide gap. TR-P box/RXR heterodimers selectively bound to the hybrid response element in which the GRE half-site was the downstream half-site, whereas TR alpha/ RXR bound to hybrid response elements in which GREs were in either position. Additionally, TR/TRAP or TR/ RXR heterodimer required two half-sites for binding to DNA, with strong binding to at least one of the half-sites. Last, co-transfection assays and methylation interference studies using the hybrid response elements suggest that the sequential arrangement of strong and weak half-sites in the TRE may be a critical determinant of TR/RXR heterodimer binding and transcriptional activation.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	YEN, PM (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,GW THORN RES BLDG,RM 905,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RIBIERO RCJ, 1992, MOL ENDOCRINOL, V6, P1142; Sambrook J, 1989, MOL CLONING LABORATO; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J BIOL CHEM, V267, P23248; YEN PM, 1993, ENDOCR J, V1, P461; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J	45	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12704	12709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175681				2022-12-27	WOS:A1994NH71600053
J	BENYA, RV; KUSUI, T; SHIKADO, F; BATTEY, JF; JENSEN, RT				BENYA, RV; KUSUI, T; SHIKADO, F; BATTEY, JF; JENSEN, RT			DESENSITIZATION OF NEUROMEDIN-B RECEPTORS (NMB-R) ON NATIVE AND NMB-R-TRANSFECTED CELLS INVOLVES DOWN-REGULATION AND INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBESIN-LIKE PEPTIDES; PANCREATIC ACINAR-CELLS; EPIDERMAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; SWISS 3T3 CELLS; PHOSPHOINOSITIDE HYDROLYSIS; GASTROINTESTINAL-TRACT; INOSITOL PHOSPHATES; LIGAND-BINDING	The receptor for neuromedin B (NMB-R), a mammalian bombesin-related peptide, is widely distributed in the central nervous system and gastrointestinal tract. While it is known that this receptor is coupled to phospholipase C, like many other phospholipase C-activating receptors, little is known about regulation of the NMB-R subsequent to agonist stimulation. We studied both native NMB-R on C-6 rat glioblastoma cells and wild type NMB-R cloned from rat esophageal muscle which was stably transfected into Balb/3T3 fibroblasts. Both cell types rapidly increased [H-3]inositol phosphates and [Ca2+](i) in response to 1 mu M NMB, whereas preincubation with 3 nM NMB for 3 h markedly attenuated the ability of 1 mu M NMB, but not 1 mu M endothelin-1, to alter either cell type's biological activity. Prolonged exposure to 3 nM NMB caused a rapid decrease in the number of NMB-R, with the maximal receptor down-regulation seen at 24 h due to NMB-R internalization. After maximal downregulation, removal of agonist resulted in a rapid restoration of NMB-R to the cell surface of both cell types. NMB-R recovery at 6 h was blocked by monensin, an inhibitor of receptor recycling, but was not affected by cycloheximide, a protein synthesis inhibitor. Resensitization to agonist paralleled the recovery of MMB-R in both cell types, and resensitization likewise was blocked by monensin. Our data demonstrate that the NMB-R undergoes rapid homologous desensitization consequent to agonist stimulation, which is mediated by receptor down-regulation and which, in turn, is regulated by internalization. During resensitization, NMB-R reappearance on the cell surface membrane is independent of protein synthesis and is due to a recycling from an intracellular site.	NCI, BIOL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BENYA, RV (corresponding author), NIDDKD, DIGEST DIS BRANCH, BETHESDA, MD 20892 USA.							ALBERS HE, 1991, J NEUROSCI, V11, P846; ASSELIN J, 1987, AM J PHYSIOL, V252, pG392, DOI 10.1152/ajpgi.1987.252.3.G392; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1993, GASTROENTEROLOGY, V104, pA812; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOLOGNA M, 1989, CANCER, V63, P1714; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; BROWN MR, 1988, ANN NY ACAD SCI, V547, P174, DOI 10.1111/j.1749-6632.1988.tb23885.x; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CHAU LY, 1991, LIPIDS, V26, P1076, DOI 10.1007/BF02536505; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; GHATEI MA, 1982, J CLIN ENDOCR METAB, V54, P980, DOI 10.1210/jcem-54-5-980; GLADHAUG IP, 1988, J BIOL CHEM, V263, P12199; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HOOTMAN SR, 1991, AM J PHYSIOL, V261, pG128, DOI 10.1152/ajpgi.1991.261.1.G128; HU JR, 1991, J PHARMACOL EXP THER, V257, P938; JENSEN RT, 1988, ANN NY ACAD SCI, V547, P138, DOI 10.1111/j.1749-6632.1988.tb23882.x; KANETO A, 1978, METABOLISM, V27, P549, DOI 10.1016/0026-0495(78)90021-5; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LADENHEIM EE, 1990, BRAIN RES, V537, P233, DOI 10.1016/0006-8993(90)90363-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE L, 1983, EUR J PHARMACOL, V95, P215, DOI 10.1016/0014-2999(83)90637-4; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; MANTEY S, 1993, MOL PHARMACOL, V43, P762; MASTERS SB, 1985, MOL PHARMACOL, V27, P325; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MORAN TH, 1988, PEPTIDES, V9, P643, DOI 10.1016/0196-9781(88)90177-5; MORRISON WJ, 1988, MOL PHARMACOL, V33, P58; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; RETTORI V, 1992, P NATL ACAD SCI USA, V89, P3035, DOI 10.1073/pnas.89.7.3035; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STEIN BS, 1984, J BIOL CHEM, V259, P4762; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; SWOPE SL, 1990, MOL PHARMACOL, V37, P758; SWOPE SL, 1987, BIOCHEM J, V247, P731, DOI 10.1042/bj2470731; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; VIGNA SR, 1987, GASTROENTEROLOGY, V93, P1287, DOI 10.1016/0016-5085(87)90257-5; VINAYEK R, 1990, DIGESTION, V46, P112, DOI 10.1159/000200374; VINAYEK R, 1990, AM J PHYSIOL, V258, pG107, DOI 10.1152/ajpgi.1990.258.1.G107; VONSCHRENCK T, 1989, AM J PHYSIOL, V256, pG747, DOI 10.1152/ajpgi.1989.256.4.G747; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WANG LH, 1992, BIOCHEM J, V286, P641, DOI 10.1042/bj2860641; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	65	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11721	11728						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163469				2022-12-27	WOS:A1994NG37700011
J	GOROSPE, M; BAGLIONI, C				GOROSPE, M; BAGLIONI, C			DEGRADATION OF UNSTABLE INTERLEUKIN-1-ALPHA MESSENGER-RNA IN A RABBIT RETICULOCYTE CELL-FREE SYSTEM - LOCALIZATION OF AN INSTABILITY DETERMINANT TO A CLUSTER OF AUUUA MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; URIDINE BINDING-FACTOR; RICH SEQUENCES; C-FOS; REGION; IDENTIFICATION; LYMPHOKINE; REMOVAL; PROTEIN; POLY(A)	Labeled transcripts of interleukin-1 alpha (IL-1 alpha) cDNA were rapidly degraded in incubations with rabbit reticulocyte lysate (RRL). In contrast, a transcript of superoxide dismutase cDNA was stable in control incubations. A transcript of the 3'-untranslated region (UTR) of IL-1 alpha was rapidly degraded while that of the 5'-UTR and coding region was stable. This degradative activity was present in the post-ribosomal supernatant. Degradation of the 3'-UTR transcript was inhibited by the addition of a large excess of an 80-base RNA containing four AUUUA repeats, but not by the same RNA without such repeats. This suggested that AUUUA motifs were responsible for the instability of the 3'-UTR transcript. The 80-base RNA did not act as a competitive substrate for a nuclease since it was not degraded. Partial transcripts of IL-1 alpha 3'-UTR were incubated with RRL to localize instability determinants. Transcripts containing at least three clustered AUUUA motifs were rapidly degraded, while transcripts containing four scattered AUUUA motifs were stable. To study the mechanism of RNA degradation, the RRL was passed through an affinity column that retained AUUUA-binding proteins. The flow-through or the fraction eluted from such a column were inactive, but the two fractions together degraded the 3'-UTR transcript. This indicated that proteins bound by the affinity column did not have nuclease activity but targeted this RNA for degradation.	SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GUBLER U, 1986, J IMMUNOL, V136, P2492; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HEPLER JE, 1990, ENDOCRINOLOGY, V127, P1550, DOI 10.1210/endo-127-3-1550; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MELENDEZ JA, 1993, FREE RADICAL BIO MED, V14, P601, DOI 10.1016/0891-5849(93)90141-G; RAYMOND V, 1989, ONCOGENE RES, V5, P1; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; WEBER LA, 1978, METHODS ENZYMOLOGY N, P351; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x	24	38	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11845	11851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163483				2022-12-27	WOS:A1994NG37700029
J	HARRIS, HW; ZEIDEL, ML; JO, IH; HAMMOND, TG				HARRIS, HW; ZEIDEL, ML; JO, IH; HAMMOND, TG			CHARACTERIZATION OF PURIFIED ENDOSOMES CONTAINING THE ANTIDIURETIC HORMONE-SENSITIVE WATER CHANNEL FROM RAT RENAL PAPILLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; STIMULATED TOAD BLADDER; DUCT PRINCIPAL CELLS; COLLECTING DUCT; PERMEABILITY RESPONSE; ENDOCYTIC VESICLES; CHIP28 PROTEIN; COATED PITS; PROTON; CONTAIN	Antidiuretic hormone (ADH) stimulation of renal epithelial cells elicits a large increase in apical membrane osmotic water permeability (P-f) produced by the fusion of water channel containing vesicles with the apical membrane. Removal of ADH stimulation results in retrieval of apical water channels into a specialized nonacidic endosomal compartment. Previous studies (Sabolic, I., Wuarin, E., and Shi, L, B. (1992) J. Cell Biol. 119, 111-122) have shown that water channel containing papillary endosomes labeled with fluorescein-dextran can be isolated from rat renal papilla. We have utilized small particle flow sorting methodology to both monitor and improve upon the purification of these water channel containing endosomes (WCV). Flow cytometry analysis on a vesicle-by-vesicle basis demonstrates that WCV are homogenous with respect to entrapped fluorescein-dextran, the apical membrane enzyme marker leucine amino peptidase and ultrastructural morphology. WCV do not acidify their luminal contents after addition of Mg-ATP but contain abundant functional water channels (P-f 0.28 cm/s at 23 degrees C) as determined by stopped flow fluorimetry. SDS-polyacrylamide gel electrophoresis analysis shows that purified WCV are composed of 20 major protein bands. To determine the identity of WCV water channels, WCV proteins were probed with affinity purified antisera recognizing two renal water channel proteins. These include Aquaporin-CHIP found in the proximal tubule and thin descending limb of Henle and the candidate ADH water channel protein WCH-1 or Aquaporin- (AQP) CD present in the ADH-responsive epithelial cells of the collecting duct. These data reveal that WCV contained little or no AQP-CHIP protein. In contrast, WCV are highly enriched for AQP-CD protein. Together, these data define the protein composition of the papillary WCV and link directly the presence of functional apical membrane water channels with the presence of the AQP-CD protein.	BROCKTON W ROXBURY VET ADM MED CTR,DIV NEPHROL,BOSTON,MA 02115; UNIV PITTSBURGH,SCH MED,DIV RENAL & ELECTROLYTE,PITTSBURGH,PA 15213; UNIV WISCONSIN HOSP & CLIN,WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53792	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	HARRIS, HW (corresponding author), CHILDRENS HOSP,DIV NEPHROL,HUNNEWELL 3,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046117, R01DK038874, R01DK043955] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43955, DK 38874, DK 46117] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; BROWN D, 1983, NATURE, V302, P253, DOI 10.1038/302253a0; BROWN D, 1988, EUR J CELL BIOL, V46, P336; COLEMAN RA, 1992, EUR J CELL BIOL, V58, P44; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DING G, 1993, AM J PHYSIOL, V255, pC641; DOLBEARE FA, 1977, CLIN CHEM, V23, P1485; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HAMMON DTG, 1993, CYTOMETRY, V14, P411; HAMMOND TG, 1993, BIOCHEM J, V295, P471, DOI 10.1042/bj2950471; HARRIS HW, 1990, AM J PHYSIOL, V259, pF366, DOI 10.1152/ajprenal.1990.259.2.F366; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HARRIS HW, 1990, AM J PHYSIOL, V258, pF237, DOI 10.1152/ajprenal.1990.258.2.F237; HARRIS HW, 1992, J BIOL CHEM, V267, P22115; HARRIS HW, 1987, J MEMBRANE BIOL, V96, P175, DOI 10.1007/BF01869243; HARRIS HW, 1988, J MEMBRANE BIOL, V103, P207, DOI 10.1007/BF01993980; HARRIS HW, 1991, AM J PHYSIOL, V261, pC143, DOI 10.1152/ajpcell.1991.261.1.C143; HARRIS HW, 1993, AM J PHYSIOL, V265, pC822; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; HUMBERT F, 1977, EXPERIENTIA, V33, P1364, DOI 10.1007/BF01920184; KNEPPER MA, 1993, AM J PHYSIOL, V265, pF214, DOI 10.1152/ajprenal.1993.265.2.F214; LANKFORD SP, 1991, AM J PHYSIOL, V261, pF554, DOI 10.1152/ajprenal.1991.261.3.F554; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOON C, 1993, J BIOL CHEM, V268, P15772; MULLER J, 1984, AM J PHYSIOL, V247, pC90, DOI 10.1152/ajpcell.1984.247.1.C90; NADLER SP, 1990, AM J PHYSIOL, V258, pF266, DOI 10.1152/ajprenal.1990.258.2.F266; NEILSEN S, 1993, P NATL ACAD SCI USA, V90, P7275; NEILSEN S, 1993, J CELL BIOL, V120, P371; NEILSEN S, 1993, P NATL ACAD SCI USA, V90, P11663; NEILSEN S, 1993, AM J PHYSIOL, V265, pF225; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, J CELL BIOL, V119, P111, DOI 10.1083/jcb.119.1.111; SABOLIC I, 1992, AM JPHYSL, V263, pC1223; SHI LB, 1990, J GEN PHYSIOL, V95, P941, DOI 10.1085/jgp.95.5.941; SMITH BL, 1991, J BIOL CHEM, V266, P6407; STRANGE K, 1988, J MEMBRANE BIOL, V103, P17, DOI 10.1007/BF01871929; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1989, J BIOL CHEM, V264, pC237; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; WANG YX, 1991, BIOCHEMISTRY-US, V30, P2888, DOI 10.1021/bi00225a023; ZEIDEL ML, 1992, AM J PHYSIOL, V263, pF62, DOI 10.1152/ajprenal.1992.263.1.F62; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1993, J CELL BIOL, V120, P13261	48	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11993	12000						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163502				2022-12-27	WOS:A1994NG37700051
J	KOKENYESI, R; BERNFIELD, M				KOKENYESI, R; BERNFIELD, M			CORE PROTEIN-STRUCTURE AND SEQUENCE DETERMINE THE SITE AND PRESENCE OF HEPARAN-SULFATE AND CHONDROITIN SULFATE ON SYNDECAN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; AMINO-ACID-SEQUENCES; SURFACE PROTEOGLYCAN; MEMBRANE PROTEOGLYCAN; GROWTH-FACTOR; RECEPTOR; CLONING; BETA; LOCALIZATION; EXPRESSION	Most proteoglycans bear either chondroitin sulfate or heparan sulfate chains linked to serine residues at Ser-Gly attachment sites on the core protein. However, only a fraction of proteins with Ser-Gly sites exhibit glycosaminoglycan chains. A variable proportion of these sites may be glycanated, and an unknown mechanism distinguishes whether these sites are for chondroitin sulfate or heparan sulfate. To evaluate the core protein features that determine whether and where chondroitin sulfate or heparan sulfate will be linked, we have studied mouse syndecan-1, a transmembrane proteoglycan that is invariably glycanated and can contain both chondroitin sulfate and heparan sulfate chains. The extracellular domain of the syndecan-1 core protein contains five Ser-Gly sites, three clustered near its N terminus and two adjacent to the transmembrane domain near its C terminus. We have established the distribution of glycosaminoglycans on these attachment clusters. In contrast to the C-terminal cluster, the N terminal cluster was always glycanated, suggesting that this domain of the core protein contains sequences responsible for the invariable attachment of glycosaminoglycan chains. Solely chondroitin sulfate was found on the C-terminal cluster. This cluster contains the sequences EGSGE and ETSGE, both estimated to be on the protein surface in a hydrophilic environment. Heparan sulfate was found solely on the N-terminal cluster, which also bears some chondroitin sulfate. This cluster contains the sequences FSGSGTG and DGSGD, the former estimated to be in a hydrophobic pocket and the latter, similar to the sequence on the C-terminal cluster, in an exposed hydrophilic region. This glycosaminoglycan distribution was identical on mouse syndecan-1 produced by either mouse epithelial (NMuMG) or hamster mesenchymal (CHO) cells, suggesting that site-specific attachment of glycosaminoglycans is independent of cell type. These results implicate a cellular mechanism that distinguishes among the potential sites and attaches the correct glycosaminoglycan type unambiguously. Thus, structural elements of the core protein other than the Ser-Gly attachment sites determine if a site will be glycanated and, if so, whether with chondroitin sulfate or heparan sulfate.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, JOINT PROGRAM NEONATOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School					NCI NIH HHS [CA28735] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON A, 1988, J CELL BIOL, V106, P479, DOI 10.1083/jcb.106.2.479; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; COUCHMAN JR, 1985, J BIOL CHEM, V260, P3755; DAVID G, 1979, P NATL ACAD SCI USA, V76, P786, DOI 10.1073/pnas.76.2.786; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Engvall E, 1980, Methods Enzymol, V70, P419; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUGHES WL, 1957, ANN NY ACAD SCI, V70, P3, DOI 10.1111/j.1749-6632.1957.tb35373.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; INKI P, 1992, LAB INVEST, V67, P225; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIRJAVAINEN J, 1993, MOL BIOL CELL, V4, P849, DOI 10.1091/mbc.4.8.849; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KODA JE, 1985, J BIOL CHEM, V260, P8157; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEPPA S, 1991, CELL REGUL, V2, P1; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; WEITZHANDLER M, 1988, J BIOL CHEM, V263, P6949; WOODS A, 1992, ADV EXP MED BIOL, V313, P87	46	128	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12304	12309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163535				2022-12-27	WOS:A1994NG37700095
J	JENKINS, GH; FISETTE, PL; ANDERSON, RA				JENKINS, GH; FISETTE, PL; ANDERSON, RA			TYPE-I PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE ISOFORMS ARE SPECIFICALLY STIMULATED BY PHOSPHATIDIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-D; GROWTH-FACTOR; POLYACRYLAMIDE GELS; RAT-BRAIN; KINASE; PURIFICATION; MEMBRANES; PROTEINS; DIACYLGLYCEROL	A phosphatidylinositol 4-phosphate (PIP) kinase was isolated and purified to near homogeneity from bovine erythrocyte membranes. The PIP kinase was extracted from bovine erythrocyte membranes with a high salt wash, followed by phosphocellulose and phenyl-Sepharose chromatography. The predominant protein after phenyl-Sepharose purification had a molecular size of 68 kDa. Renaturation of PIP kinase activity after SDS-PAGE showed that a 68-kDa protein was able to phosphorylate PIP. An antibody developed against the 68-kDa protein Western blots the 68-kDa protein and is able to immunoprecipitate the 68-kDa protein and PIP kinase activity from membrane extracts. Based on functional studies, the 68-kDa protein is indistinguishable from the type I PIP kinase previously characterized from human erythrocyte membranes (Bazenet, C. E., Ruano, A. R., Brockman, J. L., and Anderson, R. A. (1990) J. Biol. Chem. 265,18012-18022). These studies also show that the type I PIP kinases, but not the type II PIP kinase, are stimulated by phosphatidic acid, suggesting alternative roles for these enzymes. Two immunoreactive isoforms of the type I PIP kinase, of 68 and 90 kDa, were identified in rat brain and partially purified. Both of these isoforms are also stimulated by phosphatidic acid.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,1300 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Anderson, Richard/0000-0001-6265-8359	NIGMS NIH HHS [GM38906] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038906, R29GM038906] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11156; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; COCHET C, 1991, J BIOL CHEM, V266, P637; COCHET C, 1986, BIOCHEM J, V237, P25, DOI 10.1042/bj2370025; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1992, BIOCHEM J, V288, P637, DOI 10.1042/bj2880637; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JENKINS GH, 1991, BIOCHIM BIOPHYS ACTA, V1080, P11, DOI 10.1016/0167-4838(91)90105-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; KONDO T, 1992, J BIOL CHEM, V267, P23609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING LE, 1989, J BIOL CHEM, V264, P5080; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MORITZ A, 1990, J NEUROCHEM, V54, P351, DOI 10.1111/j.1471-4159.1990.tb13322.x; MORITZ A, 1992, J BIOL CHEM, V267, P7207; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URUMOW T, 1990, BIOCHIM BIOPHYS ACTA, V1052, P152, DOI 10.1016/0167-4889(90)90070-T; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; VANDONGEN CJ, 1984, BIOCHEM J, V223, P197, DOI 10.1042/bj2230197	33	374	380	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11547	11554						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157686				2022-12-27	WOS:A1994NF96600085
J	SHAPIRO, MJ; KOSHLAND, DE				SHAPIRO, MJ; KOSHLAND, DE			MUTAGENIC STUDIES OF THE INTERACTION BETWEEN THE ASPARTATE RECEPTOR AND METHYLTRANSFERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; ACCEPTING CHEMOTAXIS PROTEINS; BACTERIAL CHEMOTAXIS; COVALENT MODIFICATION; SIGNAL TRANSDUCTION; METHYL ESTERIFICATION; GENE-PRODUCT; SITES; CHEMORECEPTOR; SYSTEM	The 4 glutamate residues that are the sites of methylation in the aspartate receptor, which mediates bacterial chemotaxis, were systematically mutated to aspartate residues. None of the aspartate residues were methylated. In each case, the presence of the aspartate mutations altered the methylation rates at glutamate residues on the same receptor. Methylation was nearly eliminated at residues two turns of a helix, in the N-terminal direction, from a site of mutation, whereas less severe changes occurred at other positions. The methyltransferase apparently must contact a glutamate or glutamine residue two turns of helix in the C-terminal direction from the site of modification in order to methylate that position at a maximal rate. Mutations from glutamate to aspartate at any of the four sites also appear to alter the methylation rate at the other sites through a change in the structure of the receptor. The aspartate mutations did not substantially alter the affinity of the methyltransferase for the receptor.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORCZUK A, 1986, BIOCHEM BIOPH RES CO, V141, P918, DOI 10.1016/S0006-291X(86)80130-9; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; DUNTEN P, 1991, J BIOL CHEM, V66, P491; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HARRING H, 1986, BIOCHEM J, V234, P59; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KEHRY MR, 1982, J BIOL CHEM, V257, P378; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P482; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; Sambrook J, 1989, MOL CLONING LABORATO; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIMMS SA, 1991, J BIOL CHEM, V266, P12741; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TERWILLIGER TC, 1983, J BIOL CHEM, V258, P9608; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987	32	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11054	11059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157631				2022-12-27	WOS:A1994NF96600016
J	TARTARE, S; MOTHE, I; KOWALSKICHAUVEL, A; BREITTMAYER, JP; BALLOTTI, R; VANOBBERGHEN, E				TARTARE, S; MOTHE, I; KOWALSKICHAUVEL, A; BREITTMAYER, JP; BALLOTTI, R; VANOBBERGHEN, E			SIGNAL-TRANSDUCTION BY A CHIMERIC INSULIN-LIKE GROWTH-FACTOR-I (IGF-1) RECEPTOR HAVING THE CARBOXYL-TERMINAL DOMAIN OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR-I; PHOSPHATIDYLINOSITOL 3'-KINASE; MOLECULAR MECHANISM; INTACT-CELLS; PROTEIN; BINDING; IRS-1; PHOSPHORYLATION; STIMULATION	Insulin-like growth factor-1 receptors (IGF-1R) and insulin receptors (IR) are closely related tyrosine kinases. However, the IR plays a major role in metabolism control, whereas the IGF-1R is mainly involved in growth and differentiation. With these observations in mind, we wished to define the regions of IR and IGF-1R responsible for generation of biological specificity. We constructed a chimeric IGF-1R in which the carboxyl-terminal domain was replaced by that of IR. This receptor (IGF/(CT)IR) was expressed in NIH3T3 cells, and we compared its biological activity with that of wild-type receptors. The IGF/(CT)IR was fully functional regarding kinase activity and biological properties. Comparison of insulin and IGF-1 effects on IR and IGF-1R cells, respectively, indicated that the IR is more efficient in stimulating glycogen synthesis and p44mapk activity than is the IGF-1R. Interestingly, in IGF/(CT)IR16 cells expressing only 250,000 receptors glycogen synthesis was better stimulated than in IGF-1R cells with 600,000 receptors. Similarly, p44mapk activation was slightly higher in IGF/(CT)IR16 cells than in IGF-1R cells. These results suggest that the carboxyl-terminal domain of IR is more tightly coupled to the stimulation of glycogen synthesis and to the p44mapk pathway than is that of IGF-1R. We propose that this domain plays a crucial role in the transmission of biological effects and could account, at least in part, for receptor specificity.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE; FAC MED NICE,INSERM,U343,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Kowalski-Chauvel, Aline/O-9212-2014; BALLOTTI, Robert/F-8825-2013; TARTARE-DECKERT, Sophie/P-6057-2015; MOTHE-SATNEY, ISABELLE/Q-6377-2016	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; BALLOTTI, Robert/0000-0002-7322-4908; MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALLOTTI R, 1991, EXP CELL RES, V197, P300, DOI 10.1016/0014-4827(91)90436-X; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GOTTSCHALK WK, 1992, BIOCHEM BIOPH RES CO, V189, P906; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAHN CR, 1985, ANNU REV MED, V36, P429; KATO H, 1993, J BIOL CHEM, V268, P2655; KHUNE MR, 1993, J BIOL CHEM, V268, P11479; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P913; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOSS MA, 1992, J BIOL CHEM, V267, P12955; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11449	11455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157675				2022-12-27	WOS:A1994NF96600070
J	POWELL, LD; VARKI, A				POWELL, LD; VARKI, A			THE OLIGOSACCHARIDE BINDING SPECIFICITIES OF CD22-BETA, A SIALIC ACID-SPECIFIC LECTIN OF B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-MUCUS GLYCOPROTEINS; BOMBARDMENT MASS-SPECTROMETRY; 500-MHZ H-1-NMR SPECTROSCOPY; QUANTITATIVE SUGAR ANALYSIS; SIALYLATED OLIGOSACCHARIDES; LINKED OLIGOSACCHARIDES; AFFINITY-CHROMATOGRAPHY; BOVINE COLOSTRUM; T-CELLS; ANTIGEN	CD22 beta is a B cell surface glycoprotein involved in cell adhesion and activation, We previously reported that a recombinant soluble form termed CD22 beta Rg is capable of binding alpha 2-6 sialylated complex N-linked oligosaccharides purified from lymphocyte glycoprotein ligands (Powell, L. D., Sgroi, D., Sjoberg, E. R, Stamenkovic, I., and Varki, A. (1993) J. Biol. Chem. 268, 7019-7027). Here, we utilize a number of naturally and enzymatically sialylated oligosaccharides and sialoglycoproteins to further define its lectin specificity and demonstrate that the minimal structure recognized is Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc). Reduction of the glucose residue of Neu5Ac alpha 2-6Gal beta 1-4Glc diminishes the interaction, while truncation of the sialic acid side chain by mild periodate oxidation abolishes it. Branched oligosaccharides with two alpha 2-6 sialyl residues bind better, regardless of whether they were derived from N- or O-Linked oligosaccharides or from gangliosides. alpha 2-3-Sialyl residues have no effect on binding, whereas increasing the number of alpha 2-6-sialyl residues on multiantennary oligosaccharides progressively improves binding. No specific feature of the core region affects binding, although the spacing of the alpha 2-6-sialyl residues on tetraantennary chains appears to have a significant effect. Of several model sialoglycoproteins examined, fetuin and transferrin had an apparent affinity no greater than that observed with free sialylated N-linked oligosaccharides. Some subfractions of these proteins displayed unexpectedly weak binding, suggesting that the protein backbone can exert a negative effect. In contrast, a subfraction of alpha(1)-acid glycoprotein was identified as having a substantially higher apparent affinity than free oligosaccharides derived from it, indicating that multiple glycosylation sites may increase the apparent binding affinity. Thus, CD22 beta Rg contains a lectin activity specific for the minimal motif Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc), and branched, multisialylated oligosaccharides are better ligands, regardless of the core sequences. Intact sialoglycoproteins can also interact, although with a variable affinity not directly predictable from the precise structure of their sialylated oligosaccharides chains. These data may help to explain why certain T and B cell surface sialoglycoproteins with the Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc) motif are superior ligands, capable of mediating CD22 beta-mediated adhesion and activation events.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [KO1 CA01649] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BERZOFSKY JA, 1989, FUNDAMENTAL IMMUNOLO, P315; BREG J, 1989, EUR J BIOCHEM, V178, P727, DOI 10.1111/j.1432-1033.1989.tb14504.x; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; DELAU WBM, 1993, J IMMUNOL, V150, P4911; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; ENGEL P, 1993, J IMMUNOL, V150, P4719; FU DT, 1992, ANAL BIOCHEM, V206, P53, DOI 10.1016/S0003-2697(05)80010-7; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; FUKUDA MN, 1986, J BIOL CHEM, V261, P5145; GREEN ED, 1988, J BIOL CHEM, V263, P25; GUY K, 1991, IMMUNOLOGY, V74, P206; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; Hynes RO, 1990, FIBRONECTINS; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KLEIN A, 1988, EUR J BIOCHEM, V171, P631, DOI 10.1111/j.1432-1033.1988.tb13834.x; KNIEP B, 1990, FEBS LETT, V261, P347, DOI 10.1016/0014-5793(90)80588-A; LEE RT, 1988, BIOCHEM BIOPH RES CO, V155, P1444, DOI 10.1016/S0006-291X(88)81303-2; LEE YC, 1983, J BIOL CHEM, V258, P199; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MANZI AE, 1990, J BIOL CHEM, V265, P8094; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; POWELL LD, 1993, J BIOL CHEM, V268, P7019; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TAI GH, 1992, BIOCHEM J, V286, P231, DOI 10.1042/bj2860231; TAKI T, 1992, CANCER RES, V52, P4805; TONG PY, 1989, J BIOL CHEM, V264, P7970; TOWNSEND RR, 1989, ANAL BIOCHEM, V182, P1; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VARKI A, 1983, J BIOL CHEM, V258, P2808; WANG XC, 1993, J BIOL CHEM, V268, P4355; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEN DX, 1992, J BIOL CHEM, V267, P2512; WHITEHEART SW, 1987, ANAL BIOCHEM, V163, P123, DOI 10.1016/0003-2697(87)90102-3; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	49	149	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10628	10636						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144652				2022-12-27	WOS:A1994NF01700067
J	HAYAKAWA, Y				HAYAKAWA, Y			CELLULAR IMMUNOSUPPRESSIVE PROTEIN IN THE PLASMA OF PARASITIZED INSECT LARVAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOPLUSIA-INCLUDENS; MICROPLITIS-DEMOLITOR; PSEUDALETIA-SEPARATA; APANTELES-KARIYAI; HOST; HEMOCYTES; PEPTIDE; IMMUNITY; HORMONE; GROWTH	Evidence that endoparasitoid wasps may suppress the host cellular defense reaction in order to survive within the hemocoel of their host insects was obtained by isolating a cellular immunosuppressive factor from the larval plasma (hemolymph without cells) of the armyworm Pseudaletia separata parasitized with the wasp Cotesia kariyai. The purified proteinaceous factor suppresses hemocyte degranulation and subsequent immune reactions such as nodule formation and encapsulation in the armyworm larvae. The immunosuppressive protein exists not only in the plasma of parasitized larvae but also in the plasma of unparasitized larvae. However, its concentration is much less in unparasitized than in parasitized larvae. Purification procedures involved gel exclusion, ion exchange, and reversed phase high performance liquid chromatography (HPLC). Gel exclusion HPLC and SDS-polyacrylamide gel electrophoresis suggest an approximately 470-kDa hexamer composed of identical subunits of 82 kDa. Aryl amino acids such as tyrosine and phenylalanine comprise about 20% of the total protein amino acid. The sequence of 28 amino acid residues at the amino terminus of the factor was determined to be as follows: Ser-Val-Val-Pro-Thr-Lys-His-Glu-Ile-Lys -Val-Lys-Ala-Val-Glu-Pro-Gln-Tyr-Ile-Xaa-Tyr-Gln-Arg-Lys-Ile-Leu-Ala-Leu-Phe-.			HAYAKAWA, Y (corresponding author), HOKKAIDO UNIV, INST LOW TEMP SCI, BIOCHEM LAB, SAPPORO, HOKKAIDO 060, JAPAN.							BAINES D, 1992, ARCH INSECT BIOCHEM, V21, P303, DOI 10.1002/arch.940210407; BAINES D, 1992, J INSECT PHYSIOL, V38, P905, DOI 10.1016/0022-1910(92)90102-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHINZEI Y, 1983, J COMP PHYSIOL, V152, P13, DOI 10.1007/BF00689722; DAVIES DH, 1987, J INSECT PHYSIOL, V33, P143, DOI 10.1016/0022-1910(87)90140-5; EDSON KM, 1981, SCIENCE, V211, P582, DOI 10.1126/science.7455695; GOTZ P, 1985, COMPREHENSIVE INSECT, V3, P452; Gupta AP, 1985, COMPREHENSIVE INSECT, P85; GUZO D, 1985, PARASITOLOGY, V90, P1, DOI 10.1017/S0031182000048964; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1993, INSECT BIOCHEM MOLEC, V23, P225, DOI 10.1016/0965-1748(93)90003-B; HAYAKAWA Y, 1992, BIOCHEM BIOPH RES CO, V185, P1141, DOI 10.1016/0006-291X(92)91745-C; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; KITANO H, 1974, J INSECT PHYSIOL, V20, P315, DOI 10.1016/0022-1910(74)90064-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; Mullins D.E., 1985, P355; Nappi A.J., 1975, P293; NAPPI AJ, 1969, J INSECT PHYSIOL, V15, P1551, DOI 10.1016/0022-1910(69)90175-9; Nappi AJ, 1974, CONTEMPORARY TOPICS, V4, P207; Ratcliffe N.A., 1979, P331, DOI 10.1017/CBO9780511759987.014; RIZKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P6154, DOI 10.1073/pnas.81.19.6154; RIZKI RM, 1990, P NATL ACAD SCI USA, V87, P8388, DOI 10.1073/pnas.87.21.8388; SMITH EM, 1992, P NATL ACAD SCI USA, V89, P782, DOI 10.1073/pnas.89.2.782; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P6307, DOI 10.1073/pnas.86.16.6307; STOLTZ DB, 1986, J INSECT PHYSIOL, V32, P377, DOI 10.1016/0022-1910(86)90051-X; STRAND MR, 1991, J INSECT PHYSIOL, V37, P503, DOI 10.1016/0022-1910(91)90027-W; STRAND MR, 1991, J INSECT PHYSIOL, V37, P839, DOI 10.1016/0022-1910(91)90080-J; STREAMS FA, 1969, J INVERTEBR PATHOL, V13, P371, DOI 10.1016/0022-2011(69)90188-8; STROKA P, 1978, INSECT BIOCHEM, V8, P399; TANAKA T, 1987, DEV COMP IMMUNOL, V11, P57, DOI 10.1016/0145-305X(87)90008-5; TANAKA T, 1987, J INSECT PHYSIOL, V33, P413, DOI 10.1016/0022-1910(87)90020-5; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; VINSON SB, 1990, ARCH INSECT BIOCHEM, V13, P3, DOI 10.1002/arch.940130103; VINSON SB, 1977, EXP PARASITOL, V41, P112, DOI 10.1016/0014-4894(77)90136-9; WILLOTT E, 1989, J BIOL CHEM, V264, P19052	38	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14536	14540						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182060				2022-12-27	WOS:A1994NM06500037
J	CHEN, Q; OSTERYOUNG, K; VIERLING, E				CHEN, Q; OSTERYOUNG, K; VIERLING, E			A 21-KDA CHLOROPLAST HEAT-SHOCK PROTEIN ASSEMBLES INTO HIGH-MOLECULAR-WEIGHT COMPLEXES IN-VIVO AND IN ORGANELLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CRYSTALLIN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA DEVELOPMENT; RODENT CELLS; EXPRESSION; LOCALIZATION; SUPERFAMILY; RESISTANCE; CHAPERONE; SEQUENCE	The conservation of the carboxyl terminal ''heat shock'' domain among small (sm) cytoplasmic and chloroplast heat shock proteins (HSPs) suggests that these smHSPs perform similar functions. Previous studies have established that cytoplasmic smHSPs are found in higher order structures in vivo (approximately 500 kDa). To determine if the chloroplast smHSP is found in similar complexes, we examined the size of the 21-kDa chloroplast smHSP from Pisum sativum, PsHSP21, under non-denaturing conditions. Following sedimentation of chloroplast stromal extracts on sucrose gradients PsHSP21 is detected in fractions corresponding to 10-11 S. Upon non-denaturing gel electrophoresis, PsHSP21 was detected in two high molecular mass complexes of approximately 230 and 200 kDa, in good agreement with the sucrose gradient data. These PsHSP21 containing particles were stable under different salt and Mg2+ conditions, and their integrity was not affected by 1.0% Triton X-100 or 10 mM ATP. To study assembly of the high molecular weight complexes containing PsHSP21, in vitro translated PsHSP21 was imported into chloroplasts and its size was examined. Following import into chloroplasts isolated from heat-stressed plants, greater than 50% of PsHSP21 was recovered in the higher molecular weight forms. In contrast, following import into chloroplasts isolated from control plants the protein was recovered exclusively in a 5 S (approximately 42-kDa) form. These data suggest that preexisting PsHSP21 or other heat-induced factors may be required for assembly of the higher molecular weight particles. We propose that the 10-11 S particles are the functional form of PsHSP21.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	University of Arizona				chen, qiang/0000-0003-1498-7013; Vierling, Elizabeth/0000-0002-0066-4881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013953, R01GM042762] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM13953-10A1, R01 GM42762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; ARRIGO AP, 1988, EXP CELL RES, V175, P169, DOI 10.1016/0014-4827(88)90264-9; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1987, DEV BIOL, V122, P39, DOI 10.1016/0012-1606(87)90330-7; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; CHEN Q, 1990, J CELL BIOL, V110, P1873, DOI 10.1083/jcb.110.6.1873; CHEN Q, 1991, MOL GEN GENET, V226, P425, DOI 10.1007/BF00260655; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HELM KW, 1993, MOL CELL BIOL, V13, P238, DOI 10.1128/MCB.13.1.238; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUOT J, 1991, CANCER RES, V51, P5245; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KLOPPSTECH K, 1985, EMBO J, V4, P1901, DOI 10.1002/j.1460-2075.1985.tb03869.x; KRAUSE GH, 1975, PLANTA, V127, P285, DOI 10.1007/BF00380726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NIETOSOTELO J, 1990, PLANT PHYSIOL, V93, P1321, DOI 10.1104/pp.93.4.1321; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; OSTERYOUNG KW, 1994, IN PRESS NATO ASI H; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PLESOFSKYVIG N, 1992, J MOL EVOL, V35, P537, DOI 10.1007/BF00160214; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; SHAVIT N, 1967, BIOCHEM BIOPH RES CO, V28, P277, DOI 10.1016/0006-291X(67)90441-X; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; SUSS KH, 1986, PLANT PHYSIOL, V81, P192, DOI 10.1104/pp.81.1.192; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VIERLING E, 1989, MOL CELL BIOL, V9, P461, DOI 10.1128/MCB.9.2.461; VIERLING E, 1986, P NATL ACAD SCI USA, V83, P361, DOI 10.1073/pnas.83.2.361; VIERLING E, 1988, EMBO J, V7, P575, DOI 10.1002/j.1460-2075.1988.tb02849.x; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WENG J, 1991, PLANT MOL BIOL, V17, P255, DOI 10.1007/BF00039500; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	46	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13216	13223						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175751				2022-12-27	WOS:A1994NK18400028
J	JI, ZS; FAZIO, S; MAHLEY, RW				JI, ZS; FAZIO, S; MAHLEY, RW			VARIABLE HEPARAN-SULFATE PROTEOGLYCAN BINDING OF APOLIPOPROTEIN-E VARIANTS MAY MODULATE THE EXPRESSION OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; HERITABLE HYPERLIPIDEMIC RABBITS; CULTURED-CELLS; CLEARANCE; LIVER; MICE; HYPERCHOLESTEROLEMIA; CHOLESTEROL; HEPATOCYTES	The initial step in the clearance of apolipoprotein (apo) E-enriched remnant lipoproteins from the plasma appears to be sequestration within the liver mediated by their binding to heparan sulfate proteoglycans (HSPG). The surface-bound remnants are believed to be internalized by their interaction with the low density lipoprotein (LDL) receptor-related protein or by the LDL receptor. Cholesterol-induced rabbit beta-very low density lipoproteins (beta-VLDL) enriched in human apoE3 display 4-5-fold enhanced binding to cultured cells. The present study attempts to determine whether recessive versus dominant type III hyperlipoproteinemia might be explained, at least in part, by a variable interaction of the mutant forms of apoE with the HSPG and impaired uptake. The beta-VLDL + apoE2(Arg(158) --> Cys), which is associated with recessive type III hyperlipoproteinemia, bound more poorly than beta-VLDL + apoE3 but still possessed significant enhanced binding (similar to 2-2.5-fold compared with beta-VLDL without added apoE) to HepG2 and McA-RH7777 cells. In comparison, beta-VLDL + apoE(Arg(142) --> Cys), beta-VLDL + apoE(Arg(145) --> Cys), and beta-VLDL + apoE-Leiden, which are associated with dominant type III hyperlipoproteinemia, bound more poorly. This same hierarchy of binding and uptake was determined by [C-14]oleate incorporation into cholesteryl esters in LDL receptor-negative cells and by secretion of apoE3 and the variant apoE forms from McA-RH7777 cells. Furthermore, the enhanced binding of the apoE-enriched beta-VLDL was almost totally inhibited by heparinase treatment of the cells, and the basal binding activity was inhibited by 80-90% following addition of an LDL receptor antibody capable of blocking receptor-ligand interaction. The beta-VLDL enriched in apoE or apoE dimyristoylphosphatidylcholine complexes bound to isolated HSPG from McA-RH7777 cells or the rat liver to a very similar degree. Likewise, the binding of beta-VLDL plus the various forms of apoE to the LDL receptor-related protein on ligand blots paralleled the results of other studies. In conclusion, all of the type III hyperlipoproteinemic apoE variants are defective in displaying enhanced binding to HSPG and in the cellular uptake initiated by HSPG. However, apoE2(Arg(158) --> Cys) displayed more activity than the variants associated with the dominant forms of type III hyperlipoproteinemia. The hierarchy of binding and uptake was as follows: apoE3 > apoE2(Arg(158) --> Cys) > apoE(Arg(145) --> Cys) > apoE(Arg(142) --> Cys) approximate to apoE-Leiden (the latter two usually displaying very little, if any, enhanced binding and uptake). Thus, a correlation exists between the mode of expression of type III hyperlipoproteinemia and the binding and uptake of the specific apoE mutation.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes					NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; FAZIO S, 1993, J LIPID RES, V34, P447; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HERZ J, 1990, J BIOL CHEM, V265, P21355; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HIXSON JE, 1990, J LIPID RES, V31, P545; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13926; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOHSE P, 1991, J BIOL CHEM, V266, P10479; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RALLSC, 1992, J INTERN MED, V231, P653; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SMIT M, 1990, J LIPID RES, V31, P45; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; STOW JL, 1985, J CELL BIOL, V100, P975, DOI 10.1083/jcb.100.3.975; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; THUREN T, 1992, BIOCHEMISTRY-US, V31, P2332, DOI 10.1021/bi00123a018; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WERNETTEHAMMOND ME, 1989, ARTERIOSCLEROSIS, V9, P501, DOI 10.1161/01.ATV.9.4.501; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	122	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13421	13428						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175773				2022-12-27	WOS:A1994NK18400056
J	MROCZKOWSKI, BS; HUVAR, A; LERNHARDT, W; MISONO, K; NIELSON, K; SCOTT, B				MROCZKOWSKI, BS; HUVAR, A; LERNHARDT, W; MISONO, K; NIELSON, K; SCOTT, B			SECRETION OF THERMOSTABLE DNA-POLYMERASE USING A NOVEL BACULOVIRUS VECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; RECOMBINANT BACULOVIRUS; HONEYBEE PREPROMELITTIN; ALKALINE-PHOSPHATASE; PYROCOCCUS-FURIOSUS; EXPRESSION VECTORS; INFLUENZA-VIRUS; SIGNAL PEPTIDE; SEQUENCE; PROTEINS	Baculovirus-mediated expression has become a powerful tool for the high yield production of functionally active recombinant proteins. In order to further enhance the utility of this expression system, we constructed versatile transfer vectors that facilitate the secretion of recombinant proteins from host insect cells by inserting functional secretory leader sequences down-stream of the polyhedrin promoter. In-frame insertion of cDNA sequences results in the synthesis of fusion proteins containing a heterologous signal sequence which directs the recombinant protein to the secretory pathway. Human and insect leader sequences were successfully tested with a number of proteins including the thermostable Pyrococcus furiosus (Pfu) DNA polymerase in an effort to maximize secretion of heterologous proteins from insect cells. The human placental alkaline phosphatase signal sequence (MLGPCMLLLLLLLGLR-LQLSLG) proved to be optimal for the secretion of not only this thermostable bacterial enzyme but also for the secretion of other biologically active polypeptides.	STRATAGENE INC,DIV RES & DEV,LA JOLLA,CA 92037; CLEVELAND CLIN FDN,CLEVELAND,OH 44195	Cleveland Clinic Foundation	MROCZKOWSKI, BS (corresponding author), AGOURON INST,LA JOLLA,CA 92037, USA.							AYOLA B, 1993, VIROLOGY, V194, P370, DOI 10.1006/viro.1993.1270; BESMAN M, 1985, J BIOL CHEM, V260, P1190; BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; BUSTOS MM, 1988, PLANT MOL BIOL, V10, P475, DOI 10.1007/BF00033603; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COBB RR, 1992, BIOCHEM BIOPH RES CO, V185, P1022, DOI 10.1016/0006-291X(92)91729-A; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; ERTL PF, 1991, J GEN VIROL, V72, P1729, DOI 10.1099/0022-1317-72-7-1729; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; FURLONG AM, 1988, BIOTECHNOL APPL BIOC, V10, P454; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; KLOC M, 1991, J BIOL CHEM, V266, P8206; KOBAYASHI M, 1992, VIRUS RES, V22, P235, DOI 10.1016/0168-1702(92)90055-E; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBACQVERHEYDEN AM, 1988, MOL CELL BIOL, V8, P3129, DOI 10.1128/MCB.8.8.3129; LERNHARDT W, 1993, STRATEGIES, V5, P21; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAEDA S, 1989, ANNU REV ENTOMOL, V34, P351, DOI 10.1146/annurev.en.34.010189.002031; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOLLAY C, 1982, P NATL ACAD SCI-BIOL, V79, P2260, DOI 10.1073/pnas.79.7.2260; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SUCHANEK G, 1978, P NATL ACAD SCI USA, V75, P701, DOI 10.1073/pnas.75.2.701; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P10; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	43	20	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13522	13528						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175786				2022-12-27	WOS:A1994NK18400069
J	DIIANNI, CL; STEVENS, JT; BOLGAR, M; OBOYLE, DR; WEINHEIMER, SP; COLONNO, RJ				DIIANNI, CL; STEVENS, JT; BOLGAR, M; OBOYLE, DR; WEINHEIMER, SP; COLONNO, RJ			IDENTIFICATION OF THE SERINE RESIDUE AT THE ACTIVE-SITE OF THE HERPES-SIMPLEX VIRUS TYPE-1 PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE DNA-SEQUENCE; ASSEMBLY PROTEIN; GENE; BACTERIOPHAGE-T4; CLEAVAGE; BINDING; VIRION; DOMAIN; HEAD	Herpes simplex virus type 1 (HSV-1) encodes a protease that is essential for proteolytic processing of itself and of the nucleocapsid-associated protein, ICP35 (infected cell protein 35) (Liu, F., and Roizman, B. (1991) J. Virol. 65, 5149-5156). Inhibitor studies indicated that the HSV-1 protease is sensitive to the serine protease inactivator diisopropyl fluorophosphate (DFP). Inactivation is irreversible and dependent on time and concentration of DFP. Loss of activity correlates linearly with the incorporation of [H-3]DFP. Analysis of completely inactivated protease by mass spectrometry indicated a stoichiometry of 1 DFP/protease. In order to identify the specific residue modified by DFP, the protease was labeled with [H-3]DFP and subsequently digested with trypsin or chymotrypsin. The peptides resulting from each digestion were separated by reverse phase HPLC, and the radioactivity was recovered in a single peak. Mass spectrometric studies and sequencing analysis by Edman degradation identified Ser-129 as the residue modified by DFP. This residue and the region in which it is found is highly conserved among the herpes viral proteases. These data demonstrate that HSV-1 protease is a serine protease and that Ser-129 is the active site nucleophile.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT ANALYT RES & DEV,PRINCETON,NJ 08543	Bristol-Myers Squibb	DIIANNI, CL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT VIROL,POB 4000,PRINCETON,NJ 08543, USA.							ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BRAUN DK, 1984, J VIROL, V49, P142, DOI 10.1128/JVI.49.1.142-153.1984; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DAVISON MD, 1992, J GEN VIROL, V73, P2709, DOI 10.1099/0022-1317-73-10-2709; DECKMAN IC, 1992, J VIROL, V66, P7362, DOI 10.1128/JVI.66.12.7362-7367.1992; DIIANNI CL, 1993, J BIOL CHEM, V268, P25449; DILANNI CL, 1993, J BIOL CHEM, V268, P2028; GIBSON W, 1972, J VIROL, V10, P1044, DOI 10.1128/JVI.10.5.1044-1052.1972; GIBSON W, 1974, J VIROL, V13, P155, DOI 10.1128/JVI.13.1.155-165.1974; GRIFFIN AM, 1990, NUCLEIC ACIDS RES, V18, P3664, DOI 10.1093/nar/18.12.3664; KELLER B, 1986, GENE, V49, P245, DOI 10.1016/0378-1119(86)90285-4; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; LAEMMLI UK, 1974, VIROLOGY, V62, P483, DOI 10.1016/0042-6822(74)90409-7; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1991, J VIROL, V65, P206, DOI 10.1128/JVI.65.1.206-212.1991; LIU FY, 1993, J VIROL, V67, P1300, DOI 10.1128/JVI.67.3.1300-1309.1993; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; LUFTIG RB, 1973, P NATL ACAD SCI USA, V70, P1636, DOI 10.1073/pnas.70.6.1636; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; NEWCOMB WW, 1989, J VIROL, V63, P4697, DOI 10.1128/JVI.63.11.4697-4702.1989; ONORATO L, 1978, J VIROL, V27, P409, DOI 10.1128/JVI.27.2.409-426.1978; PERDUE ML, 1974, VIROLOGY, V59, P201, DOI 10.1016/0042-6822(74)90216-5; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SHOWE MK, 1976, J MOL BIOL, V107, P55, DOI 10.1016/S0022-2836(76)80017-4; SHOWE MK, 1976, J MOL BIOL, V107, P35, DOI 10.1016/S0022-2836(76)80016-2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	33	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12672	12676						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175677				2022-12-27	WOS:A1994NH71600048
J	LEW, RA; TETAZ, TJ; GLUCKSMAN, MJ; ROBERTS, JL; SMITH, AI				LEW, RA; TETAZ, TJ; GLUCKSMAN, MJ; ROBERTS, JL; SMITH, AI			EVIDENCE FOR A 2-STEP MECHANISM OF GONADOTROPIN-RELEASING-HORMONE METABOLISM BY PROLYL ENDOPEPTIDASE AND METALLOENDOPEPTIDASE EC-3.4.24.15 IN OVINE HYPOTHALAMIC EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ENKEPHALIN-CONTAINING PEPTIDES; RABBIT BRAIN; SOLUBLE METALLOENDOPEPTIDASE; NEUTRAL ENDOPEPTIDASE; CONVERTING ENZYME; NATURAL PEPTIDES; RAT TESTES; DEGRADATION; SPECIFICITY	The metalloendopeptidase EC 3.4.24.15 is believed to degrade gonadotropin releasing hormone (GnRH) (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) by cleavage at the Tyr(5)Gly(6) bond. We compared the ability of crude and partially purified endopeptidase 24.15 from ovine hypothalamus with recombinant rat testicular endopeptidase 24.15 to degrade synthetic GnRH. Both soluble and membrane hypothalamic fractions degraded GnRH to GnRH(1-5) with some production of GnRH(1-9) and GnRH(1-3). Generation of the smaller fragments was blocked by a specific endopeptidase 24.15 inhibitor (CFP-AAY-pAB), but production of GnRH(1-9) was reciprocally enhanced, suggesting this peptide may be an intermediate generated by prolyl endopeptidase. In deed, both bacitracin and Z-Pro-prolinal, inhibitors of this enzyme, markedly reduced GnRH degradation to any product. Degradation of synthetic GnRH(1-9) was more rapid than that of GnRH and was inhibited by CFP-AAY-pAB but not bacitracin. Activity against either substrate was greater in the soluble fraction. Repeated washing of the membrane fraction followed by extraction with Triton X-114 suggested that both endopeptidase 24.15 and prolyl endopeptidase, although predomi nantly soluble, can be peripherally associated with membranes, When fractionated by hydrophobic interaction chromatography, soluble endopeptidase 24.15 degraded GnRH only in fractions that also exhibited prolyl endopeptidase activity. In contrast, maximal degradation of GnRH(1-9) was observed in adjacent fractions, which also contained the highest levels of immunoreactive endopeptidase 24.15. The affinity of recombinant endopeptidase 24.15 for GnRH was low (K-m = 1.35 mM), was improved 10-15-fold by removal of the COOH-terminal amide or glycinamide (K-m = 90 and 119 mu M, respectively), and could be inhibited by CFP-AAY-pAB but not bacitracin. Taken together, these results suggest that GnRH metabolism in the hypothalamus may occur via a two step process involving first removal of Gly(10)-NH2, by prolyl endopeptidase, followed by cleavage by endopeptidase 24.15 at the Tyr(5)-Gly(6) bond.	BAKER MED RES INST,PEPTIDE BIOL LAB,PRAHRAN,VIC 3181,AUSTRALIA; CUNY MT SINAI SCH MED,DR AUTHOR M FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	Baker Heart and Diabetes Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Lew, Rebecca A/C-5454-2008	Smith, Ian/0000-0002-4143-2892				ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; ADVIS JP, 1982, ANAL BIOCHEM, V125, P41, DOI 10.1016/0003-2697(82)90380-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAMARGO ACM, 1973, BIOCHEMISTRY-US, V12, P1838, DOI 10.1021/bi00733a028; CARVALHO KM, 1981, BIOCHEMISTRY-US, V20, P7082, DOI 10.1021/bi00528a005; CHAPPELL MC, 1992, PEPTIDES, V13, P943, DOI 10.1016/0196-9781(92)90053-6; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; DECAMARGO ACM, 1982, J BIOL CHEM, V257, P9265; DRESDNER K, 1982, J NEUROCHEM, V38, P1151, DOI 10.1111/j.1471-4159.1982.tb05362.x; HORSTHEMKE B, 1982, BIOCHEMISTRY-US, V21, P1033, DOI 10.1021/bi00534a032; LABRIE F, 1984, LHRH ITS ANALOGUES B, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPP CA, 1986, NEUROENDOCRINOLOGY, V43, P230, DOI 10.1159/000124531; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDERMOTT JR, 1982, REGUL PEPTIDES, V3, P257, DOI 10.1016/0167-0115(82)90131-8; MCDERMOTT JR, 1983, PEPTIDES, V4, P25, DOI 10.1016/0196-9781(83)90160-2; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; MCKELVY JF, 1976, BIOCHEM BIOPH RES CO, V73, P507, DOI 10.1016/0006-291X(76)90736-1; MCKIE N, 1993, BIOCHEM J, V295, P57, DOI 10.1042/bj2950057; MOLINEAUX CJ, 1988, J NEUROCHEM, V51, P624, DOI 10.1111/j.1471-4159.1988.tb01084.x; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PIEROTTI A, 1994, IN PRESS BIOCHEMISTR; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SKIDGEL RA, 1987, NEUROPEPTIDES THEIR, P165; SMITH AI, 1992, SERONO SYM, V86, P207; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; TISLJAR U, 1989, ARCH BIOCHEM BIOPHYS, V274, P138, DOI 10.1016/0003-9861(89)90424-4; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; YOSHIMOTO T, 1979, BIOCHIM BIOPHYS ACTA, V569, P184, DOI 10.1016/0005-2744(79)90053-6	33	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12626	12632						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175672				2022-12-27	WOS:A1994NH71600042
J	BUSH, AI; PETTINGELL, WH; PARADIS, MD; TANZI, RE				BUSH, AI; PETTINGELL, WH; PARADIS, MD; TANZI, RE			MODULATION OF A-BETA ADHESIVENESS AND SECRETASE SITE CLEAVAGE BY ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; TANGLE-BEARING NEURONS; ALZHEIMERS-DISEASE; PARKINSONISM-DEMENTIA; DOWNS-SYNDROME; NEUROFIBRILLARY TANGLES; ALUMINUM ACCUMULATION; CEREBRAL-HEMORRHAGE; BRAIN; RAT	Abnormalities of zinc homeostasis occur in Alzheimer's disease (AD), a dementia characterized by the aggregation of A beta in the brain, and in Down syndrome, a condition characterized by premature AD, We studied the binding of Zn2+ to a synthetic peptide representing residues 1-40 (A beta(1-40)), as well as other domains of A beta. Two classes of Zn2+ binding were identified by Zn-65(2+) labeling: highly specific pH-dependent high affinity (K-alpha = 107 nM) binding, and lower affinity (K-alpha = 5.2 mu M) binding. Gel filtration chromatography identified monomeric, dimeric, and polymeric A beta species. Zinc induced a marked loss of A beta solubility upon chromatographic analysis. This was attributed to precipitation onto the column glass, which contains aluminosilicate, and was confirmed by the observation of zinc-accelerated precipitation of A beta by kaolin, a hydrated aluminum silicate suspension. Zinc binding also increased A beta resistance to tryptic cleavage at the secretase site, indicating that a small (<3 mu M) increase in brain Zn2+ concentration could significantly alter A beta metabolism, We propose that elevated brain interstitial zinc levels may increase A beta adhesiveness and interfere with A beta catabolism. Consequently, abnormalities of regional zinc concentrations in the brains of patients with AD or Down syndrome may contribute to A beta amyloidosis in these disorders.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GENET & AGING LAB, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital			Bush, Ashley I/A-1186-2007; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley/Y-2457-2019	Bush, Ashley I/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley/0000-0001-8259-9069; Paradis, Marc d./0000-0003-2387-3157				ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BJORKSTEN B, 1980, ACTA PAEDIATR SCAND, V69, P183, DOI 10.1111/j.1651-2227.1980.tb07057.x; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CANDY JM, 1986, LANCET, V1, P354; CANDY JM, 1992, BIOCHEM SOC T, V21, pS53; CONSTANTINIDIS J, 1990, Encephale, V16, P231; CORRIGAN FM, 1993, BIOMETALS, V6, P149; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRANCESCHI C, 1988, J MENT DEFIC RES, V32, P169; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J HISTOCHEM CYTOCHEM, V35, P579, DOI 10.1177/35.5.2435783; FREDERICQ E, 1956, ARCH BIOCHEM BIOPHYS, V65, P218, DOI 10.1016/0003-9861(56)90189-8; GARRUTO RM, 1984, P NATL ACAD SCI-BIOL, V81, P1875, DOI 10.1073/pnas.81.6.1875; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLDMAN J, 1974, BIOCHEMISTRY-US, V13, P4566, DOI 10.1021/bi00719a015; GUIROY DC, 1987, P NATL ACAD SCI USA, V84, P2073, DOI 10.1073/pnas.84.7.2073; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LUI E, 1990, J AM GERIATR SOC, V38, P633, DOI 10.1111/j.1532-5415.1990.tb01421.x; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PERL DP, 1982, SCIENCE, V217, P1053, DOI 10.1126/science.7112111; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; WEISS JH, 1989, NATURE, V338, P212, DOI 10.1038/338212b0; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P; WOLF G, 1984, NEUROSCI LETT, V51, P277, DOI 10.1016/0304-3940(84)90564-0; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	60	303	321	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12152	12158						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163520				2022-12-27	WOS:A1994NG37700073
J	LIU, JJ; MCLENNAN, AG				LIU, JJ; MCLENNAN, AG			PURIFICATION AND PROPERTIES OF GTP-GTP GUANYLYLTRANSFERASE FROM ENCYSTED EMBRYOS OF THE BRINE SHRIMP ARTEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN; TETRAPHOSPHATE; ENZYME; ACCUMULATE; ANTIBODIES; SALINA; FORMS; GEL	GTP:GTP guanylyltransferase has been purified from the yolk platelets of Artemia cysts. The 480-kDa enzyme catalyzes the reversible reaction 2GTP <-> Gp(4)G + PPi and contains immunologically related polypeptides of 142, 88, and 45 kDa and a distinct 80-kDa component. The 88 and 45 kDa species can be covalently labeled with [alpha-P-32]GTP. Even in crude extracts, the enzyme appears to be partially proteolyzed, suggesting that it is a nonfunctional residue of the pre-encystment stages of development. A native alpha(2) beta(2) structure comprising 2 mol each of the 142- and 80-kDa polypeptides is proposed. The reaction follows ping pong kinetics with a covalent enzyme-guanylate intermediate containing a phosphoramidate linkage, probably phospholysine. The enzyme has two GTP-binding sites: a ''donor'' site in which the enzyme-guanylate is formed and which is highly specific for guanine nucleotides (GTP, p(4)G, dGTP, and GppNHp) and an ''acceptor'' site which additionally binds XTP, ITP, GDP, and ADP. Thus, the enzyme will form the homodinucleotides Gp(4)G, Gp(5)G, Gp(3)G, dGp(4)dG, and GppNHppG and the heterodinucleotides Gp(4)X, Gp(4)I, and Gp(3)A, but not Xp(4)X, Ip(4)I, or Gp(4)A. The K-m for GTP was 6.7 mM and k(cat) was 1.6 s(-1). XTP was a fully uncompetitive inhibitor of Gp(4)G synthesis while ITP was a partially uncompetitive inhibitor. In the reverse reaction, certain pyrophosphate analogs could substitute for PPi. The structure and mechanism of this enzyme suggest an evolutionary relationship to mRNA capping enzymes.	UNIV LIVERPOOL,DEPT BIOCHEM,CELLULAR & METAB REGULAT GRP,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool								AKHREM AA, 1989, ANAL BIOCHEM, V179, P86, DOI 10.1016/0003-2697(89)90205-4; BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; BREVET A, 1987, BIOCHEMISTRY-US, V26, P4763, DOI 10.1021/bi00389a025; CANALES J, 1985, COMP BIOCHEM PHYS B, V81, P837, DOI 10.1016/0305-0491(85)90076-8; CLEGG JS, 1967, J BIOL CHEM, V242, P1938; CLEGG JS, 1980, BRINE SHRIMP ARTEMIA, V2, P11; CONG PJ, 1993, J BIOL CHEM, V268, P7256; COSTE H, 1987, J BIOL CHEM, V262, P12096; FARR SB, 1989, P NATL ACAD SCI USA, V86, P5010, DOI 10.1073/pnas.86.13.5010; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GILMOUR SJ, 1978, J BIOL CHEM, V253, P4960; HARLOW E, 1988, ANTIBODIES LABORATOR; HENTSCHEL CC, 1976, TRENDS BIOCHEM SCI, V1, P97, DOI 10.1016/0968-0004(76)90317-0; ITOH N, 1987, J BIOL CHEM, V262, P1989; KURA G, 1988, J CHROMATOGR, V447, P91, DOI 10.1016/0021-9673(88)90009-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEHMAN IR, 1974, SCIENCE, V186, P790; LIRAS A, 1992, J COMP PHYSIOL B, V162, P263, DOI 10.1007/BF00357533; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MCLENNAN AG, 1984, NUCLEIC ACIDS RES, V12, P1609, DOI 10.1093/nar/12.3.1609; McLennan AG., 1992, AP4A OTHER DINUCLEOS; MEER JVD, 1983, EMBO J, V2, P233; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MUILERMAN HG, 1982, ANAL BIOCHEM, V120, P46, DOI 10.1016/0003-2697(82)90315-3; OIKAWA TG, 1966, BIOCHEMISTRY-US, V5, P1517, DOI 10.1021/bi00869a010; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRESCOTT M, 1989, BIOCHEM J, V259, P831, DOI 10.1042/bj2590831; RENART MF, 1976, BIOCHEMISTRY-US, V15, P4962, DOI 10.1021/bi00668a003; ROTH MJ, 1984, J BIOL CHEM, V259, P3488; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1982, J BIOL CHEM, V257, P7237; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SMITH RE, 1982, J BIOL CHEM, V257, P485; VANDENBOS G, 1974, J BIOL CHEM, V249, P2816; WARNER A, 1992, AP4A OTHER DINUCLEOS, P81; WARNER AH, 1985, J BIOL CHEM, V260, P7008; WARNER AH, 1972, EXP CELL RES, V70, P365, DOI 10.1016/0014-4827(72)90148-6; WARNER AH, 1968, DEV BIOL, V18, P278, DOI 10.1016/0012-1606(68)90036-5; WARNER AH, 1974, CAN J BIOCHEM CELL B, V52, P241, DOI 10.1139/o74-037; WARNER AH, 1974, CAN J BIOCHEM CELL B, V52, P231, DOI 10.1139/o74-036; WARNER AH, 1965, BIOCHEMISTRY-US, V4, P1568, DOI 10.1021/bi00884a016; WARNER AH, 1979, REGULATION MACROMOLE, P161; WOODLEY CL, 1987, ARTEMIA RES APPLICAT, V2, P499; YAGI Y, 1984, J BIOL CHEM, V259, P4695	46	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11787	11794						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163476				2022-12-27	WOS:A1994NG37700020
J	MELIKIAN, HE; MCDONALD, JK; GU, H; RUDNICK, G; MOORE, KR; BLAKELY, RD				MELIKIAN, HE; MCDONALD, JK; GU, H; RUDNICK, G; MOORE, KR; BLAKELY, RD			HUMAN NOREPINEPHRINE TRANSPORTER - BIOSYNTHETIC-STUDIES USING A SITE-DIRECTED POLYCLONAL ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; PLASMA-MEMBRANE; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; EXPRESSION CLONING; COCAINE; PROTEINS; PURIFICATION; TOPOGRAPHY; RECEPTORS	Antibodies have been raised against synthetic peptides derived from the predicted primary sequence of the human cocaine and antidepressant-sensitive norepinephrine (NE) transporter (NET). One antibody (N430), raised and purified against a putative intracellular human norepinephrine transporter (hNET) epitope, detects hNET expression in a stably transfected cell line (LLC-NET) by indirect immunofluorescence only in the presence of detergent, while no immunoreactivity is observed in either the parental cells (LLC-PK1) or in LLC-NET cells incubated with preimmune sera or peptide absorbed antibody. N430 immunoblots of LLC-NET cell extracts reveal two major immunoreactive hNET species in these cells, migrating at 80 and 54 kDa, respectively. Pulse-chase N430 immunoprecipitation studies confirm that the 54-kDa species is a transient, glycosylated intermediate of a longer lived, more highly glycosylated protein with an apparant M(r) of 80,000. In contrast, a 54-kDa species is the primary hNET product in vaccinia virus T7-infected HeLa cells, transiently transfected with hNET cDNA PNGase F digestion of extracts prepared from LLC-NET- and hNET-transfected HeLa cells convert all immunoreactive species to a 46-kDa form, equivalent to that observed following incubation of whole cells with the glycosylation inhibitor tunicamycin. As transiently transfected HeLa and stable LLC-NET cells exhibit a pharmacologically similar NE transport activity, it appears likely that the additional glycosylation evident in the stable line does not contribute significantly to antagonist sensitivity. On the other hand, NE transport and antagonist ([I-125]RTI-55) binding assays on whole LLC-NET cells treated with tunicamycin reveal a pronounced reduction in NE transport activity and hNET membrane density paralleled by an inability of NET proteins to replenish the higher M(r) hNET pool. These findings suggest an obligate role for N-linked glycosylation in hNET biosynthetic maturation, stability, and functional expression. In summary, N430 antibody is a useful tool for the visualization and characterization of hNET gene products and has permitted the first direct evaluation of biosynthetic steps leading to functional catecholamine transporter expression.	EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, DIV BIOL & BIOMED SCI, GRAD PROGRAM NEUROSCI, ATLANTA, GA 30322 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Emory University; Emory University; Yale University			Melikian, Haley/S-8301-2016	Melikian, Haley/0000-0002-9694-5556	NIDA NIH HHS [DA07390, DA8213, DA7259] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390, R01DA008213, R01DA007259] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASHTON H, 1987, BRAIN SYSTEMS DISORD, P331; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BERGER SP, 1991, MOL PHARMACOL, V39, P429; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1992, CURR OPIN PSYCHIATR, V5, P69; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHMAN MW, 1987, PSYCHOPHARMACOLOGY 3, P1543; GOLDSTEIN DS, 1988, CIRCULATION, V78, P41, DOI 10.1161/01.CIR.78.1.41; GRAHAM D, 1992, BIOCHEM J, V286, P801, DOI 10.1042/bj2860801; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; GU H, 1993, IN PRESS J BIOL CHEM; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWARD BD, 1990, J NEUROSCI RES, V26, P149, DOI 10.1002/jnr.490260204; Iversen L., 1967, UPTAKE STORAGE NORAD; IVERSEN LL, 1965, J PHARM PHARMACOL, V17, P62, DOI 10.1111/j.2042-7158.1965.tb07572.x; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LEW R, 1992, BRAIN RES, V584, P266, DOI 10.1016/0006-8993(92)90905-O; Melikian H. E., 1993, Society for Neuroscience Abstracts, V19, P494; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PATEL A, 1993, J NEUROCHEM, V61, P496; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; SALLEE FR, 1989, FEBS LETT, V256, P219, DOI 10.1016/0014-5793(89)81752-1; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; TAKAGI T, 1991, ADV ELECTROPHORESIS, V4, P391; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG HY, 1989, J BIOL CHEM, V264, P14424; ZALESKA MM, 1987, NEUROSCI LETT, V82, P107, DOI 10.1016/0304-3940(87)90179-0; ZHU JH, 1992, NEUROCHEM INT, V21, P521, DOI 10.1016/0197-0186(92)90083-4; [No title captured]	47	104	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12290	12297						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163533				2022-12-27	WOS:A1994NG37700093
J	OBLONG, JE; BERGGREN, M; GASDASKA, PY; POWIS, G				OBLONG, JE; BERGGREN, M; GASDASKA, PY; POWIS, G			SITE-DIRECTED MUTAGENESIS OF ACTIVE-SITE CYSTEINES IN HUMAN THIOREDOXIN PRODUCES COMPETITIVE INHIBITORS OF HUMAN THIOREDOXIN REDUCTASE AND ELIMINATION OF MITOGENIC PROPERTIES OF THIOREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; PROTEIN DISULFIDE-ISOMERASE; DNA-BINDING ACTIVITY; RECOMBINANT HUMAN THIOREDOXIN; PURIFICATION; SUBSTITUTION; INVOLVEMENT; INVITRO; SYSTEMS	Thioredoxin and thioredoxin reductase comprise a redox system ubiquitous in all organisms. To better understand the thiol chemistry of the mammalian thioredoxin-thioredoxin reductase redox system, mutants of human thioredoxin were produced by site directed mutagenesis in which the two active site cysteines were replaced by serine residues, individually (C32S and C35S) and in combination (C32S/C35S). C35S and C32S/C35S were found to be competitive inhibitors of the reduction of human thioredoxin by human thioredoxin reductase with K-i values of 1.8 and 6.7 mu M, respectively. C32S did not inhibit thioredoxin reductase, apparently due to aggregation of the oxidized C32S species. Examination of the three mutant forms of thioredoxin by circular dichroism spectroscopy indicated that there were significant differences in the secondary structures when compared with thioredoxin. There were detectable changes in the circular dichroism spectra when thioredoxin, C35S, and C32S/C35S were bound to thioredoxin reductase, whereas C32S with thioredoxin reductase underwent only a small spectral change. Recombinant human thioredoxin stimulated DNA synthesis and the proliferation of murine fibroblasts. The ability of thioredoxin to stimulate cell proliferation could not be duplicated by either dithiothreitol or glutathione. C32S, C35S, and C32S/C35S failed to stimulate cell proliferation, showing that the redox active form of thioredoxin is necessary for eliciting growth stimulation.			OBLONG, JE (corresponding author), ARIZONA CANC CTR,1515 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NATIONAL CANCER INSTITUTE [R01CA042286, T32CA009213] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42286, CA 09213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMS RLP, 1969, EXP CELL RES, V56, P49, DOI 10.1016/0014-4827(69)90392-9; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; FORMANKAY JD, 1989, BIOCHEMISTRY-US, V28, P7088, DOI 10.1021/bi00443a045; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; FORMANKAY JD, 1992, BIOCHEMISTRY-US, V31, P3442, DOI 10.1021/bi00128a019; GASDASKA PY, 1994, IN PRESS BIOCH BIOPH; GRIPPO JF, 1983, J BIOL CHEM, V258, P3658; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HELLINGA HW, 1992, BIOCHEMISTRY-US, V31, P11203, DOI 10.1021/bi00160a034; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KIMURA T, 1982, FLAVINS FLAVOPROTEIN, P695; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1613, DOI 10.1016/0006-2952(92)90220-D; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; OKUNO H, 1993, ONCOGENE, V8, P695; PELEG S, 1989, BIOCHEMISTRY-US, V28, P7373, DOI 10.1021/bi00444a034; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORQUE PG, 1970, J BIOL CHEM, V245, P371; STRYER L, 1967, BIOCHEMISTRY-US, V6, P1016, DOI 10.1021/bi00856a009; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; WYNN R, 1993, PROTEIN SCI, V2, P395	36	120	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11714	11720						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163468				2022-12-27	WOS:A1994NG37700010
J	KIARASH, A; BOYD, B; LINGWOOD, CA				KIARASH, A; BOYD, B; LINGWOOD, CA			GLYCOSPHINGOLIPID RECEPTOR FUNCTION IS MODIFIED BY FATTY-ACID CONTENT - VEROTOXIN-1 AND VEROTOXIN-2C PREFERENTIALLY RECOGNIZE DIFFERENT GLOBOTRIAOSYL CERAMIDE FATTY-ACID HOMOLOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGA-LIKE TOXIN; HEMOLYTIC UREMIC SYNDROME; ESCHERICHIA-COLI STRAINS; GLYCOLIPID-BINDING; EDEMA DISEASE; PSEUDOMONAS-AERUGINOSA; NUCLEOTIDE-SEQUENCE; DISTINCT TOXINS; HELA-CELLS; B-CISTRON	Verotoxins (VT) are a family of Escherichia coli-derived toxins which have been associated with hemolytic uremic syndrome, the leading cause of acute pediatric renal failure, and hemorrhagic colitis. Verotoxins (VT1 and VT2c) both show terminal galalpha1-4gal-dependent binding to globotriaosylceramide (Galalpha1-4Galbeta1-4Glc-Cer; Gb3), yet VT2c shows a thousandfold lower specific cytotoxic activity in vitro. Our previous studies have shown this discrepancy is a function of the receptor binding B subunit and that VT1/Gb3 binding in a lipid matrix is affected by heterogeneity in the ceramide fatty acid chain length. The influence of the fatty acid composition of Gb3 on the binding of VT1 and VT2c has now been compared using 14 homogeneous semisynthetic Gb3 molecular species of differing fatty acid chain length and degree of saturation from C12 to C24. The binding of verotoxin was quantitated by Scatchard analysis using a solid-phase binding assay in the presence of auxiliary lipids, which may in some respects approximate to receptor function within the plasma membrane of sensitive cells. Differential binding was observed for several of these species in the lipid matrix, indicating that the fatty acid moiety of Gb3 is important for VT binding-under such conditions. The short chain fatty acid containing Gb3 (C12 and C14) showed minimal binding. Middle and long chain fatty acid Gb3 homologues (C16, C18, C20, C22, and C24) were effectively recognized by VTs. The presence of an unsaturated fatty acid in Gb3 significantly increased VT binding in all cases. C20.0 and C22:1 containing Gb3 had the greatest capacity to bind VT1. In contrast, C18-O and C18:1 homologues showed the greatest capacity for VT2c binding (higher than VT1). These results were, in general, reflected in cell cytotoxicity in that receptor-deficient cells reconstituted with C22:1Gb3 were maximally sensitive to VTI in vitro whereas cells reconstituted with C18:1Gb3 were maximally sensitive to VT2c. VT2c was an ineffective inhibitor of I-125-VTI binding to C22:1 Gb3 but in contrast, more effective than VTI to compete binding to C18:1 Gbs. Similarly, VT1 was less effective than VT2c to compete binding of I-125-VT2c to C18:1 but more effective than VT2c to compete for C22:1 Gb3 binding. These results suggest that VT1 and VT2c bind selectively to different but overlapping carbohydrate epitopes on the Gb3 molecule which are differentially available in these Gb3 fatty acid homologues in a lipid environment. These data provide a molecular basis for the different in vivo pathology observed for VT1 and VT2c and suggest a previously unrecognized mechanism for the modulation of membrane glycolipid receptor function whereby a single cell membrane glycolipid carbohydrate sequence may bind different ligands according to its fatty acid moiety.	UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A1, ONTARIO, CANADA; HOSP SICK CHILDREN, RES INST, DEPT MICROBIOL, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT MICROBIOL, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ALI S, 1991, BIOCHEMISTRY-US, V30, P11198, DOI 10.1021/bi00111a002; BAKER N, 1990, INFECT IMMUN, V58, P2361, DOI 10.1128/IAI.58.7.2361-2366.1990; BASTA M, 1989, J CLIN MICROBIOL, V127, P617; BOCK E, 1993, J BIOL CHEM, V268, P4311; BOCK K, 1985, J BIOL CHEM, V260, P8545; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; BRENNAN MJ, 1991, J BIOL CHEM, V266, P18827; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; COHEN A, 1987, J BIOL CHEM, V262, P17088; COHEN A, 1990, INT IMMUNOL, V2, P1, DOI 10.1093/intimm/2.1.1; CROOK SJ, 1986, BIOCHEMISTRY-US, V25, P7488, DOI 10.1021/bi00371a035; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; GOLD BD, 1993, INFECT IMMUN, V61, P2632, DOI 10.1128/IAI.61.6.2632-2638.1993; HAYASHI A, 1991, BIOCHIM BIOPHYS ACTA, V1083, P179, DOI 10.1016/0005-2760(91)90040-O; HEAD SC, 1988, LANCET, V2, P751; HEAD SC, 1988, FEMS MICROBIOL LETT, V51, P211, DOI 10.1111/j.1574-6968.1988.tb02999.x; HEAD SC, 1991, J BIOL CHEM, V266, P3617; HII JH, 1991, J CLIN MICROBIOL, V29, P2704, DOI 10.1128/JCM.29.12.2704-2709.1991; IGARASHI K, 1987, FEMS MICROBIOL LETT, V44, P91; ITO H, 1990, MICROB PATHOGENESIS, V8, P47, DOI 10.1016/0882-4010(90)90007-D; JACEWICZ M, 1989, J INFECT DIS, V159, P881, DOI 10.1093/infdis/159.5.881; JACKSON MP, 1987, FEMS MICROBIOL LETT, V44, P109, DOI 10.1016/0378-1097(87)90210-2; JIMENEZLUCHO V, 1990, INFECT IMMUN, V58, P2085, DOI 10.1128/IAI.58.7.2085-2090.1990; KANNAGI R, 1982, P NATL ACAD SCI-BIOL, V79, P3470, DOI 10.1073/pnas.79.11.3470; KANNAGI R, 1983, CANCER RES, V43, P4997; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KRIVAN H, 1988, J BIOL CHEM, V264, P9283; KRIVAN HC, 1991, BIOCHEM BIOPH RES CO, V175, P1082, DOI 10.1016/0006-291X(91)91676-4; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; LINGGOOD MA, 1987, J MED MICROBIOL, V24, P359, DOI 10.1099/00222615-24-4-359; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LINGWOOD CA, 1993, INFECT IMMUN, V61, P2474, DOI 10.1128/IAI.61.6.2474-2478.1993; LINGWOOD CA, 1990, BIOL REPROD, V43, P694, DOI 10.1095/biolreprod43.4.694; LINGWOOD CA, 1991, ADV LIPID RES, V1, P39; LINGWOOD CA, 1993, ADV LIPID RES, P25; LU DL, 1993, BIOCHEMISTRY-US, V32, P290, DOI 10.1021/bi00052a037; MANGENEY M, 1993, CANCER RES, V53, P5314; MARQUES LRM, 1987, FEMS MICROBIOL LETT, V44, P33, DOI 10.1016/0378-1097(87)90195-9; MARTENSSON E, 1966, BIOCHIM BIOPHYS ACTA, V116, P296, DOI 10.1016/0005-2760(66)90012-9; MOROOKA T, 1990, ANN M AM SOC MICR AN, P60; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NYHOLM PG, 1993, BIOCHEMISTRY-US, V32, P1225, DOI 10.1021/bi00056a005; NYHOLM PG, 1993, INT J BIOL MACROMOL, V15, P43, DOI 10.1016/S0141-8130(05)80087-X; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; OBRIEN AD, 1982, INFECT IMMUN, V35, P1151, DOI 10.1128/IAI.35.3.1151-1154.1982; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; PELLIZZARI A, 1992, BIOCHEMISTRY-US, V31, P1363, DOI 10.1021/bi00120a011; PETRIC M, 1987, FEMS MICROBIOL LETT, V41, P63; RAMOTAR K, 1990, BIOCHEM J, V272, P805, DOI 10.1042/bj2720805; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; RICHARDSON SE, 1992, INFECT IMMUN, V60, P4151; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; SAITOH T, 1992, EUR J GASTROEN HEPAT, V4, pS49; SAMUEL JE, 1990, INFECT IMMUN, V58, P611, DOI 10.1128/IAI.58.3.611-618.1990; SANDVIG K, 1992, EXP CELL RES, V200, P253, DOI 10.1016/0014-4827(92)90171-4; SAUKKONEN K, 1992, P NATL ACAD SCI USA, V89, P118, DOI 10.1073/pnas.89.1.118; SCHMITT CK, 1991, INFECT IMMUN, V59, P1065, DOI 10.1128/IAI.59.3.1065-1073.1991; SCOTLAND SM, 1985, LANCET, V2, P885; SHAROM FJ, 1975, BIOCHEM BIOPH RES CO, V67, P1501, DOI 10.1016/0006-291X(75)90196-5; SRNKA CA, 1992, VIROLOGY, V190, P794, DOI 10.1016/0042-6822(92)90917-E; STRASBERG P, 1989, J LIPID RES, V30, P121; STROCKBINE NA, 1986, INFECT IMMUN, V53, P135, DOI 10.1128/IAI.53.1.135-140.1986; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; STROMBERG N, 1990, J BIOL CHEM, V265, P11244; STROMBERG N, 1988, FEBS LETT, V232, P193, DOI 10.1016/0014-5793(88)80415-0; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TAYLOR CM, 1990, PEDIATR NEPHROL, V4, P59, DOI 10.1007/BF00858441; WADDELL T, 1990, P NATL ACAD SCI USA, V87, P7898, DOI 10.1073/pnas.87.20.7898; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3; WINSBORROW BG, 1992, BIOPHYS J, V63, P428, DOI 10.1016/S0006-3495(92)81620-X; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W; ZOJA C, 1992, J LAB CLIN MED, V120, P229	77	179	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11138	11146						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157640				2022-12-27	WOS:A1994NF96600028
J	LARIMER, FW; HARPEL, MR; HARTMAN, FC				LARIMER, FW; HARPEL, MR; HARTMAN, FC			BETA-ELIMINATION OF PHOSPHATE FROM REACTION INTERMEDIATES BY SITE-DIRECTED MUTANTS OF RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; ACTIVE-SITE; 1,5-BISPHOSPHATE CARBOXYLASE; TRIOSEPHOSPHATE ISOMERASE; CRYSTALLOGRAPHIC ANALYSIS; DIPHOSPHATE OXYGENASE; CRYSTAL-STRUCTURE; PYRUVATE-KINASE	Five residues (Thr-53, Asn-54, Gly-370, Gly-393, and Gly-394) of Rhodospirillum rubrum ribulose-bisphosphate carboxylase/oxygenase are positioned to serve as hydrogen-bond donors for the C1 phosphate of ribulose bisphosphate and thereby constrain conformational flexibility of the initial enediol(ate) intermediate (Knight, S., Andersson, I., and Branden, C.-I. (1990) J. Mol. Biol. 215, 113-160). To study the functional contributions of the residues implicated in ribulose bisphosphate binding and intermediate stabilization, we have replaced them individually with alanine, either to remove the H-bonding group (T53A, N54A) or to introduce bulk (G370A, G393A, G394A). Consequences of substitutions include diminution of carboxylase activity (with a lesser impact on enolization activity), increase of K(m) (ribulose bisphosphate), and decrease of carboxylation: oxygenation specificity. During catalytic turnover of ribulose bisphosphate by several mutants, substantial amounts of the substrate are diverted to 1-deoxy-D-glycero-2,3-pentodiulose 5-phosphate, reflecting beta-elimination of phosphate from the enediol(ate) intermediate. This side product is not observed with wild-type enzyme, nor has it been reported with mutant enzymes characterized previously. Another consequence of disruption of the phosphate binding site is enhanced production of pyruvate, relative to wild-type enzyme, by some of the mutants due to decomposition of the aci-carbanion of 3-phosphoglycerate (the terminal intermediate). These data provide direct evidence that phosphate ligands stabilize conformations of intermediates that favor productive turnover and mitigate beta-elimination at two stages of overall catalysis.			LARIMER, FW (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831, USA.							ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ANDRES J, 1992, CHEM PHYS LETT, V198, P515, DOI 10.1016/0009-2614(92)80037-C; ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; ANDREWS TJ, 1973, BIOCHEMISTRY-US, V12, P11, DOI 10.1021/bi00725a003; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BOWES G, 1971, BIOCHEM BIOPH RES CO, V45, P716, DOI 10.1016/0006-291X(71)90475-X; DONNELLY MI, 1983, BIOCHEMISTRY-US, V22, P4346, DOI 10.1021/bi00287a028; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; FRANKVOORT W, 1978, THERMOCHIM ACTA, V25, P35, DOI 10.1016/0040-6031(78)80038-0; HARPEL MR, 1993, ANAL BIOCHEM, V209, P367, DOI 10.1006/abio.1993.1136; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; HARTMAN FC, 1993, ADV ENZYMOL RAMB, V67, P1; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1973, BIOCHEMISTRY-US, V12, P18, DOI 10.1021/bi00725a004; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; PAECH C, 1978, BIOCHEM BIOPH RES CO, V83, P1084, DOI 10.1016/0006-291X(78)91506-1; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROSE IA, 1981, PHILOS T ROY SOC B, V293, P131, DOI 10.1098/rstb.1981.0067; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SUE JM, 1982, BIOCHEMISTRY-US, V21, P5404, DOI 10.1021/bi00265a004; Tapia O, 1992, MOL ENG, V2, P37, DOI [10.1007/BF00999521, DOI 10.1007/BF00999521]; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	45	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11114	11120						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157638				2022-12-27	WOS:A1994NF96600025
J	PANG, L; MILARSKI, KL; OHMICHI, M; TAKATA, Y; OLEFSKY, JM; SALTIEL, AR				PANG, L; MILARSKI, KL; OHMICHI, M; TAKATA, Y; OLEFSKY, JM; SALTIEL, AR			MUTATION OF THE 2 CARBOXYL-TERMINAL TYROSINES IN THE INSULIN-RECEPTOR RESULTS IN ENHANCED ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; SRC HOMOLOGY-2 DOMAINS; MAP KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; THREONINE KINASE; 85-KDA SUBUNIT; GENE-PRODUCT; CELLS; PHOSPHORYLATION	Activation of mitogen-activated protein (MAP) kinase represents an important mechanism in hormonal regulation. To clarify the role of MAP kinase activation in insulin action, we compared the activation of the enzyme in Rat-1 cells transfected with Wild-type (Hire) and mutant insulin receptors in which the 2 carboxyl-terminal tyrosines were substituted with phenylalanine (Y/F2). Expression of the Y/F2 mutant receptor enhanced the responsiveness of MAP kinase to insulin. Moreover, the insulin responsiveness of the activator of this enzyme, MAP kinase kinase, was also increased in these cells. To explore the early signaling events that might account for this increase in responsiveness, we evaluated the tyrosine phosphorylation of the insulin receptor substrate, IRS-1, and its subsequent association with phosphatidylinositol (PI)-3 kinase. In both cell types, insulin led to a dose dependent increase in the association of tyrosine phosphorylated IRS-1 with the SH2 domain of the p85 regulatory subunit of PI-3 kinase, and also increased the amount of PI kinase activity detected in anti-IRS-1 immunoprecipitates. The effect of insulin was significantly greater in Y/F2 cells, as determined in both assays. In previous studies, cells bearing this receptor mutant exhibited an identical metabolic response but enhanced mitogenic response to insulin when compared with wild-type receptor. These data provide further evidence for divergence of the mitogenic and metabolic signaling pathways at or near the insulin receptor.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; VET AFFAIRS MED CTR,MED RES SERV,SAN DIEGO,CA 92093; VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92093	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	PHS HHS [33651] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; GIOGETTI S, 1992, EUR J BIOCHEM, V207, P599; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTTSCHALK WK, 1992, BIOCHEM BIOPH RES CO, V189, P906; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOSHI M, 1988, J BIOL CHEM, V263, P5396; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG B, 1992, J BIOL CHEM, V267, P18320	54	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10604	10608						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144649				2022-12-27	WOS:A1994NF01700063
J	ZHANG, GH; MELVIN, JE				ZHANG, GH; MELVIN, JE			INTRACELLULAR MG2+ MOVEMENT DURING MUSCARINIC STIMULATION - MG2+ UPTAKE BY THE INTRACELLULAR CA2+ STORE IN RAT SUBLINGUAL MUCOUS ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE MAGNESIUM; CHICKEN HEART-CELLS; CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ELECTRON-PROBE; FLUORESCENT INDICATOR; PLASMA-MEMBRANE; CA-2+; SECRETION; CHANNELS	The muscarinic agonist carbachol produces a sustained elevation in the cytosolic free Mg2+ concentration ([Mg2+](i)) by mobilizing an intracellular Mg2+ pool in rat sublingual mucous acini (Zhang, G. H., and Melvin, J. E. (1992) J. Biol. Chem. 267, 20721-20727). In the present study, we investigated the relationship between the agonist-induced mobilization of the intracellular Ca2+ store and Mg2+ movement in acini loaded with the Ca2+-selective chelator bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) by monitoring [Mg2+](i) using dual wavelength microfluorometry of the Mg2+-sensitive fluorescent indicator mag-fura-2. The resting [Mg2+](i) in BAPTA-loaded acini was comparable to unloaded acini (0.36 +/- 0.01 mM (n = 29) Dersus 0.35 +/- 0.01 mM (n = 119)). In contrast to the >40% sustained increase in [Mg2+](i) in unloaded acini, carbachol stimulation of BAPTA-loaded acini induced a rapid transient [Mg2+](i) decrease (similar to 30%), followed by a slower recovery to the prestimulated [Mg2+](i). in 3-4 min. Furthermore, in Ca2+-free medium or when Ca2+ influx was blocked with La3+ or Ni2+, carbachol induced a sustained decrease in [Mg2+](i) (similar to 40%). Reintroducing extracellular Ca2+ resulted in recovery of [Mg2+](i), even in the absence of extracellular Mg2+. 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate, an inhibitor of the inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ release pathway, completely blocked the carbachol-induced decrease in [Mg2+](i), whereas thapsigargin, a Ca2+-ATPase inhibitor that empties the inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ store, stimulated a decrease in [Mg2+](i). The thapsigargin-induced Mg2+ uptake was into the same intracellular pool as that activated by carbachol because stimulation with thapsigargin after carbachol did not induce a further decrease in [Mg2+](i). Taken together, these results strongly suggest that depletion of the inositol 1,4,5-trisphosphate-sensitive Ca2+ store activates Mg2+ uptake, most Likely to maintain charge balance of the intracellular Ca2+ pool.	UNIV ROCHESTER, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE007003, R37DE008921, R03DE010655] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07003, DE08921, DE10655] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; AGUS ZS, 1989, AM J PHYSIOL, V256, pC452, DOI 10.1152/ajpcell.1989.256.2.C452; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; DUCHATELLEGOURDON I, 1989, J PHYSIOL-LONDON, V415, P251, DOI 10.1113/jphysiol.1989.sp017721; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FREUDENRICH CC, 1992, AM J PHYSIOL, V262, pC1024, DOI 10.1152/ajpcell.1992.262.4.C1024; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; MAIRBAURL H, 1992, J GEN PHYSIOL, V99, P721, DOI 10.1085/jgp.99.5.721; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUKAWA R, 1990, ARCH BIOCHEM BIOPHYS, V280, P362, DOI 10.1016/0003-9861(90)90343-W; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Parker J. C., 1989, American Journal of Physiology, V257, P1038; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; QUAMME GA, 1993, AM J PHYSIOL, V265, pH281, DOI 10.1152/ajpheart.1993.265.1.H281; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROMANI A, 1991, J BIOL CHEM, V266, P24376; ROMANI A, 1993, J BIOL CHEM, V268, P15489; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; ROTEVATN S, 1991, ACTA PHYSIOL SCAND, V142, P125; RUBBS RD, 1991, AM J PHYSIOL, V260, pC1158; SHUTTLEWORTH TJ, 1992, CELL CALCIUM, V13, P541, DOI 10.1016/0143-4160(92)90034-P; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54; ZHANG GH, 1992, J BIOL CHEM, V267, P20721; ZHANG GH, 1992, J MEMBRANE BIOL, V129, P311; ZHANG GH, 1993, FEBS LETT, V327, P1, DOI 10.1016/0014-5793(93)81026-V	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10352	10356						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144616				2022-12-27	WOS:A1994NF01700028
J	CHENG, Q; CANT, CA; MOLL, T; HOFERWARBINEK, R; WAGNER, E; BIRNSTIEL, ML; BACH, FH; DEMARTIN, R				CHENG, Q; CANT, CA; MOLL, T; HOFERWARBINEK, R; WAGNER, E; BIRNSTIEL, ML; BACH, FH; DEMARTIN, R			NF-KAPPA-B SUBUNIT-SPECIFIC REGULATION OF THE I-KAPPA-B-ALPHA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; ELAM-1 GENE-TRANSCRIPTION; REL ONCOGENE; PROTEIN; ACTIVATION; CLONING; INDUCTION; ENCODES; CELLS; P50	Stimulation of endothelial cells by cytokines and bacterial lipopolysaccharide leads to activation of the transcription factor NF-kappa B. NF-kappa B in turn regulates the expression of several genes involved in the inflammatory reaction, including cell adhesion molecules, interleukins, and transcription factors. One of these induced genes encodes an inhibitor of NF-kappa B, ECI-6/I kappa B alpha, that contains in its 5' regulatory region six consensus binding sites for NF-kappa B. We demonstrate here that these sites display striking differences in their ability in vitro to bind to various NF-kappa B subunits. In vivo, all six sites contribute, though to varying degrees, to transcription from the ECI-6/I kappa B alpha promoter, as demonstrated by deletion and mutation analysis. Among the NF-kappa B subunits tested p65, the p65/p50 heterodimer and, to a lesser extent, c-Rel, are able to activate transcription, whereas p50 or p50/RelB were inactive. Since many genes regulated by NF-kappa B contain only one or two DNA-binding sites for this transcription factor, the presence of six functional NF-kappa B-binding sites in the ECI-6/I kappa B alpha promoter represents a unique feature of this gene.	VIENNA INT RES COOP CTR,A-1235 VIENNA,AUSTRIA; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,SANDOZ CTR IMMUNOBIOL,BOSTON,MA 02215	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Harvard University; Harvard Medical School; Novartis; Sandoz			Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BLANK V, 1992, TIBS TRENDS BIOCH SC, V17, P136; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM J, 1983, NUCLEIC ACIDS RES, V11, P1445; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANNINK M, 1990, ONCOGENE, V5, P1843; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUUNSCH C, 1993, MOL CELL BIOL, V12, P4412; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SPARACIO SM, 1992, NEUROIMMUNOLOGY, V39, P231; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WARREN JB, 1990, ENDOTHELIUM, P253; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	57	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13551	13557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175790				2022-12-27	WOS:A1994NK18400073
J	RUBINCHIK, S; PARRIS, W; GOLD, M				RUBINCHIK, S; PARRIS, W; GOLD, M			THE IN-VITRO ATPASES OF BACTERIOPHAGE-LAMBDA TERMINASE AND ITS LARGE SUBUNIT, GENE-PRODUCT-A - THE RELATIONSHIP WITH THEIR DNA HELICASE AND PACKAGING ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COHESIVE END SITE; ESCHERICHIA-COLI; INVITRO; PURIFICATION; SYSTEM; ATP; MECHANISM; LOCATION; ENZYME; GP16	The bacteriophage lambda terminase is composed of two subunits, gpNu1 and gpA. In vitro, the holoenzyme is a site specific endonuclease, helicase, ATPase, and can package lambda DNA into proheads. gpApossesses ATPase and helicase activities which are similar to those of the holoenzyme. Both terminase and gpA can hydrolyze a wide range of deoxyribo- and ribonucleoside triphosphates to inorganic phosphate and the corresponding diphosphate. Nucleoside diphosphates are not substrates for either protein. ATPase of both proteins is stimulated by double stranded DNA. The ATPase of gpA is protein concentration dependent, while that of terminase is not. Helicase activity of both proteins is not concentration-dependent, and requires a hydrolyzable triphosphate. ATP, dATP, and GTP supported helicase activity, while adenosine 5'-(beta,gamma>-methylene)triphosphate, adenosine 5'3- O-(thio)triphosphate, ADP, CTP, and UTP did not. The kinetic parameters of ATPase and helicase activities were similar for both proteins, but packaging with terminase was optimal only at a significantly higher level of ATP. Packaging was detectable at significant levels with CTP and UTP, but not with GTP. Packaging also differed from ATPase and helicase in the utilization of divalent metal cations and susceptibility to various inhibitors.	DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA									BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1988, J MOL BIOL, V199, P219, DOI 10.1016/0022-2836(88)90391-9; BECKER A, 1978, P NATL ACAD SCI USA, V75, P4199, DOI 10.1073/pnas.75.9.4199; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; FUJISAWA H, 1987, VIROLOGY, V161, P228, DOI 10.1016/0042-6822(87)90189-9; GOLD M, 1983, J BIOL CHEM, V258, P4619; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAMADA K, 1986, VIROLOGY, V151, P110, DOI 10.1016/0042-6822(86)90108-X; HAMADA K, 1987, VIROLOGY, V159, P244, DOI 10.1016/0042-6822(87)90461-2; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; MURIALDO H, 1987, NUCLEIC ACIDS RES, V15, P119, DOI 10.1093/nar/15.1.119; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PARRIS W, 1994, J BIOL CHEM, V269, P13564; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; Sambrook J, 1989, MOL CLONING LABORATO; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; YANG YC, 1993, THESIS U TORONTO	32	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13586	13593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175794				2022-12-27	WOS:A1994NK18400077
J	ENDO, H; MATSUDA, C; KAGAWA, Y				ENDO, H; MATSUDA, C; KAGAWA, Y			EXCLUSION OF AN ALTERNATIVELY SPLICED EXON IN HUMAN ATP SYNTHASE GAMMA-SUBUNIT PRE-MESSENGER-RNA REQUIRES DE-NOVO PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; EARLY MESSENGER-RNAS; SEXUAL-DIFFERENTIATION; GENE-EXPRESSION; SINGLE GENE; KINASE-C; CELLS; FACTOR-SF2; TRANSCRIPTION; DEHYDROGENASE	Tissue-specific isoforms of the mitochondrial ATP synthase gamma-subunit are generated by alternative splicing, and the heart/skeletal muscle specific transcript lacks exon 9 in a cassette fashion (Matsuda, C., Endo, H., Hirata, H., Morosawa, H., Nakanishi, M., and Kagawa, Y. (1993) FEBS Lett. 325, 281-284; and Matsuda, C., Endo, H., Ohta, S., and Kagawa, Y. (1993) J. Biol. Chem. 268, 24950-24958). Here, we show that the endogenous heart-type mRNA is cell-specifically induced by the extracellular pH value in the HT1080 (human fibrosarcoma) and KYM-1 (human rhabdomyosarcoma) cell lines. In these cells, a low extracellular pH value induced exclusion of exon 9, and this induction was inhibited by cycloheximide treatment. In contrast, a high extracellular pH value resulted in mRNA transcription of the liver type, including exon 9, and did not require de novo protein synthesis. These results suggest that alternative splicing in the gamma-subunit pre-mRNA is regulated by on-off switching of protein synthesis of a trans-acting factor involved in this exon-excluding step. The signal of low pH value was blocked by the protein kinase inhibitor H-7 or Calphostin C (protein kinase C inhibitor), indicating the involvement of protein kinase C in the alternative splicing. This is a good model system for studies on the induction mechanism of alternative splicing in cultured mammalian cells, in which intracellular factors play a pivotal role for the exon-excluding step in the tissue-specific alternative splicing mechanism.			ENDO, H (corresponding author), JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDO H, 1989, AM J HUM GENET, V44, P358; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; Maniatis T., 1982, MOL CLONING; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; ROESSER JR, 1993, J BIOL CHEM, V268, P8366; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	39	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12488	12493						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175656				2022-12-27	WOS:A1994NH71600021
J	HART, SL; KNIGHT, AM; HARBOTTLE, RP; MISTRY, A; HUNGER, HD; CUTLER, DF; WILLIAMSON, R; COUTELLE, C				HART, SL; KNIGHT, AM; HARBOTTLE, RP; MISTRY, A; HUNGER, HD; CUTLER, DF; WILLIAMSON, R; COUTELLE, C			CELL-BINDING AND INTERNALIZATION BY FILAMENTOUS PHAGE DISPLAYING A CYCLIC ARG-GLY-ASP-CONTAINING PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Ligands that bind mammalian cell surface integrins with high affinity can mediate cellular internalization. We show that particles of the bacteriophage fd that display the cyclic integrin-binding peptide sequence GGCRGDMFGC in a proportion of their major coat protein subunits bind to cells and are efficiently internalized. In the displayed peptide the conformation of the RGD motif is restricted within a hairpin loop formed by a disulfide bridge between the 2 cysteine residues. Cellular internalization of phage was demonstrated by confocal and non confocal immunofluorescence microscopy of tissue-cultured cells incubated with phage particles. The phage were contained in juxtanuclear vesicles in the same serial sections as transferrin receptor but were not colocalized with the cell surface marker alkaline phosphatase. Cell binding and internalization was in- hibited by preincubation of cells with the integrin-binding peptide GRGDSP, whereas the control peptide GRGESP had no inhibitory effect. These results indicate that cyclic integrin-binding peptides can be used to target and enter cells and that it should be possible to exploit such peptides for the introduction of DNA, drugs, or other macromolecules.	MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY; UNIV LONDON UNIV COLL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of London; University College London	HART, SL (corresponding author), ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, NORFOLK PL, LONDON W2 1PG, ENGLAND.		Hart, Stephen L/C-1615-2008	Hart, Stephen L/0000-0001-8254-376X; Harbottle, Richard/0000-0002-3332-8024; Cutler, Daniel/0000-0002-4288-7530				BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CURIEL DT, 1992, AM J RESP CELL MOL, V6, P247, DOI 10.1165/ajrcmb/6.3.247; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; GAO L, 1993, HUM GENE THER, V4, P17, DOI 10.1089/hum.1993.4.1-17; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HUNGER HD, 1990, ANAL BIOCHEM, V186, P159, DOI 10.1016/0003-2697(90)90590-6; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROWITCH DH, 1988, J MOL BIOL, V204, P663, DOI 10.1016/0022-2836(88)90363-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621	39	145	180	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12468	12474						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175653				2022-12-27	WOS:A1994NH71600018
J	MAURUS, R; BOGUMIL, R; LUO, YG; TANG, HL; SMITH, M; MAUK, AG; BRAYER, GD				MAURUS, R; BOGUMIL, R; LUO, YG; TANG, HL; SMITH, M; MAUK, AG; BRAYER, GD			STRUCTURAL CHARACTERIZATION OF HEME LIGATION IN THE HIS(64)-]TYR VARIANT OF MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPERM WHALE MYOGLOBIN; HORSE HEART METMYOGLOBIN; FERRIC HEME; 3-DIMENSIONAL STRUCTURE; DISTAL HISTIDINE; RESONANCE RAMAN; LIGAND-BINDING; HEMOGLOBINS-M; M BOSTON	A site specific mutant of horse heart myoglobin has been prepared in which the distal heme pocket residue, His(64), is replaced by tyrosine. The structure pf this myoglobin variant has been determined to 2.0-Angstrom resolution using x-ray diffraction techniques and refined to a final crystallographic R-factor of 16.9%. The polypeptide backbone conformation of the His(64) --> Tyr variant of myoglobin is very similar to that of the wild-type protein. However, in the variant the water normally found coordinated to the heme iron atom and hydrogen-bonded to His(64) has been displaced by the hydroxyl oxygen of the Tyr(64) Side chain. The tyrosine oxygen atom is directly coordinated to the heme iron atom with a bond length of 2.18 Angstrom. Distortion of heme planarity and changes in the packing of the Leu(29) and Leu(104) side chains are related to this mutation. The ligand environment of the ferric iron has been studied by electron paramagnetic resonance (EPR) spectroscopy using crystalline material and protein in solution. The protein in solution exhibits a rhombically split ferric high spin EPR spectrum with g values of 6.64, 5.34, and 1.98. The EPR spectrum of the crystalline sample consists of two different ferric high spin signals. The main signal is similar to the signal observed in solution and is assigned to His(93)-Fe(III)-Tyr(64) coordination. The relatively high rhombicity of this signal can be explained as arising from distortions of the heme plane seen in the crystal structure. The second, more axial high spin signal found in the crystalline state can be tentatively assigned to another form of iron ligation with a different iron-tyro-sine bond length and a less distorted heme plane.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,PROT ENGN NETWORK CTR EXCELLENCE,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia								Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CRUICKSHANK DWJ, 1985, INT TABLES XRAY CRYS, V2, P317; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; EVANS SV, 1988, J BIOL CHEM, V263, P4263; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; HAYASHI A, 1969, BIOCHIM BIOPHYS ACTA, V194, P6, DOI 10.1016/0005-2795(69)90173-1; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; PEISACH J, 1971, J BIOL CHEM, V246, P3342; PULSINELLI PD, 1973, P NATL ACAD SCI USA, V70, P3870, DOI 10.1073/pnas.70.12.3870; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SATO F, 1990, J BIOL CHEM, V265, P18823; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TANG HL, 1994, IN PRESS BIOCH BIOPH; TONG H, 1994, IN PRESS J APPL CRYS	24	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12606	12610						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175669				2022-12-27	WOS:A1994NH71600039
J	MEZGUELDI, M; DERANCOURT, J; CALAS, B; KASSAB, R; FATTOUM, A				MEZGUELDI, M; DERANCOURT, J; CALAS, B; KASSAB, R; FATTOUM, A			PRECISE IDENTIFICATION OF THE REGULATORY F-ACTIN-BINDING AND CALMODULIN-BINDING SEQUENCES IN THE 10-KDA CARBOXYL-TERMINAL DOMAIN OF CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; SMOOTH-MUSCLE; PROTEIN; PEPTIDE; REGION; MYOSIN; PHOSPHORYLATION; LOCALIZATION; PURIFICATION; FRAGMENT	The precise location of the regulatory F-actin- and calmodulin-binding sites in the COOH-terminal sequence Trp(659)-Pro(756) of gizzard caldesmon was investigated by subjecting the corresponding 10-kDa CNBr fragment, characterized earlier (Bartegi, A., Fattoum, A., Derancourt, J., and Kassab, R. (1990) J. Biol. Chem. 265, 15231-15238), to limited chymotryptic reactions conducted in the absence and presence of F-actin-tropomyosin. As a result, the F-actin-binding and actomyosin ATPase inhibitory activity was separated from the regulatory Ca2+-calmodulin-binding site. Seven chymotryptic peptides accounting for the entire primary structure of the CB10 fragment were isolated, and their complete amino acid sequences were established by combining NH2-terminal sequencing, mass spectrometry, and gel electrophoresis. Reversed-phase high performance liquid chromatography analyses of the binding of F-actin to these peptides revealed the 30-residue sequence Leu(693)-Trp(722) as the unique crucial stretch for actin interaction and ATPase inhibition. This segment was also specifically protected by F-actin against proteolytic degradation. We further determined the functional properties of three synthetic peptides which successively cover the sequences Asn(675)-Lys(695), Leu(693)-Trp(722), and Arg(711)-Lys(729). The first peptide segment specifically bound Ca2+-calmodulin as assessed by affinity chromatography and spectrofluorometry and should contain a potent novel calmodulin-binding subsite. The second immediately adjacent peptide inhibited the actomyosin ATPase in a tropomyosin-sensitive manner, as expected. In contrast, the third peptide displayed no detectable function, The results indicate that the overall sequence Asn(675)-Trp(722) represents the essential regulatory unit of the COOH terminal 10-kDa domain of caldesmon.	UNIV MONTPELLIER 1,CNRS,CTR RECH BIOCHIM MACROMOLEC,INSERM,U249,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BARTEGI A, 1991, BIOPHYS J, V59, pA65; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CZURYLO EA, 1991, BIOPHYS CHEM, V40, P181, DOI 10.1016/0301-4622(91)87007-R; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KOHAMA K, 1992, BIOCHEM BIOPH RES CO, V184, P1204, DOI 10.1016/S0006-291X(05)80010-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; REDWOOD CS, 1993, BIOPHYS J, V64, pA30; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SOBUE K, 1991, J BIOL CHEM, V266, P12115; VALEMBOIS C, 1992, TETRAHEDRON LETT, V33, P4005, DOI 10.1016/0040-4039(92)88085-J; VOROTNIKOV AV, 1992, BIOCHEM J, V284, P911, DOI 10.1042/bj2840911; WANG CLA, 1991, J BIOL CHEM, V266, P9166; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	32	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12824	12832						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175696				2022-12-27	WOS:A1994NH71600070
J	BULLIONS, LC; MEJEAN, V; CLAVERYS, JP; BESSMAN, MJ				BULLIONS, LC; MEJEAN, V; CLAVERYS, JP; BESSMAN, MJ			PURIFICATION OF THE MUTX PROTEIN OF STREPTOCOCCUS-PNEUMONIAE, A HOMOLOG OF ESCHERICHIA-COLI MUTT - IDENTIFICATION OF A NOVEL CATALYTIC DOMAIN FOR NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; MUTATOR GENE	The mutX gene of Streptococcus pneumoniae, a homologue of the Escherichia coli mutT mutator gene (Mejean, V., Salles, C., Bullions, L. C., Bessman, M. J., and Claverys, J.-P. (1993) Mol. Microbiol. 11, 323-330) has been cloned into an expression vector, and its gene product, the MutX protein, has been purified to apparent homogeneity. Like MutT, the pure MutX protein hydrolyzes all of the canonical nucleoside triphosphates at different rates with a preference for dGTP, yielding nucleoside monophosphates and inorganic pyrophosphate. Despite this similarity in enzymatic activity, the two proteins have notably dissimilar primary and quaternary structures, They share only a small region of amino acid homology, and under the same conditions in which MutT exists as a monomer in solution, MutX behaves as a trimer. The small region of conserved amino acid sequence most likely identifies a protein domain responsible for the novel nucleoside triphosphate pyrophosphohydrolase activity shared by the two enzymes, and by another protein of unknown function, the product of the E. coli orf17 gene (Takahagi, M., Iwasaki, H., Nakata, A., and Shinegawa, H. (1991) J. Bacteriol. 173, 5747-5753).	JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; UNIV TOULOUSE 3,CNRS,UPR 9007,F-31062 TOULOUSE,FRANCE	Johns Hopkins University; Johns Hopkins University; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Mejean, Vincent/0000-0001-6533-5846	NIGMS NIH HHS [GM-18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; BESSMAN MJ, 1958, P NATL ACAD SCI USA, V44, P633, DOI 10.1073/pnas.44.7.633; BESSMAN MJ, 1963, MOLECULAR GENETICS 1, P1; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1993, THESIS J HOPKINS U; BULLIONS LC, 1993, FASEB J, V7, pA1384; COX EC, 1973, GENETICS, V73, P67; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; GREEN AA, 1955, METHOD ENZYMOL, V1, P67, DOI 10.1016/0076-6879(55)01014-8; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MEJEAN V, 1991, NUCLEIC ACIDS RES, V19, P5525, DOI 10.1093/nar/19.20.5525; MEJEAN V, 1993, MOL MICROBIOL, V11, P323; Miller J. H., 1972, EXPT MOL GENETICS, P431; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SCHAAPER RM, 1987, J BIOL CHEM, V262, P16267; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TAVALE SS, 1970, J MOL BIOL, V48, P109, DOI 10.1016/0022-2836(70)90222-6; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	26	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12339	12344						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163538				2022-12-27	WOS:A1994NG37700100
J	DEMORAIS, SMF; GIANNONE, JV; OKEY, AB				DEMORAIS, SMF; GIANNONE, JV; OKEY, AB			PHOTOAFFINITY-LABELING OF THE AH RECEPTOR WITH 3-[H-3]METHYLCHOLANTHRENE AND FORMATION OF A 165-KDA COMPLEX BETWEEN THE LIGAND-BINDING SUBUNIT AND A NOVEL CYTOSOLIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; RAT HEPATIC CYTOSOLS; HEAT-SHOCK PROTEIN; CELL-LINE; GLUCOCORTICOID RECEPTOR; DIOXIN RECEPTOR; NUCLEAR FORMS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; MOUSE; INDUCTION	The aromatic hydrocarbon (Ah) receptor is a cytosolic protein that binds halogenated ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and nonhalogenated ligands such as 3-methylcholanthrene (MC) and benzo[alpha]pyrene. The best characterized biological response mediated by the Ah receptor is induction of cytochrome P4501A1 (CYP1A1). Photoaffinity labeling of the Ah receptor has been reported only with halogenated ligands such as TCDD and some of its iodinated derivatives. In this study, photolabeling of the Ah receptor was achieved with the nonhalogenated aromatic hydrocarbon [H-3]MC. Sources of Ah receptor were the mouse hepatoma cell line Hepa-1c1c9 and the human colon adenocarcinoma line LS180. Cytosolic fractions either were used in a crude form or were enriched by glycerol density gradient centrifugation. These then were incubated with [H-3]MC, irradiated with UV light (>300 nm), precipitated with acetone, and analyzed by SDS-polyacrylamide gel electrophoresis. The yield of photoadduct formation was lower with [H-3]MC (similar to 1%) compared with [H-3]TCDD (3.5%) in Hepa-1c1c9 cells. The same was true in LS180 cells, i.e. the yield was 0.2% for [H-3]MC versus 5.48 +/- 0.26% for [H-3]TCDD. The relative molecular mass of the [H-3]MC-labeled receptor estimated by SDS-polyacrylamide gel electrophoresis was 94,600 +/- 2,400 (mean +/- S.E.) for Hepa-1c1c9 cells and 113,600 +/- 3,200 for LS180 cells; these are the same molecular masses as determined by photolabeling with [H-3]TCDD. In velocity sedimentation assays of mouse cytosol, [H-3]MC binds specifically to two cytosolic proteins: the 4 S carcinogen-binding protein and the Ah receptor (9 S). However, no photolabeling of the 4 S protein was detected in our experiments. [H-3]MC photolabeling of the human Ah receptor from LS180 cells was detected only in experiments using enriched cytosolic preparations. In addition to the 95-kDa ligand-binding subunit, a specifically radiolabeled protein of 164,900 +/- 5,800 kDa was also detected in Hepa-1c1c9 cytosol photolabeled with [H-3]MC, suggesting cross-linking, by MC, of another subunit of the multimeric Ah receptor complex to the ligand-binding subunit. Immunochemical analysis showed that the ligand-binding subunit of the Ah receptor is one component of the 165-kDa complex. The other protein in the complex could not be identified with antibodies to the heat shock proteins hsp90 or hsp70 or with antibodies to the p59 protein or Ah receptor nuclear translocator protein. The identity and function of the protein that becomes cross-linked to the ligand-binding subunit require further investigation.	UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ON,CANADA	University of Toronto								ARNOLD PS, 1987, BIOCHEM J, V242, P375, DOI 10.1042/bj2420375; Bayley H, 1977, Methods Enzymol, V46, P69; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COLLINS S, 1986, BIOCHEMISTRY-US, V25, P4322, DOI 10.1021/bi00363a022; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, CHEMOSPHERE, V15, P1665, DOI 10.1016/0045-6535(86)90452-2; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; HANKINSON O, 1993, ARCH BIOCHEM BIOPHYS, V300, P1, DOI 10.1006/abbi.1993.1001; HARPER PA, 1988, CANCER RES, V48, P2388; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOROWITZ KB, 1988, AFFINITY LABELLING C, P186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1989, J BIOL CHEM, V264, P18463; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LESCA P, 1987, J BIOL CHEM, V262, P4827; LORENZEN A, 1991, TOXICOL APPL PHARM, V107, P203, DOI 10.1016/0041-008X(91)90203-Q; MANCHESTER DK, 1987, CANCER RES, V47, P4861; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OKEY AB, 1982, EUR J BIOCHEM, V127, P39, DOI 10.1111/j.1432-1033.1982.tb06834.x; OKEY AB, 1984, CANCER RES, V44, P1426; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OKEY AB, 1988, MICROSOMES DRUG OXID, P31; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1975, MOL PHARMACOL, V11, P389; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1974, MOL PHARMACOL, V10, P349; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND A, 1988, ARCH BIOCHEM BIOPHYS, V261, P103, DOI 10.1016/0003-9861(88)90109-9; POLLAND A, 1987, BIOCHEM BIOPH RES CO, V146, P1439; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PROKIPCAK RD, 1989, ARCH BIOCHEM BIOPHYS, V274, P648, DOI 10.1016/0003-9861(89)90480-3; PROKIPCAK RD, 1990, BIOCHEM BIOPH RES CO, V172, P698, DOI 10.1016/0006-291X(90)90730-B; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; ROBERTS EA, 1986, CANCER RES, V46, P3739; RUOHO AE, 1973, P NATL ACAD SCI USA, V70, P2567, DOI 10.1073/pnas.70.9.2567; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WAITHE WI, 1991, BIOCHEM PHARMACOL, V41, P85, DOI 10.1016/0006-2952(91)90014-V; WANG X, 1991, ARCH BIOCHEM BIOPHYS, V287, P186, DOI 10.1016/0003-9861(91)90405-8; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	48	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12129	12136						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163517				2022-12-27	WOS:A1994NG37700069
J	BALDWIN, AN; SHOOTER, EM				BALDWIN, AN; SHOOTER, EM			DISULFIDE MUTANTS OF THE BINDING DOMAIN OF THE RAT LOW-AFFINITY NERVE GROWTH-FACTOR RECEPTOR (P75(NGFR))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NUCLEAR MAGNETIC-RESONANCE; MONOCLONAL-ANTIBODY 217C; MOLECULAR-CLONING; NGF RECEPTOR; EXPRESSION; PROTEINS; CONFORMATION; ANTIGEN; CELLS	The binding domain of the low affinity nerve growth factor receptor (p75NGFR) is built from four ''cysteine repeats,'' with almost identical patterns of half-cystine residues. To study the pattern of disulfide bridging within each cysteine repeat, we have mutated pairs of cysteine residues, primarily in the fourth repeat, and have tested the relative ability of each mutant to be cross-linked to the nerve growth factor after transient expression in COS 7 cells. The results give an indication of the relative importance of different disulfide bonds for the stability of the active conformation. Immunofluorescent staining shows that all of these proteins, even those that may be partially misfolded, are expressed to varying degrees on the surface of COS cells. They can also be detected by the monoclonal antibody MC192 on a Western blot following electrophoresis on a nondenaturing gel. Some cannot, however, be detected by MC192 on a Western blot after heat denaturation in SDS. The ability to refold under these conditions correlates in general with the ability of the mutant protein to bind nerve growth factor on the surface of COS cells.			BALDWIN, AN (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.				NINDS NIH HHS [NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHARYA AS, 1977, P NATL ACAD SCI USA, V74, P2362, DOI 10.1073/pnas.74.6.2362; BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHRAMBACH A, 1976, METHODS PROTEIN SEPA, V2, P27; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; CREIGHTON TE, 1980, FEBS LETT, V118, P283, DOI 10.1016/0014-5793(80)80239-0; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; CREIGHTON TE, 1975, J MOL BIOL, V96, P767, DOI 10.1016/0022-2836(75)90151-5; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FERRARI G, 1991, EXP NEUROL, V112, P183, DOI 10.1016/0014-4886(91)90068-N; FLORY PJ, 1956, J AM CHEM SOC, V78, P5222, DOI 10.1021/ja01601a025; GOTO Y, 1987, J BIOCHEM, V101, P319, DOI 10.1093/oxfordjournals.jbchem.a121916; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P223; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; YAN H, 1991, J BIOL CHEM, V266, P12099	36	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11456	11461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157676				2022-12-27	WOS:A1994NF96600071
J	LEE, YH; OKAR, D; LIN, K; PILKIS, SJ				LEE, YH; OKAR, D; LIN, K; PILKIS, SJ			MECHANISM OF MODULATION OF RAT-LIVER FRUCTOSE-2,6-BISPHOSPHATASE BY NUCLEOSIDE TRIPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; ESCHERICHIA-COLI; RNA-POLYMERASE; PHOSPHO GROUP; EXPRESSION; SEQUENCE; DOMAIN; BINDING; FRUCTOSE-6-PHOSPHATE	The mechanism of modulation of fructose-2,6-bisphosphatase of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by nucleoside triphosphates was studied by employing the Escherichia coli-expressed bisphosphatase domain and a COOH-terminal 30-amino acid truncated form. These forms had K(m) values for substrate and K(i) values for products which were similar to those of the bisphosphatase of the intact bifunctional enzyme, but turnover numbers were 5-fold higher. All forms also exhibited substrate inhibition that was relieved by GTP and ATP. The nucleoside triphosphates bound to the active site, since they were competitive inhibitors at subsaturating substrate concentrations. Guanosine was also a competitive inhibitor at subsaturating substrate concentrations but did not activate at saturating substrate. ATP and GTP had K(d) values of 467 and 110 muM, respectively, and 1 mol of nucleoside triphosphate/mol bound per mol of bisphosphatase. The K(i) values for guanosine of two mutants, Lys36 --> Ala and Arg360 --> Ala, were unchanged from that of the wild-type enzyme. However, the K(i) for GTP for Arg360 --> Ala was 17-fold higher than that of the wild-type enzyme, whereas that for Lys356 --> Ala was unchanged. It was concluded that 1) nucleoside triphosphate modulation of the bisphosphatase of the bifunctional enzyme involves a direct interaction with the active site of the bisphosphatase domain; and 2) the activation is caused by the phosphate moieties of GTP and ATP competing with the 2-phospho group of fructose-2,6-bisphosphate for the phosphoenzyme intermediate, thus relieving substrate inhibition.	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIDDK NIH HHS [DK 38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adair GS, 1925, J BIOL CHEM, V63, P529; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURLAND IJ, 1993, J BIOL CHEM, V268, P14056; LANGE AJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P258, DOI 10.1016/0003-9861(91)90617-R; LANGE AJ, 1990, NUCLEIC ACIDS RES, V18, P3652, DOI 10.1093/nar/18.12.3652; LEE YH, 1994, J MOL BIOL, V235, P1147, DOI 10.1006/jmbi.1994.1065; LI L, 1992, J BIOL CHEM, V267, P21588; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P19163; LIN K, 1992, J BIOL CHEM, V267, P6556; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; PILKIS S, 1990, FRUCTOSE 2 6 BISPHOS, P125; PILKIS SJ, 1982, MOL CELL ENDOCRINOL, V25, P245, DOI 10.1016/0303-7207(82)90082-X; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; RIDER MH, 1992, EUR J BIOCHEM, V207, P967, DOI 10.1111/j.1432-1033.1992.tb17131.x; ROSENBERG AH, 1987, GENE, V59, P191, DOI 10.1016/0378-1119(87)90327-1; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAULER A, 1988, P NATL ACAD SCI USA, V85, P6642, DOI 10.1073/pnas.85.18.6642; TAULER A, 1990, J BIOL CHEM, V265, P15617; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VENTURA F, 1992, J BIOL CHEM, V267, P17939	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11002	11010						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157626				2022-12-27	WOS:A1994NF96600009
J	JIANG, SW; EBERHARDT, NL				JIANG, SW; EBERHARDT, NL			THE HUMAN CHORIONIC SOMATOMAMMOTROPIN GENE ENHANCER IS COMPOSED OF MULTIPLE DNA ELEMENTS THAT ARE HOMOLOGOUS TO SEVERAL SV40 ENHANSONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL-LACTOGEN; TRANSCRIPTION; PITUITARY; EVOLUTION; SEQUENCE; TEF-1; SPECIFICITY; EXPRESSION; PREGNANCY; PROTEIN	Previous studies indicate that a human chorionic somatomammotropin (hCS) gene enhancer (CSEn) associated with the growth hormone (hGH) gene locus is involved in directing cell-specific expression of the hCS genes in placenta. In the current studies, we report a detailed structural analysis of this enhancer. CSEn stimulated transcription of a variety of promoters, including the hCS, human growth hormone, thymidine kinase, and Rous sarcoma virus promoters, in human choriocarcinoma cell lines (BeWo and JEG-3) but not HeLa cells or rat somatolactotrophes (GC). Maximal enhancer activity was confined to a 242-base pair DNA segment. Of several CSEn subfragments, only the En 57/242 subfragment retained activity (33.5% wild-type). The CSEn DNA sequence contained direct and inverted repeat motifs and sequences related to the SV40 enhansons, GT-IIC, GT-I, and SphI/SphII. DNase I footprint analysis revealed that most of these sites were protected by nuclear proteins derived from BeWo, JEG-3, HeLa, and GC cells. Site-specific block mutation of the GT-IIC-related and inverted repeat moths virtually abolished enhancer activity, and mutation of all but the GT-I-related motif resulted in significant loss (30-60%) of activity. These data demonstrate that the CS enhancer is comprised of multiple elements related to SV40 enhansons that interact cooperatively to generate enhancer function.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NIDDK NIH HHS [DK41206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FITZPATRICK SL, 1990, MOL ENDOCRINOL, V4, P1815, DOI 10.1210/mend-4-12-1815; HANDWERGER S, 1991, ENDOCR REV, V12, P329, DOI 10.1210/edrv-12-4-329; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; JJONES BK, 1992, ENDOCRINE SOC PROGRA, V74, P446; LOSARDO JE, 1990, J VIROL, V64, P1756, DOI 10.1128/JVI.64.4.1756-1763.1990; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; NACHTIGAL MW, 1993, J BIOL CHEM, V268, P8473; NEILSEN PV, 1979, AM J OBSTET GYNECOL, V135, P322; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; RODGERS BL, 1986, NUCLEIC ACIDS RES, V14, P7647; SCHIER AF, 1993, EMBO J, V12, P1111, DOI 10.1002/j.1460-2075.1993.tb05752.x; Snedecor G. W., 1980, STATISTICAL METHODS, P116; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WURZEL JM, 1982, DNA-J MOLEC CELL BIO, V1, P251, DOI 10.1089/dna.1.1982.1.251; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	27	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10384	10392						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144621				2022-12-27	WOS:A1994NF01700033
J	YANG, ZT; BERGSTROM, J; KARLSSON, KA				YANG, ZT; BERGSTROM, J; KARLSSON, KA			GLYCOPROTEINS WITH GAL-ALPHA-4GAL ARE ABSENT FROM HUMAN ERYTHROCYTE-MEMBRANES, INDICATING THAT GLYCOLIPIDS ARE THE SOLE CARRIERS OF BLOOD-GROUP-P ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; ANTIGENS; BINDING; GLYCOSPHINGOLIPIDS; SPECIFICITY; ANTIBODIES; INTESTINE; CERAMIDE; BACTERIA; STRAIN	The antigenic determinants of the blood group P family (P-1, P, P-k and LKE antigens) are chemically based on Gal alpha 4Gal. For human erythrocytes it has been claimed that the majority of P-1 determinants are expressed in glycoproteins, mainly band 4.5 (Haselberger, C. G., and Schenkel-Brunner, H. (1982) PEBS Lett. 149, 126-128). In the present work, the existence of Gal alpha 4Gal in glycoproteins of erythrocyte membranes (ghosts) of P-1 positive and negative human individuals was carefully analyzed on replicas of sodium dodecyl sulfate-polyacrylamide electrophoresis gels using specific reagents (Escherichia coli HB101/pDC1 expressing the Pop gene and monoclonal antibodies with specificities for P-1 and P-k antigens). No binding to glycoproteins was detected with any of these ligands when the ghosts had been pretreated with butanol to remove glycolipids. Therefore, all antigenic determinants of the P blood group family on human red cells are exclusively expressed in glycolipids and are absent from glycoproteins.	UNIV GOTHENBURG, DEPT BIOCHEM MED, S-41390 GOTHENBURG, SWEDEN	University of Gothenburg				Bergstrom, Jorgen/0000-0003-3255-5150				ANSTEE DJ, 1990, J IMMUNOGENET, V17, P219; BOCK K, 1985, J BIOL CHEM, V260, P8545; BRUCE M, 1988, VOX SANG, V55, P237, DOI 10.1111/j.1423-0410.1988.tb04704.x; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HANSSON GC, 1983, BIOCHIM BIOPHYS ACTA, V750, P214, DOI 10.1016/0005-2760(83)90224-2; HASELBERGER CG, 1982, FEBS LETT, V149, P126, DOI 10.1016/0014-5793(82)81086-7; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARLSSON KA, 1992, FEMS SYMP, V61, P115; LEWIS M, 1990, VOX SANG, V58, P152; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MARKLUND BI, 1991, THESIS U UMEA SWEDEN; MCKIBBIN JM, 1982, J BIOL CHEM, V257, P755; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Steck T L, 1974, Methods Enzymol, V31, P172; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; THURIN J, 1988, CURR TOP MICROBIOL, V139, P59; TIPPETT P, 1986, VOX SANG, V51, P53, DOI 10.1111/j.1423-0410.1986.tb00209.x	22	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14620	14624						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182069				2022-12-27	WOS:A1994NM06500050
J	BULLESBACH, EE; SCHWABE, C				BULLESBACH, EE; SCHWABE, C			FUNCTIONAL IMPORTANCE OF THE A-CHAIN LOOP IN RELAXIN AND INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SITE; SEQUENCE DETERMINATION; PORCINE RELAXIN; PURIFICATION; GENE	Relaxin and insulin are disulfide homologues with divergent functions and antigenicity. We have synthesized human relaxin II and porcine insulin and several A chain loop variants of each and measured the effect of substitutions in vivo and in vitro. Substitution of Ile(A10) in insulin with glycine reduced the receptor binding ability by 2 orders of magnitude. Conversely, exchange of the glycine A14 residue in relaxin, which corresponds to the insulin position A10 for isoleucine, reduced the bioactivity and the receptor binding capacity of relaxin about 100-fold. Substitution of L-Ala in insulin as well as relaxin represented a compromise that allowed both hormones to recover about 30% of the native potency. X-ray analysis and computer derived energy calculation confirm our receptor binding and biological potency studies, which suggest that the functional difference be tween derivatives and native hormones is based upon a structural change introduced into the A chain loop by substitution of the penultimate, intrachain loop residue. In order to achieve a conformation that favors dynamic or passive interaction with the receptor, insulin and relaxin require a different A chain loop structure in spite of the striking overall similarity.			BULLESBACH, EE (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425, USA.				NIDDK NIH HHS [DK38348] Funding Source: Medline; NIGMS NIH HHS [GM48829] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048829] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler A J, 1973, Methods Enzymol, V27, P675; BERNATOWICZ MS, 1986, INT J PEPT PROT RES, V28, P107; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; BULLESBACH EE, 1980, H-S Z PHYSIOL CHEM, V361, P865, DOI 10.1515/bchm2.1980.361.1.865; BULLESBACH EE, 1987, BIOCHEM BIOPH RES CO, V143, P273; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; BULLESBACH EE, 1986, EUR J BIOCHEM, V161, P335, DOI 10.1111/j.1432-1033.1986.tb10452.x; CRAWFORD RJ, 1989, J MOL ENDOCRINOL, V3, P169, DOI 10.1677/jme.0.0030169; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; GOWAN LK, 1981, FEBS LETT, V129, P80, DOI 10.1016/0014-5793(81)80760-0; HOCK RA, 1980, J BIOL CHEM, V255, P731; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; JAMES R, 1977, NATURE, V267, P544, DOI 10.1038/267544a0; LEE YA, 1992, ENDOCRINOLOGY, V130, P1165, DOI 10.1210/en.130.3.1165; LINDE S, 1986, J CHROMATOGR, V369, P327, DOI 10.1016/S0021-9673(00)90139-0; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCHWABE C, 1976, BIOCHEM BIOPH RES CO, V70, P397, DOI 10.1016/0006-291X(76)91059-7; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SIEBER P, 1977, HELV CHIM ACTA, V60, P27, DOI 10.1002/hlca.19770600105; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEWART DR, 1991, ENDOCRINOLOGY, V129, P375, DOI 10.1210/endo-129-1-375; STEWART DR, 1992, J PROTEIN CHEM, V11, P247, DOI 10.1007/BF01024863; WOODS AS, 1991, INT J MASS SPECTROM, V111, P77, DOI 10.1016/0168-1176(91)85049-R; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	29	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13124	13128						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175738				2022-12-27	WOS:A1994NK18400014
J	KUMAR, C; MWANGI, V; NUTHULAGANTI, P; WU, HL; PULLEN, M; BRUN, K; AIYAR, H; MORRIS, RA; NAUGHTON, R; NAMBI, P				KUMAR, C; MWANGI, V; NUTHULAGANTI, P; WU, HL; PULLEN, M; BRUN, K; AIYAR, H; MORRIS, RA; NAUGHTON, R; NAMBI, P			CLONING AND CHARACTERIZATION OF A NOVEL ENDOTHELIN RECEPTOR FROM XENOPUS HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTYPE-SELECTIVE LIGANDS; FUNCTIONAL EXPRESSION; IDENTIFICATION; CDNA; TISSUES; BINDING; FAMILY; CORTEX; GENE; ACID	Endothelin (ET) receptors display subtype heterogeneity and so far three subtypes of ET receptors, namely ET(A), ET(B), and ET(C), have been identified, cloned, sequenced, and characterized. Based on the binding profile of ET and related peptides, a novel ET receptor (ET(AX)) was identified in the follicular membranes of Xenopus laevis oocytes (Kumar, C. S., Nuthulaganti, P., Pullen, M., and Nambi, P. (1993). Mol. Pharmacol. 44, 153-157). Here we report the cloning and characterization of this ET(AX) subtype from X. Laevis heart. A cDNA was isolated that encodes a protein of 415 amino acids that shares 74, 60, and 51% identities with human ET(A), human ET(B), and Xenopus ET(C) receptors, respectively. Competition binding studies of the cloned receptor expressed in COS cells using ET-related peptides suggested that this receptor is pharmacologically identical to that expressed in Xenopus oocyte follicular, heart, and lung membranes. Phosphoinositide turnover and oocyte electrophysiological studies indicated that the cloned receptor is functionally coupled to a second messenger system.	SMITHKLINE BEECHAM PHARMACEUT,DEPT RENAL PHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	KUMAR, C (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,UE0548,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; AIYAR N, 1986, LIFE SCI, V39, P37, DOI 10.1016/0024-3205(86)90435-2; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BROOKS DP, 1994, IN PRESS J PHARM EXP; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EDWARDS RM, 1992, AM J PHYSIOL, V263, pF1020, DOI 10.1152/ajprenal.1992.263.6.F1020; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; HOSODAK, 1992, J BIOL CHEM, V267, P18797; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; KARNE S, 1993, J BIOL CHEM, V268, P19126; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUMAR CS, 1993, MOL PHARMACOL, V44, P153; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MIZUNO T, 1992, BIOCHEM J, V287, P305, DOI 10.1042/bj2870305; NAMBI P, 1992, MOL PHARMACOL, V42, P336; NAMBI P, 1994, NEUROPEPTIDES, V26, P181, DOI 10.1016/0143-4179(94)90128-7; NAMBI P, 1992, ENDOCRINOLOGY, V131, P1081, DOI 10.1210/en.131.3.1081; NAMBI P, 1990, NEUROPEPTIDES, V16, P195, DOI 10.1016/0143-4179(90)90062-4; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SOKOLOVSKY M, 1993, BIOCHEM BIOPH RES CO, V196, P32, DOI 10.1006/bbrc.1993.2212; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; WHITE MM, 1985, P NATL ACAD SCI USA, V82, P4852, DOI 10.1073/pnas.82.14.4852; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V180, P475, DOI 10.1016/S0006-291X(05)81089-7; YANAGISAWA M, 1988, NATURE, V332, P1111	40	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13414	13420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175772				2022-12-27	WOS:A1994NK18400055
J	SANDERSON, RD; TURNBULL, JE; GALLAGHER, JT; LANDER, AD				SANDERSON, RD; TURNBULL, JE; GALLAGHER, JT; LANDER, AD			FINE-STRUCTURE OF HEPARAN-SULFATE REGULATES SYNDECAN-1 FUNCTION AND CELL BEHAVIOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; SURFACE PROTEOGLYCAN; MOLECULAR POLYMORPHISM; BINDING SEQUENCE; MEMBRANE; GLYCOSAMINOGLYCANS; RECEPTOR; AFFINITY	Two myeloma cell lines, MPC-11 and P3X63Ag8.653 (P3), have almost identical amounts of syndecan-1 at their cell surface. The syndecan-1 molecules from both lines are similar in size, have indistinguishable core proteins, and have similarly sized heparan sulfate chains. Nevertheless, syndecan-1 on MPC-11 mediates cell adhesion to type I collagen, whereas P3 cells do not bind collagen. Affinity co-electrophoresis reveals that intact syndecan-1 isolated from P3 cells binds collagen poorly and that syndecan-1 heparan sulfate isolated from MPC-11 has a 20-fold higher affinity for collagen than syndecan-1 heparan sulfate from P3. Analysis of disaccharide composition and oligosaccharide mapping also reveals differences between MPC-11 and P3 heparan sul fate. Most notably, the level of N-sulfation and 2-O-sulfation is higher, and 6-O-sulfation lower, in syndecan-1 heparan sulfate from MPC-11 than from P3. Interestingly, levels of total sulfation of syndecan-1 heparan sulfate from MPC-11 and P3 are similar (75.6 and 72.6 sulfates/100 disaccharides, respectively), indicating that the difference in their affinity for collagen is not due to a difference in net charge. These data indicate that the fine structure of heparan sulfate can differ on identical proteoglycan core proteins, and these differences can control fundamental cellular properties such as cell matrix adhesion.	UNIV ARKANSAS MED SCI HOSP, DEPT ANAT, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, CTR MUSCULOSKELETAL RES, LITTLE ROCK, AR 72205 USA; UNIV MANCHESTER, CHRISTIE HOSP, CRC, DEPT MED ONCOL, MANCHESTER M20 9BX, LANCS, ENGLAND; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Massachusetts Institute of Technology (MIT)	SANDERSON, RD (corresponding author), UNIV ARKANSAS MED SCI HOSP, DEPT PATHOL, SLOT 517, 4301 W MARKHAM, LITTLE ROCK, AR 72205 USA.		Lander, Arthur/L-2827-2019; Lander, Arthur D/C-9008-2011	Lander, Arthur/0000-0002-4380-5525; Lander, Arthur D/0000-0002-4380-5525	NCI NIH HHS [CA55879] Funding Source: Medline; NINDS NIH HHS [NS26862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HINKES MT, 1993, J BIOL CHEM, V268, P11440; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1991, Journal of Cell Biology, V115, p125A; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RIDLEY RC, 1993, BLOOD, V81, P767; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TURNBULL JE, 1988, BIOCHEM J, V251, P597, DOI 10.1042/bj2510597; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; WALKER A, 1994, J BIOL CHEM, V269, P931	35	158	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13100	13106						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175735				2022-12-27	WOS:A1994NK18400011
J	ZHOU, J; DING, M; ZHAO, ZH; REEDERS, ST				ZHOU, J; DING, M; ZHAO, ZH; REEDERS, ST			COMPLETE PRIMARY STRUCTURE OF THE 6TH CHAIN OF HUMAN BASEMENT-MEMBRANE COLLAGEN, ALPHA-6(IV) - ISOLATION OF THE CDNAS FOR ALPHA-6(IV) AND COMPARISON WITH 5 OTHER TYPE-IV COLLAGEN CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPORT SYNDROME; BIDIRECTIONAL PROMOTER; ALPHA-2(IV) COLLAGEN; GOODPASTURE ANTIGEN; EXTENSIVE HOMOLOGY; CELL-ADHESION; IDENTIFICATION; DOMAIN; ALPHA-1(IV); REGION	Basement membranes were previously believed to contain five distinct type IV collagen subunits. We have recently isolated part of the cDNA for a novel type IV collagen, alpha 6(IV), and shown that COL4A6, the gene encoding this new chain, is deleted in Alport syndrome-associated leiomyomatosis (Zhou, J., Mochizuki, T., Smeets, H., Antignac, C., Laurila, P., de Paepe, A., Tryg- gvason, K., and Reeders, S. T. (1993) Science 261, 1167-1169). Here, we describe the entire human (alpha 6(IV) cDNA and show that the gene encodes a classical type IV collagen with homology throughout its length to all the other five chains. There is a 21-residue signal peptide, a 1417-residue collagenous domain interrupted at 25 points, and a 228-residue carboxyl-terminal non-collagenous domain. When the complete primary structure of this new chain was compared with all the other known chains, it became clear that (alpha 6(IV) has the most resemblance to alpha 2(IV) and alpha 4(IV). The evolution of the six chains was deduced, allowing a new classification of the type IV collagen family. The alpha 6(IV) chain is a candidate gene for X-linked Alport syndrome; knowledge of the complete structure of the chain will permit us to screen systematically for mutations in patients and to generate recombinant proteins and synthetic peptides for further study of cell-matrix interactions involving the alpha 6(IV) chain.			ZHOU, J (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEPHROL,BOSTON,MA 02115, USA.							BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1987, FEBS LETT, V216, P281, DOI 10.1016/0014-5793(87)80706-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KURKINEN M, 1987, J BIOL CHEM, V262, P8496; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NETZER KO, 1992, KIDNEY INT, V42, P1336, DOI 10.1038/ki.1992.425; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RISTELI J, 1980, EUR J BIOCHEM, V108, P239, DOI 10.1111/j.1432-1033.1980.tb04717.x; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHUPPAN D, 1984, BIOCHEM J, V220, P227, DOI 10.1042/bj2200227; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SMEETS HJM, 1992, KIDNEY INT, V42, P83, DOI 10.1038/ki.1992.264; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1993, KIDNEY INT, V43, P722, DOI 10.1038/ki.1993.103; ZHOU J, 1992, J BIOL CHEM, V267, P12475	39	99	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13193	13199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175748				2022-12-27	WOS:A1994NK18400025
J	BUSCH, AE; WALDEGGER, S; HERZER, T; BIBER, J; MARKOVICH, D; MURER, H; LANG, F				BUSCH, AE; WALDEGGER, S; HERZER, T; BIBER, J; MARKOVICH, D; MURER, H; LANG, F			ELECTROGENIC COTRANSPORT OF NA+ AND SULFATE IN XENOPUS-OOCYTES EXPRESSING THE CLONED NA+/SO42- TRANSPORT PROTEIN NASI-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BORDER MEMBRANE-VESICLES; GLUCOSE COTRANSPORTER	The Na+/sulfate cotransporter cloned from rat kidney cortex (NaSi-1) has been expressed in oocytes of Xenopus laevis and subjected to electrophysiological analysis by current and voltage clamp methods. In current-clamped oocytes, superfusion with 1 mM sulfate resulted in a 12-mV depolarization of the cell membrane. Accordingly, in voltage-clamped oocytes sulfate induced an inward current (I-S), which was dependent on both the concentration of Na+ and sulfate in the superfusate. Half-maximal I-S was observed at about 0.1 mM sulfate and 70 mM Na+. The Hill coefficients were 1 and 2.8 for sulfate and Na+, respectively. Thiosulfate and selenate created similar currents as sulfate with a similar K-m. At saturating concentrations of thiosulfate and selenate, addition of sulfate could not induce an additive current. Phosphate (1 mM) did not inhibit sulfate-induced currents. Finally, I-S was dependent on the holding potential being larger at more negative potentials. The results of this study strongly suggest an electrogenic cotransport of sulfate and Na+ with a stoichiometry of 1:3.	UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich	BUSCH, AE (corresponding author), UNIV TUBINGEN,INST PHYSIOL 1,GMELINSTR 5,D-72076 TUBINGEN,GERMANY.		Markovich, Daniel/F-7884-2012					AHEARN GA, 1984, J MEMBRANE BIOL, V78, P177, DOI 10.1007/BF01925966; BAESTLEIN C, 1986, AM J PHYSIOL, V250, pF226; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; COHEN JJ, 1957, AM J PHYSIOL, V189, P331, DOI 10.1152/ajplegacy.1957.189.2.331; DENNIS VW, 1982, KIDNEY INT, V22, P498, DOI 10.1038/ki.1982.203; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LUCKE H, 1979, BIOCHEM J, V182, P223; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MURER H, 1992, HDB PHYSL 8, V2, P2165; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RENFRO JL, 1989, AM J PHYSIOL, V256, pR1176, DOI 10.1152/ajpregu.1989.256.6.R1176; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; TURNER RJ, 1984, AM J PHYSIOL, V247, pF793, DOI 10.1152/ajprenal.1984.247.5.F793	17	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12407	12409						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175644				2022-12-27	WOS:A1994NH71600007
J	DUNWOODIE, SL; JOYA, JE; ARKELL, RM; HARDEMAN, EC				DUNWOODIE, SL; JOYA, JE; ARKELL, RM; HARDEMAN, EC			MULTIPLE REGIONS OF THE HUMAN CARDIAC ACTIN GENE ARE NECESSARY FOR MATURATION-BASED EXPRESSION IN STRIATED-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; SKELETAL-MUSCLE; MESSENGER-RNA; BETA-ACTIN; DEVELOPMENTAL REGULATION; ALPHA-SKELETAL; PROMOTER; MOUSE; TRANSCRIPTION	In order to elucidate mechanisms involved in striated muscle contractile protein isoform expression, we have defined regulatory elements in the cardiac actin gene necessary for postnatal expression at the level of transcript accumulation in the heart and hindlimb muscles of transgenic mice. During this developmental period in the rodent, cardiac actin expression essentially remains constant in the heart, but declines significantly in skeletal muscle. We determined that a 13-kilobase human cardiac actin gene fragment contains sufficient information to direct this maturation-based developmental ex- pression, as well as striated muscle-specific and high level expression. We localized an element responsible for maturation-based down-regulation in the 3' flank of the gene between approximately 950 and 2120 base pairs downstream of the polyadenylation site. Furthermore, we determined that -800 base pairs of 5'-flanking DNA, which contains multiple MyoD1 binding sites, as well as serum response element and AP1 binding sites, can account for striated muscle specific expression, but not high level expression. Findings indicate that sequence(s) responsible for high level expression of the gene must be located within the body of the gene. We conclude that the human cardiac actin gene contains distinct sequences which confer developmental, tissue-specific, and high level expression.	CHILDRENS MED RES INST,MUSCLE DEV UNIT,WENTWORTHVILLE,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Dunwoodie, Sally L/M-4019-2018; Hardeman, Edna C/F-8872-2012; arkell, ruth m/D-1525-2009	Dunwoodie, Sally L/0000-0002-2069-7349; arkell, ruth m/0000-0002-6213-7323; Hardeman, Edna/0000-0003-1649-7712				ALONSO S, 1990, J MOL BIOL, V211, P727, DOI 10.1016/0022-2836(90)90073-U; BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; EPSTEIN HF, 1991, SCIENCE, V251, P1029; GARNER I, 1989, DEV BIOL, V134, P236, DOI 10.1016/0012-1606(89)90093-6; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUNNING P, 1984, CELL, V36, P709, DOI 10.1016/0092-8674(84)90351-9; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; HARDEMAN EC, 1986, CELL, V47, P123, DOI 10.1016/0092-8674(86)90373-9; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HOGAN B, 1986, MANIPULATING MOUSE E; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; LACY E, 1983, CELL, V34, P343, DOI 10.1016/0092-8674(83)90369-0; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; LOHSE P, 1988, NUCLEIC ACIDS RES, V167, P2787; Maniatis T., 1982, MOL CLONING; MAYER Y, 1984, NUCLEIC ACIDS RES, V12, P1087, DOI 10.1093/nar/12.2.1087; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MCKNIGHT GS, 1983, CELL, V34, P335; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHACHAT FH, 1985, J BIOL CHEM, V260, P1108; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TAYLOR MV, 1991, GENE DEV, V5, P1149, DOI 10.1101/gad.5.7.1149; WADE R, 1989, ANNU REV PHYSIOL, V51, P179, DOI 10.1146/annurev.physiol.51.1.179; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661	51	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12212	12219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163527				2022-12-27	WOS:A1994NG37700082
J	LEW, AM; YAO, H; ELSHOLTZ, HP				LEW, AM; YAO, H; ELSHOLTZ, HP			G(I-ALPHA-2)-MEDIATED AND G(O-ALPHA)-MEDIATED SIGNALING IN THE PIT-1-DEPENDENT INHIBITION OF THE PROLACTIN GENE PROMOTER - CONTROL OF TRANSCRIPTION BY DOPAMINE D2 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; INOSITOL PHOSPHATE PRODUCTION; CYCLIC-AMP ACCUMULATION; RAT LACTOTROPH CELLS; G-PROTEIN; GROWTH-HORMONE; FACTOR PIT-1; EXPRESSION; BINDING; PHOSPHORYLATION	Dopaminergic signaling in pituitary lactotrophs is dependent on coupling of D2 receptors to several inhibitory G-protein subtypes, resulting in the activation of multiple signaling pathways. In prolactin-secreting GH4 cells that express cloned D2 receptors, dopamine selectively inhibits the activity of the prolactin gene promoter, a response mediated in part by the pituitary transcription factor Pit-1. Transfected gain-of-function mutants of the G(alpha) subtypes, G(i alpha 2) (Q205L) and G(o alpha) (Q205L), mimic the promoter-specific and Pit-1-dependent inhibition by dopamine. Whereas the activated G(i alpha 2) subtype suppresses cAMP levels, the G(o alpha) mutant does not, demonstrating a cAMP-independent pathway in the inhibition of the prolactin gene. This alternate pathway could involve other regulators, possibly calcium. Interestingly, in Ltk(-) cells in which cloned D2 receptors modestly suppress cAMP,but elevate [Ca2+](i), the activity of the prolactin promoter is enhanced rather than inhibited by dopamine. The response is promoter-specific, dependent on Pit-1, and completely blocked by low concentrations of EGTA, consistent with a calcium-regulated pathway. Last, in GH4 cells, the absence of additivity between G(i alpha 2) and G(o alpha) mutants suggests a convergent mechanism in the reduction of prolactin promoter activity, in which either signaling pathway may be sufficient for maximum inhibition. This apparent redundancy in inhibitory control mechanisms may be of physiological importance for maintaining efficient tonic suppression of prolactin synthesis.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ON,CANADA; UNIV TORONTO,BANTING & BEST DIABET CTR,TORONTO M5G 1L5,ON,CANADA	University of Toronto; University of Toronto								ALBERT PR, 1990, J BIOL CHEM, V265, P2098; BAERTSCHI AJ, 1992, MOL ENDOCRINOL, V6, P2257, DOI 10.1210/me.6.12.2257; BENJONATHAN N, 1985, ENDOCR REV, V6, P564, DOI 10.1210/edrv-6-4-564; BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CIVELLI O, 1991, EUR J PHARM-MOLEC PH, V207, P277, DOI 10.1016/0922-4106(91)90001-X; COLLU R, 1988, ENDOCRINOLOGY, V122, P1176, DOI 10.1210/endo-122-3-1176; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1989, J BIOL CHEM, V264, P431; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; ENJALBERT A, 1990, J BIOL CHEM, V265, P18816; FLORIO T, 1992, J BIOL CHEM, V267, P24169; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; JACKSON AE, 1988, MOL ENDOCRINOL, V2, P1139, DOI 10.1210/mend-2-11-1139; JCKSON SM, 1992, MOL CELL BIOL, V12, P2708; JOURNOT L, 1987, J BIOL CHEM, V262, P15106; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; LIU YF, 1992, J NEUROCHEM, V59, P2311; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LLEDO PM, 1990, NEUROENDOCRINOLOGY, V52, P545, DOI 10.1159/000125650; LLEDO PM, 1990, J PHYSIOL-LONDON, V435, pP49; MALGAROLI A, 1987, J BIOL CHEM, V262, P13920; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MCCHESNEY R, 1991, MOL CELL ENDOCRINOL, V79, pR1, DOI 10.1016/0303-7207(91)90110-E; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMMONDS SH, 1985, NEUROSCI LETT, V60, P267, DOI 10.1016/0304-3940(85)90588-9; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; VALLAR L, 1988, J BIOL CHEM, V263, P10127; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	48	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12007	12013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163504				2022-12-27	WOS:A1994NG37700053
J	LIU, LW; REZAIE, AR; CARSON, CW; ESMON, NL; ESMON, CT				LIU, LW; REZAIE, AR; CARSON, CW; ESMON, NL; ESMON, CT			OCCUPANCY OF ANION-BINDING EXOSITE-2 ON THROMBIN DETERMINES CA2+ DEPENDENCE OF PROTEIN-C ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; RECOMBINANT HUMAN THROMBOMODULIN; PROTHROMBIN FRAGMENT-2; BLOOD-COAGULATION; ANTITHROMBIN-III; ACTIVE-SITE; SPECIFICITY; CALCIUM; REGION; ANTICOAGULANT	Thrombomodulin (TM) binds thrombin to form a complex that activates the plasma anticoagulant zymogen protein C. TM is an integral membrane glycoprotein that contains a chondroitin sulfate moiety. Interaction with thrombin involves both the protein component of TM, specifically the growth factor-like repeats 4-6 (TM 4-6), and chondroitin sulfate. Removal of chondroitin sulfate decreases the affinity for thrombin approximate to 10-fold and shifts the Ca2+ dependence of protein C activation from simple saturation at greater than or equal to 500 mu M Ca2+ to a distinct optimum at approximate to 100 mu M Ca2+. Thrombin possesses two regions of high positive charge, anion binding exosites 1 and 2. Anion binding exosite 1 interacts with the growth factor region of TM while exosite 2 is involved in binding prothrombin activation fragment 2 or heparin. We demonstrate that recombinant TM, truncated at the membrane-spanning domain, or TM 4-6 can bind thrombin when fragment 2 is present either covalently attached (meizothrombin des-fragment 1) or in reversible association. With meizothrombin des-fragment 1, the Ca2+ dependence of protein C activation is independent of the presence of the chondroitin sulfate on TM. At 0.27 mM Ca2+, TM containing chondroitin sulfate binds thrombin (K-d(app) = 0.3 nM) approximate to 45 times tighter than meizothrombin des-fragment 1 (K-d(app) = 14 nM). However, the chondroitin-free form thrombin (K-d(app) = 2.4 nM) only approximate to 4 times tighter than meizothrombin des-fragment 1 (K-d(app) = 9.4 nM). These studies suggest that occupancy of anion binding exosite 2 by either chondroitin sulfate or fragment 2 alters thrombin conformation resulting in the altered Ca2+ dependence of protein C activation.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [R37 HL30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DITTMAN WA, 1990, BLOOD, V75, P329; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1974, J BIOL CHEM, V249, P7791; ESMON NL, 1988, CIRCULATION, V78, P317; JAKUBOWSKI HV, 1989, J BIOL CHEM, V264, P11117; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; MARTIN PD, 1993, 16TH C INT UN CRYST; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; OWEN WG, 1974, J BIOL CHEM, V249, P594; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WU QY, 1992, J BIOL CHEM, V267, P7083; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	33	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11807	11812						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163479				2022-12-27	WOS:A1994NG37700023
J	NAKAJIMA, K; HASHIMOTO, T; YAMADA, Y				NAKAJIMA, K; HASHIMOTO, T; YAMADA, Y			OPPOSITE STEREOSPECIFICITY OF 2 TROPINONE REDUCTASES IS CONFERRED BY THE SUBSTRATE-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEHYDROGENASE; ENZYMES	Two tropinone reductases (TRs) catalyze opposite stereospecific reductions at a branching point in the biosynthetic pathway of tropane alkaloids. The two TRs, TR-I and TR-II, reduce the 3-keto group of the common substrate tropinone stereospecifically to 3 alpha- and 3 beta-hydroxy groups, to produce the stereoisomeric alkamines tropine and pseudotropine, respectively. Sixteen chimeric TR enzymes were expressed in Escherichia coli, and their stereospecificities, substrate specificities, and K-m values for tropinone were compared with those of the wild-type enzymes. Stereospecificity and substrate specificity of the chimeric enzymes were closely correlated, and the carboxyl-terminal peptides of about 120 amino acid residues, in which 53 residues were different between TR-I and TR-II were shown to determine both specificities. Further dissection of these peptide segments resulted in either enzymes with both TR activities or inactive enzymes. The substrate binding affinity of many chimeric enzymes was much lower than that of wild-type enzymes. These results indicate that the stereospecificity of TR is determined by the orientation of tropinone at the substrate binding site, which is composed mainly of the carboxyl-terminal half region, and also that the amino terminal half region constitutes the NADPH-binding site as postulated for short chain nonmetal dehydrogenases.	KYOTO UNIV,FAC AGR,DEPT AGR CHEM,KYOTO 60601,JAPAN	Kyoto University				Nakajima, Keiji/0000-0002-1580-3354				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARREA G, 1984, BIOCHIM BIOPHYS ACTA, V784, P16, DOI 10.1016/0167-4838(84)90167-5; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HASHIMOTO T, 1992, PLANT PHYSIOL, V100, P836, DOI 10.1104/pp.100.2.836; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; NAKAJIMA K, 1993, P NATL ACAD SCI USA, V90, P9591, DOI 10.1073/pnas.90.20.9591; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; PORTSTEFFEN A, 1992, PHYTOCHEMISTRY, V31, P1135, DOI 10.1016/0031-9422(92)80247-C; Sambrook J, 1989, MOL CLONING LABORATO; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; Yamada Y., 1990, SECONDARY PRODUCTS P, P227	12	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11695	11698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163465				2022-12-27	WOS:A1994NG37700006
J	FINI, ME; STRISSEL, KJ; GIRARD, MT; MAYS, JW; RINEHART, WB				FINI, ME; STRISSEL, KJ; GIRARD, MT; MAYS, JW; RINEHART, WB			INTERLEUKIN-1-ALPHA MEDIATES COLLAGENASE SYNTHESIS STIMULATED BY PHORBOL 12-MYRISTATE 13-ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL CELL COLLAGENASE; MESSENGER-RNA; METALLOPROTEINASE EXPRESSION; RECEPTOR ANTAGONIST; SIGNAL TRANSDUCTION; FIBROBLASTS; GENE; STROMELYSIN; MATRIX; JUN	Stimulation of collagenase expression in cultures of normal diploid fibroblasts by the tumor promotor phorbol 12-myristate 13-acetate (PMA) occurs secondarily to synthesis of unknown intermediary proteins. We have investigated the hypothesis that a form of the cytokine interleukin 1 (IL-1) is one intermediate controlling PMA-stimulated collagenase expression. Treatment with an IL-1 receptor antagonist inhibits the constitutive synthesis of collagenase in early passage fibroblast cultures from rabbit. Radioimmunoassay demonstrates that, of the two known IL-1 forms, IL-1alpha and IL-1beta, only IL-1alpha is synthesized and released into the medium of corneal fibroblast cultures. PMA treatment of cells increases the level of IL-1alpha mRNA; this occurs prior to the increase in collagenase mRNA and corresponds with increased synthesis and release of IL-1alpha protein. Neutralizing antiserum to EL-1alpha inhibits constitutive collagenase synthesis. Reagents that inhibit the activity of IL-1alpha (IL-1 receptor antagonist or neutralizing antibody) also inhibit the PMA-mediated stimulation of collagenase synthesis. These results indicate that constitutive and PMA-stimulated expression of collagenase is regulated through an IL-1alpha intermediate. In vivo, regulation of the lytic phase of tissue remodeling through the IL-1alpha intermediate may ensure the recruitment of cells adjacent to the one that received the initial stimulus.	HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02129	Harvard University; Harvard Medical School	FINI, ME (corresponding author), MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,13TH ST,BOSTON,MA 02129, USA.				NEI NIH HHS [R01-EY08408, R01-EY09828] Funding Source: Medline; NIAMS NIH HHS [T32-AR07098] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009828, R01EY008408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ALLEN RW, 1987, J BIOL CHEM, V262, P649; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; ANSEL JC, 1988, J IMMUNOL, V140, P2274; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BIRKEDALHANSEN H, 1992, MATRIX METALLOPROTEI; BISWAS C, 1979, CELL, V18, P1035, DOI 10.1016/0092-8674(79)90216-2; BORASCHI D, 1990, EUR J IMMUNOL, V20, P317, DOI 10.1002/eji.1830200213; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; BRINCKERHOFF CE, 1987, DEV DISEASES CARTILA, P299; CONCA W, 1991, J BIOL CHEM, V266, P16265; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOANE KJ, 1991, EXP CELL RES, V195, P432, DOI 10.1016/0014-4827(91)90394-A; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; ELIAS JA, 1989, P NATL ACAD SCI USA, V86, P6171, DOI 10.1073/pnas.86.16.6171; ENK AH, 1993, J IMMUNOL, V150, P3698; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINI ME, 1990, J CELL SCI, V97, P373; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FINI ME, 1987, ARTHRITIS RHEUM, V30, P1254, DOI 10.1002/art.1780301108; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FURUTANI Y, 1985, NUCLEIC ACIDS RES, V13, P5869, DOI 10.1093/nar/13.16.5869; GIRARD MT, 1993, J CELL SCI, V104, P1001; GIRARD MT, 1991, INVEST OPHTH VIS SCI, V32, P2441; GROSS J, 1982, CELL BIOL EXTRACELLU, P217; GROSS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1981, DOI 10.1073/pnas.81.7.1981; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HULEIHEL M, 1990, EUR J IMMUNOL, V20, P731, DOI 10.1002/eji.1830200404; JOHNSONMULLER B, 1978, P NATL ACAD SCI USA, V75, P4417, DOI 10.1073/pnas.75.9.4417; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; KUTER I, 1989, J CELL SCI, V92, P423; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1639; NAKAGAWA M, 1992, DEV DYNAM, V195, P87, DOI 10.1002/aja.1001950203; NATHAN C, 1991, J CELL BIOL, V113, P25; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SAKLATVALA J, 1991, AGENT ACTION SUPPL, V35, P35; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; UNEMORI EN, 1988, J BIOL CHEM, V263, P16252; WANG Z, 1993, J BIOL CHEM, V268, P16270; WERB Z, 1978, P NATL ACAD SCI USA, V75, P1839, DOI 10.1073/pnas.75.4.1839; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WERB Z, 1986, J CELL BIOL, V102, P679; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	53	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11291	11298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157661				2022-12-27	WOS:A1994NF96600050
J	BRASIER, AR; KUMAR, A				BRASIER, AR; KUMAR, A			IDENTIFICATION OF A NOVEL DETERMINANT FOR BASIC DOMAIN-LEUCINE ZIPPER DNA-BINDING ACTIVITY IN THE ACUTE-PHASE INDUCIBLE NUCLEAR FACTOR-INTERLEUKIN-6 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTION; ANGIOTENSINOGEN GENE; C/EBP FAMILY; ACTIVATOR PROTEIN; RESPONSE ELEMENT; GCN4; MEMBER; EXPRESSION; EXCHANGE; NF-IL6	Nuclear factor-interleukin-6 (NF-IL6), a member of the CCAAT box/enhancer-binding protein (C/EBP) family, contains a basic domain leucine zipper (bZIP) DNA binding motif. Controlled protease digestion was used to probe free and DNA-complexed NF-IL6 protein. Digestion with trypsin in the absence of DNA produced the leucine zipper domain (containing residues 303-345). In contrast, digestion of NF-IL6.DNA complexes produced a stable domain, spanning residues 266-345, termed the tryptic core domain (TCD). The NH2-terminal boundary of the TCD is longer than tryptic peptides reported from C/EBP alpha.DNA complexes. Digestion of NF-IL6 with endoprotease Asp-N produced a domain smaller than the TCD (NF-IL6 bZIP domains (NFBD) (272-345)), a domain identified either in the absence or the presence of DNA. Both recombinant peptides bind acute-phase response element DNA in a sequence-specific fashion. The equilibrium disassociation constant (K-d) for the TCD was 36 +/- nM, whereas the K-d for NFBD (272-345) was 283 +/- 160 nM. Moreover, in comparison with the TCD, NFBD (272-345) formed unstable DNA complexes with a 15-fold faster off-rate. We conclude that the amino acids represented between 266 and 272 termed the complex stabilizing subdomain, influences DNA complex formation independent of DNA binding specificity, and may be one mechanism for heterogeneity of DNA interaction by C/EBP family members.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	BRASIER, AR (corresponding author), UNIV TEXAS,MED BRANCH,DEPT MED,DIV ENDOCRINOL,GALVESTON,TX 77555, USA.				NHLBI NIH HHS [R29 HL45500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIULIAN GG, 1985, FED PROC, V44, P686; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUMAR A, 1993, BIOCHEMISTRY-US, V32, P7466, DOI 10.1021/bi00080a018; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIUCHI H, 1969, J BIOL CHEM, V244, P4600; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	38	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10341	10351						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144615				2022-12-27	WOS:A1994NF01700027
J	LESSARD, IAD; PERHAM, RN				LESSARD, IAD; PERHAM, RN			EXPRESSION IN ESCHERICHIA-COLI OF GENES ENCODING THE E1-ALPHA AND E1-BETA SUBUNITS OF THE PYRUVATE-DEHYDROGENASE COMPLEX OF BACILLUS-STEAROTHERMOPHILUS AND ASSEMBLY OF A FUNCTIONAL E1 COMPONENT (ALPHA(2)BETA(2)) IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTI-ENZYME COMPLEX; MULTIENZYME COMPLEX; SEQUENCE-ANALYSIS; ACETYLTRANSFERASE COMPONENT; INTERDOMAIN SEGMENT; POLYPEPTIDE-CHAIN; GENOMIC SEQUENCES; SITE; PROTEIN; BINDING	The E1 alpha and E1 beta subunits of the pyruvate decarboxylase (E1) component of the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus were produced from two genes overexpressed separately in Escherichia coli. A functional E1 enzyme was generated from disrupted mixtures of cells containing the separately overexpressed E1 alpha and E1 beta genes. The purified E1 enzyme exhibited an apparent molecular mass of 150,000 Da, consistent with an alpha(2) beta(2) structure. The K-m for pyruvate and k(cat) (30 degrees C) were found to be 0.9 +/- 0.2 mu M and 0.47 +/- 0.03 s(-1), respectively. The purified E1 alpha subunit existed as a monomer (42,000 Da), whereas the E1 beta subunit existed mainly (95%) in a tetrameric form (145,000 Da). Mixing equimolar amounts of the pure recombinant E1 alpha and E1 beta subunits in vitro generated a functional E1 enzyme with a molecular mass and an E1 activity similar to those of the E1(alpha(2) beta(2)) enzyme purified from disrupted mixtures of cells containing individually expressed subunits. Mixing individual subunits in vitro with one of the subunits in excess resulted in complete assembly of the lesser subunit into the intact E1(alpha(2) beta 2()) enzyme. Thus, no chaperonin is needed in vitro to promote the assembly of the separate subunits to form the E1 component of the pyruvate dehydrogenase multienzyme complex of B. stearothermophilus.	UNIV CAMBRIDGE, CAMBRIDGE CTR MOLEC RECOGNIT, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND	University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1980, BIOCHEMISTRY-US, V19, P4208, DOI 10.1021/bi00559a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATE RL, 1980, J BIOL CHEM, V255, P7556; DANSON MJ, 1978, P NATL ACAD SCI USA, V75, P5386, DOI 10.1073/pnas.75.11.5386; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; DIEFENBACH RJ, 1992, FEBS LETT, V296, P95, DOI 10.1016/0014-5793(92)80411-9; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; GUEST JR, 1989, ANN N Y ACAD SCI, V573, P76; HACKERT ML, 1989, BIOCHEMISTRY-US, V28, P6816, DOI 10.1021/bi00443a006; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HAWKINS CF, 1990, EUR J BIOCHEM, V191, P337, DOI 10.1111/j.1432-1033.1990.tb19128.x; HENDERSON CE, 1980, BIOCHEM J, V189, P161, DOI 10.1042/bj1890161; HORN F, 1983, J BIOL CHEM, V258, P6912; JAENICKE R, 1982, BIOCHEMISTRY-US, V21, P3378, DOI 10.1021/bi00257a020; KAHILOVA LS, 1977, BIOKHIMIYA, V42, P113; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KOIKE K, 1992, BIOCHIM BIOPHYS ACTA, V1118, P223, DOI 10.1016/0167-4838(92)90279-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; MATTEVI A, 1993, J MOL BIOL, V230, P1200, DOI 10.1006/jmbi.1993.1236; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; MATUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P1, DOI 10.1016/0167-4781(91)90076-X; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; PACKMAN LC, 1988, BIOCHEM J, V252, P79, DOI 10.1042/bj2520079; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROBIEN MA, 1992, BIOCHEMISTRY-US, V31, P3463, DOI 10.1021/bi00128a021; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; WYNN RM, 1992, J BIOL CHEM, V267, P1881; WYNN RM, 1992, J BIOL CHEM, V267, P12400	48	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10378	10383						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144620				2022-12-27	WOS:A1994NF01700032
J	MACDONALD, JIS; KENT, C				MACDONALD, JIS; KENT, C			IDENTIFICATION OF PHOSPHORYLATION SITES IN RAT-LIVER CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; CHINESE-HAMSTER OVARY; MEMBRANE-ASSOCIATED CTP; RNA POLYMERASE-II; HEP G2 CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASES; TRANSLOCATION	CTP:phosphocholine cytidylyltransferase (CT) is an important regulatory enzyme in phosphatidylcholine biosynthesis. The enzyme exists as a soluble, inactive form that is highly phosphorylated; activation of the enzyme is accompanied by dephosphorylation and translocation to the membrane. we have used a recombinant baculovirus clone to obtain CT labeled in vivo with (PO4)-P-32. The tryptic phosphopeptide pattern of the baculovirus-expressed CT was the same as for CT expressed in mammalian cells, indicating that insect cells modify the same phosphorylation sites as do mammalian cells. (PO4)-P-32-labeled, baculovirus-expressed CT was digested with trypsin and the peptides purified by reversed phase high performance liquid chromatography. Phosphoamino acid analysis of the complete protein as well as individual peptides revealed that only serine residues were phosphorylated. Sequence analysis of purified radioactive peptides revealed that phosphorylation of CT was confined to the carboxyl-terminal region and that all or nearly all Ser residues from Ser(315) to the carboxyl terminus were labeled. Ser(315), Ser(319), Ser(329), Ser(323), Ser(331), Ser(343), and Ser(347) all reside in potential sites for proline-directed kinases. Two other phosphorylated serine residues, Ser(315) and Ser(333), are found within protein kinase C consensus phosphorylation sites. Ser(321), Ser(322), Ser(333), Ser(345), Ser(346), Ser(350), Ser(352), and Ser(362) were also found to be phosphorylated. Serine(362) resides within a putative casein kinase II phosphorylation site, and there are five potential sites for phosphorylation by glycogen synthase kinase 3. Identification of these sites will allow investigations that focus on the establishment of the physiological function of phosphorylation at each site.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan								ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DVIR A, 1993, J BIOL CHEM, V268, P10440; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FELDMAN DA, 1993, J BIOL CHEM, V268, P3127; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOLMES CFB, 1987, FEBS LETT, V215, P21, DOI 10.1016/0014-5793(87)80106-0; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MAK AS, 1991, J BIOL CHEM, V266, P19971; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NAKAMURA S, 1993, J BIOL CHEM, V268, P11670; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SWEITZER TD, 1994, IN PRESS ARCH BIOCH; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; YAO ZM, 1990, J BIOL CHEM, V265, P4326	52	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10529	10537						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144639				2022-12-27	WOS:A1994NF01700053
J	GOVINDJEE, R; BALASHOV, S; EBREY, T; OESTERHELT, D; STEINBERG, G; SHEVES, M				GOVINDJEE, R; BALASHOV, S; EBREY, T; OESTERHELT, D; STEINBERG, G; SHEVES, M			LOWERING THE INTRINSIC PK(A) OF THE CHROMOPHORES SCHIFF-BASE CAN RESTORE ITS LIGHT-INDUCED DEPROTONATION IN THE INACTIVE TYR-57-]ASN MUTANT OF BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINAL PROTEINS; TRANSLOCATION; MECHANISM; ANALOGS; MODEL	Following light absorption, at neutral pH the bacterio rhodopsin mutant Y57N does not show Schiff base deprotonation (no M intermediate) or proton pumping activity. We reasoned that this might be due to improper Delta pK(a) between the proton-donating Schiff base and the proton-accepting Asp-85 after light absorption. To test this, we reduced the intrinsic pK(a) of the protonated Schiff base in the pigment (and thus in the photointermediates) by replacing the retinal chromophore with an analogue, 14-F retinal. This substitution restores light-induced M formation, strongly suggesting that light-induced Schiff base deprotonation is accomplished by lowering its pK(a) during the photochemical cycle. Thus, while it is generally accepted that the Schiff base deprotonation during the photocycle takes place because of the light-induced reduction in its pK(a), we provide here the first experimental evidence of this phenomenon.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL	University of Illinois System; University of Illinois Urbana-Champaign; Max Planck Society; Weizmann Institute of Science	GOVINDJEE, R (corresponding author), UNIV ILLINOIS,CTR BIOPHYS & COMP BIOL,URBANA,IL 61801, USA.							ASATO AE, 1978, J AM CHEM SOC, V100, P5957, DOI 10.1021/ja00486a066; DRUCKMANN S, 1982, BIOCHEMISTRY-US, V21, P4953, DOI 10.1021/bi00263a019; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; ELSAYED MA, 1992, ACCOUNTS CHEM RES, V25, P279, DOI 10.1021/ar00019a002; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; GOVINDJEE R, 1992, STRUCTURE FUNCTION R, V221, P115; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MOGI T, 1987, P NATL ACAD SCI USA, V84, P5595, DOI 10.1073/pnas.84.16.5595; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; SHEVES M, 1986, P NATL ACAD SCI USA, V83, P3262, DOI 10.1073/pnas.83.10.3262; SOPPA J, 1989, J BIOL CHEM, V264, P13049	14	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14353	14354						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182036				2022-12-27	WOS:A1994NM06500007
J	KRUSZKA, KK; GROSSI, RW				KRUSZKA, KK; GROSSI, RW			THE ATP-INDEPENDENT AND COA-INDEPENDENT SYNTHESIS OF ARACHIDONOYLETHANOLAMIDE - A NOVEL MECHANISM UNDERLYING THE SYNTHESIS OF THE ENDOGENOUS LIGAND OF THE CANNABINOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BRAIN CONSTITUENT; RAT-LIVER; ANANDAMIDE; ACYLATION; AGONIST; ACIDS	Recently, arachidonoylethanolamide was identified as the endogenous ligand of the Delta(9) tetrahydrocannabinol receptor. Herein, we demonstrate that the synthesis of arachidonoylethanolamide is catalyzed by a novel CoA- and ATP-independent pathway, which is highly selective for arachidonic acid as the aliphatic constituent, is specific for ethanolamine as the polar moiety and occurs through a mechanism that utilizes a critical sulfhydryl residue. The production of arachidonoylethanolamide was calcium-independent and heat-labile and was selectively catalyzed by brain microsomal and cytosolic proteins among the tissues examined. Four independent lines of evidence demonstrate that the synthesis of arachidonoylethanolamide occurs through an ATP- and CoA-independent process. 1) The depletion of endogenous rabbit brain cytosolic or microsomal CoA and ATP by dialysis, or depletion of ATP by apyrase treatment, did not diminish the production of arachidonoylethanolamide; 2) the addition of exogenous ATP or CoA to cofactor depleted cytosol or microsomes did not stimulate arachidonoylethanolamide production; 3) the synthesis of arachidonoylethanolamide occurred in the absence of detectable arachidonoyl-CoA and did not correlate with either the amount of arachidonoyl-CoA in the incubation medium or the amount of arachidonoyl-CoA incorporated into polar and nonpolar lipids; 4) the addition of a 20-fold molar excess of unlabeled arachidonoyl-CoA to incubations containing [H-3]arachidonic acid and ethanolamine did not attenuate the production of [H-3]arachidonoylethanolamide by rabbit brain cytosolic or microsomal proteins. Collectively, these results demonstrate a novel chemical paradigm for the ATP- and CoA-independent conjugation of the carboxylate moiety of arachidonic acid to yield arachidonoylethanolamide, the first member of a new class of biologically active eicosanoid second messengers.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV BIOORGAN CHEM & MOLEC PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					PHS HHS [35864] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DAAE LNW, 1970, BIOCHIM BIOPHYS ACTA, V210, P92; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HERSH LB, 1967, J BIOL CHEM, V242, P3468; JACKIE K, 1993, MOL PHARMACOL, V44, P496; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1960, J BIOL CHEM, V235, P3608; KORNBERG A, 1953, J BIOL CHEM, V204, P329; LOEB LA, 1986, J BIOL CHEM, V261, P467; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; MONROY G, 1972, J BIOL CHEM, V247, P6884; MOORE SA, 1982, J BIOL CHEM, V257, P882; MOURAD N, 1966, J BIOL CHEM, V241, P271; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; Numa S, 1974, Curr Top Cell Regul, V8, P197; ONTKO JA, 1972, J BIOL CHEM, V247, P1788; SILVERSTEIN R, 1967, J BIOL CHEM, V242, P1338; STERN W, 1978, J BIOL CHEM, V253, P8047; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x	20	122	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14345	14348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182035				2022-12-27	WOS:A1994NM06500005
J	LABRIE, ST; CRAWFORD, NM				LABRIE, ST; CRAWFORD, NM			GLYCINE TO ASPARTIC-ACID CHANGE IN THE MOCO DOMAIN OF NITRATE REDUCTASE REDUCES BOTH ACTIVITY AND PHOSPHORYLATION LEVELS IN ARABIDOPSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DARK MODULATION; REVERSIBLE PHOSPHORYLATION; PROTEIN-PHOSPHORYLATION; FUNCTIONAL DOMAINS; RAPID MODULATION; PLANTS; THALIANA; PHOTOSYNTHESIS; EXPRESSION; LEAVES	Nitrate reductase (NR), the first enzyme in the nitrate assimilation pathway, is regulated post-transcriptionally in response to light and CO2. In spinach, it has been shown that phosphorylation is one mechanism that mediates this regulation. In this paper, the phosphorylation of NR in Arabidopsis is described in both wild-type and NR(-) mutant plants. A 110-kDa protein radiolabeled in vivo with (PO4)-P-32, was immunoprecipitated with anti-NR antibody from extracts of wild-type plants but not of mutant plants in which the NR gene NIA2 had been deleted. Phosphoamino acid and phosphopeptide analysis showed that, as for spinach, NR from Arabidopsis is phosphorylated on serine and produces multiple phosphopeptides upon digestion with CNBr or trypsin. Analysis of three mutants with lesions in the NIA2 NR structural gene showed that one mutant, chl3-1, has a reduced phosphorylation phenotype that is not complemented by a NR deletion mutant. Comparison of the sequences of the wild-type and chl3-1 NIA2 genes revealed a single base mutation changing a glycine codon to an aspartic acid codon. This glycine, at position 308 in the MoCo domain of NR, is completely conserved in all known eukaryotic NR sequences. Thus, glycine 308 is required for normal activity and phosphorylation of NR, and substitution of this residue with aspartic acid disrupts both processes, most likely by altering the conformation of the NR MoCo domain.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040672, R01GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JF, 1992, TRENDS BIOCHEM SCI, V17, P12, DOI 10.1016/0968-0004(92)90418-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAAKSMA FJ, 1982, THEOR APPL GENET, V64, P83, DOI 10.1007/BF00303657; BRAAKSMA FJ, 1982, THESIS U GRONINGEN; BUDDE RJA, 1990, PLANT PHYSIOL, V94, P1501, DOI 10.1104/pp.94.4.1501; BUDDE RJA, 1988, PHYSIOL PLANTARUM, V72, P435, DOI 10.1111/j.1399-3054.1988.tb05857.x; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CHENG CL, 1988, EMBO J, V7, P3309, DOI 10.1002/j.1460-2075.1988.tb03201.x; CHENG CL, 1992, P NATL ACAD SCI USA, V89, P1861, DOI 10.1073/pnas.89.5.1861; CHENG CL, 1991, PLANT PHYSIOL, V96, P275, DOI 10.1104/pp.96.1.275; Crawford N. M., 1992, Genetic engineering: principles and methods. Volume 14., P89; CRAWFORD NM, 1990, PLANT CELL, V2, P829; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CRAWFORD NM, 1992, AUST J PLANT PHYSIOL, V19, P377, DOI 10.1071/PP9920377; DECIRES A, 1993, PLANTA, V190, P277, DOI 10.1007/BF00196622; HUBER JL, 1992, ARCH BIOCHEM BIOPHYS, V296, P58, DOI 10.1016/0003-9861(92)90544-7; HUBER JL, 1991, PLANT PHYSIOL, V95, P291, DOI 10.1104/pp.95.1.291; HUBER SC, 1990, CURR T PL B, V9, P329; HUGHES RK, 1992, BIOCHEM J, V285, P507, DOI 10.1042/bj2850507; JIAO JA, 1991, PLANT PHYSIOL, V95, P981, DOI 10.1104/pp.95.4.981; JOLLY SO, 1978, PLANT PHYSIOL, V62, P197, DOI 10.1104/pp.62.2.197; KAISER WM, 1989, PLANT PHYSIOL, V91, P970, DOI 10.1104/pp.91.3.970; KAISER WM, 1992, PLANTA, V186, P236, DOI 10.1007/BF00196253; KAISER WM, 1991, PLANT PHYSIOL, V96, P368, DOI 10.1104/pp.96.2.368; KAISER WM, 1993, PHYSIOL PLANTARUM, V89, P557, DOI 10.1111/j.1399-3054.1993.tb05213.x; KAISER WM, 1991, PLANT PHYSIOL, V96, P363, DOI 10.1104/pp.96.2.363; Kleinhofs A., 1990, BIOCH PLANTS, P89, DOI [DOI 10.1016/B978-0-08-092616-2.50009-7, 10.1016/B978-0-08-092616-2.50009-7]; LABRIE ST, 1991, PLANT PHYSIOL, V97, P873, DOI 10.1104/pp.97.3.873; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MACKINTOSH C, 1992, BIOCHIM BIOPHYS ACTA, V1137, P121, DOI 10.1016/0167-4889(92)90109-O; Redei G. P., 1974, STADLER S, V6, P135; REDINBAUGH MG, 1991, PHYSIOL PLANTARUM, V82, P640, DOI 10.1111/j.1399-3054.1991.tb02958.x; REMMLER JL, 1986, PLANT PHYSIOL, V80, P442, DOI 10.1104/pp.80.2.442; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RIENS B, 1992, PLANT PHYSIOL, V98, P573, DOI 10.1104/pp.98.2.573; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1984, ARCH BIOCHEM BIOPHYS, V233, P469, DOI 10.1016/0003-9861(84)90469-7; VINCENTZ M, 1991, EMBO J, V10, P1027, DOI 10.1002/j.1460-2075.1991.tb08041.x; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; Wray J.L., 1989, MOL GENETIC ASPECTS; YAMAGISHI K, 1988, PLANT CELL PHYSIOL, V29, P371	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14497	14501						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182055				2022-12-27	WOS:A1994NM06500031
J	VANDEWATER, B; ZOETEWEIJ, JP; DEBONT, HJGM; MULDER, GJ; NAGELKERKE, JF				VANDEWATER, B; ZOETEWEIJ, JP; DEBONT, HJGM; MULDER, GJ; NAGELKERKE, JF			ROLE OF MITOCHONDRIAL CA2+ IN THE OXIDATIVE STRESS-INDUCED DISSIPATION OF THE MITOCHONDRIAL-MEMBRANE POTENTIAL - STUDIES IN ISOLATED PROXIMAL TUBULAR CELLS USING THE NEPHROTOXIN 1,2-DICHLOROVINYL-L-CYSTEINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE BETA-LYASE; RAT-KIDNEY; LIPID-PEROXIDATION; MECHANISM; CALCIUM; TOXICITY; CA-2+; DEATH; HYDROPEROXIDES; PERMEABILITY	The relationship between mitochondrial Ca2+, oxidative stress, and a dissipation of the mitochondrial membrane potential (Delta psi) was investigated in proximal tubular kidney cells. Freshly isolated proximal tubular cells from rat kidney were exposed to the nephrotoxin 1,2-dichlorovinyl-L-cysteine (DCVC). DCVC stimulated the formation of hydroperoxides as determined by flow cytometry using the hydroperoxide-sensitive compound dichlorofluorescin. This was prevented by the antioxidant diphenylphenylenediamine (DPPD) and the iron chelator desferrioxamine. Studies in individual cells with video-intensified fluorescence microscopy showed that a DCVC-induced increase in the intracellular fi ee calcium concentration ([Ca2+](i)) was accompanied by an increase in the mitochondrial free calcium concentration ([Ca2+](m)). The latter increase was selectively prevented by an inhibitor of the mitochondrial calcium uniporter, ruthenium red (RR). Chelation of cellular Ca2+ with EGTA acetoxymethyl ester (EGTA/AM) completely prevented the formation of hydroperoxides, whereas inhibition of the uptake of Ca2+ by the mitochondria with RR reduced it. This indicates that the increase in [Ca2+](m) is important for the induction of oxidative stress by DCVC. DPPD and desferrioxamine did not protect against a DCVC-induced increase in [Ca2+](i) and [Ca2+](m), indicating that oxidative stress is the consequence rather than the cause of the cellular calcium perturbations. DCVC decreased Delta psi and caused cell death; both effects were clearly delayed by EGTA/AM and RR, although they could not prevent a decrease in Delta psi. The latter decrease was completely prevented by inhibition of the beta-lyase-mediated metabolism of DCVC with aminooxyacetic acid. Like EGTA/AM, inhibition of oxidative stress with DPPD and desferrioxamine delayed the decrease in Delta psi This strongly suggests that the decrease in Delta psi caused by metabolites of DCVC directly is potentiated by Ca2+-dependent DCVC-induced hydroperoxide formation. The importance of both hydroperoxide formation and mitochondrial damage in DCVC-induced cell billing is discussed.	LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV TOXICOL,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								BOOGAARD PJ, 1989, TOXICOL APPL PHARM, V101, P135, DOI 10.1016/0041-008X(89)90219-6; BUROW S, 1987, EUR J CELL BIOL, V43, P128; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHACON E, 1991, TOXICOL APPL PHARM, V107, P117, DOI 10.1016/0041-008X(91)90336-D; CHACONE, 1992, BIOCHEM J, V281, P871; CHEN Q, 1990, J BIOL CHEM, V265, P21603; COMMANDEUR JNM, 1990, CHEM RES TOXICOL, V3, P212, DOI 10.1021/tx00015a005; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; ELFARRA AA, 1986, MOL PHARMACOL, V31, P208; GROVES CE, 1991, TOXICOL APPL PHARM, V107, P54, DOI 10.1016/0041-008X(91)90330-H; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HARRIS EJ, 1982, FEBS LETT, V146, P267, DOI 10.1016/0014-5793(82)80932-0; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HEMMELFARB J, 1992, CYTOMETRY, V13, P83; LASH LH, 1987, MOL PHARMACOL, V32, P549; LOCK EA, 1988, CRIT REV TOXICOL, V19, P23, DOI 10.3109/10408448809040816; LOCK EA, 1989, TOXICOL LETT, V46, P93, DOI 10.1016/0378-4274(89)90120-3; MALIS CD, 1986, J BIOL CHEM, V261, P14201; NAGELKERKE JF, 1991, LIFE SCI, V49, P1769; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; NOVGORODOV SA, 1991, BIOCHIM BIOPHYS ACTA, V1058, P242, DOI 10.1016/S0005-2728(05)80243-9; NOVGORODOV SA, 1989, FEBS LETT, V247, P255, DOI 10.1016/0014-5793(89)81347-X; NOVGORODOV SA, 1989, FEBS LETT, V248, P179, DOI 10.1016/0014-5793(89)80456-9; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; SCOTT JA, 1988, FREE RADICAL BIO MED, V4, P79, DOI 10.1016/0891-5849(88)90067-6; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STEVENS JL, 1988, J BIOL CHEM, V263, P3395; VANDEWATER B, 1993, BIOCHEM PHARMACOL, V45, P2259, DOI 10.1016/0006-2952(93)90197-5; VANDEWATER B, 1992, TOXICOL LETT S, P209; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207; ZOETEWEIJ JP, J BIOL CHEM, V2684, P93	35	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14546	14552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182062				2022-12-27	WOS:A1994NM06500039
J	OBUNIKE, JC; EDWARDS, IJ; RUMSEY, SC; CURTISS, LK; WAGNER, WD; DECKELBAUM, RJ; GOLDBERG, IJ				OBUNIKE, JC; EDWARDS, IJ; RUMSEY, SC; CURTISS, LK; WAGNER, WD; DECKELBAUM, RJ; GOLDBERG, IJ			CELLULAR DIFFERENCES IN LIPOPROTEIN LIPASE-MEDIATED UPTAKE OF LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE CELLS; BINDING; METABOLISM; ATHEROSCLEROSIS; CHYLOMICRONS; LOCALIZATION; DEGRADATION; FIBROBLASTS	Lipoprotein lipase (LPL) increases the cellular uptake and degradation of LDL by fibroblasts and macrophages via a heparin-sensitive process. The roles of the LDL receptor, LDL receptor related protein (LRP), and proteoglycans in this process were studied. In up regulated human fibroblasts, LPL increased degradation of I-125-low density lipoprotein (LDL) (5 mu g/ml) only 30% during a 6-h incubation at 37 degrees C. Monoclonal antibody 47 (which interacts with the receptor binding region of apoB) decreased LDL degradation 93% in the absence of LPL, but did not reduce the LPL mediated increase in degradation. In contrast, addition of the 39-kDa receptor-associated protein (RAP) caused a 43% decrease in the LPL-dependent LDL degradation in non-up-regulated fibroblasts. Monoclonal antibody 47 did not decrease LDL degradation by THP-1 macrophages and RAP caused a <13% decrease in LPL-mediated LDL degradation. LPL also increased the association of acetyl LDL with the surface of the macrophages but did not increase acetyl LDL degradation. The kinetics of LPL- mediated LDL metabolism in macrophages was then compared with that in fibroblasts. The half lives of cell surface LDL and LPL during a subsequent 37 degrees C incubation were approximately 1 h in THP-1 cells versus 6 h in fibroblasts. In addition, 50% of the I-125-LDL and 30% of the I-125-LPL were degraded within 3 h. After metabolic labeling of THP-1 proteoglycans with (SO4)-S-35, >30% of pericellular heparan sulfate was lost between 2-4 h of the chase period. Therefore, some of the LPL-mediated LDL degradation in the THP-1 cells could be accounted for by internalization of cell surface proteoglycans. We conclude that LRP, but not the LDL receptor, is involved in LPL mediated degradation of LDL in fibroblasts. This process is much more rapid in THP-1 cells and in addition to LRP may involve other receptors and internalization of proteoglycans.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Columbia University; Columbia University; Wake Forest University; Wake Forest Baptist Medical Center; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197, R01HL040404, R01HL045095, R37HL045095] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40404, HL-45095, HL-14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHATTERJEE S, 1976, P NATL ACAD SCI USA, V73, P4339, DOI 10.1073/pnas.73.12.4339; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; EDWARDS IJ, 1992, AM J PATHOL, V140, P193; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JACKLE S, 1993, J LIPID RES, V34, P309; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; VILARO S, 1988, BIOCHEM J, V249, P549, DOI 10.1042/bj2490549; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	41	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13129	13135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175739				2022-12-27	WOS:A1994NK18400015
J	PAWLOWSKI, JE; PENNING, TM				PAWLOWSKI, JE; PENNING, TM			OVEREXPRESSION AND MUTAGENESIS OF THE CDNA FOR RAT-LIVER 3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE - ROLE OF CYSTEINES AND TYROSINES IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ESTRADIOL 17-BETA-DEHYDROGENASE; TRANS-DIHYDRODIOL OXIDATION; ANTI-INFLAMMATORY DRUGS; ALDOSE REDUCTASE; ALDEHYDE REDUCTASE; MULTIPLE FORMS; ACTIVE-SITE; IDENTIFICATION; INHIBITION; PURIFICATION	The overexpression and purification of recombinant rat liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase (3 alpha-HSD; EC 1.1.1.50) in Escherichia coli are described. The properties of the homogeneous recombinant 3 alpha-HSD (r3 alpha-HSD) confirm that a single polypeptide can function as a HSD, as a dihydrodiol dehydrogenase, and as an aromatic aldehyde, ketone, and quinone reductase. Cys-170, Cys-242, and Cys-217, implicated by bromoacetoxysteroid affinity-labeling agents as points of contact for the C-3, C-11, and C-17 positions of steroid ligands, were mutated to alanines. Unexpectedly, the homogeneous C170A and C242A mutants were kinetically similar to wild-type r3 alpha-HSD. By contrast, the C217A mutant gave K-m values that were 4-fold higher for androstanedione and 2-fold higher for NADH. Inspection of the recently solved crystal structure of rat liver 3 alpha-HSD (Hoog, S. S., Pawlowski, J. E., Alzari, P. M., Penning, T. M., and Lewis, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2517-2521) places Cys-170 and Cys-242 on the periphery of an alpha/beta-barrel so that they cannot be involved in catalysis or steroid recognition. This demonstrates that bromoacetoxysteroid affinity-labeling agents may provide misleading information regarding the topography of steroid hormone binding sites. When NADPH was modeled into the crystal structure of 3 alpha-HSD, Tyr-55 was implicated as the general acid, since it is in close proximity to the C-4 position of the nicotinamide ring and could polarize the substrate carbonyl. In support of this model, the purified Y55F mutant was found to be catalytically inactive, but still formed an E.NADPH complex (measured by fluorescence titration) and an E.NADH testosterone complex (measured by equilibrium dialysis). The ability of the Y55F mutant to form binary and ternary complexes, but not aid in hydride transfer, is consistent with Tyr-55 acting as the general acid. 3 alpha-HSD is a member of the aldo-keto reductase superfamily, and Tyr-55 is invariant in members of this family where it may perform a similar function. Tyr-205 is present in a pentapeptide sequence that is conserved in HSDs that belong to the short-chain alcohol dehydrogenase family and has been implicated as the general acid within these enzymes. The Y205F mutant was found to be kinetically similar to wild-type r3 alpha-HSD. Our data support the concept that the tyrosines used as general acids in catalysis are different for the HSDs that belong to the aldo-keto reductase and short chain alcohol dehydrogenase families.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania				Penning, Trevor/0000-0002-3937-1066	NATIONAL CANCER INSTITUTE [R01CA039504, R01CA055711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER; NCI NIH HHS [CA39504, CA55711] Funding Source: Medline; NIDDK NIH HHS [DK47015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBARRACIN CT, 1993, 75TH ANN M END SOC L; ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; BHATNAGAR YM, 1978, J BIOL CHEM, V253, P811; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; CHENG KC, 1991, MOL ENDOCRINOL, V5, P823, DOI 10.1210/mend-5-6-823; CHIN CC, 1982, BIOCHEMISTRY-US, V21, P3322, DOI 10.1021/bi00257a012; CHUNG S, 1989, J BIOL CHEM, V264, P14775; Cleland W W, 1979, Methods Enzymol, V63, P103; Cory M, 1977, Methods Enzymol, V46, P115; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; HARA A, 1985, BIOCHEM J, V225, P177, DOI 10.1042/bj2250177; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFF HG, 1973, H-S Z PHYSIOL CHEM, V354, P507, DOI 10.1515/bchm2.1973.354.1.507; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; IKEDA M, 1981, H-S Z PHYSIOL CHEM, V362, P511, DOI 10.1515/bchm2.1981.362.1.511; IVINS JK, 1987, CANCER RES, V47, P680; KLEIN J, 1992, EUR J BIOCHEM, V205, P1155, DOI 10.1111/j.1432-1033.1992.tb16885.x; LACY WR, 1993, MOL ENDOCRINOL, V7, P58, DOI 10.1210/me.7.1.58; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEVY MA, 1987, BIOCHEMISTRY-US, V26, P2270, DOI 10.1021/bi00382a030; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LOWRY OH, 1961, J BIOL CHEM, V236, P2756; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1987, BIOCHIM BIOPHYS ACTA, V912, P270, DOI 10.1016/0167-4838(87)90097-5; MURDOCK GL, 1983, J BIOL CHEM, V258, P1460; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; MURDOCK GL, 1986, BIOCHIM BIOPHYS ACTA, V1076, P197; NAKAGAWA M, 1989, CHEM PHARM BULL, V37, P2852; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PENNING TM, 1987, BIOCHEM BIOPH RES CO, V148, P646, DOI 10.1016/0006-291X(87)90925-9; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1991, J BIOL CHEM, V266, P8826; PETRASH JM, 1989, CURR EYE RES, V8, P1021, DOI 10.3109/02713688908997394; RICIGLIANO JW, 1990, BIOCHEM J, V269, P749, DOI 10.1042/bj2690749; SAWADA H, 1988, BIOCHEM PHARMACOL, V37, P453, DOI 10.1016/0006-2952(88)90214-6; SMITHGALL TE, 1986, CARCINOGENESIS, V7, P583, DOI 10.1093/carcin/7.4.583; SMITHGALL TE, 1988, BIOCHEM J, V254, P715, DOI 10.1042/bj2540715; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SMITHGALL TE, 1988, J BIOL CHEM, V263, P1814; STOLZ A, 1991, J BIOL CHEM, V266, P15253; STOLZ A, 1987, J CLIN INVEST, V79, P427, DOI 10.1172/JCI112829; STOLZ A, 1993, J BIOL CHEM, V268, P10448; TOMKINS GM, 1956, J BIOL CHEM, V218, P437; WARREN JC, 1993, BIOCHEMISTRY-US, V32, P1401, DOI 10.1021/bi00057a003; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	52	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13502	13510						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175784				2022-12-27	WOS:A1994NK18400067
J	CHEN, J; ALBERTI, S; MATTHEWS, KS				CHEN, J; ALBERTI, S; MATTHEWS, KS			WILD-TYPE OPERATOR BINDING AND ALTERED COOPERATIVITY FOR INDUCER BINDING OF LAC REPRESSOR DIMER MUTANT R3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE REPRESSOR; LEUCINE ZIPPER; DNA COMPLEX; COILED COIL; PROTEIN; RECOGNITION; DISSOCIATION; MUTATIONS	Substitution of the C-terminal leucine heptad repeat region of the normally tetrameric lactose repressor by the leucine heptad repeat dimerization domain of GCN4 protein resulted in cell extracts containing protein, designated R3, which behaved as a dimer based on gel retardation analysis of DNA binding (Alberti, S., Oehler, S., von Wilcken-Bergmann, B., and Muller-Hill, B. (1993) EMBO J. 12, 3227-3236). We have purified this R3 protein and characterized its properties in comparison with the wild-type repressor. R3 protein elutes from a molecular sieve with a Stokes radius characteristic of a dimer and a deduced molecular mass of 66 kDa. Unlike other dimeric repressors, produced by deletion or mutation in the leucine heptad repeat region, which display reduced apparent operator affinity R3 binds to operator DNA sequences with wild-type equilibrium and kinetic properties. Although inducer affinity at neutral pH is similar for R3 and wild-type protein, at elevated pH the R3 protein undergoes a slightly smaller decrease in affinity and exhibits minimal cooperativity in sugar binding compared with the wild-type protein. Interestingly, in the presence of operator DNA, a state in which inducer binding to wild-type repressor is also of reduced affinity and slightly cooperative, R3 binding affinity is decreased to a greater extent, and the protein displays higher cooperativity than wild-type repressor. Consistent with inducer binding data in the presence of operator, the release of operator from R3 protein requires a higher sugar concentration than wild-type protein. These results are interpreted in the context of alterations involving the subunit interface which affect the allosteric behavior of the repressor protein.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	Rice University; University of Cologne				Chen, Jie/0000-0002-7887-3747	NIGMS NIH HHS [GM22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHARLIER M, 1981, J MOL BIOL, V153, P177, DOI 10.1016/0022-2836(81)90533-7; CHARLIER M, 1980, NATURE, V286, P423, DOI 10.1038/286423a0; CHEN J, 1992, GENE, V111, P145, DOI 10.1016/0378-1119(92)90618-Y; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; CULARD F, 1982, FEBS LETT, V146, P153, DOI 10.1016/0014-5793(82)80724-2; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KISTERSWOIKE B, 1991, EUR J BIOCHEM, V198, P411, DOI 10.1111/j.1432-1033.1991.tb16030.x; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MCKAY DB, 1982, J MOL BIOL, V156, P175, DOI 10.1016/0022-2836(82)90465-X; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PILZ I, 1980, BIOCHEMISTRY-US, V19, P4087, DOI 10.1021/bi00558a028; PLATT T, 1973, J BIOL CHEM, V248, P110; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROYER CA, 1986, BIOCHEMISTRY-US, V25, P8308, DOI 10.1021/bi00373a027; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; STEITZ TA, 1974, P NATL ACAD SCI USA, V71, P593, DOI 10.1073/pnas.71.3.593; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016	47	26	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12482	12487						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175655				2022-12-27	WOS:A1994NH71600020
J	OKAZAKI, M; TAKESHITA, S; KAWAI, S; KIKUNO, R; TSUJIMURA, A; KUDO, A; AMANN, E				OKAZAKI, M; TAKESHITA, S; KAWAI, S; KIKUNO, R; TSUJIMURA, A; KUDO, A; AMANN, E			MOLECULAR-CLONING AND CHARACTERIZATION OF OB-CADHERIN, A NEW MEMBER OF CADHERIN FAMILY EXPRESSED IN OSTEOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; SEQUENCE-ANALYSIS; CYTOPLASMIC REGION; T-CADHERIN; BONE; MOUSE; DIFFERENTIATION; UVOMORULIN; EMBRYO; LINES	The preferential screening of cDNA libraries derived from the mouse osteoblastic cell line MC3T3-E1 has yielded a cDNA clone encoding 796 amino acids including the typical 24-residue-long signal sequence. The predicted amino acid sequence revealed that this protein constitutes a new member of the cadherin family. We propose the name OB-cadherin (OB for osteoblast) for this new protein. RNA analyses revealed that the OB-cadherin gene is selectively expressed in osteoblastic cell lines, precursor cell lines of osteoblasts, and primary osteoblastic cells from calvaria, as well as in lung, testis, and brain tissues at low levels. Transfection of OB-cadherin cDNA into L cells resulted in the acquisition of the Ca2+-dependent adhesive property. Two different forms of the human OB-cadherin cDNA were subsequently cloned; one is a counterpart of mouse OB-cadherin gene, and the other encodes a protein with a truncated cytoplasmic domain. The results suggest that the newly found OB-cadherin might have an important role in bone formation.			OKAZAKI, M (corresponding author), HOECHST JAPAN LTD,PHARMA RES LABS,MOLEC BIOL LAB,1-3-2 MINAMIDAI,KAWAGOE,SAITAMA 35011,JAPAN.		Kudo, Akira/C-7340-2015	Kudo, Akira/0000-0001-6289-3391				COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RANSCHT B, 1991, DEVELOPMENT, V111, P15; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SIMPSON E, 1984, TRENDS BIOCHEM SCI, V9, P527, DOI 10.1016/0968-0004(84)90282-2; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	37	220	231	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12092	12098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163513				2022-12-27	WOS:A1994NG37700064
J	SKEIKY, YAW; DREVET, JR; SWEVERS, L; IATROU, K				SKEIKY, YAW; DREVET, JR; SWEVERS, L; IATROU, K			PROTEIN-PHOSPHORYLATION AND CONTROL OF CHORION GENE ACTIVATION THROUGH TEMPORAL MOBILIZATION OF A PROMOTER DNA-BINDING FACTOR FROM THE CYTOPLASM INTO THE NUCLEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BOMBYX-MORI; TRANSCRIPTIONAL REGULATION; DEVELOPMENTAL REGULATION; IFN-GAMMA; SEQUENCE; DROSOPHILA; EXPRESSION; CHROMATIN; CACTUS	The transcriptional activation of high cysteine chorion genes in the follicular cells of the silkworm Bombyx mori occurs at the end of oogenesis and coincides with the appearance of a chorion promoter DNA binding factor, BCFI, in follicular cell nuclei. Follicular cells of vitellogenic and choriogenic follicles that do not express high cysteine chorion genes contain high levels of a latent form of BCFI in their cytoplasm. The abundance of the cytoplasmic factor, termed cBCFI, is dramatically reduced during late choriogenesis, coincident with the appearance of factor BCFI in the nucleus and the transcriptional activation of high cysteine genes. Mobility shift assays performed with partially proteolyzed nuclear and cytoplasmic extracts of follicular cells, DNA binding assays carried out in the presence of anti- BCFI antibodies, and electrophoretic analyses of the proteins present in the nuclear and cytoplasmic fractions of follicular cells and recognized by the same antibodies suggest that factor cBCFI represents a covalently modified version of BCFI. The DNA-binding sites of BCFI and cBCFI include a core sequence, AGATAA, but, while this sequence is sufficient for specific binding of BCFI, it only constitutes part of the DNA-binding site of cBCFI. Dephosphorylation of cBCFI results in a change of its binding specificity to that of BCFI. The cytoplasmic sequestration of cBCFI appears to be mediated by a phosphorylation-dependent, reversible association of this factor with an ancillary cytoplasmic factor.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA	University of Calgary			Drevet, Joël/W-2692-2019	Drevet, Joël/0000-0003-3077-6558				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CANNON PD, 1989, THESIS U CALGARY CAN; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DREVET JR, 1994, IN PRESS J BIOL CHEM, V269; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IATROU K, 1980, CELL, V20, P659, DOI 10.1016/0092-8674(80)90312-8; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kafatos F.C, 1977, Results Probl Cell Differ, V8, P45; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SKEIKY YAW, 1991, J MOL BIOL, V218, P517, DOI 10.1016/0022-2836(91)90698-6; SKEIKY YAW, 1990, J MOL BIOL, V213, P53, DOI 10.1016/S0022-2836(05)80121-4; SKEIKY YAW, 1991, MOL CELL BIOL, V11, P1954, DOI 10.1128/MCB.11.4.1954; SWEVERS L, 1992, DEV BIOL, V150, P12, DOI 10.1016/0012-1606(92)90003-Y; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0	31	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12196	12203						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163525				2022-12-27	WOS:A1994NG37700080
J	WALDRON, RT; SHORT, AD; MEADOWS, JJ; GHOSH, TK; GILL, DL				WALDRON, RT; SHORT, AD; MEADOWS, JJ; GHOSH, TK; GILL, DL			ENDOPLASMIC-RETICULUM CALCIUM-PUMP EXPRESSION AND CONTROL OF CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; THAPSIGARGIN; INHIBITION; PROTEINS; MUSCLE; CA-2+; GTP; CA-2+-ATPASE; INVOLVEMENT; MECHANISM	Intracellular Ca2+ pump expression and Ca2+ pool function are shown to be closely associated with growth and proliferation of DDT(1)MF-2 hamster smooth muscle cells. The Ca2+ pump blocker thapsigargin induces sustained Ca2+ pool emptying and entry of cells into a quiescent G(0)-like state (Short, A. D., Bian, J., Ghosh, T. K., Waldron, R. T., Rybak, S. L., and Gill, D. L. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 4986-4990). Using DDT(1)MF-2 cells growth-arrested by exposure to 3 mu M thapsigargin for 24 h, treatment with 20% serum for 6 h without thapsigargin induced expression of functional Ca2+ pump protein detected as a 110-kDa thapsigargin-sensitive phosphorylated intermediate; 2.5% serum treatment resulted in no functional pump expression. Western analysis revealed only a slight serum-induced increase in total Ca2+ pump protein, New functional Ca2+ pump protein could be detected within 1 h of high serum treatment of thapsigargin-arrested cells, increasing over a 6-h period and correlating with the appearance of new Ca2+ pools. Induction of Ca2+ pools required serum at 10% or higher; no pools appeared with 5% serum or less, Significantly, high serum was required for only a brief but precise period of time. Exposure of thapsigargin-arrested cells to a 45-min pulse of 20% serum followed by continued culture in 2.5% serum was sufficient for full induction of new functional Ca2+ pump protein and Ca2+ pools; in contrast, no primps or pools were detected after a 30-min serum pulse. A 40-min high serum pulse resulted in arrested cells reentering the cell cycle, synthesizing DNA, and resuming normal proliferation; in contrast, 35 min of serum treatment resulted in cells remaining totally quiescent. The results provide important evidence for the necessity of functional endoplasmic reticulum Ca2+ pumps in serum-induced cell growth and reflect a remarkably precise signaling period during which quiescent cells become committed to a progression of events including Ca2+ pump expression, Ca2+ pool function, reentry into the cell cycle, and cell division.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore			Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19304] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER K, 1969, J BIOL CHEM, V244, P4406; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071	42	95	99	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11927	11933						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163492				2022-12-27	WOS:A1994NG37700040
J	FERBER, S; BELTRANDELRIO, H; JOHNSON, JH; NOEL, RJ; CASSIDY, LE; CLARK, S; BECKER, TC; HUGHES, SD; NEWGARD, CB				FERBER, S; BELTRANDELRIO, H; JOHNSON, JH; NOEL, RJ; CASSIDY, LE; CLARK, S; BECKER, TC; HUGHES, SD; NEWGARD, CB			GLUT-2 GENE-TRANSFER INTO INSULINOMA CELLS CONFERS BOTH LOW AND HIGH-AFFINITY GLUCOSE-STIMULATED INSULIN RELEASE - RELATIONSHIP TO GLUCOKINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ISLET CELLS; MESSENGER-RNAS; RAT; EXPRESSION; SECRETION; TRANSPORTER; METABOLISM; LIVER; LINE	The rat insulinoma cell line RIN 1046-38 loses glucose-stimulated insulin secretion as a function of time in culture. We found that the loss of glucose sensing in these cells was correlated with the loss of expression of GLUT-2 and glucokinase. Stable transfection of RIN cells with a plasmid containing the GLUT-2 cDNA conferred glucose-stimulated insulin release in intermediate but not high passage cells, with the near-maximal 3-fold increase occurring at 50 muM glucose. GLUT-2 expressing cells also exhibited a larger response to the combination of 5 mM glucose + 1 muM forskolin than untransfected cells (7.9 versus 1.6-2.7-fold, respectively). GLUT-2 expressing intermediate passage, but not high passage, RIN cells exhibited a 4-fold increase in glucokinase enzymatic activity relative to nonexpressing controls. Glucokinase activity was also increased by transfer of the GLUT-2 gene into intermediate passage RIN cells via recombinant adenovirus. Preincubation of GLUT-2 expressing intermediate passage RIN cells with 2-deoxyglucose to inhibit low K(m) hexokinases resulted in a glucose-stimulated insulin secretion response that was shifted toward the physiologic range. These studies indicate that GLUT-2 expression confers both a high and low affinity glucose-stimulated insulin secretion response to intermediate passage RIN cells.	UNIV TEXAS, SW MED CTR,GIFFORD LABS DIABET RES,RM 48222, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; VET AFFAIRS MED CTR, DALLAS, TX 75216 USA; UNIV MASSACHUSSETTS, MED CTR, WORCESTER, MA 01655 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Ferber, Sarah/0000-0003-2764-2786	NIDDK NIH HHS [P01-DK42582, R01-DK46492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046492, P01DK042582] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4512, DOI 10.1021/bi00338a005; BECKER TC, 1994, IN PRESS METHODS CEL; CHEN C, 1993, DIABETES, V42, pA11; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HALBAN PA, 1983, BIOCHEM J, V212, P439, DOI 10.1042/bj2120439; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NEWGARD CB, 1992, BIO-TECHNOL, V10, P1112, DOI 10.1038/nbt1092-1112; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; NEWGARD CB, 1992, DIABETES NUTR METAB, V5, P15; NISHI S, 1992, DIABETOLOGIA, V35, P743; PURRELLO F, 1993, DIABETES, V42, P199, DOI 10.2337/diabetes.42.1.199; QUAADE C, 1991, FEBS LETT, V280, P47, DOI 10.1016/0014-5793(91)80201-D; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; YIN L, 1992, DIABETES, V41, P792	36	101	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11523	11529						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157682				2022-12-27	WOS:A1994NF96600081
J	LEHMANN, M; TSHISUAKA, B; FETZNER, S; ROGER, P; LINGENS, F				LEHMANN, M; TSHISUAKA, B; FETZNER, S; ROGER, P; LINGENS, F			PURIFICATION AND CHARACTERIZATION OF ISOQUINOLINE 1-OXIDOREDUCTASE FROM PSEUDOMONAS-DIMINUTA-7, A NOVEL MOLYBDENUM-CONTAINING HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ELECTRON-PARAMAGNETIC-RESONANCE; RHODOCOCCUS-SPEC B1; MICROBIAL-METABOLISM; XANTHINE-OXIDASE; SULFITE OXIDASE; NICOTINIC-ACID; FORMYLMETHANOFURAN DEHYDROGENASE; QUINOLINE-4-CARBOXYLIC ACID; QUINOLINE OXIDOREDUCTASE	Isoquinoline 1-oxidoreductase, which catalyzes the hydroxylation of isoquinoline to 1-oxo-1,2-dihydroisoquinoline with concomitant reduction of a suitable electron acceptor, was purified from the isoquinoline degrading bacterium Pseudomonas diminuta 7 to apparent homogeneity. The native enzyme was a heterodimer with a molecular mass of 95 kDa consisting of a 16- and a 80-kDa subunit. It contained 0.85 g atom molybdenum, 3.95 g atom iron, 3.9 g atom acid-labile sulfur, 2.1 mol of phosphate, and 1 mol of CMP/mol of enzyme. CMP and phosphate are suggested to originate from molybdopterin cytosine dinucleotide of the pterin molybdenum cofactor. It is assumed that the iron and the acid-labile sulfur are arranged in two (2Fe-2S) clusters. The isoelectric point of the isoquinoline 1-oxidoreductase was within the range of pH 6.2 to 6.8. Cytochrome c, ferricyanide, and several non-physiological electron acceptors served as oxidizing substrates, whereas O2 and NAD were not used. Isoquinoline 1-oxidoreductase revealed a high specificity toward the reducing substrates isoquinoline, 5-hydroxyisoquinoline, quinazoline, and phthalazine. Isoquinoline 1-oxidoreductase was inactivated by methanol, arsenite, p-hydroxymercuribenzoate, 1,10-phenanthroline, and cyanide. Additionally, the enzyme was inactivated upon incubation with its substrates isoquinoline, which slowly inhibited the enzyme in the absence of an electron acceptor, and 5-hydroxyisoquinoline, which rapidly and very effectively inactivated the enzyme in the presence as well as in the absence of the electron acceptors iodonitrotetrazolium chloride, phenazine methosulfate, or ferricyanide.	UNIV HOHENHEIM,INST MIKROBIOL 250,D-70593 STUTTGART,GERMANY	University Hohenheim				Fetzner, Susanne/0000-0002-7228-1871				AISLABIE J, 1989, APPL ENVIRON MICROB, V55, P3247, DOI 10.1128/AEM.55.12.3247-3249.1989; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; BABSON AL, 1973, CLIN CHEM, V19, P766; BAUDER R, 1990, BIOL CHEM H-S, V371, P1137, DOI 10.1515/bchm3.1990.371.2.1137; BAUER G, 1992, BIOL CHEM H-S, V373, P699, DOI 10.1515/bchm3.1992.373.2.699; BEHRMAN EJ, 1957, J BIOL CHEM, V228, P923; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BENNETT J L, 1985, Microbios Letters, V29, P147; BLASCHKE M, 1991, ARCH MICROBIOL, V155, P164, DOI 10.1007/BF00248612; BORNER G, 1991, FEBS LETT, V290, P31, DOI 10.1016/0014-5793(91)81218-W; BOTT G, 1991, BIOL CHEM H-S, V372, P381, DOI 10.1515/bchm3.1991.372.1.381; BRANZOLI U, 1974, J BIOL CHEM, V249, P4339; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; Britton HTS, 1931, J CHEM SOC, P1456, DOI 10.1039/jr9310001456; BUDER R, 1989, EUR J BIOCHEM, V185, P629, DOI 10.1111/j.1432-1033.1989.tb15159.x; CHERVENKA CH, 1969, MANUAL METHODS ANAL, P23; COUGHLAN MP, 1980, J BIOL CHEM, V255, P2694; COUGHLAN MP, 1969, J BIOL CHEM, V244, P2658; DAGLEY S, 1963, BIOCHIM BIOPHYS ACTA, V78, P577, DOI 10.1016/0006-3002(63)91023-0; DEBEYER A, 1993, BIOL CHEM H-S, V374, P101, DOI 10.1515/bchm3.1993.374.1-6.101; DILWORTH GL, 1983, ARCH BIOCHEM BIOPHYS, V221, P565, DOI 10.1016/0003-9861(83)90176-5; DIXON M, 1971, BIOCHIM BIOPHYS ACTA, V226, P259, DOI 10.1016/0005-2728(71)90093-4; FETZNER S, 1993, BIOL CHEM H-S, V374, P363, DOI 10.1515/bchm3.1993.374.1-6.363; FREUDENBERG W, 1988, FEMS MICROBIOL LETT, V52, P13; FRUNZKE K, 1991, BIOFORUM, V4, pP278; GEORGE GN, 1983, BIOCHEMISTRY-US, V22, P1013, DOI 10.1021/bi00274a003; GEORGE GN, 1983, BIOCHEMISTRY-US, V22, P5443, DOI 10.1021/bi00292a028; GRANT DJW, 1976, MICROBIOS, V15, P177; HAMES BD, 1990, GEL ELECTROPHORESIS, P36; HAWKES TR, 1984, BIOCHEM J, V218, P961, DOI 10.1042/bj2180961; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1983, J BIOL CHEM, V258, P4849; HIRSCHBERG R, 1971, J BACTERIOL, V108, P751, DOI 10.1128/JB.108.2.751-756.1971; HOCHSTEIN LI, 1965, BIOCHEM BIOPH RES CO, V21, P644, DOI 10.1016/0006-291X(65)90535-8; HOCHSTEIN LI, 1967, BIOCHIM BIOPHYS ACTA, V139, P56, DOI 10.1016/0005-2744(67)90113-1; HUND HK, 1990, BIOL CHEM H-S, V371, P1005, DOI 10.1515/bchm3.1990.371.2.1005; HUNT AL, 1958, BIOCHEM J, V69, P170, DOI 10.1042/bj0690170; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; JOHNSON JL, 1974, J BIOL CHEM, V249, P859; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1974, J BIOL CHEM, V249, P5046; JOHNSON JL, 1991, BIOFACTORS, V3, P103; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JOHNSON JL, 1976, J BIOL CHEM, V251, P5505; KANDA M, 1972, J BIOL CHEM, V247, P765; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MEYER O, 1986, FEMS MICROBIOL LETT, V39, P161, DOI 10.1111/j.1574-6968.1986.tb01858.x; MEYER O, 1982, J BIOL CHEM, V257, P1333; Morsdorf G., 1992, Biodegradation, V3, P61, DOI 10.1007/BF00189635; MOURA JJG, 1976, BIOCHEM BIOPH RES CO, V72, P782, DOI 10.1016/S0006-291X(76)80201-X; NAGEL M, 1989, FEMS MICROBIOL LETT, V59, P147; NAGEL M, 1990, ARCH MICROBIOL, V154, P605; PEREZVICENTE R, 1992, BIOCHIM BIOPHYS ACTA, V1117, P159, DOI 10.1016/0304-4165(92)90074-5; PESCHKE B, 1991, BIOL CHEM H-S, V372, P1081, DOI 10.1515/bchm3.1991.372.2.1081; PICK FM, 1971, EUR J BIOCHEM, V18, P65, DOI 10.1111/j.1432-1033.1971.tb01215.x; RAJAGOPALAN KV, 1968, J BIOL CHEM, V243, P3797; RAJAGOPALAN KV, 1968, J BIOL CHEM, V243, P3784; RAJAGOPALAN KV, 1964, J BIOL CHEM, V239, P1509; RAJAGOPALAN KV, 1962, J BIOL CHEM, V237, P922; ROGER P, 1990, BIOL CHEM H-S, V371, P511, DOI 10.1515/bchm3.1990.371.1.511; RUGER A, 1993, BIOL CHEM H-S, V374, P479, DOI 10.1515/bchm3.1993.374.7-12.479; SAUTER M, 1993, BIOL CHEM H-S, V374, P1037, DOI 10.1515/bchm3.1993.374.7-12.1037; SCHACH S, 1993, BIOL CHEM H-S, V374, P175, DOI 10.1515/bchm3.1993.374.1-6.175; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SCHICKLE H, SDRE01 PHARM B; SCHMIDT M, 1991, BIOL CHEM H-S, V372, P1015, DOI 10.1515/bchm3.1991.372.2.1015; SCHWARZ G, 1989, BIOL CHEM H-S, V370, P1183, DOI 10.1515/bchm3.1989.370.2.1183; SHUKLA O P, 1987, Biological Memoirs, V13, P115; SHUKLA OP, 1986, APPL ENVIRON MICROB, V51, P1332, DOI 10.1128/AEM.51.6.1332-1342.1986; SHUKLA OP, 1989, MICROBIOS, V59, P47; SIEGMUND I, 1990, FEMS MICROBIOL LETT, V67, P281, DOI 10.1111/j.1574-6968.1990.tb04033.x; STUBLEY C, 1979, XENOBIOTICA, V9, P475, DOI 10.3109/00498257909087261; TATE RL, 1974, CAN J MICROBIOL, V20, P695, DOI 10.1139/m74-106; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12928, DOI 10.1021/bi00210a047; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	85	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11254	11260						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157655				2022-12-27	WOS:A1994NF96600044
J	ZHANG, Y; AGARWAL, KC; BEYLOT, M; SOLOVIEV, MV; DAVID, F; REIDER, MW; ANDERSON, VE; TSERNG, KY; BRUNENGRABER, H				ZHANG, Y; AGARWAL, KC; BEYLOT, M; SOLOVIEV, MV; DAVID, F; REIDER, MW; ANDERSON, VE; TSERNG, KY; BRUNENGRABER, H			NONHOMOGENEOUS LABELING OF LIVER EXTRA-MITOCHONDRIAL ACETYL-COA - IMPLICATIONS FOR THE PROBING OF LIPOGENIC ACETYL-COA VIA DRUG ACETYLATION AND FOR THE PRODUCTION OF ACETATE BY THE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; PEROXISOMAL FATTY-ACID; INTERMEDIARY METABOLISM; QUANTITATIVE-ANALYSIS; SUBSTRATE MIXTURE; BETA-OXIDATION; HEPATOCYTES; 3-BETA-HYDROXYSTEROL; ACETOACETATE; PURIFICATION	The labeling of liver extra-mitochondrial acetyl-CoA was investigated in isolated rat livers perfused with [2-C-13]acetate, [1-C-13]]octanoate, or [1,2,3,4-C-13(4)]docosanoate and with drugs that undergo acetylation (phenylaminobutyrate, paraaminobenzoate, and sulfamethoxazole; singly or in combination). The C-13 enrichment of mitochondrial acetyl-CoA was probed by the enrichment of R-beta-hydroxybutyrate. The latter was not enriched from [1,2,3,4-C-13(4)]docosanoate, thus excluding mitochondrial beta-oxidation of docosanoate. The C-13 enrichment of extra-mitochondrial acetyl-CoA was probed by the enrichments of acetylated drugs and of free acetate. In most cases, the four probes yielded different enrichments. Thus, extra-mitochondrial acetyl-CoA appears nonhomogeneous. Competition between drugs alters the labeling of individual acetyl-CoA sub. pools. The labeling pattern of acetylated drugs suggests the existence of more than the two N-acetyltransferases identified so far by others. Our data question the possibility of probing the pool of lipogenic acetyl-CoA via drug acetylation.	CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; INSERM, U197, F-69008 LYON, FRANCE	Case Western Reserve University; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm)				Anderson, Vernon Emmett/0000-0002-1699-7621	NIDDK NIH HHS [DK35543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BRUNENGRABER H, 1978, EUR J BIOCHEM, V82, P373, DOI 10.1111/j.1432-1033.1978.tb12032.x; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; BRUNENGRABER H, 1993, FASEB J, V7, pA169; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CRABTREE B, 1989, BIOCHEM J, V257, P673, DOI 10.1042/bj2570673; CRABTREE B, 1990, BIOCHEM J, V270, P219, DOI 10.1042/bj2700219; du Vigneaud V, 1938, J BIOL CHEM, V122, P349; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; GAVINO VC, 1987, J BIOL CHEM, V262, P6735; GRIGAT KP, 1979, BIOCHEM J, V177, P71, DOI 10.1042/bj1770071; HEIN DW, 1991, DRUG METAB DISPOS, V19, P933; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; HEMMELGARN E, 1979, BIOCHIM BIOPHYS ACTA, V572, P298, DOI 10.1016/0005-2760(79)90045-6; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; IZAI K, 1992, J BIOL CHEM, V267, P1027; JUNGERMANN K, 1986, ENZYME, V35, P161, DOI 10.1159/000469338; KAZ J, 1985, AM J PHYSIOL, V248, pR391; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; MONTGOMERY JA, 1993, J BIOL CHEM, V268, P20185; PRASS RL, 1980, J BIOL CHEM, V255, P5215; RABKIN M, 1985, BIOCHEM J, V225, P761, DOI 10.1042/bj2250761; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SEUFERT CD, 1974, BIOCHEM BIOPH RES CO, V57, P901, DOI 10.1016/0006-291X(74)90631-7; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; SOBOLL S, 1974, USE ISOLATED HEPATOC, P29; SOLING HD, 1985, EUR J BIOCHEM, V147, P111, DOI 10.1111/j.1432-1033.1985.tb08726.x; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; TSUNASAWA S, 1984, METHOD ENZYMOL, V106, P165; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WATSON JA, 1970, J BIOL CHEM, V245, P5993; WEBER WW, 1980, ENZYMATIC BASIS DETO, P169; WICK MJ, 1990, BIOCHEM PHARMACOL, V40, P1389, DOI 10.1016/0006-2952(90)90408-D; YING Z, 1993, ANAL BIOCHEM, V212, P481, DOI 10.1006/abio.1993.1357; YUAN SS, 1984, J LABELLED COMPD RAD, V21, P525, DOI 10.1002/jlcr.2580210606	38	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11025	11029						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157628				2022-12-27	WOS:A1994NF96600012
J	ZHOU, DG; STEPHENS, DS; GIBSON, BW; ENGSTROM, JJ; MCALLISTER, CF; LEE, FKN; APICELLA, MA				ZHOU, DG; STEPHENS, DS; GIBSON, BW; ENGSTROM, JJ; MCALLISTER, CF; LEE, FKN; APICELLA, MA			LIPOOLIGOSACCHARIDE BIOSYNTHESIS IN PATHOGENIC NEISSERIA - CLONING, IDENTIFICATION, AND CHARACTERIZATION OF THE PHOSPHOGLUCOMUTASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZAE TYPE-B; HAEMOPHILUS-INFLUENZAE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; HEMOPHILUS-INFLUENZAE; GONORRHOEAE; MUTANTS; LIPOPOLYSACCHARIDE; PHOSPHOMANNOMUTASE; SEQUENCE	The lipooligosaccharide (LOS) of pathogenic Neisseria is an important factor in disease pathogenesis. Little is known about the genes involved in neisserial LOS biosynthesis. To elucidate specific LOS biosynthetic genes, we screened a Tn916 library that was constructed in Neisseria meningitidis strain NMB. This strain expresses a single LOS that has an molecular mass of 4.5 kDa and binds monoclonal antibody (mAb) 3F11. This library was screened using a mAb panel that recognizes structural differences in neisserial LOS oligosaccharides. A stable LOS mutant of strain NMB was identified which we designated NMB-R6. This mutant expressed an LOS with an molecular mass of approximately 3.1-3.2 kDa and did not bind mAb 3F11. Genomic DNA from this mutant transformed N. meningitidis strain NMB to the tetracycline resistant NMB-R6 phenotype greater than 10(-4)/recipient/mug of DNA. In addition, we transformed Neisseria gonorrhoeae strain 1291 (LOS phenotype molecular mass 4.5 kDa, mAb 3F11+) to the NMB-R6 LOS phenotype with N. meningitidis NMB-R6 genomic DNA. Analysis of N. gonorrhoeae strain 1291-R6 LOS by mass spectroscopy showed that the LOS oligosaccharide structure is GlcNAc-->Hep2phosphoethanolamine-->2-keto-3-deoxymannooctulosonic acid (where Hep is heptose). Sequence analysis showed that the transposon is inserted into the 3' end of a gene that has homology to the human phosphoglucomutase (PGM) gene. Sequence comparison indicated that the putative PGM gene in N. gonorrhoeae 1291 and N. meningitidis NMB had 92% identity at the DNA level. PGM and glucokinase activity was present in cell free extracts of N. meningitidis NMB and N. gonorrhoeae strain 1291. N. meningitidis NMB-R6 and N. gonorrhoeae strain 1291-R6 had no detectable PGM activity, whereas glucokinase activity was similar to the wild type strains. PGM activity can be reconstituted in N. meningitidis strain NMB-R6 by transformation with the cloned PGM gene. SDS-polyacrylamide gel electrophoresis demonstrated that NMB-R6 transformed with the PGM gene expressed the 3F11+, 4.5-kDa LOS of the parent NMB strain. The inability of N. meningitidis NMB-R6 and N. gonorrhoeae strain 1291-R6 to convert glucose 6-phosphate to glucose 1-phosphate results in the truncated LOS phenotype expressed by these mutants.	EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30333; EMORY UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,ATLANTA,GA 30333; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	Emory University; Emory University; University of California System; University of California San Francisco	ZHOU, DG (corresponding author), UNIV IOWA,DEPT MICROBIOL,BSB 3-401,51 NEWTON RD,IOWA CITY,IA 52242, USA.		Stephens, David S/A-8788-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024616, R01AI018384, R01AI033517, R01AI024616] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24616, AI18384, AI 33517] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; APICELLA MA, 1986, J INFECT DIS, V153, P520, DOI 10.1093/infdis/153.3.520; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DAI JB, 1992, J BIOL CHEM, V267, P6322; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUDAS KC, 1988, INFECT IMMUN, V56, P499, DOI 10.1128/IAI.56.2.499-504.1988; GIBSON BW, 1993, J BACTERIOL, V175, P2072; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; INZANA TJ, 1983, J INFECT DIS, V148, P492, DOI 10.1093/infdis/148.3.492; JOHN CM, 1991, J BIOL CHEM, V266, P19303; JOSHI JG, 1982, METHOD ENZYMOL, V89, P599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YS, 1992, J BIOL CHEM, V267, P21080; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MANDRELL RE, 1990, J EXP MED, V171, P1649, DOI 10.1084/jem.171.5.1649; MAROLDA CL, 1993, J BACTERIOL, V175, P148, DOI 10.1128/JB.175.1.148-158.1993; MCLAUGHLIN R, 1992, J BACTERIOL, V174, P6455, DOI 10.1128/JB.174.20.6455-6459.1992; NASSIF X, 1991, J BACTERIOL, V173, P2147, DOI 10.1128/JB.173.7.2147-2154.1991; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; Pilkis S J, 1975, Methods Enzymol, V42, P31; RAY WJ, 1983, J BIOL CHEM, V258, P9166; RILEY MI, 1984, J BACTERIOL, V158, P705, DOI 10.1128/JB.158.2.705-712.1984; SACORREIA I, 1987, J BACTERIOL, V169, P3224, DOI 10.1128/jb.169.7.3224-3231.1987; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPINOLA SM, 1990, INFECT IMMUN, V58, P1558, DOI 10.1128/IAI.58.6.1558-1564.1990; STEIN DC, 1983, GENE, V25, P241, DOI 10.1016/0378-1119(83)90228-7; STEPHENS DS, 1991, INFECT IMMUN, V59, P4097, DOI 10.1128/IAI.59.11.4097-4102.1991; TSAI CM, 1981, ANAL BIOCHEM, V199, P115; WHITEHOUSE DB, 1992, P NATL ACAD SCI USA, V89, P411, DOI 10.1073/pnas.89.1.411; ZIELINSKI NA, 1991, J BIOL CHEM, V266, P9754	34	56	61	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11162	11169						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157643				2022-12-27	WOS:A1994NF96600031
J	ARREBOLA, R; OLMO, A; RECHE, P; GARVEY, EP; SANTI, DV; RUIZPEREZ, LM; GONZALEZPACANOWSKA, D				ARREBOLA, R; OLMO, A; RECHE, P; GARVEY, EP; SANTI, DV; RUIZPEREZ, LM; GONZALEZPACANOWSKA, D			ISOLATION AND CHARACTERIZATION OF A MUTANT DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE FROM METHOTREXATE-RESISTANT LEISHMANIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; EXTRACHROMOSOMAL CIRCLES; HETEROLOGOUS EXPRESSION; CRYSTAL-STRUCTURES; DNA AMPLIFICATION; DRUG-RESISTANCE; H-REGION; SYNTHETASE; BINDING	The MTX-resistant Leishmania major promastigote cell line D7BR1000 displays extrachromosomal amplified R-region DNA, which contains the gene for dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Garvey, E. P., and Santi, D, V. (1986) Science 233, 535-540). Now we report that these methotrexate (MTX)-resistant cells also possessed a structurally altered DHFR-TS. We have performed the cloning, expression, and characterization of the altered DHFR-TS gene. The DNA sequence of the altered DHFR-TS gene revealed a single base change in position 158 which resulted in the substitution of a methionine in position 53 of DHFR for an arginine. Steady-state measurements of the purified recombinant enzyme indicated that the mutation did not cause significant modifications in the K-m for DHFR or TS substrates but lowered the K-cat by 4-fold. Of greater interest, there was a modification in the effect on MTX inhibition of DHFR The initial inhibition complex appeared to have been unaffected by the alteration, but the subsequent slow-binding step of inhibition in the wild-type enzyme is absent in the altered enzyme. Consequently, the overall K-i for MTX was 30-fold greater for the mutant than for the wild-type enzyme. Transfection of L. major with the mutant DHFR-TS gene gives parasites that are capable of growing in medium containing 10 mM methotrexate, showing that the altered DHFR gene is in itself capable of conferring MTX resistance in Leishmania.	CSIC,INST PARASITOL & BIOMED LOPEZ NEYRA,E-18001 GRANADA,SPAIN; WELLCOME RES LABS,RES TRIANGLE PK,NC 27709; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Wellcome Research Laboratories; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838; Gonzalez-Pacanowska, Dolores/0000-0002-4303-5209; Ruiz-Perez, Luis M./0000-0001-7681-4471	NIAID NIH HHS [R01 AI 19358] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRWEILER PM, 1988, J BACTERIOL, V170, P3301, DOI 10.1128/jb.170.7.3301-3304.1988; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BETHELL GS, 1979, J BIOL CHEM, V254, P2572; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BRUCHOVSKY N, 1982, DRUG HORMONE RESISTA, V1; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; FERONE R, 1980, P NATL ACAD SCI-BIOL, V77, P5802, DOI 10.1073/pnas.77.10.5802; GALINDO I, 1989, MOL BIOCHEM PARASIT, V34, P245, DOI 10.1016/0166-6851(89)90053-4; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; GARVEY EP, 1985, P NATL ACAD SCI USA, V82, P7188, DOI 10.1073/pnas.82.21.7188; GARVEY EP, 1985, MOL BIOCHEM PARASIT, V17, P79, DOI 10.1016/0166-6851(85)90129-X; GARVEY EP, 1986, SCIENCE, V233, P535, DOI 10.1126/science.3726545; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; Harrap K R, 1978, Antibiot Chemother (1971), V23, P228; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KATAKURA K, 1989, MOL BIOCHEM PARASIT, V34, P189, DOI 10.1016/0166-6851(89)90010-8; KAUR K, 1988, J BIOL CHEM, V263, P7020; LAWRIE JM, 1985, AM J TROP MED HYG, V34, P257, DOI 10.4269/ajtmh.1985.34.257; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; MACIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENNER MH, 1985, J BIOL CHEM, V260, P5366; PETRILLOPEIXOTO ML, 1988, MOL CELL BIOL, V8, P5188, DOI 10.1128/MCB.8.12.5188; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; STAMMERS DK, 1987, FEBS LETT, V218, P178, DOI 10.1016/0014-5793(87)81042-6; STONE SR, 1984, BIOCHEM PHARMACOL, V33, P175, DOI 10.1016/0006-2952(84)90472-6; THILLET J, 1988, J BIOL CHEM, V263, P12500; VOLZ KW, 1982, J BIOL CHEM, V257, P2528; WHITE TC, 1988, J BIOL CHEM, V263, P16977; Williams J W, 1979, Methods Enzymol, V63, P437; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021	50	31	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10590	10596						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144647				2022-12-27	WOS:A1994NF01700061
J	DEROSSI, D; JOLIOT, AH; CHASSAING, G; PROCHIANTZ, A				DEROSSI, D; JOLIOT, AH; CHASSAING, G; PROCHIANTZ, A			THE 3RD HELIX OF THE ANTENNAPEDIA HOMEODOMAIN TRANSLOCATES THROUGH BIOLOGICAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; HOMEOBOX PEPTIDE; PROTEINS; GENES	The 60-amino acid long homeodomain of Antennapedia crosses biological membranes by an energy-independent mechanism, a phenomenon abolished by directed mutagenesis within the polypeptide C-terminal region. This finding led us to study the internalization of several chemically synthesized peptides derived from the third helix of the homeodomain. We report here that a polypeptide of 16 amino acids in length corresponding to the third helix of the homeodomain deleted of its N-terminal glutamate is still capable of translocating through the membrane. A longer peptide of 20 amino acids also translocates, whereas shorter peptides (15 amino acids) are not internalized by the cells. As is also the case for the entire homeodomain, the 20- and 16-amino acid long peptides are internalized at 4 degrees C, suggesting an energy-independent mechanism of translocation not involving classical endocytosis. The two translocated peptides can be recovered, intact, within the cells, strongly suggesting that they are not targeted to the lysosomal compartment. Finally, substitution of two tryptophans by two phenylalanines strongly diminishes translocation, raising the possibility that the internalization of the third helix is not solely based on its general hydrophobicity.	ECOLE NORMALE SUPER,CNRS,UNITE RECH 1414,F-75230 PARIS 05,FRANCE; UNIV PARIS 06,CNRS,UNITE RECH 493,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite								BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BLOCHGALLEGO E, 1993, J CELL BIOL, V120, P485, DOI 10.1083/jcb.120.2.485; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GLICK B, 1991, ANNU REV GENET, V25, P21; HOLLAND P, 1992, BIOESSAYS, V14, P267, DOI 10.1002/bies.950140412; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; JIANG JX, 1991, J BIOL CHEM, V266, P24003; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; JOLIOT AH, 1991, NEW BIOL, V3, P1121; LAFONT F, 1992, DEVELOPMENT, V114, P17; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PEREZ F, 1992, J CELL SCI, V102, P717; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; VALLETTE FM, 1994, IN PRESS J BIOL CHEM	25	1648	1936	1	131	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10444	10450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144628				2022-12-27	WOS:A1994NF01700041
J	KONIG, S; SCHELLENBERGER, A; NEEF, H; SCHNEIDER, G				KONIG, S; SCHELLENBERGER, A; NEEF, H; SCHNEIDER, G			SPECIFICITY OF COENZYME BINDING IN THIAMIN DIPHOSPHATE-DEPENDENT ENZYMES - CRYSTAL-STRUCTURES OF YEAST TRANSKETOLASE IN COMPLEX WITH ANALOGS OF THIAMIN DIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE; COLLECTION; DETECTOR; SYSTEM; SITE	The three-dimensional structures of complexes of yeast apotransketolase with the coenzyme analogs 6'-methyl, N1'-pyridyl, and N3'-pyridyl thiamin diphosphate, respectively, were determined with protein crystallographic methods. All three coenzyme analogs bind to the enzyme in a fashion highly similar to the cofactor thiamin diphosphate. Thus, either one of the hydrogen bonds of the pyrimidine ring nitrogens to the protein is sufficient for proper binding and positioning of the cofactor. The lack of catalytic activity of the N3'-pyridyl analog is not due to incorrect orientation of the pyrimidine ring, but results from the absence of the hydrogen bond between the N1' nitrogen atom and the conserved residue Glu(418). The structure analysis provides further evidence for the importance of this conserved interaction for enzymatic thiamin catalysis.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT MOLEC BIOL,S-75124 UPPSALA,SWEDEN; UNIV HALLE WITTENBERG,INST BIOCHEM,DEPT BIOCHEM & BIOTECHNOL,D-06099 HALLE,GERMANY	Swedish University of Agricultural Sciences; Martin Luther University Halle Wittenberg			Koenig, Stephan/GRX-2480-2022	Schneider, Gunter/0000-0003-0622-5713				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CAVALIERI SW, 1975, ARCH BIOCHEM BIOPHYS, V171, P527, DOI 10.1016/0003-9861(75)90062-4; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; HEINRICH PC, 1972, EUR J BIOCHEM, V30, P533, DOI 10.1111/j.1432-1033.1972.tb02124.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN F, 1982, ANN NY ACAD SCI, V378, P14; KLUGER R, 1984, J BIOL CHEM, V259, P8960; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; LINDQVISTY, 1992, EMBO J, V11, P2373; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLERYA, 1993, SCIENCE, V259, P965; NEEF H, 1990, LIEBIGS ANN CHEM, P913; NILSSON U, 1993, FEBS LETT, V326, P145, DOI 10.1016/0014-5793(93)81779-Y; OBRIEN TA, 1980, J BIOL CHEM, V255, P3302; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SCHELLENBERGER A, 1967, H-S Z PHYSIOL CHEM, V348, P506, DOI 10.1515/bchm2.1967.348.1.506; SCHELLENBERGER A, 1967, ANGEW CHEM INT EDIT, V6, P1024, DOI 10.1002/anie.196710241; SCHELLENBERGER A, 1967, H-S Z PHYSIOL CHEM, V348, P501, DOI 10.1515/bchm2.1967.348.1.501; SCHELLENBERGER A, 1982, ANN NY ACAD SCI, V378, P51, DOI 10.1111/j.1749-6632.1982.tb31185.x; SCHNEIDER G, 1989, J BIOL CHEM, V264, P21619; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; USMANOV RA, 1985, BIOCHEM INT, V10, P479; 1979, 4 DAR LAB SCI ENG CO	26	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10879	10882						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144674				2022-12-27	WOS:A1994NF01700101
J	YUN, HY; KEUTMANN, HT; EIPPER, BA				YUN, HY; KEUTMANN, HT; EIPPER, BA			ALTERNATIVE SPLICING GOVERNS SULFATION OF TYROSINE OR OLIGOSACCHARIDE ON PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN; PEPTIDE AMIDATION; MESSENGER-RNA; ATT-20 CELLS; FACTOR-VIII; PROTEIN; FORMS; EXPRESSION; MEMBRANE; SECRETION	Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the COOH-terminal alpha-amidation of neuroendocrine peptides through the sequential action of monooxygenase and lyase domains contained within this bifunctional protein. Alternative splicing leads to the expression of soluble and integral membrane bifunctional PAM proteins as well as a soluble monofunctional monooxygenase. In order to determine how alternative splicing affects post-translational modification of PAM proteins, we investigated the sulfation of PAM proteins expressed in stably transfected hEK-293 cells. Metabolic labeling with [S-35]SO42- or [S-35]methionine and immunoprecipitation demonstrated that [S-35]SO42- was efficiently incorporated into PAM proteins that have the noncatalytic exon A region following the monooxygenase domain (PAM-1 and PAM-4) and into a soluble bifunctional PAM protein (PAM-3). Alkaline hydrolysis, radiosequencing, and deglycosylation experiments demonstrated the presence of a sulfated tyrosine (Tyr(965)) in the COOH-terminal domain of PAM-3 and multiple sulfated O-glycans in the exon A region of PAM-1 and PAM-4. A mutant PAM-3 protein in which Tyr(965) was changed to Ala(965) (PAM-3/Y965A) was not sulfated and exhibited monooxygenase and lyase activities similar to those of wild type PAM-3. Pulse-chase and temperature block experiments showed that the PAM-3/Y965A protein exits the trans-Golgi network faster than wild type PAM-3. Thus inclusion of exon A results in the sulfation of O-glycans, while elimination of the transmembrane domain results in the sulfation of Tyr(965).	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114	Johns Hopkins University; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032949, R56DK032949, R01DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000098] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00098] Funding Source: Medline; NIDDK NIH HHS [DK-32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BODANSZKY M, 1978, J MED CHEM, V21, P1030, DOI 10.1021/jm00208a006; BRAAS KM, 1992, ENDOCRINOLOGY, V130, P2778, DOI 10.1210/en.130.5.2778; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1993, PROTEIN SCI, V2, P489; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GIBLIN P, 1989, P NATL ACAD SCI USA, V86, P998, DOI 10.1073/pnas.86.3.998; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V151, P417, DOI 10.1016/0006-291X(88)90609-2; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1988, ANN REV PHYSL, V50, P353; IMAI Y, 1993, NATURE, V361, P555; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUKKOLA A, 1990, BIOCHEM BIOPH RES CO, V170, P264, DOI 10.1016/0006-291X(90)91269-X; KATO I, 1990, FEBS LETT, V269, P319, DOI 10.1016/0014-5793(90)81184-P; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KLEIN RS, 1992, J NEUROCHEM, V58, P2011, DOI 10.1111/j.1471-4159.1992.tb10941.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MALTESE JY, 1992, MOL ENDOCRINOL, V6, P1998, DOI 10.1210/me.6.12.1998; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MILGRAM SL, 1994, IN PRESS J CELL SCI; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OUAFIK L, 1992, MOL ENDOCRINOL, V6, P1571, DOI 10.1210/me.6.10.1571; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; RHODES CH, 1990, J HISTOCHEM CYTOCHEM, V38, P1301, DOI 10.1177/38.9.2387985; SMITH PL, 1993, J BIOL CHEM, V268, P795; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117	49	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10946	10955						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144680				2022-12-27	WOS:A1994NF01700110
J	YARFITZ, S; HURLEY, JB				YARFITZ, S; HURLEY, JB			TRANSDUCTION MECHANISMS OF VERTEBRATE AND INVERTEBRATE PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-KINASE-C; LOLIGO-FORBESI PHOTORECEPTORS; GTP-BINDING PROTEIN; CYCLIC-GMP PHOSPHODIESTERASE; COUPLED RECEPTOR KINASES; BOVINE RETINAL RODS; GAMMA-SUBUNIT; LIMULUS PHOTORECEPTORS; PHOTOEXCITED RHODOPSIN; OUTER SEGMENTS		UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle								ANANT JS, 1992, J BIOL CHEM, V267, P687; ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BACIGALUPO J, 1991, P NATL ACAD SCI USA, V88, P7938, DOI 10.1073/pnas.88.18.7938; BATTELLE BA, 1991, J COMP NEUROL, V305, P527, DOI 10.1002/cne.903050402; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BINDER BM, 1989, J BIOL CHEM, V264, P8857; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRITT SG, 1993, NEURON, V11, P29, DOI 10.1016/0896-6273(93)90268-V; BROWN JE, 1992, EXP EYE RES, V54, P403, DOI 10.1016/0014-4835(92)90052-T; BRUC AO, 1993, BIOCHEMISTRY-US, V32, P8636; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Copenhagen D R, 1991, Curr Opin Neurobiol, V1, P258, DOI 10.1016/0959-4388(91)90087-N; DEEB SS, 1994, CURR OPIN NEUROL, V3, P506; Detwiler P B, 1992, Curr Opin Neurobiol, V2, P433, DOI 10.1016/0959-4388(92)90176-L; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1994, IN PRESS NEURON; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DOZA YN, 1992, EUR J BIOCHEM, V209, P1035, DOI 10.1111/j.1432-1033.1992.tb17379.x; EISENBERG RS, 1989, CELL SIGNAL, V1, P519; FARBER DB, 1976, J CYCLIC NUCL PROT, V2, P139; FEIN A, 1986, TRENDS NEUROSCI, V9, P110, DOI 10.1016/0166-2236(86)90037-8; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FRANK TM, 1991, J GEN PHYSIOL, V97, P697, DOI 10.1085/jgp.97.4.697; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GOLDSMITH TH, 1990, Q REV BIOL, V65, P281, DOI 10.1086/416840; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; HALL MD, 1991, BIOCHEM J, V274, P35, DOI 10.1042/bj2740035; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARDIE RC, 1993, NATURE, V366, P113, DOI 10.1038/366113a0; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JACKSON T, 1991, PHARMACOL THERAPEUT, V50, P425, DOI 10.1016/0163-7258(91)90052-N; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; LOTT JS, 1992, FEBS LETT, V312, P241, DOI 10.1016/0014-5793(92)80943-B; MARGULIS A, 1993, BIOCHEM BIOPH RES CO, V194, P855, DOI 10.1006/bbrc.1993.1900; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MILLER JL, 1993, J GEN PHYSIOL, V101, P933, DOI 10.1085/jgp.101.6.933; MINKE B, 1992, SENSORY TRANSDUCTION, P202; NAGY K, 1993, NEUROSCI LETT, V152, P1, DOI 10.1016/0304-3940(93)90468-Z; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NOBES C, 1992, BIOCHEM J, V287, P545, DOI 10.1042/bj2870545; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; ODAY PM, 1991, ANN NY ACAD SCI, V639, P285, DOI 10.1111/j.1749-6632.1991.tb17317.x; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Oprian D D, 1992, Curr Opin Neurobiol, V2, P428, DOI 10.1016/0959-4388(92)90175-K; OPRIAN DD, 1992, J BIOENERG BIOMEMBR, V24, P211, DOI 10.1007/BF00762679; OVCHINNIKOV YA, 1988, FEBS LETT, V232, P69, DOI 10.1016/0014-5793(88)80388-0; PAGES F, 1992, J BIOL CHEM, V267, P22018; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; POTTINGER JDD, 1991, BIOCHEM J, V279, P323, DOI 10.1042/bj2790323; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; QIN N, 1993, FEBS LETT, V321, P6, DOI 10.1016/0014-5793(93)80609-X; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RAYER B, 1990, J PHOTOCH PHOTOBIO B, V7, P107, DOI 10.1016/1011-1344(90)85151-L; RYBA NJ, 1993, BIOCHEM J, V292, P333, DOI 10.1042/bj2920333; RYBA NJP, 1991, BIOCHEM J, V273, P225, DOI 10.1042/bj2730225; SARTHY PV, 1991, J NEUROCHEM, V57, P1757, DOI 10.1111/j.1471-4159.1991.tb06378.x; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHNETKAMP PPM, 1991, J GEN PHYSIOL, V98, P555, DOI 10.1085/jgp.98.3.555; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STRYER L, 1991, J BIOL CHEM, V266, P10711; TSUDA M, 1992, PHOTOCHEM PHOTOBIOL, V56, P1167, DOI 10.1111/j.1751-1097.1992.tb09741.x; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; Yau K W, 1991, Curr Opin Neurobiol, V1, P252, DOI 10.1016/0959-4388(91)90086-M; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0; YOSHIZAWA T, 1992, PHOTOCHEM PHOTOBIOL, V56, P859, DOI 10.1111/j.1751-1097.1992.tb09707.x; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	128	234	238	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14329	14332						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182033				2022-12-27	WOS:A1994NM06500001
J	HAGA, K; KAMEYAMA, K; HAGA, T				HAGA, K; KAMEYAMA, K; HAGA, T			SYNERGISTIC ACTIVATION OF A G-PROTEIN-COUPLED RECEPTOR KINASE BY G-PROTEIN BETA-GAMMA-SUBUNITS AND MASTOPARAN OR RELATED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; AGONIST-DEPENDENT PHOSPHORYLATION; BINDING REGULATORY PROTEINS; ADRENERGIC-RECEPTOR; RHODOPSIN KINASE; AMINO-ACIDS; FAMILY; TRANSDUCIN; LOCALIZATION; INHIBITION	Muscarinic acetylcholine receptors (mAChR, m2 subtype) are phosphorylated in an agonist-dependent manner by a G protein-coupled receptor kinase (GR kinase) at sites located in the central part of mAChR. The GR kinase phosphorylated a glutathione S-transferase fusion protein containing the m2 phosphorylation sites (I3-GST). Phosphorylation of I3-GST was markedly stimulated by mastoparan: the K-m for I3-GST decreased from 7.3 to 0.17 mu M in the presence of 100 mu M mastoparan and the V-max increased 23-fold. beta gamma Subunits of G proteins synergistically stimulated the phosphorylation of I3-GST in the presence of 1-10 mu M mastoparan by increasing the affinity of mastoparan for the GR kinase. The phosphorylation of mAChR by the GR kinase was also synergistically stimulated by 1-10 mu M mastoparan in the presence of beta gamma subunits, but was inhibited by 100 mu M mastoparan. Similar stimulatory and inhibitory effects on the phosphorylation of I3-GST and mAChR were observed using synthetic peptides of 15-20 amino acid residues corresponding to sequences of intracellular segments adjacent to the transmembrane segments of mAChR. These results are consistent with and support the idea that the GR kinase is synergistically activated by both G protein beta gamma subunits and agonist-bound receptors.			HAGA, K (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA T, 1994, IN PRESS J NEUROCHEM; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM CM, 1993, J BIOL CHEM, V268, P15412; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MORO O, 1993, J BIOL CHEM, V268, P22273; NAKATA H, 1994, IN PRESS EUR J BIOCH; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REN Q, 1993, J BIOL CHEM, V268, P16483; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12594	12599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175667				2022-12-27	WOS:A1994NH71600037
J	MOORE, SEH; SPIRO, RG				MOORE, SEH; SPIRO, RG			INTRACELLULAR COMPARTMENTALIZATION AND DEGRADATION OF FREE POLYMANNOSE OLIGOSACCHARIDES RELEASED DURING GLYCOPROTEIN-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The intracellular site for the degradation of free polymannose oligosaccharides released during glycoprotein biosynthesis has been studied by permeabilizing the plasma membrane of metabolically radiolabeled HepG2 cells with streptolysin O. This pore-forming agent permitted us to examine the breakdown in both the cytosolic and vesicular compartments of the previously recognized (Anumula, K. R., and Spiro, R. G. (1983) J. Biol. Chem. 258, 15274-15282) polymannose components terminating in a di-N-acetylchitobiose sequence (OS-Glc-NAc2) or a single N-acetylglucosamine residue (OS-Glc-NAc1) residue. Pulse-chase studies indicated that although the OS-GlcNAc(2) saccharides were about equally distributed between vesicles and cytosol and rapidly disappeared after reaching the Man(8) stage, the OS-GlcNAc(1) species were found predominantly in the extravesicular compartment and there underwent a distinctive demannosylation sequence resulting in the formation of a Man(5)GlcNAc isomer (Man alpha 1-->2Man alpha 1--> 2Man alpha 1-->3(Man alpha 1-->6)Man beta 1-->4GlcNAc) which was different from the product of Golgi processing enzymes. Further trimming of this cytosolic limit product required its translocation into a vesicular compartment, believed to be lysosomes, in which Man(2-4)GlcNAc components appeared as the metabolic chase progressed. The accumulation of Glc(1)Man(5)GlcNAc in the cytosol during the chase suggested that glucose interferes with the cytosolic-vesicular transfer and this became even more evident by the pronounced pile-up of extravesicular Glc(3)Man(5)GlcNAc when the cells were incubated in the presence of castanospermine. Although the biological significance and mechanism of free polymannose oligosaccharide entry into the cytosol is not yet known, the possibility that it may reflect an endoplasmic reticulum-situated degradative process of glycoproteins merits consideration.	JOSLIN DIABET CTR, ELLIOTT P JOSLIN RES LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Moore, Stuart/AAF-3920-2021	Moore, Stuart/0000-0002-1020-2242	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ALDAHER S, 1992, BIOCHEM J, V286, P47, DOI 10.1042/bj2860047; ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; CACAN R, 1987, EUR J BIOCHEM, V166, P469, DOI 10.1111/j.1432-1033.1987.tb13539.x; CACAN R, 1989, EUR J BIOCHEM, V185, P173, DOI 10.1111/j.1432-1033.1989.tb15099.x; DEGASPERI R, 1992, J BIOL CHEM, V267, P9706; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRINNA LS, 1979, J BIOL CHEM, V254, P8814; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KLAUSNER R D, 1989, New Biologist, V1, P3; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; PIERCE RJ, 1979, BIOCHEM J, V180, P673, DOI 10.1042/bj1800673; SPIRO MJ, 1980, ARCH BIOCHEM BIOPHYS, V202, P35, DOI 10.1016/0003-9861(80)90403-8; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TULSIANI DRP, 1987, J BIOL CHEM, V262, P6506; VARKI A, 1983, J BIOL CHEM, V258, P2808; WENG SA, 1993, J BIOL CHEM, V268, P25656	31	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12715	12721						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175683				2022-12-27	WOS:A1994NH71600055
J	WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB				WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB			STRUCTURAL BASIS OF THE 70-KILODALTON HEAT-SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY .1. KINETIC ANALYSES OF ACTIVE-SITE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION; MUTAGENESIS; FRAGMENT	The 70-kDa heat shock cognate protein is a member of a highly conserved family of molecular chaperones in which the binding and release of target polypeptides are coupled to the chaperones' ATPase activity. The ATPase activity resides in the amino-terminal 44-kDa fragment of the protein. Four acidic residues of the ATPase fragment which might participate in catalysis (Asp-10 and Asp-199, which are Mg2+ ion ligands; Glu-175 and Asp-206, which are candidates for a role as catalytic base) have been individually mutated to both the cognate amide residue (aspartate to asparagine, glutamate to glutamine) and to serine, and the effects of the mutations on the kinetics (this manuscript) and structure (Flaherty, K. M., Wilbanks, S. M., DeLuca-Flaherty, C., and McKay, D. B. (1994) J. Biol. Chem. 269, 12899-12907) have been determined. Changes at Asp-10 and Asp-199 reduced k(cat) to similar to 1% of wild type; changes at Glu-175 and Asp-206 reduced k(cat) to similar to 10% of wild type. Changes to Asp-199 and Asp-206 had little effect on K-m; changes to Asp-10 and Glu-175 increased K-m 10-100-fold. These data suggest that the bound magnesium ion and its local environment are crucial to catalysis; they argue against a single residue acting as the sole essential general base catalyst in the hydrolytic reaction.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University				Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P235; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HUANG SP, 1993, J BIOL CHEM, V268, P2063; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PLAUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO	23	92	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12893	12898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175706				2022-12-27	WOS:A1994NH71600080
J	CALI, JJ; ZWAAGSTRA, JC; MONS, N; COOPER, DMF; KRUPINSKI, J				CALI, JJ; ZWAAGSTRA, JC; MONS, N; COOPER, DMF; KRUPINSKI, J			TYPE-VIII ADENYLYL-CYCLASE - A CA2+/CALMODULIN-STIMULATED ENZYME EXPRESSED IN DISCRETE REGIONS OF RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MESSENGER-RNA; INSITU HYBRIDIZATION; CLONING; PROTEIN; RECEPTOR; CALCIUM; SEQUENCE; FAMILY; SYSTEM	A cDNA that encodes type VIII adenylyl cyclase has been isolated from two rat brain libraries. The open reading frame encodes a 1248-amino acid protein predicted to have two sets of six transmembrane spans and two putative nucleotide binding domains as is characteristic of other mammalian adenylyl cyclases. Two type VIII messages are detected in rat brain with estimated sizes of 5.5 and 4.4 kilobases. In situ hybridization indicates that the type VIII messages are most abundantly expressed in the granule cells of the dentate gyrus, the pyramidal cells of hippocampal fields CA1-CA3, the entorhinal cortex, and the piriform cortex. Hybridization is also detected in the neocortex, the amygdaloid complex, and regions of the thalamus and hypothalamus. Stable expression of the type VIII cDNA in human embryonal kidney cells leads to the appearance of a novel 165-kDa glycoprotein in the membrane fraction. Stimulation of these cells with agents that increase intracellular Ca2+ results in up to 43-fold increases in cAMP accumulation over that of control cells transfected with the expression vector. Addition of isoproterenol alone does not lead to type VIII-specific effects in intact cells. Adenylyl cyclase activity in membranes prepared from type VIII-transformed cells is stimulated up to 40-fold by the addition of Ca2+/calmodulin (EC(50) = 53 nM calmodulin). The addition of activated recombinant alpha subunit of G(s) synergistically increases the Ca2+/calmodulin-stimulated activity. A possible role for type VIII adenylyl cyclase in long-term potentiation is discussed.	GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822; UNIV BORDEAUX 1,NEUROCYTOCHIM FONCT LAB,CNRS,URA 339,F-33405 TALENCE,FRANCE; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	Geisinger Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Mons, Nicole/AAD-5541-2019		NIGMS NIH HHS [GM32483, GM46395] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483, R29GM046395] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KRUPINSKI J, 1991, MOL CELL BIOCHEM, V104, P73; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	46	301	306	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12190	12195						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163524				2022-12-27	WOS:A1994NG37700079
J	ROYCHOUDHURY, S; DOTZLAF, JE; GHAG, S; YEH, WK				ROYCHOUDHURY, S; DOTZLAF, JE; GHAG, S; YEH, WK			PURIFICATION, PROPERTIES, AND KINETICS OF ENZYMATIC ACYLATION WITH BETA-LACTAMS OF SOLUBLE PENICILLIN-BINDING PROTEIN 2A - A MAJOR FACTOR IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTICS; AFFINITY; PEPTIDOGLYCAN; EPIDERMIDIS; ISOLATE; GENE	Intrinsic resistance toward beta-lactams in methicillin-resistant Staphylococcus aureus strains, a major source of nosocomial infections, is believed to be caused mainly by penicillin-binding protein 2a (PBP2a). This protein resembles other penicillin-binding proteins that are in volved in bacterial cell wall biosynthesis and are the targets of active site acylation by beta-lactam antibiotics. PBP2a, however, presumably remains active at thera peutic concentrations of beta-lactams. In this paper, we describe a three-step purification of a soluble form of PBP2a (PBP2a') to apparent homogeneity using anion-and cation-exchange, and dye ligand affinity chro matographies. Purified PBP2a' was a 74-kDa monomeric protein that appeared to be folded. The protein was evaluated for its enzymatic acylation with beta-lactams initially by fluorescence quenching and then kinetically by radioactive labeling. Using a modified I-125-labeled penicillin V-acylation assay, the apparent K-m of PBP2a' for penicillin V was 1.2 mM. Three other beta-lactams, each of which exhibited significant fluorescence quenching, acted as strong competitive inhibitors of penicillin V with apparent K-i values of 123.4, 36.1, and 12.4 mu M, respectively. By a new beta-lactam preincubation analysis, these compounds could function as substrates with similar K-m values. Also, the acylation rates of different beta-lactams could be readily ascertained. The enzymatic acylation data substantiate the major causative role of PBP2a in the bacterial resistance. The quantitative radioactive acylation assays are potentially useful in screening for a potent inhibitor of the enzyme.	ELI LILLY & CO,LILLY CORP CTR,LILLY RES LABS,INDIANAPOLIS,IN 46285	Eli Lilly								ADAM M, 1991, BIOCHEM J, V279, P601, DOI 10.1042/bj2790601; ADAM M, 1990, BIOCHEM J, V270, P525, DOI 10.1042/bj2700525; BLASZCZAK LC, 1989, J LABELLED COMPD RAD, V27, P401, DOI 10.1002/jlcr.2580270406; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DOTZLAF JE, 1993, 93 GEN M AM SOC MICR, P239; ELKHARROUBI A, 1991, BIOCHEM J, V280, P463, DOI 10.1042/bj2800463; GEORGOPAPADAKOU NH, 1993, ANTIMICROB AGENTS CH, V37, P2045, DOI 10.1128/AAC.37.10.2045; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; HACKBARTH CJ, 1993, ANTIMICROB AGENTS CH, V37, P1144, DOI 10.1128/AAC.37.5.1144; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HAYES MV, 1981, FEMS MICROBIOL LETT, V10, P119, DOI 10.1111/j.1574-6968.1981.tb06220.x; JAMIN M, 1991, BIOCHEM J, V280, P499, DOI 10.1042/bj2800499; JAMIN M, 1993, BIOCHEM J, V292, P735, DOI 10.1042/bj2920735; LABISCHINSKI H, 1992, MED MICROBIOL IMMUN, V181, P241, DOI 10.1007/BF00198846; MATSUHASHI M, 1986, J BACTERIOL, V167, P975, DOI 10.1128/jb.167.3.975-980.1986; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NICHOLAS RA, 1993, J BIOL CHEM, V268, P5632; OHARA DM, 1989, FEMS MICROBIOL LETT, V57, P97, DOI 10.1111/j.1574-6968.1989.tb03228.x; PIRAS G, 1990, J BACTERIOL, V172, P6856, DOI 10.1128/jb.172.12.6856-6862.1990; PRESTON DA, 1990, ANTIMICROB AGENTS CH, V34, P533; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SONG MD, 1987, FEBS LETT, V221, P167, DOI 10.1016/0014-5793(87)80373-3; TERNANSKY RJ, 1993, J MED CHEM, V36, P1971, DOI 10.1021/jm00066a006; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WU CYE, 1992, ANTIMICROB AGENTS CH, V36, P533, DOI 10.1128/AAC.36.3.533; WU CYE, 1989, 29TH INT C ANT AG CH, P231	27	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12067	12073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163510				2022-12-27	WOS:A1994NG37700060
J	BARRANS, A; COLLET, X; BARBARAS, R; JASPARD, B; MANENT, J; VIEU, C; CHAP, H; PERRET, B				BARRANS, A; COLLET, X; BARBARAS, R; JASPARD, B; MANENT, J; VIEU, C; CHAP, H; PERRET, B			HEPATIC LIPASE INDUCES THE FORMATION OF PRE-BETA(1) HIGH-DENSITY-LIPOPROTEIN (HDL) FROM TRIACYLGLYCEROL-RICH HDL(2) - A STUDY COMPARING LIVER PERFUSION TO IN-VITRO INCUBATION WITH LIPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; PHOSPHOLIPASE-MODIFIED-HDL; CELL-DERIVED CHOLESTEROL; ESTER TRANSFER PROTEIN; PRE-BETA; RAT-LIVER; CULTURED-HEPATOCYTES; PARTICLE SURFACE; LIPID CORE; HYDROLYSIS	High density lipoprotein subfractions with a pre-beta migration play a key role in the reverse cholesterol transport. The origin of these particles is not yet clearly defined. We propose to verify a possible origin of these particles during the catabolism of high density lipoprotein 2 (HDL2) by hepatic lipase using two different models. A rat liver perfusion of native human HDL2 in the presence of heparin induced, after 30 min, the formation of the pre-beta1, HDL subspecies. Human HDL2 enriched with triacylglycerols, perfused in the same conditions, led after 15 min to an enhanced production of this pre-beta1 HDL population, as compared with the results obtained with native HDL2. A reduction of the alpha-HDL2 fraction was also evident. After perfusion, a similar formation of pre-beta1 HDL from triacylglycerol-rich HDL2 was observed in absence of heparin. When these HDL2 were incubated in vitro for 120 min at 37-degrees-C in the presence of partially purified rat hepatic lipase, the appearance of pre-beta1 HDL was again found and associated with a decrease in size of the remaining alpha-HDL subfractions as compared with original HDL2. On the contrary, the incubation of the same HDL2 with snake venom phospholipase A2 produced no pre-beta HDL. These results evidence the role of the triacylglycerol lipase activity of hepatic lipase in the formation of pre-beta1 HDL from triacylglycerol-rich HDL2.	HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Collet, Xavier/M-6938-2017; PERRET, Bertrand/Y-2326-2019	Jaspard-Vinassa, Beatrice/0000-0003-1623-7742				ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; AZEMA C, 1990, BIOCHIM BIOPHYS ACTA, V1046, P73, DOI 10.1016/0005-2760(90)90096-G; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CASTLE CK, 1991, J LIPID RES, V32, P439; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CISAR LA, 1987, BIOCHIM BIOPHYS ACTA, V927, P305, DOI 10.1016/0167-4889(87)90094-2; CLAY MA, 1991, ARTERIOSCLER THROMB, V11, P415, DOI 10.1161/01.ATV.11.2.415; CLAY MA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P52, DOI 10.1016/0005-2760(92)90125-F; COLLET X, 1991, J BIOL CHEM, V266, P9145; COLLET X, 1990, BIOCHIM BIOPHYS ACTA, V1043, P301, DOI 10.1016/0005-2760(90)90031-R; COLLET X, 1991, BIOCHIM BIOPHYS ACTA, V1081, P211, DOI 10.1016/0005-2760(91)90028-G; DECKELBAUM RJ, 1986, J BIOL CHEM, V261, P5201; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EHNHOLM C, 1986, METHOD ENZYMOL, V29, P716; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GROOT PHE, 1981, FEBS LETT, V129, P269, DOI 10.1016/0014-5793(81)80181-0; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HENNESSY LK, 1993, BIOCHEMISTRY-US, V32, P5759, DOI 10.1021/bi00073a006; HIXENBAUGH EA, 1989, J BIOL CHEM, V264, P4222; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; ISHIDA BY, 1987, J LIPID RES, V28, P778; JANSEN H, 1985, BIOCHEM SOC T, V13, P24, DOI 10.1042/bst0130024; KUNITAKE ST, 1985, J LIPID RES, V26, P549; KUNITAKE ST, 1992, J LIPID RES, V33, P1807; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINNON M, 1986, J BIOL CHEM, V261, P2548; MARQUESVIDAL P, 1991, BIOCHIM BIOPHYS ACTA, V1082, P185, DOI 10.1016/0005-2760(91)90193-L; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MOWRI HO, 1992, J LIPID RES, V33, P1269; NEARY R, 1991, ATHEROSCLEROSIS, V89, P35, DOI 10.1016/0021-9150(91)90005-N; NEWNHAM HH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P57, DOI 10.1016/0005-2760(90)90218-M; NILSSONEHLE P, 1977, ARTERY, V3, P194; PARINAUD J, 1987, J CLIN ENDOCR METAB, V64, P409, DOI 10.1210/jcem-64-3-409; PATSCH JR, 1984, J CLIN INVEST, V74, P2017, DOI 10.1172/JCI111624; PERRET BP, 1987, EUR J BIOCHEM, V162, P279, DOI 10.1111/j.1432-1033.1987.tb10597.x; ROSCHLAU P, 1974, Z KLIN CHEM KLIN BIO, V12, P403; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SIMARD G, 1990, ANN BIOL CLIN-PARIS, V48, P61; SIMARD G, 1989, BIOCHIM BIOPHYS ACTA, V1001, P225, DOI 10.1016/0005-2760(89)90152-5; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; WEISGRABER KH, 1980, J LIPID RES, V21, P316	46	187	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11572	11577						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157689				2022-12-27	WOS:A1994NF96600088
J	INOKUCHI, Y; YUYAMA, N; HIRASHIMA, A; NISHIKAWA, S; OHKAWA, J; TAIRA, K				INOKUCHI, Y; YUYAMA, N; HIRASHIMA, A; NISHIKAWA, S; OHKAWA, J; TAIRA, K			A HAMMERHEAD RIBOZYME INHIBITS THE PROLIFERATION OF AN RNA COLIPHAGE SP IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-Q-BETA; SELF-CLEAVAGE; IMMUNE-SYSTEM; TRIMMING PLASMID; VIRAL-INFECTION; EXPRESSION; SEQUENCE; PROTEIN; COMPLEMENTARY; CONSTRUCTION	Ribozymes are potentially powerful tools for the suppression of intracellular gene expression. However, the few reports that exist of their activities in bacteria have described mixed success. Chuat and Galibert (Chuat, J.- C., and Galibert, F. (1989) Biochem. Biophys. Res. Commun. 162, 1025-1029) failed to detect any trans-activities of hammerhead ribozymes in Escherichia coli, while Sioud and Drlica (Sioud, M., and Drlica, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,7303-7307) reported complete inhibition of expression of the gene for a nonbacterial protein, HIV-1 integrase, by trans-acting hammerhead ribozymes in E. coli. It is of interest to determine whether ribozymes can really be used in natural bacterial systems (Altman, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10898-10900). We now report that a ribozyme designed to cleave the A2 gene of RNA coliphage SP, when transcribed from a plasmid in E. coli caused failure of the proliferation of progeny phage. Inactive ribozymes with altered catalytic sequences did not affect phage growth. These results indicate that it is mainly the catalytic activity of the ribozyme and not its function as an antisense molecule that is responsible for suppressing the proliferation of the RNA phage. Moreover, an analysis based on numbers of plaque-forming units and the function of the A2 protein indicated that antisense RNA may successfully compete with ribosomes in targeting mRNA while ribozymes in this study may not compete with ribosomes in naturally occurring bacterial transcription/translation-coupled systems.	IBARAKI UNIV, FAC AGR, AMI, IBARAKI 30003, JAPAN; TEIKYO UNIV, DEPT BIOSCI, UTSUNOMIYA 320, JAPAN; YAKULT CENT INST MICROBIOL RES, TOKYO 186, JAPAN; MINIST INT TRADE & IND, IND SCI & TECHNOL AGCY, NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA 305, JAPAN	Ibaraki University; Teikyo University; Yakult Honsha Company, Limited; National Institute of Advanced Industrial Science & Technology (AIST)								ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; BUZAYAN JM, 1986, P NATL ACAD SCI USA, V83, P8859, DOI 10.1073/pnas.83.23.8859; CECH TR, 1990, ANGEW CHEM INT EDIT, V29, P759, DOI 10.1002/anie.199007591; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUAT JC, 1989, BIOCHEM BIOPH RES CO, V162, P1025, DOI 10.1016/0006-291X(89)90776-6; COLEMAN J, 1985, NATURE, V315, P601, DOI 10.1038/315601a0; COLEMAN J, 1984, CELL, V37, P429, DOI 10.1016/0092-8674(84)90373-8; DROPULIC B, 1992, J VIROL, V66, P1432; ENDO Y, 1990, J BIOL CHEM, V265, P2216; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ERICKSON RP, 1992, GENE REGULATION BIOL; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HIRASHIMA A, 1986, P NATL ACAD SCI USA, V83, P7726, DOI 10.1073/pnas.83.20.7726; HIRASHIMA A, 1989, J BIOCHEM-TOKYO, V106, P163; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; INOKUCHI Y, 1988, NUCLEIC ACIDS RES, V16, P6205, DOI 10.1093/nar/16.13.6205; KARNIK S, 1983, EMBO J, V2, P1521, DOI 10.1002/j.1460-2075.1983.tb01617.x; KOIZUMI M, 1988, FEBS LETT, V228, P228, DOI 10.1016/0014-5793(88)80004-8; MORI H, 1978, J BIOCHEM, V84, P681, DOI 10.1093/oxfordjournals.jbchem.a132173; MURRAY JAH, 1992, ANTISENSE RNA DNA; NISHIKAWA S, 1991, FUNDAMENTAL INVESTIG, P109; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; Parker R., 1992, Gene regulation: biology of antisense RNA and DNA., P55; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; Taira K., 1992, Gene regulation: biology of antisense RNA and DNA., P35; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; van Duin J., 1988, BACTERIOPHAGES, P117, DOI [10.1007/978-1-4684-5424-6_4, DOI 10.1007/978-1-4684-5424-6_4]; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WINTER RB, 1983, CELL, V33, P877, DOI 10.1016/0092-8674(83)90030-2; YUYAMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1271, DOI 10.1016/S0006-291X(05)81543-8	44	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11361	11366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157667				2022-12-27	WOS:A1994NF96600059
J	NICKELS, JT; BUXEDA, RJ; CARMAN, GM				NICKELS, JT; BUXEDA, RJ; CARMAN, GM			REGULATION OF PHOSPHATIDYLINOSITOL 4-KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE BY CDP-DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; PHOSPHOLIPID BIOSYNTHESIS; PLASMA-MEMBRANE; SYNTHASE ACTIVITY; KINETIC-ANALYSIS; MIXED MICELLES; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; CELL-PROLIFERATION; STRUCTURAL GENE; PURIFICATION	Regulation of the 45- and 55-kDa forms of Saccharomyces cerevisiae membrane-associated phosphatidylinositol (PI) 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase) by phospholipids was examined using Triton X-100/phospholipid-mixed micelles. CDP-diacylglycerol and phosphatidylglycerol inhibited 45-kDa PI 4-kinase activity in a dose-dependent manner. Kinetic analyses of the 45-kDa PI 4-kinase showed that phosphatidylglycerol was a competitive inhibitor with respect to PI (K(i) = 2 mol %), and CDP-diacylglycerol was a mixed type of inhibitor with respect to PI (K(i) = 4 mol %) and MgATP (K(i) = 5 mol %). 55-kDa PI 4-kinase activity was not significantly affected by phospholipids. The physiological relevance of CDP-diacylglycerol inhibition of 45-kDa PI 4-kinase activity was examined using plasma membranes from inositol auxotrophic (ino1) cells. Immunoblot analysis showed that 45-kDa PI 4-kinase expression in plasma membranes was not affected by inositol starvation of ino1 cells. However, both 45-kDa PI 4-kinase activity and its product PI 4-phosphate were reduced in plasma membranes from inositol-starved ino1 cells. The CDP-diacylglycerol concentration (9.6 mol %) in plasma membranes of inositol-starved ino1 cells was 12-fold higher than its concentration (0.8 mol %) in plasma membranes of inositol-supplemented cells. Plasma membranes of inositol-starved ino1 cells also had increased levels of phosphatidate, phosphatidylserine, phosphatidylethanolamine, and cardiolipin. However, these phospholipids did not affect pure 45-kDa PI 4-kinase activity. The concentration of CDP-diacylglycerol in plasma membranes of inositol-starved ino1 cells was in the range of the inhibitor constants determined for CDP-diacylglycerol by kinetic analyses using pure 45-kDa PI 4-kinase. These results raised the suggestion that 45-kDa PI 4-kinase activity may be regulated in vivo by CDP-diacylglycerol.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-28140, GM-35655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655, R01GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; CARTER JR, 1966, J LIPID RES, V7, P678; CHANG YY, 1967, J LIPID RES, V8, P447; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; CULBERTSON MR, 1975, GENETICS, V80, P23; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Dennis EA, 1983, ENZYMES, P307; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; JUND R, 1970, J BACTERIOL, V102, P607, DOI 10.1128/JB.102.3.607-615.1970; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KINNEY AJ, 1990, J BACTERIOL, V172, P4115, DOI 10.1128/jb.172.7.4115-4117.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1989, J BIOL CHEM, V264, P8641; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PAULUS H, 1960, J BIOL CHEM, V235, P1303; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	60	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11018	11024						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157627				2022-12-27	WOS:A1994NF96600011
J	STAPPEN, R; KRAMER, R				STAPPEN, R; KRAMER, R			KINETIC MECHANISM OF PHOSPHATE PHOSPHATE AND PHOSPHATE OH- ANTIPORTS CATALYZED BY RECONSTITUTED PHOSPHATE CARRIER FROM BEEF-HEART MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ASPARTATE GLUTAMATE CARRIER; TRANSPORT PROTEIN; SACCHAROMYCES-CEREVISIAE; INORGANIC-PHOSPHATE; CARNITINE CARRIER; LAC PERMEASE; SEQUENCE; EXCHANGE; PROTEOLIPOSOMES	In an optimized reconstituted system, the basic kinetic properties of the phosphate carrier from bovine heart mitochondria, e.g. the influence of membrane potential, pH, and proton gradient, were investigated for the two physiological modes of transport (P(i)-/P(i)- antiport and electroneutral, unidirectional phosphate transport). On the basis of these data, which closely resemble the function known from mitochondria, the reaction mechanism of the phosphate carrier was determined using bireactant initial velocity studies in both transport modes. Translocation occurred according to a simultaneous (sequential) mechanism, involving a ternary complex in transport catalysis. This mechanism indicates that the phosphate carrier falls into the same functional family as most other mitochondrial carriers. A detailed analysis of the different effects of pH on transport substrates and carrier protein in both possible transport modes, in combination with the identity of the kinetic mechanism in both modes, provides evidence that the unidirectional phosphate transport is catalyzed by P(i)-/OH- antiport rather than by P(i)-/H+ symport. We furthermore observed noncompetitive inhibition of phosphate transport by other anions. The consequences of this result with respect to a functional model of the carrier protein are discussed.	FORSCHUNGSZENTRUM JULICH,INST BIOTECHNOL 1,D-52425 JULICH,GERMANY	Helmholtz Association; Research Center Julich								AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; BISACCIA F, 1993, BIOCHIM BIOPHYS ACTA, V1142, P139, DOI 10.1016/0005-2728(93)90095-W; Cleland W. W, 1970, ENZYMES, V2, P1; COTY WA, 1974, J BIOL CHEM, V249, P2593; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FREITAG H, 1978, EUR J BIOCHEM, V83, P53, DOI 10.1111/j.1432-1033.1978.tb12067.x; GARCIA ML, 1983, BIOCHEMISTRY-US, V22, P2524, DOI 10.1021/bi00279a033; GENCHI G, 1988, BIOCHIM BIOPHYS ACTA, V936, P413, DOI 10.1016/0005-2728(88)90018-7; GREENBAUM NL, 1985, J BIOL CHEM, V260, P873; GUERIN B, 1990, J BIOL CHEM, V265, P19736; INDIVERI C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P310, DOI 10.1016/0005-2728(93)90202-Q; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; INDIVERI C, 1991, EUR J BIOCHEM, V198, P339, DOI 10.1111/j.1432-1033.1991.tb16021.x; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P231, DOI 10.1016/0005-2736(91)90235-Z; INDIVERI C, 1994, IN PRESS BIOCH BIOPH; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KADENBACH B, 1978, FEBS LETT, V89, P161, DOI 10.1016/0014-5793(78)80545-6; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KOLBE HVJ, 1985, J BIOL CHEM, V260, P5899; KRAMER R, 1982, BIOCHEMISTRY-US, V21, P1082; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V863, P289, DOI 10.1016/0005-2736(86)90269-5; KRAMER R, 1992, MOL MECHANISMS BIOEN, V23, P359; KRAMER R, 1994, IN PRESS BIOCH BIOPH; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LANOUE KF, 1984, BIOENERGETICS, P221; LIGETI E, 1985, BIOCHEMISTRY-US, V24, P4423, DOI 10.1021/bi00337a025; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P1284, DOI 10.1021/bi00219a018; MCGIVAN JD, 1971, EUR J BIOCHEM, V20, P392, DOI 10.1111/j.1432-1033.1971.tb01405.x; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Segel, 1975, ENZYME KINETICS BEHA, P274; SLUSE FE, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P183; SLUSE FE, 1991, BIOCHIM BIOPHYS ACTA, V1058, P329, DOI 10.1016/S0005-2728(05)80128-8; SLUSE FE, 1979, EUR J BIOCHEM, V100, P3, DOI 10.1111/j.1432-1033.1979.tb02028.x; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; WOHLRAB H, 1982, J BIOL CHEM, V257, P28	47	72	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11240	11246						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157653				2022-12-27	WOS:A1994NF96600042
J	VONMOLLARD, GF; STAHL, B; KHOKHLATCHEV, A; SUDHOF, TC; JAHN, R				VONMOLLARD, GF; STAHL, B; KHOKHLATCHEV, A; SUDHOF, TC; JAHN, R			RAB3C IS A SYNAPTIC VESICLE PROTEIN THAT DISSOCIATES FROM SYNAPTIC VESICLES AFTER STIMULATION OF EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; LOCALIZATION; ASSOCIATION; GLUTAMATE; SEQUENCES; MEMBRANE; CLONING; BRAIN	Rab3 proteins are small GTP-binding proteins of the Ras superfamily. Four highly homologous Rab3 proteins termed Rab3A, Rab3B, Rab3C, and Rab3D have been described. Rab3A has previously been shown to be a constituent of synaptic vesicles in neurons that undergoes membrane dissociation-association cycles during synaptic vesicle recycling. Here we report that Rab3C copurifies with Rab3A during the isolation of synaptic vesicles. Organelles immunoisolated with monoclonal antibodies directed against Rab3A led to a coenrichment of Rab3A and Rab3C, demonstrating that both Rab3 proteins are colocalized on the same organelle. In isolated nerve terminals, stimulation of neurotransmitter release resulted in a dissociation of Rab3C from synaptic vesicle and/or recycling membranes. This dissociation parallels that of Rab3A observed under the same conditions. In contrast, no change was observed in the membrane-association of Rab5, a Rab protein localized on early endosomes. We conclude that in the nervous system Rab3C is localized on synaptic vesicles and, like Rab3A, cycles on and off the synaptic vesicle membrane in parallel with exocytotic release of neurotransmitter.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,POB 9812,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498	NCI NIH HHS [P01 CA 46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CORMONT M, 1993, J BIOL CHEM, V268, P19491; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	29	138	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10971	10974						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157621				2022-12-27	WOS:A1994NF96600002
J	DALLASTA, V; ROSSI, PA; BUSSOLATI, O; GAZZOLA, GC				DALLASTA, V; ROSSI, PA; BUSSOLATI, O; GAZZOLA, GC			RESPONSE OF HUMAN FIBROBLASTS TO HYPERTONIC STRESS - CELL SHRINKAGE IS COUNTERACTED BY AN ENHANCED ACTIVE-TRANSPORT OF NEUTRAL AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; ION-TRANSPORT; L-ARGININE; GLUTAMINE; VOLUME	Regulatory volume increase (RVI) has been studied in cultured human fibroblasts (CHF) incubated in a complete hypertonic growth medium (400 mosmol/kg). After the initial cell shrinkage induced by hypertonic treatment, cells recover their volume almost completely within 3 h. This RVI response is associated with a marked increase of the cell content of free amino acids. The cell content of potassium increases only slightly. Chromatographic analysis of the intracellular amino acid pool shows that the RVI-associated increase in cell amino acids is mainly a result of changes in the L-glutamine content. The intracellular accumulation of the analog 2-methylaminoisobutyric acid, a specific substrate of transport system A, is increased in CHF undergoing RVI. Hypertonic treatment causes an immediate and sustained cell hyperpolarization, as demonstrated by changes in the trans-membrane distribution ratio of L-arginine and in the fluorescence of the potential-sensitive dye bis-1,3,-diethylthiobarbiturate-trimethineoxonol. Because of cell hyperpolarization, at the end of RVI the trans-membrane gradient of the sodium electrochemical potential is higher than that of the control. The increase in the extracellular potassium concentration ([K+](out) = 40 mM) abolishes the hyperpolarization induced by hypertonic treatment and delays volume recovery. Cycloheximide suppresses RVI at a high but not at physiologic [K+](out). It is proposed that CHF counteract hypertonic shrinkage through an enhanced accumulation of substrates of transport system A sustained, initially, by an increase in the energy available for transport and, subsequently, also by the synthesis of new site A carriers.	UNIV PARMA,IST PATOL GEN,I-43100 PARMA,ITALY	University of Parma			Bussolati, Ovidio/B-7589-2013; Dall'Asta, Valeria/M-6698-2015	Bussolati, Ovidio/0000-0002-4301-2939; Dall'Asta, Valeria/0000-0001-8540-0916				BANNAI S, 1988, J CELL PHYSIOL, V137, P360, DOI 10.1002/jcp.1041370221; BODE BP, 1991, J BIOL CHEM, V266, P7376; BUSSOLATI O, 1989, AM J PHYSIOL, V256, pC930, DOI 10.1152/ajpcell.1989.256.4.C930; BUSSOLATI O, 1987, AM J PHYSIOL, V253, pC391, DOI 10.1152/ajpcell.1987.253.3.C391; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; DALLASTA V, 1991, J BIOL CHEM, V266, P1591; DALLASTA V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P106, DOI 10.1016/0167-4889(90)90063-J; DARMAUN D, 1988, J CELL PHYSIOL, V134, P143, DOI 10.1002/jcp.1041340118; GAZZOLA G, 1991, Cellular Physiology and Biochemistry, V1, P131, DOI 10.1159/000154601; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; LAW RO, 1987, J PHYSIOL-LONDON, V386, P45, DOI 10.1113/jphysiol.1987.sp016521; MARCHHELLI R, 1992, J SCI FOOD AGR, V57, P217; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; SPRING KR, 1992, KIDNEY PHYSL PATHOPH, P147; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	18	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10485	10491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144632				2022-12-27	WOS:A1994NF01700046
J	ERASO, P; PORTILLO, F				ERASO, P; PORTILLO, F			MOLECULAR MECHANISM OF REGULATION OF YEAST PLASMA-MEMBRANE H+-ATPASE BY GLUCOSE - INTERACTION BETWEEN DOMAINS AND IDENTIFICATION OF NEW REGULATORY SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; CA2+ PUMP; DNA; CONSEQUENCES; ACTIVATION; PROMOTER; SEQUENCE; BINDING; GROWTH	The carboxyl terminus of yeast plasma membrane H+-ATPase is an autoinhibitory domain, and its effect is counteracted by modification of the enzyme triggered by glucose metabolism (Portillo, F., Larrinoa, I. F., and Serrano, R. (1989) FEBS Lett. 247, 381-385). To identify interacting domains involved in this regulation, we have performed intragenic suppressor analysis. A double mutation at the carboxyl terminus (S911A/T912A) results in no activation of the ATPase by glucose and lack of yeast growth on this sugar (Portillo, F., Eraso, P., and Serrano, R. (1991) FEBS Lett. 287, 71-74). Random in vitro mutagenesis of this mutant ATPase gene resulted in 29 revertants. Six corresponded to full revertants of the initial double mutation. Fourteen suppressor (second-site) mutations are located within three functional domains of the enzyme. Four mutations (A165V, V169I/D170N, A350T, and A351T) are localized at the cytoplasmic ends of predicted transmembrane helices 2 and 4; six mutations (P536L, A565T, G587N, G648S, P669L,and G670S) map within the proposed ATP binding domain, and the other four substitutions (P890opa, S896F, R898K, and M907I) are located at the carboxyl terminus. These results demonstrate the interaction, direct or indirect, between these three domains far apart in the linear sequence of the ATPase. All the second-site mutations caused constitutive activation of the ATPase in the absence of glucose metabolism. Second site mutations at the carboxyl terminus were close to Ser-899 and suggested phosphorylation of this amino acid during glucose activation. Accordingly, the introduction of a negative charge, in a S899D mutant constructed by site-directed mutagenesis, partially mimics the glucose effect on the ATPase.			ERASO, P (corresponding author), UNIV AUTONOMA MADRID, FAC MED,CSIC,INST INVEST BIOMED,DEPT BIOQUIM, ARTURO DUPERIER 4, E-28029 MADRID, SPAIN.		Mazmela, Pilar Eraso/E-9248-2016	Mazmela, Pilar Eraso/0000-0002-6928-3219; Portillo Perez, Francisco/0000-0003-4922-346X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CID A, 1988, J BIOL CHEM, V263, P14134; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; ERASO P, 1987, FEBS LETT, V224, P187, DOI 10.1016/0014-5793(87)80445-3; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Freeman E. R., 1971, Computer designer's conference and exhibition (abstracts); GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NA SQ, 1993, J BIOL CHEM, V268, P11792; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RAO R, 1993, J BIOL CHEM, V268, P6708; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1992, ACTA PHYSIOL SCAND, V146, P131; SERRANO R, 1986, FEBS LETT, V208, P143, DOI 10.1016/0014-5793(86)81549-6; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; [No title captured]	36	95	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10393	10399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144622				2022-12-27	WOS:A1994NF01700034
J	GACK, S; VALLON, R; SCHAPER, J; RUTHER, U; ANGEL, P				GACK, S; VALLON, R; SCHAPER, J; RUTHER, U; ANGEL, P			PHENOTYPIC ALTERATIONS IN FOS-TRANSGENIC MICE CORRELATE WITH CHANGES IN FOS/JUN-DEPENDENT COLLAGENASE TYPE-I EXPRESSION - REGULATION OF MOUSE METALLOPROTEINASES BY CARCINOGENS, TUMOR PROMOTERS, CAMP, AND FOS ONCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SYNOVIAL FIBROBLASTS; EPIDERMAL GROWTH-FACTOR; BONE-RESORBING AGENTS; C-FOS; MESSENGER-RNA; TISSUE INHIBITOR; GENE-EXPRESSION; RAT FIBROBLASTS; CYSTEINE SWITCH; INDUCED TRANSIN	Using specific cDNAs isolated from mouse fibroblasts we determined tissue-specific expression of different matrix metalloproteinase genes: both stromelysin-1 and collagenase IV are highly expressed in heart and lung, whereas collagenase I is expressed most abundantly in skeletal muscle, kidney, and bone. High basal level expression of stromelysin-2 is found in heart and kidney. Like in man and rat, the expressions of collagenase I, stromelysin-1, and stromelysin-2 are regulated by the tumor promoter 12-O-tetradecanoyl-phorbol 13-acetate and by UV irradiation, but not by cAMP. In contrast, the expression of the 72-kDa collagenase IV is not affected by either stimuli. We and others have shown previously that under cell culture conditions, the regulation of human collagenase I is regulated by the transcription factor Fos/Jun (AP-1). Here we show that in c-fos transgenic mice transcription of collagenase I is induced in thymus, spleen, and, most dominantly, in bone upon overexpression of Fos. Neither collagenase IV nor stromelysin-1 or stromelysin-2 expression is affected by c-Fos. The sites of induced collagenase I expression correlate with the sites of Fos-induced long-term cellular alterations in transgenic mice including bone remodeling and T cell development. In fact, in the developing bone tumors strongly enhanced levels of collagenase I transcripts were detectable. These results identify collagenase I as a Fos-regulated gene in vivo and suggest a possible role for Fos/Jun heterodimers in establishing the pathological phenotype of c-fos transgenic mice.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH, INST GENET, D-76021 KARLSRUHE, GERMANY; HANNOVER MED SCH, INST MOLEK BIOL, D-30623 HANNOVER, GERMANY	Helmholtz Association; Karlsruhe Institute of Technology; Hannover Medical School			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Angel P, 1992, Matrix Suppl, V1, P156; BACHILLER D, 1990, Archiv fuer Geschwulstforschung, V60, P357; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; FRISCH SM, 1990, ONCOGENE, V5, P75; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GROSS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1981, DOI 10.1073/pnas.81.7.1981; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HEATH JK, 1990, BIOCHEM BIOPH RES CO, V168, P1171, DOI 10.1016/0006-291X(90)91152-I; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KRAMER M, 1993, J BIOL CHEM, V268, P6734; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARTIN GR, 1985, TRENDS BIOCHEM SCI, V10, P285, DOI 10.1016/0968-0004(85)90089-1; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1985, J BIOL CHEM, V260, P3079; Murphy Gillian, 1993, P287; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; REPONEN P, 1992, J BIOL CHEM, V267, P7856; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SAKAI M, 1989, CANCER RES, V49, P5633; SAKAMOTO S, 1985, BIOCHEM BIOPH RES CO, V133, P709, DOI 10.1016/0006-291X(85)90962-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHONTHAL A, 1988, COLD SPRING HARB SYM, V53, P779, DOI 10.1101/SQB.1988.053.01.088; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	70	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10363	10369						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144618				2022-12-27	WOS:A1994NF01700030
J	MARRERO, MB; PAXTON, WG; DUFF, JL; BERK, BC; BERNSTEIN, KE				MARRERO, MB; PAXTON, WG; DUFF, JL; BERK, BC; BERNSTEIN, KE			ANGIOTENSIN-II STIMULATES TYROSINE PHOSPHORYLATION OF PHOSPHOLIPASE C-GAMMA-1 IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PROTEIN-KINASE; C-GAMMA; ACTIVATION; RECEPTOR; MOBILIZATION; RESIDUES; CALCIUM; ISOZYME; ALPHA	The receptor for angiotensin II (Ang II) has recently been cloned; it is a receptor with seven transmembrane spanning domains that stimulates phosphoinositide hydrolysis upon ligand binding. The physiologic effects of Ang II are important in the regulation of vascular function. In this study, we examined the ability of Ang II to regulate the enzymatic activity of phospholipase C (PLC) in rat aortic vascular smooth muscle cells (VSMC). In cultured VSMC, PLC-gamma 1 and PLC-delta 1 isozymes, but not PLC-beta 1, were identified by Western analysis. Ang II (10(-7) M)-stimulated PLC-gamma 1 phosphotyrosine phosphorylation with a maximum increase of 4.5-fold at 0.5 min. This followed the same time course as the Ang II-stimulated increase in inositol 1,4,5-trisphosphate (1,4,5-IP3) levels. 1,4,5-IP3 formation was inhibited 75% by the tyrosine kinase inhibitor genistein (120 mu M). Several growth factor receptors, such as the platelet-derived growth factor (PDGF) receptor are themselves tyrosine kinases and have been shown to phosphorylate PLC-gamma 1 and increase intracellular Ca2+ concentrations. The time course for PLC-gamma 1 phosphorylation, IP3 formation, and Ca2+ mobilization by PDGF differed from Ang II in VSMC. The kinetics of the PDGF effects were slower in onset and more prolonged than those of Ang II. In summary, these findings show that Ang II stimulates VSMC phosphoinositide hydrolysis in association with tyrosine phosphorylation of PLC-gamma 1 and support the concept that Ang II-stimulated tyrosine phosphorylation is responsible for early signal transduction events.	EMORY UNIV, DEPT PATHOL & LAB MED, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT MED, DIV CARDIOL, ATLANTA, GA 30322 USA	Emory University; Emory University				Bernstein, Kenneth/0000-0001-8097-3272; Berk, Bradford/0000-0002-2767-4115	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R01DK039777, R37DK039777, P50DK045215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45215, DK44280, DK39777] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BERK BC, 1987, J BIOL CHEM, V262, P5065; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; EMORI Y, 1989, J BIOL CHEM, V264, P21885; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HOMMA Y, 1993, BIOCHEM J, V290, P649, DOI 10.1042/bj2900649; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM UH, 1989, J BIOL CHEM, V264, P20167; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMITH JB, 1986, AM J PHYSIOL, V250, pF759, DOI 10.1152/ajprenal.1986.250.5.F759; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584	35	201	203	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10935	10939						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144678				2022-12-27	WOS:A1994NF01700108
J	BETTENDORFF, L; WINS, P				BETTENDORFF, L; WINS, P			MECHANISM OF THIAMINE TRANSPORT IN NEUROBLASTOMA-CELLS - INHIBITION OF A HIGH-AFFINITY CARRIER BY SODIUM-CHANNEL ACTIVATORS AND DEPENDENCE OF THIAMINE UPTAKE ON MEMBRANE-POTENTIAL AND INTRACELLULAR ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; VOLTAGE-GATED SODIUM; BLOOD-BRAIN-BARRIER; NA+ IONOPHORE; PHOSPHATE-ESTERS; PYROPHOSPHOKINASE; NEUROTOXINS; ASTROCYTES; METABOLISM; SYSTEM	Nerve cells are particularly sensitive to thiamine deficiency. We studied thiamine transport in mouse neuroblastoma (Neuro 2a) cells. At low external concentration, [C-14]thiamine was taken up through a saturable high affinity mechanism (K-m = 35 nM). This was blocked by low concentrations of the Na+ channel activators veratridine (IC50 = 7 +/- 4 mu M) and batrachotoxin (IC50 = 0.9 mu M). These effects were not antagonized by tetrodotoxin and were also observed in cell lines devoid of Na+ channels, suggesting that these channels are not involved in the mechanism of inhibition. At high extracellular concentrations, thiamine uptake proceeds essentially via a low affinity carrier (K-m = 0.8 mM), insensitive to veratridine but blocked by divalent cations. In both cases, the uptake was independent on external sodium, partially inhibited (10-35%) by depolarization and sensitive to metabolic inhibitors. A linear relationship between the rate of thiamine transport and intracellular ATP concentration was found. When cells grown in a medium of low thiamine concentration (6 nM) were exposed to 100 nM extracellular thiamine, a 3-fold increase in intracellular thiamine diphosphate was observed after 2 h while the concomitant increase in intracellular free thiamine was barely significant. These data suggest a secondary active transport of thiamine, the main driving force being thiamine phosphorylation rather than the sodium gradient.			BETTENDORFF, L (corresponding author), UNIV LIEGE,GEN & COMPARAT BIOCHEM LAB,17 PL DELCOUR,B-4020 LIEGE,BELGIUM.							BENOS DJ, 1992, REV PHYSL BIOCH PHAR, V120, P21; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BETTENDORFF L, 1993, J MEMBRANE BIOL, V136, P281; BETTENDORFF L, 1991, ANAL BIOCHEM, V198, P52, DOI 10.1016/0003-2697(91)90505-N; BETTENDORFF L, 1986, J CHROMATOGR, V382, P297, DOI 10.1016/S0378-4347(00)83533-1; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; BEVAN S, 1985, PROC R SOC SER B-BIO, V225, P299, DOI 10.1098/rspb.1985.0063; BLASS JP, 1982, J NEUROCHEM, V39, P729, DOI 10.1111/j.1471-4159.1982.tb07953.x; CASIROLA D, 1988, J PHYSIOL-LONDON, V398, P329, DOI 10.1113/jphysiol.1988.sp017045; CASIROLA D, 1990, J MEMBRANE BIOL, V118, P11, DOI 10.1007/BF01872201; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1977, J BIOL CHEM, V252, P8669; CATTERALL WA, 1975, P NATL ACAD SCI USA, V72, P1782, DOI 10.1073/pnas.72.5.1782; CATTERALL WA, 1973, P NATL ACAD SCI USA, V70, P3759, DOI 10.1073/pnas.70.12.3759; CATTERALL WA, 1976, P NATL ACAD SCI USA, V73, P2682, DOI 10.1073/pnas.73.8.2682; COOPER JR, 1979, NEUROCHEM RES, V4, P223, DOI 10.1007/BF00964146; GREENWOOD J, 1986, BRAIN RES, V399, P148, DOI 10.1016/0006-8993(86)90609-8; GREENWOOD J, 1982, J PHYSIOL-LONDON, V327, P95, DOI 10.1113/jphysiol.1982.sp014222; HILL M, 1988, FEBS LETT, V230, P47, DOI 10.1016/0014-5793(88)80639-2; JOHNSON LR, 1968, BIOCHIM BIOPHYS ACTA, V156, P85, DOI 10.1016/0304-4165(68)90107-4; KSIEZAKREDING H, 1982, J NEUROCHEM, V38, P1627, DOI 10.1111/j.1471-4159.1982.tb06643.x; LUMENG L, 1979, J BIOL CHEM, V254, P7265; MATSUDA T, 1985, EXPERIENTIA, V41, P924, DOI 10.1007/BF01970015; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON JW, 1975, BIOCHIM BIOPHYS ACTA, V397, P377, DOI 10.1016/0005-2744(75)90127-8; POUYSSEGUR J, 1980, NATURE, V286, P162, DOI 10.1038/286162a0; REED JK, 1986, BIOCHEM CELL BIOL, V64, P1153, DOI 10.1139/o86-152; SHARMA SK, 1965, BIOCHEM J, V94, P790, DOI 10.1042/bj0940790; SMITH TC, 1989, J MEMBRANE BIOL, V107, P169, DOI 10.1007/BF01871722; SPECTOR R, 1976, AM J PHYSIOL, V230, P1101, DOI 10.1152/ajplegacy.1976.230.4.1101; YAMAMOTO S, 1981, J BIOCHEM-TOKYO, V89, P809, DOI 10.1093/oxfordjournals.jbchem.a133263; YOSHIOKA K, 1984, BIOCHIM BIOPHYS ACTA, V778, P201, DOI 10.1016/0005-2736(84)90463-2; YOSHIOKA K, 1985, BIOCHIM BIOPHYS ACTA, V815, P499, DOI 10.1016/0005-2736(85)90378-5	33	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14379	14385						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182042				2022-12-27	WOS:A1994NM06500014
J	CHIEN, KY; CHIANG, CM; HSEU, YC; VYAS, AA; RULE, GS; WU, WG				CHIEN, KY; CHIANG, CM; HSEU, YC; VYAS, AA; RULE, GS; WU, WG			2 DISTINCT TYPES OF CARDIOTOXIN AS REVEALED BY THE STRUCTURE AND ACTIVITY RELATIONSHIP OF THEIR INTERACTION WITH ZWITTERIONIC PHOSPHOLIPID DISPERSIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAJA-NAJA-ATRA; MEMBRANE-FUSION; PHOSPHATIDYLSERINE VESICLES; NIGRICOLLIS; CURVATURE; KINETICS; VENOM	Cardiotoxins (CTXs) are a group of homologous proteins found in cobra snake venom and consist of 60-62 amino acid residues. Although CTXs are known to consist of three extended beta-sheet loops similar to neurotoxins, the target and interaction of CTXs with membranes unlike those of neurotoxins are not well understood. Herein, we report comparative studies of 10 CTXs purified from Taiwan cobra (Naja naja atra) and Mozambique spitting cobra (Naja mossambica mossambica) snake venoms with respect to their interactions with zwitterionic phospholipids. Based on the CTX-induced mixing of sphingomyelin vesicles and the binding of CTX to lysophosphatidylcholine micelles, two distinct types of CTX, i.e. P- and S-type CTX, are identified. P-type CTXs are characterized by the presence of Pro-31 within a putative phospholipid binding site near the tip of loop 2; whereas S-type CTXs are characterized by the presence of Ser-29 within the same but more hydrophilic region. Although binding of all CTXs to phospholipid membranes involves a phospholipid binding site at loop 1, P-type CTXs exhibit higher fusion and binding activity than S-type CTXs, presumably due to the additional phospholipid binding site at loop 2. The binding modes of P- and S-type CTX are thus different. Analysis of the primary structures of 46 CTXs from the genus Naja indicates that these two types of CTXs exist in all species examined. Reasonable structure/activity correlation can be detected for the effects of CTXs on muscle and red blood cells, although notable exceptions are also found. S-type CTXs are generally found to exhibit higher muscle cell depolarization activity, whereas P-type CTXs are found to possess a higher hemolytic activity. Thus the mechanism of action of CTXs seems to involve CTX-membrane interactions and depends on the type of the cell membrane and CTX molecules under study. The two lipid binding sites in P-type CTXs and one lipid binding site in S-type CTXs show large variation in their amino acid residues, but they do display some common distribution of residue type. Analogous to the signal sequences for protein import, these regions are characterized by the coexistence of an exposed hydrophobic surface flanked on either side by a cationic residue. A hypothesis is proposed to explain the general cytotoxic and specific cardiotoxic effect of CTXs based on the two CTX subtypes in snake venom.	NATL TSING HUA UNIV, INST LIFE SCI, HSINCHU 30043, TAIWAN; UNIV VIRGINIA, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA	National Tsing Hua University; University of Virginia			Rule, Gordon S/Q-2422-2015	Rule, Gordon S/0000-0002-4396-3363				BATENBURG AM, 1985, BIOCHEMISTRY-US, V24, P7101, DOI 10.1021/bi00346a013; BATENBURG AM, 1988, BIOSCIENCE REP, V8, P299, DOI 10.1007/BF01115220; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BOUGIS P, 1983, MOL CELL BIOCHEM, V55, P49, DOI 10.1007/BF00229242; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; DESORMEAUX A, 1992, BIOCHEMISTRY-US, V31, P12173, DOI 10.1021/bi00163a029; DUFOURCQ J, 1982, TOXICON, V20, P165, DOI 10.1016/0041-0101(82)90187-8; Dufton M.J., 1991, P259; FLETCHER JE, 1993, TOXICON, V31, P669, DOI 10.1016/0041-0101(93)90375-S; GATINEAU E, 1987, BIOCHEMISTRY-US, V26, P8046, DOI 10.1021/bi00399a004; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GROGNET JM, 1988, EUR J BIOCHEM, V172, P383, DOI 10.1111/j.1432-1033.1988.tb13898.x; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HARVEY AL, 1991, HDB NATURALTOXINS, V5, P103; HILLE JDR, 1981, BIOCHEMISTRY-US, V20, P4068, DOI 10.1021/bi00517a019; HODGES SJ, 1987, EUR J BIOCHEM, V165, P373, DOI 10.1111/j.1432-1033.1987.tb11450.x; LAUTERWEIN J, 1978, FEBS LETT, V93, P181, DOI 10.1016/0014-5793(78)81100-4; LOUW AI, 1978, BIOCHIM BIOPHYS ACTA, V512, P163, DOI 10.1016/0005-2736(78)90227-4; LOYTER A, 1988, METHOD BIOCHEM ANAL, V33, P129; MENEZ A, 1990, BIOCHIMIE, V72, P575, DOI 10.1016/0300-9084(90)90121-V; OCONNELL JF, 1993, EUR J BIOCHEM, V213, P891, DOI 10.1111/j.1432-1033.1993.tb17833.x; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; Samson M. S. P., 1991, PROG BIOPHYS MOL BIO, V55, P139; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGHAL AK, 1993, BIOCHEMISTRY-US, V32, P8036, DOI 10.1021/bi00082a026; SUN JJ, 1986, TOXICON, V24, P233, DOI 10.1016/0041-0101(86)90149-2; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011; WILSCHUT J, 1981, BIOCHEMISTRY-US, V20, P3126, DOI 10.1021/bi00514a022; WU WG, 1993, FASEB J, V7, pA1235	34	107	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14473	14483						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182052				2022-12-27	WOS:A1994NM06500028
J	EXPOSITO, JY; SUZUKI, H; GEOURJON, C; GARRONE, R; SOLURSH, M; RAMIREZ, F				EXPOSITO, JY; SUZUKI, H; GEOURJON, C; GARRONE, R; SOLURSH, M; RAMIREZ, F			IDENTIFICATION OF A CELL LINEAGE-SPECIFIC GENE CODING FOR A SEA-URCHIN ALPHA-2(IV)-LIKE COLLAGEN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGEN; BASEMENT-MEMBRANE; GOODPASTURE ANTIGEN; PROCOLLAGEN; EXPRESSION; EMBRYO; ALPHA-1(IV); SEQUENCE	We report the isolation of several overlapping cDNAs from an embryonic library of Strongylocentrotus purpuratus coding for a novel sea urchin collagen chain. The conceptual amino acid translation of the cDNAs indicated that the protein displays the structural features of a vertebrate type IV-like collagen a chain. In addition to a putative 31-residue signal peptide, the sea urchin molecule contains a 14-residue amino terminal non collagenous segment, a discontinuous 1,477 amino acid triple helical domain, and a 225-residue carboxyl-terminal domain rich in cysteines. The amino- and carboxyl-terminal non collagenous regions of the echinoid molecule are remarkably similar to the 7 S and carboxyl-terminal non-collagenous (NC1) domains of the alpha 1 and alpha 2 chains of vertebrate type IV collagen. The sequence similarity and distinct structural features of the 7 S and NC1 domains strongly suggest that the sea urchin polypeptide is evolutionarily related to the alpha 2(TV) class of collagen chains. Finally, in situ hybridizations revealed that expression of this collagen gene is restricted to the mesenchyme cell lineage of the developing sea urchin embryo.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; INST BIOL & CHIM PROT,CNRS,UPR 412,F-69367 LYON 07,FRANCE; UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Centre National de la Recherche Scientifique (CNRS); University of Iowa				Exposito, Jean-Yves/0000-0002-4926-4942	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041849] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41849] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1989, P NATL ACAD SCI USA, V265, P7050; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; EXPOSITO JY, 1992, J BIOL CHEM, V267, P17404; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; GLANVILLE RW, 1987, STRUCTURE FUNCTION C, P47; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUO XD, 1989, J BIOL CHEM, V264, P17574; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; LEAHY PS, 1986, METHOD CELL BIOL, V27, P1, DOI 10.1016/S0091-679X(08)60339-8; MORRISON KE, 1991, J BIOL CHEM, V266, P34; NEMER M, 1988, BIOCHIM BIOPHYS ACTA, V950, P445, DOI 10.1016/0167-4781(88)90143-1; PETTITT J, 1991, J BIOL CHEM, V266, P16149; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; SWALLA BJ, 1988, DEV BIOL, V125, P51, DOI 10.1016/0012-1606(88)90057-7; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5; WESSEL GM, 1991, DEV BIOL, V148, P261, DOI 10.1016/0012-1606(91)90335-Z; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	32	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13167	13171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175744				2022-12-27	WOS:A1994NK18400021
J	PANDEY, VN; KAUSHIK, N; MODAK, MJ				PANDEY, VN; KAUSHIK, N; MODAK, MJ			ROLE OF LYSINE-758 OF ESCHERICHIA-COLI DNA-POLYMERASE-I AS ASSESSED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; PROTEOLYTIC FRAGMENT; TEMPLATE-PRIMER; BINDING DOMAIN; IDENTIFICATION; INHIBITION; SUBSTRATE; CATALYSIS	Lys-758 of Escherichia coli DNA polymerase I has been implicated in the process of substrate dNTP binding (Basu, A., and Modak, M. J. (1987) Biochemistry 26, 1704-1709). To confirm and define the role of Lys-758 in the catalytic mechanism, we carried out site-directed mutagenesis of this residue. Catalytic activity of the purified mutant enzymes, K758A and K758R, showed severe reduction in the polymerase activity but little difference in the 3' --> 5' exonuclease activity. Most interestingly, the catalytic ability of both mutant enzymes was maximally affected (300-1,000-fold decrease in k(cat)) with poly(dA).(dT)(15) as template primer (TP), whereas the ability to use poly(dC) templates decreased by only 20-fold in K758A and remained nearly unchanged with K758R. Kinetic characterization showed that K-m(dNTP) increased moderately only with K758A, whereas K-d(TP) remained unchanged for both the mutants, However, binary complex formation between K758A and dNTP, but not between K758A and TP, was severely reduced. Analysis of the processive mode of DNA synthesis by K758A indicated that the mutant enzyme pauses at dA bases but does not dissociate from TP, suggesting a defect in its translocation ability. Thus, Lys-758 in polymerase I appears to participate in two distinct functions: (a) it facilitates the dNTP binding, and (b) it is required for the translocation along the template polynucleotide,	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center				Pandey, Virendra N/0000-0001-6041-6786	NIGMS NIH HHS [GM-36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASU A, 1985, BIOCHEM BIOPH RES CO, V128, P1395, DOI 10.1016/0006-291X(85)91095-2; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DERBYSHIRE V, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; KAUSHIK NA, 1993, CURR SCI INDIA, V64, P102; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCUS SL, 1974, BIOCHEM BIOPH RES CO, V56, P516, DOI 10.1016/0006-291X(74)90873-0; MARTIN JL, 1993, J BIOL CHEM, V268, P2565; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MODAK MJ, 1980, BIOCHEM BIOPH RES CO, V96, P931, DOI 10.1016/0006-291X(80)91444-8; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANDEY VN, 1990, J BIOL CHEM, V265, P3679; PANDEY VN, 1993, EUR J BIOCHEM, V214, P59, DOI 10.1111/j.1432-1033.1993.tb17896.x; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PANDEY VN, 1988, J BIOL CHEM, V263, P6068; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RUSH J, 1990, J BIOL CHEM, V265, P4821; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETLOW P, 1972, J BIOL CHEM, V247, P224; YADAV PNS, 1992, BIOCHEMISTRY-US, V31, P2879, DOI 10.1021/bi00126a006	30	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13259	13265						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175756				2022-12-27	WOS:A1994NK18400034
J	PARRIS, W; RUBINCHIK, S; YANG, YC; GOLD, M				PARRIS, W; RUBINCHIK, S; YANG, YC; GOLD, M			A NEW PROCEDURE FOR THE PURIFICATION OF THE BACTERIOPHAGE-LAMBDA TERMINASE ENZYME AND ITS SUBUNITS - PROPERTIES OF GENE-PRODUCT-A, THE LARGE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TERMINASE; COS DNA; PROTEIN; BINDING; HEAD; MUTATIONS; CLEAVAGE; INVITRO; END; OVERPRODUCTION	New methods for the purification of highly active bacteriophage lambda terminase holoenzyme, and its individual subunits, gene products (gp) A and gpNu1, have been developed. These methods are rapid, simple, reproducible, and give high yields of unaggregated protein from small volumes of culture. The procedures involve fractionation of extracts of Esherichia coli strains harboring plasmids engineered to overproduce the respective proteins. Ah purified proteins exist as monomers or dimers at moderate concentrations. At concentrations where holoenzyme efficiently promotes in vitro cosN-cleavage and lambda DNA packaging, gpA displays neither of these activities unless supplemented with gpNu1 and the E. coli protein integration host factor. At high protein concentrations, however, gpA can promote cos-cleavage by itself. Although gpNu1 itself cannot promote either cosN-cleavage or DNA packaging, it does modulate these activities of gpA. GpA is a DNA-stimulated ATPase whose catalytic parameters closely resemble those of the holoenzyme. Like the holoenzyme, gpA displays a DNA helicase activity which is able to melt the annealed cosN overhangs. Certain preparations of gpA appear to undergo a time-dependent amino-terminal clipping at discrete sites even in the presence of as many as four protease inhibitors and at low temperature.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA	University of Toronto								BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1988, J MOL BIOL, V199, P219, DOI 10.1016/0022-2836(88)90391-9; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DAVIDSON A, 1991, J BACTERIOL, V173, P5086, DOI 10.1128/jb.173.16.5086-5096.1991; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1982, P NATL ACAD SCI-BIOL, V79, P3498, DOI 10.1073/pnas.79.11.3498; FEISS M, 1983, LAMBDA, V2, P305; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GOLD M, 1983, J BIOL CHEM, V258, P4619; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HSIAO CL, 1977, P NATL ACAD SCI USA, V74, P3652, DOI 10.1073/pnas.74.9.3652; JENKINS WT, 1991, ANAL BIOCHEM, V194, P136, DOI 10.1016/0003-2697(91)90160-U; JOHNSON G, 1991, J BACTERIOL, V173, P2733, DOI 10.1128/JB.173.9.2733-2738.1991; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KALLWASS HKW, 1992, J AM CHEM SOC, V114, P4551, DOI 10.1021/ja00038a016; KEELER CL, 1987, THESIS U MARYLAND BA; KYPR J, 1986, J MOL BIOL, V191, P139, DOI 10.1016/0022-2836(86)90430-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P51; MILLER G, 1985, J MOL BIOL, V183, P246, DOI 10.1016/0022-2836(85)90217-7; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MIWA T, 1983, GENE, V24, P199; MIWA T, 1982, GENE, V20, P265; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; MURIALDO H, 1987, NUCLEIC ACIDS RES, V15, P119, DOI 10.1093/nar/15.1.119; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; REYES O, 1979, VIROLOGY, V94, P400, DOI 10.1016/0042-6822(79)90470-7; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SIPPY J, 1992, J BACTERIOL, V174, P850, DOI 10.1128/jb.174.3.850-856.1992; SMITH MP, 1993, J BACTERIOL, V175, P2393, DOI 10.1128/JB.175.8.2393-2399.1993; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIS RC, 1992, THESIS U TORONTO; WU WF, 1988, GENETICS, V119, P477; XU S, 1989, THESIS U IOWA; YANG YC, 1993, THESIS U TORONTO; YANOFSKY C, 1966, J MOL BIOL, V21, P313, DOI 10.1016/0022-2836(66)90102-1	49	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13564	13574						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175792				2022-12-27	WOS:A1994NK18400075
J	QUINN, GB; TRIMBOLI, AJ; BARBER, MJ				QUINN, GB; TRIMBOLI, AJ; BARBER, MJ			CONSTRUCTION AND EXPRESSION OF A FLAVOCYTOCHROME B(5) CHIMERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH NITRATE REDUCTASE; NUCLEOTIDE-SEQUENCE; PROTEOLYSIS; DOMAINS; CDNA	A gene has been constructed coding for a chimeric flavocytochrome b(5) protein that comprises the soluble domain of rat hepatic cytochrome b(5) as the NH2-terminal portion of the chimera and the flavin-containing domain of spinach assimilatory NADH:nitrate reductase as the C terminus. The chimeric protein has been expressed in Escherichia coli and purified to homogeneity using a combination of ammonium sulfate precipitation, affinity chromatography on 5'-ADP-agarose, anion-exchange chromatography, and fast protein liquid chromatography gel filtration with an estimated molecular mass of 43 kDa from polyacrylamide gel electrophoresis. Visible and fluorescence spectroscopy indicated the purified protein contained both a b-type cytochrome and FAD prosthetic groups. The chimeric hemoflavoprotein immunologically cross-reacted with both anti-rat cytochrome b(5) and anti-spinach nitrate reductase polyclonal antibodies, indicating the conservation of antigenic determinants from both native domains. NH2 terminal and internal amino acid sequencing of the native and CNBr-digested protein confirmed the presence of peptides derived from both the heme- and flavin-binding portions of the sequence which were identical to the deduced amino acid sequence. The chimera exhibited both NADH:ferricyanide reductase and NADH:cytochrome c reductase activities with V-max values of 88 and 37 mu mol of NADH consumed per min/nmol of heme (mu = 0.05 and pH 7.0) and K-m values of 2.1, 32, and 1.4 mu M for NADH, ferricyanide, and cytochrome c, respectively. This work represents the first successful bacterial expression of a mammalian-plant chimeric metalloflavoprotein. The chimera exhibited properties extremely similar to those of the native cytochrome b(5) heme and spinach nitrate reductase FAD components.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA; INST BIOMOLEC SCI, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida					NIGMS NIH HHS [GM 32696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1986, J BIOL CHEM, V261, P14125; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NOTTON BA, 1989, PHYTOCHEMISTRY, V28, P2261, DOI 10.1016/S0031-9422(00)97964-0; OZOLS J, 1982, BIOCHIM BIOPHYS ACTA, V704, P163, DOI 10.1016/0167-4838(82)90143-1; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; SHIRAISHI N, 1991, PLANT CELL PHYSIOL, V32, P1031, DOI 10.1093/oxfordjournals.pcp.a078166; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1992, J BIOL CHEM, V267, P2519; UNGER BP, 1986, J BIOL CHEM, V261, P1158; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WEBER G, 1950, BIOCHEM J, V47, P114, DOI 10.1042/bj0470114	21	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13375	13381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175767				2022-12-27	WOS:A1994NK18400050
J	TELFER, A; BISHOP, SM; PHILLIPS, D; BARBER, J				TELFER, A; BISHOP, SM; PHILLIPS, D; BARBER, J			ISOLATED PHOTOSYNTHETIC REACTION-CENTER OF PHOTOSYSTEM-II AS A SENSITIZER FOR THE FORMATION OF SINGLET OXYGEN - DETECTION AND QUANTUM YIELD DETERMINATION USING A CHEMICAL TRAPPING TECHNIQUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER COMPLEX; CHLOROPHYLL-ALPHA; ELECTRON-ACCEPTOR; MOLECULAR-OXYGEN; PISUM-SATIVUM; BETA-CAROTENE; OXIDATION; LIGHT; PHOTOSENSITIZERS; CHLOROPLASTS	Singlet oxygen formation by photosystem II reaction centers isolated from Pisum sativum has been detected by two chemical trapping techniques: histidine dependent oxygen uptake and bleaching of p-nitrosodimethylaniline by the intermediary endoperoxide of histidine. The quantum yield of singlet oxygen formation determined by these methods was estimated to be 0.16 by comparison with the known quantum yields of standard singlet oxygen sensitizers. Singlet oxygen was formed on illumination of reaction centers under conditions that lead to formation of the triplet state of the primary electron donor, P680. Experiments with deuterated buffer and active oxygen scavengers indicated that singlet oxygen was the only active oxygen species produced by this reaction. Neither azide nor histidine, which are scavengers of singlet oxygen, protected against photobleaching of the chlorophyll of reaction centers that occurs concomitantly with singlet oxygen formation, suggesting that bleaching involves singlet oxygen generated within the protein matrix of the complex. Singlet oxygen sensitized exogenously by rose bengal (when excited specifically at 550 nm) was also found to bleach reaction center chlorophyll in a manner similar to the intrinsic mechanism. We conclude that singlet oxygen formed within the hydrophobic interior of the reaction center attacks the chlorophylls of P680, and presumably also amino acids in the vicinity, and that only the singlet oxygen that escapes to the medium is affected by added scavengers or deuterated medium. These experiments extend our earlier report of the detection of singlet oxygen by its luminescence at 1270 nm when isolated photosystem II reaction centers are illuminated (Macpherson, A. N., Telfer, A., Barber, J., and Truscott, T. G. (1993) Biochim. Biophys. Acta 1143, 301-309). Moreover, our results support the hypothesis that production of singlet oxygen underlies the vulnerability of photosystem II to photodamage and hence necessitates the rapid turnover of the D1 protein of the reaction center.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT CHEM, LONDON SW7 2AY, ENGLAND	Imperial College London	TELFER, A (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, AGR & FOOD RES COUNCIL, LONDON SW7 2AY, ENGLAND.							AMBROZ M, 1991, J PHOTOCH PHOTOBIO B, V9, P87, DOI 10.1016/1011-1344(91)80006-4; ANDERSON IC, 1960, PLANT PHYSIOL, V35, P531, DOI 10.1104/pp.35.4.531; ASADA K, 1987, TOPICS PHOTOSYNTHESI, V9, P227; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Barber J., 1992, P125; BARBER J, 1993, PHOTOSYNTHETICA PRAG, V27, P63; BEEBY A, 1992, INT CONGR SER, V1011, P732; BEEBY A, 1993, SCI ENG RES COUNCIL, P158; BIELSKI BHJ, 1971, J PHYS CHEM-US, V75, P2263, DOI 10.1021/j100684a006; BISHOP SM, 1993, THESIS U LONDON; BODANNES RS, 1979, FEBS LETT, V105, P195, DOI 10.1016/0014-5793(79)80609-2; BOOTH PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P141, DOI 10.1016/0005-2728(90)90053-7; CHAPMAN DJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P423, DOI 10.1016/0005-2728(88)90077-1; CHAPMAN DJ, 1989, PHOTOSYNTHETICA, V23, P411; CHAPMAN DJ, 1990, METHODS PLANT BIOCH, V5, P171; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DAVILA J, 1989, PHOTOCHEM PHOTOBIOL, V50, P29, DOI 10.1111/j.1751-1097.1989.tb04126.x; DEISENHOFER J, 1991, ANNU REV BIOPHYS BIO, V20, P247; DELASRIVAS J, 1993, BIOCHIM BIOPHYS ACTA, V1142, P155, DOI 10.1016/0005-2728(93)90097-Y; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; EGOROV SY, 1989, CHEM PHYS LETT, V163, P421, DOI 10.1016/0009-2614(89)85161-9; EGOROV SY, 1988, OPT SPEKTROSK+, V65, P899; ELSTNER EF, 1978, PLANT SCI LETT, V13, P15, DOI 10.1016/0304-4211(78)90059-7; FIREY PA, 1988, PHOTOCHEM PHOTOBIOL, V47, P615, DOI 10.1111/j.1751-1097.1988.tb02756.x; FOOTE CS, 1970, ANN NY ACAD SCI, V171, P139, DOI 10.1111/j.1749-6632.1970.tb39317.x; Foote CS., 1990, FUTURE DIRECTIONS AP, P115; Gollnick K., 1968, ADV PHOTOCHEM, V6, P1; GOUNARIS K, 1990, FEBS LETT, V265, P88, DOI 10.1016/0014-5793(90)80890-U; GRIFFITHS M, 1955, NATURE, V176, P1211, DOI 10.1038/1761211a0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAWORTH P, 1988, PLANT PHYSIOL, V86, P672, DOI 10.1104/pp.86.3.672; JOSHI PC, 1984, J INVEST DERMATOL, V82, P67, DOI 10.1111/1523-1747.ep12259146; JUNG J, 1990, PHOTOCHEM PHOTOBIOL, V52, P1003, DOI 10.1111/j.1751-1097.1990.tb01817.x; KEIR WF, 1987, PHOTOCHEM PHOTOBIOL, V46, P587, DOI 10.1111/j.1751-1097.1987.tb04818.x; KIM CS, 1993, PHOTOCHEM PHOTOBIOL, V57, P1069, DOI 10.1111/j.1751-1097.1993.tb02973.x; KLIMOV VV, 1979, DOKL AKAD NAUK SSSR+, V249, P227; KNOX JP, 1985, PHYTOCHEMISTRY, V24, P889, DOI 10.1016/S0031-9422(00)83147-7; KOBAYASHI M, 1990, FEBS LETT, V260, P138, DOI 10.1016/0014-5793(90)80086-X; KOKA P, 1978, PHOTOCHEM PHOTOBIOL, V28, P509, DOI 10.1111/j.1751-1097.1978.tb06959.x; KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x; KYLE DJ, 1987, TOPICS PHOTOSYNTHESI, V9, P197; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MATHEWS MM, 1964, NATURE, V203, P1092, DOI 10.1038/2031092a0; MAXWELL WA, 1964, PHOTOCHEM PHOTOBIOL, V5, P567; MCTAVISH H, 1989, PLANT PHYSIOL, V89, P452, DOI 10.1104/pp.89.2.452; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NILSSON R, 1972, PHOTOCHEM PHOTOBIOL, V16, P117, DOI 10.1111/j.1751-1097.1972.tb07343.x; NUGENT JHA, 1989, FEBS LETT, V255, P53, DOI 10.1016/0014-5793(89)81059-2; Okamura MY., 1987, PROGR PHOTOSYNTHESIS, V1, P379; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; ROSENTHAL I, 1986, RADIAT RES, V107, P136, DOI 10.2307/3576857; SAGER R, 1958, NATURE, V182, P98, DOI 10.1038/182098a0; SATOH K, 1981, PHOTOBIOCH PHOTOBIOP, V2, P189; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P216, DOI 10.1016/0005-2728(82)90014-7; SINGH A, 1982, CAN J PHYSIOL PHARM, V60, P1330, DOI 10.1139/y82-200; TAKAHASHI Y, 1989, FEBS LETT, V255, P133, DOI 10.1016/0014-5793(89)81076-2; TAKAHASHI Y, 1987, BIOCHIM BIOPHYS ACTA, V893, P49, DOI 10.1016/0005-2728(87)90147-2; TELFER A, 1991, BIOCHIM BIOPHYS ACTA, V1060, P106, DOI 10.1016/S0005-2728(05)80125-2; TELFER A, 1989, FEBS LETT, V246, P223, DOI 10.1016/0014-5793(89)80287-X; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VELTHUYS BR, 1981, FEBS LETT, V126, P272, DOI 10.1016/0014-5793(81)80259-1; VERLHAC JB, 1984, NOUV J CHIM, V8, P401; WILKINSON F, 1981, J PHYS CHEM REF DATA, V10, P809, DOI 10.1063/1.555655	67	211	214	2	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13244	13253						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175754				2022-12-27	WOS:A1994NK18400032
J	TOUSSAINT, C; BOUSQUETLEMERCIER, B; GARLATTI, M; HANOUNE, J; BAROUKI, R				TOUSSAINT, C; BOUSQUETLEMERCIER, B; GARLATTI, M; HANOUNE, J; BAROUKI, R			TESTIS-SPECIFIC TRANSCRIPTION START SITE IN THE ASPARTATE-AMINOTRANSFERASE HOUSEKEEPING GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MESSENGER-RNAS; TRANSGENIC MICE; MOUSE; EXPRESSION; RAT; ELEMENT; BINDING; ACID; SPERMATOGENESIS	We have studied the expression and regulation of the rat testis cytosolic aspartate aminotransferase gene. The cytosolic aspartate aminotransferase activity was 5-fold lower in the testis than in the liver and kidney. A 1.9 kilobase mRNA form was detected in the rat testis in contrast to the 2.1- and 1.8-kilobase forms present in other organs. Using Northern blot and S1 mapping analyses, we found that the proximal polyadenylation site was almost exclusively used in the testis as opposed to other organs where the distal site was preferentially used. RNase protection and primer extension analysis showed that transcription was initiated at multiple sites in all organs, but the pattern of those start sites was different in the testis; in particular, a novel transcription start site was specifically detected in this organ (at position -115 from the translation start site). This site was first observed in 29-day-old rats and was maximally utilized in the adult testis. DNase I footprinting using testis nuclear extracts revealed the presence of three sites of DNA-protein interaction in the 250-base pair proximal promoter, a pattern similar to the one found using liver nuclear extracts. However, the proteins bound had different properties as shown by gel retardation experiments. We conclude that the pattern of transcription initiation and the polyadenylation site selection of a housekeeping gene can be tissue-specific.	HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAROUKI R, 1989, EUR J BIOCHEM, V186, P79, DOI 10.1111/j.1432-1033.1989.tb15180.x; BOUSQUETLEMERCIER B, 1990, BIOCHEMISTRY-US, V29, P5293, DOI 10.1021/bi00474a011; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTEN P, 1985, TRANSAMINASES, P173; COOPER AJL, 1985, TRANSAMINASES, P534; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FABER PW, 1993, J BIOL CHEM, V268, P9296; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1989, PERSPECTIVES ANDROLO, P25; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; OBARU K, 1988, J MOL BIOL, V200, P13, DOI 10.1016/0022-2836(88)90329-4; PARLI JA, 1987, BIOCHIM BIOPHYS ACTA, V925, P175, DOI 10.1016/0304-4165(87)90107-3; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; PROSPST F, 1988, TRENDS GENET, V4, P183; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STARBORG M, 1992, MOL REPROD DEV, V33, P243, DOI 10.1002/mrd.1080330303; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WEISINGER G, 1992, J BIOL CHEM, V267, P4508; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	44	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13318	13324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175762				2022-12-27	WOS:A1994NK18400042
J	MIESBAUER, LR; ZHOU, XJ; YANG, ZC; YANG, ZY; SUN, YP; SMITH, DL; SMITH, JB				MIESBAUER, LR; ZHOU, XJ; YANG, ZC; YANG, ZY; SUN, YP; SMITH, DL; SMITH, JB			POSTTRANSLATIONAL MODIFICATIONS OF WATER-SOLUBLE HUMAN LENS CRYSTALLINS FROM YOUNG-ADULTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Post-translational modifications of the water-soluble human lens crystallins from young adult donors were identified and located using electrospray ionization mass spectrometric analysis of the intact proteins and fast atom bombardment mass spectrometry of enzymatic digests. Peptides corresponding to all of the sequences of alpha A, alpha B, and beta B2 crystallins were found, per- mitting the entire sequences to be searched for modifications. The major portions of these three crystallins were not modified. Modifications of alpha A-crystallin that were detected included 2 phosphorylated Ser residues (1 of which appears to be unique to human lenses), deamidation at some Gln and Asn residues, a disulfide bond between Cys-131 and Cys-142, and loss of the COOH-terminal Ser residue. Three phosphorylated Ser residues, but no deamidation, were found in alpha B crystallin. The molecular weights of neither the intact protein nor the peptides in the enzymatic digests indicated any post-translational modification of the principal beta-crystallin, beta B2. The molecular weights of the other beta- and gamma-crystallins for which sequences have been published suggested the presence of post-translational modifications or errors in the published sequences. Although enough peptides were found to establish the presence of specific proteins, peptides corresponding to all portions of these proteins were not found, and elucidation of these structures is not yet complete. This mass spectrometric characterization of the total water-soluble proteins from normal young adult lenses provides a reference data base for future investigations of the modifications present in aged and cataractous lenses.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA; PROCTER & GAMBLE CO, MIAMI VALLEY LABS, CINCINNATI, OH 45239 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Procter & Gamble					NEI NIH HHS [EY RO1 07609] Funding Source: Medline; NIGMS NIH HHS [GM 08298] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008298] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARTS HJM, 1989, J MOL EVOL, V28, P313, DOI 10.1007/BF02103427; AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BINDELS JG, 1981, EXP EYE RES, V33, P333, DOI 10.1016/S0014-4835(81)80056-5; BLOEMENDAL H, 1989, EXP EYE RES, V48, P465, DOI 10.1016/0014-4835(89)90029-8; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; BLOEMENDAL H, 1972, EXP EYE RES, V14, P80, DOI 10.1016/0014-4835(72)90147-9; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1987, J BIOL CHEM, V262, P1438; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; DEJONG WW, 1977, BIOCHIM BIOPHYS ACTA, V491, P573, DOI 10.1016/0005-2795(77)90303-8; DEJONG WW, 1981, NATURE, V292, P538, DOI 10.1038/292538a0; DEJONG WW, 1975, FEBS LETT, V58, P310, DOI 10.1016/0014-5793(75)80286-9; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DENDUNNEN JT, 1985, GENE, V38, P197, DOI 10.1016/0378-1119(85)90218-5; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P247, DOI 10.1016/S0065-3233(08)60066-2; HOGG D, 1986, J BIOL CHEM, V261, P2420; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KODAMA T, 1988, INVEST OPHTH VIS SCI, V29, P145; KRAMPS JA, 1977, FEBS LETT, V74, P82, DOI 10.1016/0014-5793(77)80757-6; KRAMPS JA, 1978, BIOCHIM BIOPHYS ACTA, V533, P487, DOI 10.1016/0005-2795(78)90394-X; LOO JA, 1989, ANAL BIOCHEM, V179, P404, DOI 10.1016/0003-2697(89)90153-X; Lorand L, 1988, Adv Exp Med Biol, V231, P79; LOU MF, 1989, CURR EYE RES, V8, P883; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MEAKIN SO, 1985, MOL CELL BIOL, V5, P1408, DOI 10.1128/MCB.5.6.1408; MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671; MIESBAUER LR, 1993, PROTEIN SCI, V2, P290; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OZAKI Y, 1987, J BIOL CHEM, V262, P15445; PADGAONKAR V, 1989, EXP EYE RES, V49, P887, DOI 10.1016/S0014-4835(89)80047-8; PALMER WG, 1969, P NATL ACAD SCI USA, V64, P404, DOI 10.1073/pnas.64.1.404; PARVEEN R, 1993, J PROTEIN CHEM, V12, P93, DOI 10.1007/BF01024920; PERRY RE, 1986, J CHROMATOGR, V351, P103, DOI 10.1016/S0021-9673(01)83476-2; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SIEZEN RJ, 1987, P NATL ACAD SCI USA, V84, P6088, DOI 10.1073/pnas.84.17.6088; SMITH JB, 1991, INT J MASS SPECTROM, V111, P229, DOI 10.1016/0168-1176(91)85057-S; SMITH JB, 1991, ANAL BIOCHEM, V193, P118, DOI 10.1016/0003-2697(91)90050-4; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SPECTOR A, 1978, P NATL ACAD SCI USA, V75, P3244, DOI 10.1073/pnas.75.7.3244; STEADMAN BL, 1989, BIOCHEMISTRY-US, V28, P9653, DOI 10.1021/bi00451a017; SUN YP, 1988, ANAL BIOCHEM, V172, P130, DOI 10.1016/0003-2697(88)90421-6; TAKEMOTO L, 1991, EXP EYE RES, V53, P811, DOI 10.1016/0014-4835(91)90119-Y; TAKEMOTO L, 1992, INVEST OPHTH VIS SCI, V33, P2024; TAKEMOTO LJ, 1982, INVEST OPHTH VIS SCI, V22, P336; TAKEMOTO LJ, 1993, INVEST OPHTH VIS SCI, V34, P1340; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; VANVENROOIJ WJ, 1974, EXP EYE RES, V19, P157, DOI 10.1016/0014-4835(74)90031-1; VOORTER CEM, 1989, FEBS LETT, V259, P50; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAGNER BJ, 1991, EXP EYE RES, V53, P609, DOI 10.1016/0014-4835(91)90220-9; WATSON E, 1992, J CHROMATOGR, V606, P165, DOI 10.1016/0021-9673(92)87021-Y; WEN Q, 1992, EXP EYE RES, V54, P23, DOI 10.1016/0014-4835(92)90065-Z; YAZDANPARAST R, 1987, J BIOL CHEM, V262, P2507; YU NT, 1985, P NATL ACAD SCI USA, V82, P7965, DOI 10.1073/pnas.82.23.7965; ZARINA S, 1992, BIOCHEM J, V287, P375, DOI 10.1042/bj2870375; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; ZIGLER JS, 1980, EXP EYE RES, V31, P41, DOI 10.1016/0014-4835(80)90089-5	66	173	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12494	12502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175657				2022-12-27	WOS:A1994NH71600022
J	HELBING, CC; ATKINSON, BG				HELBING, CC; ATKINSON, BG			3,5,3'-TRIIODOTHYRONINE-INDUCED CARBAMYL-PHOSPHATE SYNTHETASE GENE-EXPRESSION IS STABILIZED IN THE LIVER OF RANA-CATESBEIANA TADPOLES DURING HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ORNITHINE TRANSCARBAMYLASE; INDUCED METAMORPHOSIS; PROTEIN-SYNTHESIS; THYROID-HORMONE; CELL FERRITIN; CDNA SEQUENCE; IDENTIFICATION; ENZYME; BIOSYNTHESIS	One of many changes occurring during spontaneous and 3,5,3'-triiodothyronine (T-3) induced metamorphosis of the Rana catesbeiana tadpole is the permanent transition from an ammonotelic, aquatic larva to a ureotelic, terrestrial adult. T-3-induced urea production is preceded by T-3-induced elevation in the synthesis and level of liver-specific urea cycle enzymes essential for detoxication of ammonia in a terrestrial environment. This report focuses on establishing the effects heat shock (hs) has on the T-3-induced expression of genes encoding three essential urea cycle enzymes. We demonstrate that hs stabilizes the intracellular existing levels of carbamyl-phosphate synthetase I(CPS I), the first enzyme in the urea cycle, while concurrently depressing its new synthesis. To establish the effects of hs on CPS I mRNA levels, we characterized cDNAs encoding an amphibian CPS I and demonstrate that it may represent an evolutionary link between microbial CPS and mammalian CPS I. Using this CPS I cDNA and other R. catesbeiana gene specific probes, we demonstrate that hs depresses the level of T-3-induced thyroid hormone receptor beta mRNAs but does not affect the level of T-3-induced CPS I, ornithine transcarbamylase, and arginase mRNAs. These results support the contention that the hs response may involve the selective protection of some pre-existing mRNAs and proteins essential for an organism's survival.	UNIV WESTERN ONTARIO,WESTERN SCI CTR,DEPT ZOOL,MOLEC GENET UNIT,LONDON N6A 5B7,ON,CANADA	Western University (University of Western Ontario)				Helbing, Caren/0000-0002-8861-1070				ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; Atkinson B, 1985, CHANGES EUKARYOTIC G; ATKINSON BG, 1972, DEV BIOL, V29, P162, DOI 10.1016/0012-1606(72)90053-X; ATKINSON BG, 1993, IN PRESS PERSPECTIVE; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BROWN GW, 1959, J BIOL CHEM, V234, P1775; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COHEN PHILIP P., 1966, HARVEY LECT, V60, P119; COHEN PP, 1970, SCIENCE, V168, P533, DOI 10.1126/science.168.3931.533; COHEN PP, 1978, HORMONAL PROTEINS PE, P273; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; DIDSBURY JR, 1986, J BIOL CHEM, V261, P949; FRIEDEN E, 1961, AM ZOOL, V1, P115; FRIEDMAN KD, 1990, PCR PROTOCOLS GUIDE, P253; GALTON VA, 1991, ENDOCRINOLOGY, V129, P2298, DOI 10.1210/endo-129-5-2298; Galton VA, 1983, MOL BASIS THYROID HO, P445; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HELBING C, 1992, DEV GENET, V13, P289, DOI 10.1002/dvg.1020130406; HELBING C, 1993, THESIS U W ONTARIO L; JONES ME, 1961, ARCH BIOCHEM BIOPHYS, V95, P499, DOI 10.1016/0003-9861(61)90182-5; KETOLAPIRIE CA, 1983, CAN J BIOCHEM CELL B, V61, P462, DOI 10.1139/o83-062; KIM KH, 1968, BIOCHIM BIOPHYS ACTA, V166, P574, DOI 10.1016/0005-2787(68)90246-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MARSHALL M, 1961, J BIOL CHEM, V236, P2229; METZENBERG R, 1961, J BIOL CHEM, V236, P162; Morimoto RI, 1990, STRESS PROTEINS BIOL; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V259, P144, DOI 10.1016/0003-9861(87)90479-6; NOVER L, 1990, NATURWISSENSCHAFTEN, V77, P310, DOI 10.1007/BF01138384; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; POST LE, 1990, J BIOL CHEM, V265, P7742; POUCHELET M, 1981, BIOCHIM BIOPHYS ACTA, V654, P67, DOI 10.1016/0005-2787(81)90137-4; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RATNER S, 1973, ADV ENZYMOL RELAT AR, V39, P91; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER M, 1990, STRESS PROTEINS INDU; SHAMBAUGH GE, 1969, J BIOL CHEM, V244, P5295; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; TAKIGUCHI M, 1989, BIOESSAYS, V10, P163, DOI 10.1002/bies.950100506; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; TATA JR, 1993, J STEROID BIOCHEM, V46, P105, DOI 10.1016/0960-0760(93)90286-6; TAYLOR AC, 1946, ANAT REC, V94, P7, DOI 10.1002/ar.1090940103; WIXOM RL, 1972, J BIOL CHEM, V247, P3684; WOLFFE AP, 1984, EMBO J, V3, P2763, DOI 10.1002/j.1460-2075.1984.tb02207.x	53	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11743	11750						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163471				2022-12-27	WOS:A1994NG37700014
J	UNO, T; MOGI, T; TSUBAKI, M; NISHIMURA, Y; ANRAKU, Y				UNO, T; MOGI, T; TSUBAKI, M; NISHIMURA, Y; ANRAKU, Y			RESONANCE RAMAN AND FOURIER-TRANSFORM INFRARED STUDIES ON THE SUBUNIT-I HISTIDINE MUTANTS OF THE CYTOCHROME-BO COMPLEX IN ESCHERICHIA-COLI - MOLECULAR-STRUCTURE OF REDOX METAL CENTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; CARBON-MONOXIDE BINDING; O UBIQUINOL OXIDASE; LOW-SPIN HEME; C-OXIDASE; TERMINAL OXIDASE; QUINOL OXIDASE; COPPER; SPECTROSCOPY; SPECTRA	The cytochrome bo complex is a heme-copper terminal ubiquinol oxidase in the aerobic respiratory chain of Escherichia coli. Site directed mutagenesis studies were greatly successful in identifying ligands of the redox centers in the oxidase (Minagawa, J., Mogi, T., Gennis, R. B., and Anraku, Y. (1992) J. Biol. Chem. 267, 2096-2104). In the present study, resonance Raman and Fourier transform infrared spectroscopies were applied to the subunit I histidine mutant oxidases, and the active-site structure was studied in detail. In the dithionite-reduced state, the wild-type oxidase and the His-284 --> Ala and His-333 --> Ala mutant oxidases showed two Raman lines (nu(3)) at similar to 1492 and 1472 cm(-1), which are attributable to low- and high spin heme components, respectively. The Ala substitutions at His-106 and His-421 reduced the low-spin line, whereas the His-419 --> Ala mutation eliminated the high-spin line. This indicates that His-106 and His-421 are the axial ligands of the low-spin heme B, while His-419 acts as a proximal ligand of the high-spin heme O. The nu(Fe-CO) stretching frequency in the wild-type oxidase down-shifted from 523 to 498 cm(-1) in Cu-B-deficient mutant oxidase (His-333 --> Ala), while the nu(C-O) stretching frequency up shifted from 1960 to 1970 cm(-1). These frequency differences were ascribed to the contribution from the reduced Cu-B at binuclear center. It may indicate that delocalization of electrons at the Cu-B center toward the heme O iron is facilitated by a bridge ligand structure at the binuclear center and is essential for driving dioxygen reduction chemistry, and therefore, redox coupled proton pumping.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Tokushima University; University of Hyogo; Yokohama City University			Uno, Tadayuki/E-1622-2013	Uno, Tadayuki/0000-0003-2056-5781; Nishimura, Yoshifumi/0000-0002-5148-3458				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ADAR F, 1978, BIOCHIM BIOPHYS ACTA, V502, P80, DOI 10.1016/0005-2728(78)90133-0; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BISSON R, 1990, BIOELECTROCHEMISTRY, P125; CAUGHEY WS, 1976, ENZYMES, V13, P299; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; DYER RB, 1989, J AM CHEM SOC, V111, P7657, DOI 10.1021/ja00201a080; DYER RB, 1991, J AM CHEM SOC, V113, P6276, DOI 10.1021/ja00016a057; DYER RB, 1989, J AM CHEM SOC, V111, P8962, DOI 10.1021/ja00206a053; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P13641; FIAMINGO FG, 1982, J BIOL CHEM, V257, P1639; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; INGLEDEW WJ, 1991, BIOCHEM SOC T, V19, P613, DOI 10.1042/bst0190613; KERR EA, 1983, BIOCHEMISTRY-US, V22, P4373, DOI 10.1021/bi00288a005; KERR EA, 1984, THESIS GEORGIA I TEC; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; MAKINO R, 1986, J BIOL CHEM, V261, P8376; MATSUSHITA K, 1983, P NATL ACAD SCI-BIOL, V80, P4889, DOI 10.1073/pnas.80.16.4889; MATSUSHITA K, 1992, J BACTERIOL, V174, P122, DOI 10.1128/jb.174.1.122-129.1992; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINAGAWA J, 1992, THESIS U TOKYO; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKAMURA H, 1990, THESIS U TOKYO; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; OGURA T, 1991, B CHEM SOC JPN, V64, P2901, DOI 10.1246/bcsj.64.2901; OHNISHI T, 1989, J BIOL CHEM, V264, P735; PARTHASARATHI N, 1987, J AM CHEM SOC, V109, P3865, DOI 10.1021/ja00247a009; PENG SM, 1976, J AM CHEM SOC, V98, P8032, DOI 10.1021/ja00441a025; POWERS L, 1981, BIOPHYS J, V34, P465, DOI 10.1016/S0006-3495(81)84863-1; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SHAPLEIGH JP, 1992, J BACTERIOL, V174, P2338, DOI 10.1128/JB.174.7.2338-2343.1992; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4789; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SPAULDING LD, 1975, J AM CHEM SOC, V97, P2517, DOI 10.1021/ja00842a032; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SPIRO TG, 1985, ADV PROTEIN CHEM, V37, P111, DOI 10.1016/S0065-3233(08)60064-9; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1992, BIOPHYS J, V63, P1564, DOI 10.1016/S0006-3495(92)81747-2; TSUBAKI M, 1986, BIOCHEMISTRY-US, V25, P3563, DOI 10.1021/bi00360a014; TSUBAKI M, 1985, BIOCHIM BIOPHYS ACTA, V827, P268, DOI 10.1016/0167-4838(85)90211-0; UNO T, 1985, J BIOL CHEM, V260, P6755; UNO T, 1987, J BIOL CHEM, V262, P4549; UNO T, 1985, J BIOL CHEM, V260, P2023; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945; YU NT, 1986, METHOD ENZYMOL, V130, P350; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028	71	42	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11912	11920						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163490				2022-12-27	WOS:A1994NG37700038
J	ADLER, V; UNLAP, T; KRAFT, AS				ADLER, V; UNLAP, T; KRAFT, AS			A PEPTIDE ENCODING THE C-JUN DELTA-DOMAIN INHIBITS THE ACTIVITY OF A C-JUN AMINO-TERMINAL PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; V-JUN; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION; ONCOGENE; AP-1; MEMBER; FAMILY	Evidence suggests that the c-Jun protooncogene delta (delta) domain (amino acids 31-60) helps regulate the transcriptional activating capacity of c-Jun by modulating the amino-terminal phosphorylation of this protein. By using a peptide encoding the delta domain and purified amino-terminal c-Jun protein kinase, we demonstrate that the delta domain peptide inhibits phosphorylation of the amino terminus of both c-Jun and the related protein JunD. The delta domain peptide inhibited the activation of the c-Jun amino-terminal protein kinase by phorbol esters in permeabilized U937 leukemic cells. Mutation of c-Jun followed by transfection into U937 leukemic cells demonstrated that partial deletions of the delta domain are sufficient to block phosphorylation of the amino terminus of c-Jun. In vitro deletion of the amino-terminal (amino acids 31-44) half of the delta domain inhibited the phosphorylation of c-Jun. However, deletion of the carboxyl-terminal (amino acids 45-60) half only partially inhibited c-Jun phosphorylation. Therefore, these results indicate that the delta domain sequence is an important regulator of c-Jun amino-terminal phosphorylation.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; DEFIZE LHK, 1993, J CELL BIOCHEM, V17, P298; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507	20	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11186	11191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157646				2022-12-27	WOS:A1994NF96600034
J	CAMERON, CE; RIDKY, TW; SHULENIN, S; LEIS, J; WEBER, IT; COPELAND, T; WLODAWER, A; BURSTEIN, H; BIZUBBENDER, D; SKALKA, AM				CAMERON, CE; RIDKY, TW; SHULENIN, S; LEIS, J; WEBER, IT; COPELAND, T; WLODAWER, A; BURSTEIN, H; BIZUBBENDER, D; SKALKA, AM			MUTATIONAL ANALYSIS OF THE SUBSTRATE-BINDING POCKETS OF THE ROUS-SARCOMA VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN RETROVIRAL PROTEASE; HIV-1 PROTEASE; POL POLYPROTEINS; TYPE-1 PROTEASE; RESOLUTION; INHIBITOR; COMPLEX; GAG; CLEAVAGE; PROTEINS	Mutations, designed by analysis of the crystal structures of Rous sarcoma virus (RSV) and human immunodeficiency virus type 1 (HIV-1) protease (PR), were introduced into the substrate binding pocket of RSV PR. The mutations substituted nonconserved residues of RSV PR, located within 10 angstrom of the substrate, for those in structurally equivalent positions of HIV-1 PR. Changes in the activity of purified mutants were detected in vitro by following cleavage of synthetic peptides representing wild-type and modified RSV and HIV-1 gag and pol polyprotein cleavage sites. Substituting threonine for valine 104 (V104T), S107N, I44V, Q63M or deletion of residues 61-63 produced enzymes that were 2.5-7-fold more active than the wild type RSV PR. Substituting I42D, M73V, and A100L produced enzymes with lower activity, whereas a mutant that included both M73V and A100L was as active as wild type. Several substitutions altered the specificity for substrate. These include I42D and I44V, which contribute to the S2 and S2' subsites. These proteins exhibited HIV-1 PR specificity for P2- or P2'-modified peptide substrates but unchanged specificity with P4-, P3-, P1-, P1'-, and P3'-modified substrates. Changes in specificity in the S4 subsite were detected by deletion of residues 61-63. These results confirm the hypothesis that the subsites of the substrate binding pocket of the retroviral protease are capable of acting independently in the selection of substrate amino acids.	CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LAB,BASIC RES PROGRAM,FREDERICK,MD 21702; FOX CHASE CANC CTR,INST CANC,PHILADELPHIA,PA 19111	Case Western Reserve University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Fox Chase Cancer Center					NCI NIH HHS [CA06937, CA47486, R01 CA052047, CA52047, R01 CA052047-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052047, R35CA047486] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BIZUB D, 1991, J BIOL CHEM, V266, P4951; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; CAMERON CE, 1992, J BIOL CHEM, V267, P23735; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRINDE B, 1992, J BIOL CHEM, V267, P9481; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GUSTCHINA A, 1994, INPRESS PROTEIN ENG; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KENT S, 1989, CURRENT COMMUNICATIO, P223; KOHL N, 1988, P NATL ACAD SCI USA, V85, P4185; KOTLER M, 1989, J BIOL CHEM, V264, P3428; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008	25	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11170	11177						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157644				2022-12-27	WOS:A1994NF96600032
J	JAISWAL, AK				JAISWAL, AK			HUMAN NAD(P)H-QUINONE OXIDOREDUCTASE(2) - GENE STRUCTURE, ACTIVITY, AND TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; PLANAR AROMATIC-COMPOUNDS; QUINONE REDUCTASE; OXIDATIVE STRESS; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; OXIDOREDUCTASE GENE; DT-DIAPHORASE; NAD(P)H	Human NAD(P)H:quinone oxidoreductase, (NQO(2)) gene, 1336 base pairs (bp) of the 5'-flanking region and 165 bp of the 3'-flanking region, have been sequenced. NQO(2) gene is 20 kilobase pairs in length and has seven exons interrupted by six introns as compared to the previously cloned NQO(1) gene which contains six exons. 187 bp of the first exon in the NQO(2) gene are noncoding and are absent in the NQO(1) gene. 92 bp of the second exon in the NQO(2) gene corresponded to the first exon of the NQO(1) gene and so on. The sizes and nucleotide sequences of exons 3-6 are highly conserved between NQO(2) and NQO(1) genes. The last exon in the NQO(2) gene is 1603 bp shorter than the last exon of the NQO(1) gene and encodes for 58 amino acids as compared to 101 amino acids encoded by the NQO(1) gene. This makes NQO(2) protein 43 amino acids shorter than the NQO(1) protein. The high degree of conservation between NQO(2) and NQO(1) gene organization and sequence confirmed that NQO(2) gene encodes for a second member of the NQO gene family in human. Nucleotide sequence analysis of the 5'-flanking region of the NQO(2) gene revealed presence of four SP1 binding sites at positions -214, -170, -106, and -75, a single copy of the antioxidant response element (ARE) at nucleotide -936, and three copies of xenobiotic response element (XRE) at positions -708, -557, and -51. ARE and XRE elements have previously been found in the promoters of the NQO(1) and glutathione S-transferase Ya subunit genes and mediate increases in their expression in response to polycyclic aromatic compounds, phenolic antioxidants, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), respectively. The NQO(2) cDNA-derived protein in monkey kidney COS1 cells efficiently catalyzed nitroreduction of anti-tumor compound CB10-200, an analog of nitrophenylaziridine. Northern blot analysis indicates that NQO(2) gene is expressed in human heart, brain, lung, liver, and skeletal muscle but does not express in placenta. In contrast, the NQO(1) gene was expressed in all human tissues. Large variations were noticed for expression of the NQO(2) and NQO(1) genes among various tissues. 1336 bp of the 5'-flanking region of the NQO(2) gene containing ARE and XRE was found sufficient to increase expression of the CAT gene in response to beta-naphthoflavone and TCDD in transfected human hepatoblastoma (Hep-G2) cells.			JAISWAL, AK (corresponding author), FOX CHASE CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19111, USA.				NIGMS NIH HHS [GM 47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSUBEL FM, 1989, CURRENT PROTOCOLS MO; BAYNEY RM, 1989, J BIOL CHEM, V264, P21793; BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIES LG, 1980, BASIC METHODS MOL BI, P244; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DENNINGER PL, 1983, ANAL BIOCHEM, V129, P216; EDWARDS YH, 1980, BIOCHEM J, V187, P429, DOI 10.1042/bj1870429; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KHAN AH, 1971, CHEM-BIOL INTERACT, V4, P11, DOI 10.1016/0009-2797(71)90029-9; KNOX RJ, 1988, BIOCHEM PHARMACOL, V37, P4671, DOI 10.1016/0006-2952(88)90336-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1992, BIOCHEM BIOPH RES CO, V188, P992, DOI 10.1016/0006-291X(92)91329-O; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SAL GD, 1989, BIOTECHNIQUES, V7, P514; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEGERS J, 1985, PROTIDES BIOL FLUIDS, V33, P589; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKACS B, 1979, IMMUNOLOGICAL METHOD, P69; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P1157; TALALAY P, 1992, CANCER BIOL THERAPEU, P197; THOR H, 1982, J BIOL CHEM, V257, P2419; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	46	99	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14502	14508						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182056				2022-12-27	WOS:A1994NM06500032
J	BURNS, CM; SAKAGUCHI, K; APPELLA, E; ASHWELL, JD				BURNS, CM; SAKAGUCHI, K; APPELLA, E; ASHWELL, JD			CD45 REGULATION OF TYROSINE PHOSPHORYLATION AND ENZYME-ACTIVITY OF SRC FAMILY KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ZETA-CHAIN; PHOSPHOTYROSINE PHOSPHATASE; CATALYTIC ACTIVITY; SURFACE-ANTIGENS; MICE LACKING; T-CELLS	Previous analyses have suggested that the CD45 tyrosine phosphatase activates src family tyrosine kinases p56(lck) and p59(fyn) by dephosphorylating regulatory COOH-terminal residues. We have examined the status of p56(lck) and p59(fyn) in murine and human CD45(-) T cell lines. Surprisingly, despite the fact that p56(lck) and p59(fyn) were spontaneously hyperphosphorylated, the tyrosine kinase activity of both enzymes was increased in CD45(-) versus CD45(+) cells. In vitro exposure of hyperphosphorylated p56(lck) to CD45 decreased enzyme activity to near-basal levels. Lck from CD45(-) cells was hyperphosphorylated on the cyanogen bromide digestion fragment that contains the negative regulatory residue Tyr-505, and the identity of this site of phosphorylation was confirmed by trypsin digestion followed by high performance liquid chromatography. Loss of CD45 results, therefore, in a paradoxical hyperphosphorylation of the COOH-terminal tyrosine and increased src family kinase enzymatic activity.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BURNS, CM (corresponding author), NCI, BIOL RESPONSE MODIFIERS PROGRAM, IMMUNE CELL BIOL LAB, BETHESDA, MD 20892 USA.			Sakaguchi, Kazuyasu/0000-0002-8434-4171				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNS CM, 1993, CURR BIOL, V3, P97, DOI 10.1016/0960-9822(93)90164-J; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; EISEMAN E, 1992, NATURE, V355, P78; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KITAS EA, 1990, J ORG CHEM, V55, P4181, DOI 10.1021/jo00300a041; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, ONCOGENES, P121; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415	49	95	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13594	13600						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175795				2022-12-27	WOS:A1994NK18400078
J	JAFFE, AB; TORANALLERAND, CD; GREENGARD, P; GANDY, SE				JAFFE, AB; TORANALLERAND, CD; GREENGARD, P; GANDY, SE			ESTROGEN REGULATES METABOLISM OF ALZHEIMER AMYLOID-BETA PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-BREAST-CANCER; CELL-LINES; DISEASE; GROWTH; PREVALENCE; DEMENTIA; PEPTIDE; PHOSPHORYLATION; IDENTIFICATION; SECRETION	We have investigated the possible effect of estrogen on the metabolism of the Alzheimer amyloid precursor protein (APP). Using a cell line that contains high levels of estrogen receptors, we have found that treatment with physiological concentrations of 17 beta-estradiol is associated with accumulation in the conditioned medium of an amino-terminal cleavage product of APP (soluble APP or protease nexin-2), indicative of non-amyloidogenic processing. There were no obvious changes in the levels of intracellular immature or mature APP holoproteins, suggesting that estrogen may increase the secretory metabolism of APP.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Cornell University; Rockefeller University; Columbia University					NATIONAL INSTITUTE ON AGING [P01AG009464, P01AG010491, R01AG011508, R55AG011508] Funding Source: NIH RePORTER; NIA NIH HHS [AG09464, AG 10491, AG 11508] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLERAND CDT, 1991, NEW BIOL STEROID HOR, P311; ALLERAND CDT, 1992, P NATL ACAD SCI USA, P4668; ALLERAND CDT, 1992, BRAIN RES, V576, P25; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; BARCLAY LL, 1985, NEUROLOGY, V35, P834, DOI 10.1212/WNL.35.6.834; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; DICKSON RB, 1986, ENDOCRINOLOGY, V118, P138, DOI 10.1210/endo-118-1-138; DICKSON RB, 1986, CANCER RES, V46, P1707; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DROUVA SV, 1990, ENDOCRINOLOGY, V126, P536, DOI 10.1210/endo-126-1-536; DUARA R, 1993, NEUROLOGY, V43, P1377, DOI 10.1212/WNL.43.7.1377; ENGEL LW, 1978, CANCER RES, V38, P3352; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FEINGOLD KR, 1990, CECILS ESSENTIALS ME, P478; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FUKUYAMA R, 1993, MOL BRAIN RES, V17, P17, DOI 10.1016/0169-328X(93)90067-Y; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDERSON VW, 1994, IN PRESS ARCH NEUROL; KAMEL F, 1988, AM J PHYSIOL-ENDOC M, V255, P314; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LIPPMAN ME, 1988, J STEROID BIOCHEM, V30, P53, DOI 10.1016/0022-4731(88)90076-3; MAEDA T, 1993, LAB INVEST, V68, P472; MAIZELS ET, 1992, J BIOL CHEM, V267, P17061; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; MIRANDA RC, 1993, MOL CELL NEUROSCI, V4, P510, DOI 10.1006/mcne.1993.1063; MOLSA PK, 1982, ACTA NEUROL SCAND, V65, P541; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; RUEDL C, 1990, J STEROID BIOCHEM, V37, P195, DOI 10.1016/0960-0760(90)90327-H; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Singh M., 1993, Society for Neuroscience Abstracts, V19, P1254; SINHA S, 1992, NEURODEGENERATION, V1, P169; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STAM FC, 1986, PATHOL RES PRACT, V181, P558, DOI 10.1016/S0344-0338(86)80149-2; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; Tomlinson B.E., 1992, GREENFIELDS NEUROPAT, P1284; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; YU ESH, 1989, J GERONTOL, V44, pS97, DOI 10.1093/geronj/44.3.S97; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412	64	316	325	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13065	13068						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175728				2022-12-27	WOS:A1994NK18400003
J	KEPHART, DD; WANG, BQ; BURTON, ZF; PRICE, DH				KEPHART, DD; WANG, BQ; BURTON, ZF; PRICE, DH			FUNCTIONAL-ANALYSIS OF DROSOPHILA FACTOR-5 (TFIIF), A GENERAL TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; INITIATION-FACTOR; PREINITIATION COMPLEX; ELONGATION COMPLEXES; SUBUNIT; BINDS; DNA; IDENTIFICATION; FRACTIONATION; PURIFICATION	Factor 5 is a Drosophila RNA polymerase II initiation factor that also affects the elongation phase of transcription. We have used a cDNA encoding the large subunit of factor 5 (F5a) to produce recombinant F5a (rF5a). Antibodies directed against peptides deduced from the sequence of the F5a cDNA recognized rF5a and the large subunit of factor 5 purified from Kc cells. A chimeric human/fly factor composed of the small subunit of human TFIIF (RAP30) and rF5a stimulated elongation by Drosophila RNA polymerase II when assayed using a dC-tailed template. In addition, the chimeric human/fly factor functioned during initiation in either the Drosophila or human system. Therefore, the structure of the large subunit of TFIIF is sufficiently conserved from human to fly to allow functional interaction with both the small subunit of TFIIF and RNA polymerase II from either species. Analysis of deletion mutants of F5a indicated that almost all of the protein was required for initiation while only the NH2-terminal region was required for stimulating transcriptional elongation. A comparison of our results with those obtained with RAP74 suggest that the carboxyl terminal region of the protein may be involved in interactions with RNA polymerase II or other factors during initiation.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,AGR EXPT STN,E LANSING,MI 48824	University of Iowa; Michigan State University; Michigan State University; Michigan State University AgBioResearch			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500, R01GM040708] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40708, GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GONG DW, 1992, NUCLEIC ACIDS RES, V20, P6414, DOI 10.1093/nar/20.23.6414; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KEPHART DD, 1993, NUCLEIC ACIDS RES, V21, P1319, DOI 10.1093/nar/21.5.1319; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1984, CELL, V38, P423, DOI 10.1016/0092-8674(84)90497-5; PRICE DH, 1987, J BIOL CHEM, V262, P3244; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273	35	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13536	13543						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175788				2022-12-27	WOS:A1994NK18400071
J	KIM, U; GARNER, TL; SANFORD, T; SPEICHER, D; MURRAY, JM; NISHIKURA, K				KIM, U; GARNER, TL; SANFORD, T; SPEICHER, D; MURRAY, JM; NISHIKURA, K			PURIFICATION AND CHARACTERIZATION OF DOUBLE-STRANDED-RNA ADENOSINE-DEAMINASE FROM BOVINE NUCLEAR EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDING MODIFYING ACTIVITY; BIASED HYPERMUTATION; POLYACRYLAMIDE GELS; MEASLES VIRUSES; MAMMALIAN-CELLS; REV PROTEIN; BINDING; SEQUENCE; INVITRO; INOSINE	The double-stranded RNA (dsRNA) adenosine deaminase (DRADA) deaminates adenosine residues to inosines and creates I-U mismatched base pairs in dsRNAs. Its involvement in RNA editing of glutamate-gated ion channel gene transcripts in mammalian brains has been proposed as one of the biological functions for this recently identified cellular enzyme. We purified a mixture of three forms, 93, 88, and 83 kDa, of bovine DRADA proteins, all likely to be active enzymes. We determined that DRADA has a native molecular mass of approximately 100 kDa, suggesting that the enzyme exists as a monomer. The purified enzyme was not inhibited by 2'-deoxycoformycin, a transition state analog inhibitor of adenosine deaminase and AMP deaminase, suggesting that the catalytic mechanism of DRADA might be different from that of other deaminases. DRADA binds specifically to dsRNA with a dissociation constant of 0.23 nM for a synthetic dsRNA, and the Michaelis constant is 0.85 nM. These values indicate that DRADA has a much higher affinity for its substrate than other deaminases such as adenosine deaminase and AMP deaminase. DRADA may need this extremely high affinity to catalyze efficiently the modification of relatively rare substrate RNAs in the cell nucleus.	UNIV PENN, SCH MED, WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH DENT MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA10815] Funding Source: Medline; NIGMS NIH HHS [GM40536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL RP, 1975, BIOCHEM PHARMACOL, V24, P693, DOI 10.1016/0006-2952(75)90245-2; AGARWAL RP, 1977, BIOCHEM PHARMACOL, V26, P359, DOI 10.1016/0006-2952(77)90192-7; BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1989, CELL, V56, P331, DOI 10.1016/0092-8674(89)90234-1; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BURK RR, 1983, METHOD ENZYMOL, V91, P247; CATIGNOL A, 1993, MOL CELL BIOL, V13, P2193; CATTANEO R, 1989, VIROLOGY, V173, P415, DOI 10.1016/0042-6822(89)90554-0; CATTANEO R, 1988, CELL, V55, P255, DOI 10.1016/0092-8674(88)90048-7; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GROSSHANS J, 1993, BIOCHIM BIOPHYS ACTA, V1161, P28, DOI 10.1016/0167-4838(93)90191-S; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HODGES P, 1993, RNA EDITING ALTERATI, P125; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RA, 1989, NATURE, V337, P19, DOI 10.1038/337019a0; Lomant A J, 1975, Prog Nucleic Acid Res Mol Biol, V15, P185, DOI 10.1016/S0079-6603(08)60120-8; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MARGOLIASH E, 1962, J BIOL CHEM, V237, P3397; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHARA PJ, 1984, CELL, V36, P915, DOI 10.1016/0092-8674(84)90041-2; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; THAKKAR JK, 1993, BIOCHEM J, V290, P335, DOI 10.1042/bj2900335; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WANG AC, 1971, J MOL BIOL, V62, P591, DOI 10.1016/0022-2836(71)90158-6; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WOO PWK, 1974, J HETEROCYCLIC CHEM, V11, P641, DOI 10.1002/jhet.5570110438; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	47	106	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13480	13489						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175781				2022-12-27	WOS:A1994NK18400064
J	YASUHARA, T; NAKAI, T; OHASHI, A				YASUHARA, T; NAKAI, T; OHASHI, A			AMINOPEPTIDASE-Y, A NEW AMINOPEPTIDASE FROM SACCHAROMYCES-CEREVISIAE - PURIFICATION, PROPERTIES, LOCALIZATION, AND PROCESSING BY PROTEASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST VACUOLE LYSOSOME; PROTEINASE YSCB; PRECURSOR; ENZYMES; DEGRADATION; BIOGENESIS; MATURATION; ACTIVATION; CATALYSTS; HYDROLASE	A novel aminopeptidase, termed aminopeptidase Y, was purified from yeast, Saccharomyces cerevisiae, as two molecular forms of 70 and 75 kDa, which were identical immunologically, catalytically and in N-terminal sequence up to 14 residues. They contained 0.81 and 0.84 mol of zinc atom/mol of protein, respectively. N-G1ycanase generated a single 53-kDa species from both forms, and endoglycosidase H gave a 54-kDa species. Immunoblotting after subcellular fractionation showed that aminopeptidase Y is localized in the vacuole/lysosome-soluble compartment as the 70-kDa form. Aminopeptidase Y hydrolyzed all amino acid-4-methylcoumaryl-7-amides (MCA) examined, especially Lys- and Arg-MCA Dipeptidyl-MCAs were far more rapidly hydrolyzed (Lys-Ala-MCA/Lys-MCA = 350-fold, Arg-Arg-MCA/Arg-MCA = 150-fold). Hydrolysis of amino acid-MCAs or dipeptides was markedly enhanced by Co2+, whereas that of dipeptidyl-MCAs, tripeptides, and larger peptides was inhibited. Rabbit anti-aminopeptidase Y antiserum adsorbed over half the aminopeptidase activities in vacuolar extract from wild-type yeast cells. ABYS1 mutant cells from which the genes of four vacuolar proteases had been deleted contained aminopeptidase Y as a 74-kDa preform. This was converted to the mature form (70 kDa) by vacuolar extract of wild-type cells and by purified yeast vacuolar protease B.	MEIJI INST HLTH SCI,ODAWARA 250,JAPAN									ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Ben-Bassat A., 1987, NATURE, V326, P315; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FREY J, 1979, EUR J BIOCHEM, V97, P169, DOI 10.1111/j.1432-1033.1979.tb13099.x; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HANSEN RJ, 1977, BIOCHIM BIOPHYS ACTA, V496, P103, DOI 10.1016/0304-4165(77)90119-2; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HIRSCH HH, 1992, EUR J BIOCHEM, V203, P641, DOI 10.1111/j.1432-1033.1992.tb16594.x; HUBERWALCHLI V, 1979, ARCH MICROBIOL, V120, P141, DOI 10.1007/BF00409100; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; LABBE P, 1977, ANAL BIOCHEM, V81, P416, DOI 10.1016/0003-2697(77)90712-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON TL, 1973, J BIOL CHEM, V248, P1346; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MECHLER B, 1982, BIOCHEM BIOPH RES CO, V107, P770, DOI 10.1016/0006-291X(82)90590-3; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NISHIZAWA M, 1994, J BIOL CHEM, V269, P13651; OHASHI A, 1980, J BIOL CHEM, V255, P7740; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; RIORDAN JF, 1984, METHOD ENZYMAT AN, V5, P44; SAHEKI T, 1975, BIOCHIM BIOPHYS ACTA, V384, P203, DOI 10.1016/0005-2744(75)90109-6; SAHEKI T, 1974, EUR J BIOCHEM, V42, P621, DOI 10.1111/j.1432-1033.1974.tb03377.x; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; Strobel H W, 1978, Methods Enzymol, V52, P89; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WEINER S, 1981, J CHROMATOGR, V213, P501, DOI 10.1016/S0021-9673(00)80501-4; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; YASUHARA T, 1990, J BIOCHEM-TOKYO, V107, P273, DOI 10.1093/oxfordjournals.jbchem.a123038	36	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13644	13650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175799				2022-12-27	WOS:A1994NK18400085
J	KONG, XM; MANCHESTER, J; SALMONS, S; LAWRENCE, JC				KONG, XM; MANCHESTER, J; SALMONS, S; LAWRENCE, JC			GLUCOSE TRANSPORTERS IN SINGLE SKELETAL-MUSCLE FIBERS - RELATIONSHIP TO HEXOKINASE AND REGULATION BY CONTRACTILE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Glucose transport and phosphorylation are the first steps in the utilization of extracellular glucose by skeletal muscle. We have examined the relationships between proteins mediating these steps in single fibers of identified type dissected from rabbit skeletal muscle. The level of the glucose transporter isoform GLUT4, measured by immunoblotting, varied among fibers by a factor of 20 (slow oxidative > fast oxidative glycolytic > fast glycolytic). In fibers from the tibialis anterior muscle, GLUT4 was correlated (r(2) = 0.75) with the activity of malate dehydrogenase, an enzyme representative of oxidative energy metabolism. In these fibers a strong correlation (r(2) = 0.70) was also observed between GLUT4 and hexokinase activity. GLUT1 levels were barely detectable, regardless of fiber type. To investigate the possible role of muscle activity in controlling the expression of transporters, tibialis anterior muscles were activated by chronic electrical stimulation of the peroneal nerves. GLUT1 levels increased after 1 day of stimulation to a plateau that was severalfold higher than the level in non-stimulated cells. Hexokinase activity and the GLUT4 level changed in parallel: both were increased by approximately 2.5-fold after 1 day and by 14-fold after 21 days. Thus, while both GLUT1 and GLUT4 were regulated by muscle activity, only GLUT4 expression was coordinated with the expression of hexokinase.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; UNIV LIVERPOOL, SCH MED, DEPT HUMAN ANAT & CELL BIOL, LIVERPOOL L69 3BX, ENGLAND	Washington University (WUSTL); University of Liverpool					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BERGER M, 1975, BIOCHEM J, V146, P231, DOI 10.1042/bj1460231; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHI MMY, 1986, AM J PHYSIOL, V251, pC633, DOI 10.1152/ajpcell.1986.251.4.C633; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; CRANE RK, 1954, J BIOL CHEM, V210, P597; DANIEL PM, 1975, J PHYSIOL-LONDON, V247, P273, DOI 10.1113/jphysiol.1975.sp010931; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HARLOW E, 1988, ANTIBODIES; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HENRIKSSON J, 1988, AM J PHYSIOL, V255, pC543, DOI 10.1152/ajpcell.1988.255.4.C543; HENRIKSSON J, 1986, AM J PHYSIOL, V251, pC614, DOI 10.1152/ajpcell.1986.251.4.C614; HINTZ CS, 1984, J HISTOCHEM CYTOCHEM, V32, P655, DOI 10.1177/32.6.6202737; HINTZ CS, 1982, AM J PHYSIOL, V242, pC218, DOI 10.1152/ajpcell.1982.242.3.C218; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; LAWRENCE JC, 1986, J BIOL CHEM, V261, P8556; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LOWRY OH, 1992, FLEXIBLE SYSTEM ENZY; LUECK JD, 1974, J BIOL CHEM, V249, P1341; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; NEUFER PD, 1992, CAN J PHYSIOL PHARM, V70, P1286, DOI 10.1139/y92-178; PARK CR, 1968, J GEN PHYSIOL, V52, pS296, DOI 10.1085/jgp.52.1.296; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PETTE D, 1975, PFLUG ARCH EUR J PHY, V361, P1, DOI 10.1007/BF00587333; PETTE D, 1973, PFLUG ARCH EUR J PHY, V338, P257, DOI 10.1007/BF00587391; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REICHMANN H, 1985, PFLUGERS ARCH, V412, P1; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; SALMONS S, 1969, J PHYSIOL-LONDON, V201, P535, DOI 10.1113/jphysiol.1969.sp008771; SALMONS S, 1991, MED BIOL ENG COMPUT, V29, P554, DOI 10.1007/BF02442330; SIMONEAU JA, 1988, PFLUG ARCH EUR J PHY, V412, P86, DOI 10.1007/BF00583735; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; WEBER FE, 1990, EUR J BIOCHEM, V191, P85, DOI 10.1111/j.1432-1033.1990.tb19096.x; WEBER FE, 1988, FEBS LETT, V238, P71, DOI 10.1016/0014-5793(88)80227-8; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	48	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12963	12967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175714				2022-12-27	WOS:A1994NH71600089
J	KRYSTEK, SR; PATEL, PS; ROSE, PM; FISHER, SM; KIENZLE, BK; LACH, DA; LIU, ECK; LYNCH, JS; NOVOTNY, J; WEBB, ML				KRYSTEK, SR; PATEL, PS; ROSE, PM; FISHER, SM; KIENZLE, BK; LACH, DA; LIU, ECK; LYNCH, JS; NOVOTNY, J; WEBB, ML			MUTATION OF PEPTIDE BINDING-SITE IN TRANSMEMBRANE REGION OF A G-PROTEIN-COUPLED RECEPTOR ACCOUNTS FOR ENDOTHELIN RECEPTOR SUBTYPE SELECTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; VASOCONSTRICTOR PEPTIDE; 3-DIMENSIONAL STRUCTURE; RAT ENDOTHELIN; LIGAND-BINDING; DOMAIN; IDENTIFICATION; ANTAGONISTS; CLONING; BACTERIORHODOPSIN	The molecular basis for endothelin (ET) isopeptide selectivity between ET(A) and ET(B) receptors was studied by examining ligand binding to several site-specific mutants of the human ET(A) receptor. Based on a computer-built three-dimensional model of the ET(A) receptor, five non-conserved amino acids, clustered around the putative ligand binding site, were targeted for mutation to alanine. Expression of the wild-type and mutant ET(A) receptors in COS-7 cells revealed that the binding profile of one of the ET(A) mutants, Tyr(129) --> Ala, was characteristic of the ET(B) receptor. In the Tyr(129) --> Ala ET(A) receptor mutant the affinity of two ET(B)-selective agonists, endothelin-3 and sarafotoxin S6c, was increased 10-200-fold, whereas that for two ET(A)-selective antagonists, BQ-123 and BMS-182874, was reduced 350-2,000-fold. Thus, mutation of a single amino acid in the second transmembrane region of the wild-type ET(A) receptor results in subtype conversion. In addition, these data represent the first example of peptide interactions with a transmembrane region of a G protein-coupled receptor and indicate that Tyr(129), located in the second transmembrane region of the ET(A) receptor, is a critical component for determination of endothelin receptor subtype-selective ligand binding.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT CARDIOVASC BIOCHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC MODELING,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MICROBIAL MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb								ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BRUCCOLERI RE, 1993, MOL SIMULAT, V10, P151, DOI 10.1080/08927029308022163; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CRONET P, 1993, PROTEIN ENG, V6, P59, DOI 10.1093/protein/6.1.59; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; FONG TM, 1993, NATURE, V362, P350; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HAYZER DJ, 1992, AM J MED SCI, V304, P231, DOI 10.1097/00000441-199210000-00002; HUGGINS JP, 1993, EUR J PHARM-MOLEC PH, V245, P203, DOI 10.1016/0922-4106(93)90098-T; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MARTIN ER, 1989, BIOCHEM BIOPH RES CO, V162, P130, DOI 10.1016/0006-291X(89)91972-4; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RIEK P, 1991, FASEB J, V5, pA396; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SECREST RJ, 1989, LIFE SCI, V45, P1365, DOI 10.1016/0024-3205(89)90023-4; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; STEIN PD, 1994, J MED CHEM, V37, P329, DOI 10.1021/jm00029a001; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOTA MR, 1990, J BIOL CHEM, V265, P16891; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; WEBB ML, 1993, MOL PHARMACOL, V44, P959; WEBER H, 1994, MOL ENDOCRINOL, V8, P148, DOI 10.1210/me.8.2.148; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1988, P NATL ACAD SCI USA, V85, P6964, DOI 10.1073/pnas.85.18.6964	47	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12383	12386						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175640				2022-12-27	WOS:A1994NH71600001
J	PORRAS, A; MUSZYNSKI, K; RAPP, UR; SANTOS, E				PORRAS, A; MUSZYNSKI, K; RAPP, UR; SANTOS, E			DISSOCIATION BETWEEN ACTIVATION OF RAF-1 KINASE AND THE 42-KDA MITOGEN-ACTIVATED PROTEIN-KINASE 90-KDA-S6 KINASE (MAPK/RSK) CASCADE IN THE INSULIN/RAS PATHWAY OF ADIPOCYTIC DIFFERENTIATION OF 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL TRANSDUCTION; XENOPUS OOCYTES; RAS; SERINE; PHOSPHORYLATION; EXPRESSION; STIMULATION; P21RAS; RECEPTOR	Insulin treatment of untransfected 3T3 L1 cells quickly induced activation of a cytosolic 42-kDa mitogen-activated protein kinase (MAPK) and a 90-kDa S6 kinase (RSK). The activation of these cytosolic kinases was also mimicked by Res expression (in the absence of insulin) in the same cells transfected with inducible ras oncogenes. Furthermore, insulin-induced activation of MAPK and RSK could be blocked by expression of a transfected inducible dominant negative Ras mutant (Asn-17). These results indicate that Ras proteins are obligatory intermediates in the activation of the cytosolic MAPK/RSK cascade by insulin. Insulin treatment of 3T3 L1 cells or expression of transfected res oncogenes resulted also in hyperphosphorylation of cellular Raf-l. Insulin-induced Raf hyperphosphorylation was inhibited by expression of an inducible dominant negative Res mutant (Asn-17). We also showed that expression of transfected raf oncogenes induces adipocytic differentiation, as detected by expression of the specific adipocytic marker aP2. In addition, insulin-induced differentiation was significantly blocked by expression of a dominant negative raf mutant. Interestingly, however, the expression of transfected raf oncogenes did not induce MAPK or RSK activation, and the insulin-induced activation of these kinases was not blocked by expression of transfected dominant negative raf mutants. These results are consistent with Raf kinases acting downstream of Ras, but not upstream of MAPK and RSK in insulin-signaling pathways leading to 3T3 L1 differentiation.	NCI,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Porras, Almudena/N-2121-2015	Porras, Almudena/0000-0002-6495-3308				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUADRADO A, 1993, ONCOGENE, V8, P2443; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, ONCOGENE, V8, P467; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12741	12748						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175686				2022-12-27	WOS:A1994NH71600058
J	VIGERS, GPK; CAFFES, P; EVANS, RJ; THOMPSON, RC; EISENBERG, SP; BRANDHUBER, BJ				VIGERS, GPK; CAFFES, P; EVANS, RJ; THOMPSON, RC; EISENBERG, SP; BRANDHUBER, BJ			X-RAY STRUCTURE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AT 2.0-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTORS; 3-DIMENSIONAL STRUCTURE; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; REFINEMENT; INHIBITOR; SPECTROSCOPY; 1-ALPHA; BINDS; CELL	Interleukin-1 receptor antagonist (IL-1ra) is a natural competitive antagonist of IL-1. In order to further elucidate the mechanism by which IL-1ra binds without activating the IL-1 receptor, we have solved the crystal structure of IL-1ra at 2.0-Angstrom resolution. IL-1ra has the same overall beta-trefoil fold as IL-1 alpha and IL-1 beta and has a very similar hydrophobic core. However, there are a number of structural differences between the molecules, including significant differences at the open end of the beta-barrel, which has been identified in IL-1 beta as a receptor binding site.	SYNERGEN INC,BOULDER,CO 80301					Vigers, Guy/0000-0003-4451-8453				BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Eisenberg Stephen P., 1993, Lymphokine and Cytokine Research, V12, P376; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; EVANS R J, 1991, Journal of Cellular Biochemistry Supplement, V15, P172; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FITZGERALD PMD, 1967, J APPL CRYSTALLOGR, V23, P544; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; VEERAPANDIAN B, 1992, BIOPHYS J, V62, P112, DOI 10.1016/S0006-3495(92)81796-4; ZEMKE KJ, 1991, FEBS LETT, V279, P240, DOI 10.1016/0014-5793(91)80158-Y; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12874	12879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175703				2022-12-27	WOS:A1994NH71600077
J	DINTZIS, SM; VELCULESCU, VE; PFEFFER, SR				DINTZIS, SM; VELCULESCU, VE; PFEFFER, SR			RECEPTOR EXTRACELLULAR DOMAINS MAY CONTAIN TRAFFICKING INFORMATION - STUDIES OF THE 300-KDA MANNOSE 6-PHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-II RECEPTOR; EGF RECEPTOR; CYTOPLASMIC DOMAIN; LIPOPROTEIN RECEPTOR; MEDIATED ENDOCYTOSIS; KINASE-ACTIVITY; BINDING-SITE; AMINO-ACIDS; CELLS	The 300-kDa mannose 6-phosphate receptor cycles between the trans Golgi network and late endosomes, and between the plasma membrane and early endosomes, to deliver lysosomal enzymes to prelysosomes. Mannose 6-phosphate receptor trafficking requires structural determinants present in the cytoplasmic domain. However, when this domain was joined with the extracellular and transmembrane domains of the epidermal growth factor receptor, it was not sufficient to direct this chimera to late endosomes and the trans Golgi network (Dintzis, S. M., and Pfeffer, S. R. (1990) EMBO J. 9, 77-84). These findings suggested a role for extracellular and/or transmembrane domains in mannose 6-phosphate receptor trafficking. We describe here the construction and expression of chimeric receptors comprised of mannose 6-phosphate receptor extracellular and transmembrane sequences joined with cytoplasmic domain sequences derived from the human epidermal growth factor receptor or the human low density lipoprotein receptor. The chimeras were stable proteins which were efficiently endocytosed and competent to bind a mannose 6-phosphate-containing ligand. Antibody binding assays and indirect immunofluorescence showed that the chimeras containing the mannose 6-phosphate receptor extracellular domain colocalized with mannose 6-phosphate receptors in intracellular compartments, These experiments suggest that the presence of the mannose 6-phosphate receptor extracellular domain may interfere with the rapid recycling of receptors from early endosomes to the cell surface and detain receptors within endosomes.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HARLOW E, 1988, ANTIBODIES; HHARE JF, 1990, J BIOL CHEM, V265, P21758; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAHAGIAN GG, 1984, BIOL CELL, V51, P207, DOI 10.1111/j.1768-322X.1984.tb00300.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	43	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12159	12166						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163521				2022-12-27	WOS:A1994NG37700074
J	PRINS, BA; HU, RM; NAZARIO, B; PEDRAM, A; FRANK, HJL; WEBER, MA; LEVIN, ER				PRINS, BA; HU, RM; NAZARIO, B; PEDRAM, A; FRANK, HJL; WEBER, MA; LEVIN, ER			PROSTAGLANDIN E(2) AND PROSTACYCLIN INHIBIT THE PRODUCTION AND SECRETION OF ENDOTHELIN FROM CULTURED ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; VASCULAR ENDOTHELIUM; GENE-EXPRESSION; CYCLIC-GMP; RAT; PROLIFERATION; RELEASE; STIMULATION; RECEPTOR	Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor yet identified. This peptide plays an important role in the regulation of arterial tone, in part through its interaction with endogenous vasodilator compounds. To understand the interactions of endothelin with the vasoactive prostaglandins (PGs), we determined the effects of prostaglandin E(2) (PGE(2)), prostacyclin (PGI(2)), and thromboxane A(2) on ET-1 synthesis and secretion from cultured bovine aortic endothelial cells and on ET-1 action in aortic smooth muscle cells. Both PGE(2) and PGI(2) (vasodilator prostaglandins) caused an similar to 40% inhibition of basal ET-1 secretion and a 50% inhibition of serum-stimulated ET-1 secretion in a dose-related and time course fashion. In contrast, the vasoconstrictor prostaglandin, thromboxane A(2), had no effect on ET-1 secretion. PGE(2) and PGI(2) similarly inhibited the basal production of new ET-1 protein (translation) by 40-50% and inhibited the basal steady-state mRNA expression of ET-1 in bovine aortic endothelial cells by 60-70%. Both prostaglandins also caused an similar to 55% inhibition of ET-1 transcription, as shown by chloramphenicol acetyltransferase reporter studies. PGE(2) and PGI(2) strongly stimulated cGMP generation; both the PG stimulation of cGMP and the inhibition of ET-1 secretion and translation were reversed by LY83583, a general inhibitor of cGMP generation. The PG-induced inhibition of ET-1 Secretion and translation was also reversed by KT5823, an inhibitor of cGMP-dependent protein kinase, but not by (R(p))-adenosine cyclic 3':5'-monophosphate, an inhibitor of protein kinase A activation. PGE(2) and PGI(2) also inhibited both basal and ET-1-stimulated DNA synthesis in aortic smooth muscle cells by similar to 45% through a cGMP-dependent mechanism. Therefore, two endogenous PGs, known to be important vasodilators in vivo, significantly inhibit the transcription, translation, secretion, and action of ET-1. We propose that the vasodilator action of the PGs results, in part, from their ability to inhibit the production of this potent vasoconstrictor.	LONG BEACH VET HOSP,MED SERV 111I,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine			Levin, Ellis/J-5402-2013		NHLBI NIH HHS [1RO1HL50161] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTI F, 1990, PROSTAGLANDINS, V40, P337, DOI 10.1016/0090-6980(90)90099-H; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CHOU SY, 1990, AM J PHYSIOL, V259, pF645, DOI 10.1152/ajprenal.1990.259.4.F645; DORN GW, 1992, J BIOL CHEM, V267, P24897; FILEP JG, 1991, BIOCHEM BIOPH RES CO, V177, P171, DOI 10.1016/0006-291X(91)91964-E; GELFAND R, 1991, AM J PHYSIOL, V261, pR453; GLASS DB, 1977, J CYCLIC NUCL PROT, V3, P37; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; HU RM, 1992, J BIOL CHEM, V267, P17384; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEVIN ER, 1992, J NEUROCHEM, V58, P659, DOI 10.1111/j.1471-4159.1992.tb09768.x; LUSCHER TF, 1993, J HYPERTENS, V11, P7; MIURA K, 1991, J PHARMACOL EXP THER, V256, P11; MIURA K, 1989, EUR J PHARMACOL, V170, P91, DOI 10.1016/0014-2999(89)90139-8; NEUSER D, 1990, ARTERY, V17, P311; NOLAND TD, 1992, AM J PHYSIOL, V263, pC1208, DOI 10.1152/ajpcell.1992.263.6.C1208; NOVERAL JP, 1992, AM J PHYSIOL, V263, pL317, DOI 10.1152/ajplung.1992.263.3.L317; ODONNELL ME, 1986, J BIOL CHEM, V261, P5461; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RAE GA, 1989, J CARDIOVASC PHARM, V13, pS89, DOI 10.1097/00005344-198900135-00022; REYNOLDS EE, 1990, J PHARMACOL EXP THER, V252, P915; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P718; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHMIDT MJ, 1985, J PHARMACOL EXP THER, V232, P764; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1993, PHYSIOL REV, V73, P375, DOI 10.1152/physrev.1993.73.2.375; SINZINGER H, 1987, PROSTAGLANDINS, V33, P915, DOI 10.1016/0090-6980(87)90118-3; SMITH DL, 1984, PROSTA LEUKOTR MED, V16, P1, DOI 10.1016/0262-1746(84)90080-5; THIEMERMANN C, 1989, J CARDIOVASC PHARM, V13, pS138, DOI 10.1097/00005344-198900135-00034; VANE JR, 1990, NEW ENGL J MED, V323, P27; WANG YX, 1992, HYPERTENSION, V19, P255, DOI 10.1161/01.HYP.19.2_Suppl.II255; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WARNER TD, 1992, AM J PHYSIOL, V262, pH1600, DOI 10.1152/ajpheart.1992.262.5.H1600; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZIV I, 1992, STROKE, V23, P1014, DOI 10.1161/01.STR.23.7.1014	40	142	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11938	11944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163494				2022-12-27	WOS:A1994NG37700042
J	RUVINOV, SB; MILES, EW				RUVINOV, SB; MILES, EW			THERMAL INACTIVATION OF TRYPTOPHAN SYNTHASE - STABILIZATION BY PROTEIN-PROTEIN INTERACTION AND PROTEIN-LIGAND INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DODECAMERIC GLUTAMINE-SYNTHETASE; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ALPHA-SUBUNIT; BETA-SUBUNIT; ALPHA-2-BETA-2 COMPLEX; BIENZYME COMPLEX; FLEXIBLE LOOP; SCANNING CALORIMETRY	This study investigates effects of ligands on thermal inactivation of the tryptophan synthase alpha and beta(2) subunits alone and in the alpha(2) beta(2) complex. Addition of pyridoxal phosphate to the apo-beta(2) subunit increases the temperature of one-half inactivation (T-i) from 52 to 77 degrees C. Ligands that promote association of the alpha and holo-beta(2) subunits markedly stabilize the more temperature-labile alpha subunit in the alpha(2) beta(2) complex from irreversible thermal denaturation. The combination of a beta(2) subunit ligand (L-serine) with an a subunit ligand (alpha-glycerol 3-phosphate) raises the inactivation temperature (T-i) of the alpha subunit in the holo-alpha(2) beta(2) complex from 54 to 66 degrees C. In contrast, values of T-i for inactivation of the alpha and beta subunits in the holo-alpha(2) beta(2) complex are more similar to respective values for the isolated alpha subunit (50 degrees C) and holo-beta(2) subunit (77 degrees C). Surprisingly, the addition of L- serine results in a larger decrease in the T-i of the beta(2) subunit in the holo-alpha(2) beta(2) complex (78 degrees C --> 64 degrees C) than in T-i of the holo-beta(2) subunit alone (77 degrees C --> 71 degrees C). The observation that ligands have different effects on the isolated and associated subunits provides evidence that the alpha and beta(2) subunits do not fully dissociate during thermal inactivation of the alpha(2) beta(2) complex at pH 7.8 and at similar to 0.1 ionic strength. Our results demonstrate that linkage between protein-ligand interactions and protein-protein interactions affects the conformational stability of the tryptophan synthase alpha(2) beta(2) complex.	NIDDK, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BRZOVLC P, 1991, INT UNION B, V199, P277; CHAFFOTTE AF, 1983, BIOCHEMISTRY-US, V22, P2708, DOI 10.1021/bi00280a019; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; EDGE V, 1988, BIOCHEMISTRY-US, V27, P8081, DOI 10.1021/bi00421a017; GINSBURG A, 1991, BIOCHEMISTRY-US, V30, P9421, DOI 10.1021/bi00103a005; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; MATTHEWS CR, 1980, BIOCHEMISTRY-US, V19, P1290, DOI 10.1021/bi00548a004; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; OGASAHARA K, 1984, INT J PEPT PROT RES, V24, P147; REMETA D P, 1992, Biophysical Journal, V61, pA213; REMETA DP, 1993, BIOPHYS J, V64, pA175; RUVINOV SB, 1992, FEBS LETT, V299, P197, DOI 10.1016/0014-5793(92)80246-D; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SUGISAKI Y, 1990, THERMOCHIM ACTA, V163, P117, DOI 10.1016/0040-6031(90)80386-D; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1977, P NATL ACAD SCI USA, V74, P286, DOI 10.1073/pnas.74.1.286; YANOFSKY C, 1972, ENZYMES, V7, P1; YUTANI K, 1982, INT J PEPT PROT RES, V20, P331; YUTANI K, 1984, ARCH BIOCHEM BIOPHYS, V229, P448, DOI 10.1016/0003-9861(84)90174-7; ZETINA CR, 1980, J MOL BIOL, V137, P401, DOI 10.1016/0022-2836(80)90165-5; ZETINA CR, 1980, J BIOL CHEM, V255, P4381; ZOLKIEWSKI M, 1992, BIOCHEMISTRY-US, V31, P11991, DOI 10.1021/bi00163a006	43	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11703	11706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163467				2022-12-27	WOS:A1994NG37700008
J	COTE, HCF; STEVENS, WK; BAJZAR, L; BANFIELD, DK; NESHEIM, ME; MACGILLIVRAY, RTA				COTE, HCF; STEVENS, WK; BAJZAR, L; BANFIELD, DK; NESHEIM, ME; MACGILLIVRAY, RTA			CHARACTERIZATION OF A STABLE FORM OF HUMAN MEIZOTHROMBIN DERIVED FROM RECOMBINANT PROTHROMBIN (R155A, R271A, AND R284A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-V; FACTOR-XA; FACTOR-IX; PHOSPHOLIPID-BINDING; CATALYZED ACTIVATION; PROTEIN-C; EXPRESSION; THROMBIN; INTERMEDIATE	Meizothrombin is a transient intermediate produced during the activation of prothrombin by the prothrombinase complex. Because meizothrombin is very sensitive to further activation and autolysis, its isolation is possible only in the presence of active site thrombin inhibitors. This complicates studies of the activities and functions of meizothrombin. As a model, we have expressed a mutant human prothrombin cDNA (R155A, R271A, R284A) with three of the cleavage sites modified so that they are no longer cleaved by factor Xa or thrombin. Several stable baby hamster kidney cell lines were isolated that secreted up to 20 mug/ml of carboxylated mutant prothrombin. After purification, the mutant prothrombin was activated by the prothrombinase complex or by ecarin, resulting in the formation of a meizothrombin-like molecule. Electrophoretic analysis and NH2-terminal sequence analysis were consistent with cleavage of a single bond between Arg320-Ile321 and proper processing of the prepropeptide. The meizothrombin was stable for weeks at 4-degrees-C. Activation in the presence of dansylarginine N-(3-ethyl-1,5-pentanediyl) amide confirmed the conversion of prothrombin via meizothrombin. Compared with human plasma-derived thrombin, recombinant meizothrombin demonstrated approximately 7% clotting activity, 100% p-toluene-sulfonylarginine methyl ester esterase activity, and approximately 35% S2238 amidolytic activity, and could attenuate fibrinolysis.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA	University of British Columbia; Queens University - Canada; Queens University - Canada			Cote, Helene/K-7896-2012					ANSON DS, 1985, NATURE, V315, P683, DOI 10.1038/315683a0; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10360; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7798; FALKNER FG, 1992, THROMB HAEMOSTASIS, V68, P119; FRANZA BR, 1975, J BIOL CHEM, V250, P7057; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINNELL BW, 1987, BIOTECHNOLOGY, V5, P1188; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P1; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MACGILLIVRAY RTA, ANN NY ACAD SCI, V485, P73; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OWEN WG, 1974, J BIOL CHEM, V249, P594; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PEI G, 1991, J BIOL CHEM, V266, P9598; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; WOLF DL, 1991, J BIOL CHEM, V266, P13726; WU QY, 1992, J BIOL CHEM, V267, P7083; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655	42	53	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11374	11380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157669				2022-12-27	WOS:A1994NF96600061
J	NALAMACHU, SR; SONG, LX; FRICKER, LD				NALAMACHU, SR; SONG, LX; FRICKER, LD			REGULATION OF CARBOXYPEPTIDASE-E - EFFECT OF CA2+ ON ENZYME-ACTIVITY AND STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-SYNTHESIZING CARBOXYPEPTIDASE; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; THERMOACTINOMYCES-VULGARIS; STREPTOMYCES-GRISEUS; CRYSTAL-STRUCTURE; CDNA; PURIFICATION; PROTEINS; CONVERTASE	Carboxypeptidase E (CPE), an enzyme that functions in the post-translational processing of bioactive peptides, is a member of the metallocarboxypeptidase gene family. A 12-residue region of CPE has 70% amino acid identity with the bacterial enzyme carboxypeptidase T (CPT); in CPT, this region has been identified previously as the Ca2+-binding region (Teplyakov, A., Polyakov, K., Obmolova, G., Strokopytov, B., Kuranova, I., Osterman, A., Grishin, N., Smulevitch, S., Zagnitko, O., Galperina, O., Matz, M., and Stepanov, V. (1992) Eur. J. Biochem. 208, 281-288). Using Ca-45(2+) binding, we determined that CPE binds Ca2+. To investigate the potential function for the interaction of CPE with Ca2+, we investigated the effect of Ca2+ on aggregation, thermostability, and enzyme activity of CPE. CPE does not aggregate under a variety of Ca2+ concentrations at either pH 5.5 or 7.5, and with protein concentrations ranging from 10 to 100 mug/ml. Whereas Ca2+ generally stabilizes proteins to thermal denaturation, CPE was destabilized by Ca2+ and stabilized by low concentrations of EGTA. The Ca2+-induced destabilization of CPE was more pronounced at pH 8 than at lower pH values. At pH 8, CPE was unstable even at 37-degrees-C, with approximately 40% loss of activity upon incubation for 30 min in the absence of added Ca2+ and 70% loss of activity upon incubation in the presence of 10 mM CaCl2. Enzyme activity was not influenced by added Ca2+, but was stimulated by micromolar concentrations of EGTA; kinetic analysis showed this stimulation to be due to a change in V(max), and not K(m). Taken together, these data suggest that Ca2+ plays a role in the regulation of CPE activity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDA NIH HHS [DA-00194, DA-04494] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Battey, 1986, BASIC METHODS MOL BI; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; EATON DL, 1991, J BIOL CHEM, V266, P21833; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1990, ANAL BIOCHEM, V184, P21, DOI 10.1016/0003-2697(90)90005-T; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GREENE D, 1992, BIOCHEM J, V285, P613, DOI 10.1042/bj2850613; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NARAHASHI Y, 1990, J BIOCHEM-TOKYO, V107, P879, DOI 10.1093/oxfordjournals.jbchem.a123142; NARAHASHI Y, 1979, J BIOCHEM-TOKYO, V86, P683, DOI 10.1093/oxfordjournals.jbchem.a132572; OSTERMAN A L, 1984, Biokhimiya, V49, P292; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; ROTH WW, 1991, MOL CELL ENDOCRINOL, V78, P171, DOI 10.1016/0303-7207(91)90120-H; SMULEVITCH SV, 1991, FEBS LETT, V291, P75, DOI 10.1016/0014-5793(91)81107-J; TAN FL, 1989, J BIOL CHEM, V264, P13165; TEPLYAKOV A, 1992, EUR J BIOCHEM, V208, P281, DOI 10.1111/j.1432-1033.1992.tb17184.x; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666	28	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11192	11195						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157647				2022-12-27	WOS:A1994NF96600035
J	PENG, SB; ZHANG, Y; TSAI, SJ; XIE, XS; STONE, DK				PENG, SB; ZHANG, Y; TSAI, SJ; XIE, XS; STONE, DK			RECONSTITUTION OF RECOMBINANT 33-KDA SUBUNIT OF THE CLATHRIN-COATED VESICLE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATING COMPLEX; KIDNEY; INHIBITORS; PUMP	Evidence suggests that the ATP hydrolytic sector of the clathrin-coated vesicle proton-translocating ATPase is composed of four subunits of molecular masses of 70, 58, 40, and 33 kDa (Xie, X. S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We have now expressed recombinant 33-kDa polypeptide in Escherichia coli and in Spodoptera frugiperda (Sf9) cells. This subunit, renatured and purified from both sources, lacks intrinsic ATPase activity. Co-reconstitution of these recombinant 33-kDa polypeptides and recombinant 40-kDa subunit to a biochemically prepared 70-58-kDa subcomplex results in a 6-fold stimulation of calcium-activated, N-ethylmaleimide-sensitive ATPase activity, documenting the essential role of the 33- and 40-kDa components in vacuolar type proton pump function and furthering the aim of reconstitution of a purely recombinant hydrolytic core.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK RO1 33627] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RA, 1990, KIDNEY, P318; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; PENG SB, 1993, J BIOL CHEM, V268, P23519; QIAGEN, 1992, QIAEXPRESSIONIST; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEIDMAN JG, 1989, SHORT PROTOCOLS MOL; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN SZ, 1987, J BIOL CHEM, V262, P14790; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1993, J BIOL CHEM, V268, P25063	26	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11356	11360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157666				2022-12-27	WOS:A1994NF96600058
J	ROMANIC, AM; SPOTILA, LD; ADACHI, E; ENGEL, J; HOJIMA, Y; PROCKOP, DJ				ROMANIC, AM; SPOTILA, LD; ADACHI, E; ENGEL, J; HOJIMA, Y; PROCKOP, DJ			SELF-ASSEMBLY OF COLLAGEN-I FROM A PROBAND HOMOZYGOUS FOR A MUTATION THAT SUBSTITUTED SERINE FOR GLYCINE AT POSITION-661 IN THE ALPHA-2(I) CHAIN - POSSIBLE RELATIONSHIP BETWEEN THE EFFECTS OF MUTATIONS ON CRITICAL CONCENTRATION AND THE SEVERITY OF THE PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; OSTEOGENESIS IMPERFECTA; N-PROTEINASE; ALPHA-1(I) CHAIN; FIBRILS INVITRO; V COLLAGEN; PROCOLLAGEN; CYSTEINE; CLEAVAGE; COPOLYMERIZATION	Procollagen I was isolated from cultured skin fibroblasts from a proband who was homozygous for a mutation in the COL1A2 gene that substituted a serine codon for a glycine codon at position 661 of the alpha2(I) chain. The procollagen I was cleaved to pCcollagen I by procollagen N-proteinase and the pCcollagen I was used as a substrate for assay of self-assembly of collagen I into fibrils. The mutated pCcollagen I was cleaved to collagen I by procollagen C-proteinase at the same rate as control pCcollagen I. However, self-assembly of the mutated collagen I had a lag period that was 15-fold greater than the lag period observed with normal collagen I under the same conditions. Also, self-assembly of the mutated collagen I had a propagation rate of about one-fourth of the propagation rate of normal collagen I. In addition, the critical concentration for fibril assembly was slightly increased. Rotary shadowing electron microscopy of the mutated procollagen I did not reveal any increased flexibility of the triple helix as was seen previously with two mutated procollagens I in which there were substitutions of cysteine for glycine residues in the alpha1(I) chain (Vogel, B. E., Doelz, R., Kadler, K. E., Hojima, Y., Engel, J., and Prockop, D. J. (1988) J. Biol. Chem. 263, 19249-19255; Lightfoot, S. J., Holmes, D. F., Brass, A., Grant, M. E., Byers, P. H., and Kadler, K. E. (1992) J. Biol. Chem. 267, 25521-25528). However, morphometric analysis by dark-field light microscopy and electron microscopy showed that the fibrils formed from the mutated collagen I appeared thicker in diameter than the fibrils formed from the normal collagen I. Comparison of the results with similar data on four mutated procollagens previously studied raised the possibility that mutations which markedly increase the critical concentration of fibril assembly produce more severe phenotypes than mutations which change other parameters of fibril assembly.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND	Jefferson University; University of Basel					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, P01AR038188] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39740, AR38188] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI E, 1985, COLLAGEN REL RES, V5, P225; ADACHI E, 1989, MATRIX, V9, P232, DOI 10.1016/S0934-8832(89)80055-1; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P145; CONSTANTINOU CD, 1989, J CLIN INVEST, V83, P574, DOI 10.1172/JCI113920; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTFOOT SJ, 1992, J BIOL CHEM, V267, P25521; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; OOSAWA F, 1975, THERMODYNAMICS POLYM, P26; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; SPOTILA LD, 1992, AM J HUM GENET, V51, P1396; SPOTILA LD, 1991, P NATL ACAD SCI USA, V88, P5423, DOI 10.1073/pnas.88.12.5423; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; VOGEL BE, 1988, J BIOL CHEM, V263, P19249	27	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11614	11619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157695				2022-12-27	WOS:A1994NF96600095
J	WAGA, S; BAUER, G; STILLMAN, B				WAGA, S; BAUER, G; STILLMAN, B			RECONSTITUTION OF COMPLETE SV40 DNA-REPLICATION WITH PURIFIED REPLICATION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA-PRIMASE; LAGGING STRAND SYNTHESIS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; EXCISION REPAIR; PROTEIN-A; LIGASE-I	The identification and purification of human cell proteins required for the production of form I DNA following DNA replication from the simian virus 40 (SV40) origin is described. Using these proteins, complete SV40 DNA replication was reconstituted with only purified DNA replication factors: SV40 large tumor antigen (TAg), replication protein A (RPA), DNA topoisomerases I and II, DNA polymerase alpha-primase, replication factor C (RFC), the proliferating cell nuclear antigen (PCNA), DNA polymerase delta, maturation factor 1 (MF1), and DNA ligase I. MF1, a 5' to 3' exonuclease and DNA ligase I were both identified as essential components for production of covalently closed circular relaxed (form I) DNA. MF1 is probably the same exonuclease previously shown by others to function during DNA synthesis on artificial DNA templates or in conjunction with DNA polymerase alpha from the SV40 origin. Combined with these previous studies, our results suggest that MF1 functions to remove an RNA primer attached to every Okazaki fragment during lagging strand DNA synthesis. Interestingly, whereas mammalian DNA ligase I functioned in the reconstituted replication system, mammalian DNA ligase III did not substitute and the phage T4 DNA ligase functioned inefficiently, suggesting that DNA ligase I has a specific role as a replicative DNA ligase in eukaryotic cells.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				Waga, Shou/0000-0003-4986-8735; Stillman, Bruce/0000-0002-9453-4091	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KESTI T, 1993, J BIOL CHEM, V268, P10238; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LEE MYW, 1984, BIOCHEMISTRY-US, V2, P1906; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LEHMANN AR, 1988, CANCER RES, V48, P6343; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; Maniatis T., 1982, MOL CLONING; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; OLIVERA BM, 1968, J MOL BIOL, V36, P261, DOI 10.1016/0022-2836(68)90380-X; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; PROGENT C, 1992, EMBO J, V11, P2925; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIMANIS V, 1985, VIROLOGY, V144, P80; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	80	355	357	3	118	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10923	10934						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144677				2022-12-27	WOS:A1994NF01700107
J	ZARAINHERZBERG, A; MARQUES, J; SUKOVICH, D				ZARAINHERZBERG, A; MARQUES, J; SUKOVICH, D			THYROID-HORMONE RECEPTOR MODULATES THE EXPRESSION OF THE RABBIT CARDIAC SARCO(ENDO)PLASMIC RETICULUM CA2+-ATPASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; MESSENGER-RNA; CA-2+-ATPASE GENE; RESPONSE ELEMENT; CHLORAMPHENICOL ACETYLTRANSFERASE; MOLECULAR-CLONING; SKELETAL-MUSCLE; CA-2+ ATPASE; GROWTH; ACID	We have analyzed the effect of thyroid hormone (T3) on SERCA2 gene expression using fetal chicken primary cardiac myocytes and C2C12 skeletal muscle cells in culture. Northern blot analysis of both cell types demonstrated that T3 induced a 3-fold accumulation of SERCA2 mRNA compared with cells grown in medium lacking T3. We have engineered deletion constructs containing various lengths of the 5'-flanking region from the rabbit SERCA2 gene which we have cloned previously (Zarain-Herzberg, A., MacLennan, D. H., and Periasamy, M. (1990) J. Biol. Chem. 265, 4670-4677). A stable transfectant in C2C12 containing a chimeric SERCA2/CAT gene construct including -254 base pairs (bp) of SERCA2 5'-flanking region showed increased transcription activity upon the addition of 50 nm T3. We have analyzed the expression of several deletion constructs spanning 1,102 bp of the 5'-upstream sequence of the SERCA2 gene by functional expression assays. Transient coexpression of the T3 receptor alpha1 with various SERCA2/CAT deletion constructs showed trans-activation of chimeric constructs containing more than -267 bp, indicating that a thyroid hormone-responsive element was localized, at least in part, to the region -267 to -72 bp. T3 receptor-DNA binding assays demonstrated binding of the rat T3 receptor al to a fragment containing a proposed T3 response element located between position -254 and -72 in the 5'-flanking region of the SERCA2 gene.	DUPONT MERCK PHARMACEUT CO, CARDIOVASC SCI, EXPTL STN, WILMINGTON, DE 19880 USA	DuPont	ZARAINHERZBERG, A (corresponding author), UNIV MANITOBA, ST BONIFACE GEN HOSP,RES CTR,DEPT PHYSIOL, DIV CARDIOVASC SCI, 351 TACHE AVE, WINNIPEG R2H 2A6, MB, CANADA.			Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL28001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT NR, 1987, PATHOPHYSIOLOGY HEAR, P99; ARAI M, 1991, CIRC RES, V69, P266, DOI 10.1161/01.RES.69.2.266; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURK SE, 1989, J BIOL CHEM, V264, P18561; CASANOVA J, 1985, J BIOL CHEM, V260, P1744; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK WA, 1976, DEV BIOL, V52, P263, DOI 10.1016/0012-1606(76)90245-1; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KOHTZ DS, 1989, J CELL BIOL, V108, P1067, DOI 10.1083/jcb.108.3.1067; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, HEART CARDIOVASCULAR, V2, P1203; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYEN MR, 1992, MOL CELL ENDOCRINOL, V87, P87, DOI 10.1016/0303-7207(92)90236-Y; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	42	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1460	1467						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8166809				2022-12-27	WOS:A1994MR22000105
J	WEMMIE, A; WU, AL; HARSHMAN, KD; PARKER, CS; MOYEROWLEY, WS				WEMMIE, A; WU, AL; HARSHMAN, KD; PARKER, CS; MOYEROWLEY, WS			TRANSCRIPTIONAL ACTIVATION MEDIATED BY THE YEAST AP-1 PROTEIN IS REQUIRED FOR NORMAL CADMIUM TOLERANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; YAP1 ENCODES; DNA; BINDING; GENE; JUN; GCN4; FOS	The yeast YAP1 gene encodes a transcriptional regulatory protein that utilizes a basic region-leucine zipper (bZip) DNA-binding domain to recognize its cognate DNA element. A synthetic reporter gene containing a SV40 AP-1 response element (ARE) cloned upstream of a TRP5 promoter-lacZ gene fusion shows yAP-1-dependent transactivation in vivo. Recent work has shown that changes in the gene dosage of this factor can dramatically alter the ability of a cell to tolerate a host of toxic agents including cadmium, cycloheximide, and sulfometuron methyl. We have focused on the YAP1-dependent cadmium resistance as cells that lack a functional YAP1 gene are hypersensitive to this metal. Deletion mapping experiments define two domains in the carboxyl-terminal region of the yAP-1 protein that are required for normal cadmium tolerance and ARE-TRP5-lacZ expression. Single amino acid substitutions in the bZip domain of yAP-1 indicate that this region is required for normal DNA binding and in vivo function of the protein. Replacement of a non-canonical asparagine with leucine in the yAP-1 leucine zipper leads to production of a defective protein. A substitution mutation in the basic domain converts this mutant protein into a dominant negative factor. The ability of yAP-1 to act as a positive regulator of transcription is required for its biological action.	UNIV IOWA,PROGRAM MOLEC BIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; CALTECH,DIV CHEM,PASADENA,CA 91125	University of Iowa; University of Iowa; California Institute of Technology			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Wemmie, John/0000-0001-7531-9065	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CURRAN T, 1988, COLD SPRING HARB SYM, V53, P769, DOI 10.1101/SQB.1988.053.01.087; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARLOW E, 1988, ANTIBODIES LABORATOR; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANUSKA AP, 1988, GENETIKA+, V24, P773; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEPPERT G, 1990, GENETICS, V125, P13; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MOYEROWLEY WS, 1988, COLD SPRING HARB SYM, V53, P711, DOI 10.1101/SQB.1988.053.01.081; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WU AL, 1993, J BIOL CHEM, V268, P18850; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	36	77	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14690	14697						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182076				2022-12-27	WOS:A1994NM06500061
J	FENG, Y; FORGAC, M				FENG, Y; FORGAC, M			INHIBITION OF VACUOLAR H+-ATPASE BY DISULFIDE BOND FORMATION BETWEEN CYSTEINE-254 AND CYSTEINE-532 IN SUBUNIT-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; NADP-MALATE-DEHYDROGENASE; NUCLEOTIDE BINDING-SITES; BETA-SUBUNIT; CHROMAFFIN GRANULES; ESCHERICHIA-COLI; ALPHA-SUBUNIT; THIOREDOXIN; PROTEINS	We have previously demonstrated that the coated vesicle vacuolar H+-ATPase (V-ATPase) can be inactivated by formation of intramolecular disulfide bonds (Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 19769-19772). The disulfide bond responsible for inactivation can be distinguished from other disulfide bonds that form by the fact that formation of the inactivating disulfide bond is blocked by ATP or high ionic strength. By taking advantage of these properties, we selectively labeled the ATPase at the relevant cysteine residues with fluorescein maleimide. After analyzing the proteolytic fragments that contain the labeled cysteine residues, we found that cysteine 254 and cysteine 532 in subunit A of the bovine V-ATPase are the residues that form the disulfide bond resulting in inactivation of the enzyme. Cysteine 254 and cysteine 532 correspond to 2 of the 3 cysteine residues that are conserved in all available V-ATPase A subunit sequences. Cysteine 254 is located in the consensus motif, G(X)(4)GKT, corresponding to residues 250-257, which is conserved in many nucleotide binding proteins. Cysteine 532 is located in a region not previously shown to be in proximity to the nucleotide binding site. Modification of cysteine 254 by disulfide bond formation with cysteine 532 or thio-disulfide exchange with cystine does not impair binding of 2-azido[P-32]ATP to the A subunit. The inhibition is therefore likely caused by disruption of the catalytic function of the ATPase on formation of the disulfide bond. A possible role in regulating intracellular acidification by reversible sulfhydryl oxidation and reduction is discussed.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02111	Tufts University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, GM-34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DENDA K, 1988, J BIOL CHEM, V263, P6012; DROUX M, 1987, CR ACAD SCI III-VIE, V305, P335; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; HALLIWELL B, 1978, PLANTA, V139, P9, DOI 10.1007/BF00390803; HAMMEL KE, 1983, P NATL ACAD SCI-BIOL, V80, P3681, DOI 10.1073/pnas.80.12.3681; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; LAW MY, 1983, BIOCHEM J, V210, P899, DOI 10.1042/bj2100899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1988, P NATL ACAD SCI USA, V85, P5379, DOI 10.1073/pnas.85.15.5379; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MELESE T, 1985, J BIOL CHEM, V260, P5398; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MYERS M, 1993, J BIOL CHEM, V268, P9184; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1990, J BIOL CHEM, V265, P20390; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PORTER MA, 1988, J BIOL CHEM, V263, P123; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; REBEILLE F, 1986, ARCH BIOCHEM BIOPHYS, V249, P164, DOI 10.1016/0003-9861(86)90571-0; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG SY, 1988, J BIOL CHEM, V263, P17638; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	48	138	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13224	13230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175752				2022-12-27	WOS:A1994NK18400029
J	TADDIE, JA; HURLEY, TR; HARDWICK, BS; SEFTON, BM				TADDIE, JA; HURLEY, TR; HARDWICK, BS; SEFTON, BM			ACTIVATION OF B-CELLS AND T-CELLS BY THE CYTOPLASMIC DOMAINS OF THE B-CELL ANTIGEN RECEPTOR PROTEINS IG-ALPHA AND IG-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTES-B; TYROSINE PHOSPHORYLATION; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; CROSS-LINKING; SRC-FAMILY; COMPLEX; GENE; COMPONENTS; EXPRESSION	In addition to membrane immunoglobulin (mIg), the B-cell antigen receptor contains Ig-alpha/Ig-beta heterodimers that link mIg to intracellular signaling molecules. To compare the ability of the cytoplasmic domains of Ig-alpha and Ig-beta to transduce signals in B- and T-cells, we con constructed chimeric genes encoding the extracellular and transmembrane domains of human CD8 alpha and the cytoplasmic domain of murine Ig-alpha (CD8/Ig-alpha) or Ig-beta (CD8/Ig-beta). In murine B-cell hybridoma LK 35.2 cells, antibody-mediated cross-linking of mIg, CD8/Ig-alpha, or CD8/Ig-beta induced similar increases in intracellular calcium levels and protein tyrosine phosphorylation. Substitution of alanine for the conserved leucine, but not the conserved isoleucine, residue within the putative activation motif of CD8/Ig-beta destroyed signaling ability. In murine T-cell hybridoma DO-11.10 cells, cross-linking of the T-cell antigen receptor, CD8/Ig-alpha, or CD8/Ig-beta stimulated equivalent protein tyrosine phosphorylation and interleukin-2 production. Thus, the cytoplasmic domains of Ig-a! and Ig-p are equally capable of initiating early signaling events downstream of B- and T cell antigen receptors as well as evoking a complete biological effector response in lymphocytes.	UNIV CALIF SAN DIEGO, DEPT BIOMED SCI, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego	TADDIE, JA (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NCI NIH HHS [CA14195, CA17289] Funding Source: Medline; NIAID NIH HHS [AI08685] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R01CA017289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008685] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DENNERT G, 1980, NATURE, V287, P47, DOI 10.1038/287047a0; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13529	13535						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175787				2022-12-27	WOS:A1994NK18400070
J	PRAGER, D; LI, HL; YAMASAKI, H; MELMED, S				PRAGER, D; LI, HL; YAMASAKI, H; MELMED, S			HUMAN INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR INTERNALIZATION - ROLE OF THE JUXTAMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTOSIS; ADAPTORS; SEQUENCE; SIGNALS; REGION	Cytoplasmic submembrane domains of the insulin-like growth factor I (IGF-1) receptor ranging from glycine 940 to proline 959 were investigated for their role in endocytosis of the IGF-1 ligand in rat pituitary GC cells stably expressing mutant human IGF-1 receptors. Replacement of each of three tyrosine residues within the juxtamembrane domain reduced the internalization rate (K-e) by 33% (943Y --> A), 47% (950Y --> A), and 41% (957 --> A), respectively. Other substitutions within the submembrane region variably retarded receptor-mediated IGF-1 ligand endocytosis. Thus, each amino acid appears to independently contribute to the overall ligand-stimulated IGF-1 receptor internalization rate. The effect of receptor occupancy on IGF-1 receptor endocytosis was also tested. The rate of I-125-labeled IGE-1 internalization by transfectants overexpressing the wild type IGF-1 receptor was rapid but decreased markedly in the presence of increasing unlabeled IGF-1 (ED(50) = 44,000 receptors/cell). Substitution by alanine for any of the three submembrane tyrosines increased the ED(50) to >56,000 receptors/cell, decreased the slope (K-ic), and had a variable effect on V-max in the presence of increasing unlabeled IGF-1. In contrast, I-125-labeled IGF-1 endocytosis by the mutant kinase-deficient (STOP)-S-952 cells was slow and not further retarded by unlabeled IGF-1. These results suggest that ligand-mediated internalization of the human IGF-I is consistent with saturable interactions between the IGF-I receptor juxtamembrane region (glycine 940-tyrosine 957) and components of the endocytic apparatus.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV ENDOCRINOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002023, R01DK034824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02023, DK 34824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2223; LUND KA, 1990, J BIOL CHEM, V265, P15713; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; THIES RS, 1990, J BIOL CHEM, V265, P10132; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; YAMASAKI H, 1993, MOL ENDOCRINOL, V7, P681, DOI 10.1210/me.7.5.681; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953	18	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11934	11937						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163493				2022-12-27	WOS:A1994NG37700041
J	RASCON, A; DEGERMAN, E; TAIRA, M; MEACCI, E; SMITH, CJ; MANGANIELLO, V; BELFRAGE, P; TORNQVIST, H				RASCON, A; DEGERMAN, E; TAIRA, M; MEACCI, E; SMITH, CJ; MANGANIELLO, V; BELFRAGE, P; TORNQVIST, H			IDENTIFICATION OF THE PHOSPHORYLATION SITE IN-VITRO FOR CAMP-DEPENDENT PROTEIN-KINASE ON THE RAT ADIPOCYTE CGMP-INHIBITED CAMP-PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; ADIPOSE-TISSUE; INSULIN; PURIFICATION; PARTICULATE; ACTIVATION; SEPARATION; LIPOLYSIS	Rat adipocyte cGMP-inhibited cAMP phosphodiesterase (cGI-PDE) appears to be dually regulated in intact cells by serine phosphorylations induced by isoprenaline and insulin, respectively (Degerman, E., Smith, C. J., Tornqvist, H., Vasta, V., Belfrage, P., and Manganiello, V. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 533-537; Smith, C. J., Vasta, V., Degerman, E., Belfrage, P., and Manganiello, V. C. (1991) J. Biol. Chem. 266, 13385-13390). Since cAMP-dependent protein kinase (cAMP-PK) catalyzes the beta-adrenergic effects, the site in the isolated cGI-PDE phosphorylated by this kinase was explored. A peptide, LRRSSGASGLLTSEHHSR (P18), corresponding to the amino acid sequence Leu(429)-Arg(440) in the putative regulatory domain of the rat adipocyte cGI-PDE was synthesized. It contains a consensus substrate sequence -RRXS- for cAMP-PK within two tryptic cleavage sites and was readily phosphorylated by cAMP-PK. Two phosphopeptides, identified as RS-[P-32]SGASGLLTSEHHSR and S-[P-32]SGASGLLTSEHHSR, were obtained after stoichiometric phosphorylation and trypsinization of the peptide. These two peptides and the two main tryptic phosphopeptides obtained from immunoisolated [P-32]cGI-PDE phosphorylated with cAMP-PK in a solubilized crude adipocyte membrane fraction were immunoprecipitated by an affinity-purified polyclonal antibody raised against P18 and exhibited the same chromatographic and electrophoretic profiles in three different separation systems. Similar radiosequencing profiles indicated that the second most N-terminal serine, corresponding to Ser-427 in the intact cGI-PDE, was phosphorylated by cAMP-PK in both P18 and authentic cGI-PDE. It is concluded that serine 427 is the target for cAMP-PK phosphorylation of the rat adipocyte cGI-PDE in vitro.	LUND UNIV, DEPT MED & PHYSIOL CHEM, S-22100 LUND, SWEDEN; LUND UNIV, DEPT PAEDIAT, S-22100 LUND, SWEDEN; NHLBI, CELLULAR METAB LAB, BETHESDA, MD 20892 USA	Lund University; Lund University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANG KJ, 1974, J BIOL CHEM, V249, P6854; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEGERMAN E, 1988, SEC MESS PHOSPHOPROT, V12, P171; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; KEMP BE, 1977, J BIOL CHEM, V260, P15122; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGANIELLO VC, 1992, ADV SEC MESS PHOSPH, V25, P147; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; TAIRA M, 1993, J BIOL CHEM, V268, P18573; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X	19	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11962	11966						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163498				2022-12-27	WOS:A1994NG37700046
J	SANZ, MA; PEREZ, L; CARRASCO, L				SANZ, MA; PEREZ, L; CARRASCO, L			SEMLIKI FOREST VIRUS 6K PROTEIN MODIFIES MEMBRANE-PERMEABILITY AFTER INDUCIBLE EXPRESSION IN ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; POLIOVIRUS NONSTRUCTURAL PROTEINS; VALENT CATION-TRANSPORT; VIRAL-INFECTION; MAMMALIAN-CELLS; CHICK-CELLS; TRANSLATION; RELEASE; INHIBITION; SYSTEM	Semliki Forest virus encodes a small protein, known as 6K, that is associated with cellular membranes in the infected cells. This protein has been cloned and expressed in an inducible manner using pET vectors in Escherichia coli cells. Two different plasmids have been utilized; either the 6K gene is placed directly under the T7 promoter (pET3-6K) or the iac operator is located between the T7 promoter and the 6K gene (pET11-6K). In both systems, efficient synthesis of the 6K protein is achieved by induction with isopropyl-1-thio-beta-D-galactopyranoside plus rifampicin. The synthesis of the 6K protein is very toxic for E. coli causing increased membrane permeability and cell lysis as shown by alterations in permeability to either choline or hygromycin B. These results indicate that the togavirus 6K is a membrane-active protein that shows structural and functional similarities to poliovirus 3A protein. The function that the 6K protein could play during the virus replication cycle is discussed in the light of these findings.	UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	SANZ, MA (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN.		Carrasco, Luis/H-3001-2017; Carrasco, Luis/E-2435-2012; Sanz, Miguel A/H-1914-2015; sanz-gomez, miguel/Y-6244-2019	Carrasco, Luis/0000-0003-3833-8835; Sanz, Miguel A/0000-0001-6573-883X; sanz-gomez, miguel/0000-0002-5761-9010; Perez Garcia-Estan, Luis/0000-0003-4078-8763				ALONSO MA, 1982, EMBO J, V1, P913, DOI 10.1002/j.1460-2075.1982.tb01271.x; ALONSO MA, 1980, EUR J BIOCHEM, V109, P535, DOI 10.1111/j.1432-1033.1980.tb04825.x; BARTH BU, 1992, J VIROL, V66, P7560, DOI 10.1128/JVI.66.12.7560-7564.1992; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1977, FEBS LETT, V76, P11, DOI 10.1016/0014-5793(77)80110-5; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CARRASCO L, 1983, PHARMACOL THERAPEUT, V23, P109, DOI 10.1016/0163-7258(83)90028-1; CARRASCO L, 1987, MECHANISM VIRAL TOXI, P1; Carrasco L., 1993, REGULATION GENE EXPR; CARRASCO L, 1979, MODERN TRENDS HUMAN, P277; CARRASCO L, 1983, ANTIBIOTICS, V6, P1980; COLLINS PL, 1993, J GEN VIROL, V74, P1445, DOI 10.1099/0022-1317-74-7-1445; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P274, DOI 10.1016/0042-6822(90)90209-A; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; GARRY RF, 1979, VIROLOGY, V96, P108, DOI 10.1016/0042-6822(79)90177-6; HOLSEY C, 1990, J CELL PHYSIOL, V142, P586, DOI 10.1002/jcp.1041420319; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; IRURZUN A, 1993, J GEN VIROL, V74, P1063, DOI 10.1099/0022-1317-74-6-1063; LACAL JC, 1982, EUR J BIOCHEM, V127, P359, DOI 10.1111/j.1432-1033.1982.tb06880.x; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LAMA J, 1992, GENE, V117, P185, DOI 10.1016/0378-1119(92)90728-8; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, J VIROL, V65, P147; LOPEZRIVAS A, 1987, J GEN VIROL, V68, P335, DOI 10.1099/0022-1317-68-2-335; LUSA S, 1991, VIROLOGY, V185, P843, DOI 10.1016/0042-6822(91)90556-Q; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; MUNOZ A, 1985, VIROLOGY, V146, P203, DOI 10.1016/0042-6822(85)90004-2; NAIR CN, 1984, J GEN VIROL, V65, P1135, DOI 10.1099/0022-1317-65-6-1135; PEREZ L, 1993, VIROLOGY, V194, P28, DOI 10.1006/viro.1993.1231; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER MJ, 1993, VIROLOGY, V193, P424, DOI 10.1006/viro.1993.1139; SCHLESINGER S, 1993, VIROLOGY, P697; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; ULUG ET, 1984, VIROLOGY, V132, P118, DOI 10.1016/0042-6822(84)90096-5; ULUG ET, 1989, VIROLOGY, V172, P42, DOI 10.1016/0042-6822(89)90105-0; ULUG ET, 1987, MECHANISMS VIRAL TOX, P91	42	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12106	12110						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163515				2022-12-27	WOS:A1994NG37700066
J	USHKARYOV, YA; HATA, Y; ICHTCHENKO, K; MOOMAW, C; AFENDIS, S; SLAUGHTER, CA; SUDHOF, TC				USHKARYOV, YA; HATA, Y; ICHTCHENKO, K; MOOMAW, C; AFENDIS, S; SLAUGHTER, CA; SUDHOF, TC			CONSERVED DOMAIN-STRUCTURE OF BETA-NEUREXINS - UNUSUAL CLEAVED SIGNAL SEQUENCES IN RECEPTOR-LIKE NEURONAL CELL-SURFACE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Neurexins, a family of neuronal cell-surface proteins, consist of the longer alpha-neurexins (I alpha, II alpha, and III alpha) and the shorter beta-neurexins (I beta and II beta) with identical C termini but distinct N termini. alpha-Neurexins have the structure of cell surface receptors, but the membrane topology and conservation of beta-neurexins is unknown. We have now characterized cDNA clones encoding bovine neurexins I beta and III beta, thereby demonstrating the presence of a beta-form for neurexin III and the evolutionary conservation of beta-neurexins in mammals. Similar to alpha-neurexins, beta-neurexins were found to be highly O-glycosylated after expression by transfection in COS cells, suggesting that alpha- and beta-neurexins utilize the same O-glycosylation cassette and have similar transmembrane orientations. To determine if beta-neurexins contain a cleaved or uncleaved signal sequence for membrane translocation, beta-neurexin-IgG fusion proteins were expressed in COS cells, and their N termini were directly sequenced. This revealed that the N terminus of all three beta-neurexins contains an unusual cleaved signal sequence. Together our data show that all known neurexin genes generate alpha and beta forms with similar transmembrane organizations and receptor-like structures. Due to the presence of a long atypical cleaved signal peptide, beta-neurexins contain only a short unique sequence before splicing into the a neurexin sequence, Thus, beta-neurexins are essentially N terminally truncated alpha-neurexins.	UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; GEPPERT M, 1992, COLD SPRING HARB SYM, V57, P483, DOI 10.1101/SQB.1992.057.01.053; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HORTSCH M, 1986, INT REV CYTOL, V102, P215, DOI 10.1016/S0074-7696(08)61276-0; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; ROBINSON PJ, 1993, NATURE, V349, P79; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	11	126	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11987	11992						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163501				2022-12-27	WOS:A1994NG37700050
J	DAIHO, T; KANAZAWA, T				DAIHO, T; KANAZAWA, T			REDUCTION OF DISULFIDE BONDS IN SARCOPLASMIC-RETICULUM CA2+-ATPASE BY DITHIOTHREITOL CAUSES INHIBITION OF PHOSPHOENZYME ISOMERIZATION IN CATALYTIC CYCLE - THIS REDUCTION REQUIRES BINDING OF BOTH PURINE NUCLEOTIDE AND CA2+ TO ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CA-2+-ATPASE; VESICLES	Sarcoplasmic reticulum vesicles were treated with 6 mM dithiothreitol in the presence of 2 mM ATP and 0.1 mM Ca2+ at 25-degrees-C and pH 7.0 for various periods. The Ca2+-ATPase was inhibited almost completely in 100 min. The content of the sulfhydryl group, which was measured in 2.5% SDS with 5,5'-dithiobis(2-nitrobenzoic acid), increased during the treatment. Extrapolation of the plot of the Ca2+-ATPase activity versus the increment of the sulfhydryl group showed that reduction of two disulfide bonds per phosphorylation site leads to a complete inhibition of the enzyme. This reduction required binding of both Ca2+ (with a high affinity) and a purine nucleotide to the enzyme. Adenosine 5'-(beta,gamma-methylene) triphosphate (a nonhydrolyzable ATP analog) was also effective for the reduction, while phosphorylation of the enzyme with acetyl phosphate or P(i) did not trigger the reduction. These results indicate that formation of a substrate-enzyme-calcium complex is responsible for the dithiothreitol-induced disulfide bond reduction. The partial reactions of the Ca2+-ATPase were examined with the vesicles that had been treated with dithiothreitol in the presence of ATP and Ca2+ for 100-200 min. Neither isomerization of the unphosphorylated enzyme from the low Ca2+ affinity form to the high Ca2+ affinity form nor phosphorylation of the enzyme with ATP or P(i) was inhibited. In contrast, isomerization of the phosphoenzyme intermediate from the ADP-sensitive form to the ADP-insensitive form was strongly inhibited. These results show that the observed inhibition of the Ca2+-ATPase is due to a selective blockage of the phosphoenzyme isomerization.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,JAPAN	Asahikawa Medical College								ABRAMSON JJ, 1978, J MEMBRANE BIOL, V44, P233, DOI 10.1007/BF01944223; ANDERSEN JP, 1977, BIOCHIM BIOPHYS ACTA, V485, P188, DOI 10.1016/0005-2744(77)90206-6; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GEORGOUSSI Z, 1985, BIOCHEM BIOPH RES CO, V126, P1196, DOI 10.1016/0006-291X(85)90312-2; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1974, BIOCHEM SOC SPEC PUB, V4, P159; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWASHIMA T, 1990, J BIOL CHEM, V265, P10993; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MURPHY AJ, 1976, BIOCHEMISTRY-US, V15, P4492, DOI 10.1021/bi00665a025; Mutoh Yoshinobu, 1992, Journal of UOEH, V14, P253; PANET R, 1970, EUR J BIOCHEM, V14, P440, DOI 10.1111/j.1432-1033.1970.tb00308.x; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739	22	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11060	11064						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157632				2022-12-27	WOS:A1994NF96600017
J	JUST, I; FRITZ, G; AKTORIES, K; GIRY, M; POPOFF, MR; BOQUET, P; HEGENBARTH, S; VONEICHELSTREIBER, C				JUST, I; FRITZ, G; AKTORIES, K; GIRY, M; POPOFF, MR; BOQUET, P; HEGENBARTH, S; VONEICHELSTREIBER, C			CLOSTRIDIUM-DIFFICILE TOXIN-B ACTS ON THE GTP-BINDING PROTEIN-RHO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; ACTIVATING PROTEIN; ESCHERICHIA-COLI; PARTIAL-PURIFICATION; MAMMALIAN-CELLS; GENE-PRODUCT; C2 TOXIN; RAS; GDP	Clostridium difficile toxin B exhibits cytotoxic activity that is characterized by the disruption of the microfilamental cytoskeleton. Here we studied whether the GTP-binding Rho protein, which reportedly participates in the regulation of the actin cytoskeleton, is involved in the toxin action. Toxin B treatment of Chinese hamster ovary cells reveals a time- and concentration-dependent decrease in the ADP-ribosylation of Rho by Clostridium botulinum C3 exoenzyme in the cell lysate. Disruption of the microfilament system induced by C. botulinum C2 toxin or cytochalasin D does not cause impaired ADP-ribosylation of Rho. Toxin B exhibits its effects on Rho not only in intact cells but also when added to cell lysates. Besides endogenous Rho, RhoA-glutathione S-transferase (Rho-GST) fusion protein added to cell lysate showed decreased ADP-ribosylation after toxin B treatment. Immunoblot analysis reveals identical amounts of Rho-GST and no change in molecular mass after toxin B treatment compared with controls. ADP-ribosylation of Rho-GST purified from toxin B-treated cell lysate is inhibited, indicating a modification of Rho itself. Finally, transfection of rhoA DNA under the control of a strong promoter into cells protects them from the activity of toxin B. Altogether, the data indicate that C. difficile toxin B acts directly or indirectly on Rho proteins to inhibit ADP-ribosylation and suggest that the cytotoxic effect of toxin B involves Rho.	INST PASTEUR,UNITE TOXINES BACTERIENNES,F-75724 PARIS 15,FRANCE; UNIV MAINZ,INST MED MICROBIOL,D-55101 MAINZ,GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johannes Gutenberg University of Mainz	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMACOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIESIELSKITRESKA J, 1989, EUR J CELL BIOL, V48, P191; CIESIELSKITRESKA J, 1991, EUR J CELL BIOL, V56, P68; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; FIORENTINI C, 1989, TOXICON, V27, P1209, DOI 10.1016/0041-0101(89)90029-9; FLORIN I, 1986, MICROB PATHOGENESIS, V1, P373, DOI 10.1016/0882-4010(86)90069-0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HARTENSTEIN JH, 1993, PERSPECTIVES MED CHE, P99; HIDIKA H, 1984, BIOCHEMISTRY-US, V23, P5036; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1992, BIOCHEM BIOPH RES CO, V183, P931, DOI 10.1016/S0006-291X(05)80279-7; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1992, BIOCHEMISTRY-US, V31, P12863; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MITCHELL MJ, 1987, INFECT IMMUN, V55, P1610, DOI 10.1128/IAI.55.7.1610-1615.1987; MORII N, 1991, J BIOL CHEM, V266, P7646; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OHISHI I, 1980, INFECT IMMUN, V30, P668; OTTLINGER ME, 1988, EXP CELL RES, V174, P215, DOI 10.1016/0014-4827(88)90156-5; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1990, J BIOL CHEM, V265, P9373; VONEICHELSTREIB.C, 1993, GENETICS MOL BIOL AN, P264; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H	48	171	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10706	10712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144660				2022-12-27	WOS:A1994NF01700077
J	LEE, YH; ALBERTA, JA; GONZALEZ, FJ; WAXMAN, DJ				LEE, YH; ALBERTA, JA; GONZALEZ, FJ; WAXMAN, DJ			MULTIPLE, FUNCTIONAL DBP SITES ON THE PROMOTER OF THE CHOLESTEROL 7-ALPHA-HYDROXYLASE P450 GENE, CYP7 - PROPOSED ROLE IN DIURNAL REGULATION OF LIVER GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; BILE-ACID BIOSYNTHESIS; MESSENGER-RNA LEVELS; RAT-LIVER; CIRCADIAN-RHYTHM; BINDING-PROTEIN; ALPHA-HYDROXYLASE; MOLECULAR-CLONING; HEPATOMA-CELLS; ENZYME	Hepatic cytochrome P450 cholesterol 7 alpha-hydroxylase, CYP7, is regulated in vivo at the protein and the mRNA level in response to multiple physiological factors, including liver cholesterol synthesis, bile acid feedback inhibition, and diurnal rhythm. In the present study we investigated whether the liver transcription factor DBP (albumin promoter D-site binding protein), which undergoes a striking diurnal rhythm in rat liver (DBP levels during evening/morning similar to 100:1), contributes to the diurnal regulation of CYP7 gene expression. DNase I footprinting analysis using bacterially expressed DEP and a cloned 5'-flanking DNA segment of the rat CYP7 gene revealed five distinct DBP-binding sites, designated A-E, distributed between nucleotides (nts) -41 and -295 relative to the CYP7 transcription start site. CYP7-directed gene transcription in HepG2 cells transfected with a 5'-CYP7 promoter-chloramphenicol acetyltransferase reporter was activated up to 12-fold upon cotransfection of a DBP expression vector, whereas an HNF-1 alpha expression vector did not stimulate CYP7 gene activity. 5'-Deletion analyses and site-specific mutagenesis revealed that this stimulating effect of DBP can in part be ascribed to its functional interaction with DBP binding sites B (nts -115/-125), C (nts -172/-195), and D (nts -214/-230). C/EBP beta (LAP), another liver enriched basic-leucine zipper transcription factor, bound to these same sites but effected a more modest increase in CYP7-directed gene transcription (up to 3-4-fold) when expressed in HepG2 cells. Competition for CYP7 promoter-binding sites between C/EBP, which undergoes less than or equal to 2-fold diurnal change in rat liver, and the diurnally regulated DBP is proposed to determine the relative rates of basal versus diurnally regulated CYP7 gene transcription and thus may be a primary mechanism for setting the 3-6-fold amplitude that characterizes the circadian rhythm of liver CYP7 expression. Moreover, since DBP is first expressed in rat liver 3-4 weeks after birth, these findings may account for both the enhanced expression and the onset of the diurnal pattern of CYP7 enzyme levels at this stage of development.	NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; CLARKE CF, 1984, J BIOL CHEM, V259, P439; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUANE WC, 1979, AM J PHYSIOL, V236, pR175, DOI 10.1152/ajpregu.1979.236.3.R175; DUANE WC, 1983, J CLIN INVEST, V72, P1930, DOI 10.1172/JCI111157; FEARS R, 1986, CHOLESTEROL 7 ALPHA, P1; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIELEN J, 1975, EUR J BIOCHEM, V55, P41, DOI 10.1111/j.1432-1033.1975.tb02136.x; GIELEN JE, 1976, ARCH TOXICOL, V36, P255, DOI 10.1007/BF00340533; GONZALEZ F J, 1992, Keio Journal of Medicine, V41, P68; GONZALEZ FJ, 1990, DNA CELL BIOL, V9, P771, DOI 10.1089/dna.1990.9.771; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HASSAN AS, 1992, BIOCHEM PHARMACOL, V44, P1475, DOI 10.1016/0006-2952(92)90553-U; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE YH, 1994, IN PRESS MOL CELL BI; LI YC, 1990, J BIOL CHEM, V265, P12012; MCGUIRE DM, 1985, J BIOL CHEM, V260, P5435; MEIER AH, 1975, ENDOCRINOLOGY, V98, P1475; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MITROPOULOS KA, 1973, BIOCHIM BIOPHYS ACTA, V326, P428, DOI 10.1016/0005-2760(73)90143-4; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MYANT NB, 1977, J LIPID RES, V18, P135; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NISHIMOTO M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P147, DOI 10.1016/0167-4781(93)90281-H; NISHIMOTO M, 1991, J BIOL CHEM, V266, P6467; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SPADY DK, 1992, J BIOL CHEM, V267, P5584; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WAXMAN DJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P335, DOI 10.1016/0003-9861(86)90592-8; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847	54	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14681	14689						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182075				2022-12-27	WOS:A1994NM06500060
J	POUSTISDELPONT, C; THAON, S; AUBERGER, P; GERARDILAFFIN, C; SUDAKA, P; ROSSI, B				POUSTISDELPONT, C; THAON, S; AUBERGER, P; GERARDILAFFIN, C; SUDAKA, P; ROSSI, B			MONOMERIC 55-KDA GUANIDINOBENZOATASE SWITCHES TO A SERINE PROTEINASE ACTIVITY UPON TETRAMERIZATION - TETRAMERIC PROTEINASE SP-220-K APPEARS AS THE NATIVE FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS; PURIFICATION; CARCINOMA; MEMBRANE; CANCER	Guanidinobenzoatases are cell surface enzymes present in cells capable of migration or remodeling. The guanidinobenzoatase purified to homogeneity from human renal carcinoma did not display gelatinase activity under the 55-kDa form (Poustis-Delpont, C., Descomps, R., Auberger, P., Delque-Bayer, P., Sudaka, P., and Rossi, B. (1992) Cancer Res. 52, 3622-3628). We bring new insights into the structure-activity relationships of this enzyme using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, [H-3]diisopropyl fluorophosphate labeling, gelatin zymography, and immunodetection using a polyclonal antibody raised against the 55-kDa entity. Upon aggregation into a 220-kDa form, the enzyme exhibited [H-3]diisopropyl fluorophosphate labeling and diisopropyl fluorophosphate-inhibitable gelatinase activity whereas its capability to cleave p-nitrophenyl p'-guanidinobenzoate as a substrate was abolished. Thus, the guanidinobenzoatase property appears as a feature of a 55-kDa inactive form of a serine proteinase subunit. After boiling in the presence of sodium dodecyl sulfate (3% w/v), the 220-kDa entity subjected to SDS-polyacrylamide gel electrophoresis could be dissociated into a 55-kDa protein as shown by silver staining. The resulting 55-kDa band remained [H-3]diisopropyl fluorophosphate-labeled and reacted with anti-55-kDa guanidinobenzoatase antibodies, strongly suggesting that the 220-kDa proteinase was a noncovalently associated tetramer. Interestingly, Triton X-100 extracts of renal carcinoma plasma membranes exhibited a 220-kDa serine proteinase activity, as expressed in gelatin zymography, which was barely detectable in the non-tumoral counterpart. It is noteworthy that an anti-55-kDa guanidinobenzoatase reactive 220-kDa species was also observed in renal carcinoma plasma membranes extracts as assessed by Western blot, whereas it was hardly visible in the non-tumoral counterpart. No signal was immunodetected at M(r) 55,000 in renal carcinoma and kidney cortex membranes in Western blot experiments. Taken together, our data support the idea that the enzyme is expressed under its tetrameric form in the membrane. The purified enzyme is able to exhibit a serine proteinase activity when it recovers its native tetrameric form. This high molecular weight tetrameric proteinase SP 220 K appears as a new member of the cell surface serine protease family.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	POUSTISDELPONT, C (corresponding author), FAC MED NICE,BIOCHIM LAB,AVE VALOMBROSE,F-06107 NICE 02,FRANCE.		AUBERGER, Patrick/G-1491-2013; Rossi, Benedito/A-1138-2017	AUBERGER, Patrick/0000-0002-2481-8275; Rossi, Benedito/0000-0003-2614-4910				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; GEIGER M, 1987, BIOCHIM BIOPHYS ACTA, V912, P34, DOI 10.1016/0167-4838(87)90244-5; HANATANI M, 1984, J BIOCHEM-TOKYO, V95, P1349, DOI 10.1093/oxfordjournals.jbchem.a134742; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; POUSTISDELPONT C, 1992, CANCER RES, V52, P3622; POWERS JC, 1988, PROTEINASE INHIBITOR, V12, P55; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SHEIKH MI, 1982, BIOCHEM J, V208, P276; STEVEN FS, 1983, EUR J BIOCHEM, V130, P335, DOI 10.1111/j.1432-1033.1983.tb07157.x; TORIMOTO Y, 1992, MOL IMMUNOL, V29, P183, DOI 10.1016/0161-5890(92)90099-J	14	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14666	14671						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182074				2022-12-27	WOS:A1994NM06500058
J	ZHANG, L; GUARENTE, L				ZHANG, L; GUARENTE, L			HAP1 IS NUCLEAR BUT IS BOUND TO A CELLULAR FACTOR IN THE ABSENCE OF HEME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; UPSTREAM ACTIVATION SITES; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; DNA-BINDING; SEQUENCE; GENE; IDENTIFICATION; DOMAIN; SIGNAL	The activity of the yeast transcriptional activator HAP1 is controlled by heme. Previously, it has been shown that a heme-responsive domain containing multiple repeats of a conserved motif blocks DNA binding in the absence of heme. In this report, we show that HAP1 is sequestered in a high molecular weight complex in the absence of heme. Titration of the high molecular weight complex by addition of a non-DNA-binding form of HAP1 allows the protein to form dimeric complexes in the absence of heme in vitro and acquires partial transcriptional activity in vivo. The results indicate that one or more cellular factor(s) complexes with HAP1 and represses its activity in the absence of heme. Deletion of the heme domain prevents sequestration of HAP1 in the high molecular weight complex. We discuss these findings in a model that postulates that the heme domain of HAP1 can interact with other cellular factors to regulate HAP1.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)			Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HALDI M, 1989, J BIOL CHEM, V264, P17107; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; ROSE MD, 1988, METHODS YEAST GENETI; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; VERDIERE J, 1988, J MOL BIOL, V204, P277, DOI 10.1016/0022-2836(88)90575-X; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851	24	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14643	14647						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182072				2022-12-27	WOS:A1994NM06500054
J	WITCHER, DR; MCPHERSON, PS; KAHL, SD; LEWIS, T; BENTLEY, P; MULLINNIX, MJ; WINDASS, JD; CAMPBELL, KP				WITCHER, DR; MCPHERSON, PS; KAHL, SD; LEWIS, T; BENTLEY, P; MULLINNIX, MJ; WINDASS, JD; CAMPBELL, KP			PHOTOAFFINITY-LABELING OF THE RYANODINE RECEPTOR CA2+ RELEASE CHANNEL WITH AN AZIDO DERIVATIVE OF RYANODINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE SARCOPLASMIC-RETICULUM; JUNCTIONAL TERMINAL CISTERNAE; FAST SKELETAL-MUSCLE; CALCIUM RELEASE; CA2+ RELEASE; FUNCTIONAL EXPRESSION; PHOSPHORYLATION SITE; MOLECULAR-CLONING; FEET STRUCTURES; CARDIAC-MUSCLE	Ryanodine receptors/Ca2+ release channels play an important role in regulating the intracellular free calcium concentrations in both muscle and nonmuscle cells. Ryanodine, a neutral plant alkaloid, specifically binds to and modulates these Ca2+ release channels. In the work described here, we characterize the interaction of a tritium- labeled, photoactivable derivative of ryanodine (H-3-labeled 10 O-[3-(4-azidobenzamido)propionyl]ryanodine ([H-3]ABRy)) with the ryanodine receptor of skeletal, cardiac, and brain membranes. Scatchard analysis demonstrates that this ligand binds to a single class of high affinity sites in skeletal muscle triads. Furthermore, competition binding assays of [[H-3]ryanodine with skeletal, cardiac, and brain membranes in the presence of increasing concentrations of unlabeled ABRy illustrate that this azido derivative of ryanodine is able to specifically displace [H-3]ryanodine from its binding site(s). Analysis of the effects of Ca2+, ATP, and KCI on [H-3]ABRy binding in triad membranes shows a similar modulation of binding to that seen in these membranes with [H-3]ryanodine. Photoaffinity labeling of triads with [H-3]ABRy resulted in specific and covalent incorporation of [H-3]ABRy into a 565-kDa protein that was shown to be the skeletal muscle ryanodine receptor. Digestion of the labeled ryanodine receptor revealed a [H-3]ABRy-labeled 76-kDa tryptic fragment that was identified with an antibody directed against the COOH-terminal of the receptor. These results demonstrate that the 76-kDa COOH- terminal tryptic fragment contains the high affinity binding site for ryanodine.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, PROGRAM NEUROSCI, IOWA CITY, IA 52242 USA; ZENECA AGROCHEM, JEALOTTS HILL RES STN, BRACKNELL RG12 6EY, BERKS, ENGLAND	Howard Hughes Medical Institute; University of Iowa; University of Iowa				Kahl, Steven/0000-0001-7085-9556; Campbell, Kevin/0000-0003-2066-5889				CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HILKERT R, 1992, ARCH BIOCHEM BIOPHYS, V292, P1, DOI 10.1016/0003-9861(92)90043-V; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; KAHL SD, 1994, ANAL BIOCHEM, V218, P55, DOI 10.1006/abio.1994.1140; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SALAMA G, 1992, CELL CALCIUM, V13, P635, DOI 10.1016/0143-4160(92)90074-3; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZARKA A, 1993, EUR J BIOCHEM, V213, P147, DOI 10.1111/j.1432-1033.1993.tb17744.x; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	40	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13076	13079						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175731				2022-12-27	WOS:A1994NK18400006
J	KATAYAMA, T; KORNBERG, A				KATAYAMA, T; KORNBERG, A			HYPERACTIVE INITIATION OF CHROMOSOMAL REPLICATION IN-VIVO AND IN-VITRO BY A MUTANT INITIATOR PROTEIN, DNAACOS, OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								DnaA protein initiates genomic replication in Escherichia coli. A cold sensitive dnaAcos mutant caused excessive initiation at a restrictive temperature without an increase in the level of DnaA protein. The chromosomal origin (oriC) was essential for the lethality caused by the dnaAcos product. Increased initiation activity was neutralized by multiple copies of oriC on a plasmid (pBR322). OriC plasmids were replicated efficiently in vitro in a crude extract prepared from a dnaAcos mutant, with a specific activity for the DnaAcos protein 8-fold greater than that for the DnaA(+) protein in a wildtype extract. OriC dependent replication in the dnaAcos extract was inhibited by rifampicin and by gyrase inhibitors as was replication in the dnaA(+) extract. As a control, replication of single-stranded phage phi X174 DNA, which did not require DnaA protein, was similar in extracts prepared from dnaA(+) and dnaAcos cells. Thus, initiation at oriC by DnaAcos protein appears to be highly activated both in vivo and in vitro.			KATAYAMA, T (corresponding author), STANFORD UNIV, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA.			Katayama, Tsutomu/0000-0001-9994-1684				ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1987, J BACTERIOL, V169, P3898, DOI 10.1128/jb.169.9.3898-3903.1987; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HWANG DS, 1988, J BIOL CHEM, V263, P10625; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; Kornberg A., 1992, DNA REPLICATION; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LARK KG, 1972, J MOL BIOL, V64, P47, DOI 10.1016/0022-2836(72)90320-8; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, V2, P564; Miller J.H., 1972, EXPT MOL GENETICS; MURAKAMI Y, 1987, J BACTERIOL, V169, P1724, DOI 10.1128/jb.169.4.1724-1730.1987; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PIERUCCI O, 1987, J BACTERIOL, V169, P1871, DOI 10.1128/jb.169.5.1871-1877.1987; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER C, 1989, EMBO J, V8, P1609, DOI 10.1002/j.1460-2075.1989.tb03545.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHAUS N, 1981, J BACTERIOL, V145, P904, DOI 10.1128/JB.145.2.904-913.1981; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; XU YC, 1988, MOL GEN GENET, V211, P138, DOI 10.1007/BF00338404; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	39	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12698	12703						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175680				2022-12-27	WOS:A1994NH71600052
J	METTERS, KM; SAWYER, N; NICHOLSON, DW				METTERS, KM; SAWYER, N; NICHOLSON, DW			MICROSOMAL GLUTATHIONE-S-TRANSFERASE IS THE PREDOMINANT LEUKOTRIENE C-4 BINDING-SITE IN CELLULAR MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Dimethyl sulfoxide differentiated U937 (dU937) cells express high affinity G-protein-coupled receptors for leukotriene (LT)D-4 and LTB(4) and, as described here, specific binding sites for LTC(4). The specific binding of [H-3]LTC(4) was of low affinity (K-D = 26 nM) and high abundance (B-max = 33 pmol/mg of protein), as compared to LTD(4) and LTB(4) receptors. In addition, although [H-3]LTC(4), specific binding was enhanced by divalent cations, it was not inhibited by nonhydrolyzable GTP analogs. [H-3]LTC(4) specific binding to dU937 cell membranes does not have, therefore, the characteristics of binding to a G-protein-coupled receptor. Competition for [H-3]LTC(4) specific binding to dU937 cell membranes by leukotrienes and related analogs, including N-methylated LTC(4), as well as glutathione, suggested a dependence on the presence of an arachidonic acid backbone, although varying degrees of saturation were well tolerated, and that the glutathione moiety of LTC(4) in particular was important in determining affinity. The possibility that [H-3]LTC(4) specific binding was to a member of the glutathione S-transferase (GST) family of enzymes, such as LTC(4) synthase, cytosolic GST, or microsomal GST, was therefore investigated. [H-3]LTC(4) specific binding sites could be separated from LTC(4) synthase and cytosolic GSTs by differential detergent solubilization, but cofractionated with microsomal GST during solubilization and subsequent anion exchange chromatography. In membranes that were depleted of LTC(4) synthase and cytosolic GSTs, I-125-azido-LTC(4) (a photoaffinity probe based on LTC(4)) specifically photolabeled in a cation dependent manner a 17-kDa polypeptide that was comparable in mass to the microsomal GST polypeptide. Furthermore, [H-3]LTC(4) bound specifically to purified human microsomal GST with the same characteristics as to the endogenous dU937-cell membrane specific binding sites. The principal [H-3]LTC(4) specific binding site present in dU937 cells, therefore, is not a G-protein-coupled receptor, LTC(4) synthase, or cytosolic GSTs, but is microsomal GST. Finally, the 1:3 stoichiometry of [H-3]LTC(4) specific binding to purified microsomal GST is consistent with the enzyme functioning as a homotrimer.			METTERS, KM (corresponding author), MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM & MOLEC BIOL, DORVAL H9R 4P8, PQ, CANADA.							BALLERMANN BJ, 1985, CIRC RES, V56, P324, DOI 10.1161/01.RES.56.3.324; BAUD L, 1987, IMMUNOLOGY, V62, P53; BOYER TD, 1986, J BIOL CHEM, V261, P6963; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAU LY, 1986, J IMMUNOL, V137, P1985; CHIONO M, 1992, J PHARMACOL EXP THER, V262, P1248; CIVELLI M, 1987, J PHARMACOL EXP THER, V242, P1019; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK MA, 1985, EUR J PHARMACOL, V116, P207, DOI 10.1016/0014-2999(85)90155-4; FITZ TA, 1990, PROSTAG OTH LIPID M, V40, P417, DOI 10.1016/0090-6980(90)90106-6; FORDHUTCHINSON AW, 1991, TRENDS PHARMACOL SCI, V12, P68, DOI 10.1016/0165-6147(91)90500-R; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; GHIGLIERIBERTEZ C, 1986, BIOCHIM BIOPHYS ACTA, V879, P97, DOI 10.1016/0005-2760(86)90271-7; GOFFINET A, 1987, EUR J PHARMACOL, V140, P343, DOI 10.1016/0014-2999(87)90291-3; GOFFINET AM, 1989, EUR J PHARMACOL, V161, P99, DOI 10.1016/0014-2999(89)90186-6; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HERMAN CA, 1992, J EXP ZOOL, V262, P1, DOI 10.1002/jez.1402620102; HOGABOOM GK, 1985, MOL PHARMACOL, V27, P236; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; KRILIS S, 1984, P NATL ACAD SCI-BIOL, V81, P4529, DOI 10.1073/pnas.81.14.4529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM BK, 1989, J BIOL CHEM, V264, P12885; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LUI YX, 1990, PROSTAGLANDINS, V40, P431; LUNDQVIST G, 1992, J BIOL CHEM, V159, P103; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; METTERS KM, 1993, J BIOL CHEM, V268, P6487; METTERS KM, 1991, EUR J PHARMACOL, V194, P51, DOI 10.1016/0014-2999(91)90123-8; MODAT G, 1987, PROSTAGLANDINS, V33, P531, DOI 10.1016/0090-6980(87)90276-0; MONG S, 1985, J PHARMACOL EXP THER, V234, P316; MONG S, 1991, LIPOXYGENASES THEIR, P185; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MOSIALOU E, 1990, CHEM-BIOL INTERACT, V74, P275, DOI 10.1016/0009-2797(90)90044-N; MULLER A, 1988, BRIT J DERMATOL, V119, P275, DOI 10.1111/j.1365-2133.1988.tb03218.x; NICHOLSON DW, 1992, EUR J BIOCHEM, V209, P725, DOI 10.1111/j.1432-1033.1992.tb17341.x; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; NORMAN P, 1987, EUR J PHARMACOL, V143, P323, DOI 10.1016/0014-2999(87)90456-0; OWEN WF, 1987, J IMMUNOL, V138, P532; PENDLEY CE, 1989, PROSTAG OTH LIPID M, V38, P237, DOI 10.1016/0090-6980(89)90086-5; PHAN SH, 1988, BIOCHEMISTRY-US, V27, P2846, DOI 10.1021/bi00408a028; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; PONG SS, 1983, J BIOL CHEM, V258, P9616; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; ROVATI GE, 1985, BIOCHEM PHARMACOL, V34, P2831, DOI 10.1016/0006-2952(85)90003-6; Samuelsson B, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SARAU HM, 1989, ADV PROSTAG THROMB L, V19, P180; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLING M, 1986, EUR J PHARMACOL, V122, P251, DOI 10.1016/0014-2999(86)90110-X; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; SLIPETZ DM, 1993, EUR J PHARM-MOLEC PH, V244, P161, DOI 10.1016/0922-4106(93)90022-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUN FF, 1986, J BIOL CHEM, V261, P8540; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	63	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12816	12823						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175695				2022-12-27	WOS:A1994NH71600069
J	MOLLICONE, R; REGUIGNE, I; FLETCHER, A; AZIZ, A; RUSTAM, M; WESTON, BW; KELLY, RJ; LOWE, JB; ORIOL, R				MOLLICONE, R; REGUIGNE, I; FLETCHER, A; AZIZ, A; RUSTAM, M; WESTON, BW; KELLY, RJ; LOWE, JB; ORIOL, R			MOLECULAR-BASIS FOR PLASMA ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE DEFICIENCY (FUT6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; DETERMINES EXPRESSION; HUMAN-SERUM; LEWIS-X; CLONING; BLOOD; SPECIFICITY; EPITOPES; ENZYMES; TISSUES	While most humans express an alpha(1,3)-fucosyltransferase in plasma, 9% of individuals on the isle of Java (Indonesia) do not express this enzyme. Ninety five percent of these plasma alpha(1,3) fucosyltransferase-deficient individuals have Lewis negative phenotype on red cells, suggesting strong linkage disequilibrium between these two traits. To define the molecular basis for this plasma deficiency and to determine which of two candidate hu man alpha(1,3)-fucosyltransferase genes encode this enzyme (FUT5 and FUT6), we cloned and analyzed alleles at these two loci from an Indonesian individual deficient in plasma alpha(1,3)-fucosyltransferase activity. Single base pair changes were identified in the coding region of each gene, relative to previously published wild type alleles. These changes in turn yield three codon changes in FUT5 and three in FUT6 The codon changes in the FUT5 gene do not yield detectable diminutions in (alpha(1,3)fucosyltransferase activity when tested by expression in transfected COS-1 cells, and none of the FUT5 alleles co segregate with plasma alpha(1,3)-fucosyltransferase deficiency in Indonesian pedigrees. By contrast, two of the codon changes in the FUT6 alleles inactivate this gene when tested by expression in transfected COS-1 cells. One of these inactivating changes is a missense mutation (Glu-247 --> Lys) within the enzyme's catalytic domain. The other inactivating mutation represents a nonsense mutation (Tyr-315 --> stop) that truncates the COOH terminus of the enzyme by 45 amino acids. The Glu-247 --> Lys missense mutation is present in double dose in the nine plasma alpha(1,3)-fucosyltransferase deficient individuals tested, whereas the nonsense mutation at tyrosine 315 is present in double dose in just one of these persons. These results demonstrate that the (alpha(1,3)fucosyltransferase activity in human plasma is encoded by the FUT6 gene and that the missense mutation within codon 247 of this gene is responsible for deficiency of this activity in these Indonesian families.	NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY,NSW 2000,AUSTRALIA; INDONESIAN RED CROSS SOC,CENT BLOOD TRANSFUS SERV,JAKARTA 10002,INDONESIA; UNIV N CAROLINA,DEPT PEDIAT,DIV HEMATOL ONCOL,RALEIGH,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,RALEIGH,NC 27599; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Australian Red Cross Blood Service; University of North Carolina; University of North Carolina; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	MOLLICONE, R (corresponding author), INSERM,U178,16 AV PAUL VAILLANT COURIER,F-94807 VILLEJUIF,FRANCE.		/L-2667-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47455] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; Battey, 1986, BASIC METHODS MOL BI; Berger S. L., 1987, GUIDE MOL CLONING TE; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BREGUET G, 1982, HUM HERED, V32, P52, DOI 10.1159/000153259; BROADBERRY RE, 1991, HUM HERED, V41, P290, DOI 10.1159/000154015; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CHANDANAYINGYONG D, 1967, TRANSFUSION, V7, P269, DOI 10.1111/j.1537-2995.1967.tb05516.x; CHENEVIXTRENCH G, 1990, AM J HUM GENET, V46, P635; EASTON EW, 1993, BLOOD, V81, P2978; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HENRY SM, 1993, VOX SANG, V65, P62, DOI 10.1111/j.1423-0410.1993.tb04527.x; JOHNSON PH, 1988, BIOCHEM SOC T, V17, P133; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEPENDU J, 1982, AM J HUM GENET, V34, P402; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOURANT AE, 1976, DISTRIBUTION HUMAN B, P191; NAKAMURA Y, 1988, Genomics, V3, P67, DOI 10.1016/0888-7543(88)90161-9; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; ORIOL R, 1992, APMIS, V100, P28; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1991, GLYCOCONJUGATE J, V8, P147; REGUIGNE I, 1993, CYTOGENET CELL GENET, V66, P104; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SIMMONS R T, 1951, Med J Aust, V1, P173; VENTURA M, 1988, HUM HERED, V38, P36, DOI 10.1159/000153752; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VOS GH, 1967, ACTA GENET STAT MED, V17, P495; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	38	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12662	12671						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175676				2022-12-27	WOS:A1994NH71600047
J	LENTER, M; VESTWEBER, D				LENTER, M; VESTWEBER, D			THE INTEGRIN CHAINS BETA(1) AND ALPHA(6) ASSOCIATE WITH THE CHAPERONE CALNEXIN PRIOR TO INTEGRIN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BINDING-PROTEIN; CELL-ADHESION; EXPRESSION; HEMAGGLUTININ; MODULATION; RECEPTORS; COMPLEX	Integrins are alpha beta heterodimers that mediate cell-cell adhesion, as well as cell-substrate adhesion. The largest subclass is formed by 10 heterodimers (the very late antigens) that all share the beta(1)-chain. We have found a 90-kDa protein that co-isolates with mouse integrin beta(1)-chain. This 90-kDa protein was identified as the mouse homolog of calnexin, a membrane-bound chaperone and resident protein of the endoplasmic reticulum. First, the sequence of the 15 NH2-terminal amino acids of the 90-kDa protein is 80% and 87% identical to the corresponding sequences of canine and human calnexin, respectively. Second, the 90-kDa protein was recognized by a monoclonal antibody against calnexin/IP90. Association of calnexin with the integrin beta(1)-chain was directly demonstrated by chemical cross-linking. As pulse-chase experiments revealed, the association of the beta(1)-chain with calnexin occurred prior to the assembly with integrin alpha(6)-chain. Additionally, the alpha(6)-chain bound to calnexin before integrin assembly and dissociated again at the time of integrin-assembly. Our data suggest that calnexin is involved in the assembly of beta(1) integrins, as well as in the retention of a pool of immature integrin beta(1)-chains in the ER.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,W-7800 FREIBURG,GERMANY	Max Planck Society				Vestweber, Dietmar/0000-0002-3517-732X				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Ellis R J, 1990, Semin Cell Biol, V1, P1; Gething M J, 1990, Semin Cell Biol, V1, P65; GETHING MJ, 1989, BIOCHEM SOC SYMP, V55, P155; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARDER R, 1991, EXP CELL RES, V197, P259, DOI 10.1016/0014-4827(91)90431-S; HEINO J, 1989, J BIOL CHEM, V264, P380; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; WADA I, 1991, J BIOL CHEM, V266, P19599; WELLER A, 1992, J BIOL CHEM, V267, P15176	21	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12263	12268						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163531				2022-12-27	WOS:A1994NG37700089
J	WU, XJ; SAKATA, N; LUI, E; GINSBERG, HN				WU, XJ; SAKATA, N; LUI, E; GINSBERG, HN			EVIDENCE FOR A LACK OF REGULATION OF THE ASSEMBLY AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEIN FROM HEPG2 CELLS BY CHOLESTERYL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; G2 CELLS; INTRACELLULAR DEGRADATION; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; OLEIC-ACID; METABOLISM; TRANSPORT; REDUCTASE; HEP-G2	Although some previous studies have suggested that triglyceride, a major core lipid, plays a key role in the assembly and secretion of apolipoprotein B-containing lipoproteins from HepG2 cells, other reports have indicated the importance of cholesteryl ester, another core lipid. We attempted to better define the roles of triglyceride and cholesteryl ester in the assembly and secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by determining the effects of Sandoz 58-035, a potent acyl-CoA acyltransferase inhibitor, which significantly inhibits cholesteryl synthesis, and Triacsin D, a potent fatty acyl-CoA synthetase inhibitor, which significantly inhibits triglyceride synthesis, on the secretion of apolipoprotein B-containing lipoproteins. Sandoz 58-035 (2 mu g/ml) decreased very low density lipoproteins (VLDL)-stimulated cellular cholesteryl ester content by 60-80%, and blocked oleate-stimulated cholesteryl ester synthesis by 100%, but did not decrease VLDL- or oleate-stimulated apolipoprotein B secretion. Triacsin D (12.5 mu M), which significantly inhibited VLDL and oleate stimulation of triglyceride synthesis, without affecting cholesteryl ester synthesis, blocked the stimulation of apolipoprotein B secretion by both agents. In HepG2 cells transfected with 3-hydroxy-methylglutaryl-CoA reductase cDNA, cholesteryl ester synthesis and mass were increased by 100%, but apolipoprotein B secretion was unaffected. Sandoz 58-035 decreased cholesteryl ester synthesis significantly but did not decrease apolipoprotein B secretion from this cell line. When these transfected cells were incubated with oleate, apolipoprotein B secretion increased; Triacsin D blocked this effect. Finally, sphingomyelinase treatment (which shifts cholesterol from plasma membranes to intracellular pools) increased cholesteryl ester synthesis 4-5-fold, but apolipoprotein E secretion was unaffected. Changes in cellular cholesteryl ester synthesis or mass did not affect the intracellular degradation of newly synthesized apolipoprotein B, but changes in triglyceride synthesis were always associated with corresponding changes in the intracellular degradation of apolipoprotein B. In conclusion, neither long term nor short term changes in cholesteryl ester synthesis or mass regulate the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University			Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36000, HL 21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CIANFLONE K, 1992, ARTERIOSCLER THROMB, V12, P271, DOI 10.1161/01.ATV.12.3.271; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FUNGWE TV, 1992, J LIPID RES, V33, P179; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GLAUMANN H, 1975, J CELL BIOL, V64, P356, DOI 10.1083/jcb.64.2.356; HASHIMOTO S, 1980, J BIOL CHEM, V255, P8678; HIGGINS JA, 1984, J LIPID RES, V25, P1295; KHAN B, 1989, BIOCHEM J, V259, P807; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; KOSYKH VA, 1991, LIPIDS, V26, P799, DOI 10.1007/BF02536161; KOSYKH VA, 1988, FEBS LETT, V232, P103, DOI 10.1016/0014-5793(88)80395-8; KRAUSE BR, 1993, J LIPID RES, V34, P279; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RASH JM, 1981, BIOCHIM BIOPHYS ACTA, V666, P294, DOI 10.1016/0005-2760(81)90120-X; RIBEIRO A, 1991, BIOCHIM BIOPHYS ACTA, V1086, P279, DOI 10.1016/0005-2760(91)90171-D; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SAKATA N, 1992, CIRCULATION, V86, P208; Sambrook J, 1989, MOL CLONING LABORATO; SATO R, 1990, J BIOL CHEM, V265, P11880; SATO R, 1990, BIOCHIM BIOPHYS ACTA, V1042, P36, DOI 10.1016/0005-2760(90)90053-Z; SCHNITZERPOLOKOFF R, 1991, COMP BIOCHEM PHYS A, V99, P665, DOI 10.1016/0300-9629(91)90147-5; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P191; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANAKA M, 1993, J BIOL CHEM, V268, P12713; VANCE JE, 1991, J LIPID RES, V32, P1971; YAO ZM, 1988, J BIOL CHEM, V263, P2998	37	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12375	12382						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163541				2022-12-27	WOS:A1994NG37700105
J	YANG, BL; GATHY, KN; COLEMAN, MS				YANG, BL; GATHY, KN; COLEMAN, MS			MUTATIONAL ANALYSIS OF RESIDUES IN THE NUCLEOTIDE-BINDING DOMAIN OF HUMAN TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-BETA; B-CELLS; IDENTIFICATION; EXPRESSION; SITE; GENE; MUTAGENESIS; RECOMBINASE; EFFICIENT; PEPTIDES	Human terminal deoxynucleotidyl transferase (TdT) was overexpressed in a baculovirus system. The pure recombinant enzyme was identical in size, activity, kinetic constants, and metal effects to native enzyme. Three amino acids, within either the putative nucleotide binding domain and part of a DNA polymerase consensus sequence, YGDTDSLF, or a TdT consensus sequence, GGFRRGK, were altered by site directed mutagenesis. The four mutant forms of terminal transferase were also overexpressed in the baculovirus expression system and purified from Trichoplusia ni larvae by a monoclonal antibody affinity column and compared with wild-type enzyme with respect to thermostabilities, secondary structure, metal effects, and kinetic parameters. Three of the four mutants retained 3-16% of wild-type activity under varying metal conditions, and one of the mutants, D343E, consistently exhibited less than 0.2% of wild type TdT activity with dATP and no activity with dGTP. All mutants had alterations in the K-m for dATP. Variations in K-m for dGTP were not as consistent. The K-m for the other substrate, DNA initiator ((dA)(50)) in the presence of dATP remained essentially the same as that of wild-type TdT for all mutants except D343E. The enzyme activity of all mutants was stimulated by Zn2+ at low concentrations, and this effect was diminished and reversed at higher concentrations of ZnSO4. Ah mutants still retained significant amounts of the secondary structure as measured by circular dichroism. These results indicated that the aspartic acid residue at position 343 is located at or near the active site and is critical for the nucleotide binding and catalytic activity.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NCI NIH HHS [CA26391] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RS, 1987, GENE, V60, P163, DOI 10.1016/0378-1119(87)90224-1; Ausubel FM, 1988, MOL REPROD DEV; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BOLLUM FJ, 1963, PROG NUCLEIC ACID RE, V1, P1, DOI 10.1016/S0079-6603(08)60637-6; BOLLUM FJ, 1979, NATURE, V278, P191, DOI 10.1038/278191a0; BOLLUM JF, 1974, ENZYMES, V10, P145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P10272, DOI 10.1021/bi00157a014; CHANG LMS, 1982, J BIOL CHEM, V257, P9588; CHANG LMS, 1990, J BIOL CHEM, V265, P17436; COLEMAN MS, 1974, P NATL ACAD SCI USA, V71, P4404, DOI 10.1073/pnas.71.11.4404; COLEMAN MS, 1977, ARCH BIOCHEM BIOPHYS, V182, P525, DOI 10.1016/0003-9861(77)90533-1; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DATE T, 1990, BIOCHEMISTRY-US, V29, P5027, DOI 10.1021/bi00473a005; DEIBEL MR, 1980, J BIOL CHEM, V255, P4206; DEIBEL MR, 1981, J CLIN INVEST, V67, P725, DOI 10.1172/JCI110089; DEIBEL MR, 1979, J BIOL CHEM, V254, P8634; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P707, DOI 10.1021/bi00428a044; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; FULLER SA, 1985, BIOCHEM J, V231, P105, DOI 10.1042/bj2310105; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOLDSCHNEIDER I, 1977, P NATL ACAD SCI USA, V74, P734, DOI 10.1073/pnas.74.2.734; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KATO KI, 1967, J BIOL CHEM, V242, P2780; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOIWAI O, 1986, NUCLEIC ACIDS RES, V14, P5777, DOI 10.1093/nar/14.14.5777; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KORNBERG A, 1992, DNA REPLICATION, P135; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MEDIN JA, 1990, P NATL ACAD SCI USA, V87, P2760, DOI 10.1073/pnas.87.7.2760; MEDIN JA, 1992, J BIOL CHEM, V267, P5199; PANDEY V, 1988, J BIOL CHEM, V263, P3744; RECUPERO AJ, 1992, BIOCHEMISTRY-US, V31, P7989, DOI 10.1021/bi00149a033; RILEY LK, 1988, P NATL ACAD SCI USA, V85, P2489, DOI 10.1073/pnas.85.8.2489; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	46	38	47	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11859	11868						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163485				2022-12-27	WOS:A1994NG37700031
J	GOWING, E; ROHER, AE; WOODS, AS; COTTER, RJ; CHANEY, M; LITTLE, SP; BALL, MJ				GOWING, E; ROHER, AE; WOODS, AS; COTTER, RJ; CHANEY, M; LITTLE, SP; BALL, MJ			CHEMICAL CHARACTERIZATION OF A-BETA-17-42 PEPTIDE, A COMPONENT OF DIFFUSE AMYLOID DEPOSITS OF ALZHEIMER-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENILE PLAQUES; COMPLEMENT ACTIVATION; PREAMYLOID DEPOSITS; DOWNS-SYNDROME; PROTEIN; CORTEX	A peptide corresponding to the amino acid sequence of Abeta17-42 (LVFFAEDVGSNKGAIIGLMVGGWIA) was isolated from Alzheimer Disease patient brains containing large deposits of diffuse-type amyloid. Brain homogenates were lysed in SDS and submitted to high speed centrifugations. Abeta peptides were purified by size exclusion chromatography on Superose 12 and TSK 3000 SW columns. An Abeta peptide with M(r) of 3,000 was recovered that on automatic gas-phase Edman degradation yielded the amino acid sequence of Abeta starting at residue 17 (Leu). The 3-kDa peptide was subsequently hydrolyzed with trypsin and reacted with CNBr, and the resulting peptides were separated by reverse phase high pressure liquid chromatography and characterized by amino acid analyses, peptide microsequencing, and mass spectrometry. Hydrolysis of beta-amyloid precursor protein 695 at Lys612-Leu613 or at Lys16-Leu17 of its Abeta1-42 derivative prevents the generation of neurotoxic Abeta filaments, thus leading to the formation of Abeta17-42 localized in the diffuse amyloid deposits. An outstanding feature in the pathology of Alzheimer Disease is that the predominant Abeta peptides have their C termini at position 42, whether in the cores of the neuritic plaques, in the vascular walls, or in the diffuse deposits. Based on these observations, we postulate that the accumulation of insoluble Abeta(N-42) in Alzheimer Disease is due to the anomalous processing of the C-terminal region.	WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48201 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, MIDDLE ATLANTIC MASS SPECT LAB, BALTIMORE, MD 21205 USA; ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA	Wayne State University; Johns Hopkins University; Eli Lilly; Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE ON AGING [P30AG008017] Funding Source: NIH RePORTER; NIA NIH HHS [AG08017] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HUNG AY, 1993, J BIOL CHEM, V268, P22959; IKEDA S, 1990, HUM PATHOL, V21, P1221, DOI 10.1016/S0046-8177(06)80034-1; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LUE LF, 1992, DEMENTIA, V3, P308, DOI 10.1159/000107031; MASLIAH E, 1990, AM J PATHOL, V137, P1293; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MCKENZIE JE, 1992, NEUROSCI LETT, V143, P23, DOI 10.1016/0304-3940(92)90224-U; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OGHGAMI T, 1991, ACTA NEUROPATHOL, V81, P242; POTTER H, 1992, PROG BRAIN RES, V94, P447; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, IN PRESS AM J PATHOL, V144; SPARGO E, 1992, J NEUROL SCI, V111, P26, DOI 10.1016/0022-510X(92)90108-W; SPARKS DL, 1993, J NEUROPATH EXP NEUR, V52, P135, DOI 10.1097/00005072-199303000-00006; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; ULRICH J, 1990, ACTA NEUROL SCAND, V82, P5; VERGA L, 1989, NEUROSCI LETT, V105, P294, DOI 10.1016/0304-3940(89)90636-8; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P337, DOI 10.1007/BF00688170; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593	36	205	222	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10987	10990						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157623				2022-12-27	WOS:A1994NF96600006
J	KULICH, SM; YAHR, TL; MENDEMUELLER, LM; BARBIERI, JT; FRANK, DW				KULICH, SM; YAHR, TL; MENDEMUELLER, LM; BARBIERI, JT; FRANK, DW			CLONING THE STRUCTURAL GENE FOR THE 49-KDA FORM OF EXOENZYME-S (EXOS) FROM PSEUDOMONAS-AERUGINOSA STRAIN 388	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; HEAT-LABILE ENTEROTOXIN; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; ENZYMIC ACTIVITY; EXOTOXIN-A; PROTEINS; SEQUENCE	We report the purification and proteolytic characterization of the 49-kDa form of exoenzyme S and the cloning of the structural gene for the 49-kDa form of exoenzyme S (exoS). The 49-kDa form of exoenzyme S was purified from SDS-polyacrylamide gels. Conditions were established that allowed efficient trypsin digestion of the 49-kDa form of exoenzyme S. Amino acid sequence determination of the amino terminus and tryptic peptides of the 49-kDa form of exoenzyme S allowed the generation of degenerate oligonucleotides, which were used to amplify DNA encoding an amino-terminal sequence and an internal sequence of the 49-kDa form of exoenzyme S. These DNA fragments were used to clone the entire structural gene for the 49-kDa form of exoenzyme S (exoS) from a cosmid library of Pseudomonas aeruginosa strain 388. The 49-kDa form of exoenzyme S (ExoS) is predicted to be a 453 amino acid protein. The predicted amino acid sequence indicates that ExoS is secreted from Pseudomonas without cleavage of an aminoterminal sequence. BESTFIT analysis identified three regions of alignment between ExoS and the active site of Escherichia coli heat-labile enterotoxin. One region of homology appears to be shared among several members of the family of bacterial ADP-ribosyltransferases.	MED COLL WISCONSIN, PROT NUCLEIC ACID FACIL, DEPT MICROBIOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, PROT NUCLEIC ACID FACIL, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin			Kulich, Scott/G-3592-2010	Yahr, Timothy/0000-0001-9054-8704	NIAID NIH HHS [AI01087, AI31665] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001087, R01AI031665, R29AI031665] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; BODEY GP, 1983, REV INFECT DIS, V5, P279; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHUNG DW, 1977, INFECT IMMUN, V16, P832, DOI 10.1128/IAI.16.3.832-841.1977; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1991, J BIOL CHEM, V266, P6438; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; COBURN J, 1992, CURR TOP MICROBIOL, V175, P133; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; IGLEWSKI BH, 1988, HDB TOXINS, V4, P249; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; LORY S, 1980, INFECT IMMUN, V28, P494; Maniatis T., 1982, MOL CLONING; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; Nicas T I, 1985, Antibiot Chemother (1971), V36, P40; NICAS TI, 1985, EUR J CLIN MICROBIOL, V4, P175, DOI 10.1007/BF02013593; NICAS TI, 1985, CAN J MICROBIOL, V31, P387, DOI 10.1139/m85-074; NICAS TI, 1984, INFECT IMMUN, V45, P270; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4361; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; RIVIERE LE, 1991, TECH PROTEIN CHEM, V2, P170; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SOKOL PA, 1990, MICROB PATHOGENESIS, V8, P243, DOI 10.1016/0882-4010(90)90051-Q; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; VASIL ML, 1977, INFECT IMMUN, V16, P353, DOI 10.1128/IAI.16.1.353-361.1977; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; Wood R E, 1976, Hosp Pract, V11, P91; WOODS DE, 1985, EUR J CLIN MICROBIOL, V4, P163, DOI 10.1007/BF02013591; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	47	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10431	10437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144626				2022-12-27	WOS:A1994NF01700039
J	CHASSANDE, O; RENARD, S; BARBRY, P; LAZDUNSKI, M				CHASSANDE, O; RENARD, S; BARBRY, P; LAZDUNSKI, M			HUMAN GENE FOR DIAMINE OXIDASE, AN AMILORIDE BINDING-PROTEIN - MOLECULAR-CLONING, SEQUENCING, AND CHARACTERIZATION OF THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; AMINE OXIDASE; FUNCTIONAL EXPRESSION; ENHANCER ELEMENTS; MAMMALIAN-CELLS; TRANSCRIPTION; MESSENGER; SITE; KERATIN; REGION	The amiloride binding protein (ABP) is detected in many epithelium-rich and/or hematopoietic tissues (Lingueglia, E., Renard, S., Voilley, N., Waldmann, R, Chassande, O., Lazdunski, M., and Barbry, P. (1993) Eur. J. Biochem. 216, 679-687). The protein binds amiloride and some of its derivatives, such as phenamil, benzamil, and ethylpropylamiloride. These properties have previously suggested that ABP might be associated with an amiloride-sensitive Na+ channel. It corresponds in fact to an amiloride-sensitive diamine oxidase (DAO) that catalyzes the degradation of compounds such as putrescine or histamine. The analysis of the organization of the sequence of the human ABP/DAO gene reveals that the 2.4-kilobase messenger RNA is transcribed from two close origins identifying the proximal promoter. After sequencing, some corrections within the initial cDNA sequence have been made. Human ABP/DAO corresponds to a 751-residue polypeptide. The promoter activity of 1800 base pairs upstream of the transcription start sites of the long form has been analyzed. Two bulks of cis-activating sequences have been identified. One of them constitutes the proximal promoter. It contains a palindromic sequence previously described as E-PAL. This motif is essential for the full activity of the promoter and behaves like a composite element. This first molecular cloning of a human gene coding for a diamine oxidase will allow us to further understand its regulation during cell growth and/or embryonic development.	INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483; Renard, Stephane/0000-0002-1374-4960				BACHRACH U, 1985, STRUCTURE FUNCTIONS, P5; BARBRY P, 1987, P NATL ACAD SCI USA, V84, P4836, DOI 10.1073/pnas.84.14.4836; BARBRY P, 1990, HUM GENET, V85, P587, DOI 10.1007/BF00193579; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BELIAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRELIN C, 1987, KIDNEY INT, V32, P785, DOI 10.1038/ki.1987.277; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KLEYMAN TR, 1986, J BIOL CHEM, V261, P2839; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; NOVOTNY WF, 1994, J BIOL CHEM, V269, P9921; RANGACHARI PK, 1992, AM J PHYSIOL, V262, pG1, DOI 10.1152/ajpgi.1992.262.1.G1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSSI A, 1992, FEBS LETT, V301, P253, DOI 10.1016/0014-5793(92)80251-B; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	30	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14484	14489						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182053				2022-12-27	WOS:A1994NM06500029
J	KRYCH, M; CLEMENZA, L; HOWDESHELL, D; HAUHART, R; HOURCADE, D; ATKINSON, JP				KRYCH, M; CLEMENZA, L; HOWDESHELL, D; HAUHART, R; HOURCADE, D; ATKINSON, JP			ANALYSIS OF THE FUNCTIONAL DOMAINS OF COMPLEMENT RECEPTOR-TYPE-1 (C3B/C4B RECEPTOR, CD35) BY SUBSTITUTION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; CONTROL PROTEIN MODULE; C3B C4B RECEPTOR; 3RD COMPONENT; VACCINIA VIRUS; LIGAND-BINDING; SECONDARY STRUCTURE; FACTOR-H; SITES; CR-1	The complement receptor type 1 (CR1; CD35), carrying 30 short consensus repeats (SCRs), has two sites. Site 1 contains SCR-1 and SCR-2 and binds C4b. Site 2 contains SCR-8 and SCR-9 and was reported to bind mainly C3b (Klickstein, L. B., Bartow, T. J., Miletic, V., Rabson, L. D., Smith, J. A, and Fearon, D. T. (1988) J. Exp. Med. 168, 1699-1717). For the functional analysis we used two constructs, each with one site. CR1-4, composed of eight and one-half initial SCRs, carries site 1, binds C4b, and is cofactor for C4b cleavage. CR1-4(8,9), obtained from CR1-4 by converting site 1 to site 2, binds iC3/C3b and, unexpectedly, C4b. It is a cofactor for cleavage of both ligands. Its cofactor activity for C4b cleavage is greater than that of site 1. Analysis of the mutants constructed by interchanging homologous peptides between the two sites identified no sequences necessary for cofactor activity other than those required for binding. In site 2, peptides important for both ligands were found. Some modifications of either site led to higher activity for both ligands. Thus the activity of complement regulators can be increased by changing a few amino acids within SCRs, an important step toward the generation of more effective inhibitors of complement activation. Knowledge of the active sites of CR1 should be applicable to other SCR-containing proteins and should provide insights into the evolution of these proteins.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Atkinson, John/0000-0002-2514-3441				ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1992, DEV COMP IMMUNOL, V16, P63, DOI 10.1016/0145-305X(92)90052-E; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BARLOW PN, 1992, 18TH INT C IMM BUD, P168; BECHERER JD, 1988, J BIOL CHEM, V263, P14586; BECHERER JD, 1989, CURRENT TOPICS MICRO; CAMPBELL ID, 1991, PHILOS T R SOC B, V332, P165, DOI 10.1098/rstb.1991.0045; CAREL JC, 1990, J BIOL CHEM, V265, P12293; CARROLL MC, 1983, P NATL ACAD SCI-BIOL, V80, P264, DOI 10.1073/pnas.80.1.264; COYNE KE, 1992, J IMMUNOL, V149, P2906; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DOMDEY H, 1982, P NATL ACAD SCI-BIOL, V79, P7619, DOI 10.1073/pnas.79.24.7619; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; DYKMAN TR, 1983, J EXP MED, V157, P2160, DOI 10.1084/jem.157.6.2160; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HOGG N, 1984, EUR J IMMUNOL, V14, P236, DOI 10.1002/eji.1830140307; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; MARTIN DR, 1991, J EXP MED, V174, P1299, DOI 10.1084/jem.174.6.1299; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; MCNEARNEY TA, 1987, J EXP MED, V166, P1525, DOI 10.1084/jem.166.5.1525; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; MOLINA H, 1991, J BIOL CHEM, V266, P12173; MULLIGAN MS, 1992, J IMMUNOL, V148, P1479; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; OGATA RT, 1993, J IMMUNOL, V150, P2273; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REILLY BD, 1993, J IMMUNOL, V150, pA224; SEIDELDUGAN C, 1990, J VIROL, V64, P1897, DOI 10.1128/JVI.64.5.1897-1906.1990; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YEH CG, 1991, J IMMUNOL, V146, P250	44	90	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13273	13278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175757				2022-12-27	WOS:A1994NK18400036
J	LI, JZ; ROBERTS, RM				LI, JZ; ROBERTS, RM			INTERFERON-TAU AND INTERFERON-ALPHA INTERACT WITH THE SAME RECEPTORS IN BOVINE ENDOMETRIUM - USE OF A READILY IODINATABLE FORM OF RECOMBINANT INTERFERON-TAU FOR BINDING-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE TROPHOBLAST PROTEIN-1; PREGNANCY RECOGNITION HORMONE; CONCEPTUS SECRETORY PROTEINS; COMMON RECEPTORS; SHEEP; EXPRESSION; SEQUENCE; GENES; PURIFICATION; INDUCTION	Trophoblasts of ruminant species secrete multiple forms of a novel Type I interferon (IFN-tau) for a few days preceding implantation. These IFN-tau are structurally distinct from IFN-alpha, -beta, and -omega, but it remains unclear whether they have any distinguishing biological properties. It has been of interest, therefore, to study their interaction with Type I IFN receptors. However, a recombinant bovine IFN-tau (boIFN-tau 1) prepared for such use is rapidly inactivated during chemical iodination with I-125, presumably because a critical tyrosine becomes modified. Here we describe the synthesis of a novel IFN-tau 1 in which Leu(169) and Leu(171) in the carboxyl terminus have been replaced by 2 tyrosine residues. The recombinant product (rboIFN-tau 1Y2) can be readily iodinated without significant loss of antiviral and antiproliferative activities, provided that reaction time with I-125 is minimized. Both rboIFN-tau 1Y2 and rboIFN-alpha 1 compete with each other for binding to bovine endometrial cell membranes and Madin-Darby bovine kidney cells. Dissociation constants of both IFN are quite similar (K-d = 3.7 x 10(-10) and 3.5 x 10(-10) M, respectively). Cross-linking studies reveal a single size class of receptor polypeptide on endometrium and Madin-Darby canine kidney cells whose molecular weight is reduced from similar to 130,000 to similar to 70,000 by treatment with N-glycosidase. These studies with a single recombinant form of boIFN-tau avoid the difficulties that arise from use of a mixture of naturally occurring isoforms. They provide further evidence for the presence of a receptor common to both IFN-tau and IFN-alpha in bovine tissues and no indication for a unique IFN-tau-binding polypeptide in endometrium.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT ANIM SCI,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021896, R37HD021896] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21896] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUET M, 1984, VIROLOGY, V132, P211, DOI 10.1016/0042-6822(84)90105-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCA AA, 1987, J INTERFERON RES, V7, P77, DOI 10.1089/jir.1987.7.77; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; CROSS JC, 1991, P NATL ACAD SCI USA, V88, P3817, DOI 10.1073/pnas.88.9.3817; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FILLION C, 1991, J REPROD IMMUNOL, V19, P237, DOI 10.1016/0165-0378(91)90038-R; FINCHER KB, 1986, J REPROD FERTIL, V76, P425, DOI 10.1530/jrf.0.0760425; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GODKIN JD, 1984, ENDOCRINOLOGY, V114, P120, DOI 10.1210/endo-114-1-120; HANNIGAN GE, 1983, BIOCHEM BIOPH RES CO, V110, P537, DOI 10.1016/0006-291X(83)91183-X; HANSEN TR, 1989, J INTERFERON RES, V9, P215, DOI 10.1089/jir.1989.9.215; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KLEMANN SW, 1990, MOL ENDOCRINOL, V4, P1506, DOI 10.1210/mend-4-10-1506; KLEMANN SW, 1990, NUCLEIC ACIDS RES, V18, P6724, DOI 10.1093/nar/18.22.6724; KNICKERBOCK JJ, 1986, PROSTAG OTH LIPID M, V31, P777, DOI 10.1016/0090-6980(86)90180-2; KNICKERBOCKER JJ, 1989, BIOL REPROD, V40, P361, DOI 10.1095/biolreprod40.2.361; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEAMAN DW, 1994, IN PRESS MOL ENDOCRI; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; MOUCHELVIELH E, 1992, FEBS LETT, V313, P255, DOI 10.1016/0014-5793(92)81204-Y; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NEDDEN DLZ, 1986, METHOD ENZYMOL, V119, P276; OLSEN MK, 1989, J BIOTECHNOL, V9, P179, DOI 10.1016/0168-1656(89)90107-7; PONTZER CH, 1991, CANCER RES, V51, P5304; PONTZER CH, 1988, BIOCHEM BIOPH RES CO, V152, P801, DOI 10.1016/S0006-291X(88)80109-8; ROBERTS RM, 1989, J INTERFERON RES, V9, P175, DOI 10.1089/jir.1989.9.175; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; ROBERTS RM, 1989, BIOL REPROD, V40, P449, DOI 10.1095/biolreprod40.3.449; SARKAR FH, 1986, METHOD ENZYMOL, V119, P263; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; UZE G, 1985, EMBO J, V4, P64; VALLET JL, 1988, J REPROD FERTIL, V84, P493, DOI 10.1530/jrf.0.0840493; YONEHARA S, 1983, J BIOL CHEM, V258, P9046	42	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13544	13550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175789				2022-12-27	WOS:A1994NK18400072
J	YAN, ZF; WINAWER, S; FRIEDMAN, E				YAN, ZF; WINAWER, S; FRIEDMAN, E			2 DIFFERENT SIGNAL-TRANSDUCTION PATHWAYS CAN BE ACTIVATED BY TRANSFORMING GROWTH-FACTOR-BETA-1 IN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE THREONINE KINASE; ERK-1 GENE-PRODUCT; PROTEIN-KINASE; MAP KINASE; EXPRESSION CLONING; PHOSPHORYLATION; RAS; RECEPTOR; FACTOR-BETA-1; CASCADE	Signal transduction initiated by transforming growth factor beta 1 (TGF beta 1) was studied in two sublines of the same colon carcinoma cell line, which respond in opposite ways to TGF beta 1, by proliferation or by growth inhibition. TGF beta 1 activates ras proteins within 5 min of addition when it acts to inhibit growth but not when it acts as a mitogen. In both cases TGF beta 1 also rapidly modulates the activities of three protein kinases, detected by their in gel kinase activity on the mitogen-activated protein kinase (MAP kinase) substrate, myelin basic protein (MBP), When TGF beta 1 acts as a mitogen for U9 cells, it increases the activity of MBP kinases of 57, 105, and 130 kDa within 10 min of the addition without detectably activating ras proteins. When TGF beta 1 inhibits the growth of HD3 cells, it activates ras proteins and the 57-kDa MBP kinase within 5 min but inhibits the activity of the 105- and 130-kDa MBP kinases. In HD3 cells ras activation occurred in two signal transduction pathways, one from TGF beta 1 leading to growth inhibition and one from epidermal growth factor (EGF) leading to proliferation. In addition to ras proteins, EGF activates a different set of MBP kinases in HD3 cells than does TGF beta 1, MBP kinases of 85, 57, and 44 kDa. The latter is likely to be the 44-kDa MAP kinase extracellular signal-regulated kinase (erk) 1, because EGF treatment of HD3 cells activates erk1 by increasing its phosphotyrosine level. Therefore, in two closely related epithelial cell lines TGF beta 1 activates two different signal transduction pathways, one ras-dependent and one ras-independent, and modulates the activities of a set of MBP kinases.	MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01 CA50645, IT32CA09628, CA45783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045783, T32CA009628, R01CA050645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, IN PRESS CELL GROWTH; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE HS, 1993, J BIOL CHEM, V268, P5255; LENGECARTER CA, 1993, SCIENCEE, V260, P315; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULDER KM, 1992, J BIOL CHEM, V267, P5029; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHROY P, 1990, CANCER RES, V50, P261; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS G, 1993, CELL, V68, P3; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1992, ONCOGENE, V7, P801	56	147	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13231	13237						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175753				2022-12-27	WOS:A1994NK18400030
J	MACH, L; MORT, JS; GLOSSL, J				MACH, L; MORT, JS; GLOSSL, J			MATURATION OF HUMAN PROCATHEPSIN-B - PROENZYME ACTIVATION AND PROTEOLYTIC PROCESSING OF THE PRECURSOR TO THE MATURE PROTEINASE, IN-VITRO, ARE PRIMARILY UNIMOLECULAR PROCESSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; CYSTEINE PROTEINASES; RAT MACROPHAGES; IDENTIFICATION; BIOSYNTHESIS; INVITRO; LOCALIZATION; ENDOPROTEASE; FIBROBLASTS; PEPSINOGEN	Recombinant latent human procathepsin B produced in yeast was purified to near homogeneity. The purified recombinant proenzyme is activated in vitro under acidic conditions resulting in rapid conversion into the mature form of the proteinase. Activation as well as proteolytic maturation of the recombinant cathepsin B precursor were shown to be primarily concentration-independent processes indicating a unimolecular (i.e. intramolecular) mechanism. Only one cleavage site was identified, yielding a mature polypeptide with the same amino-terminal sequence as that found in recombinant active human cathepsin B obtained from yeast culture media. The same peptide bond is cleaved during processing of a nonactivatable mutant of procathepsin B by the purified mature enzyme (i.e. intermolecular processing). Thus, the complete proregion is liberated during procathepsin B processing. This peptide may then act as a reversible inhibitor and stabilizer of the mature proteinase, and it appears likely that cathepsin B-propeptide complexes occur transiently during proteolytic maturation.	AGR UNIV VIENNA,ZENTRUM ANGEW GENET,A-1180 VIENNA,AUSTRIA; SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL H3G 1A6,PQ,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3A 2T6,PQ,CANADA	University of Natural Resources & Life Sciences, Vienna; McGill University; McGill University			Glössl, Josef/H-8208-2013	Glössl, Josef/0000-0002-5042-8828; Mach, Lukas/0000-0001-9013-5408				Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; ALJANABI J, 1972, J BIOL CHEM, V247, P4628; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROMME D, 1993, J BIOL CHEM, V268, P4832; BUTTLE DJ, 1992, BIOCHEM J, V287, P657, DOI 10.1042/bj2870657; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DUNN AD, 1991, J BIOL CHEM, V266, P20198; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HARA K, 1988, FEBS LETT, V231, P229, DOI 10.1016/0014-5793(88)80737-3; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KAWABATA T, 1993, J BIOCHEM-TOKYO, V113, P389, DOI 10.1093/oxfordjournals.jbchem.a124056; KEPPLER D, 1988, BIOL CHEM H-S, V369, P185; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONALD JK, 1988, BIOCHEM BIOPH RES CO, V151, P827; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V262, P159, DOI 10.1016/0003-9861(88)90178-6; PAGANO M, 1989, CR ACAD SCI III-VIE, V309, P7; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW E, 1980, BIOCHEM J, V186, P385, DOI 10.1042/bj1860385; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNET T, 1991, J BIOL CHEM, V266, P21451; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708	45	164	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13030	13035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175723				2022-12-27	WOS:A1994NH71600099
J	RAY, A; PREFONTAINE, KE; RAY, P				RAY, A; PREFONTAINE, KE; RAY, P			DOWN-MODULATION OF INTERLEUKIN-6 GENE-EXPRESSION BY 17-BETA-ESTRADIOL IN THE ABSENCE OF HIGH-AFFINITY DNA-BINDING BY THE ESTROGEN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The mechanism of repression of the interleukin-6 (IL-6) promoter by 17 beta-estradiol (E(2)) was investigated in cells transfected with wild-type (wt) or mutant estrogen receptor (ER) expression vectors. In transient transfection experiments, IL-1-induced activation of the IL-6 promoter was efficiently inhibited by wt ER. However, estrogen receptors carrying mutations within or overlapping with the DNA binding domain did not repress IL-6 promoter activity. A mutant receptor lacking the N-terminal transactivator function-1 but retaining the C-terminal transactivator function-2 also repressed activation of the IL-6 promoter. Our recent experiments indicate the requirement for both the nuclear factor (NF)-IL6 and the NF-kappa B sites in the IL-6 promoter for activation by IL-1. We now show that activation of the IL-6 promoter, elicited by a combination of NF-IL6 and the p65 subunit of NF-kappa B, can be inhibited by the wt receptor but not by a receptor containing a mutation in its DNA binding domain. Although a deletion within the DNA binding domain of ER abolished the repressor function of the receptor, a chimeric receptor ER-GR CAS1, in which the DNA binding domain of ER was swapped with the complementary region from the glucocorticoid receptor, retained the inhibitory effects on the IL-6 promoter. This was in contrast to the absolute dependence of ER on its own DNA binding domain for activation of typical estrogen response element-containing promoters, as reported previously by other investigators. Furthermore, the repression of the IL-6 promoter by a combination of ER and E(2), unlike activation of estrogen response elements by the same combination, did not appear to be mediated via high affinity binding of the receptor to the promoter. In functional experiments, the transactivator function of ER was totally inhibited by overexpression of p65 and to a lesser extent by that of NF-IL6. These results indicate that ER may repress gene expression in the absence of high affinity DNA binding.			RAY, A (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED, PULM & CRIT CARE MED SECT,333 CEDAR ST, POB 208057, NEW HAVEN, CT 06520 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI/CA 31137] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1991, TRANSCRIPTION, P409; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MATHEW S, 1993, ONCOGENE, V8, P191; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCOTT GK, 1991, J CLIN INVEST, V88, P700, DOI 10.1172/JCI115356; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	59	273	283	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12940	12946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175711				2022-12-27	WOS:A1994NH71600086
J	BASTIEN, L; SAWYER, N; GRYGORCZYK, R; METTERS, KM; ADAM, M				BASTIEN, L; SAWYER, N; GRYGORCZYK, R; METTERS, KM; ADAM, M			CLONING, FUNCTIONAL EXPRESSION, AND CHARACTERIZATION OF THE HUMAN PROSTAGLANDIN E(2) RECEPTOR EP(2) SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; PROTEIN	A cDNA clone encoding the human prostaglandin (PG) E(2) receptor EP(2) subtype has been isolated from a human lung cDNA library. The 1.9-kilobase pair cDNA, hEP(2), encodes for a 488-amino acid protein with a predicted molecular mass of 53,115 and has the seven putative transmembrane domains characteristic of G protein-coupled receptors. The specific binding of [H-3]PGE(2) to COS cell membranes transfected with the hEP(2) cDNA was of high affinity with an equilibrium dissociation constant (K-d) of 1 nM and the rank order of potency for prostaglandins in competition for [H-3]PGE(2) specific binding was PGE(1) = PGE(2) >> iloprost > PGF(2 alpha) > PGD(2). In competition studies using more selective prostanoid-receptor agonist and antagonists, the [H-3]PGE(2) specific binding was competed by MB28767, an EP(3) agonist, but not by the EP(1)-preferring antagonists AH6809 and SC19220, or by the EP(2) agonist butaprost. Electrophysiological studies of Xenopus oocytes co-injected with hEP(2) and cystic fibrosis transmembrane conductance regulator (cAMP-activated Cl- channel) cDNAs detected PGE(2)-specific inward Cl- currents, demonstrating that the hEP(2) cDNA encoded a functional receptor which produced an increase in cAMP levels. Thus, we have cloned the human EP(2) receptor subtype which is functionally coupled to increase in cAMP. Northern blot analysis showed that hEP(2) is expressed as a 3.8-kilobase mRNA in a number of human tissues with the highest expression levels present in the small intestine.	MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,POINTE CLAIRE H9R 4P8,PQ,CANADA; MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,POINTE CLAIRE H9R 4P8,PQ,CANADA	Merck & Company; Merck & Company				Grygorczyk, Ryszard/0000-0002-9798-7651				ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; Campbell W. B., 1990, PHARMACOL BASIS THER, P600; Cathala G, 1983, DNA CELL BIOL, V2, P327; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; Colman A., 1984, TRANSCRIPTION TRANSL, P49; DAVIES P, 1992, INFLAMMATION BASIC P, P123; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; FUNK CD, 1993, J BIOL CHEM, V268, P26767; GARDINER PJ, 1986, BRIT J PHARMACOL, V87, P45, DOI 10.1111/j.1476-5381.1986.tb10155.x; HANRAHAN JW, 1993, CYSTIC FIBROSIS CURR, V1, P93; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HONDA A, 1993, J BIOL CHEM, V268, P7759; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P817, DOI 10.1111/j.1476-5381.1992.tb09063.x; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SADLER SE, 1987, J BIOL CHEM, V262, P10644; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SELSEN RF, 1987, CURRENT PROTOCOLS MO; SENIOR J, 1993, BRIT J PHARMACOL, V108, P501, DOI 10.1111/j.1476-5381.1993.tb12832.x; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TAKEUCHI K, 1993, BIOCHEM BIOPH RES CO, V194, P885, DOI 10.1006/bbrc.1993.1904; WATABE A, 1993, J BIOL CHEM, V268, P20175; WATSON S, 1993, TRENDS PHARM SCI R S, V14, P31	29	234	246	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11873	11877						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163486				2022-12-27	WOS:A1994NG37700033
J	BOGAZZI, F; HUDSON, LD; NIKODEM, VM				BOGAZZI, F; HUDSON, LD; NIKODEM, VM			A NOVEL HETERODIMERIZATION PARTNER FOR THYROID-HORMONE RECEPTOR - PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							9-CIS RETINOIC ACID; RXR-BETA; RESPONSE ELEMENTS; GENE; BINDING	Retinoid-like receptors play a central role in hormonal responses by forming heterodimers with other nuclear hormone receptors. In this study we have identified the peroxisome proliferator-activated receptor (PPAR) as a new thyroid hormone receptor (THR) auxiliary nuclear protein, heterodimerizing with THR in solution. Although these heterodimers do not recognize a classical thyroid hormone response element (TRE) characterized by direct repeat separated by four nucleotides (DR + 4), PPAR behaves as a dominant negative regulator of thyroid hormone (TH) action. However a TH-dependent positive effect is elicited by selective interaction of the THR beta-PPAR but not the THR alpha-PPAR heterodimer with a novel TRE (DR + 2). The critical region of THR beta was mapped to 3 amino acids in the distal box of the DNA binding domain. Hence, PPAR can positively or negatively influence TH action depending on TRE structure and THR isotype.	NIDDK,MECHANISMS GENE REGULAT SECT,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			BOGAZZI, FAUSTO/I-2087-2012	BOGAZZI, FAUSTO/0000-0001-5975-4411				BERNDT JA, 1992, J BIOL CHEM, V267, P14730; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	18	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11683	11686						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163464				2022-12-27	WOS:A1994NG37700003
J	BHATNAGAR, RS; JACKSONMACHELSKI, E; MCWHERTER, CA; GORDON, JI				BHATNAGAR, RS; JACKSONMACHELSKI, E; MCWHERTER, CA; GORDON, JI			ISOTHERMAL TITRATION CALORIMETRIC STUDIES OF SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA-PROTEIN N-MYRISTOYLTRANSFERASE - DETERMINANTS OF BINDING-ENERGY AND CATALYTIC DISCRIMINATION AMONG ACYL-COA AND PEPTIDE LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY VIRUS-I; FATTY-ACID ANALOGS; COENZYME-A BINDING; SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; CHLORAMPHENICOL ACETYLTRANSFERASE; MEDIUM-CHAIN; RAT-LIVER; TRANSFERASE; DEHYDROGENASE	Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) is an essential, monomeric enzyme that catalyzes the transfer of myristate from COA to the amino-terminal Gly residue of cellular proteins. Product inhibition studies indicate that Nmt1p has an ordered Bi Bi reaction mechanism with myristoyl-CoA binding to the apo-enzyme to form a high affinity binary complex followed by binding of peptide with subsequent release of CoA and then the myristoylpeptide product. We have used isothermal titration calorimetry to quantify the effects of varying acyl chain length and removing the 3'-phosphate group of CoA on the energetics of interaction between Nmt1p and acyl-CoA ligands. Myristoyl-CoA binds to apo-Nmt1p with an affinity of 15 nM, corresponding to a binding free energy of -10.9 kcal/mol. This free energy is composed of a large favorable enthalpy of -24 kcal/mol and a large unfavorable entropic term. This large negative DELTAH-degrees is consistent with a conformational change in the enzyme upon ligation, allowing synthesis of a functional peptide binding site. Binding of palmitoyl-CoA and lauroyl-CoA is driven by an exothermic enthalpy change which is much smaller than the corresponding parameter for myristoyl-CoA binding. The large differences in binding enthalpy and entropy (DELTADELTAH-degrees and TDELTADELTAS-degrees = 8-9 kcal/mol) demonstrate that the ''off-length'' acyl-CoAs bind to Nmt1p in a significantly different energetic fashion from myristoyl-CoA, even though the enzyme does not have a great deal of specificity among these ligands in terms of binding free energy (DELTADELTAG-degrees less-than-or-equal-to 1 kcal/mol). The effect of removing the CoA 3'-phosphate group from myristoyl-CoA is similar to the effect of a two-carbon change in acyl chain length: i.e. an enthalpy dominated reduction in binding affinity. However, kinetic studies reveal that removing the 3'-phosphate from myristoyl-CoA has little effect on Nmt1p's catalytic efficiency, indicating that the 3'-phosphate group contributes binding free energy but little catalytic destabilization. The greater DELTADELTAG-degrees, with smaller DELTADELTAH-degrees and DELTADELTAS-degrees components, produced by removing the 3'-phosphate compared to increasing chain length suggests that it is not primarily the interactions of the 3'-phosphate which are disrupted when palmitoyl-CoA is substituted for myristoyl-CoA. No detectable interactions were noted between apo-Nmt1p and the substrate peptide, GAAPSKIV-NH2, providing additional support for the preferred ordered reaction mechanism. In contrast, GAAPSKIV-NH2 is able to bind with high affinity to Nmt1p saturated with either nonhydrolyzable myristoyl-CoA or palmitoyl-CoA analogs. The 3.6 muM dissociation constant for binding of GAAPSKIV-NH2 to Nmt1p.S-(2-oxo)pentadecyl-CoA is driven by favorable enthalpy (-6.5 kcal/mol) and entropy (0.9 kcal/mol at 300 K). The fact that a high affinity peptide binding site is also formed with a nonhydrolyzable palmitoyl-CoA analog, S-(2-oxo)heptadecyl-CoA, indicates that the energy of binding of the off-length acyl-CoA is sufficient to induce the cooperative transition which allows peptide binding but not to generate a highly efficient active site. The similar affinities of Nmt1p for myristoyl-CoA, palmitoyl-CoA, and lauroyl-CoA provide little specificity for binding one acyl-CoA rather than another, suggesting that for this myristoyltransferase to avoid catalyzing the transfer of other acyl chains or being competitively inhibited by them, there must be some form of functional segregation of cellular acyl-CoA pools.	WASHINGTON UNIV, SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; MONSANTO CO, CORP RES LABS, CHESTERFIELD, MO 63198 USA	Washington University (WUSTL); Monsanto					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27179, AI 30188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARIF A, 1969, J LIPID RES, V10, P344; Chow M, 1992, LIPID MODIFICATIONS, P59; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DAY PJ, 1992, J BIOL CHEM, V267, P5122; DAY PJ, 1992, BIOCHEMISTRY-US, V31, P4198, DOI 10.1021/bi00132a007; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DEVADAS B, 1993, BIOORG MED CHEM LETT, V31, P779; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FIERKE CA, 1986, J BIOL CHEM, V261, P7603; FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002; FRERMAN FE, 1980, J BIOL CHEM, V255, P1192; GHISLA S, 1992, PROG CLIN BIOL RES, V375, P127; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LU TB, 1994, J BIOL CHEM, V269, P5346; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; PAIGE LA, 1989, J MED CHEM, V32, P1667; PIETZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436; POWELL PJ, 1987, BIOCHEMISTRY-US, V26, P3704, DOI 10.1021/bi00386a066; REMINGTON S, 1982, J MOL BIOL, V158, P11; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; Vetterling W.T., 1988, NUMERICAL RECIPES C; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	48	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11045	11053						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157630				2022-12-27	WOS:A1994NF96600015
J	DUKES, ID; MCINTYRE, MS; MERTZ, RJ; PHILIPSON, LH; ROE, MW; SPENCER, B; WORLEY, JF				DUKES, ID; MCINTYRE, MS; MERTZ, RJ; PHILIPSON, LH; ROE, MW; SPENCER, B; WORLEY, JF			DEPENDENCE ON NADH PRODUCED DURING GLYCOLYSIS FOR BETA-CELL GLUCOSE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA STRAND BREAKS; PANCREATIC-ISLETS; POLY(ADP-RIBOSE) SYNTHETASE; ELECTRICAL-ACTIVITY; INSULIN RELEASE; INHIBITION; STREPTOZOTOCIN; METABOLISM; SECRETION; PHOSPHATE	An increase in cytosolic ATP following glucose metabolism by pancreatic beta-cells is the key signal initiating insulin secretion by causing blockade of ATP-dependent K+ channels (K(APT)). This induces membrane depolarization, leading to an elevation in cytosolic Ca2+ ([Ca2+]i) and insulin secretion. In this report we identify the critical metabolic step by which glucose initiates changes in beta-cell K(ATP) channel activity, membrane potential, and [Ca2+]i. The signal stems from the glycolytic production of NADH during the oxidation of glyceraldehyde 3-phosphate, which is subsequently processed into ATP by mitochondria via the operation of discrete shuttle systems.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago	DUKES, ID (corresponding author), GLAXO RES INST,RES TRIANGLE PK,NC 27709, USA.							ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJH, 1991, ISLETS LANGERHANS BI, P117; Atwater I, 1980, Horm Metab Res Suppl, VSuppl 10, P100; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; CLARKE DD, 1991, NEUROCHEM RES, V16, P1055, DOI 10.1007/BF00965850; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUGGLEBY RG, 1974, J BIOL CHEM, V249, P175; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GILON P, 1992, J BIOL CHEM, V267, P20713; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; HARRIS RA, 1992, TXB BIOCH, P308; HUTTON JC, 1980, DIABETOLOGIA, V18, P395; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KIRANADI B, 1991, FEBS LETT, V283, P93, DOI 10.1016/0014-5793(91)80561-G; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1993, AM J PHYSIOL, V264, pE428, DOI 10.1152/ajpendo.1993.264.3.E428; MALAISSE WJ, 1993, ACTA DIABETOL, V30, P1, DOI 10.1007/BF00572865; MISLER S, 1992, PFLUG ARCH EUR J PHY, V424, P289; NOWAK T, 1981, BIOCHEMISTRY-US, V20, P6901, DOI 10.1021/bi00527a025; ONISHI H, 1993, J NEUROL SCI, V114, P205, DOI 10.1016/0022-510X(93)90299-E; RAGAN CI, 1973, J BIOL CHEM, V248, P6876; ROE MW, 1993, J BIOL CHEM, V268, P9953; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SENER A, 1992, J BIOL CHEM, V267, P13251; SMOLEN P, 1992, J MEMBRANE BIOL, V127, P9; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; TRENTHAM DR, 1968, BIOCHEM J, V109, P603, DOI 10.1042/bj1090603; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P94; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	35	127	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10979	10982						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157622				2022-12-27	WOS:A1994NF96600004
J	GEIGER, O; THOMASOATES, JE; GLUSHKA, J; SPAINK, HP; LUGTENBERG, BJJ				GEIGER, O; THOMASOATES, JE; GLUSHKA, J; SPAINK, HP; LUGTENBERG, BJJ			PHOSPHOLIPIDS OF RHIZOBIUM CONTAIN NODE-DETERMINED HIGHLY UNSATURATED FATTY-ACID MOIETIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ATOM-BOMBARDMENT; ACYL-CARRIER PROTEIN; SYM PLASMID PRL1JI; HOST SPECIFICITY; ESCHERICHIA-COLI; AGROBACTERIUM-TUMEFACIENS; MASS-SPECTROMETRY; MELILOTI 1021; LEGUMINOSARUM; PHOSPHATIDYLETHANOLAMINE	In Rhizobium leguminosarum the nodABC and nodFEL operons are involved in the production of lipooligosaccharide signals, which mediate host specificity. A nodE-determined highly unsaturated C18.4 fatty acid (trans-2,trans-4,trans-6,cis-11-octadecatetraenoic acid) is essential for the ability of the signals to induce nodule primordia (Spaink, H. P., Sheeley, D. M., van Brussel, A. A. N., Glushka, J., York, W. S., Tak, T., Geiger, O., Kennedy, E. P., Reinhold, V. N., and Lugtenberg, B. J. J. (1991) Nature 354, 125-130) and preinfection thread structures (van Brussel, A. A. N., Bakhuizen, R., van Spronsen, P. C., Spaink, H. P., Tak, T., Lugtenberg, B. J. J., and Kijne, J. W. (1992) Science 257, 70-72) on the host plant Vicia sativa. We presently focus on the question of how these lipooligosaccharide signals are synthesized in Rhizobium. Here we show that after the induction of the nodFE genes, even in the absence of the nodABC genes, the trans-2,trans-4,trans-6,cis-11-octadecatetraenoic acid, which has a characteristic absorbance maximum of 303 nm, is synthesized; this shows that the biosynthesis of the unusual fatty acid is not dependent on the synthesis of the lipooligosaccharides. This finding also suggests that the biosynthesis of the unusual fatty acid is completed before it is linked to the sugar backbone of the lipooligosaccharide. In an attempt to identify the lipid fraction with which the unusual C18:4 fatty acid is associated, we found that it is linked to the sn-2 position of the phospholipids. Even when lipooligosaccharide signals are produced in a wild type Rhizobium cell, a fraction of the unusual fatty acid is still bound to all major phospholipids. These findings offer interesting possibilities. 1) The phospholipids might be biosynthetic intermediates for the synthesis of lipooligosaccharide signals, and 2) phospholipids, containing nodFE-derived fatty acids, might have a signal function of their own.	LEIDEN UNIV, INST MOLEC PLANT SCI, 2333 AL LEIDEN, NETHERLANDS; UNIV UTRECHT, DEPT MASS SPECTROMETRY, 3508 TB UTRECHT, NETHERLANDS; COMPLEX CARBOHYDRATE RES CTR, ATHENS, GREECE	Leiden University; Leiden University - Excl LUMC; Utrecht University			Spaink, Herman P./S-3586-2017; Geiger, Otto/F-6356-2019	Spaink, Herman P./0000-0003-4128-9501; Geiger, Otto/0000-0002-7794-1568				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLE MJ, 1991, ANAL CHEM, V63, P1032, DOI 10.1021/ac00010a020; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; GEIGER O, 1991, J BACTERIOL, V173, P3021, DOI 10.1128/JB.173.9.3021-3024.1991; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GUPTA SD, 1991, J BIOL CHEM, V266, P9983; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; HOOYKAAS PJJ, 1981, NATURE, V291, P351, DOI 10.1038/291351a0; HUANG ZH, 1992, J AM SOC MASS SPECTR, V3, P71, DOI 10.1016/1044-0305(92)85020-K; HUBAC C, 1992, J GEN MICROBIOL, V138, P1973, DOI 10.1099/00221287-138-9-1973; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; JOSEY DP, 1979, J APPL BACTERIOL, V46, P343, DOI 10.1111/j.1365-2672.1979.tb00830.x; Kates M, 1986, LAB TECHNIQUES BIOCH, V3; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, P672; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MILLER KJ, 1988, J BACTERIOL, V170, P4569, DOI 10.1128/jb.170.10.4569-4575.1988; PATTON GM, 1990, METHOD ENZYMOL, V187, P195; PATTON GM, 1982, J LIPID RES, V23, P190; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; SPAINK HP, 1989, PLANT MOL BIOL, V12, P59, DOI 10.1007/BF00017448; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; SPAINK HP, 1993, CURR PLANT SCI BIOT, V14, P151; THOMPSON EA, 1983, LIPIDS, V18, P602, DOI 10.1007/BF02534669; VANBRUSSEL AAN, 1992, SCIENCE, V257, P70, DOI 10.1126/science.257.5066.70; VANBRUSSEL AAN, 1977, J GEN MICROBIOL, V101, P51, DOI 10.1099/00221287-101-1-51; ZAAT SAJ, 1987, J BACTERIOL, V169, P198, DOI 10.1128/jb.169.1.198-204.1987	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11090	11097						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157634				2022-12-27	WOS:A1994NF96600021
J	KRAMER, W; WESS, G; NECKERMANN, G; SCHUBERT, G; FINK, J; GIRBIG, F; GUTJAHR, U; KOWALEWSKI, S; BARINGHAUS, KH; BOGER, G; ENHSEN, A; FALK, E; FRIEDRICH, M; GLOMBIK, H; HOFFMANN, A; PITTIUS, C; URMANN, M				KRAMER, W; WESS, G; NECKERMANN, G; SCHUBERT, G; FINK, J; GIRBIG, F; GUTJAHR, U; KOWALEWSKI, S; BARINGHAUS, KH; BOGER, G; ENHSEN, A; FALK, E; FRIEDRICH, M; GLOMBIK, H; HOFFMANN, A; PITTIUS, C; URMANN, M			INTESTINAL-ABSORPTION OF PEPTIDES BY COUPLING TO BILE-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RAT SMALL-INTESTINE; SALT-BINDING POLYPEPTIDES; TRANSPORT-SYSTEM; VESICLES; PROTEIN; INSULIN; IDENTIFICATION; CHARGE	Poor intestinal absorption of peptides greatly limits their use as drugs for the treatment of chronic diseases. Since bile acids are efficiently absorbed by an active, Na+-dependent transport system in the ileum of mammals, model peptides of different chain length were attached to the 3-position of modified 3 beta-(omega-amino-alkoxy)-7 alpha,12 alpha-dihydroxy-5 beta-cholan-24-oic acid. These peptide-bile acid conjugates inhibited Na+-dependent [H-3]taurocholate uptake into brush-border membrane vesicles isolated from rabbit ileum in a concentration-dependent manner. Furthermore, photoaffinity labeling of the bile acid-binding proteins of M(r) 93,000 and 14,000, identified as the protein components of the ileal Na+-dependent bile acid transport system in rabbit ileum (Kramer, W., Girbig, F., Gutjahr, U., Kowalewski, S., Jouvenal, K., Muller, G., Tripler D., and Wess, G. (1993) J. Biol. Chem. 268, 18035-18046) by the photoreactive taurocholate analogue, (3,3-azo-7 alpha,12 alpha-dihydroxy-5 beta[7 beta,-12 beta-H-3]cholan-24-oyl)-2-aminoethanesulfonic acid, was inhibited by the peptide-bile acid conjugates. In contrast, the parent peptides and amino acids neither had a significant effect on [H-3]taurocholate uptake by ileal brush-border membrane vesicles nor on photoaffinity labeling of the ileal bile acid-binding membrane proteins. The inhibitory effect of peptide-bile acid conjugates on [H-3]taurocholate transport and photoaffinity labeling of the bile acid-binding proteins in rabbit ileal vesicles decreased with increasing chain length of the attached peptide radical. By in vivo ileum perfusion in anesthetized rats an intestinal absorption of the bile acid conjugate S3744 of the fluorescent oxaprolylpeptide 4-nitrobenzo-2-ora-1,3-diazol-beta-Ala-Phe-5-Opr-Gly (S1037) and secretion of the intact compound into bile could be demonstrated, whereas the parent peptide S1037 or its t-butylester S4404 were not absorbed. The intestinal absorption of S3744 showed a similar temperature dependence as [H-3]taurocholate absorption and was inhibited by the presence of taurocholate indicating a carrier-mediated uptake of S3744 via the ileal bile acid transporter. In conclusion, these results indicate that oligopeptides can be made enterally absorbable by coupling to modified bile acid molecules making use of the specific intestinal absorption pathway for bile acids. This finding may be of great importance for the design and development of orally active peptide drugs.			KRAMER, W (corresponding author), HOECHST AG, SBU METAB, D-65926 FRANKFURT, GERMANY.							ALDINI R, 1982, J LIPID RES, V23, P1167; ANWER MS, 1985, AM J PHYSIOL, V249, pG479, DOI 10.1152/ajpgi.1985.249.4.G479; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; Bergmann M, 1932, BER DTSCH CHEM GES, V65, P1192, DOI 10.1002/cber.19320650722; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND E, 1952, J AM CHEM SOC, V74, P1849, DOI 10.1021/ja01127a505; BURCKHARDT G, 1983, J BIOL CHEM, V258, P3618; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FUJII S, 1985, J PHARM PHARMACOL, V37, P545, DOI 10.1111/j.2042-7158.1985.tb03064.x; HARDISON WGM, 1991, HEPATOLOGY, V13, P68, DOI 10.1002/hep.1840130111; HO NFH, 1987, ANN NY ACAD SCI, V507, P315, DOI 10.1111/j.1749-6632.1987.tb45811.x; HOLMES CP, 1993, PERSPECTIVES MED CHE, P489; HOPFER U, 1973, J BIOL CHEM, V248, P25; HOUBENWEYL, 1974, METHODEN ORGANISCHEN, V15; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAMER W, 1992, J BIOL CHEM, V267, P18598; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; KRAMER W, 1993, FALK SYMP, V68, P161; KRAMER W, 1992, BIOCHIM BIOPHYS ACTA, V1111, P93, DOI 10.1016/0005-2736(92)90278-T; KRAMER W, 1993, J BIOL CHEM, V268, P18035; KRAMER W, 1990, J CHROMATOGR, V521, P199, DOI 10.1016/0021-9673(90)85044-V; KRAMER W, 1987, BIOCHIM BIOPHYS ACTA, V905, P65, DOI 10.1016/0005-2736(87)90009-5; KRAMER W, 1988, BIOCHEM PHARMACOL, V37, P2427, DOI 10.1016/0006-2952(88)90370-X; KRAMER W, 1989, J LIPID RES, V30, P1281; KRAMER W, 1983, J LIPID RES, V24, P910; KRAMER W, 1983, J BIOL CHEM, V258, P3623; KRAMER W, 1980, H-S Z PHYSIOL CHEM, V361, P1307; KRAMER W, 1979, EUR J BIOCHEM, V102, P1, DOI 10.1111/j.1432-1033.1979.tb06257.x; KRAMER W, 1981, IDENTIFIZIERUNG GALL, P1; KRAMER W, 1993, HEPATOLOGY, V18, P299; KRCHNAK V, 1988, COLLECT CZECH CHEM C, V53, P2542, DOI 10.1135/cccc19882542; LACK L, 1967, BIOCHIM BIOPHYS ACTA, V135, P1065, DOI 10.1016/0005-2736(67)90078-8; LACK L, 1979, ENVIRON HEALTH PERSP, V33, P79, DOI 10.2307/3429075; LEE V H L, 1989, Advanced Drug Delivery Reviews, V4, P171, DOI 10.1016/0169-409X(89)90018-5; LEE VHL, 1988, CRIT REV THER DRUG, V5, P69; LIN MC, 1988, J MEMBRANE BIOL, V106, P1, DOI 10.1007/BF01871762; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; Matthews DM, 1991, PROTEIN ABSORPTION D; MERGLER M, 1988, TETRAHEDRON LETT, V29, P4005, DOI 10.1016/S0040-4039(00)80405-0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIFIELD RB, 1988, ANAL BIOCHEM, V174, P399, DOI 10.1016/0003-2697(88)90039-5; Russell-Jones G.J., 1988, P INT S CONTROLLED R, V15, P142; SAFFRAN M, 1986, SCIENCE, V233, P1081, DOI 10.1126/science.3526553; SCHMASSMANN A, 1990, GASTROENTEROLOGY, V99, P1092, DOI 10.1016/0016-5085(90)90630-J; SCHWARZ LR, 1975, EUR J BIOCHEM, V55, P617, DOI 10.1111/j.1432-1033.1975.tb02199.x; SMITH PL, 1992, ADV DRUG DELIVER REV, V8, P253, DOI 10.1016/0169-409X(92)90005-B; STEPHAN ZF, 1992, BIOCHEM PHARMACOL, V43, P1969, DOI 10.1016/0006-2952(92)90640-5; VLAHCEVIC ZR, 1990, HEPATOLOGY TXB LIVER, P341; WESS G, 1993, TETRAHEDRON LETT, V34, P817, DOI 10.1016/0040-4039(93)89020-Q; WESS G, 1992, TETRAHEDRON LETT, V33, P195, DOI 10.1016/0040-4039(92)88048-A; WESS G, 1993, TETRAHEDRON LETT, V34, P819, DOI 10.1016/0040-4039(93)89021-H; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON FA, 1981, AM J PHYSIOL, V241, pG83, DOI 10.1152/ajpgi.1981.241.2.G83; ZIV E, 1981, LIFE SCI, V29, P803, DOI 10.1016/0024-3205(81)90036-9; [No title captured]	55	81	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10621	10627						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144651				2022-12-27	WOS:A1994NF01700066
J	NISHIKI, T; KAMATA, Y; NEMOTO, Y; OMORI, A; ITO, T; TAKAHASHI, M; KOZAKI, S				NISHIKI, T; KAMATA, Y; NEMOTO, Y; OMORI, A; ITO, T; TAKAHASHI, M; KOZAKI, S			IDENTIFICATION OF PROTEIN-RECEPTOR FOR CLOSTRIDIUM-BOTULINUM TYPE-B NEUROTOXIN IN RAT-BRAIN SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; TETANUS TOXIN; BINDING; GANGLIOSIDES; PURIFICATION; QUANTITIES; MEMBRANES; CLEAVAGE; CALCIUM	The protein receptor for Clostridium botulinum type B neurotoxin was purified 340-fold from rat synaptosomes by successive chromatography on DEAE-Sepharose, phenyl-Toyopearl, and heparin-Toyopearl columns. I-125-Labeled neurotoxin bound to lipid vesicles containing the protein receptor and ganglioside G(T1b) or G(D1a). The reconstituted receptor showed the same affinities as the native receptor on synaptosomes. Chemical crosslinking of I-125-toxin to the receptor in the presence of gangliosides resulted in formation of a cross-linked product of 161 kDa under reducing conditions. Crosslinking was specific, as it was inhibited by the presence of excess unlabeled toxin. A monoclonal antibody against the purified 58-kDa receptor protein and a monoclonal antibody against the heavy chain (103 kDa) of the neurotoxin reacted with the cross-linked product of 161 kDa in immunoblotting experiments. We determined partial amino acid sequences of the 58-kDa protein, which were identical to synaptotagmin, a synaptic vesicle membrane protein. In addition, the monoclonal antibody against the 58-kDa receptor protein recognized recombinant rat synaptotagmin. These results suggest that synaptotagmin in association with ganglioside G(T1b) or G(D1a)receptor for C. botulinum type B neurotoxin at the nerve terminals.	UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 593,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Osaka Metropolitan University								BAKRY N, 1991, J PHARMACOL EXP THER, V258, P830; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EVANS DM, 1986, EUR J BIOCHEM, V154, P409, DOI 10.1111/j.1432-1033.1986.tb09413.x; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; IKEDA S, 1991, EUR J PHARM-MOLEC PH, V208, P199, DOI 10.1016/0922-4106(91)90096-Z; IWAMORI M, 1978, BIOCHIM BIOPHYS ACTA, V528, P257; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KITAMURA M, 1980, BIOCHIM BIOPHYS ACTA, V628, P328, DOI 10.1016/0304-4165(80)90382-7; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZAKI S, 1987, INFECT IMMUN, V55, P3051, DOI 10.1128/IAI.55.12.3051-3056.1987; KOZAKI S, 1984, FEMS MICROBIOL LETT, V21, P219; KOZAKI S, 1979, N-S ARCH PHARMACOL, V308, P67, DOI 10.1007/BF00499721; KOZAKI S, 1977, INFECT IMMUN, V18, P761, DOI 10.1128/IAI.18.3.761-766.1977; KOZAKI S, 1974, INFECT IMMUN, V10, P750, DOI 10.1128/IAI.10.4.750-756.1974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; OGASAWARA J, 1991, FEMS MICROBIOL LETT, V79, P351, DOI 10.1111/j.1574-6968.1991.tb04554.x; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REVERCHON S, 1987, GENE, V55, P125, DOI 10.1016/0378-1119(87)90255-1; Sakagichi G, 1983, PHARMACOL THERAPEUT, V19, P165; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P11142; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SIMPSON LL, 1971, J NEUROCHEM, V18, P1751, DOI 10.1111/j.1471-4159.1971.tb03750.x; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIYAMA H, 1980, MICROBIOL REV, V44, P419, DOI 10.1128/MMBR.44.3.419-448.1980; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKAMIZAWA K, 1986, FEBS LETT, V201, P229, DOI 10.1016/0014-5793(86)80614-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADSWORTH JDF, 1990, BIOCHEM J, V268, P123, DOI 10.1042/bj2680123; WHITTAKER VP, 1959, BIOCHEM J, V72, P694, DOI 10.1042/bj0720694; [No title captured]	42	263	292	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10498	10503						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144634				2022-12-27	WOS:A1994NF01700048
J	CROWE, DT; CHIU, H; FONG, S; WEISSMAN, IL				CROWE, DT; CHIU, H; FONG, S; WEISSMAN, IL			REGULATION OF THE AVIDITY OF INTEGRIN ALPHA(4)BETA(7) BY THE BETA(7) CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE-MOLECULE; AMINO-ACID-SEQUENCE; PLATELET GPIIB-IIIA; ALPHA-CHAIN; LYMPHOCYTE ADHERENCE; FIBRONECTIN RECEPTOR; ADHESION MOLECULE-1; LEUKOCYTE ADHESION; GLYCOPROTEIN-IIIA; FOCAL ADHESIONS	Integrins are cell-surface heterodimeric receptors with adhesive and transmembrane signaling properties. Their cytoplasmic domains can affect receptor avidity, cytoskeletal association, and post-receptor occupancy events. The alpha(4) beta(7) integrin mediates cell adhesion to Peyer's patch high walled endothelial venules (HEV), VCAM, and CS-1/fibronectin. To determine the role of the beta(7) cytoplasmic domain in these interactions, wild-type and truncated beta(7) subunits were stably expressed in the alpha(4)(+)/beta(1)(-)/beta(7)(-) B cell lymphoma 38C13. The cell line Delta 727 lacks the entire beta(7) cytoplasmic domain, Delta 753 lacks the 34 C-terminal residues, and LXSN is vector-transfected 38C13. Cells expressing wild-type beta(7) bound Peyer's patch HEV, fibronectin, and immobilized VCAM constitutively and did not require prior activation with phorbol esters. Interestingly, Delta 753 displayed no ligand binding activity, while Delta 727 was constitutively active for all ligands and displayed greater avidity for fibronectin and Peyer's patch HEV than the wild-type beta(7). beta(7), Delta 753, Delta 727, and LXSN were also tested for the ability to bind soluble VCAM in the presence of various divalent cations. In the presence of Ca2+, but not Mg2+, Delta 727 constitutively bound soluble VCAM, whereas beta(7), Delta 753, and LXSN did not. beta(7) and Delta 753 could bind soluble VCAM if first activated with Mn2+. The results suggest that: (i) alpha(4) beta(7) can be expressed in a constitutively active state, (ii) the beta(7) cytoplasmic domain regulates the avidity of alpha(4) beta(7), and (iii) 38C13 cell lines expressing wild-type and truncated beta(7) subunits define three stable activation states of alpha(4) beta(7): inactive (Delta 753), partially active (beta(7)), and fully active (Delta 727) receptors.	STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA	Stanford University; Stanford University; Roche Holding; Genentech					NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER; NCI NIH HHS [CA42551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BERGMAN Y, 1977, EUR J IMMUNOL, V7, P413, DOI 10.1002/eji.1830070702; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTCHER EC, 1979, J IMMUNOL, V123, P1996; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHAN PY, 1993, J BIOL CHEM, V268, P24655; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HOLERS VM, 1989, J EXP MED, V169, P1589, DOI 10.1084/jem.169.5.1589; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LESLEY J, 1982, IMMUNOGENETICS, V15, P313, DOI 10.1007/BF00364339; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PINK JRL, 1979, RES METHODS IMMUNOLO, P169; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; Sambrook J, 1989, MOL CLONING LABORATO; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TAPLEY P, 1989, ONCOGENE, V4, P325; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; WILSON RW, 1989, NUCLEIC ACIDS RES, V17, P5397, DOI 10.1093/nar/17.13.5397; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YUAN Q, 1992, J BIOL CHEM, V267, P7352	75	83	84	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14411	14418						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182047				2022-12-27	WOS:A1994NM06500019
J	LECOMTE, M; LANEUVILLE, O; JI, C; DEWITT, DL; SMITH, WL				LECOMTE, M; LANEUVILLE, O; JI, C; DEWITT, DL; SMITH, WL			ACETYLATION OF HUMAN PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 (CYCLOOXYGENASE-2) BY ASPIRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INFLAMMATORY DRUGS; H SYNTHASE; G/H SYNTHASE; HEME-BINDING; POLYACRYLAMIDE GELS; COMPLEMENTARY-DNA; MESSENGER-RNA; ACID; GENE; PURIFICATION	Aspirin (acetylsalicylate) treatment of human (h) prostaglandin endoperoxide H synthase (PGHS)-1 expressed in cos-1 cells caused a time-dependent inactivation of oxygenase activity. Aspirin treatment of hPGHS-2 produced an enzyme which retained oxygenase activity but formed exclusively 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15 HETE) instead of PGH(2). The 15-HETE was exclusively of the 15R configuration. The K-m values for arachidonate of native and aspirin-treated hPGHS-2 were about the same suggesting that arachidonate binds to both aspirin-treated and native hPGHS-2 in a similar manner. If, as expected, the formation of 15R-HETE proceeds through abstraction of the 13proS hydrogen from arachidonate, O-2, insertion must occur from the same side as the hydrogen abstraction; with all other lipoxy-genases and cyclooxygenases, O-2 addition is antarafacial. When microsomal hPGHS-2 was incubated with [acetyl-C-14]aspirin, the enzyme was acetylated. An S516A mutant of hPGHS-2, which retains enzyme activity, was not acetylated. This indicates that Ser-516 is the site of aspirin acetylation of PGHS-2; this residue is homologous to the ''active site'' serine of PGHS-1. An S516N mutant of hPGHS-2 was catalytically active; in contrast, an S516Q mutant lacked cyclooxygenase but retained peroxidase activity. Because in the case of PGHS-1 a smaller asparagine substitution is sufficient to eliminate cyclooxygenase activity, we conclude that the active site of PGHS-2 is slightly larger than that of PGHS-1. An S516M mutant of hPGHS-2 was obtained which resembled aspirin-acetylated hPGHS-2 in that this mutant made 15R-HETE as its major product; however, unlike the aspirin-acetylated hPGHS-2, the K-m value of the S516M mutant for arachidonate was 100 times that of native hPGHS-2.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232	Michigan State University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042, R01DK042509] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK22042, DK42509] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASH AR, 1986, METHOD ENZYMOL, V58, P187; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1980, BIOCHEM BIOPH RES CO, V95, P1090, DOI 10.1016/0006-291X(80)91584-3; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE O, 1994, IN PRESS J PHARM EXP; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAAS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2884, DOI 10.1073/pnas.80.10.2884; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; OTTO JC, 1993, J BIOL CHEM, V268, P18234; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1982, METHOD ENZYMOL, V86, P213; SMITH WL, 1994, CURR OPIN INVEST DR, V3, P1; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WOLLARD PM, 1989, PROSTAGLANDINS, V38, P465, DOI 10.1016/0090-6980(89)90129-9; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	57	325	333	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13207	13215						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175750				2022-12-27	WOS:A1994NK18400027
J	MUKAIDA, N; MORITA, M; ISHIKAWA, Y; RICE, N; OKAMOTO, S; KASAHARA, T; MATSUSHIMA, K				MUKAIDA, N; MORITA, M; ISHIKAWA, Y; RICE, N; OKAMOTO, S; KASAHARA, T; MATSUSHIMA, K			NOVEL MECHANISM OF GLUCOCORTICOID-MEDIATED GENE REPRESSION - NUCLEAR FACTOR-KAPPA-B IS TARGET FOR GLUCOCORTICOID-MEDIATED INTERLEUKIN-8 GENE REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; CYCLOSPORINE-A; LYMPHOCYTES-T; MESSENGER-RNA; DNA-BINDING; C-JUN; RECEPTOR; EXPRESSION	A glucocorticoid, dexamethasone, inhibited the production of a leukocyte chemotactic cytokine, interleukin 8 (IL-8), as well as mRNA expression by a glioblastoma cell line, T98G, stimulated with interleukin 1 (IL-1). Dexamethasone also inhibited IL-8 promoter-driven chloramphenicol acetyltransferase (CAT) activities induced by IL-1, suggesting that dexamethasone inhibited IL-8 production mainly at the transcriptional level. Moreover, CAT assay revealed that the nuclear factor-kappa B (NF-kappa B) binding site was the crucial cis-element required for conferring IL-1 responsiveness in conjunction with the CCAAT enhancer binding protein/nuclear factor-IL-6 (NF-IL6) and/or the AP-1 binding site(s). Mutation of either the AP-1 or NF-IL6 binding site did not abolish IL-8 gene repression by dexamethasone, suggesting that these sites were not targets for dexamethasone. Trimerized kappa B sequence in the IL-8 gene was enough for conferring the induction by IL-1 and inhibition by dexamethasone of CAT activity. Finally, dexamethasone diminished the IL-l-induced formation of NF-kappa B complexes, which were identified immunochemically to consist of p50 and p65, without reducing the amount of translocated factors. Collectively, dexamethasone interfered with the binding of the most essential transcription factor, NF-kappa B, to its cognate cis-element, thereby suppressing the transcription of IL-8 gene.	JICHI MED SCH, DEPT NEUROL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; JICHI MED SCH, DEPT MED BIOL & PARASITOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	Jichi Medical University; Jichi Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MUKAIDA, N (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, KANAZAWA 920, JAPAN.		Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851	NCI NIH HHS [NCI N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BROWNELL E, 1989, ONCOGENE, V4, P935; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCARONE VC, 1990, J IMMUNOL, V144, P725; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; ENDO H, 1991, LYMPHOKINE CYTOK RES, V10, P245; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FURIE MB, 1991, BLOOD, V78, P2089; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARADA A, 1993, INT IMMUNOL, V5, P681, DOI 10.1093/intimm/5.6.681; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LARSEN CG, 1991, BIOCHEM BIOPH RES CO, V176, P1020, DOI 10.1016/0006-291X(91)90384-J; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MIMS CA, 1986, PATHOGENESIS INFECTI; MUKAIDA N, 1992, IMMUNOLOGY, V75, P674; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; OLIVEIRA IC, 1992, P NATL ACAD SCI USA, V89, P9049, DOI 10.1073/pnas.89.19.9049; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZIPFEL PF, 1991, BIOCHEM BIOPH RES CO, V181, P179, DOI 10.1016/S0006-291X(05)81398-1	48	408	417	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13289	13295						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175759				2022-12-27	WOS:A1994NK18400038
J	NISHIKIMI, M; FUKUYAMA, R; MINOSHIMA, S; SHIMIZU, N; YAGI, K				NISHIKIMI, M; FUKUYAMA, R; MINOSHIMA, S; SHIMIZU, N; YAGI, K			CLONING AND CHROMOSOMAL MAPPING OF THE HUMAN NONFUNCTIONAL GENE FOR L-GULONO-GAMMA-LACTONE OXIDASE, THE ENZYME FOR L-ASCORBIC-ACID BIOSYNTHESIS MISSING IN MAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIGS; KEY ENZYME; LOCALIZATION	Man is among the exceptional higher animals that are unable to synthesize L-ascorbic acid because of their deficiency in L-gulono-gamma-lactone oxidase, the enzyme catalyzing the terminal step in L-ascorbic acid biosynthesis. In the present study, we isolated a segment of the nonfunctional L-gulono-gamma-lactone oxidase gene from a human genomic library, and mapped it on chromosome 8p21.1 by spot blot hybridization using flow-sorted human chromosomes and fluorescence in situ hybridization. Sequencing analysis indicated that the isolated segment represented a 3'-part of the gene, where the regions corresponding to exons VII, IX, X, and XII of the rat L-gulono-gamma-lactone oxidase gene remain with probable deletion of the regions corresponding to exons VIII and XI. In the identified exon regions were found various anomalous nucleotide changes, such as deletion and insertion of nucleotide(s) and nonconformance to the GT/AG rule at intron/exon boundaries. When the conceptual amino acid sequences deduced from the four exon sequences were compared with the corresponding rat sequences, there were a large number of nonconservative substitutions and also two stop codons. These findings indicate that the human nonfunctional L-gulono-gamma-lactone oxidase gene has accumulated a large number of mutations without selective pressure since it ceased to function during evolution.	KEIO UNIV,SCH MED,DEPT MOLEC BIOL,TOKYO 160,JAPAN	Keio University	NISHIKIMI, M (corresponding author), INST APPL BIOCHEM,YAGI MEM PK,MITAKE,GIFU 50501,JAPAN.							BURNS JJ, 1976, METABOLIC PATHWAYS, V1, P394; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEININGER PL, 1986, TRENDS GENET, V2, P76, DOI 10.1016/0168-9525(86)90183-6; FUKUYAMA R, 1991, GENOMICS, V11, P410, DOI 10.1016/0888-7543(91)90149-9; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; MARTENSSON J, 1992, P NATL ACAD SCI USA, V89, P11566, DOI 10.1073/pnas.89.23.11566; MINOSHIMA S, 1990, CYTOMETRY, V11, P539, DOI 10.1002/cyto.990110413; MINOSHIMA S, 1991, CYTOGENET CELL GENET, V57, P30, DOI 10.1159/000133108; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAJIMA Y, 1969, HISTOCHEMISTRY, V18, P293; NEVIN NC, 1990, J MED GENET, V27, P135, DOI 10.1136/jmg.27.2.135; NISHIKIMI M, 1977, TRENDS BIOCHEM SCI, V2, P111, DOI 10.1016/0968-0004(77)90175-X; NISHIKIMI M, 1992, J BIOL CHEM, V267, P21967; NISHIKIMI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P842, DOI 10.1016/0003-9861(88)90093-8; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; SAKAI K, 1992, GENOMICS, V14, P175, DOI 10.1016/S0888-7543(05)80301-5; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5	17	343	355	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13685	13688						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175804				2022-12-27	WOS:A1994NK18400091
J	ZLOTNICK, A; REDDY, VS; DASGUPTA, R; SCHNEEMANN, A; RAY, WJ; RUECKERT, RR; JOHNSON, JE				ZLOTNICK, A; REDDY, VS; DASGUPTA, R; SCHNEEMANN, A; RAY, WJ; RUECKERT, RR; JOHNSON, JE			CAPSID ASSEMBLY IN A FAMILY OF ANIMAL VIRUSES PRIMES AN AUTOPROTEOLYTIC MATURATION THAT DEPENDS ON A SINGLE ASPARTIC-ACID RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE; PROTEINS	Maturation of noninfectious nodavirus provirions occurs by autoproteolytic cleavage of most of the 180 copies of the alpha-protein that make up, the icosahedral capsid. This maturation, which is much slower than viral assembly, produces an infectious particle that is more stable than the provirion and makes viral uncoating thermodynamically distinct from assembly, allowing assembly and (a time delayed) uncoating to occur under similar conditions. The results of structural, computational, and molecular genetic studies suggest that maturation depends both on intrasubunit strain, produced during assembly, and on a critical aspartic acid residue. This residue lies in a hydrophobic pocket that is stabilized by intersubunit contacts. It is close to the scissile bond and exhibits an environmentally elevated pK(a). The apparent involvement of a single acidic residue in the hydrolytic cleavage of a peptide bond contrasts with the involvement of 2 such residues in acid proteases.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV WISCONSIN,INST MOLEC VIROL,MADISON,WI 53706	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Wisconsin System; University of Wisconsin Madison				Zlotnick, Adam/0000-0001-9945-6267	NIAID NIH HHS [AI22813] Funding Source: Medline; NIGMS NIH HHS [GM34220, GM08296] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034220, T32GM008296, R37GM034220] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISHOP NE, 1993, VIROLOGY, V197, P616, DOI 10.1006/viro.1993.1636; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHENG RH, 1994, IN PRESS STRUCTURE; CREIGHTON TE, 1984, PROTEIN STRUCTURE MO, P449; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GALLAGHER TM, 1988, J VIROL, V62, P3399, DOI 10.1128/JVI.62.9.3399-3406.1988; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HENDRY DA, 1991, VIRUSES INVERTEBRATE, P227; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; HOSUR MV, 1984, VIROLOGY, V133, P119, DOI 10.1016/0042-6822(84)90430-6; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; KAESBERG P, 1990, J MOL BIOL, V214, P423, DOI 10.1016/0022-2836(90)90191-N; KAESBERG P, 1987, MOL BIOL POSITIVE ST, P207; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEW JB, 1985, CRC CR REV BIOCH MOL, V18, P91, DOI 10.3109/10409238509085133; MORI KI, 1992, VIROLOGY, V187, P368, DOI 10.1016/0042-6822(92)90329-N; RUECKERT RR, 1990, VIROLOGY, P507; SCHNEEMANN A, 1992, J VIROL, V66, P6728, DOI 10.1128/JVI.66.11.6728-6734.1992; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SMITH TJ, 1993, J APPL CRYSTALLOGR, V26, P496, DOI 10.1107/S0021889892013153; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304	24	85	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13680	13684						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175803				2022-12-27	WOS:A1994NK18400090
J	ZOU, LL; HAGEN, SG; STRAIT, KA; OPPENHEIMER, JH				ZOU, LL; HAGEN, SG; STRAIT, KA; OPPENHEIMER, JH			IDENTIFICATION OF THYROID-HORMONE RESPONSE ELEMENTS IN RODENT PCP-2, A DEVELOPMENTALLY-REGULATED GENE OF CEREBELLAR PURKINJE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID X-RECEPTOR; TRANS-ACTIVATION; ENHANCES BINDING; ACID; EXPRESSION; PROTEIN; RAT; SEQUENCE; LEADER; TESTIS	In a previous study, we have shown that in vivo expression of the cerebellar Purkinje cell-specific gene Pcp-2 is regulated by thyroid hormone (T-3) during neonatal development. In addition, transient cotransfection studies using thyroid hormone receptors (TRs) and a Pcp-2-lacZ construct pointed to direct regulation of Pcp-2 gene expression by T-3. Therefore, we have initiated the following series of studies to define more precisely the location of the thyroid hormone regulatory elements in the Pcp-2 gene. By transfection and in vitro receptor binding analyses, we have identified two thyroid hormone response elements, A1 (-295/-268) and B1 (+207/+227). A1 contains a central half site flanked by two similar half-sites. B1 contains two pairs of alternate half-sites. When these elements were ligated to the modified mouse mammary tumor virus promoter (Delta MMTV), both induced a 8-14-fold expression of the reporter gene, but only in the presence of T-3. Gel mobility assays demonstrated that both A1 and B1 bind TRs in the presence of thyroid hormone receptor auxiliary proteins or the retinoid X beta receptor. Mutations of the G residues to T within the individual half-site sequences of A1 caused a variable decrease in the transactivation of the MMTV-CAT construct and a corresponding reduction in TR binding in vitro. Thus, mutational analysis of A1 pointed to the interaction of the flanking half-site motifs with the central AGGTCA half-site. Interestingly, lengthening of the A1 sequence at its 3'-end caused a progressive dampening of the T-3 response. The results suggest that the neighboring sequence may function as a silencer of the A1 element. Since thyroid hormone regulation of Pcp-2 is manifest only during the first 2 weeks after birth, we hypothesize that A1 and B1 act as T-3-dependent response elements operative only during early neonatal Purkinje cell development and that their function is suppressed by a neighboring silencer element operative when expression of Pcp-2 becomes hormone-independent.	UNIV MINNESOTA,DEPT MED,DIABET ENDOCRINOL & METAB SECT,THYROID RES UNIT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019812] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-RO1-19812] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1988, J BIOL CHEM, V263, P9630; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DeLong GR, 1989, IODINE BRAIN, P231; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEGRAND J, 1967, ARCH ANAT MICROSC MO, V56, P291; Legrand J, 1986, THYROID HORMONE META, P503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	26	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13346	13352						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175765				2022-12-27	WOS:A1994NK18400046
J	ESCALANTE, R; SASTRE, L				ESCALANTE, R; SASTRE, L			STRUCTURE OF ARTEMIA-FRANCISCANA SARCO/ENDOPLASMIC RETICULUM CA-ATPASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG SMOOTH-MUSCLE; CA-2+ PUMP; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CA-2+-ATPASE GENE; CRUSTACEAN ARTEMIA; SKELETAL-MUSCLE; MYOD FAMILY; EXPRESSION; IDENTIFICATION	Genomic clones coding for the Artemia franciscana sarco(endo)plasmic reticulum Ca-ATPase have been isolated. The restriction map of the overlapping clones covers a region of 65 kilobases of DNA, Nucleotide sequence of mRNA coding regions shows that the gene is divided into 18 exons separated by 17 introns. Compared with the structure of the rabbit sarco(endo)plasmic reticulum Ca-ATPase 1 gene, 12 of the introns are in the same position, 8 introns present in the rabbit gene are absent from A. franciscana, 4 introns present in A. franciscana are not found in rabbit, and the position of 1 intron is shifted one base between both genes. Southern blot analysis strongly suggests that this is the only sarco(endo)plasmic reticulum Ca-ATPase gene present in A. franciscana. Primer extension and nuclease S1 protection experiments have shown the existence of two main regions of transcription initiation separated by 30 nucleotides. Transcription is initiated in both regions at two or three consecutive bases. A hexanucleotide that includes the initiation sites is repeated in both transcription initiation regions. The nucleotide sequence of the promoter region shows the existence of several putative regulatory sites, including some that are muscle-specific such as one CArG box, 3 MEF-2, and 8 putative binding sites for muscle transcription factors of the MyoD family.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Escalante, Ricardo/G-8272-2015	Escalante, Ricardo/0000-0001-8547-531X; Sastre, Leandro/0000-0003-3613-5938				BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CRUCES J, 1981, BIOCHEM BIOPH RES CO, V98, P404, DOI 10.1016/0006-291X(81)90854-8; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; EGGERMONT JA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P448, DOI 10.1016/0167-4781(91)90143-A; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; ESCALANTE R, 1993, J BIOL CHEM, V268, P14090; GIL I, 1987, NUCLEIC ACIDS RES, V15, P6007, DOI 10.1093/nar/15.15.6007; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LIAUD MF, 1990, P NATL ACAD SCI USA, V87, P8918, DOI 10.1073/pnas.87.22.8918; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PALMERO I, 1989, J MOL BIOL, V210, P737, DOI 10.1016/0022-2836(89)90106-X; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SUKOVICH DA, 1993, NUCLEIC ACIDS RES, V21, P2723, DOI 10.1093/nar/21.11.2723; TRIEZENBERG SJ, 1993, CURRENT PROTOCOLS MO; VARADI A, 1993, FEBS LETT, V258, P203; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	30	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13005	13012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175720				2022-12-27	WOS:A1994NH71600096
J	FLAHERTY, KM; WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB				FLAHERTY, KM; WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB			STRUCTURAL BASIS OF THE 70-KILODALTON HEAT-SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY .2. STRUCTURE OF THE ACTIVE-SITE WITH ADP OR ATP BOUND TO WILD-TYPE AND MUTANT ATPASE FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION DATA; AUTOPHOSPHORYLATION; RESOLUTION	The ATPase fragment of the bovine 70-kDa heat shock cognate protein is an attractive construct in which to study its mechanism of ATP hydrolysis. The three-dimensional structure suggests several residues that might participate in the ATPase reaction. Four acidic residues (Asp-10, Glu-175, Asp-199, and Asp-206) have been individually mutated to both the cognate amine (asparagine/glutamine) and to serine, and the effects of the mutations on the kinetics of the ATPase activity (Wilbanks, S. M., DeLuca-Flaherty, C., and McKay, D. B. (1994) J. Biol. Chem. 269, 12893-12898) and the structure of the mutant ATPase fragments have been determined, typically to similar to 2.4 Angstrom resolution. Additionally, the structures of the wild type protein complexed with MgADP and P-i, MgAMPPNP (5'-adenylyl-beta,gamma-imidodiphosphate) and CaAMPPNP have been refined to 2.1, 2.4, and 2.4 Angstrom, respectively. Combined, these structures provide models for the prehydrolysis, MgATP-bound state and the post-hydrolysis, MgADP-bound state of the ATPase fragment. These models suggest a pathway for the hydrolytic reaction in which 1) the gamma phosphate of bound ATP reorients to form a beta,gamma-bidentate phosphate complex with the Mig(2+) ion, allowing 2) in-line nucleophilic attack on the gamma phosphate by a H2O molecule or OH- ion, with 3) subsequent release of inorganic phosphate.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University				Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P235; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STEIGEMANN W, 1974, THESIS TU MUNCHEN; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	22	139	146	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12899	12907						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175707				2022-12-27	WOS:A1994NH71600081
J	GAMBAROTTA, G; PISTOI, S; GIORDANO, S; COMOGLIO, PM; SANTORO, C				GAMBAROTTA, G; PISTOI, S; GIORDANO, S; COMOGLIO, PM; SANTORO, C			STRUCTURE AND INDUCIBLE REGULATION OF THE HUMAN MET PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The MET oncogene, encoding the tyrosine kinase receptor for the hepatocyte growth factor/scatter factor, is expressed in epithelial cells and overexpressed in a significant proportion of human epithelial cancers, suggesting the occurrence of transcriptional alteration(s). To identify the MET promoter, we isolated recombinant cDNA clones encompassing the entire 5'- noncoding sequence of MET messenger RNAs. Using probes derived from this region, we cloned the entire genomic region spanning the first MET exon and the flanking regulatory sequences. The first exon, containing the entire untranslated sequence, is present in the MET mRNAs of 7.1, 5.9, and 4.6 kilobases, showing that the expression of the multiple transcripts is regulated by a single promoter. The start site of transcription was determined by primes extension and by rapid amplification of cDNA ends. We show that a 300-base pair fragment, containing sequences upstream from the start site, efficiently drives the expression of a reporter gene in transfected epithelial cells. This promoter fragment also contains the cis-acting elements responsible for phorbol-ester induction.	INTERUNIV CONSORTIUM BIOTECHNOL, LN CIB, I-34012 TRIESTE, ITALY; UNIV TURIN, SCH MED, DEPT BIOMED SCI & ONCOL, I-10126 TURIN, ITALY; UNIV TURIN, SCH MED, DEPT GENET BIOL & MED CHEM, I-10126 TURIN, ITALY	University of Turin; University of Turin			Gambarotta, Giovanna/I-8473-2012; santoro, claudio/G-6819-2012; Giordano, Silvia/J-9858-2018	Gambarotta, Giovanna/0000-0002-8380-5925; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328				ADNANE J, 1991, ONCOGENE, V6, P659; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAKI E, 1987, J BIOL CHEM, V262, P16186; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COHEN JA, 1989, ONCOGENE, V4, P81; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FABER PW, 1993, J BIOL CHEM, V268, P9296; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INNIS JW, 1991, J BIOL CHEM, V266, P21765; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ITOH F, 1992, ONCOGENE, V7, P1201; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1989, CANCER RES, V49, P4185; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; KURY FD, 1990, ONCOGENE, V5, P1403; LIBERMANN TA, 1985, J CELL SCI, P161; LIU C, 1992, ONCOGENE, V7, P181; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1986, NUCLEIC ACIDS RES, V14, P2863, DOI 10.1093/nar/14.7.2863; SCHULZ AS, 1993, ONCOGENE, V8, P509; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	56	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12852	12857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175700				2022-12-27	WOS:A1994NH71600074
J	PRADO, GN; THOMAS, KM; SUZUKI, H; LAROSA, GJ; WILKINSON, N; FOLCO, E; NAVARRO, J				PRADO, GN; THOMAS, KM; SUZUKI, H; LAROSA, GJ; WILKINSON, N; FOLCO, E; NAVARRO, J			MOLECULAR CHARACTERIZATION OF A NOVEL RABBIT INTERLEUKIN-8 RECEPTOR ISOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEUTROPHIL CHEMOTACTIC FACTOR; CLONING; IL-8	Interleukin-8 (IL-8) mediates the transendothelial migration and activation of neutrophils to the site of inflammation. Two human IL-8 receptor isotype (A and B) and one rabbit IL-8 receptor isotype (A) cDNAs have been previously cloned and characterized on the basis of their pharmacological profile. Human and rabbit IL-8 receptor subtype A binds IL-8 and structurally related peptide melanoma growth-stimulating activity (MGSA) and neutrophil-activating peptide-2 (NAP-2) according to the following affinity binding profile: IL-8 >>> MGSA > NAP-2, whereas the human IL-8 receptor subtype B profile is IL-8 = MGSA > NAP-2 (LaRosa, G., Thomas, K. M., Kaufmann, M., Mark, R., White, M., Taylor, L., Gray, G., Witt, D., and Navarro, J. (1992) J. Biol. Chem. 267, 25402-25406). In this study, we isolated a cDNA clone (5B1a) from a rabbit neutrophil Library encoding a G-protein-coupled receptor of the interleukin-8 receptor family. The 5B1a clone encodes a 358-amino acid protein exhibiting 80% amino acid identity to the human IL-8 receptor B, 74% to the rabbit IL-8 receptor A, and 73% to the human IL-8 receptor A Tissue distribution by Northern blot analysis reveals that the 5B1a mRNA is expressed preferentially in neutrophils. In contrast to previously described IL-8 receptors, the 5B1a receptor exhibited specific I-125-IL-8 binding with a novel affinity binding profile of IL-8 >> NAP-2 > MGSA. The corresponding apparent K-i values for IL-8, NAP-2, and MGSA were 4, 120, and 320 nM, respectively. IL-8 induced intracellular calcium mobilization and desensitization in Chinese hamster ovary cells stably transfected with 5B1a, indicating that this cDNA encodes a functional IL-8 receptor. Sequence analysis of the 5B1a protein with other IL-8 receptor subtypes within the framework of their pharmacological profile reveals putative structural motifs that may correspond to the ligand binding site of the IL-8 receptor.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039602] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 39602] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTENBERG GA, 1992, J GEN PHYSIOL, V99, P241, DOI 10.1085/jgp.99.2.241; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J IMMUNOL, V148, P1261; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHRODER JM, 1986, J INVEST DERMATOL, V87, P53, DOI 10.1111/1523-1747.ep12523566; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	16	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12391	12394						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175642				2022-12-27	WOS:A1994NH71600003
J	MUHLRAD, A; CHEUNG, P; PHAN, BC; MILLER, C; REISLER, E				MUHLRAD, A; CHEUNG, P; PHAN, BC; MILLER, C; REISLER, E			DYNAMIC PROPERTIES OF ACTIN - STRUCTURAL-CHANGES INDUCED BY BERYLLIUM FLUORIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN SUBFRAGMENT-1; SLIDING MOVEMENT; F-ACTIN; MUSCLE-CONTRACTION; FLUORESCENT-PROBE; BINDING; ATP; POLYMERIZATION; FILAMENTS; COMPLEXES	Beryllium fluoride (BeFx) has been widely used as a phosphate analogue in nucleotide-binding proteins. It was found to bind tightly to F- but not G-actin (Combeau C., and Carlier M. F. (1988) J. Biol. Chem. 263, 17429-17436) and to affect the three-dimensional structure of filaments by stabilizing the subdomain 2 region of the actin protomer (Orlova, A., and Egelman, E. H. (1992) J. Mol. Biol. 227, 1043-1053). In this work we examined the BeFx-induced structural and functional changes in G- and F-actin by using proteolysis, chemical modifications, ATPase, and in vitro motility assays. The results of proteolysis studies show that BeFx binds also to MgADP-G-actin and renders its subdomain 2 region more similar to that in MgATP-G-actin. This is manifested in enhanced subtilisin and decreased tryptic digestions in subdomain 2 of G-actin. BeFx had a strong effect on the proteolysis of MgADP-F-actin: both the tryptic and sub digestions in subdomain 2 were completely inhibited. Significant protection against proteolysis in this region was observed even at 1:14 molar ratios of BeFx to actin indicating cooperative effects on the structure of the actin filament. A similar although milder effect of phosphate on the proteolysis of F-actin suggests that BeFx acts as a phosphate analogue in this system. BeFx also induces changes in the subdomain 1 region of F-actin. This is revealed via reduced rates of Cys-374 alkylation with 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin and an increased subtilisin cleavage near the C terminus of actin in the presence of BeFx. The BeFx-induced structural changes in actin have little effect on its interactions with myosin. BeFx inhibits only slightly the actin-activated ATPase activity of S1 by decreasing V-max without affecting K-M. Additionally, the binding of BeFx to actin does not change the sliding velocity of actin filaments in the in vitro motility assays. The BeFx-induced specific and distinct changes in G- and F-actin point to the dynamic nature of actin structure and the local differences between monomeric and polymeric forms of actin.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; HEBREW UNIV JERUSALEM, HADASSAH SCH DENT MED, DEPT ORAL BIOL, IL-91010 JERUSALEM, ISRAEL	University of California System; University of California Los Angeles; Hebrew University of Jerusalem	MUHLRAD, A (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA-9056] Funding Source: Medline; NHLBI NIH HHS [HL 07386] Funding Source: Medline; NIAMS NIH HHS [R01 AR022031, AR22031] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR022031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHANTLER PD, 1975, EUR J BIOCHEM, V60, P67, DOI 10.1111/j.1432-1033.1975.tb20976.x; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COOK RK, 1993, J BIOL CHEM, V268, P2410; DREWES G, 1993, EUR J BIOCHEM, V212, P247, DOI 10.1111/j.1432-1033.1993.tb17656.x; DREWES G, 1991, J BIOL CHEM, V266, P5508; FRIEDEN C, 1985, BIOCHEMISTRY-US, V24, P4192, DOI 10.1021/bi00336a056; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JACOBSON GR, 1976, P NATL ACAD SCI USA, V73, P2742, DOI 10.1073/pnas.73.8.2742; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KHAITLINA SY, 1991, FEBS LETT, V279, P49, DOI 10.1016/0014-5793(91)80247-Z; KONNO K, 1987, BIOCHEMISTRY-US, V26, P3582, DOI 10.1021/bi00386a050; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MIKI M, 1982, BIOCHEMISTRY-US, V21, P3661, DOI 10.1021/bi00258a021; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; NONOMURA Y, 1975, J BIOCHEM, V78, P1101, DOI 10.1093/oxfordjournals.jbchem.a130988; ORLOVA A, 1992, J MOL BIOL, V227, P1047; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PHAN CB, 1993, BIOCHEMISTRY-US, V32, P7713; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; PROCHNIEWICZ E, 1993, BIOPHYS J, V65, P113, DOI 10.1016/S0006-3495(93)81057-9; RICHARD JE, 1986, J MOL BIOL, V191, P273; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; SCHUTT CE, 1992, FEBS LETT, V325, P59; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023	40	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11852	11858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163484				2022-12-27	WOS:A1994NG37700030
J	HENRICKSEN, LA; UMBRICHT, CB; WOLD, MS				HENRICKSEN, LA; UMBRICHT, CB; WOLD, MS			RECOMBINANT REPLICATION PROTEIN-A - EXPRESSION, COMPLEX-FORMATION, AND FUNCTIONAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; LARGE-TUMOR-ANTIGEN; CYCLE-DEPENDENT PHOSPHORYLATION; POLYMERASE-ALPHA-PRIMASE; CASEIN KINASE-II; LARGE T-ANTIGEN; BINDING-PROTEIN; SV40 ORIGIN; TOPOISOMERASE-II	Replication protein A (RPA) is a multisubunit, single-stranded DNA-binding protein that is absolutely required for replication of SV40 DNA. The three cDNAs encoding the subunits of human replication protein A (70, 32, and 14 kDa) have been expressed individually and in combination in Escherichia coli. When subunits were expressed individually, appropriately sized polypeptides were synthesized, but were found to be either insoluble or aggregated with other proteins. We examined the interactions between individual RPA subunits by expressing pairs of subunits and determining if they formed stable complexes. Only the 32- and 14-kDa subunits formed a soluble complex when coexpressed. This complex was purified and characterized. The 32.14 kDa subcomplex did not have any effect on DNA replication and was not phosphorylated efficiently in vitro. We believe that the 32.14-kDa subcomplex may be a precursor in the assembly of the complete RPA complex. Coexpression of all three subunits of RPA resulted in a significant portion of each polypeptide forming a soluble complex. We have purified recombinant RPA complex from E. coli and demonstrated that it has properties similar to those of human RPA. Recombinant human RPA has the same subunit composition and the same activities as the authentic complex from human cells. Recombinant human RPA binds single-stranded DNA and is capable of supporting SV40 DNA replication in vitro. In addition, recombinant RPA became phosphorylated when incubated under replication conditions.	UNIV IOWA, DEPT BIOCHEM, 51 NEWTON RD, IOWA CITY, IA 52242 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	University of Iowa; Johns Hopkins University			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NATIONAL CANCER INSTITUTE [K11CA001469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721] Funding Source: NIH RePORTER; NCI NIH HHS [5 K11 CAO1469-04] Funding Source: Medline; NIGMS NIH HHS [GM44721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ATRAZHEV A, 1992, EUR J BIOCHEM, V210, P855, DOI 10.1111/j.1432-1033.1992.tb17489.x; Ausubel FM, 1988, MOL REPROD DEV; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; CARMICHAEL EP, 1993, MOL CELL BIOL, V13, P408, DOI 10.1128/MCB.13.1.408; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ERDILE LF, 1991, COLD SH Q B, V56, P303; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN M, 1988, BIOCHIM BIOPHYS ACTA, V951, P382, DOI 10.1016/0167-4781(88)90110-8; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FRORATH B, 1991, BIOTECHNIQUES, V11, P364; GASSER SM, 1992, ANTON LEEUW INT J G, V62, P15, DOI 10.1007/BF00584459; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOESS A, 1988, BIO-TECHNOL, V6, P1214, DOI 10.1038/nbt1088-1214; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEO YS, 1991, J BIOL CHEM, V266, P13161; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	95	516	529	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11121	11132						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157639				2022-12-27	WOS:A1994NF96600026
J	KALLIO, PJ; PALVIMO, JJ; MEHTO, M; JANNE, OA				KALLIO, PJ; PALVIMO, JJ; MEHTO, M; JANNE, OA			ANALYSIS OF ANDROGEN RECEPTOR-DNA INTERACTIONS WITH RECEPTOR PROTEINS PRODUCED IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE DECARBOXYLASE GENE; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; STEROID-BINDING; TRANSCRIPTIONAL ACTIVATION; BACULOVIRUS SYSTEM; HORMONE RECEPTOR; ESCHERICHIA-COLI; EXPRESSION	Wild-type rat androgen receptor and four of its deletion mutants were produced in insect cells using the baculovirus expression system. Inclusion of androgen, but not estrogen, progesterone, or glucocorticoid, in culture medium increased the yield of soluble androgen receptors, although the majority of receptors still remained in the insoluble form (Xie, Y.-B., Sui, Y.-P., Shan, L.-X., Palvimo, J. J., Phillips, D. M., and Janne, O. A. (1992) J. Biol. Chem. 267, 4939-4948). The wild-type receptor interacted with an androgen response element (ARE) with a 2-6-fold higher affinity (K(D) = 0.5 nM) than mutants with deletions outside the DNA-binding domain (DELTA40-147, DELTA38-296, DELTA46-408, and DELTA788-902 mutants), suggesting that sequences flanking the DNA-binding region influence the stability of receptor-DNA complexes. Changes in spacing (n = 3) between the two ARE half-sites by a single nucleotide (n - 1, n + 1) or by 10 bases (n + 10) abolished the full-length receptor's ability to form stable complexes with DNA. Binding to AREs with altered spacing could not be restored by antisera against the N-terminal domain of the receptor that stabilize androgen receptor-DNA interactions with many naturally occurring strong and weak AREs. Methylation interference and 1,10-phenanthroline copper footprinting analyses revealed that the receptor binds to DNA as a dimer. Dimer formation was demonstrated directly by mixing full-length and DELTA46-408 mutant receptors, which resulted in the formation of. heterodimeric receptor-DNA complexes. The half-time of dissociation of the wild-type receptor from a consensus ARE sequence was about 3 min at 22-degrees-C. Collectively, androgen receptor binds to DNA with properties similar to, but not identical with, those of glucocorticoid receptor, indicating that regions outside the DNA-binding domain are important to ensure androgen specificity of transcriptional regulation.	UNIV HELSINKI,DEPT PHYSIOL,POB 9,SF-00014 HELSINKI,FINLAND	University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Ausubel FM, 1988, MOL REPROD DEV; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURNSTEIN KL, 1993, J CELL BIOCHEM, V51, P130, DOI 10.1002/jcb.240510203; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; DEVOS P, 1991, J BIOL CHEM, V266, P3439; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FREEDMAN LP, 1993, ENDOCR REV, V51, P130; ISOMAA V, 1982, ENDOCRINOLOGY, V111, P833, DOI 10.1210/endo-111-3-833; JANNE OA, 1993, CLIN CHEM, V39, P346; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIC SC, 1992, J BIOL CHEM, V267, P18915; MARINEZ E, 1989, EMBO J, V8, P3781; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Papavassiliou A G, 1994, Methods Mol Biol, V30, P43; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RODRIGUEZ R, 1989, MOL ENDOCRINOL, V3, P356, DOI 10.1210/mend-3-2-356; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAN J, 1992, J BIOL CHEM, V67, P4456; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WONG P, 1993, J BIOL CHEM, V268, P5021; XIE YB, 1992, J BIOL CHEM, V267, P4939	48	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11514	11522						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157681				2022-12-27	WOS:A1994NF96600080
J	ORNING, L; GIERSE, JK; FITZPATRICK, FA				ORNING, L; GIERSE, JK; FITZPATRICK, FA			THE BIFUNCTIONAL ENZYME LEUKOTRIENE-A(4) HYDROLASE IS AN ARGININE AMINOPEPTIDASE OF HIGH-EFFICIENCY AND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG; LTA4 HYDROLASE; POLYMORPHONUCLEAR LEUKOCYTES; PEPTIDASE ACTIVITY; EPOXIDE HYDROLASE; ARACHIDONIC-ACID; RAT; PURIFICATION; INHIBITION; BINDING	Leukotriene-A4 hydrolase (EC 3.3.2.6) cleaved the NH2-terminal amino acid from several tripeptides, typified by arginyl-glycyl-aspartic acid, arginyl-glycyl-glycine, and arginyl-histidyl-phenylalanine, with catalytic efficiencies (k(cat)/K(m)) greater-than-or-equal-to 1 x 10(6) M-1 s-1. This exceeds by 10-fold the k(cat)/K(m) for its lipid substrate leukotriene A4. Catalytic efficiency declined for dipeptides which had k(cat)/K(m) ratios 10-100-fold lower than tripeptides. Tetrapeptides and pentapeptides were even poorer substrates with catalytic efficiencies below 10(3) M-1 s-1. The enzyme preferentially hydrolyzed tripeptide substrates and single amino acid p-nitroanilides with L-arginine at the NH2 terminus. Peptides with proline at the second position were not hydrolyzed, suggesting a requirement for an N-hydrogen at the peptide bond cleaved. Peptides with a blocked NH2 terminus were not hydrolyzed. The specificity constant (k(cat)/K(m)) was optimal at pH 7.2 with pK values at 6.8 and 7.9; binding was maximal at pH 8.0. Serum albumins activated the peptidase, increasing tripeptide affinities (K(m)) by 3-10-fold and specificities (k(cat)/K(m)) by 4-13-fold. Two known inhibitors of arginine peptidases, arphamenine A and B, inhibited hydrolysis of L-arginine p-nitroanilide with dissociation constants = 2.0 and 2.5 muM, respectively. Although the primary role of LTA4 hydrolase is widely regarded as the conversion of the lipid substrate leukotriene A4 into the inflammatory lipid mediator leukotriene B4, our data are the first showing that tripeptides are ''better'' substrates. This is compatible with a biological role for the peptidase activity of the enzyme and may be relevant to the distribution of the enzyme in organs like the ileum, liver, lung, and brain. We present a model which accommodates the available data on the interaction of substrates and inhibitors with the enzyme. This model can account for overlap in the active site for hydrolysis of leukotriene A4 and peptide or p-nitroanilide substrates.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, 4200 E 9TH AVE, DENVER, CO 80262 USA; MONSANTO CO, ST LOUIS, MO 63167 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Monsanto					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26730] Funding Source: Medline; PHS HHS [P01 34303] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHENOWETH D, 1973, J BIOL CHEM, V248, P1672; DOUMENG C, 1979, BIOCHEM J, V177, P801, DOI 10.1042/bj1770801; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FITZPATRICK F, 1983, P NATL ACAD SCI-BIOL, V80, P5425, DOI 10.1073/pnas.80.17.5425; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1983, P NATL ACAD SCI USA, V80, P5425; FU JY, 1989, BIOCHIM BIOPHYS ACTA, V1006, P121; GIERSE JK, 1993, PROTEIN EXPRES PURIF, V4, P358, DOI 10.1006/prep.1993.1047; GRIFFIN KJ, 1992, PROSTAGLANDINS, V44, P251, DOI 10.1016/0090-6980(92)90018-O; HAEGGSTROM J, 1985, BIOCHIM BIOPHYS ACTA, V835, P378, DOI 10.1016/0005-2760(85)90294-2; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; HARBESON SL, 1988, BIOCHEMISTRY-US, V27, P7301, DOI 10.1021/bi00419a019; HAYASHI M, 1980, J BIOCHEM, V87, P1403, DOI 10.1093/oxfordjournals.jbchem.a132881; IZUMI T, 1966, BIOCHEM BIOPH RES CO, V135, P139; JAKSCHIK BA, 1983, PROSTAG OTH LIPID M, V25, P767, DOI 10.1016/0090-6980(83)90002-3; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KHILJI MA, 1979, MOL CELL BIOCHEM, V23, P45; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; MORGAN JG, 1985, EUR J BIOCHEM, V146, P429, DOI 10.1111/j.1432-1033.1985.tb08669.x; NADEL JA, 1990, LUNG, V168, P123, DOI 10.1007/BF02718124; NATHANIEL DJ, 1985, BIOCHEM BIOPH RES CO, V131, P827, DOI 10.1016/0006-291X(85)91314-2; NINAMI M, 1992, FEBS LETT, V309, P353; OHISHI N, 1990, J BIOL CHEM, V265, P7520; OHISHI N, 1987, J BIOL CHEM, V262, P10200; ORNING L, 1991, J BIOL CHEM, V266, P16507; ORNING L, 1991, J BIOL CHEM, V266, P1375; ORNING L, 1992, BIOCHEMISTRY-US, V31, P4218, DOI 10.1021/bi00132a010; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RADMARK O, 1989, ADV PROSTAG THROMB L, V19, P484; ROUISSI N, 1990, PHARMACOLOGY, V40, P185, DOI 10.1159/000138658; SACHS L, 1982, BIOCHIM BIOPHYS ACTA, V706, P229, DOI 10.1016/0167-4838(82)90491-5; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHIMIZU T, 1987, J NEUROCHEM, V48, P1541, DOI 10.1111/j.1471-4159.1987.tb05698.x; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; TOH H, 1990, BIOCHEM BIOPH RES CO, V171, P216, DOI 10.1016/0006-291X(90)91379-7; TROINRUD DE, 1992, MATRIX S, V1, P107; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEI YA, 1993, J MED CHEM, V36, P211, DOI 10.1021/jm00054a004; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; YUAN W, 1992, J AM CHEM SOC, V114, P6552, DOI 10.1021/ja00042a041	51	93	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11269	11273						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157657				2022-12-27	WOS:A1994NF96600046
J	RADIC, Z; DURAN, R; VELLOM, DC; LI, Y; CERVENANSKY, C; TAYLOR, P				RADIC, Z; DURAN, R; VELLOM, DC; LI, Y; CERVENANSKY, C; TAYLOR, P			SITE OF FASCICULIN INTERACTION WITH ACETYLCHOLINESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROASPIS-ANGUSTICEPS VENOM; ANTICHOLINESTERASE TOXINS; TORPEDO-CALIFORNICA; SNAKE-VENOM; BINDING; MUTAGENESIS; INHIBITION; PROTEIN; LIGANDS	Fasciculin, a 6750-Da peptide from the venom of Dendroaspis, is known to inhibit reversibly mammalian and fish acetylcholinesterases at picomolar concentrations, but is a relatively weak inhibitor of avian, reptile, and insect acetylcholinesterases and mammalian butyrylcholinesterases. An examination of fasciculin association with several mutant forms of recombinant DNA-derived acetylcholinesterase from mouse shows that it interacts with a cluster of residues near the rim of the gorge on the enzyme. The aromatic residues, Trp286, Tyr72, and Tyr124, have the most marked influence on fasciculin binding, whereas Asp74, a charged residue in the vicinity of the binding site that affects the binding of low molecular weight inhibitors, has little influence on fasciculin binding. The 3 aromatic residues are unique to the susceptible acetylcholinesterases and, along with Asp74, constitute part of the peripheral anionic site. Fasciculin falls in the family of three-loop toxins that include the receptor blocking alpha-toxins and cardiotoxins. From this basic structural motif, a binding site has evolved on fasciculin to be highly specific for the peripheral site on acetylcholinesterase. Acetylthiocholine affects rates of fasciculin binding at concentrations causing substrate inhibition. In the case of the mutant cholinesterases where rates of fasciculin dissociation are more rapid, steady state kinetic parameters also show acetylthiocholine-fasciculin competition to be consistent with occupation at a peripheral or substrate inhibition site rather than the active center.	CLEMENTE ESTABLE,INST INVEST BIOL,MONTEVIDEO 11600,URUGUAY	Instituto de Investigaciones Biologicas Clemente Estable Uruguay	RADIC, Z (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92103, USA.		Durán, Rosario/GQH-8502-2022	Duran, Rosario/0000-0002-8575-9651	NIGMS NIH HHS [GM-18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN WW, 1949, P SOC EXP BIOL MED, V72, P1; Aldridge W. N., 1972, ENZYME INHIBITORS SU; BLABER LC, 1962, BIOCHEM PHARMACOL, V11, P113, DOI 10.1016/0006-2952(62)90098-9; BOLGER MB, 1979, BIOCHEMISTRY-US, V18, P3622, DOI 10.1021/bi00583a029; Cervenansky C., 1991, P303; CERVENANSKY C, 1991, Toxicon, V29, P1163; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; GNATT A, 1994, J NEUROCHEM, V62, P749; GRECO WR, 1979, J BIOL CHEM, V254, P2104; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HUNTER A, 1945, J BIOL CHEM, V157, P427; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KARLSSON E, 1985, PHARMACOL THERAPEUT, V30, P259, DOI 10.1016/0163-7258(85)90051-8; KRUPKA RM, 1961, J AM CHEM SOC, V83, P1448, DOI 10.1021/ja01467a042; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LIN WW, 1987, ASIA PAC J PHARMACOL, V2, P79; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MAULET Y, 1991, CHOLINESTERASES STRU, P186; MILLARD CB, 1992, BIOCHEM BIOPH RES CO, V189, P1280, DOI 10.1016/0006-291X(92)90212-4; MUTERO A, 1992, NEUROREPORT, V3, P39, DOI 10.1097/00001756-199201000-00010; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; RADIC Z, 1984, BIOCHEM PHARMACOL, V33, P671, DOI 10.1016/0006-2952(84)90324-1; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; ROSENBERRY TL, 1979, BIOCHEMISTRY-US, V18, P3622; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; VILJOEN CC, 1973, J BIOL CHEM, V248, P4915; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	37	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11233	11239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157652				2022-12-27	WOS:A1994NF96600041
J	SCHULER, E; LIN, F; WORMAN, HJ				SCHULER, E; LIN, F; WORMAN, HJ			CHARACTERIZATION OF THE HUMAN GENE ENCODING LBR, AN INTEGRAL PROTEIN OF THE NUCLEAR-ENVELOPE INNER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B-RECEPTOR; INTERMEDIATE FILAMENT PROTEINS; SEQUENCE; IDENTIFICATION; MITOSIS; KINASE; PIECES; CHAIN; CDNA	We have characterized the human gene encoding LBR, an integral protein of the nuclear envelope inner membrane. Restriction mapping shows that the transcription unit spans approximately 35 kilobases. A transcription start site is located approximately 4 kilobases 5' to the translation initiation codon, and an RNA splice of 3863 bases occurs in the 5'-untranslated region to generate mature HeLa cell mRNA. 5' to the identified transcription start site are two CCAAT sequences and potential recognition sites for several transcription factors including Sp1, AP-1, AP-2, and NF-kB. There are 13 protein coding exons in the LBR gene. LBR's nucleoplasmic domain is encoded by exons 1-4, and its hydrophobic domain, with eight putative transmembrane segments, is encoded by exons 5-13. The hydrophobic domain is homologous to three yeast polypeptides, suggesting that this higher eukaryotic gene could have evolved from recombination between a gene that encoded a soluble nuclear protein and a membrane protein gene similar to those in yeast. These results are the first to demonstrate the structural organization of a vertebrate gene encoding an integral membrane protein of the nuclear envelope that may be a member of a family of polypeptides conserved in evolution.	CUNY MT SINAI SCH MED,DEPT MED,BOX 1269,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; COURVALIN JC, 1990, J EXP MED, V172, P961, DOI 10.1084/jem.172.3.961; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING V, 1990, EMBO J, V9, P4073, DOI 10.1002/j.1460-2075.1990.tb07629.x; EERNISSE DJ, 1992, COMPUT APPL BIOSCI, V8, P177; FAWCETT DW, 1966, AM J ANAT, V119, P129, DOI 10.1002/aja.1001190108; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAREL A, 1989, J CELL SCI, V94, P463; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN F, 1993, J BIOL CHEM, V268, P16321; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OSMAN M, 1990, GENOMICS, V8, P217, DOI 10.1016/0888-7543(90)90274-X; PADAN R, 1990, J BIOL CHEM, V265, P7808; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; TONEGAWA S, 1978, P NATL ACAD SCI USA, V75, P1485, DOI 10.1073/pnas.75.3.1485; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YE Q, 1994, J BIOL CHEM, V269, P11306; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9; ZEWE M, 1991, EUR J CELL BIOL, V56, P342	42	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11312	11317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157663				2022-12-27	WOS:A1994NF96600053
J	SHIRATORI, Y; OKWU, AK; TABAS, I				SHIRATORI, Y; OKWU, AK; TABAS, I			FREE-CHOLESTEROL LOADING OF MACROPHAGES STIMULATES PHOSPHATIDYLCHOLINE BIOSYNTHESIS AND UP-REGULATION OF CTP - PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; ACYL COENZYME-A; PLASMA-MEMBRANE SPHINGOMYELIN; MOUSE PERITONEAL-MACROPHAGES; HAMSTER OVARY CELLS; FATTY-ACIDS; ATHEROSCLEROTIC LESIONS; CULTURED FIBROBLASTS; TRANSFERASE-ACTIVITY	Atheroma macrophages accumulate large amounts of free cholesterol (FC) as well as cholesteryl ester (CE). An important adaptive response to FC loading might be increased cellular phospholipid to accommodate the excess FC. To explore this idea, J774 macrophages were incubated for 48 h without lipid, with acetyl-low density lipoprotein to induce mostly CE loading, or with acetyl-low density lipoprotein plus an acyl-CoA:cholesterol O-acyltransferase inhibitor (58035) to induce marked FC loading. The total phospholipid content approximately doubled in FC-loaded versus control or CE-loaded macrophages, with phosphatidylcholine showing the largest increase (approximately 2.5-fold versus control). Electron micrographs revealed the presence of multiple intracellular membrane whorls in the FC-loaded macrophages but not in the control or CE-loaded macrophages. [H-3]Choline incorporation into phosphatidylcholine was also greater in FC-loaded macrophages versus control or CE-loaded macrophages, whereas [H-3]phosphatidylcholine degradation was similar in all of the macrophages. In these experiments and in others that used non-lipoprotein cholesterol, there was a very close correlation between cellular FC content and phosphatidylcholine biosynthesis. To determine the mechanism of increased phosphatidylcholine synthesis, FC-loaded and CE-loaded macrophages were pulsed with [H-3]choline, then chased and assayed for labeled phosphatidylcholine biosynthetic precursors. The only major differences were a 2-fold greater disappearance of label from [H-3]choline phosphate and a 5-fold greater appearance of label in CDP-[H-3]choline in the FC-loaded macrophages. These data suggest a stimulation of CTP:phosphocholine cytidylyltransferase (CT), which was confirmed by microsomal CT assays. Further studies revealed that the increase in phosphatidylcholine biosynthesis in FC-loaded macrophages was: (a) reversible under conditions of high density lipoprotein3-mediated cellular cholesterol efflux; (b) not blocked by cycloheximide-induced protein synthesis inhibition; and (c) not associated with increased CT mRNA levels. Thus, FC loading of macrophages leads to an increase in phosphatidylcholine mass which is caused by increased phosphatidylcholine biosynthesis. The mechanism appears to be FC-mediated post-translational activation of CT. This adaptive response may be important for atheroma macrophage survival, and disruption of the response may lead to macrophage necrosis and lesion progression.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168 ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Shiratori, Yoshimune/I-6206-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39703, HL-21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; CHOBANIAN AV, 1966, J CLIN INVEST, V45, P932, DOI 10.1172/JCI105408; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELL RB, 1992, METHOD ENZYMOL, V209, P267; CORNELL RB, 1983, BIOCHIM BIOPHYS ACTA, V750, P504, DOI 10.1016/0005-2760(83)90191-1; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOWLER S, 1980, ACTA MED SCAND, P151; FUGLER L, 1985, J BIOL CHEM, V260, P4098; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; GUPTA AK, 1991, J LIPID RES, V32, P125; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HARA A, 1990, JPN J EXP MED, V60, P311; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; JACKSON RL, 1976, ATHEROSCLER REV, V1, P1; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KRIEGER M, 1978, P NATL ACAD SCI USA, V75, P5052, DOI 10.1073/pnas.75.10.5052; KUDCHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353, DOI 10.1016/0021-9150(83)90184-3; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LIM PH, 1983, BIOCHIM BIOPHYS ACTA, V753, P74, DOI 10.1016/0005-2760(83)90100-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MCCANDLESS EL, 1956, ARCH BIOCHEM BIOPHYS, V62, P402, DOI 10.1016/0003-9861(56)90138-2; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MOCK T, 1986, BIOCHEM CELL BIOL, V64, P413, DOI 10.1139/o86-058; MORRIS MD, 1982, AM J PATHOL, V108, P140; NAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V553, P307; OKWU AK, 1994, IN PRESS J LIPID RES; PELECH SL, 1983, J BIOL CHEM, V258, P6782; POST M, 1984, BIOCHIM BIOPHYS ACTA, V795, P552, DOI 10.1016/0005-2760(84)90185-1; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; RAPP JH, 1983, J LIPID RES, V24, P1329; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SCHAEFER HE, 1976, VERH DTSCH GES PATHO, V60, P259; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SCHMITZ G, 1990, J LIPID RES, V31, P1741; SHIO H, 1979, LAB INVEST, V41, P160; SHORE ML, 1955, AM J PHYSIOL, V181, P527, DOI 10.1152/ajplegacy.1955.181.3.527; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; STEIN Y, 1963, BIOCHIM BIOPHYS ACTA, V70, P33, DOI 10.1016/0006-3002(63)90716-9; STEVENS VL, 1986, BIOCHEMISTRY-US, V25, P4287, DOI 10.1021/bi00363a017; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TANGIRALA RK, 1993, J BIOL CHEM, V268, P9653; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1988, BIOCHIM BIOPHYS ACTA, V959, P1, DOI 10.1016/0005-2760(88)90143-9; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1991, BIOCH CELL BIOL, V29, P87; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; Weinhouse S, 1940, ARCH PATHOL, V29, P31; WHITLON DS, 1985, BIOCHIM BIOPHYS ACTA, V835, P369, DOI 10.1016/0005-2760(85)90293-0; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; ZILVERSMIT DB, 1954, CIRCULATION, V9, P581, DOI 10.1161/01.CIR.9.4.581	82	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11337	11348						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157665				2022-12-27	WOS:A1994NF96600056
J	SPORENO, E; PAONESSA, G; SALVATI, AL; GRAZIANI, R; DELMASTRO, P; CILIBERTO, G; TONIATTI, C				SPORENO, E; PAONESSA, G; SALVATI, AL; GRAZIANI, R; DELMASTRO, P; CILIBERTO, G; TONIATTI, C			ONCOSTATIN-M BINDS DIRECTLY TO GP130 AND BEHAVES AS INTERLEUKIN-6 ANTAGONIST ON A CELL-LINE EXPRESSING GP130 BUT LACKING FUNCTIONAL ONCOSTATIN-M RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; SIGNAL TRANSDUCER; PURIFICATION; CYTOKINES; INVITRO; IDENTIFICATION	Oncostatin M (OM) and interleukin 6 (IL-6) are functionally related cytokines, which trigger similar biological responses because they share gp130 as a common signal transducing transmembrane receptor. While IL-6 recruits gp130 only upon binding to its specific receptor subunit (IL-6Ralpha), reconstitution and cross-linking experiments on cell membranes suggest that OM can directly interact with gp130 and that this interaction is necessary but not sufficient to stimulate cells. However, the issue of the direct binding between gp130 and OM, in the absence of any additional membrane component, remained essentially unclarified. In this paper we show that, uniquely among the family of cytokines that transduce through gp130, OM directly binds in vitro with a 10(-8) M affinity sgp130, a soluble form of gp130. Moreover, titration of sgp130 with OM inhibits the formation of a ternary complex comprising IL-6, sIL-6Ralpha, and sgp130. These in vitro properties of OM are consistent with the additional finding that on human hepatoma Hep3B cells, which express gp130 but not functional OM receptors, OM does not mimic IL-6 activity, but rather behaves, at high doses, as an IL-6 antagonist.	IST RIC BIOL MOLEC P ANGELETTI,DEPT GENET,VIA PONTINA KM 30600,I-00040 POMEZIA,ITALY; IST RIC BIOL MOLEC P ANGELETTI,DEPT IMMUNOL,I-00040 POMEZIA,ITALY				Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BROWN TJ, 1987, J IMMUNOL, V139, P2977; BRUCE AG, 1992, J IMMUNOL, V149, P1271; BUSH GL, 1991, J BIOL CHEM, V266, P13811; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P2609, DOI 10.1002/eji.1830221021; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM FL, 1973, VIROLOGY, V52, P6777; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; LIU JW, 1992, J BIOL CHEM, V267, P16763; LU T, 1993, ANAL BIOCHEM, V213, P318, DOI 10.1006/abio.1993.1427; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SAVINO R, 1994, IN PRESS EMBO J; SPORENO E, 1994, IN PRESS CYTOKINE; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGA T, 1993, FASEB J, V7, P3387; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1992, IMMUNOL LETT, V31, P123, DOI 10.1016/0165-2478(92)90138-E; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YIN TG, 1993, J IMMUNOL, V151, P2555; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10991	10995						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157624				2022-12-27	WOS:A1994NF96600007
J	TANAKA, Y; TASHJIAN, AH				TANAKA, Y; TASHJIAN, AH			THIMEROSAL POTENTIATES CA2+ RELEASE MEDIATED BY BOTH THE INOSITOL 1,4,5-TRISPHOSPHATE AND THE RYANODINE RECEPTORS IN SEA-URCHIN EGGS - IMPLICATIONS FOR MECHANISTIC STUDIES ON CA2+ SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INDUCED CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; HAMSTER EGGS; CA-2+ RELEASE; INTRACELLULAR CALCIUM; XENOPUS OOCYTES; TRISPHOSPHATE; STORES	Two intracellular Ca2+ release pathways are modulated by Ca2+ itself, namely Ca-induced Ca2+ release (classical CICR), and Ca2+-sensitized inositol 1,4,5-trisphosphate (InsP3)-induced Ca2+ release (CSIICR). Both of these pathways are thought to be important in generating cytosolic Ca2+ oscillations. Caffeine and the sulfhydryl reagent thimerosal (TMS) are frequently used as selective modulators of CICR and CSIICR, respectively. We have studied the modes of action of caffeine and TMS in sea urchin egg homogenates using the Ca2+ indicator fluo-3. Cyclic ADP-ribose (cADPR), the only known endogenous compound to cause Ca2+ release via the ryanodine receptor, was used as an agonist for the classical CICR pathway. cADPR and InsP3 each alone caused release of sequestered Ca2+. Coaddition of caffeine dose-dependently and dramatically enhanced Ca2+ release induced by cADPR. InsP3-induced Ca2+ release was not affected by caffeine, but it was amplified by TMS, indicating the existence of the CSIICR pathway in this preparation. Surprisingly, cADPR-induced Ca2+ release was also markedly potentiated by TMS. TMS alone caused a slow increase in Ca2+ release which was not inhibited by heparin and/or procaine, indicating that TMS-induced Ca2+ release was not due to the actions of endogenous agonists (InsP3 or cADPR) on their receptors. All observed actions of TMS were abolished by dithiothreitol. We conclude: 1) both the InsP3- and cADPR-controlled Ca2+ release pathways are potentiated by TMS, while caffeine is specific for the cADPR pathway, indicating that TMS cannot be used as a selective reagent for probing the CSIICR mechanism; and 2) the action of TMS on intracellular Ca2+ release is independent of endogenous Ca2+ channel agonists, suggesting a novel action of TMS possibly on intravesicular Ca2+ handling.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 11011] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DELISLE S, 1992, J BIOL CHEM, V267, P7963; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; RANDRIAMAMPITA C, 1991, CELL REGUL, V2, P513, DOI 10.1091/mbc.2.7.513; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SHARP AH, 1993, J NEUROSCI, V13, P3051; STAUDERMAN KA, 1991, BIOCHEM J, V278, P643, DOI 10.1042/bj2780643; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WHITAKER M, 1993, DEVELOPMENT, V117, P1; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725	67	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11247	11253						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157654				2022-12-27	WOS:A1994NF96600043
J	HERSCHER, CJ; REGA, AF; GARRAHAN, PJ				HERSCHER, CJ; REGA, AF; GARRAHAN, PJ			THE DEPHOSPHORYLATION REACTION OF THE CA2+-ATPASE FROM PLASMA-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANES; TRANSPORT ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM ATPASE; HUMAN ERYTHROCYTE-MEMBRANES; MAGNESIUM-IONS; PHOSPHORYLATED INTERMEDIATE; CALCIUM; PHOSPHOENZYME; CA-2+; ADP	The breakdown of phosphoenzyme (EP) of the Ca2+-ATPase from pig red blood cell membranes was studied at 37 degrees C by means of a rapid chemical quenching technique. When the enzyme was phosphorylated with [gamma-P-32]ATP in media without added MgCl2, all the EP formed disappeared along two single exponential curves, a rapid one with k(app) = 90 +/- 10 s(-1) and a slow one with k(app) = 0.7 +/- 0.3 s(-1). The amount of EP involved in each reaction was close to 50% of the EP present at the beginning. Only EP of rapid breakdown could account for the steady-state hydrolysis of ATP observed under the same experimental conditions. ADP accelerated the slow reaction 45-fold (k(app) = 31 +/- 9 s(-1)) with K-0.5 = 740 +/- 120 mu M as if this reaction represented the decay of CaE(1)P, which donated its phosphate to water slowly in the forward direction and rapidly to ADP in the reverse direction of the cycle. Combination of Mg2+ with K-0.5 = 26.3 +/- 5.0 mu M at a single class of site in E(1) before phosphorylation increased EP of rapid breakdown at the expense of ADP-sensitive EP so that, at nonlimiting concentrations of Mg2+ in the phosphorylation media, all EP decomposed at high rate. Rapid decomposition was observed even with enough CDTA to chelate most of the Mg2+ remaining from phosphorylation, suggesting that the role of Mg2+ during dephosphorylation was to accelerate the transition CaE(1)P --> CaE(2)P, preparing EP for hydrolysis. The combination of ATP at a single class of site with K-m = 845 +/- 231 mu M accelerated the hydrolysis of CaE(2)P. Calmodulin alone had no effects on dephosphorylation but enhanced acceleration of hydrolysis of CaE(2)P by ATP making the decay of EP under these conditions the fastest among those measured. Comparison of the rates of dephosphorylation of EP made in the presence of Mg2+ with those of steady-state Ca2+-ATPase activity with and without calmodulin showed that the transition CaE(1)P --> CaE(2)P and decomposition of CaE(2)P by hydrolysis are compatible with their role as obligatory intermediate reactions in the cycle of hydrolysis of ATP by the Ca2+-ATPase.			HERSCHER, CJ (corresponding author), UNIV BUENOS AIRES,FAC FARM & BIOQUIM,INST QUIM & FIS BIOL,RA-1113 BUENOS AIRES,ARGENTINA.							ADAMO HP, 1990, BIOCHEM BIOPH RES CO, V169, P700, DOI 10.1016/0006-291X(90)90387-3; ADAMO HP, 1990, J BIOL CHEM, V265, P3789; ADAMO HP, 1988, J BIOL CHEM, V263, P17548; CARIDE AJ, 1986, BIOCHIM BIOPHYS ACTA, V863, P165, DOI 10.1016/0005-2736(86)90256-7; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; GARRAHAN PJ, 1978, BIOCHIM BIOPHYS ACTA, V513, P59, DOI 10.1016/0005-2736(78)90111-6; GARRAHAN PJ, 1976, BIOCHIM BIOPHYS ACTA, V448, P121, DOI 10.1016/0005-2736(76)90081-X; GIETZEN K, 1980, BIOCHEM J, V99, P147; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; INESI G, 1970, ARCH BIOCHEM BIOPHYS, V138, P285, DOI 10.1016/0003-9861(70)90309-7; JEFFERY DA, 1981, BIOCHEM J, V194, P481, DOI 10.1042/bj1940481; KANAZAWA T, 1971, J BIOCHEM-TOKYO, V70, P95, DOI 10.1093/oxfordjournals.jbchem.a129631; KRATJE RB, 1983, BIOCHIM BIOPHYS ACTA, V731, P40, DOI 10.1016/0005-2736(83)90395-4; LUDI H, 1987, J PHYSIOL-LONDON, V390, P367; LUNDAHL P, 1975, BIOCHIM BIOPHYS ACTA, V379, P304, DOI 10.1016/0005-2795(75)90033-1; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; POST RL, 1972, J BIOL CHEM, V247, P6530; REGA A, 1986, CA2PLUS PUMP PLASMA; REGA AF, 1980, BIOCHIM BIOPHYS ACTA, V596, P487, DOI 10.1016/0005-2736(80)90140-6; REGA AF, 1978, BIOCHIM BIOPHYS ACTA, V507, P182, DOI 10.1016/0005-2736(78)90386-3; REGA AF, 1975, J MEMBRANE BIOL, V22, P313, DOI 10.1007/BF01868177; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; ROSSI JPFC, 1985, BIOCHIM BIOPHYS ACTA, V816, P379, DOI 10.1016/0005-2736(85)90505-X; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P85, DOI 10.1016/0005-2736(89)90085-0; ROSSI RC, 1985, SODIUM PUMP, P443; TAKISAWA H, 1983, J BIOL CHEM, V258, P2986; YAMADA S, 1986, J BIOCHEM-TOKYO, V100, P1329, DOI 10.1093/oxfordjournals.jbchem.a121839	31	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10400	10406						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144623				2022-12-27	WOS:A1994NF01700035
J	WONG, H; DAVIS, RC; THUREN, T; GOERS, JW; NIKAZY, J; WAITE, M; SCHOTZ, MC				WONG, H; DAVIS, RC; THUREN, T; GOERS, JW; NIKAZY, J; WAITE, M; SCHOTZ, MC			LIPOPROTEIN-LIPASE DOMAIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LOW-DENSITY-LIPOPROTEIN; HEPATIC LIPASE; PANCREATIC LIPASE; TRIACYLGLYCEROL LIPASE; CATALYTIC TRIAD; GENE FAMILY; PROTEINS; BINDING; INACTIVATION	Human lipoprotein lipase (LPL) monomer consists of two domains, a larger NH2-terminal domain that contains catalytic residues and a smaller COOH-terminal domain that modulates substrate specificity and is a major determinant of heparin binding. Analyses of NH2-terminal domain function were performed after site-directed mutagenesis of the putative active-site serine residue, while COOH-terminal domain function was assessed following reaction with a monoclonal antibody. The native enzyme and mutant LPL in which serine 132 was replaced with alanine, cysteine, or glycine were transiently expressed in COS-7 cells. Mutant proteins were synthesized and secreted at levels comparable to native LPL; however, none of the mutants retained enzymatic activity. The mutant with alanine replacing serine 132 was purified and shown to be inactive with both esterase and lipase substrates; however, binding to a 1,2-didodecanoyl-sn-glycero-3-phosphatidylcholine monolayer was comparable to native LPL, These results are consistent with a catalytic, and not a lipid binding, role for serine 132. To investigate the function of the smaller COOH-terminal domain, LPL lipolytic and esterolytic activities as well as heparin binding properties were determined after reaction with a monoclonal antibody specific for this domain. Lipolytic activity was inhibited by the monoclonal antibody, whereas esterolytic activity was only marginally affected, indicating that the LPL COOH-terminal domain is required for lipolysis, perhaps by promoting interaction with insoluble substrates. Also, the affinity of antibody-reacted LPL for heparin was not significantly different from that of LPL alone, suggesting that (i) the heparin-binding site is physically distinct from the COOH-terminal domain region required for lipolysis and (ii) binding of antibody did not cause dimer dissociation. A model is proposed for the two LPL domains fulfilling different roles in the lipolytic process.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; WAKE FOREST UNIV,DEPT MED,WINSTON SALEM,NC 27103; CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,DEPT CHEM,SAN LUIS OBISPO,CA 93407	University of California System; University of California Los Angeles; Wake Forest University; California State University System; California Polytechnic State University San Luis Obispo	WONG, H (corresponding author), VET ADM WADSWORTH MED CTR,LIPID RES LAB,BLDG 113,RM 312,LOS ANGELES,CA 90073, USA.				NHLBI NIH HHS [HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1988, MOL REPROD DEV; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; Borgstrom B., 1984, P151; BOWNES M, 1992, J LIPID RES, V33, P777; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; CHAILLAN C, 1992, BIOCHEM BIOPH RES CO, V184, P206, DOI 10.1016/0006-291X(92)91179-T; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4980, DOI 10.1021/bi00668a006; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOERS JW, 1987, ANAL BIOCHEM, V168, P27; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1992, J LIPID RES, V33, P1165; RIETSCH J, 1977, J BIOL CHEM, V252, P4313; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P1; TASHIRO J, 1992, FEBS LETT, V298, P36, DOI 10.1016/0014-5793(92)80017-B; VAINIO P, 1983, J BIOL CHEM, V258, P5477; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R., 1984, P83; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10319	10323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144612				2022-12-27	WOS:A1994NF01700024
J	DEMARTINO, JA; VANRIPER, G; SICILIANO, SJ; MOLINEAUX, CJ; KONTEATIS, ZD; ROSEN, H; SPRINGER, MS				DEMARTINO, JA; VANRIPER, G; SICILIANO, SJ; MOLINEAUX, CJ; KONTEATIS, ZD; ROSEN, H; SPRINGER, MS			THE AMINO-TERMINUS OF THE HUMAN C5A RECEPTOR IS REQUIRED FOR HIGH-AFFINITY C5A BINDING AND FOR RECEPTOR ACTIVATION BY C5A BUT NOT C5A ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; INTERLEUKIN-8 RECEPTOR; ANAPHYLATOXIN C5A; MOLECULAR-CLONING; LIGAND-BINDING; IDENTIFICATION; EXPRESSION; ANTIBODIES; SITE; MECHANISM	The binding domain of the human C5a receptor consists of two distinct and physically separable subsites. One of these sites binds the C-terminal 8 amino acids of C5a and is as yet undefined, while the second site lies in the N terminus of the receptor and interacts with the core of C5a. Two deletion mutants were prepared to probe the importance of this second site. Removal of residues 2-22 decreased the binding affinity for C5a by 600-fold, while extending the deletion through residue 30 caused a further 75-fold decrease. Thus, the N terminus is responsible for at least 45% of the total energy for the binding of C5a. The five aspartic acids present in the deleted segments appear to be critical residues, as their conversion to alanines accounts for most of the affinity lost in the two truncations. Despite its importance for binding, the N terminus is not necessary for signal transduction, as a C-terminal peptide analog of C5a was able to stimulate G protein activation and to generate a Ca2+ flux through a receptor lacking residues 2-22. However, intact C5a was a very poor activator of this truncated receptor. These results imply that interaction between the N terminus of the receptor and C5a produces a conformational change in C5a that allows it's C terminus to properly interact with and activate the receptor.	MERCK SHARP & DOHME LTD,RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANALYT BIOCHEM,RAHWAY,NJ 07065	Merck & Company; Merck & Company; Merck & Company								BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; DEMARTINO JA, 1991, ANTIBODY IMMUNOCONJ, V4, P829; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEIN IM, 1988, INFLAMMATION BASIC P, P55; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; KAWAI M, 1990, WO9009162 WORLD INTE; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; MORGAN EL, 1993, J IMMUNOL, V151, P377; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; ROLLINS TE, 1988, J BIOL CHEM, V263, P520; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; SIRAGANIAN RP, 1982, FED PROC, V41, P30; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	26	105	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14446	14450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182049				2022-12-27	WOS:A1994NM06500024
J	DENNIS, EA				DENNIS, EA			DIVERSITY OF GROUP TYPES, REGULATION, AND FUNCTION OF PHOSPHOLIPASE A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; TRANSITION-STATE ANALOG; MACROPHAGE CELL-LINE; CRYSTAL-STRUCTURE; PANCREATIC PHOSPHOLIPASE-A2; PLATELET PHOSPHOLIPASE-A2; VENOM PHOSPHOLIPASE-A2; INTERFACIAL CATALYSIS		UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	DENNIS, EA (corresponding author), UNIV CALIF SAN DIEGO,REVELLE COLL,CTR MOLEC GENET,DEPT CHEM 0601,LA JOLLA,CA 92093, USA.		Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; [Anonymous], 1987, PHOSPHOLIPASES; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARBOUR SE, 1991, CHEMTRACTS BIOCH MOL, V2, P351; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Dennis EA, 1983, ENZYMES, P307; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DUFTON MJ, 1983, EUR J BIOCHEM, V137, P545, DOI 10.1111/j.1432-1033.1983.tb07860.x; FREMONT DH, 1993, P NATL ACAD SCI USA, V90, P342, DOI 10.1073/pnas.90.1.342; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEB LA, 1986, J BIOL CHEM, V261, P467; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PLESNIAK LA, 1993, BIOCHEMISTRY-US, V32, P5009, DOI 10.1021/bi00070a006; QUI ZH, 1993, J BIOL CHEM, V268, P24506; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VANDENBOSCH H, 1989, J BIOL CHEM, V264, P10008; VERGER R, 1973, J BIOL CHEM, V248, P4023; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; VERHEIJ HM, 1981, REV PHYSL BIOCH PHAR, V91, P92; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; WITTCOFF H, 1951, PHOSPHATIDES, P99; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WONG PY, 1990, PHOSPHOLIPASE A2 ROL; YU L, 1991, P NATL ACAD SCI USA, V88, P9325, DOI 10.1073/pnas.88.20.9325; YU L, 1992, J AM CHEM SOC, V114, P8757, DOI 10.1021/ja00049a001; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	67	1361	1408	3	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13057	13060						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175726				2022-12-27	WOS:A1994NK18400001
J	NAGANO, M; KELLY, PA				NAGANO, M; KELLY, PA			TISSUE DISTRIBUTION AND REGULATION OF RAT PROLACTIN RECEPTOR GENE-EXPRESSION - QUANTITATIVE-ANALYSIS BY POLYMERASE CHAIN-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; MESSENGER-RNA; MOLECULAR-CLONING; ADRENAL-MEDULLA; MULTIPLE FORMS; MAMMARY-GLAND; BINDING-SITES; FEMALE RATS; LIVER; CELLS	The rat prolactin receptor (PRLR) exists as two forms, short and long. We have developed a quantitative polymerase chain reaction (Q-PCR) in order to measure the absolute number of mRNA molecules encoding both forms of PRLR in 16 tissues of adult female rats at two stages of the estrous cycle (proestrus and diestrus I) and in the mammary gland of 20-day pregnant and 7-day lactating rats. Using this technique, it was possible to detect as few as 500 molecules of a target mRNA per mu g of total RNA. All tissues examined expressed the two forms of receptor transcripts, ranging from 1.8 x 10(3) molecules/mu g of total RNA in the skeletal muscle to 2.9 x 10(7) molecules/mu g of total RNA in the ovary. Fourteen tissues expressed the long form mRNA predominantly, the thymus and the kidney expressed both forms equally, and the liver expressed the short form predominantly. In the liver, the level of mRNA expression of the short form was similar to 2-fold higher in proestrus than in diestrus. In the ovary, uterus, and cerebral cortex, the expression of the long form transcript was higher in proestrus than in diestrus: 4-fold in the ovary, 2.8-fold in the uterus, and 1.4-fold in the cerebral cortex. In contrast, the hypothalamus and the pituitary expressed 1.6-fold more long form transcript in diestrus than in proestrus. These results indicate that PRLR mRNA is ubiquitously but variably expressed in a tissue-specific manner and is clearly regulated by the hormonal environment associated with the stage of the estrous cycle, pregnancy, and lactation.	FAC MED NECKER ENFANTS MALAD, INSERM, U344, F-75015 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008					ALBERTSON BD, 1987, ENDOCR RES, V13, P317, DOI 10.1080/07435808709035461; ALI S, 1991, J BIOL CHEM, V266, P20110; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCK K, 1992, ENDOCRINOLOGY, V130, P1108, DOI 10.1210/en.130.3.1108; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; CHEUNG CY, 1990, BIOGENIC AMINES, V7, P315; CHIU S, 1992, ENDOCRINOLOGY, V130, P1747, DOI 10.1210/en.130.3.1747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P224, DOI 10.1210/en.133.1.224; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P2594, DOI 10.1210/en.133.6.2594; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DUSANTERFOURT I, 1992, ENDOCRINOLOGY, V130, P2877, DOI 10.1210/en.130.5.2877; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FERNANDEZRUIZ J, 1987, NEUROENDOCRINOLOGY, V45, P208, DOI 10.1159/000124727; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HERNANDEZ ML, 1991, J ENDOCRINOL INVEST, V14, P201, DOI 10.1007/BF03346789; HOEFFLER JP, 1987, ENDOCRINOLOGY, V120, P1679, DOI 10.1210/endo-120-4-1679; HOLT JA, 1976, ENDOCRINOLOGY, V98, P1005, DOI 10.1210/endo-98-4-1005; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976, DOI 10.1210/endo-128-6-2976; JOLICOEUR C, 1989, MOL ENDOCRINOL, V3, P895, DOI 10.1210/mend-3-6-895; KELLY PA, 1975, ENDOCRINOLOGY, V97, P1408, DOI 10.1210/endo-97-6-1408; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KELLY PA, 1990, HORMONES, P191; KHARROUBI AT, 1984, ENDOCRINOLOGY, V115, P1283, DOI 10.1210/endo-115-4-1283; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MARSHALL S, 1978, ENDOCRINOLOGY, V102, P869, DOI 10.1210/endo-102-3-869; MEITES J, 1988, INT CONGR SER, V819, P123; MICK CCW, 1985, ENDOCRINOLOGY, V116, P2049, DOI 10.1210/endo-116-5-2049; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; Nicoll C.S., 1972, LACTOGENIC HORMONES, P299; NICOLL CS, 1988, INT CONGR SER, V819, P349; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; OUHTIT A, 1993, ENDOCRINOLOGY, V133, P135, DOI 10.1210/en.133.1.135; OUHTIT A, 1993, BIOL REPROD, V49, P528, DOI 10.1095/biolreprod49.3.528; OUHTIT A, 1994, IN PRESS AM J PHYSL; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; PIPPARD C, 1986, J ENDOCRINOL, V108, P95, DOI 10.1677/joe.0.1080095; RICHARDS JS, 1976, ENDOCRINOLOGY, V99, P1571, DOI 10.1210/endo-99-6-1571; ROBERTSON MT, 1986, ENDOCRINOLOGY, V119, P2439, DOI 10.1210/endo-119-6-2439; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; RUSSELL DH, 1988, INT CONGR SER, V819, P155; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SORENSON RL, 1987, ENDOCRINOLOGY, V121, P1447, DOI 10.1210/endo-121-4-1447; TANAKA M, 1992, BIOCHEM BIOPH RES CO, V188, P490, DOI 10.1016/0006-291X(92)91082-2; TAYA K, 1981, ENDOCRINOLOGY, V108, P2324, DOI 10.1210/endo-108-6-2324; VANDERSCHOOT P, 1983, J ENDOCRINOL, V97, P83, DOI 10.1677/joe.0.0970083; VILLALBA M, 1991, ENDOCRINOLOGY, V129, P2857, DOI 10.1210/endo-129-6-2857; WALSH RJ, 1987, ENDOCRINOLOGY, V120, P1846, DOI 10.1210/endo-120-5-1846; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	60	246	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13337	13345						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175764				2022-12-27	WOS:A1994NK18400045
J	SU, TT; MCCLURE, WR				SU, TT; MCCLURE, WR			SELECTIVE BINDING OF ESCHERICHIA-COLI RNA-POLYMERASE TO TOPOISOMERS OF MINICIRCLES CARRYING THE TAC16 AND TAC17 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; GEL-ELECTROPHORESIS; TRANSCRIPTION INITIATION; ACTIVATOR PROTEIN; DNA MINICIRCLES; INVITRO; INVIVO; HELIX; PURIFICATION; INHIBITION	We have studied the effect of DNA supercoliing on open complex formation by Escherichia coli RNA polymerase at the TAC16 and TAC17 promoters. A two dimensional gel retardation assay was used to measure the relative rate of association between RNA polymerase and the TAC promoters on individual topoisomers. Plasmid DNAs usually have several promoters that complicate the analysis of RNA polymerase binding to only one of them. We avoided this problem by using minicircles of DNA carrying only a single promoter. These were generated in vivo by the site-specific recombination system of bacteriophage lambda. Both the TAC16 and TAC17 promoters exhibited a biphasic response to negative supercoliing. Between superhelical densities of 0 and -0.04, increases in the negative linking difference favored binding. Beyond -0.04, either no effect on binding (TAC16) or a slight inhibition of binding (TAC17) was observed for increases in the negative linking difference. The unwinding at the rate-limiting step was calculated for both TAC promoters at moderate superhelical densities. This unwinding was found to be a fraction (about 20-30%) of the total unwinding measured by topoisomerase I relaxation (about one turn). In addition, the 1-base pair difference in spacer length between the TAC16 and TAC17 promoters resulted in different extents of activation and inhibition by negative supercoliing.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University					NIGMS NIH HHS [GM30375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; BACKMAN K, 1984, BIO-TECHNOL, V2, P1045, DOI 10.1038/nbt1284-1045; BAUER W, 1968, J MOL BIOL, V33, P141, DOI 10.1016/0022-2836(68)90286-6; BAUER W, 1970, Journal of Molecular Biology, V47, P419, DOI 10.1016/0022-2836(70)90312-8; BEARD P, 1984, EUR J BIOCHEM, V143, P39, DOI 10.1111/j.1432-1033.1984.tb08336.x; BERTRANDBURGGRAF E, 1990, EMBO J, V9, P2265, DOI 10.1002/j.1460-2075.1990.tb07397.x; BERTRANDBURGGRAF E, 1984, NUCLEIC ACIDS RES, V12, P7741, DOI 10.1093/nar/12.20.7741; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BLUMENTHAL T, 1973, BIOCHEM BIOPH RES CO, V55, P680, DOI 10.1016/0006-291X(73)91198-4; BOFFINI A, 1991, NUCLEIC ACIDS RES, V19, P1369, DOI 10.1093/nar/19.7.1369; BOROWIEC JA, 1987, J MOL BIOL, V195, P89, DOI 10.1016/0022-2836(87)90329-9; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BRAHMS JG, 1985, J MOL BIOL, V181, P455, DOI 10.1016/0022-2836(85)90419-X; Buc H., 1992, NUCLEIC ACIDS MOL BI, V6, P23, DOI [10.1007/978-3-642-77356-3_2, DOI 10.1007/978-3-642-77356-3_2]; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; COUREY AJ, 1988, J MOL BIOL, V202, P35, DOI 10.1016/0022-2836(88)90516-5; DAVIDSON N, 1972, J MOL BIOL, V66, P307, DOI 10.1016/0022-2836(72)90482-2; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Maniatis T., 1982, MOL CLONING LABORATO, P86; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NORDHEIM A, 1988, NUCLEIC ACIDS RES, V16, P21, DOI 10.1093/nar/16.1.21; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; SCHWARTZ M, 1988, THESIS C MELLON U PI; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; VINOGRAD J, 1968, J MOL BIOL, V33, P173, DOI 10.1016/0022-2836(68)90287-8; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011	46	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13511	13521						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175785				2022-12-27	WOS:A1994NK18400068
J	ARRIBAS, J; ARIZTI, P; CASTANO, JG				ARRIBAS, J; ARIZTI, P; CASTANO, JG			ANTIBODIES AGAINST THE C2 COOH-TERMINAL REGION DISCRIMINATE THE ACTIVE AND LATENT FORMS OF THE MULTICATALYTIC PROTEINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ATP-DEPENDENT PROTEASES; RAT HEPATOMA-CELLS; ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; SKELETAL-MUSCLE; RNA-POLYMERASE; CDNA CLONING; COMPONENT; LIVER	The mouse cDNA homologues of the rat C2, C9, and C5 subunits of the multicatalytic proteinase have been cloned and expressed in bacteria. The respective recombinant proteins were purified and used to produce specific anti-subunit antibodies. Immunoblotting of two-dimensional gels of purified rat liver multicatalytic proteinase showed that the C2 (32-kDa) and C9 (29-kDa) polypeptides are resolved into three and two isoelectric variants, respectively, likely due to post-translational modifications, i.e. phosphorylation, and the presence of two anti-C5 reacting polypeptides (25.5 and 23 kDa). Epitope mapping of the anti-C2-specific antibody with different constructs of the recombinant C2 protein allowed us to determine that one major epitope of this anti-C2 antibody is located within the last 9-11 amino acids of the C2 polypeptide. Affinity purified antibodies directed against the C2 COOH-terminal were able to discriminate the active and latent forms of the multicatalytic proteinase, supporting the conclusion that the C2 protein found in the active form of the enzyme is a polypeptide of 28 kDa, produced by the loss, at least, of the last 9-13 amino acids (DEPAEKADEPMEH) of the intact C2 (32-kDa) component. By in vitro treatment of the latent form of the enzyme with elastase, we show the conversion of the C2 (32-kDa) component to a 28-kDa protein with loss of recognition by the anti-C2 COOH-terminal affinity purified antibodies, but this limited degradation of the C2 component did not have any significant effect on the proteolytic activity (assayed with myelin basic protein and fluorogenic peptides) of the multicatalytic proteinase. It is suggested that the proteolytic cleavage of the C2 COOH-terminal region may be involved in the regulation of the interaction of the multicatalytic proteinase with other cellular proteins and/or in the translocation of the complex to the nucleus.	UNIV AUTONOMA MADRID,FAC MED,DEPT BIOQUIM,E-28029 MADRID,SPAIN; UNIV AUTONOMA MADRID,FAC MED,CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664				ARRIBAS J, 1993, J BIOL CHEM, V268, P21165; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIBAS J, 1991, J EXP MED, V173, P423, DOI 10.1084/jem.173.2.423; BROWN MG, 1993, J IMMUNOL, V151, P1193; CASTANO JG, 1986, CELL, V46, P377, DOI 10.1016/0092-8674(86)90658-6; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DEMENA IR, 1993, BIOCHEM J, V296, P93, DOI 10.1042/bj2960093; DESA CM, 1986, J MOL BIOL, V187, P479, DOI 10.1016/0022-2836(86)90328-1; FALKENBURG PE, 1989, J BIOL CHEM, V264, P6660; FRUH K, 1992, J BIOL CHEM, V267, P22131; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KANAYAMA H, 1991, CANCER RES, V51, P6677; KLEIN U, 1990, J CELL BIOL, V111, P2275, DOI 10.1083/jcb.111.6.2275; KLEINSCHMIDT JA, 1983, EUR J CELL BIOL, V32, P143; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; KUMATORI A, 1990, FEBS LETT, V264, P279, DOI 10.1016/0014-5793(90)80267-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1986, MOL CLONING; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PAL JK, 1988, J CELL SCI, V90, P555; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; SAITOH Y, 1989, BIOCHEM BIOPH RES CO, V162, P334, DOI 10.1016/0006-291X(89)92000-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V164, P1253, DOI 10.1016/0006-291X(89)91804-4; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOMEK W, 1988, FEBS LETT, V239, P155, DOI 10.1016/0014-5793(88)80564-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELTMAN D, 1992, J BIOL CHEM, V267, P6977; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YU B, 1993, J BIOL CHEM, V268, P2029; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	55	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12858	12864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175701				2022-12-27	WOS:A1994NH71600075
J	GUO, GG; GU, MZ; ETLINGER, JD				GUO, GG; GU, MZ; ETLINGER, JD			240-KDA PROTEASOME INHIBITOR (CF-2) IS IDENTICAL TO DELTA-AMINOLEVULINIC-ACID DEHYDRATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								The 240-kDa proteasome inhibitor has been reported to be an ATP-stabilized component (CF-2) of the 26 S proteasome complex. We now report that this inhibitory factor is indistinguishable from delta-aminolevulinic acid dehydratase (ALAD), the second enzyme in the pathway of heme synthesis, based upon the following observations: 1) common sequence of the first 14 N-terminal amino acids; 2) identical migration on native and SDS-polyacrylamide gel electrophoresis; 3) identical isoelectric points of pH 7.1; 4) cross-reactivity of specific polyclonal antibodies; 5) similar dehydratase and proteasome inhibitor specific activities in both proteins; and 6) the presence of both activities in recombinant ALAD. The dual role of this protein as CF-2 in the ATP/ ubiquitin-dependent pathway and in heme synthesis may be an example of ''gene sharing'' and explains the unexpected abundance of ALAD noted in earlier studies.	NEW YORK MED COLL, DEPT CELL BIOL & ANAT, VALHALLA, NY 10595 USA; SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, BROOKLYN, NY 11203 USA	New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; ASTRIN KH, 1987, ANN NY ACAD SCI, V514, P23, DOI 10.1111/j.1749-6632.1987.tb48757.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ETLINGER JD, 1980, J BIOL CHEM, V255, P4563; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JORDAN PM, 1986, METHOD ENZYMOL, V123, P427; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LI XCS, 1992, BIOCHEMISTRY-US, V31, P11963, DOI 10.1021/bi00163a001; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; NARISAWA K, 1966, BIOCHIM BIOPHYS ACTA, V123, P596, DOI 10.1016/0005-2787(66)90226-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Sassa S, 1981, Adv Hum Genet, V11, P121; SHEMIN D, 1972, ENZYMES, P323; TANAKA K, 1992, NEW BIOL, V4, P173; TSUKAMOTO I, 1980, INT J BIOCHEM, V12, P751; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WETMUR JG, 1986, GENE, V43, P123, DOI 10.1016/0378-1119(86)90015-6; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703; WU WH, 1974, P NATL ACAD SCI USA, V71, P1767, DOI 10.1073/pnas.71.5.1767	32	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12399	12402						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175643				2022-12-27	WOS:A1994NH71600005
J	RENARD, S; LINGUEGLIA, E; VOILLEY, N; LAZDUNSKI, M; BARBRY, P				RENARD, S; LINGUEGLIA, E; VOILLEY, N; LAZDUNSKI, M; BARBRY, P			BIOCHEMICAL-ANALYSIS OF THE MEMBRANE TOPOLOGY OF THE AMILORIDE-SENSITIVE NA+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CELLS; DEGRADATION	A key protein component of the amiloride-sensitive sodium channel has been cloned from rat colon and human lung. It may represent the first member of a new family of ionic channels expressed from nematode to human. The biochemical properties of the rat protein, a 699 amino acids long polypeptide, have been analyzed. Four polyclonal antibodies raised against distinct parts of the channel immunoprecipitated a glycosylated protein of 96 kDa after cRNA expression in oocytes as well as after in vitro translation. When expressed alone into oocytes, the protein was not stable; most of it remains stacked into the endoplasmic reticulum. This results in a very low yield of complete maturation of the protein at the cell surface after expression from the pure cRNA. To determine the membrane topology of the protein, in vitro translation by a rabbit reticulocyte lysate was performed followed by insertion into canine pancreatic microsomes and protease digestion. Analysis revealed a model with only two transmembrane alpha helices and a large extracellular domain of about 500 amino acids, The NH2 and COOH termini are cytoplasmic. Protease digestion results suggest the possible presence of a structural element that could have a function similar to that of the H5 segment in K+ channels. The model indicates that there is no cytoplasmic site for protein kinase A phosphorylation. The well known regulation of the channel activity by hormones that activate this kinase such as vasopressin might thus be situated on another channel component.	SOPHIA ANTIPOLIS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Barbry, Pascal/O-5021-2016; LINGUEGLIA, Eric/F-5509-2013	Barbry, Pascal/0000-0001-9632-6483; LINGUEGLIA, Eric/0000-0003-3902-3405; Renard, Stephane/0000-0002-1374-4960				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HEDGPETH J, 1983, CELL, V34, P759; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PONGS O, 1992, PHYSIOL REV, V72, P569; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; TARENTINO AL, 1978, METHOD ENZYMOL, V83, P399; VERRIER B, 1989, EUR J BIOCHEM, V183, P499, DOI 10.1111/j.1432-1033.1989.tb21077.x; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; YANASE M, 1986, AM J PHYSIOL, V250, pC517, DOI 10.1152/ajpcell.1986.250.3.C517; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	27	217	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12981	12986						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175716				2022-12-27	WOS:A1994NH71600092
J	WERNER, H; RAUSCHER, FJ; SUKHATME, VP; DRUMMOND, IA; ROBERTS, CT; LEROITH, D				WERNER, H; RAUSCHER, FJ; SUKHATME, VP; DRUMMOND, IA; ROBERTS, CT; LEROITH, D			TRANSCRIPTIONAL REPRESSION OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR (IGF-I-R) GENE BY THE TUMOR-SUPPRESSOR WT1 INVOLVES BINDING TO SEQUENCES BOTH UPSTREAM AND DOWNSTREAM OF THE IGF-I-R GENE-TRANSCRIPTION START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR; PROMOTER REGION; MESSENGER-RNA; EXPRESSION; LOCUS; INITIATOR; CLONING; KIDNEY	The insulin-like growth factor-I receptor (IGF-I-R) has been implicated in the etiology and/or progression of Wilms' tumor, a pediatric malignancy of the kidney that is often associated with deletion or mutation of the WT1 tumor suppressor gene. The expression of the IGF-I-R gene is increased in Wilms' tumor as compared with normal kidney tissue. Furthermore, the levels of IGF-I-R mRNA in individual tumors have been shown to be inversely correlated to the levels of WT1 mRNA, suggesting that the expression of the IGF-I R gene is under the negative control of WT1. The activity of an IGF-I R promoter/luciferase construct in Chinese hamster ovary cells was reduced by cotransfection of a WT1 expression vector. An analysis of various reporter constructs containing different portions of the IGF-I-R 5'-flanking and 5'-untranslated regions suggested that the effect of WT1 depends on the number of WT1 binding sites present, with sites located both upstream and downstream of the IGF-I-R transcription start site involved in mediating this effect. Using the purified zinc finger domain of WT1 in gel retardation and DNase I footprinting assays, we mapped five sites in the 5'-flanking and six sites in the 5'-untranslated regions that were involved in WT1 binding. In addition, the initiator element of the IGF-I-R gene contains a sequence that binds WT1. Thus, the repression of IGF-I-R promoter activity by the WT1 tumor suppressor gene product involves multiple interactions of its zinc finger domain with WT1 binding sites located both 5' and 3' of the transcription initiation site.	WISTER INST ANAT & BIOL,PHILADELPHIA,PA 19104; BETH ISRAEL HOSP,DIV RENAL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	The Wistar Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	WERNER, H (corresponding author), NIDDKD,DIABET BRANCH,BLDG 10,ROOM 8S-239,BETHESDA,MD 20892, USA.		Sukhatme, Vikas/W-2776-2019; Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772	NCI NIH HHS [CA 10817, CA 47983, CA 52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P01CA047983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; DICICCOBLOOM E, 1988, P NATL ACAD SCI USA, V85, P4066, DOI 10.1073/pnas.85.11.4066; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GANSLER T, 1988, AM J PATHOL, V130, P431; GANSLER T, 1989, AM J PATHOL, V135, P961; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAMULA PW, 1992, DNA CELL BIOL, V11, P43, DOI 10.1089/dna.1992.11.43; MORRIS JF, 1991, ONCOGENE, V6, P2339; PAIK S, 1989, LAB INVEST, V61, P522; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1991, INSULIN LIKE GROWTH, P17; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	31	145	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12577	12582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175666				2022-12-27	WOS:A1994NH71600034
J	ASANO, M; TAMIYAKOIZUMI, K; HOMMA, Y; TAKENAWA, T; NIMURA, Y; KOJIMA, K; YOSHIDA, S				ASANO, M; TAMIYAKOIZUMI, K; HOMMA, Y; TAKENAWA, T; NIMURA, Y; KOJIMA, K; YOSHIDA, S			PURIFICATION AND CHARACTERIZATION OF NUCLEAR PHOSPHOLIPASE-C SPECIFIC FOR PHOSPHOINOSITIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE-C; RAT-LIVER NUCLEI; BOVINE BRAIN; HUMAN-PLATELETS; PHOSPHATIDYLINOSITOL; MATRIX; FORMS; MEMBRANE; DIACYLGLYCEROL	A phosphoinositide-specific phospholipase C (PLC) was solubilized from the isolated nuclei of rat ascites hepatoma AH7974 cells by ultrasonication in 2 M KCl. The extract was then subjected to five steps of column chromatographies in the order of Sephacryl S-300, phosphocellulose, Mono Q, Mono S, and Superose 6. Four forms of PLC (tentatively designated as N1, N2, N3, and N4) were purified 440-1400-fold. N1, N2, N3, and N4 showed apparent molecular masses of 85, 83, 80, and 88 kDa, respectively, on SDS polyacrylamide gel electrophoresis. N1 cross-reacted with the antibody against the delta 1 isoform, while the other three forms did not crossreact with any of the antibodies against PLC-delta(1), -gamma(1), -gamma(2), and -beta(1). They hydrolyzed phosphatidylinositol (PI), phosphatidylinositol 4-monophosphate (PIP), and phosphatidylinositol 4,5-bisphosphate (PIP2) but did not show any activities against phosphatidylcholine and phosphatidylethanolamine. They showed the same optimal pH: pH 6.5 for PI hydrolysis and pH 7.0 for both PIP and PIP2 hydrolyses. They absolutely required Ca2+ for activity, with optimal concentrations of 10(-3)-10(-5) M for PIP and 10(-4)-10(-5) M for PIP2. For PI hydrolysis, N1, N2, and N3 required a Ca2+ concentration higher than 10(-2) M whereas N4 revealed significant activity even at 10(-5) M Ca2+ concentrations. Two forms of plasma membrane PLC and three forms of cytosolic PLC were purified from AH7974 cells by the same procedure as for nuclear PLC. Comparative study with these three groups revealed that all of the purified PLC isoforms shared similar enzymological properties except N4, which showed an exceptionally high affinity to Mono S column and was active at low concentrations of Ca2+ for PI as substrate. Furthermore, when PLC isoforms of nuclei from adult resting rat liver were compared with those from regenerating rat liver after partial hepatectomy, a PLC isoform corresponding to N4 of AH7974 cells was found only in regenerating liver nuclei. From these results, it was suggested that the nuclei of growing liver cells possessed a unique form of PLC (N4).	NAGOYA UNIV, SCH MED,DIS MECHANISM & CONTROL RES INST, CANC CELL BIOL LAB,SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT SURG 1, SHOWA KU, NAGOYA, AICHI 466, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOSIGNAL RES, TOKYO 173, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC ONCOL, MINATO KU, TOKYO 108, JAPAN	Nagoya University; Nagoya University; Tokyo Metropolitan Institute of Gerontology; University of Tokyo								BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BANNO Y, 1987, BIOCHEM J, V248, P95, DOI 10.1042/bj2480095; BANNO Y, 1990, BIOCHEM BIOPH RES CO, V167, P396, DOI 10.1016/0006-291X(90)92035-X; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BEREZNEY R, 1979, EUR J CELL BIOL, V20, P139; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; COCCO L, 1988, BIOCHEM BIOPH RES CO, V154, P1266, DOI 10.1016/0006-291X(88)90276-8; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MANZOLI FA, 1977, CANCER RES, V37, P843; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGAWA Y, 1968, J BIOCHEM-TOKYO, V64, P255, DOI 10.1093/oxfordjournals.jbchem.a128887; PAWELCZYK T, 1993, BIOCHEM J, V291, P693, DOI 10.1042/bj2910693; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; SPANGLER M, 1975, CANCER RES, V35, P3131; TAKENAWA T, 1989, INT CONGR SER, V811, P207; TAMIYAKOIZUMI K, 1989, BIOCHIM BIOPHYS ACTA, V1002, P182, DOI 10.1016/0005-2760(89)90285-3; WANG P, 1986, J BIOCHEM-TOKYO, V100, P1015, DOI 10.1093/oxfordjournals.jbchem.a121780	41	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12360	12366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163540				2022-12-27	WOS:A1994NG37700103
J	LAW, CL; SIDORENKO, SP; CHANDRAN, KA; DRAVES, KE; CHAN, AC; WEISS, A; EDELHOFF, S; DISTECHE, CM; CLARK, EA				LAW, CL; SIDORENKO, SP; CHANDRAN, KA; DRAVES, KE; CHAN, AC; WEISS, A; EDELHOFF, S; DISTECHE, CM; CLARK, EA			MOLECULAR-CLONING OF HUMAN SYK - A B-CELL PROTEIN-TYROSINE KINASE ASSOCIATED WITH THE SURFACE-IMMUNOGLOBULIN M-B CELL-RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-B; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; CONSERVED FEATURES; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; PHOSPHATASE; COMPONENTS	B cell antigen receptors are multicomponent complexes consisting of the surface immunoglobulin and accessory molecules with associating protein-tyrosine kinases. A spleen tyrosine kinase, Syk, in porcine B cells and a 72-kDa protein-tyrosine kinase, PTK72, in murine B cells associate with the B cell antigen receptor. Herein, we report the isolation of a full-length cDNA encoding the human homologue of Syk. This cDNA predicted a polypeptide consisting of two NH2-terminal SH2 domains and a COOH terminal tyrosine kinase domain. Syk is highly conserved between human and swine and is homologous to the T cell-associated protein-tyrosine kinase ZAP-70. Both Syk mRNA and protein were detected in cells derived from multiple hematopoietic lineages. Within the B cell compartment, Syk was expressed from pro-B cells to plasma cells. In vitro kinase assays conducted on the human Syk protein isolated from B cells revealed the presence of autophosphorylation activity on Syk tyrosine residues. Tyrosine phosphorylation of Syk associating with the B cell receptor complex in human was augmented rapidly after surface immunoglobulin cross linking. The human SYK locus was mapped to chromosome 9 at band q22.	UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	LAW, CL (corresponding author), UNIV WASHINGTON, DEPT MICROBIOL, SC-42, SEATTLE, WA 98195 USA.		Clark, Edward/K-3462-2012	Sidorenko, Svetlana/0000-0001-8281-8006; Clark, Edward A/0000-0001-8061-5475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508, R01GM046883, R01GM037905] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46883, GM42508, GM37905] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BRUNSWICK M, 1992, J IMMUNOL, V149, P2249; BURG DL, 1993, J BIOL CHEM, V268, P2304; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; CROSS NCP, 1990, LANCET, V335, P306, DOI 10.1016/0140-6736(90)90603-3; DESIDERIO S, 1993, NATURE, V361, P202, DOI 10.1038/361202a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LEPRINCE C, 1992, EUR J IMMUNOL, V22, P2093, DOI 10.1002/eji.1830220820; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MATSUO T, 1993, J IMMUNOL, V150, P3766; McKusick V.A., 1992, MENDELIAN INHERITANC; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOLAN DR, 1986, MOL BIOL MED, V3, P245; VANNOESEL CJM, 1991, J IMMUNOL, V146, P3881; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANGE RL, 1993, J BIOL CHEM, V268, P19797; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	56	132	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12310	12319						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163536				2022-12-27	WOS:A1994NG37700096
J	MCDONNELL, DP; GOLDMANN, ME				MCDONNELL, DP; GOLDMANN, ME			RU486 EXERTS ANTIESTROGENIC ACTIVITIES THROUGH A NOVEL PROGESTERONE-RECEPTOR-A FORM-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOMETRIUM	The human progesterone receptor (hPR) exists in two distinct forms in most cells, hPR-A and hPR-B. Both receptor isoforms exhibit distinct biological functions and demonstrate a cell- and promoter-specific ability to regulate gene transcription. Interestingly, in cell contexts where PR-A is transcriptionally inactive, it acts as a progesterone-dependent inhibitor of estrogen receptor function. Coexpression of the human estrogen receptor with the A form (but not the B form) of the human progesterone receptor resulted in a ligand-dependent inhibition of estrogen receptor-mediated gene transcription. The antiprogestins RU486 (Mifepristone) and ZK98299 (Onapristone) and related antiprogestins were ah effective ''noncompetitive'' inhibitors of the estrogen receptor in this assay as none of these compounds interacted directly with the estrogen receptor. This observation may explain in part the observed tissue-specific antiestrogenic effects of RU486 and further indicates that the antiestrogenic activities of antiprogestins may be intrinsic to their biological function. This important new information defines novel activities of progesterone receptor ligands and may alter the way in which we define progesterone receptor modulators for future clinical applications. In addition, these data reveal that the A form of the progesterone receptor plays a key role in modulating estrogen receptor function in cells where both receptors are expressed.	LIGAND PHARMACEUT INC, DEPT NEW LEADS DISCOVERY, LA JOLLA, CA 92037 USA	Ligand Pharmaceuticals	MCDONNELL, DP (corresponding author), LIGAND PHARMACEUT INC, DEPT MOLEC BIOL, 11149 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43267-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; FEIL PD, 1988, ENDOCRINOLOGY, V123, P2506, DOI 10.1210/endo-123-5-2506; FUQUA SAW, 1991, CANCER RES, V51, P105; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; HIRVONEN E, 1981, NEW ENGL J MED, V304, P560, DOI 10.1056/NEJM198103053041002; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; MARKIEWICZ L, 1990, J STEROID BIOCHEM, V35, P535, DOI 10.1016/0022-4731(90)90196-Y; PHILIBERT D, 1991, FRONT HORM RES, V19, P1; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; SLAYDEN OD, 1994, IN PRESS J CLIN ENDO; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WAKELING AE, 1991, CANCER RES, V51, P3867; WOLF JP, 1989, FERTIL STERIL, V52, P1055	16	183	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11945	11949						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163495				2022-12-27	WOS:A1994NG37700043
J	WANG, PC; VANCURA, A; DESAI, A; CARMEL, G; KURET, J				WANG, PC; VANCURA, A; DESAI, A; CARMEL, G; KURET, J			CYTOPLASMIC FORMS OF FISSION YEAST CASEIN KINASE-1 ASSOCIATE PRIMARILY WITH THE PARTICULATE FRACTION OF THE CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE DETERMINANTS; PLASMA-MEMBRANE; BUDDING YEAST; PURIFICATION; VESICLES; GENES; PHOSPHORYLATION	Two novel casein kinase-1 homologs, cki1(+) and cki2(+), have been isolated from Schizosaccharomyces pombe and characterized. Both genes reside on chromosome II and encode approximate to 50-kDa proteins that are related structurally and enzymatically to the YCK gene products of budding yeast. Subcellular fractionation experiments demonstrate that Cki1 and Cki2 are both cytoplasmic enzymes that do not overlap in subcellular distribution and that probably play distinct roles within the cell. Although gene disruption experiments show that neither cki1(+) nor cki2(+) is essential for cell viability, overexpression of cki2 leads to a severe growth defect and aberrant morphology. Cells become round or pear shaped and separate poorly following septation. These results suggest that of the four members of the casein kinase-1 family recognized in fission yeast, one member, Cki2, may contribute to the regulation of cell morphology.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory			Wang, Pa-Chun/AAD-4094-2019	Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM 42816] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHOW M, 1992, Current Opinion in Cell Biology, V4, P629, DOI 10.1016/0955-0674(92)90082-N; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LABORATOR; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; KLIMCZAK LJ, 1993, BIOCHEM J, V293, P283, DOI 10.1042/bj2930283; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; MASON TL, 1973, J BIOL CHEM, V248, P1346; MAUNDRELLK, 1993, GENE, V123, P127; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PRABHALA G, 1992, YEAST, V8, P171, DOI 10.1002/yea.320080303; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SIKORSKI RS, 1989, GENETICS, V122, P19; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P47, DOI 10.1006/abbi.1993.1391; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	48	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12014	12023						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163505				2022-12-27	WOS:A1994NG37700054
J	CHO, YJ; BATT, CA; SAWYER, L				CHO, YJ; BATT, CA; SAWYER, L			PROBING THE RETINOL-BINDING SITE OF BOVINE BETA-LACTOGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HUMAN PLASMA; PROTEIN; RESOLUTION; FORM; SIMILARITY; GENE	The retinol-binding site of beta-lactoglobulin has been located by selective modification of amino acid residues which reside in the two putative binding sites. Based upon two separate crystallographic analyses of bovine beta-lactoglobulin, different binding sites for retinol have been proposed: one proposal favors an interior cavity, the other a surface cleft. To discriminate between these two models, we have made four separate site-directed mutations introducing a W19A or a K70M in the interior pocket and a F136A or K141M in the surface pocket. The K70M beta-lactoglobulin exhibited a marked decrease in its binding of retinoic acid compared to the F136A, K141M, and wild-type proteins. Retinylidenepropylamine, a retinyl Schiff base analog of retinol, was synthesized and its absorption spectrum when bound to the wild-type, K70M, and K141M proteins was examined to probe its interaction with the respective lysine residues. The retinylidenepropylamine bound in the K70M beta-lactoglobulin exhibited a kinetic red shift as distinct from the blue shift observed when it is bound to either the K141M or wild-type beta-lactoglobulins. The blue shift indicates protonation of the Schiff base. The resulting tagged peptide was isolated after cyanogen bromide cleavage and found to be the Ala25-Met107 peptide, consistent with the Lys70 being the residue which interacts with the bound retinol. These results support the proposal that retinol binds to an evolutionarily conserved interior cavity rather than the surface pocket.	CORNELL UNIV,DEPT FOOD SCI,ITHACA,NY 14853; UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,SCOTLAND	Cornell University; University of Edinburgh								ALI S, 1988, J MOL BIOL, V199, P415, DOI 10.1016/0022-2836(88)90614-6; BATT CA, 1990, AGR BIOL CHEM TOKYO, V54, P949, DOI 10.1080/00021369.1990.10870080; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DUFOUR E, 1990, FEBS LETT, V277, P223, DOI 10.1016/0014-5793(90)80850-I; DUFOUR E, 1990, PROTEIN ENG, V4, P185, DOI 10.1093/protein/4.2.185; FARRELL HM, 1991, PROTOPLASMA, V159, P157; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; FUTTERMAN S, 1972, J BIOL CHEM, V247, P5168; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GU W, 1992, PROTEIN ENG, V5, P17, DOI 10.1093/protein/5.1.17; HAMBLING SG, 1994, ADV DAIRY CHEM, V1; HEMLEY R, 1979, BIOPHYS J, V28, P447, DOI 10.1016/S0006-3495(79)85192-9; HIROSE M, 1989, J BIOL CHEM, V264, P16867; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HORWITZ J, 1974, J BIOL CHEM, V249, P4712; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; Innis M., 1990, PCR PROTOCOLS GUIDE, P76; JENNESS R, 1974, J DAIRY RES, V46, P197; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; NORTH ACT, 1989, J MOL GRAPHICS, V7, P67, DOI 10.1016/S0263-7855(89)80001-3; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PUYOL P, 1991, AGR BIOL CHEM TOKYO, V55, P2515, DOI 10.1080/00021369.1991.10871001; REDL B, 1992, J BIOL CHEM, V267, P20282; ROBILLAR.KA, 1972, BIOCHEMISTRY-US, V11, P3835, DOI 10.1021/bi00771a001; Sambrook J, 1989, MOL CLONING LABORATO; SAWYER L, 1987, NATURE, V327, P659, DOI 10.1038/327659a0; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; TOWNEND R, 1969, ARCH BIOCHEM BIOPHYS, V129, P567, DOI 10.1016/0003-9861(69)90216-1; TOWNEND R, 1960, J AM CHEM SOC, V82, P3175, DOI 10.1021/ja01497a047; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WHITE DM, 1992, J BIOL CHEM, V267, P23202	34	175	176	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11102	11107						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157636				2022-12-27	WOS:A1994NF96600023
J	JACOBY, DB; WENSINK, PC				JACOBY, DB; WENSINK, PC			YOLK PROTEIN FACTOR-I IS A DROSOPHILA HOMOLOG OF KU, THE DNA-BINDING SUBUNIT OF A DNA-DEPENDENT PROTEIN-KINASE FROM HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; ACCURATE TRANSCRIPTION INITIATION; VIRUS-40 T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; ALCOHOL-DEHYDROGENASE; POLYACRYLAMIDE-GEL; STRUCTURAL GENE; REPEAT DOMAIN; AUTO-ANTIGEN	Yolk protein factor 1 (YPF1) is a heterodimeric DNA-binding protein from Drosophila melanogaster. In this report, we describe evidence that YPF1 is a homolog of Ku, a human autoimmune antigen that is the DNA-binding subunit of a DNA-dependent protein kinase. In vitro this kinase phosphorylates several transcription factors and, at the time of transcription initiation, the carboxyl-terminal domain of RNA polymerase II. We find that a cDNA clone for the smaller subunit (beta) of YPF1 encodes a 72-kDa protein that has extensive homology to the smaller subunit of the heterodimeric Ku protein (24% identity, 51% similarity over the entire 631 amino acid length). Further, the larger YPF1 subunit (alpha) shares immunological epitopes with the larger subunit of Ku. YPF1 and Ku also appear to bind DNA similarly. South-western blot experiments demonstrate that, like the Ku protein, the smaller YPF1 subunit binds DNA in the absence of the larger subunit. Further, cross-linking experiments indicate that, once again like the Ku protein, both subunits make contact with DNA when YPF1 binds as a heterodimer. YPF1 beta transcripts occur at low levels in all stages of Drosophila development except during oogenesis and early embryogenesis when they increase 25-fold. In situ hybridization localizes the beta gene to position 34C on the left arm of chromosome 2.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,415 SOUTH ST,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University					NIGMS NIH HHS [R01 GM21626, F32 GM13334] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021626, F32GM013334] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; AMABIS JM, 1990, CHROMOSOMA, V99, P102, DOI 10.1007/BF01735325; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ASHBURNER M, 1982, GENETICS, V102, P401; ASHBURNER M, 1982, GENETICS, V102, P421; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ASHBURNER M, 1976, GENETICS BIOL DROS A, V1, P60; BARNETT T, 1980, CELL, V21, P729, DOI 10.1016/0092-8674(80)90436-5; BARNETT T, 1981, ICN UCLA S MOL CELL, V23, P97; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BOULARD C, 1982, J IMMUNOL METHODS, V50, P221, DOI 10.1016/0022-1759(82)90228-9; BRENNAN MD, 1982, DEV BIOL, V89, P225, DOI 10.1016/0012-1606(82)90309-8; BROWN DD, 1964, P NATL ACAD SCI USA, V51, P139, DOI 10.1073/pnas.51.1.139; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; ENGELS WR, 1986, FOCUS, V8, P6; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNG MC, 1981, NUCLEIC ACIDS RES, V9, P6407, DOI 10.1093/nar/9.23.6407; IIJIMA S, 1992, EUR J BIOCHEM, V205, P595; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAHNEN W, 1990, BIOCHEM BIOPH RES CO, V166, P139, DOI 10.1016/0006-291X(90)91922-F; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; King R. C., 1970, OVARIAN DEV DROSOPHI; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5188; MITSIS PG, 1989, J BIOL CHEM, V264, P5195; NONET ML, 1989, GENETICS, V123, P715; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PORGES AJ, 1990, J IMMUNOL, V145, P4222; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290; ZHANG J, 1991, J BIOL CHEM, V266, P2297; [No title captured]	61	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11484	11491						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157678				2022-12-27	WOS:A1994NF96600075
J	MOUTIN, MJ; CUILLEL, M; RAPIN, C; MIRAS, R; ANGER, M; LOMPRE, AM; DUPONT, Y				MOUTIN, MJ; CUILLEL, M; RAPIN, C; MIRAS, R; ANGER, M; LOMPRE, AM; DUPONT, Y			MEASUREMENTS OF ATP BINDING ON THE LARGE CYTOPLASMIC LOOP OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE OVEREXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PLASMA-MEMBRANE; CATALYTIC SITE; FLUORESCEIN ISOTHIOCYANATE; ADENOSINE 5'-TRIPHOSPHATE; FUNCTIONAL CONSEQUENCES; SKELETAL-MUSCLE; CA-ATPASE; ION PUMPS; H+-ATPASE	The large cytoplasmic loop of the sarcoplasmic reticulum Ca2+-ATPase (LCL), situated between Lys329 and Phe740, is believed to contain both its phosphorylation and ATP binding domains. A cDNA fragment coding for this amino acid sequence was generated in vitro and cloned in vector pQE8 which allowed the overexpression in Escherichia coli of this Ca2+-ATPase domain fused with a cluster of 6 histidines at its NH2 terminus. The fusion protein produced in an insoluble form within bacteria was solubilized in 4 M urea, purified on immobilized Ni2+, and then renatured by elimination of urea. More than 4 mg of purified renatured fusion protein was obtained from 500 ml of culture. ATP binding on the refolded protein was demonstrated by two methods: 1) detection of ATP-induced intrinsic fluorescence change and 2) binding of the fluorescent ATP analogue 2',3'-O-(2,4,6-trinitrophenyl)adenosine-5'-triphosphate (TNP-ATP) and its chase by ATP. It is shown that the LCL protein has one single TNP-ATP binding site having a dissociation constant (K(d)) of 1.6-1.9 muM. Both methods yielded a K(d) for ATP around 200 muM. Binding of other nucleotides was detected with a sequence of K(d) identical to that found for native Ca2+-ATPase: ATP < ADP < GTP < AMP < ITP. A Mg2+ binding site was also found on the LCL protein (K(d) = 100 muM at pH 7.2). The fluorescence of bound TNP-ATP was found to be highly dependent on Mg2+ binding on this site.	ECOLE POLYTECH, ECOLE NATL SUPER TECHN AVANCEES,INSERM,U275LOA, CTR YVETTE, F-91128 PALAISEAU, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	MOUTIN, MJ (corresponding author), CEA, DBMS BMC, CNRS, URA 520, BIOPHYS MOLEC & CELLULAIRE LAB, F-38054 GRENOBLE, FRANCE.		LOMPRE, Anne-Marie/H-2872-2013; Moutin, Marie-Jo/P-7518-2017	Moutin, Marie-Jo/0000-0003-2681-9818				AINSWORTH S, 1977, STEADY STATE ENZYME, P38; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1986, FEBS LETT, V206, P86; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DAVIDSON GA, 1987, J BIOL CHEM, V262, P7041; de Meis L, 1973, J Biol Chem, V248, P3691; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; ENOUF J, 1988, J BIOL CHEM, V263, P13922; FERREIRA ST, 1989, J BIOL CHEM, V264, P15392; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORGE V, 1993, J BIOL CHEM, V268, P10953; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1989, BIOCHEM SOC T, V17, P819, DOI 10.1042/bst0170819; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; Hochuli E, 1990, Genet Eng (N Y), V12, P87; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMPRE AM, 1989, FEBS LETT, V249, P35, DOI 10.1016/0014-5793(89)80010-9; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; NOJIMA H, 1977, J MOL BIOL, V116, P429, DOI 10.1016/0022-2836(77)90078-X; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; RONJAT M, 1986, THESIS U GRENOBLE GR; RONZANI N, 1979, EUR J BIOCHEM, V101, P593, DOI 10.1111/j.1432-1033.1979.tb19754.x; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VANWINKLE WB, 1981, J BIOL CHEM, V256, P2268; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WATANABE T, 1982, J BIOL CHEM, V257, P1510; ZAK B, 1961, CLIN CHIM ACTA, V6, P665, DOI 10.1016/0009-8981(61)90112-7	52	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11147	11154						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157641				2022-12-27	WOS:A1994NF96600029
J	DAVIDSON, D; FOURNEL, M; VEILLETTE, A				DAVIDSON, D; FOURNEL, M; VEILLETTE, A			ONCOGENIC ACTIVATION OF P59(FYN) TYROSINE PROTEIN-KINASE BY MUTATION OF ITS CARBOXYL-TERMINAL SITE OF TYROSINE PHOSPHORYLATION, TYROSINE-528	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT MICE; SH3 DOMAINS; T-CELLS; P56LCK; FYN; TRANSFORMATION; ANTIGEN; GENE; RECEPTOR; REGION	As a result of alternative splicing, the Src-related tyrosine protein kinase p59(fyn) consists of two distinct isoforms termed FynB and FynT. Whereas the first product accumulates principally in brain, the second is expressed in hemopoietic cells, especially in T-lymphocytes. There is increasing evidence that the Fyn proteins are critical for normal functions of neuronal and lymphoid cells. To better understand the regulation of the catalytic function of p59(fyn), we have tested the effects of mutating the major site of in vivo tyrosine phosphorylation, tyrosine 528, on the biological and biochemical properties of this enzyme. Our studies showed that a tyrosine 528 --> phenylalanine (Y528F) mutation converted either Fyn isoform into a dominant oncoprotein, capable of full transformation of rodent fibroblasts. However, while both Y528F p54(fynT) and Y528F p59(fynB) were able to transform NTH 3T3 cells, activated FynT molecules were consistently more efficient at this process. It was also found that expression of wild-type p59(fyn) or kinase-defective Y528F Fyn molecules failed to provoke transformation of NIH 3T3 cells, implying that the transforming capabilities of Y528F Fyn relied on deregulated catalytic activity. Contrary to an earlier study (Cheng, S. H., Espino, P. C., Marshall, J., Harvey, R, Merrill, J., and Smith, A. E, (1991) J. Virol. 65, 170-179), these findings showed that mutation of the conserved carboxyl-terminal tyrosine residue markedly stimulated the catalytic function of p59(fyn) in vivo, implying that dephosphorylation of tyrosine 528 is sufficient to produce biologically relevant activation of the Fyn kinase. Moreover, our results provided further indication that the two Fyn isoforms possess distinct biochemical activities that may dictate functional differences in normal cell physiology.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; MONTREAL GEN HOSP,DEPT MED,DIV MED ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOMMA Y, 1992, J BIOL CHEM, V267, P3778; HORAK ID, 1990, ONCOGENE, V5, P597; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWINICAWORMS H, 1987, CELL, V49, P75; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARTOR O, 1993, J BIOL CHEM, V268, P21014; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TAUEN LKT, 1992, MOL CELL BIOL, V12, P5438; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	42	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10956	10963						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144681				2022-12-27	WOS:A1994NF01700111
J	MALITSCHEK, B; WITTBRODT, J; FISCHER, P; LAMMERS, R; ULLRICH, A; SCHARTL, M				MALITSCHEK, B; WITTBRODT, J; FISCHER, P; LAMMERS, R; ULLRICH, A; SCHARTL, M			AUTOCRINE STIMULATION OF THE XMRK RECEPTOR TYROSINE KINASE IN XIPHOPHORUS MELANOMA-CELLS AND IDENTIFICATION OF A SOURCE FOR THE PHYSIOLOGICAL LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; SIMIAN SARCOMA-VIRUS; FMS PROTO-ONCOGENE; GROWTH-FACTOR; EGF RECEPTOR; MALIGNANT TRANSFORMATION; MESSENGER-RNA; FOREIGN GENES; VECTORS; SIS	The melanoma-inducing gene of Xiphophorus fish encodes the Xmrk receptor tyrosine kinase. Using a highly specific antiserum produced against the recombinant receptor expressed with a baculovirus, it is shown that Xmrk is the most abundant phosphotyrosine protein in fish melanoma and thus highly activated in the tumors. Studies on a melanoma cell line revealed that these cells produce an activity that considerably stimulates receptor autophosphorylation. The stimulating activity induces receptor down-regulation and can be depleted from the melanoma cell supernatant by the immobilized recombinant receptor protein. The fish melanoma cells can thus be considered autocrine tumor cells providing a source for future purification and characterization of the Xmrk ligand.	UNIV WURZBURG,BIOCTR,THEODOR BOVERI INST,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Basel; Max Planck Society			Wittbrodt, Joachim/D-4735-2014	Wittbrodt, Joachim/0000-0001-8550-7377; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EARP HS, 1986, J BIOL CHEM, V261, P4777; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HELDIN CH, 1987, BIOCHIM BIOPHYS ACTA, V907, P219, DOI 10.1016/0304-419X(87)90007-2; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; RANKIN C, 1988, GENE, V70, P39, DOI 10.1016/0378-1119(88)90102-3; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SCHARTL M, 1990, GENETICS, V126, P1083; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P10; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10423	10430						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144625				2022-12-27	WOS:A1994NF01700038
J	OHYAMA, Y; OZONO, K; UCHIDA, M; SHINKI, T; KATO, S; SUDA, T; YAMAMOTO, O; NOSHIRO, M; KATO, Y				OHYAMA, Y; OZONO, K; UCHIDA, M; SHINKI, T; KATO, S; SUDA, T; YAMAMOTO, O; NOSHIRO, M; KATO, Y			IDENTIFICATION OF A VITAMIN-D-RESPONSIVE ELEMENT IN THE 5'-FLANKING REGION OF THE RAT 25-HYDROXYVITAMIN D-3 24-HYDROXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCALCIN GENE; D RECEPTOR INTERACTION; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; KIDNEY MITOCHONDRIA; THYROID-HORMONE; BONE TURNOVER; RETINOIC ACID; DNA; EXPRESSION; SEQUENCES	The 5'-flanking region of the rat vitamin D-3 24-hydroxylase (P450cc24) gene was examined and a vitamin D-responsive element (VDRE) responsible for the 1 alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) enhancement was identified. Unidirectional deletion analyses of the 5'-flanking region indicated that the region [-167/-102] is involved in vitamin D responsiveness. Further functional analyses showed that the segment [-204/-129] conferred the hormone responsiveness in an orientation-independent manner when it was placed upstream to the heterologous thymidine kinase promoter or the rabbit beta-globin promoter. The segment [-204/-129] contained two direct repeat motifs homologous to other VDREs found in the osteocalcin and osteopontin genes. Synthetic oligonucleotides containing the putative VDRE were used for functional analyses and gel mobility shift assays. The proximal [-151/-137], but not the distal [-169/-155] direct repeat activated the transcription in response to 1,25-(OH)(2)D-3 through the beta-globin promoter. Furthermore, the proximal direct repeat formed a complex with the vitamin D receptor and a nuclear accessory factor(s) from COS cells (or retinoid X receptor) in the presence of 1,25-(OH)(2)D-3. These results indicate that a direct repeat motif, AGGTGAgt-gAGGGCG, located at -151 base pairs upstream in the antisense strand binds to a heterologous dimer consisting of the VDR occupied with 1,25-(OH)(2)D-3 and the nuclear accessory factor and that it plays a critical role in mediating the vitamin D enhancement of the rat P450cc24 gene expression.	OSAKA MED CTR MATERNAL & CHILD HLTH, IZUMI, OSAKA 59002, JAPAN; KUREHA CHEM IND CO LTD, BIOMED RES LABS, SHINJUKU KU, TOKYO 169, JAPAN; SHOWA UNIV, SCH DENT, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN; TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN; HIROSHIMA UNIV, SCH DENT, DEPT BIOCHEM, MINAMI KU, HIROSHIMA 734, JAPAN	Showa University; Tokyo University of Agriculture; Hiroshima University	OHYAMA, Y (corresponding author), HIROSHIMA UNIV, FAC SCI, GRAD DEPT GENE SCI, 1-3-1 KAGAMIYAMA, HIGASHIHIROSHIMA 724, JAPAN.							BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHEN ML, 1993, ENDOCRINOLOGY, V132, P1782, DOI 10.1210/en.132.4.1782; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NAKAMURA T, 1992, CALCIFIED TISSUE INT, V50, P221, DOI 10.1007/BF00296286; NAKAMURA T, 1992, BONE, V13, P229, DOI 10.1016/8756-3282(92)90202-8; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OZONO K, 1990, J BIOL CHEM, V265, P21881; OZONO K, 1991, J BONE MINER RES, V6, P1021; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Sambrook J, 1989, MOL CLONING LABORATO; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SONE T, 1991, J BIOL CHEM, V266, P23296; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; UCHIDA M, 1993, J BONE MINER RES, V8, pS171; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	39	193	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10545	10550						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144641				2022-12-27	WOS:A1994NF01700055
J	ISHINO, Y; IWASAKI, H; KATO, I; SHINAGAWA, H				ISHINO, Y; IWASAKI, H; KATO, I; SHINAGAWA, H			AMINO-ACID-SEQUENCE MOTIFS ESSENTIAL TO 3'-]5' EXONUCLEASE ACTIVITY OF ESCHERICHIA-COLI DNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; 3'-5' EXONUCLEASE; POLB GENE; SITE; ALPHA; REPLICATION; APHIDICOLIN; EXPRESSION; DEFICIENT; CLONING	Many DNA polymerases have conserved sequences required for 3' --> 5' exonuclease activity, which contributes to the accuracy of DNA replication by removing misincorporated nucleotides prior to chain elongation. Using amino acid sequence alignments, we predicted the putative active site of the 3' --> 5' exonuclease of Escherichia coli DNA polymerase II. Site-directed mutagenesis at D155A, E157A, D155A/E157A, D228A, Y330F, and D334A, which are in the predicted exonuclease active regions, specifically inactivated 3' --> 5' exonucleolytic activity but not DNA-polymerizing activity of E. coli DNA polymerase II. Furthermore, all of the mutants were diminished in the in vitro proofreading ability, as judged by their increased insertion and extension of wrong nucleotides. These findings indicate that the 3' --> 5' exonuclease region of the E. coli DNA polymerase II is in the aminoterminal part of the protein, as it is in other DNA polymerases, and are consistent with the proposal of an evolutionary conserved 3' --> 5' exonuclease active site in most DNA-dependent DNA polymerases of both prokaryotic and eukaryotic origin by Bernad et al. (Bernad, A, Blanco, L., Lazaro, J.M., Martin, G., and Salas, M. (1989) Cell 59, 219-228).	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT EXPTL CHEMOTHERAPY,SUITA,OSAKA 565,JAPAN	Osaka University	ISHINO, Y (corresponding author), TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,OTSU,SHIGA 52021,JAPAN.		Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873; Ishino, Yoshizumi/0000-0001-9419-0826				BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CHEN H, 1990, NUCLEIC ACIDS RES, V18, P7185, DOI 10.1093/nar/18.23.7185; CHEN H, 1989, J BIOL CHEM, V264, P20591; CHEN H, 1990, DNA CELL BIOL, V9, P631, DOI 10.1089/dna.1990.9.631; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIBBS JS, 1985, P NATL ACAD SCI USA, V82, P7969, DOI 10.1073/pnas.82.23.7969; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GINGERAS TR, 1982, J BIOL CHEM, V257, P13475; GROSS J, 1969, NATURE, V224, P1166, DOI 10.1038/2241166a0; HIROTA Y, 1972, P NATL ACAD SCI USA, V69, P3238, DOI 10.1073/pnas.69.11.3238; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; ISHINO Y, 1992, BIOCHIMIE, V74, P131, DOI 10.1016/0300-9084(92)90036-E; ISHINO Y, 1992, BIOTECHNIQUES, V13, P936; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; IWASAKI H, 1991, MOL GEN GENET, V226, P24, DOI 10.1007/BF00273583; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KORNBERG A, 1991, DNA REPLICATION, P113; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; MATSUMOTO K, 1989, GENE, V84, P247; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PISANI FM, 1992, NUCLEIC ACIDS RES, V20, P2711, DOI 10.1093/nar/20.11.2711; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; RINGERAS, 1982, J BIOL CHEM, V257, P13475; SHERMAN LA, 1976, J MOL BIOL, V103, P61, DOI 10.1016/0022-2836(76)90052-8; SHINAGAWA H, 1991, BIOCHIMIE, V73, P433, DOI 10.1016/0300-9084(91)90110-M; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STARK MJR, 1984, NUCLEIC ACIDS RES, V12, P6011, DOI 10.1093/nar/12.15.6011; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSURUMI T, 1987, GENE, V52, P129; UEMORI T, 1993, J BIOCHEM-TOKYO, V113, P401, DOI 10.1093/oxfordjournals.jbchem.a124058; UEMORI T, 1992, NUCLEIC ACIDS RES, V21, P259; VILLANI G, 1978, P NATL ACAD SCI USA, V75, P3037, DOI 10.1073/pnas.75.7.3037; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WICKNER RB, 1972, J BIOL CHEM, V247, P489; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIKAWA H, 1982, GENE AMST, V17, P322	57	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14655	14660						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182073				2022-12-27	WOS:A1994NM06500056
J	BHAT, BG; WANG, P; COLEMAN, RA				BHAT, BG; WANG, P; COLEMAN, RA			HEPATIC MONOACYLGLYCEROL ACYLTRANSFERASE IS REGULATED BY SN-1,2-DIACYLGLYCEROL AND BY SPECIFIC LIPIDS IN TRITON X-100 PHOSPHOLIPID-MIXED MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MIXED MICELLES; RAT INTESTINE; SUCKLING RAT; ACTIVATION; ENZYMES; ACIDS; PHOSPHOLIPASE-A2; DIACYLGLYCEROL; BIOSYNTHESIS	The lipid cofactor requirement of hepatic monoacylglycerol acyltransferase (MGAT) (EC 2.3.1.22) was studied in Triton X-100/lipid-mixed micelles. Anionic phospholipids and anionic lysophospholipids stimulated MGAT activity, whereas fatty acids and sphingosine inhibited enzyme activity. Phosphatidic acid was a potent activator, stimulating MGAT 11-fold at 4.2 mol %. Kinetic studies revealed that phosphatidic acid, with an apparent K-alpha of 0.26 mol %, was a better activator than phos- phatidylserine, phosphatidylinositol, or cardiolipin. Of the anionic lysophospholipids, lysophosphatidic acid was a better activator than lysophosphatidylserine, stimulating maximally at less than 3 mol %. Oleate was a more potent inhibitor (K-i, 2.4 mol %) than sphingosine (K-i, 18.3 mol %). The dependence of MGAT on sn-2-monoacylglycerol was not cooperative in the absence or presence of anionic phospholipids, oleic acid, or sphingosine. The apparent K-m for sn-2-monoC18:1-glycerol was 1.24 mol % in the presence of maximally activating phospholipid and 0.19 mol % when phospholipid was omitted. MGAT's product sn-1,2-diacylglycerol was a weaker activator than the anionic phospholipids, but the effects of diacylglycerol and phospholipid were additive. Activation by sn-1,2-diC18:1-glycerol was highly cooperative with a Hill coefficient of 3.6. Activation was specific for the sn-1,2-stereoisomer; neither 1,3-diacylglycerol nor the ether analogs of sn-1,2- or 1,3-diacylglycerol were activators. Since several of the lipid modulators of MGAT activity are intracellular second messengers, these data suggest the possibility that regulatory links exist between signal transduction and the synthesis of complex lipids via the monoacylglycerol pathway.	UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	BHAT, BG (corresponding author), UNIV N CAROLINA,DEPT NUTR,CB 7400,CHAPEL HILL,NC 27599, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019068] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 19068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1991, J BIOL CHEM, V266, P4661; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1986, J LIPID RES, V27, P158; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DODDS PF, 1991, LIFE SCI, V49, P629, DOI 10.1016/0024-3205(91)90110-W; FERNANDOWARNAKULASURIYA GJP, 1981, J LIPID RES, V22, P668; FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATA Y, 1989, BIOCHEM J, V262, P947, DOI 10.1042/bj2620947; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; JOHNSTON JM, 1977, LIPID METABOLISM MAM, P151; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LITCHENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRILL AH, 1982, J LIPID RES, V23, P1368; MOORHOUSE KG, 1990, BIOCHEM PHARMACOL, V39, P1529, DOI 10.1016/0006-2952(90)90517-O; MOSTAFA N, 1993, BIOCHIM BIOPHYS ACTA, V1169, P189, DOI 10.1016/0005-2760(93)90205-N; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; POLHEIM D, 1973, J LIPID RES, V14, P415; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, V1082, P293, DOI 10.1016/0005-2760(91)90205-V; RAELEE M, 1990, J BIOL CHEM, V265, P7221; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; SANDERMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P235, DOI 10.1016/0005-2736(91)90130-Z; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; SINCLAIR AJ, 1972, J NEUROCHEM, V19, P1753, DOI 10.1111/j.1471-4159.1972.tb06219.x; THUREN T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P178, DOI 10.1016/0005-2760(90)90186-2; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WU WI, 1993, J BIOL CHEM, V268, P13830; XIA T, 1993, J NUTR BIOCHEM, V4, P313, DOI 10.1016/0955-2863(93)90102-3; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; YU L, 1990, J BIOL CHEM, V265, P2657	41	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13172	13178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175745				2022-12-27	WOS:A1994NK18400022
J	FREISINGER, P; ALAKOKKO, L; LEGUELLEC, D; FRANC, S; BOUVIER, R; RITVANIEMI, P; PROCKOP, DJ; BONAVENTURE, J				FREISINGER, P; ALAKOKKO, L; LEGUELLEC, D; FRANC, S; BOUVIER, R; RITVANIEMI, P; PROCKOP, DJ; BONAVENTURE, J			MUTATION IN THE COL2A1 GENE IN A PATIENT WITH HYPOCHONDROGENESIS - EXPRESSION OF MUTATED COL2A1 GENE IS ACCOMPANIED BY EXPRESSION OF GENES FOR TYPE-I PROCOLLAGEN IN CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LANGER-SALDINO ACHONDROGENESIS; TRIPLE HELICAL DOMAIN; SINGLE-BASE CHANGES; SPONDYLOEPIPHYSEAL DYSPLASIA; COLLAGEN GENE; SERINE SUBSTITUTION; GEL-ELECTROPHORESIS; CARTILAGE; CHAIN; IDENTIFICATION	A new dominant mutation in the COL2A1 gene was found in a 38-week-old fetus with hypochondrogenesis. Denaturing gradient gel electrophoresis was used to analyze all 44 exons coding for the triple helical domain of COL2A1 gene and the corresponding exon-intron boundaries. The technique detected a new sequence variation in exon 35. Sequencing of exon 35 demonstrated a single base mutation that converted the codon for glycine at position 604 to a codon for alanine. Electrophoresis of pepsin-digested collagen extracted from the diseased cartilage showed a doublet band of the alpha 1(II) chain of type II collagen and the presence of alpha 1(I) and alpha 2(I) chains of type I collagen. Two-dimensional analysis of cyanogen bromide peptides from the type II collagen revealed post-translational overmodification of peptides CB12, CB11, CB8, and CB10.5, whereas peptide CB9.7 migrated normally. Microscopic examination of cartilage showed that the mutation altered the organization of the growth plate. Also, articular chondrocytes contained large cisternae of rough endoplasmic reticulum. The density of the extracellular matrix was reduced, and the intensity of the staining with an antibody to type II collagen was diminished. In contrast, a significant staining with an antibody to type I collagen was observed. In situ hybridization with cRNA probes revealed a significant level of alpha 1(I) mRNA in the cytoplasm of the patient's chondrocytes. The signal for alpha 1(II) mRNA was about the same in control samples. The results indicated, therefore, that the genes for both type I and type II procollagens were simultaneously expressed in chondrocytes from the patient.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; HOP NECKER ENFANTS MALAD,CLIN M LAMY,CNRS,URA 584,F-75743 PARIS 15,FRANCE; UNIV OULU,BIOCTR,COLLAGEN RES UNIT,SF-90220 OULU,FINLAND; UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; INST BIOL & CHIM PROT,F-69367 LYON,FRANCE; HOP EDOUARD HERRIOT,ANAT PATHOL LAB,F-69437 LYON,FRANCE	Jefferson University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); University of Oulu; University of Oulu; CHU Lyon					NIAMS NIH HHS [AR39740] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIGNER T, 1993, J CLIN INVEST, V91, P829, DOI 10.1172/JCI116303; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BONAVENTURE J, 1989, AM J MED GENET, V33, P299, DOI 10.1002/ajmg.1320330304; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHAN D, 1991, J BIOL CHEM, V266, P12487; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; EYRE DR, 1986, AM J HUM GENET, V39, P52; FESHCHENKO SP, 1989, HUM GENET, V82, P49, DOI 10.1007/BF00288271; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; GODFREY M, 1988, AM J HUM GENET, V43, P894; GODFREY M, 1988, AM J HUM GENET, V43, P904; GRUBER HE, 1990, J ANAT, V173, P69; HELMINEN H, 1993, J CLIN INVEST, V92, P587; HORTON WA, 1987, PEDIATR RES, V22, P324, DOI 10.1203/00006450-198709000-00017; HORTON WA, 1992, P NATL ACAD SCI USA, V89, P4583, DOI 10.1073/pnas.89.10.4583; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MAROTEAUX P, 1983, EUR J PEDIATR, V141, P14, DOI 10.1007/BF00445662; METSARANTA M, 1992, J CELL BIOL, V118, P203, DOI 10.1083/jcb.118.1.203; MURRAY L W, 1987, American Journal of Human Genetics, V41, pA12; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NEVILLE DMM, 1979, METHOD ENZYMOL, V32, P82; PRENSKY W, 1971, EXP CELL RES, V68, P388, DOI 10.1016/0014-4827(71)90164-9; RITVANIEMI P, 1993, GENOMICS, V17, P218, DOI 10.1006/geno.1993.1306; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SPRANGER J, 1985, ENDOCRINE GENETICS G, P315; STENGELR.S, 1974, EXP CELL RES, V87, P313, DOI 10.1016/0014-4827(74)90487-X; Tiller G. E., 1992, American Journal of Human Genetics, V51, pA37; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; TSCHAN T, 1993, J BIOL CHEM, V268, P5156; VANDENBERG P, 1991, P NATL ACAD SCI USA, V88, P7640, DOI 10.1073/pnas.88.17.7640; VIKKULA M, 1993, GENOMICS, V16, P282, DOI 10.1006/geno.1993.1179; VISSING H, 1989, J BIOL CHEM, V264, P18265; WHITLEY CB, 1983, RADIOLOGY, V148, P693, DOI 10.1148/radiology.148.3.6878687	38	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13663	13669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175802				2022-12-27	WOS:A1994NK18400088
J	JI, ZS; LAUER, SJ; FAZIO, S; BENSADOUN, A; TAYLOR, JM; MAHLEY, RW				JI, ZS; LAUER, SJ; FAZIO, S; BENSADOUN, A; TAYLOR, JM; MAHLEY, RW			ENHANCED BINDING AND UPTAKE OF REMNANT LIPOPROTEINS BY HEPATIC LIPASE-SECRETING HEPATOMA-CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; TRIGLYCERIDE LIPASE; MONOCLONAL-ANTIBODIES; LOCALIZATION; DEFICIENCY; INVIVO; PLASMA; LIVER; ABNORMALITIES	Rat hepatoma McA-RH7777 cells transfected with a human hepatic lipase (HL) cDNA synthesized and secreted 50-80 ng of human HL/mg of cell protein at 4 h, similar to 50% of which was bound to cell-surface heparan sulfate proteoglycans (HSPG). The newly synthesized HL possessed enzymatic activity. When rabbit beta-very low density lipoproteins (beta-VLDL) and canine chylomicrons or chylomicron remnants were incubated with HL-secreting cells, remnant binding and uptake were enhanced 3-fold compared with nontransfected cells. Furthermore, fluorescence microscopy showed enhanced uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled beta-VLDL by the HL-transfected cells. When I-125-beta-VLDL were added to conditioned medium from HL-secreting cells, the HL in the media enhanced the binding and uptake of the remnant lipoproteins by nontransfected cells about 3-fold. Likewise, surface-bound HL (without HL in the medium) also was able to mediate the enhanced binding of the remnants. This HL-enhanced binding was shown to be mediated by an interaction with cell-surface HSPG. Heparinase treatment to remove cell-surface HSPG or chlorate treatment to prevent HSPG sulfation of the HL-secreting cells abolished all the HL-mediated enhanced binding and uptake. Furthermore, heparinase pretreatment of nontransfected cells prevented the enhanced binding and uptake of beta-VLDL incubated with conditioned medium from HL-secreting cells. As binding was not enhanced in the absence of HSPG, an HL-HSPG initial interaction appears essential. Addition of apolipoprotein (apo) E to the beta-VLDL did not facilitate HL-mediated binding and uptake; in fact, beta-VLDL from apoE-null mice demonstrated a similar degree of enhanced binding as did rabbit beta-VLDL with or without added apoE. On the other hand, beta-VLDL from transgenic mice overexpressing binding-defective apoE(Arg(142) --> Cys) did not display any enhanced binding and uptake by the HL-secreting cells, and it appears that the apoE(Arg(142) -->( Cys) actually inhibited the HL-mediated interaction. This mutant form of apoE is associated with a dominant mode of expression of type III hyperlipoproteinemia in contrast to the more commonly occurring recessive disorder. Impaired HL interaction with the apoE(Arg(142) --> Cys) beta-VLDL may contribute to remnant lipoprotein accumulation in the plasma of patients with this mutant form of apoE. Thus, HL contributes to the enhanced cell association of specific types of remnant lipoproteins by initiating their binding to cell-surface HSPG.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94141 USA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1990, AM J HUM GENET, V46, P470; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRASAEMLE DL, 1993, J LIPID RES, V34, P455; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CARLSON LA, 1986, ACTA MED SCAND, V219, P435; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG CF, 1985, J BIOL CHEM, V260, P720; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CISAR LA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P196, DOI 10.1016/0005-2760(89)90268-3; CISAR LA, 1985, J LIPID RES, V26, P380; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; Ehnholm C, 1986, Methods Enzymol, V129, P716; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HEGELE RA, 1991, J CLIN ENDOCR METAB, V72, P730, DOI 10.1210/jcem-72-3-730; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HIDE WA, 1992, J LIPID RES, V33, P167; HIXENBAUGH EA, 1989, J BIOL CHEM, V264, P4222; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; IKEDA Y, 1990, J LIPID RES, V31, P1911; JANSEN H, 1980, FEBS LETT, V112, P30, DOI 10.1016/0014-5793(80)80119-0; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MAHLEY RW, 1994, IN PRESS ANN NY ACAD; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; Sambrook J, 1989, MOL CLONING LABORATO; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; THUREN T, 1991, J BIOL CHEM, V266, P4853; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	45	122	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13429	13436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175774				2022-12-27	WOS:A1994NK18400057
J	BITO, H; MORI, M; SAKANAKA, C; TAKANO, T; HONDA, Z; GOTOH, Y; NISHIDA, E; SHIMIZU, T				BITO, H; MORI, M; SAKANAKA, C; TAKANO, T; HONDA, Z; GOTOH, Y; NISHIDA, E; SHIMIZU, T			FUNCTIONAL COUPLING OF SSTR4, A MAJOR HIPPOCAMPAL SOMATOSTATIN RECEPTOR, TO ADENYLATE-CYCLASE INHIBITION, ARACHIDONATE RELEASE, AND ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEAMINE-INDUCED DEPLETION; CENTRAL-NERVOUS-SYSTEM; MAP KINASE; RAT-BRAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACID METABOLITES; SENILE DEMENTIA; K+ CHANNEL; CLONING	Somatostatin has a modulatory role in regulating the membrane conductance in hippocampal neurons. To examine the signal transducing molecules involved in this process, we isolated the cDNA encoding the dominant rat hippocampal somatostatin receptor, SSTR4. Distribution of SSTR4 in the adult central nervous system was restricted to the hippocampus, cerebral cortex, striatum, hypothalamus, and thalamus, as determined by Northern blot analysis and in situ hybridization. In SSTR4-expressing Chinese hamster ovary cells, SSTR4 was functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade, with similar ED(50) values. All of these pathways, including both MAP kinase kinase and MAP kinase activation, were completely blocked by pretreatment with pertussis toxin. On the other hand, neither inositol 1,4,5-trisphosphate synthesis nor intracellular Ca2+ mobilization was induced upon SSTR4 stimulation. These data indicate that the hippocampal functions of somatostatin might be mediated through diverse but selective second messenger systems activated via SSTR4 and reveal an unsuspected coupling of a neuronal SSTR subtype to a mitogenic signaling pathway. SSTR4, in addition, provides a useful system to study the Ca2+-independent, G(i)-dependent (pertussis toxin-sensitive) pathway of MAP kinase activation.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 606,JAPAN	University of Tokyo; Kyoto University			Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BREDER CD, 1992, J NEUROSCI, V12, P3920; BROWNSTEIN M, 1975, ENDOCRINOLOGY, V96, P1456, DOI 10.1210/endo-96-6-1456; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER PE, 1981, NEUROLOGY, V31, P64; DAVIES P, 1980, NATURE, V288, P279, DOI 10.1038/288279a0; DENOBLE VJ, 1989, BRAIN RES, V482, P42, DOI 10.1016/0006-8993(89)90540-4; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DODD J, 1978, NATURE, V273, P674, DOI 10.1038/273674a0; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAROUTUNIAN V, 1987, BRAIN RES, V403, P234, DOI 10.1016/0006-8993(87)90060-6; HONDA Z, 1994, J BIOL CHEM, V269, P2307; JOELS M, 1990, REGUL PEPTIDES, V28, P215, DOI 10.1016/0167-0115(90)90019-S; KIM D, 1989, NATURE, V357, P537; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LI LL, 1992, P NATL ACAD SCI USA, V89, P6147; LI XJ, 1992, J BIOL CHEM, V267, P21307; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MAYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267; MAYERHOF W, 1991, DNA CELL BIOL, V10, P689; MCGEE R, 1988, J MEMBRANE BIOL, V102, P21, DOI 10.1007/BF01875350; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NEMEROFF CB, 1983, SCIENCE, V221, P972, DOI 10.1126/science.6136092; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PITTMAN QJ, 1981, BRAIN RES, V221, P402, DOI 10.1016/0006-8993(81)90791-5; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RAYNOR K, 1992, J PHARMACOL EXP THER, V260, P841; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; ROSSOR MN, 1980, NEUROSCI LETT, V20, P373, DOI 10.1016/0304-3940(80)90177-9; RUIZTORRES P, 1993, BIOCHEM BIOPH RES CO, V195, P1057, DOI 10.1006/bbrc.1993.2151; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHERER RW, 1990, J GEN PHYSIOL, V96, P735, DOI 10.1085/jgp.96.4.735; SCHETTINI G, 1989, BRAIN RES, V492, P65, DOI 10.1016/0006-8993(89)90889-5; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422	77	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12722	12730						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175684				2022-12-27	WOS:A1994NH71600056
J	FREY, M; ROTHE, M; WAGNER, AFV; KNAPPE, J				FREY, M; ROTHE, M; WAGNER, AFV; KNAPPE, J			ADENOSYLMETHIONINE-DEPENDENT SYNTHESIS OF THE GLYCYL RADICAL IN PYRUVATE FORMATE-LYASE BY ABSTRACTION OF THE GLYCINE C-2 PRO-S HYDROGEN-ATOM - STUDIES OF [H-2]GLYCINE-SUBSTITUTED ENZYME AND PEPTIDES HOMOLOGOUS TO THE GLYCINE-734 SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVATING ENZYME; HYPOPHOSPHITE	The active form of pyruvate formate-lyase (PFL) from Escherichia coli contains a glycyl radical in position 734 of the polypeptide chain which is produced post-translationally by pyruvate formate-lyase-activating enzyme (PFL activase) using S-adenosylmethionine (AdoMet) and dihydroflavodoxin as co-substrates (Wagner, A. F.V., Frey, M., Neugebauer, F.A., Schafer, W., and Knappe, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 996-1000). Studying radical synthesis with [2-H-2]glycine-labeled PFL, we have now found stoichiometric incorporation of a H-2 atom into the 5'-deoxyadenosine (dAdo) co product via mass and NMR spectroscopic analyses. Furthermore, a series of peptides homologous to the Gly-734 site of PFL have been synthesized for analyzing recognition determinants of PFL activase. Peptides that proved active as substrates (monitored by [C-14]dAdo formation from [C-14]AdoMet) were also competitive inhibitors of PFL conversion to the radical form. In the sequence of the standard peptide Arg-Val-Ser-Gly-Tyr-Ala-Val, which corresponds to amino acid residues 731-737 of PFL, the Gly residue was replaceable by D-Ala (actually display ing enhanced efficiency), whereas a normal Ala totally abolished the interaction with PFL activase. Our results show that the radical in pyruvate formate-lyase is produced by stereospecific abstraction of the pro-S hydrogen of glycine 734 by the 5'-dAdo radical generated in the active center of PFL activase, Gly-734 is probably located in a beta-turn segment of the protein.	UNIV HEIDELBERG,INST BIOL CHEM,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Frey, Manfred/AAN-3224-2020					CASTRO B, 1977, J CHEM RES, V182, P2118; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FREY PA, 1993, FASEB J, V7, P662, DOI 10.1096/fasebj.7.8.8500691; Grimshaw J., 1981, CHEM SULPHONIUM GROU, P141; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RODEL W, 1988, EUR J BIOCHEM, V177, P153, DOI 10.1111/j.1432-1033.1988.tb14356.x; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; Tabor H., 1971, METHODS ENZYMOLOGY B, V17B, P393; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; VETTER H, 1971, HOPPESEYLERS Z PHYSL, V352, P443; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WANG Y, 1977, CARBOHYD RES, V59, P449, DOI 10.1016/S0008-6215(00)83184-5	19	149	149	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12432	12437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175649				2022-12-27	WOS:A1994NH71600012
J	SHI, HP; TENG, CT				SHI, HP; TENG, CT			CHARACTERIZATION OF A MITOGEN-RESPONSE UNIT IN THE MOUSE LACTOFERRIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Lactoferrin is present in a variety of tissues and biological fluids; however, the amount differs significantly due to differential expressions. We have previously demonstrated that the mouse lactoferrin gene is regulated by estrogen through an estrogen-response DNA element located at -349, upstream from the transcription start site (+1). In this report, we characterized by deletion and mutation analyses a cluster of mitogen-response elements located between -80 and -40 of the mouse lactoferrin promoter. We demonstrated that the chimeric chloramphenicol acetyltransferase reporter constructs (the -103 to +1 sequence of the mouse lactoferrin gene) containing the mitogen-response unit of the lactoferrin gene were stimulated by cAMP, forskolin, 12-O-tetradecanoylphorbol-13-acetate, and epidermal growth factor/recombinant transforming growth factor-alpha (EGF/TGF-alpha) in a time- and dose-dependent manner. The sequence at position -52 to -40 (mLF-CRE) of the gene conferred transcriptional activation in the presence of forskolin, cyclic AMP, and 12-O-tetradecanoylphorbol-13-acetate in transiently transfected human endometrium carcinoma RL95-2 cells, whereas the region at -80 to -60 responded to EGF/TGF-alpha stimulation. Overexpression of the catalytic unit of protein kinase C or protein kinase A in the RL95-2 cells elevated the chloramphenicol acetyltransferase activity of the reporter construct 5-6-fold. The mobility shift assay suggested that AP1 and CREB or related proteins participated in complex formation with the mLF-CRE, whereas different proteins bound to the EGF/TGF-alpha-response element.	NIEHS, REPROD & DEV TOXICOL LAB, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ARNOLD RR, 1982, INFECT IMMUN, V35, P792, DOI 10.1128/IAI.35.3.792-799.1982; BAKER EN, 1991, INT J BIOL MACROMOL, V13, P122, DOI 10.1016/0141-8130(91)90036-T; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BOWMAN BH, 1988, ADV GENET, V25, P1; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; BROXMEYER HE, 1989, IRON IMMUNITY CANCER, P199; CUNNINGHAM GA, 1992, BIOCHEM BIOPH RES CO, V189, P1725, DOI 10.1016/0006-291X(92)90277-R; DAVIDSON LA, 1988, AM J PHYSIOL, V254, pG580, DOI 10.1152/ajpgi.1988.254.4.G580; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ESAGUY N, 1991, INFECT IMMUN, V59, P1117, DOI 10.1128/IAI.59.3.1117-1125.1991; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREEN MR, 1978, ENDOCRINOLOGY, V103, P1510, DOI 10.1210/endo-103-4-1510; HANGOC G, 1991, EXP HEMATOL, V19, P697; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IMAI E, 1993, J BIOL CHEM, V268, P5353; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JOHANSON B, 1960, ACTA CHEM SCAND, V14, P510, DOI 10.3891/acta.chem.scand.14-0510; KALMAR JR, 1988, INFECT IMMUN, V56, P2552, DOI 10.1128/IAI.56.10.2552-2557.1988; KIM KS, 1993, J BIOL CHEM, V268, P15689; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; LAMPREAVE F, 1990, INT J BIOL MACROMOL, V12, P2, DOI 10.1016/0141-8130(90)90073-J; LEGRAND D, 1992, BIOCHEMISTRY-US, V31, P9243, DOI 10.1021/bi00153a018; LEGRAND D, 1990, BIOCHEM J, V266, P575; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU YH, 1991, J BIOL CHEM, V266, P21880; LIU YH, 1992, MOL ENDOCRINOL, V6, P355, DOI 10.1210/me.6.3.355; LU L, 1991, INT J HEMATOL, V54, P117; Masson P. L., 1966, PROTIDES BIOL FLUIDS, V14, P115; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NICHOLS BL, 1987, PEDIATR RES, V21, P563, DOI 10.1203/00006450-198706000-00011; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; PARK I, 1985, P NATL ACAD SCI USA, V82, P3149, DOI 10.1073/pnas.82.10.3149; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWATZKI G, 1989, BLOOD CELLS, V15, P371; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHIRSAT NV, 1992, GENE, V110, P229, DOI 10.1016/0378-1119(92)90653-7; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SORENSEN MARGRETHE, 1939, Comptes rendus des Travaux du Laboratoire Carlsberg, V23, P55; TENG CT, 1986, BIOCHEM J, V240, P413, DOI 10.1042/bj2400413; TENG CT, 1989, ENDOCRINOLOGY, V124, P992, DOI 10.1210/endo-124-2-992; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; ZIMECKI M, 1991, IMMUNOL LETT, V30, P119, DOI 10.1016/0165-2478(91)90099-V; ZIMECKI M, 1987, ARCH IMMUNOL THER EX, V35, P351	55	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12973	12980						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175715				2022-12-27	WOS:A1994NH71600091
J	DOYLE, K; ZHANG, Y; BAER, R; BINA, M				DOYLE, K; ZHANG, Y; BAER, R; BINA, M			DISTINGUISHABLE PATTERNS OF PROTEIN-DNA INTERACTIONS INVOLVING COMPLEXES OF BASIC HELIX-LOOP-HELIX PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; BINDING MOTIF; TAL-1 GENE; MYOD; TRANSLOCATION; EXPRESSION	Myogenic factors and TAL1 possess distinguishable DNA binding characteristics when they form a complex with basic helix- loop-helix (bHLH) proteins of class A. These characteristics were evident in electrophoretic mobility shift assays showing that complexes of myogenic factors and HTF4 displayed a relatively high affinity for the enhancer in the muscle creatine kinase gene, whereas TAL1 appeared to greatly attenuate the interaction of HTF4 with this enhancer. In addition, by forming a complex with HTE4 in solution, TAL1 could exert a negative effect on the interactions of HTF4 with elements that include E box motifs of mu E2 (CAGCTG) and kappa E2/mu E5 (CACCTG) type. Similarly, heterodimers containing TAL1 and the DNA binding domain of E47 exhibited a relatively weak affinity for mu E2 and kappa E2/mu E5 core motifs. The results of both studies invoked the hypothesis that in vivo TAL1 might act as a negative regulator of mu E2 and kappa E2/mu E5 sequence motifs by forming a complex with the products of the E2A and HTF4 genes. Support for this hypothesis was obtained by transient expression analyses where TAL1 was found to inhibit the activation effects produced by E2-5 and HTF4a on a reporter gene construct containing repeated mu E2 and mu E5 motifs, derived from the immunoglobulin gene enhancer.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIAID NIH HHS [AI29121] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029121] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1991, ONCOGENE, V6, P1477; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DOYLE K, 1994, THESIS PURDUE U; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FITZGERALD TJ, 1991, BLOOD, V78, P2686; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAN YN, 1993, P NATL ACAD SCI USA, V90, P8305, DOI 10.1073/pnas.90.18.8305; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIN H, 1992, J BIOL CHEM, V267, P4773; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN HH, 1993, J BIOL CHEM, V268, P10214; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J, 1989, MOL CLONING LABORATO; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TSAY HJ, 1992, NUCLEIC ACIDS RES, V20, P1805, DOI 10.1093/nar/20.7.1805; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; YI Z, 1992, J VIROL, V66, P5631, DOI 10.1128/JVI.66.9.5631-5634.1992; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; Zhang Y, 1991, DNA Seq, V2, P197, DOI 10.3109/10425179109039690; Zhang Y, 1992, DNA Seq, V2, P397, DOI 10.3109/10425179209020819; ZHANG Y, 1992, THESIS PURDUE U	64	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12099	12105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163514				2022-12-27	WOS:A1994NG37700065
J	KENNEY, WC; HANIU, M; HERMAN, AC; ARAKAWA, T; COSTIGAN, VJ; LARY, J; YPHANTIS, DA; THOMASON, AR				KENNEY, WC; HANIU, M; HERMAN, AC; ARAKAWA, T; COSTIGAN, VJ; LARY, J; YPHANTIS, DA; THOMASON, AR			FORMATION OF MITOGENICALLY ACTIVE PDGF-B DIMER DOES NOT REQUIRE INTERCHAIN DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOROTHIOATE-MODIFIED DNA; SIGNAL TRANSDUCTION; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE; PLATELET; IDENTIFICATION; PURIFICATION; PROTEIN; CHAIN	Platelet-derived growth factor (PDGF), a major mitogen for mesenchymal cells, is a disulfide bonded dimer of two subunit polypeptides named A and B. All of the three possible dimeric forms, i.e. AA, BB, and AB, exist in nature. The dimeric structure has been presumed to be necessary for biological activity, since reduction of the dimer results in loss of activity and simultaneous conversion to monomeric form as determined by SDS-gel electrophoresis. However, reduction of the native molecule destroys intrachain, as well as interchain, disulfide bonds, and it is possible that the former rather than the latter are critical for proper conformation of the active protein. We show here that PDGF-B polypeptides in which all 8 cysteines or the 2nd, 4th, 5th, and 8th cysteines have been mutated to serines fail to form covalent dimers and possess dramatically less mitogenic activity than native PDGF-BB. Another mutant, PDGF-B(C2,4S), in which just the 2 cysteines involved in interchain disulfides were converted to serine, ran as a monomer on SDS-polyacrylamide gels as expected. Somewhat unexpectedly, however, the mitogenic activity of the PDGF-B(C2,4S) analog was similar to the activity of wild-type PDGF-BB disulfide-bonded dimer under physiological conditions. The activity of the analog was more sensitive to the effect of low pH than was the activity of wild-type PDGF-BB. Molecular weight analysis utilizing light scattering and sedimentation equilibrium demonstrated that the PDGF-B(C2,4S) analog exists as a noncovalent dimer at pH 4-7 but dissociates to a monomer at pH 2.5. Disulfide analysis of the mutant protein demonstrated that the intrachain disulfide bonds are the same as those formed in wild-type PDGF-BB homodimers. We conclude that proper formation of intrachain disulfide bonds is critical to maintaining the correct conformation of PDGF monomers, but that appropriately folded monomers can associate into active noncovalent dimers in the absence of interchain disulfide bonds. Interchain disulfide bonds thus appear to increase the stability of the PDGF dimer rather than being crucial to its existence.	AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320; UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269; UNIV CONNECTICUT,NATL ANALYT ULTRACENTRIFUGE FACIL,STORRS,CT 06269; UNIV CRETE,DEPT BIOL,IRAKLION,GREECE; UNIV CRETE,INST MOLEC BIOL & BIOTECHNOL,IRAKLION,GREECE	Amgen; University of Connecticut; University of Connecticut; University of Crete; University of Crete								ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1989, ACTA ONCOL, V28, P331, DOI 10.3109/02841868909111202; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DEUEL TF, 1983, PROG HEMATOL, V13, P201; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1988, BRIT J CANCER, V57, P591, DOI 10.1038/bjc.1988.134; HUNKAPILLER MW, 1988, PROTEIN PEPTIDE SEQU, P87; JAUMANN M, 1991, BIOCHEMISTRY-US, V30, P3303, DOI 10.1021/bi00227a019; JOHNSON ML, 1978, BIOCHEMISTRY-US, V17, P1448, DOI 10.1021/bi00601a014; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8834; NAHRI LO, 1993, J BIOL CHEM, V268, P13309; NARHI LO, 1993, INT J PEPT PROT RES, V41, P8; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403; ROBSON MC, 1992, LANCET, V339, P23, DOI 10.1016/0140-6736(92)90143-Q; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011; SCATCHARD G, 1946, J AM CHEM SOC, V68, P3215; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SQUIRE PG, 1961, J AM CHEM SOC, V83, P3521, DOI 10.1021/ja01477a039; SZUCHET S, 1976, ARCH BIOCHEM BIOPHYS, V177, P437, DOI 10.1016/0003-9861(76)90456-2; SZUCHET S, 1973, BIOCHEMISTRY-US, V12, P5115, DOI 10.1021/bi00749a015; SZUCHET S, 1976, ARCH BIOCHEM BIOPHYS, V173, P495, DOI 10.1016/0003-9861(76)90287-3; TANFORD C, 1961, PHYSICAL CHEM MACROM, P195; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YPHANTIS DA, 1979, PROTEIN INTERACTIONS, P275	48	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12351	12359						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163539				2022-12-27	WOS:A1994NG37700102
J	LAZAROWSKI, ER; HARDEN, TK				LAZAROWSKI, ER; HARDEN, TK			IDENTIFICATION OF A URIDINE NUCLEOTIDE-SELECTIVE G-PROTEIN-LINKED RECEPTOR THAT ACTIVATES PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION SYSTEMS; BETA-ADRENERGIC RECEPTORS; CANINE CEREBRAL-ARTERIES; FRTL-5 THYROID-CELLS; EXTRACELLULAR ATP; ADENYLATE-CYCLASE; P2-PURINERGIC RECEPTORS; PYRIMIDINE NUCLEOTIDES; INOSITOL TRISPHOSPHATE; URACIL NUCLEOTIDES	Incubation of C6-2B rat glioma cells with UDP or UTP resulted in a time- and concentration-dependent increase in the accumulation of inositol phosphates. In contrast, ATP, ADP, and analogs of these nucleotides known to be effective agonists at P-2U-, P-2X-, P-2Y-, P,(2T)-, and P-2Z-purinergic receptors all had no effect on inositol phosphate levels in C6-2B cells. Pyrimidine nucleotides stimulated inositol phosphate accumulation with an order of potency of UDP > 5-BrUTP > UTP > dTDP > UDP glucose. K-0.5 values for UDP, 5-BrUTP, and UTP were 2.3 +/- 0.5, 9 +/- 3, and 57 +/- 10 mu M, respectively. A similar uridine nucleotide selectivity was observed for arachidonic acid release presumably occurring as a consequence of activation of phospholipase A(2). Cross-desensitization and additivity experiments indicated that UDP and UTP interact with the same population of receptors. The effect of uridine nucleotides on inositol phosphate accumulation was inhibited markedly by pretreatment of cells with pertussis toxin. UDP also caused a guanine nudeotide-dependent increase in inositol lipid hydrolysis in streptolysin-O-permeabilized cells. Taken together these results describe the existence of a novel uridine nucleotide receptor that is not activated by adenine nucleotides. This receptor is pharmacologically distinct from the previously described P-2U- and other P-2-purinergic receptors, and likely is a member of a new class of receptors for extracellular nucleotides.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213, GM29536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536, R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; DEVELLIS J, 1974, SCIENCE, V186, P1221, DOI 10.1126/science.186.4170.1221; DEVELLIS J, 1973, TISSUE CULTURE NERVO, P231; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; FISHMAN PH, 1981, MOL PHARMACOL, V20, P310; FREDERICH RC, 1983, J CYCLIC NUCL PROT, V9, P103; GOETZ U, 1971, J PHARMACOL EXP THER, V178, P210; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARDEBO JE, 1983, GEN PHARMACOL, V14, P133, DOI 10.1016/0306-3623(83)90082-4; HARDEBO JE, 1987, BLOOD VESSELS, V24, P150; Harden T. Kendall, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P11; HARDEN TK, 1989, INOSITOL LIPIDS CELL, P113; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; HOMBURGER V, 1980, J BIOL CHEM, V255, P436; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KEPPLER D, 1970, ANAL BIOCHEM, V38, P105, DOI 10.1016/0003-2697(70)90160-0; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406, DOI 10.1152/ajpcell.1994.266.2.C406; LIN WW, 1993, NEUROCHEM RES, V18, P681, DOI 10.1007/BF00966782; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MACDONALD G, 1984, CLIN EXP PHARMACOL P, V11, P381, DOI 10.1111/j.1440-1681.1984.tb00283.x; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; RALEVIC V, 1991, CIRC RES, V69, P1583, DOI 10.1161/01.RES.69.6.1583; SAKAI K, 1979, JPN J PHARMACOL, V29, P243, DOI 10.1254/jjp.29.243; SATO K, 1992, BIOCHEM J, V283, P281, DOI 10.1042/bj2830281; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SEIFERT R, 1989, EUR J BIOCHEM, V181, P277, DOI 10.1111/j.1432-1033.1989.tb14722.x; SHIRASAWA Y, 1983, STROKE, V14, P347, DOI 10.1161/01.STR.14.3.347; SIEFERT R, 1989, BIOCHEM J, V259, P813; STUTCHFIELD J, 1990, FEBS LETT, V262, P256, DOI 10.1016/0014-5793(90)80204-V; URQUILLA PR, 1978, STROKE, V9, P133, DOI 10.1161/01.STR.9.2.133; VONKUGELGEN I, 1987, N-S ARCH PHARMACOL, V336, P556, DOI 10.1007/BF00169313; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V341, P538, DOI 10.1007/BF00171734; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; YAMADA M, 1992, CIRC RES, V70, P477, DOI 10.1161/01.RES.70.3.477	47	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11830	11836						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163481				2022-12-27	WOS:A1994NG37700027
J	SCHWEDA, EKH; SUNDSTROM, AC; ERIKSSON, LM; JONASSON, JA; LINDBERG, AA				SCHWEDA, EKH; SUNDSTROM, AC; ERIKSSON, LM; JONASSON, JA; LINDBERG, AA			STRUCTURAL STUDIES OF THE CELL-ENVELOPE LIPOPOLYSACCHARIDES FROM HAEMOPHILUS-DUCREYI STRAINS ITM-2665 AND ITM-4747	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZAE; CULTURE	The structures of the lipopolysaccharides from Haemophilus ducreyi strains ITM 2665 and ITM 4747 have been investigated. Oligosaccharides were obtained from phenol/water-extracted lipopolysaccharide by mild acid hydrolysis and were studied with methylation analysis, fast atom bombardment-mass spectrometry, and NMR spectroscopy. The major oligosaccharide obtained from strain 2665 is a nonasaccharide with the following structure: beta-D-Galp-1-->4-beta-D-GlcNAcp-1-->3-beta-D-Galp-1-->4-D-alpha-D- Hepp-1-->6-beta-D-Glcp-1-->(L-alpha-D-Hepp-1-->2-L-alpha-D-Hepp-1-->3)-4-L-alpha-D-Hepp-Kdo, where the reducing terminal 3-deoxy-D-manno-octulosonic acid (or Kdo) exists in reduced anhydro forms. The proposed structure complements the preliminary structure described for Haemophilus ducreyi strain 35000 (Melaugh, W., Phillips, N. J., Campagnari, A. A., Karalus, R., and Gibson, B. W. (1992) J. Biol. Chem. 267, 13434-13439) with the missing anomeric configurations. The saccharide isolated from strain 4747 is a markedly simpler hexasaccharide with the following structure: beta-D-Galp-1-->4-beta-D-Glcp-1-->(L-alpha-D-Hepp-1-->2-L-alpha-D-Hepp-1-->3)4-L-alpha-D-Hepp-Kdo. Apart from a different phosphorylation of the inner core region the proposed structure is identical to the structure of lipopolysaccharide from an only distantly related bacterium, viz. Haemophilus influenzae nontypable strain 2019 (Phillips, N. J., Apicella, M. A., Griffiss, J. M., and Gibson, B.W. (1992) Biochemistry 31, 4515-4526). The implications of these findings as regards the role of lipopolysaccharide as a virulence factor are discussed.	KAROLINSKA INST, HUDDINGE HOSP, DEPT CLIN BACTERIOL, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet	SCHWEDA, EKH (corresponding author), KAROLINSKA INST, HUDDINGE HOSP, NOVUM, CLIN RES CTR, S-14186 HUDDINGE, SWEDEN.							ADAMS GA, 1967, CAN J MICROBIOL, V13, P1605, DOI 10.1139/m67-210; ALFA MJ, 1992, J MED MICROBIOL, V37, P43, DOI 10.1099/00222615-37-1-43; AUZANNEAU FI, 1991, J CHEM SOC PERK T 1, P509, DOI 10.1039/p19910000509; BACKMAN I, 1988, J CHEM SOC PERK T 1, P889, DOI 10.1039/p19880000889; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; KIMURA A, 1986, INFECT IMMUN, V51, P69, DOI 10.1128/IAI.51.1.69-79.1986; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MELAUGH W, 1992, J BIOL CHEM, V267, P13434; MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137, DOI 10.1128/CMR.2.2.137-157.1989; NORROD EP, 1985, PATHOGENIC NEISSERIA, P395; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; PHILLIPS NJ, 1993, BIOCHEMISTRY-US, V32, P2003, DOI 10.1021/bi00059a017; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SCHWEDA EKH, 1993, CARBOHYD RES, V246, P319, DOI 10.1016/0008-6215(93)84043-6; SHAH L, 1992, J MED MICROBIOL, V37, P268, DOI 10.1099/00222615-37-4-268; STURM S, 1984, ARCH MICROBIOL, V140, P198, DOI 10.1007/BF00454926; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WEISER JN, 1990, J BACTERIOL, V172, P3304, DOI 10.1128/jb.172.6.3304-3309.1990; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	22	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12040	12048						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163507				2022-12-27	WOS:A1994NG37700057
J	QUISTAD, GB; SKINNER, WS				QUISTAD, GB; SKINNER, WS			ISOLATION AND SEQUENCING OF INSECTICIDAL PEPTIDES FROM THE PRIMITIVE HUNTING SPIDER, PLECTREURYS-TRISTIS (SIMON)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNNEL-WEB SPIDER; TOXINS; NEUROTOXINS; DROSOPHILA; ARANEAE; VENOM	About 50 peptide toxins were purified from venom of the primitive hunting spider, Plectreurys tristis. Bioassay by injection into larval Heliothis virescens (tobacco budworm) allowed selection of nine toxins for analysis of amino acid sequences. Total sequences were determined for six of the more insecticidal peptides (45-49 amino acids) and three contained free carboxyl-terminal amino acids. These toxins (plectoxins) are paralytic and/or lethal when injected into insect pests such as the lepidopterous larvae H. virescens, Spodoptera exigua (beet armyworm), and Manduca sexta (tobacco hornworm). We expect these plectoxins to be useful in insect control after delivery by a suitable agent such as a recombinant baculovirus.	SANDOZ AGRO INC,PALO ALTO,CA 94304	Novartis; Sandoz								ADAMS ME, 1989, INSECTICIDE ACTION M; ATKINSON RK, 1992, COMP BIOCHEM PHYS C, V102, P339, DOI 10.1016/0742-8413(92)90124-P; BLAGBROUGH IS, 1992, TOXICON, V30, P303, DOI 10.1016/0041-0101(92)90871-2; BRANTON WD, 1987, J NEUROSCI, V7, P4195; CARPENTER TL, 1991, J MED ENTOMOL, V28, P477, DOI 10.1093/jmedent/28.3.477; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; HAMMOCK BD, 1993, ARCH INSECT BIOCHEM, V22, P315, DOI 10.1002/arch.940220303; JACKSON H, 1989, ANNU REV NEUROSCI, V12, P405, DOI 10.1146/annurev.neuro.12.1.405; JACKSON H, 1987, EXCITATORY AMINO ACI, P51; KOBAYASHI K, 1992, NEW DRUGS FROM NATURAL SOURCES, P143; LEISY DJ, 1993, Patent No. 556160; LEUNG HT, 1989, NEURON, V3, P767, DOI 10.1016/0896-6273(89)90245-6; LUNDY PM, 1993, TOXICON, V31, P1249, DOI 10.1016/0041-0101(93)90398-3; MCCORMICK KD, 1993, J CHEM ECOL, V19, P2411, DOI 10.1007/BF00979674; Minch E., 1977, Bulletin Br arachnol Soc, V4, P77; POSSEE RD, 1993, PESTIC SCI, V39, P109, DOI 10.1002/ps.2780390204; QUICKE DLJ, 1990, SAFER INSECTICIDES D, P385; QUISTAD GB, 1993, TOXICON, V31, P920, DOI 10.1016/0041-0101(93)90229-C; QUISTAD GB, 1992, J ECON ENTOMOL, V85, P33, DOI 10.1093/jee/85.1.33; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SKINNER WS, 1992, TOXICON, V30, P1043, DOI 10.1016/0041-0101(92)90049-B; STAPLETON A, 1990, J BIOL CHEM, V265, P2054	22	41	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11098	11101						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157635				2022-12-27	WOS:A1994NF96600022
J	BALBOA, MA; FIRESTEIN, BL; GODSON, C; BELL, KS; INSEL, PA				BALBOA, MA; FIRESTEIN, BL; GODSON, C; BELL, KS; INSEL, PA			PROTEIN-KINASE C-ALPHA MEDIATES PHOSPHOLIPASE-D ACTIVATION BY NUCLEOTIDES AND PHORBOL ESTER IN MADIN-DARBY CANINE KIDNEY-CELLS - STIMULATION OF PHOSPHOLIPASE-D IS INDEPENDENT OF ACTIVATION OF POLYPHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C AND PHOSPHOLIPASE A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID RELEASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHATIDIC-ACID; PHOSPHOINOSITIDE HYDROLYSIS; DEPENDENT ACTIVATION; DIFFERENT MECHANISMS; HUMAN-NEUTROPHILS; MDCK-D1 CELLS; D PATHWAY	Protein kinase C (PKC) has been implicated in the activation of phospholipase D (PLD) in a number of systems. By antisense technology, we have ''knocked out'' alpha and beta isoforms of PKC to study the role of these isoforms in PLD activation in Madin-Darby canine kidney (MDCK) cells. To this end, we have studied PLD activation by phorbol 12-myristate 13 acetate (PMA), ATP, UTP, and 2-methylthio-ATP in cells labeled with [H-3]palmitic acid. [H-3]Phosphatidylethanol (PEt) production catalyzed by PLD in the presence of ethanol was time- and concentration-dependent in PMA- and nucleotide stimulated cells. In Ca2+-free medium, [H-3]PEt accumulation was diminished for all stimuli assayed. Treatment of cells with chelerythrine, an inhibitor of PKC, and phorbol ester down-regulation of PKC inhibited [H-3]PEt production by both PMA and nucleotides. In cells transfected with antisense PKCalpha or both PKCalpha and PKCbeta, PLD activation was inhibited by both PMA and nucleotides, whereas in cells transfected with antisense PKCbeta, PLD activation was similar to that of control cells. Moreover, inhibition of polyphosphoinositide-specific PLC (by neomycin) or of release of arachidonic acid and arachidonic acid metabolites (by nordihydroguaiaretic acid or by indomethacin) failed to decrease [H-3]PEt accumulation in PMA- and nucleotide-stimulated MDCK-D1 cells. From these data, we conclude that in MDCK-D1 cells PMA and nucleotide receptors utilize PKCalpha to regulate PLD activity and that PLD activation is independent of the activation of polyphosphoinositide-specific PLC and phospholipase A(2)-mediated release of arachidonic acid or arachidonic acid metabolites.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balboa, María A./V-9493-2018	Balboa, María A./0000-0002-2130-5298; Godson, Catherine/0000-0003-0655-1041; Firestein, Bonnie/0000-0002-1679-3565	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35018] Funding Source: Medline; NIGMS NIH HHS [GM 31487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BILLAH MM, 1991, BIOCHEM SOC T, V19, P324, DOI 10.1042/bst0190324; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOPER CL, 1989, J BIOL CHEM, V264, P6202; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1990, J BIOL CHEM, V265, P9761; FIRESTEIN B L, 1991, Society for Neuroscience Abstracts, V17, P81; FIRESTEIN BL, 1993, PHARMACOLOGIST, V35, P140; FOSTER KA, 1987, BIOCHEM SOC T, V15, P418, DOI 10.1042/bst0150418; GODSON C, 1990, J BIOL CHEM, V265, P8369; GODSON C, 1993, J BIOL CHEM, V268, P11946; GODSON C, 1991, FASEB J, V5, pA834; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; Heller M, 1978, Adv Lipid Res, V16, P267; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG R, 1991, J BIOL CHEM, V266, P1652; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIPSKY JJ, 1982, J PHARMACOL EXP THER, V220, P287; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MEIER KE, 1985, AM J PHYSIOL, V246, pC69; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MULLMANN TJ, 1993, J LEUKOCYTE BIOL, V53, P630, DOI 10.1002/jlb.53.6.630; NISHIZUUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P826; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; ROBISON TW, 1990, TOXICOL APPL PHARM, V105, P113, DOI 10.1016/0041-008X(90)90363-Y; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; YANG SF, 1967, J BIOL CHEM, V242, P477; YOUNG Y, 1987, BIOCHEM J, V244, P755	65	138	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10511	10516						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144636				2022-12-27	WOS:A1994NF01700050
J	WISNIEWSKI, JR; SCHULZE, E				WISNIEWSKI, JR; SCHULZE, E			HIGH-AFFINITY INTERACTION OF DIPTERAN HIGH-MOBILITY GROUP (HMG) PROTEINS-1 WITH DNA IS MODULATED BY COOH-TERMINAL REGIONS FLANKING THE HMG BOX DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; TRANSCRIPTION FACTOR; BINDING PROPERTIES; RNA-POLYMERASE; CRUCIFORM DNA; HISTONE; FLUORESCENCE; CHROMATIN; INVITRO; SITE	The cells of the dipteran insects Chironomus and Drosophila contain high mobility group (HMG) 1 proteins that are homologous to the HMG1 protein of mammals but comprise one instead of two DNA-binding HMG boxes. Mobility shift assays have revealed that Chironomus cHMG1a and cHMG1b bind double strand and four-way junction DNA in a similar way at apparent dissociation constants in the range of 7.5-20 x 10(-9) M. Both proteins are monomeric and highly asymmetric molecules in solution. cHMG1a and cHMG1b exhibit Stokes' radii of 2.4 and 2.3 nm, respectively, and both show a frictional ratio of 1.5. Despite these similarities in their hydrodynamic properties, the binding site of cHMG1a on DNA is similar to 1.5 of the size found for the cHMG1b. Enzymatically and chemically prepared peptides of cHMG1a as well as bacterially expressed cHMG1a with terminal deletions and point substitutions showed that sequences flanking the folded domain that constitutes the HMG box are essential for the interaction of the HMG box with DNA. In particular, changes in the number of positive and negative charges, respectively, within basic and acidic domains modulated the DNA binding affinity of the cHMG1a protein. The alteration of fluorescence of the Trp residues suggest that this modulation is due to interaction of the acidic domain with the positively charged HMG box.			WISNIEWSKI, JR (corresponding author), UNIV GOTTINGEN, INST ZOOL 3, DEPT DEV BIOL, HOLUMBOLDTALLEE 34A, D-37073 GOTTINGEN, GERMANY.							ACKERS GK, 1975, PROTEINS, V3, P1; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BONNE C, 1982, J BIOL CHEM, V257, P2722; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JW, 1986, J BIOL CHEM, V261, P1349; BUSTIN M, 1985, BIOCHEM BIOPH RES CO, V133, P633, DOI 10.1016/0006-291X(85)90952-0; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CARY PD, 1983, EUR J BIOCHEM, V131, P367, DOI 10.1111/j.1432-1033.1983.tb07272.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DUGUET M, 1978, J BIOL CHEM, V253, P1660; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOODWIN GH, 1975, EUR J BIOCHEM, V54, P427, DOI 10.1111/j.1432-1033.1975.tb04153.x; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLAS RH, 1982, HMG CHROMOSOMAL PROT, P41; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REECK GR, 1982, NATURE, V300, P76, DOI 10.1038/300076a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ G, 1983, J MOL BIOL, V163, P467, DOI 10.1016/0022-2836(83)90069-4; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHEFLIN LG, 1989, BIOCHEMISTRY-US, V28, P5658, DOI 10.1021/bi00439a048; SHOOTER KV, 1974, EUR J BIOCHEM, V47, P263, DOI 10.1111/j.1432-1033.1974.tb03690.x; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WATANABE F, 1989, FEBS LETT, V249, P147, DOI 10.1016/0014-5793(89)80612-X; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170	38	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10713	10719						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144661				2022-12-27	WOS:A1994NF01700078
J	BHAT, UR; FORSBERG, LS; CARLSON, RW				BHAT, UR; FORSBERG, LS; CARLSON, RW			STRUCTURE OF LIPID-A COMPONENT OF RHIZOBIUM-LEGUMINOSARUM BV PHASEOLI LIPOPOLYSACCHARIDE - UNIQUE NONPHOSPHORYLATED LIPID-A CONTAINING 2-AMINO-8-DEOXYGLUCONATE, GALACTURONATE, AND GLUCOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							27-HYDROXYOCTACOSANOIC ACID; INFECTION THREADS; ANTIGENIC CHANGES; TRIFOLII ANU-843; BIOVAR PHASEOLI; FATTY-ACIDS; VICIAE; BACTERIA; MUTANTS; RELEASE	The structure of lipid A hom the lipopolysaccharide of Rhizobium leguminosarum bv. phaseoli (wild type strain CE3) was investigated by alkylation analysis, nuclear magnetic resonance spectroscopy, and electrospray and fast atom bombardment mass spectrometry of the de-O-acylated lipid A. The lipid A carbohydrate backbone was shown to be a trisaccharide containing galacturonic acid, glucosamine, and the unique sugar 2-amino-2-deoxygluconic acid, previously unreported in lipopolysaccharides. Nuclear magnetic resonance spectroscopy and ethylation analyses revealed that the galacturonic acid is alpha-1,4-linked to the glucosamine, while the amino aldonic acid residue, which may exist as the 1,5-lactone, is attached as an aglycone to the glucosamine and, thus, occupies the reducing end of the molecule. The resulting backbone is hydrophilic and analogous to the commonly observed bisphosphorylated glucosamine disaccharide from enteric bacterial lipopolysaccharides in that both the nonreducing and reducing ends carry negatively charged substituents. The fatty acids of the R. legumino-sarum lipid A are attached both as O- and N-acyl substituents to glucosamine and 2-aminogluconate. All fatty acids are hydroxylated consisting of 3-hydroxymyristate (3-OH-C-14.0), 3-hydroxypentadecanoate (3-OH-C-15.0), 3-hydroxypalmitate (3-OH-C-16.0), 3-hydroxystearate (3-OH-C-18.0), and 27-hydroxyoctacosanoate (27-OH-C-28.0) in the approximate mole ratio 3:0.2:1:0.6:1. Unlike lipid As from enteric bacteria, the R. leguminosarum lipid A lacks 3-acyloxyacyl substituents; however, the long chain 27-hydroxy fatty acid carries ester-linked beta-hydroxybutyrate at the 27-hydroxy position. Fast atom bombardment mass spectrometry of the de-O-acylated lipid A demonstrated the presence of 2 molecular species that differ by 28 mass units due to fatty acid heterogeneity at the two amide linkages. One species carries amide-linked 3-OH-C-14.0 and 3-OH-C-16.0; the second species carries 3-OH-C-14.0 and 3-OH-C-18.0. Each molecular species also exists as the aldonolactone, yielding molecular ions at ((M + H)(+))-18. The heterogeneity in the amide-linked fatty acids further distinguishes the Rhizobium lipid A from enteric lipid As.	UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30605	University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BHAT UR, 1992, GLYCOBIOLOGY, V2, P535, DOI 10.1093/glycob/2.6.535; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BREWIN NJ, 1986, J GEN MICROBIOL, V132, P1959; BREWIN NJ, 1992, MOL MICROBIOL, V6, P2477; CARLSON RW, 1984, J BACTERIOL, V158, P1012, DOI 10.1128/JB.158.3.1012-1017.1984; CARLSON RW, 1978, PLANT PHYSIOL, V62, P912, DOI 10.1104/pp.62.6.912; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; Carlson RW, 1982, NITROGEN FIXATION, V2; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DEMAAGD RA, 1989, J BACTERIOL, V171, P1143, DOI 10.1128/jb.171.2.1143-1150.1989; DEMARY M, 1977, NOUV J CHIM, V2, P373; FORSBERG LS, 1982, J BIOL CHEM, V257, P3555; GOOSENDEROO L, 1991, J BACTERIOL, V173, P3177, DOI 10.1128/JB.173.10.3177-3183.1991; HASE S, 1976, EUR J BIOCHEM, V63, P101, DOI 10.1111/j.1432-1033.1976.tb10212.x; HOLLINGSWORTH RI, 1990, J BIOL CHEM, V265, P12752; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9294; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P14039; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; KANNENBERG EL, 1989, J BACTERIOL, V171, P4543, DOI 10.1128/jb.171.9.4543-4548.1989; KOTANI S, 1990, ADV EXP MED BIOL, V256, P13; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; OHNO K, 1979, TETRAHEDRON LETT, V45, P4405; PRIEFER UB, 1989, J BACTERIOL, V171, P6161, DOI 10.1128/jb.171.11.6161-6168.1989; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; RYAN JM, 1974, ARCH BIOCHEM BIOPHYS, V162, P530, DOI 10.1016/0003-9861(74)90213-6; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; TAKADA H, 1992, BACTERIAL ENDOTOXIC, V1, P107; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; WOOD EA, 1989, J BACTERIOL, V171, P4549, DOI 10.1128/jb.171.9.4549-4555.1989; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; ZHANG Y, 1992, CARBOHYD RES, V231, P261, DOI 10.1016/0008-6215(92)84024-M	37	132	135	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14402	14410						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182046				2022-12-27	WOS:A1994NM06500018
J	KOO, P; NAGAI, MK; FARBER, E				KOO, P; NAGAI, MK; FARBER, E			MULTIPLE SITES OF CONTROL OF GLUTATHIONE-S-TRANSFERASE P1-1 IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PROTEIN METHYLATION; PERSISTENT HEPATOCYTE NODULES; MESSENGER-RNA; CHEMICAL HEPATOCARCINOGENESIS; LEAD NITRATE; IDENTIFICATION; ACID; GENE; CELLS; POLYRIBOSOMES	Glutathione transferase P1-1, normally very low in adult rat liver, is induced by a single intravenous dose of lead nitrate. In this transient induction, there are at least three sites of regulation or control. These are transcription, post transcription, and post-translation. The increase in transcription is evident both by nuclear runoff analysis and by measurement of mRNA levels. The other two sites of control were seen in actinomycin D-treated animals in which RNA synthesis was inhibited by over 80%. Treatment with actinomycin D increases the stability of the mRNA and also somehow inhibits the conversion of a glutathione transferase protein to an enzymatically active form. These three sites offer possibilities for the study of mechanisms of control for this interesting enzyme that may play a role in chemical carcinogenesis and in drug resistance.	UNIV TORONTO, DEPT PATHOL, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ON, CANADA	University of Toronto; University of Toronto								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CAMERON RG, 1989, CANCER LETT, V47, P163, DOI 10.1016/0304-3835(89)90086-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Columbano A, 1984, Toxicol Pathol, V12, P89; COLUMBANO A, 1983, AM J PATHOL, V110, P83; DING VDH, 1990, CANCER RES, V50, P256; FARBER E, 1987, CHEM SCRIPTA, V27A, P131; FARBER E, 1990, BIOCHEM PHARMACOL, V39, P1837, DOI 10.1016/0006-2952(90)90599-G; FAUSTO N, 1984, MOL CELL BIOCHEM, V59, P131; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1990, GLUTATHIONE S TRANSF; KUZMICH S, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P513; LI Y, 1989, ONCOGENE, V4, P795; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; MOORE MA, 1987, CARCINOGENESIS, V8, P483, DOI 10.1093/carcin/8.3.483; NEAL TL, 1988, BIOCHEM BIOPH RES CO, V156, P368, DOI 10.1016/S0006-291X(88)80850-7; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PRINCEN HMG, 1982, BIOCHIM BIOPHYS ACTA, V699, P121, DOI 10.1016/0167-4781(82)90145-2; PYERIN W, 1987, BIOCHEM BIOPH RES CO, V142, P885, DOI 10.1016/0006-291X(87)91496-3; ROOMI MW, 1986, CARCINOGENESIS, V7, P1643, DOI 10.1093/carcin/7.10.1643; RUSHMORE TH, 1987, BIOCHEM BIOPH RES CO, V143, P98, DOI 10.1016/0006-291X(87)90635-8; RUSHMORE TH, 1988, CANCER RES, V48, P2805; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SATO K, 1989, ADV CANCER RES, V52, P205; SATO K, 1984, GANN, V75, P199; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHINOZUKA H, 1970, LAB INVEST, V23, P253; SIEGEL FL, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P47; SIEGEL FL, 1985, ARCH BIOCHEM BIOPHYS, V237, P347, DOI 10.1016/0003-9861(85)90286-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; VILLATREVINO S, 1966, J BIOL CHEM, V241, P4670; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524	43	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14601	14606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182066				2022-12-27	WOS:A1994NM06500047
J	REN, JM; SEMENKOVICH, CF; GULVE, EA; GAO, JP; HOLLOSZY, JO				REN, JM; SEMENKOVICH, CF; GULVE, EA; GAO, JP; HOLLOSZY, JO			EXERCISE INDUCES RAPID INCREASES IN GLUT4 EXPRESSION, GLUCOSE-TRANSPORT CAPACITY, AND INSULIN-STIMULATED GLYCOGEN-STORAGE IN MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; PLASMA-MEMBRANE; APPARENT TRANSLOCATION; ENDURANCE PERFORMANCE; POTENTIAL MECHANISM; PHORBOL ESTER; SOLEUS MUSCLE; PROTEIN; LOCALIZATION; ACTIVATION	GLUT4 glucose transporter content and glucose transport capacity are closely correlated in skeletal muscle. In this study, we tested the hypothesis that a rapid increase in GLUT4 expression occurs as part of the early adaptive response of muscle to exercise and serves to enhance glycogen storage. Rats exercised by swimming had a similar to 2-fold increase in GLUT4 mRNA and a 50% increase in GLUT4 protein expression in epitrochlearis muscle 16 h after one prolonged exercise session. After a 2nd day of exercise, muscle GLUT4 protein was increased further to similar to 2-fold while there was no additional increase in GLUT4 mRNA. Muscle hexokinase activity also doubled in response to 2 days of exercise. Glucose transport activity maximally stimulated with insulin, contractions, or hypoxia was increased roughly in proportion to the adaptive increase in GLUT4 protein in epitrochlearis muscles. Treatment with insulin prior to subcellular fractionation of muscle resulted in a similar to 2-fold greater increase in GLUT4 content of a plasma membrane fraction in the 2-day swimmers than in controls. When epitrochlearis muscles were incubated with glucose and insulin, glycogen accumulation over 3 h was twice as great in muscles from 2-day swimmers as in control muscles. Our results show that a rapid increase in GLUT4 expression is an early adaptive response of muscle to exercise. This adaptation appears to be mediated by pretranslational mechanisms. We hypothesize that the physiological role of this adaptation is to enhance replenishment of muscle glycogen stores.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Semenkovich, Clay/0000-0003-1163-1871	NHLBI NIH HHS [HL47436] Funding Source: Medline; NIA NIH HHS [AG00078] Funding Source: Medline; NIDDK NIH HHS [DK18986] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN KM, 1975, PFLUG ARCH EUR J PHY, V354, P203, DOI 10.1007/BF00584644; BERGSTROM J, 1967, ACTA PHYSIOL SCAND, V71, P140, DOI 10.1111/j.1748-1716.1967.tb03720.x; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BROZINICK JT, 1993, AM J PHYSIOL, V265, pE419, DOI 10.1152/ajpendo.1993.265.3.E419; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGGAN AR, 1992, J APPL PHYSIOL, V73, P1873, DOI 10.1152/jappl.1992.73.5.1873; COGGAN AR, 1990, J APPL PHYSIOL, V68, P990, DOI 10.1152/jappl.1990.68.3.990; CONSTABLE SH, 1984, AM J PHYSIOL, V247, pR880, DOI 10.1152/ajpregu.1984.247.5.R880; COSTILL DL, 1977, J APPL PHYSIOL, V43, P695, DOI 10.1152/jappl.1977.43.4.695; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ETGEN GJ, 1993, J BIOL CHEM, V268, P20164; FELL RD, 1982, J APPL PHYSIOL, V52, P434, DOI 10.1152/jappl.1982.52.2.434; FOSTER C, 1979, MED SCI SPORT EXER, V11, P1; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOUMARD JA, 1993, AM J PHYSIOL, V264, pE896, DOI 10.1152/ajpendo.1993.264.6.E896; HURLEY BF, 1986, J APPL PHYSIOL, V60, P562, DOI 10.1152/jappl.1986.60.2.562; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KARLSSON J, 1971, J APPL PHYSIOL, V31, P203, DOI 10.1152/jappl.1971.31.2.203; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KIPNIS DM, 1959, J BIOL CHEM, V234, P171; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SF, 1989, EXERCISE SPORT SCI R, V17, P67; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MARTIN WH, 1993, AM J PHYSIOL, V265, pE708, DOI 10.1152/ajpendo.1993.265.5.E708; MEGENEY LA, 1993, AM J PHYSIOL, V264, pE583, DOI 10.1152/ajpendo.1993.264.4.E583; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PETER JB, 1968, SCIENCE, V160, P200, DOI 10.1126/science.160.3824.200; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1993, J BIOL CHEM, V268, P16113; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; ROGERS MA, 1988, DIABETES CARE, V11, P613, DOI 10.2337/diacare.11.8.613; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; UYEDA K, 1965, J BIOL CHEM, V240, P4682; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; WEBER FE, 1990, EUR J BIOCHEM, V191, P85, DOI 10.1111/j.1432-1033.1990.tb19096.x; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	61	319	331	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14396	14401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182045				2022-12-27	WOS:A1994NM06500017
J	RIEDER, G; MERRICK, MJ; CASTORPH, H; KLEINER, D				RIEDER, G; MERRICK, MJ; CASTORPH, H; KLEINER, D			FUNCTION OF HISF AND HISH GENE-PRODUCTS IN HISTIDINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; CTP SYNTHETASE; SEQUENCE; MUTAGENESIS; PLASMIDS; BACTERIA; VECTORS	A mutant of the enterobacterium Klebsiella pneumoniae with a defect in the hisF gene (in the histidine biosynthesis pathway) was isolated, which can only grow with high but not low ammonia concentrations. The mutated hisF product can use ammonia for the formation of the imidazole ring of histidine but not glutamine provided by the hisH product. Site-directed insertional mutagenesis of hisH led to the same dependence of prototrophic growth on high ammonia levels. The nucleotide sequence of g pneumoniae hisF is almost identical to that of hisF from other enterobacteria. Similarities of the hisF product with the hisA product and of HisH sequences with the glutamine binding domains of TrpG-type amidotransferases provide additional evidence for the functions of the hisF and hisH products in histidine biosynthesis, namely that HisF catalyzes the ammonolytic cleavage of N'-(5'-phosphoribulosyl)-formimino-5-aminoimidazole-4-carboxamide ribonucleotide either utilizing free ammonia or deriving the ammonia moiety from glutamine bound to HisH.	UNIV BAYREUTH,LEHRSTUHL MIKROBIOL,D-95440 BAYREUTH,GERMANY; UNIV SUSSEX,AFRC,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND	University of Bayreuth; University of Sussex								Artz S. W., 1983, AMINO ACIDS BIOSYNTH, P379; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CASTORPH H, 1984, ARCH MICROBIOL, V139, P245, DOI 10.1007/BF00402008; COLLINS JF, 1988, COMPUT APPL BIOSCI, V4, P67; DEBRUIJN FJ, 1984, GENE, V27, P131, DOI 10.1016/0378-1119(84)90135-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; GROISMAN EA, 1984, P NATL ACAD SCI-BIOL, V81, P1480, DOI 10.1073/pnas.81.5.1480; JENSEN JS, 1982, EMBO J, V1, P197, DOI 10.1002/j.1460-2075.1982.tb01147.x; KLEINER D, 1988, J GEN MICROBIOL, V134, P1779; KLEM TJ, 1993, BIOCHEMISTRY-US, V32, P5177, DOI 10.1021/bi00070a029; MANIATIS T, 1982, MOL CLONING LABORATO, P104; Martin R. G., 1971, METHODS ENZYMOL    B, V17, P3; MEI B, 1989, J BIOL CHEM, V264, P16613; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PENGRA RM, 1958, J BACTERIOL, V75, P21, DOI 10.1128/JB.75.1.21-25.1958; PUHLER A, 1979, PLASMIDS MED ENV COM, P439; Rej R., 1983, METHODS ENZYMATIC AN, V3rd, P416; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH DWE, 1964, J BIOL CHEM, V239, P1848; STOUGAARD J, 1988, J BACTERIOL, V170, P250, DOI 10.1128/jb.170.1.250-257.1988; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; WENG M, 1987, J BACTERIOL, V169, P3023, DOI 10.1128/jb.169.7.3023-3028.1987; WENG M, 1986, J BIOL CHEM, V261, P5568; WINKLER ME, 1987, ESCHERICHIA COLI SAL, P395	28	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14386	14390						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182043				2022-12-27	WOS:A1994NM06500015
J	KUMAR, V; HEINEMANN, FS; OZOLS, J				KUMAR, V; HEINEMANN, FS; OZOLS, J			PURIFICATION AND CHARACTERIZATION OF AVIAN OLIGOSACCHARYLTRANSFERASE - COMPLETE AMINO-ACID-SEQUENCE OF THE 50-KDA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SITE-BINDING-PROTEIN; RIBOPHORINS-I; GLYCOSYLATION; MEMBRANE; TRANSFERASE; GLYCOPROTEINS; TOPOLOGY	We have purified oligosaccharyltransferase from hen oviduct microsomes some 850-fold. Oligosaccharyltransferase activity copurified with a a 200-kDa complex consisting of two 65-kDa polypeptides and a 50-kDa polypeptide. N-terminal sequence analysis indicated that the 50-kDa subunit was the avian form of OST48, a canine pancreatic microsomal protein associated with oligosaccharyltransferase. As the first step toward reconstitution of the oligosaccharyltransferase complex, the 50-kDa subunit was purified to homogeneity under nondenaturing conditions. The complete amino acid sequence of the 50-kDa subunit was determined by sequence analysis of peptides isolated by a combination of gel filtration and high performance liquid chromatography from chemical and enzymatic digests. The protein consists of 412 residues in a single polypeptide chain. The amino acid sequence of the 50-kDa subunit of avian oligosaccharyltransferase is 92% identical to the sequence of canine OST48 protein and about 25% identical to WBP1 protein from the yeast Saccharomyces cerevisiae. The yeast WBP1 protein has been shown in vitro, as well as in vivo, to be essential for the oligosaccharyltransferase activity.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA; HOAG MEM HOSP, DEPT PATHOL, NEWPORT BEACH, CA 92663 USA	University of Connecticut					NIGMS NIH HHS [GM-26351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBERT JP, 1982, BIOCHEM BIOPH RES CO, V104, P1550, DOI 10.1016/0006-291X(82)91428-0; BAKER RK, 1986, J CELL BIOCHEM, V32, P193, DOI 10.1002/jcb.240320305; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; HART GW, 1979, J BIOL CHEM, V254, P9747; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; SANDERSON CM, 1990, J CELL BIOL, V111, P2861, DOI 10.1083/jcb.111.6.2861; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; ZIMMERMAN JW, 1993, J BIOL CHEM, V268, P16746	25	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13451	13457						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175777				2022-12-27	WOS:A1994NK18400060
J	SUTTER, TR; TANG, YM; HAYES, CL; WO, YYP; JABS, EW; LI, X; YIN, H; CODY, CW; GREENLEE, WF				SUTTER, TR; TANG, YM; HAYES, CL; WO, YYP; JABS, EW; LI, X; YIN, H; CODY, CW; GREENLEE, WF			COMPLETE CDNA SEQUENCE OF A HUMAN DIOXIN-INDUCIBLE MESSENGER-RNA IDENTIFIES A NEW GENE SUBFAMILY OF CYTOCHROME-P450 THAT MAPS TO CHROMOSOME-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; AH-RECEPTOR; DIFFERENTIAL EXPRESSION; AROMATIC-HYDROCARBONS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; DNA; LIVER; PROTEIN; CLONING	Previously, levels of a novel human mRNA detected by a recombinant cDNA designated clone 1, were shown to be increased 50-fold in response to treatment of a keratinocyte cell line with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), in part as a function of increased rates of gene transcription (Sutter, T. R., Guzman, K., Dold, K. M., and Greenlee, W. F. (1991) Science 254, 415-418). Here we report the complete corresponding 5.1-kilobase cDNA sequence. A single open reading frame that predicts a protein of 543 amino acid residues was determined by computer-assisted analysis of the cDNA sequence. This predicted protein identifies a new gene subfamily of cytochrome P450, cytochrome P4501B1 (CYP1B1), that maps to human chromosome 2. Southern blot analysis of genomic DNA indicates that the human CYP1B subfamily is likely to contain only this single gene. Northern blot analysis of RNA isolated from primary cultures of normal human epidermal keratinocytes showed similar to 100-fold increased levels of the CYP1B1 mRNA after treatment with 10 nM TCDD for 24 h. Low levels of constitutive CYP1B1 mRNA were detected in 15 different human tissue samples. These results indicate that CYP1B1 is expressed in many normal human tissues and advance our understanding of the complexity of a gene family of cytochromes P450 whose expression is altered by TCDD.	JOHNS HOPKINS MED INST, DEPT ENVIRONM HLTH SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT SURG, BALTIMORE, MD 21205 USA; PURDUE UNIV, SCH PHARM & PHARMACAL SCI, DEPT PHARMACOL & TOXICOL, W LAFAYETTE, IN 47907 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Jabs, Ethylin/0000-0001-8983-5466; Sutter, Carrie/0000-0002-6088-6320	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R29ES006071] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00373] Funding Source: Medline; NIEHS NIH HHS [ES06071, ES03819] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; CONNEY AH, 1982, CANCER RES, V42, P4875; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5, P353; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GOLDSTEIN JA, 1984, MOL PHARMACOL, V25, P185; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GREENLEE WF, 1994, IN PRESS RECENT PROG; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HEILMANN LJ, 1988, DNA-J MOLEC CELL BIO, V7, P379, DOI 10.1089/dna.1.1988.7.379; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAISWAL A K, 1987, Journal of Experimental Pathology (New York), V3, P1; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; KAGAWA N, 1987, J BIOCHEM-TOKYO, V101, P1471, DOI 10.1093/oxfordjournals.jbchem.a122017; KAWAJIRI K, 1993, CRIT REV ONCOL HEMAT, V14, P77, DOI 10.1016/1040-8428(93)90007-Q; KELLY RB, 1970, J BIOL CHEM, V245, P39; KIMURA S, 1989, AM J HUM GENET, V45, P889; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KIMURA S, 1984, J BIOL CHEM, V259, P705; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NEBERT DW, 1991, METHOD ENZYMOL, V206, P3; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; POTTENGER LH, 1991, ARCH BIOCHEM BIOPHYS, V286, P488, DOI 10.1016/0003-9861(91)90070-Y; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIFKIND AB, 1983, NATURE, V303, P524, DOI 10.1038/303524a0; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESARDIC D, 1990, CARCINOGENESIS, V11, P1183, DOI 10.1093/carcin/11.7.1183; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1992, CHEMOSPHERE, V25, P223, DOI 10.1016/0045-6535(92)90519-W; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1991, BANB REPORT, V35, P379; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YABUSAKI Y, 1984, NUCLEIC ACIDS RES, V12, P2929, DOI 10.1093/nar/12.6.2929; YAMANO S, 1989, BIOCHEMISTRY-US, V28, P7340, DOI 10.1021/bi00444a029	53	457	476	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13092	13099						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175734				2022-12-27	WOS:A1994NK18400010
J	WARD, CR; STOREY, BT; KOPF, GS				WARD, CR; STOREY, BT; KOPF, GS			SELECTIVE ACTIVATION OF G(I1), AND G(I2), IN MOUSE SPERM BY THE ZONA-PELLUCIDA, THE EGGS EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; ACROSOME REACTION; ALPHA-SUBUNITS; MAMMALIAN SPERM; FERTILIZATION INVITRO; GAMETE INTERACTIONS; RECEPTOR ACTIVITY; TYROSINE KINASE; IDENTIFICATION; GI	Mammalian sperm acrosomal exocytosis as induced by the egg's zona pellucida (ZP) appears to be a G protein-mediated event. Previously, we demonstrated that ZP3, the acrosome reaction-inducing component of mouse ZP, activates one or more G(i) subtypes in isolated sperm membranes (Ward, C. R., Storey, B. T., and Kopf, G. S. (1992) J. Biol. Chen. 267, 14061-14067). To determine the identity of the G(i) subtype(s) activated in the sperm, we examined ligand-dependent decreases in pertussis toxin-catalyzed in vitro [P-32]ADP-ribosylation of the different G(i alpha) subtypes that were identified by immunoprecipitation using G(i alpha)-specific antisera. Membranes treated with solubilized ZP or mastoparan and subsequently [P-32]ADP-ribosylated using pertussis toxin displayed 35 and 56% decreases, respectively, in [P-32]ADP-ribosylation when compared with controls. These changes were quantitatively similar to the percentage increases in S-35-labeled guanosine 5'-O-(thiotriphosphate) binding in membranes treated with equivalent concentrations of ZP or mastoparan (Ward et al., 1992). Immunoprecipitation with G(i alpha) subtype-specific antisera and subsequent autoradiography revealed that mastoparan activated G(i1), G(i2), and G(i3) in the membranes. ZP, in contrast, selectively activated G(i1) and G(i2). These data demonstrate that the egg's extracellular matrix has the ability to activate selectively sperm membrane G(i) subtypes.			WARD, CR (corresponding author), UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, JOHN MORGAN BLDG 339, PHILADELPHIA, PA 19104 USA.				NICHD NIH HHS [HD00972, HD06274, HD07725] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARONS D, 1984, BIOL REPROD, V31, P811, DOI 10.1095/biolreprod31.4.811; BIRNBAUMER L, 1991, BIOL REPROD, V44, P207, DOI 10.1095/biolreprod44.2.207; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; Bookbinder L. H., 1993, Molecular Biology of the Cell, V4, p247A; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; FAUNDES D F, 1991, Journal of Cell Biology, V115, p141A; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; GLASSNER M, 1991, DEV BIOL, V146, P438, DOI 10.1016/0012-1606(91)90245-X; GOMPERTS BD, 1988, COLD SPRING HARB SYM, V53, P983, DOI 10.1101/SQB.1988.053.01.113; GORDON JH, 1988, FEBS LETT, V235, P201, DOI 10.1016/0014-5793(88)81262-6; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HINSCH KD, 1994, IN PRESS FEBS LETT; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JONES J, 1989, FEBS LETT, V243, P409, DOI 10.1016/0014-5793(89)80172-3; KALAB P, 1994, IN PRESS J BIOL CHEM, V269; KARNIK NS, 1992, DEV BIOL, V152, P393, DOI 10.1016/0012-1606(92)90146-8; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; KOPF GS, 1986, J BIOL CHEM, V261, P7327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LEYTON L, 1989, DEV BIOL, V132, P174, DOI 10.1016/0012-1606(89)90215-7; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORISHITA R, 1990, FEBS LETT, V271, P231, DOI 10.1016/0014-5793(90)80413-D; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SALING PM, 1979, J CELL BIOL, V83, P544, DOI 10.1083/jcb.83.3.544; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHUR BD, 1988, J BIOL CHEM, V263, P17706; Storey B. T., 1991, A comparative overview of mammalian fertilization., P167; STOREY BT, 1991, ANN NY ACAD SCI, V637, P459, DOI 10.1111/j.1749-6632.1991.tb27330.x; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WARD CR, 1992, J BIOL CHEM, V267, P14061; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WILLIAMS AG, 1990, BLOOD, V76, P721; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447	53	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13254	13258						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175755				2022-12-27	WOS:A1994NK18400033
J	ZACHARIAS, C; VANECHTENDECKERT, G; PLEWE, M; SCHMIDT, RR; SANDHOFF, K				ZACHARIAS, C; VANECHTENDECKERT, G; PLEWE, M; SCHMIDT, RR; SANDHOFF, K			A TRUNCATED EPOXY GLUCOSYLCERAMIDE UNCOUPLES GLYCOSPHINGOLIPID BIOSYNTHESIS BY DECREASING LACTOSYLCERAMIDE SYNTHASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED NEURONS; SERINE PALMITOYLTRANSFERASE; GLUCOCEREBROSIDE SYNTHETASE; SPHINGOLIPID BIOSYNTHESIS; GANGLIOSIDES; GOLGI; TOPOLOGY; GLYCOSYLTRANSFERASE; SPHINGANINE; MODULATION	Introduction of an epoxide function at the C4 position of the glucose moiety of a truncated glucosylceramide (GlcCer) yields two stereoisomeric products namely a gluco- and a galacto-derivative. The effects of both analogues on the [C-14]serine incorporation into glycosphingolipids as well as on lactosylceramide (LacCer) synthase activity of primary cultured neurons derived from the telencephalon of 8-day-old chick embryos were investigated. Whereas the galacto-derivative had no effect either on the pattern of labeled glycosphingolipids or on LacCer synthase activity, pretreatment (24 h) of neurons with the gluco derivative caused a concentration dependent (IC50 = 8 mu M) and irreversible decrease of the specific activity of LacCer synthase. As a consequence the biosynthetic glycosphingolipid pattern of cultured neurons treated with the glucoanalogue changed as follows: the radioactive label of all glycosphingolipids biosynthetically derived from GlcCer was decreased while labeling of GlcCer increased significantly. The inhibitory effect of the gluco derivative on LacCer synthase activity was much less pronounced in vitro. Thus 250 mu M analogue caused only about 30% inhibition of enzymatic activity.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV KONSTANZ,FAK CHEM,W-7750 CONSTANCE,GERMANY	University of Bonn; University of Konstanz								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1988, J BIOL CHEM, V263, P13017; CHATTERJEE S, 1991, BIOCHEM BIOPH RES CO, V181, P554, DOI 10.1016/0006-291X(91)91225-2; CHATTERJEE S, 1993, BIOCHIM BIOPHYS ACTA, V1167, P339, DOI 10.1016/0005-2760(93)90238-5; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DREYFUS H, 1980, NEUROSCIENCE, V5, P1647, DOI 10.1016/0306-4522(80)90028-7; FENDERSON BA, 1992, EXP CELL RES, V198, P362, DOI 10.1016/0014-4827(92)90392-L; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; INOKUCHI JI, 1987, J LIPID RES, V28, P565; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MANDON EC, 1992, J BIOL CHEM, V267, P11144; PLEWE M, 1992, LIEBIGS ANN CHEM, P699; RADIN NS, 1991, TRENDS GLYCOSCI GLYC, V3, P200; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SARMIENTOS F, 1986, EUR J BIOCHEM, V160, P527, DOI 10.1111/j.1432-1033.1986.tb10071.x; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SHAPIRO D, 1958, J AM CHEM SOC, V80, P1194, DOI 10.1021/ja01538a044; SVENNERHOLM L, 1984, CELLULAR PATHOLOGICA, V126, P21; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; WANG E, 1991, J BIOL CHEM, V266, P14486; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	30	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13313	13317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175761				2022-12-27	WOS:A1994NK18400041
J	LIST, HJ; PATZEL, V; ZEIDLER, U; SCHOPEN, A; RUHL, G; STOLLWERK, J; KLOCK, G				LIST, HJ; PATZEL, V; ZEIDLER, U; SCHOPEN, A; RUHL, G; STOLLWERK, J; KLOCK, G			METHYLATION SENSITIVITY OF THE ENHANCER FROM THE HUMAN PAPILLOMAVIRUS TYPE-16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; TYROSINE AMINOTRANSFERASE GENE; UPSTREAM REGULATORY REGION; LONG TERMINAL REPEAT; CPG BINDING-PROTEIN; NUCLEAR FACTOR-I; DNA METHYLATION; TRANSCRIPTION FACTOR; PROMOTER REGION; MESSENGER-RNA	The human papillomavirus type 16 is associated with anogenital cancer. Transcription of the viral transforming genes E6 and E7 is under the control of an epithelial cell type-specific enhancer. In the enhancer core, we have identified a regulatory element that is recognized by a novel nuclear factor named MSPF (methylation-sensitive papillomavirus transcription factor). Mutating the MSPF binding site strongly affects the enhancer activity. The MSPF recognition sequence 5'-ATGCGNNNNCGCCT-3' contains two CpG dinucleotides, potential targets for B cytidine methylation. DNA recognition by MSPF is strictly methylation-sensitive, since introduction of 5-methylcytidine into either CpG abolishes complex formation. Moreover, CpG methylation of the MSPF binding site suppresses the activity of the enhancer and of the MSPF enhanson subfragment in vivo. In the cervical carcinoma cell line CaSki, which has integrated multiple transcriptionally inactive human papilloma virus 16 genomes, a few of the viral genomes are methylated at the MSPF binding site. These findings suggest that viral transcription can be suppressed by methylation of the regulatory region, an event that prevents binding of the cellular transcription factor MSPF.	TH DARMSTADT, INST BIOCHEM, D-64287 DARMSTADT, GERMANY	Technical University of Darmstadt								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BEDNARIK DP, 1991, NEW BIOL, V3, P969; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CRIPE T P, 1990, New Biologist, V2, P450; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DESROSIERS RC, 1979, P NATL ACAD SCI USA, V76, P3839, DOI 10.1073/pnas.76.8.3839; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, ONCOGENE, V1, P251; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GISSMANN L, 1987, CANCER CELL, V5, P275; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; GLOSS B, 1989, J VIROL, V63, P1142, DOI 10.1128/JVI.63.3.1142-1152.1989; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HERMANN R, 1989, J MOL BIOL, V210, P411, DOI 10.1016/0022-2836(89)90340-9; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1993, J GEN VIROL, V74, P791, DOI 10.1099/0022-1317-74-5-791; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SIBBET GJ, 1990, J GEN VIROL, V71, P2699, DOI 10.1099/0022-1317-71-11-2699; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEIH F, 1988, NUCLEIC ACIDS RES, V16, P1628, DOI 10.1093/nar/16.4.1628; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; ZURHAUSEN H, 1977, BEHRING I MITT, V61, P23	70	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11902	11911						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163489				2022-12-27	WOS:A1994NG37700037
J	YE, JJ; REIZER, J; CUI, XW; SAIER, MH				YE, JJ; REIZER, J; CUI, XW; SAIER, MH			INHIBITION OF THE PHOSPHOENOLPYRUVATE-LACTOSE PHOSPHOTRANSFERASE SYSTEM AND ACTIVATION OF A CYTOPLASMIC SUGAR-PHOSPHATE PHOSPHATASE IN LACTOCOCCUS-LACTIS BY ATP-DEPENDENT METABOLITE-ACTIVATED PHOSPHORYLATION OF SERINE-46 IN THE PHOSPHOCARRIER PROTEIN HPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; STREPTOCOCCUS-PYOGENES; EXPULSION MECHANISMS; INDUCER EXCLUSION; ESCHERICHIA-COLI; SERYL RESIDUE; KINASE; PURIFICATION; ACCUMULATION; TRANSPORT	Lactococcus lactis takes up lactose and the nonmetabolizable lactose analogue, thiomethyl-beta-galactoside (TMG), via the phosphoenolpyruvate:sugar phosphotransferase system (PTS) which couples sugar transport to sugar phosphorylation. Earlier studies had shown that TMG-phosphate, previously accumulated in L. lactis cells, is rapidly dephosphorylated in the cytoplasm and effluxes from the cells upon addition of glucose and that glucose inhibits further uptake of TMG. We have developed a vesicular system to analyze this regulatory mechanism and have used electroporation to shock proteins and membrane-impermeable metabolites into the vesicles. Uptake of TMG was dependent on an energy source, effectively provided by intravesicular phosphoenolpyruvate at low concentrations or extravesicular phosphoenolpyruvate at high concentrations. TMG uptake into osmotically shocked vesicles was only weakly inhibited, and expulsion of preaccumulated TMG was only slightly stimulated upon addition of glucose. Intravesicular (but not extravesicular) wild-type HPr of Bacillus subtilis completely restored the regulatory behavior observed in vivo when glucose was present in the external medium. Glucose could be replaced by intravesicular (but not extravesicular) fructose 1,6-diphosphate, gluconate 6-phosphate, or 2-phosphoglycerate, but not by other phosphorylated metabolites, in agreement with the allosteric activating effects of these compounds on HPr(Ser) kinase measured in vitro. Intravesicular mutant HPr(S46A) protein could not promote regulation of lactose permease activity when electroporated into the vesicles regardless of the presence or absence of glucose or the various phosphorylated metabolites, but the HPr(S46D) mutant protein promoted regulation, even in the absence of glucose or a metabolite, and HPr(H15A) was more effective than the wildtype protein in promoting regulation. Intravesicular wild-type and H15A HPrs, but not the S46A or S46D mutant proteins, were found to be phosphorylated by ATP under the conditions which promoted TMG efflux. In toluenized vesicles, the conditions which promoted TMG efflux also promoted TMG-P hydrolysis. These results establish for the first time that HPr serine phosphorylation by the ATP dependent metabolite activated HPr kinase regulates the expulsion of intracellular sugar-phosphate as well as the uptake of sugar via the PTS in L. lactis.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702, R01AI014176] Funding Source: NIH RePORTER; NIAID NIH HHS [2RO1AI 14176, 5RO1AI 21702] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEUTSCHER J, 1984, BIOCHEMISTRY-US, V23, P4455, DOI 10.1021/bi00314a033; DEUTSCHER J, 1986, BIOCHEMISTRY-US, V25, P6543, DOI 10.1021/bi00369a031; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1984, FEMS MICROBIOL LETT, V23, P157; DEUTSCHER J, 1985, J BACTERIOL, V163, P1203, DOI 10.1128/JB.163.3.1203-1209.1985; HOISCHEN C, 1993, IN PRESS J BACTERIOL; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1968, J BIOL CHEM, V243, P3711; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER F, 1993, FEMS MICROBIOL LETT, V104, P327; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1993, J CELL BIOCHEM, V51, P19, DOI 10.1002/jcb.240510105; REIZER J, 1980, P NATL ACAD SCI-BIOL, V77, P5497, DOI 10.1073/pnas.77.9.5497; REIZER J, 1983, J BACTERIOL, V156, P354, DOI 10.1128/JB.156.1.354-361.1983; REIZER J, 1988, P NATL ACAD SCI USA, V85, P2041, DOI 10.1073/pnas.85.7.2041; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; REIZER J, 1985, TRENDS BIOCHEM SCI, V10, P32, DOI 10.1016/0968-0004(85)90014-3; REIZER J, 1983, J BACTERIOL, V156, P236, DOI 10.1128/JB.156.1.236-242.1983; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; ROMANO AH, 1987, J BACTERIOL, V169, P5589, DOI 10.1128/jb.169.12.5589-5596.1987; SAIER MH, 1989, RES MICROBIOL, V140, P349, DOI 10.1016/0923-2508(89)90010-7; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1976, J BIOL CHEM, V251, P6606; SAIER MH, 1985, MECHANISMS REGULATIO; SAIER MH, 1992, ADENINE NUCLEOTIDES, P181; SUTRINA SL, 1988, J BACTERIOL, V170, P1874, DOI 10.1128/jb.170.4.1874-1877.1988; THOMPSON J, 1981, J BACTERIOL, V146, P885, DOI 10.1128/JB.146.3.885-894.1981; THOMPSON J, 1983, J BACTERIOL, V156, P70, DOI 10.1128/JB.156.1.70-80.1983; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; YE JJ, 1994, IN PRESS P NATL ACAD	34	64	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11837	11844						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163482				2022-12-27	WOS:A1994NG37700028
J	TAKASE, K; KAKINUMA, S; YAMATO, I; KONISHI, K; IGARASHI, K; KAKINUMA, Y				TAKASE, K; KAKINUMA, S; YAMATO, I; KONISHI, K; IGARASHI, K; KAKINUMA, Y			SEQUENCING AND CHARACTERIZATION OF THE NTP GENE-CLUSTER FOR VACUOLAR-TYPE NA+-TRANSLOCATING ATPASE OF ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND ATPASE; VESICLE PROTON PUMP; ION MOTIVE ATPASES; H+-ATPASE; STREPTOCOCCUS-FAECALIS; SULFOLOBUS-ACIDOCALDARIUS; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; SACCHAROMYCES-CEREVISIAE; METHANOSARCINA-BARKERI; ALPHA-SUBUNIT	We have previously reported the DNA and amino acid sequences for the three genes (ntpA, ntpB, and ntpK) encoding the A, B, and K (proteolipid) subunits, respectively, of Na+-translocating ATPase of a eubacterium Enterococcus hirae (Kakinuma, Y., Kakinuma, S., Takase, K., Konishi, K., Igarashi, K., and Yamato, I. (1993) Biochem. Biophys. Res. Commun. 195,1063-1069). In this paper we report the entire nucleotide sequence of the ntp gene cluster coding for this multisubunit enzyme. The cluster contained eight other genes; the order of these 11 genes was ntpF, -I, -K, -E, -C, -G, -A, -B, -D, -H, and -J, encoding proteins with predicted molecular weights of 14,255, 75,619, 16,036, 22,699, 38,162, 11,409, 65,766, 51,139, 27,093, 7,164, and 48,869, respectively. The deduced amino acid sequences of these products suggested that NtpI and NtpJ are hydrophobic proteins and others are hydrophilic. The ntpI gene product, which possesses six membrane-spanning segments in its carboxyl-terminal half, resembled the 116-kDa subunit of vacuolar (V)-ATPase in clathrin-coated vesicles. In addition, the NtpE, NtpC, NtpG, and NtpD proteins resembled bovine kidney ATPase E subunit, Saccharomyces cerevisiae Vma6p, Manduca sexta V-ATPase 14-kDa subunit, and Sulfolobus acidocaldarius gamma subunit, respectively, although the similarities between their amino acid sequences were moderate. Other gene products (NtpF and NtpH) did not show significant sequence similarity to other V-ATPase subunits. Since NtpA, NtpB, and NtpK are homologous counterparts of V-ATPase, these findings suggest that the molecular architecture of E. hirae Na+-ATPase complex corresponds to the V-type H+-ATPase complex distributed in various eukaryotic endomembrane systems. The sequence of the NtpJ product was similar to those of K+ transport systems of S. cerevisiae (Trk1 and Trk2); its meaning will be discussed. This is the first demonstration of a eukaryotic V-ATPase-like Na+ pump in bacteria.	BRISTOL MEYERS SQUIBB RES INST,MEGURO KU,TOKYO 153,JAPAN; CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; TOYAMA MED & PHARMACEUT UNIV,FAC MED,DEPT BIOCHEM,TOYAMA,TOYAMA 93001,JAPAN	Chiba University; University of Toyama	TAKASE, K (corresponding author), SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,2641 YAMAZAKI,NODA,CHIBA 278,JAPAN.			Igarashi, Kazuei/0000-0003-3751-3187				ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P11006; BAUERLE C, 1993, J BIOL CHEM, V268, P12794; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BIRD CR, 1985, EMBO J, V4, P1381, DOI 10.1002/j.1460-2075.1985.tb03790.x; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; CHU CP, 1992, J BACTERIOL, V174, P1619, DOI 10.1128/jb.174.5.1619-1625.1992; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DENDA K, 1990, J BIOL CHEM, V265, P21509; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; DENDA K, 1989, J BIOL CHEM, V264, P7119; DEVOS WM, 1990, J BIOL CHEM, V265, P22554; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI K, 1989, BIOCHEM BIOPH RES CO, V162, P1585, DOI 10.1016/0006-291X(89)90856-5; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KAKINUMA Y, 1991, FEBS LETT, V292, P64, DOI 10.1016/0014-5793(91)80835-Q; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KAKINUMA Y, 1993, ALKALI CATION TRANSP, P277; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MUKOHATA Y, 1987, J BIOCHEM-TOKYO, V102, P797, DOI 10.1093/oxfordjournals.jbchem.a122118; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PADAN E, 1993, ALKALI CATION TRANSP, P3; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERIN MS, 1991, J BIOL CHEM, V266, P3877; REA PA, 1987, J BIOL CHEM, V262, P14745; SCHAFER G, 1992, ANN NY ACAD SCI, V671, P293, DOI 10.1111/j.1749-6632.1992.tb43804.x; SCHLOSSER A, 1991, J BACTERIOL, V173, P3170; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; TAKASE K, 1993, J BIOL CHEM, V268, P11610; WANG SY, 1988, J BIOL CHEM, V263, P17638; WARD JM, 1992, PLANT PHYSIOL, V99, P170, DOI 10.1104/pp.99.1.170	59	105	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11037	11044						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157629				2022-12-27	WOS:A1994NF96600014
J	NANTEL, F; MARULLO, S; KRIEF, S; STROSBERG, AD; BOUVIER, M				NANTEL, F; MARULLO, S; KRIEF, S; STROSBERG, AD; BOUVIER, M			CELL-SPECIFIC DOWN-REGULATION OF THE BETA(3)-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; BETA-3-ADRENERGIC RECEPTOR; DISTINCT PATHWAYS; ADENYLYL CYCLASE; AGONIST EXPOSURE; DESENSITIZATION; PHOSPHORYLATION; INTERNALIZATION	Previous studies have shown that beta(3) adrenergic receptors, in contrast to the beta(1) and beta(2) subtypes, do not undergo desensitization following short term activation (minutes) with agonists. Longer activation (hours) has been shown to induce desensitization of the beta(3)-adrenergic receptor in some, but not all, cases, suggesting that cell- or species-specific mechanisms may be involved. We investigated the contribution of the cell type to the pattern of beta(3)-adrenergic receptor long term desensitization by studying, in parallel, two cell lines (Chinese hamster fibroblasts and murine Ltk(-) cells) expressing the human beta(3)-adrenergic receptor. Sustained agonist-promoted down-regulation of the beta(3)-adrenergic receptor could be induced in Ltk(-) cells, whereas only a transient and weak reduction of receptor number was observed in Chinese hamster fibroblasts. The half-life of the beta(3)-adrenergic receptor was not affected by the agonist activation in either cell line, indicating that in contrast to the beta(2)-adrenergic receptor, degradation of preexisting receptor protein does not contribute to down-regulation. Sustained reduction of receptor RNA levels, monitored by reverse transcriptase polymerase chain reaction, was exclusively shown in Ltk(-) cells and probably accounted for most of the observed down-regulation. Differences in the ability of the receptor to stimulate adenylyl cyclase activity in the two cell lines may be responsible for the distinct patterns of beta(3)-adrenergic receptor down-regulation.	CNRS,UPR 0415,F-75014 PARIS,FRANCE; UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,RECH SYST NERVEUX AUTONOME GRP,MONTREAL H3C 3J7,PQ,CANADA; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montreal; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Bouvier, Michel/H-2758-2014; Marullo, Stefano/C-6142-2008	Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973; Krief, Stephane/0000-0002-5543-731X				ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BARBER R, 1992, FASEB J, V6, P78; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO EL, 1984, NEW ENGL J MED, V311, P1298, DOI 10.1056/NEJM198411153112007; CARPENE C, 1993, J PHARMACOL EXP THER, V265, P237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOSS RC, 1981, J BIOL CHEM, V256, P2281; EMORINE LJ, 1991, BIOCHEM PHARMACOL, V41, P853, DOI 10.1016/0006-2952(91)90188-B; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FREDERICH RC, 1983, J CYCLIC NUCL PROT, V9, P103; GRANNEMAN JG, 1992, J PHARMACOL EXP THER, V261, P638; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOMBURGER V, 1984, J CELL PHYSIOL, V121, P589, DOI 10.1002/jcp.1041210318; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; KRIEF S, 1994, J BIOL CHEM, V269, P6664; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LONNQVIST F, 1993, BRIT J PHARMACOL, V110, P929; MCGREGOR AM, 1990, CLIN ENDOCRINOL, V33, P683, DOI 10.1111/j.1365-2265.1990.tb03905.x; MORISHIMA I, 1980, MOL PHARMACOL, V18, P370; NANTEL F, 1993, MOL PHARMACOL, V43, P548; REVELLI JP, 1992, BIOCHEM J, V286, P743, DOI 10.1042/bj2860743; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Simon W, 1972, MATH TECHNIQUES PHYS; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; SVOBODA P, 1993, BIOCHEM J, V295, P655, DOI 10.1042/bj2950655; THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490; UNELIUS L, 1993, AM J PHYSIOL, V265, pC1340, DOI 10.1152/ajpcell.1993.265.5.C1340; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	40	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13148	13155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175742				2022-12-27	WOS:A1994NK18400018
J	JOHNSON, RP; CRAIG, SW				JOHNSON, RP; CRAIG, SW			AN INTRAMOLECULAR ASSOCIATION BETWEEN THE HEAD AND TAIL DOMAINS OF VINCULIN MODULATES TALIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Three independent lines of evidence demonstrate an interaction between the head and tail domains of vinculin. First, both the purified 30-kDa tail fragment and a fusion protein containing tail domain, vinculin residues 884-1066, protect purified 95-kDa head domain from cleavage by protease V8 in a specific, dose dependent manner. Second, direct binding studies between the 95-kDa head and the V884-1066 fusion protein and carboxyl-terminal truncations of the fusion protein indicate a tight interaction (K-d similar to 50 nM) that requires vinculin residues 1013-1043. Finally, cross-linking of vinculin demonstrates cross-linkable head tail complexes in the intact protein, which are almost exclusively intramolecular. Talin and the tail domain compete for binding to the vinculin head domain. Therefore, we propose that the loss of the intramolecular interaction of head and tail accounts for the increased affinity for talin of the head domain compared with intact vinculin. The observation that a head-tail interaction in the molecule affects the ability of vinculin to interact with another adherens junction component suggests that modulation of head-tail binding is a way to control recruitment of vinculin into an adherens junction.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041605, R56GM041605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DEPASQUALE JA, 1987, J CELL BIOL, V105, P2803, DOI 10.1083/jcb.105.6.2803; EIMER W, 1993, J MOL BIOL, V229, P146, DOI 10.1006/jmbi.1993.1014; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; GEIGER B, 1985, J CELL BIOL, V101, P1523, DOI 10.1083/jcb.101.4.1523; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GILMORE AP, 1992, J CELL SCI, V103, P719; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISENBERG G, 1982, J MOL BIOL, V158, P231, DOI 10.1016/0022-2836(82)90431-4; ITO S, 1983, J BIOL CHEM, V258, P4626; JOCKUSCH BM, 1981, COLD SPRING HARB SYM, V46, P613, DOI 10.1101/SQB.1982.046.01.057; JOHNSON R P, 1990, Journal of Cell Biology, V111, p300A; JOHNSON RP, 1992, MOL BIOL CELL, V3, pA266; KLASSE PJ, 1993, NATURE, V365, P395, DOI 10.1038/365395a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANESS PF, 1983, J BIOL CHEM, V258, P4055; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MOLONY L, 1987, J BIOL CHEM, V262, P7790; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; OHALLORAN T, 1986, METHOD ENZYMOL, V134, P69; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS M, 1993, J CELL BIOL, V121, P909, DOI 10.1083/jcb.121.4.909; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SINGER II, 1982, J CELL SCI, V56, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STRASSER P, 1993, FEBS LETT, V317, P189, DOI 10.1016/0014-5793(93)81274-4; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILLIAMS CL, 1993, J CELL BIOL, V121, P643, DOI 10.1083/jcb.121.3.643; WOODS A, 1992, J CELL SCI, V101, P277	64	201	202	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12611	12619						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175670				2022-12-27	WOS:A1994NH71600040
J	MULHERON, JG; CASANAS, SJ; ARTHUR, JM; GARNOVSKAYA, MN; GETTYS, TW; RAYMOND, JR				MULHERON, JG; CASANAS, SJ; ARTHUR, JM; GARNOVSKAYA, MN; GETTYS, TW; RAYMOND, JR			HUMAN 5-HT1A RECEPTOR EXPRESSED IN INSECT CELLS ACTIVATES ENDOGENOUS G(O)-LIKE G-PROTEIN(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Insect cell expression systems are used to characterize signaling components such as G protein-coupled receptors. As such, one must know whether endogenous G proteins couple to non-native receptors. We examined G protein linkages after infection of Sporodoptera frugiperda (Sf9) cells with a baculovirus encoding the 5-HT1A receptor. Receptor expression was confirmed by immunoblot. Some of the receptors were functional, showing guanine nucleotide-sensitive binding to the specific agonist ligand [H-3]8-hydroxy-2-(di-n-propylamino)-1,2,3,4- tetranaphthalene). Peak expression (approximate to 150 fmol/mg of membrane protein) was attained approximate to 72-96 h post-infection. 5-HT-increased covalent binding of [P-32]GTP-azidoanilide to a 40 kDa band, which was identified as a G protein by nucleotide blocking, Mg2+ dependence, and immunoblot and immunoprecipitation studies. The band comigrated with 1) pertussis toxin substrate(s), and 2) a band recognized by two G(o alpha) antisera and one common to heterotrimeric G protein alpha-subunits, but not by sera specific for G(s alpha) or G(i alpha). Labeled species could be precipitated with a G(o alpha) antiserum. 5-HT-increased labeling of the band was prevented by preincubation with pertussis toxin. These studies suggest that the 5-HT1A receptor couples effectively to native insect cell G(o) like proteins.	DUKE UNIV, MED CTR, DEPT MED NEPHROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED GASTROENTEROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, MED SERV, NEPHROL SECT, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Arthur, John/0000-0003-4342-4762; Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42486] Funding Source: Medline; NINDS NIH HHS [NS30927] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEN R, 1992, TRENDS PHARMACOL SCI, V13, P160, DOI 10.1016/0165-6147(92)90054-A; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LABRECQUE J, 1992, FEBS LETT, V304, P157, DOI 10.1016/0014-5793(92)80609-K; LAW SF, 1993, J BIOL CHEM, V268, P10721; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OKERBLOM C, 1993, BIOCHIM BIOPHYS ACTA, V1176, P269, DOI 10.1016/0167-4889(93)90055-T; PARKER EM, 1991, J BIOL CHEM, V266, P519; PROVOST NM, 1988, J BIOL CHEM, V263, P12070; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RAYMOND JR, 1989, MOL PHARMACOL, V36, P15; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RAYMOND JR, 1992, N-S ARCH PHARMACOL, V346, P127, DOI 10.1007/BF00165293; RAYMOND JR, 1993, AM J PHYSIOL, V264, pF9, DOI 10.1152/ajprenal.1993.264.1.F9; RAYMOND JR, 1992, MOL BIOL RECEPTORS C, P113; REILANDER H, 1991, FEBS LETT, V282, P441, DOI 10.1016/0014-5793(91)80532-8; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VASUDEVAN S, 1992, FEBS LETT, V311, P7, DOI 10.1016/0014-5793(92)81354-O	41	96	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12954	12962						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175713				2022-12-27	WOS:A1994NH71600088
J	SCHELLER, U; KRAFT, R; SCHRODER, KL; SCHUNCK, WH				SCHELLER, U; KRAFT, R; SCHRODER, KL; SCHUNCK, WH			GENERATION OF THE SOLUBLE AND FUNCTIONAL CYTOSOLIC DOMAIN OF MICROSOMAL CYTOCHROME-P450 52A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC PROTEOLYSIS; YEAST CANDIDA-MALTOSA; MEMBRANE TOPOLOGY; ESCHERICHIA-COLI; LODDEROMYCES ELONGISPORUS; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; INSERTION SIGNAL; PURIFICATION; EXPRESSION	The cytosolic domain of microsomal P450 52A3 (P450Cm1) was isolated as a soluble and functionally active protein. The NH2-terminal region that anchors the P450 protein to the endoplasmic reticulum was removed by sequence-specific proteolysis at a designed cleavage site. For that purpose, P450Cm1 was genetically engineered to establish at position 63-66 the sequence Ile-Glu-Gly-Arg, which is recognized by the restriction protease factor Xa. The modified P450 was produced in high yields as an integral membrane protein in Saccharomyces cerevisiae. In the microsomal fraction, it was accessible to factor Xa digestion, releasing a readily soluble, shortened P450 protein. For large scale preparation of the cytosolic domain, the modified P450Cm1 was first purified and then subjected to sequence-specific proteolysis. The highly purified Delta(1-66)P450Cm1 exhibited unchanged spectral characteristics and catalyzed the hydroxylation of n-hexadecane with 85% of the activity determined for full-length wild-type P450Cm1. The method developed for the preparation of the cytosolic domain of P450Cm1 may be more generally applicable to facilitate structure-function studies on membrane-bound P450 forms.			SCHELLER, U (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; Broach J. R., 1983, EXPT MANIPULATION GE, P83; CLARK BJ, 1992, J BIOL CHEM, V267, P24568; CULLIN C, 1992, BIOCHEM BIOPH RES CO, V184, P1490, DOI 10.1016/S0006-291X(05)80051-8; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; Higuchi R., 1989, PCR TECHNOLOGY, P61; HONECK H, 1982, BIOCHEM BIOPH RES CO, V106, P1318, DOI 10.1016/0006-291X(82)91257-8; HSU LC, 1993, J BIOL CHEM, V268, P14682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; LI YC, 1991, J BIOL CHEM, V266, P19186; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Michel H., 1991, CRYSTALLIZATION MEMB, P73; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; OMURA T, 1964, J BIOL CHEM, V239, P2370; Omura T., 1993, CYTOCHROME P 450, P1; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RIEGE P, 1981, BIOCHEM BIOPH RES CO, V98, P527, DOI 10.1016/0006-291X(81)90872-X; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SCHUNCK WH, 1989, BIOCHEM BIOPH RES CO, V161, P843, DOI 10.1016/0006-291X(89)92677-6; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TAKAGI M, 1989, AGR BIOL CHEM TOKYO, V53, P2217, DOI 10.1080/00021369.1989.10869646; VOGEL F, 1992, EUR J CELL BIOL, V57, P285; WIEDMANN B, 1993, BIOCHIM BIOPHYS ACTA, V1153, P267; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	33	34	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12779	12783						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175690				2022-12-27	WOS:A1994NH71600063
J	DECHATEAU, M; BJORCK, L				DECHATEAU, M; BJORCK, L			PROTEIN PAB, A MOSAIC ALBUMIN-BINDING BACTERIAL PROTEIN REPRESENTING THE FIRST CONTEMPORARY EXAMPLE OF MODULE SHUFFLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM ALBUMIN; IGG-BINDING; ESCHERICHIA-COLI; G-STREPTOCOCCI; GROUP-C; GENE; RECEPTORS; REGIONS; DOMAIN; MAGNUS	Some strains of the anaerobic human commensal and pathogen Peptostreptococcus magnus bind human serum albumin (HSA), whereas other strains of this species express protein L, an immunoglobulin light chain-binding surface protein. A novel HSA-binding protein called protein PAB was purified in one step from the culture supernatant of an HSA-binding strain of P. magnus by affinity chromatography on HSA-Sepharose. The apparent size of the molecule was 47 kDa on SDS-polyacrylamide gel electrophoresis. Amino acid sequence analysis of protein PAB demonstrated that the 4 NH2-terminal residues were identical to the corresponding sequence in protein L. In a polymerase chain reaction, oligonucleotides based on extragenic 5' and 3'-end sequences of the protein L gene generated a product of the expected size: 1.3 kilobase pairs. A recombinant protein with retained albumin binding capacity was expressed in Escherichia coli, and the nucleotide sequence of the protein PAB gene was determined. The structural gene is 1161 nucleotides long, corresponding to a preprotein of 387 amino acids and a molecular mass of 43,043 Da. Unlike most other Gram-positive bacterial surface proteins described, protein PAB contains no internal homologies. However, substantial homologies were found to both proteins L and G (the IgG and HSA-binding surface protein of group C and G streptococci). The derived amino acid sequence of the 135-base pair-long region homologous to protein G corresponds to the HSA-binding domain of that protein, and in protein PAB, this region is inserted between sequences showing extensive homology to COOH-terminal regions of peptostreptococcal protein L. This mosaic organization of protein PAB demonstrates that the molecule is a product of intergenic interspecies recombination of a functional domain into a common framework for peptostreptococcal surface proteins. Such an interspecies exchange of a functional protein module has previously not been described in prokaryotic cells.	LUND UNIV,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN	Lund University								AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKESSON P, 1994, IN PRESS BIOCH J; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DECHATEAU M, 1993, SCAND J IMMUNOL, V37, P399; DUNCAN KE, 1989, EVOLUTION, V43, P1585, DOI 10.1111/j.1558-5646.1989.tb02611.x; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FRICK IM, 1994, IN PRESS MOL MICROBI; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; KAO SM, 1991, J BACTERIOL, V173, P7650, DOI 10.1128/jb.173.23.7650-7664.1991; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; LAMMLER C, 1989, CAN J MICROBIOL, V35, P614; MYHRE EB, 1980, INFECT IMMUN, V27, P6, DOI 10.1128/IAI.27.1.6-14.1980; MYHRE EB, 1984, J MED MICROBIOL, V18, P189, DOI 10.1099/00222615-18-2-189; Nygren P A, 1988, J Mol Recognit, V1, P69, DOI 10.1002/jmr.300010204; OLSSON A, 1987, EUR J BIOCHEM, V168, P319, DOI 10.1111/j.1432-1033.1987.tb13423.x; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; REIS KJ, 1984, J IMMUNOL, V132, P3091; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT KH, 1990, ZBL BAKT-INT J MED M, V273, P216; SHAPIRO JA, 1989, INT REV CYTOL, V93, P25; SJOBRING U, 1992, INFECT IMMUN, V60, P3601; SJOBRING U, 1991, J BIOL CHEM, V266, P399; SJOBRING U, 1988, J IMMUNOL, V140, P1595; 1991, PROGRAM MANUAL VERSI; 1991, PROGRAM MANUAL GENET	32	69	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12147	12151						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163519				2022-12-27	WOS:A1994NG37700072
J	DECROLY, E; VANDENBRANDEN, M; RUYSSCHAERT, JM; COGNIAUX, J; JACOB, GS; HOWARD, SC; MARSHALL, G; KOMPELLI, A; BASAK, A; JEAN, F; LAZURE, C; BENJANNET, S; CHRETIEN, M; DAY, R; SEIDAH, NG				DECROLY, E; VANDENBRANDEN, M; RUYSSCHAERT, JM; COGNIAUX, J; JACOB, GS; HOWARD, SC; MARSHALL, G; KOMPELLI, A; BASAK, A; JEAN, F; LAZURE, C; BENJANNET, S; CHRETIEN, M; DAY, R; SEIDAH, NG			THE CONVERTASES FURIN AND PC1 CAN BOTH CLEAVE THE HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 ENVELOPE GLYCOPROTEIN GP160 INTO GP120 (HIV-I SU) AND GP41 (HIV-I TM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC CLEAVAGE; INFLUENZA-VIRUS; ENDOPROTEOLYTIC CLEAVAGE; MUTATIONAL ANALYSIS; HTLV-III/LAV; GENE ENCODES; PRO-PROTEIN; TYPE-1; ACTIVATION; SEQUENCE	Intracellular proteolytic processing of human immunodeficiency virus envelope glycoprotein precursor (gp160) is an essential step for virus infectivity. Northern blot analysis provided evidence that furin and PC1, but not PC2, are expressed in the CD4(+) human lymphoblastoid H9 cell line, suggesting the possible participation of these convertases in human immunodeficiency virus (HIV) gp160 proteolytic processing. Purified PC1 and furin cleaved specifically in vitro gp160 into gp120 (HIV-I SU) and gp41 (HIV-I TM). NH2-terminal sequence analysis of the produced gp41 (HIV-I TM) demonstrated that the cleavage occurred within the sequence Arg-Glu-Lys-Arg down arrow Ala-Val-Gly-Ile, which is identical to the bond cleaved in vivo. Transition state analog peptides were designed and tested in vitro for their ability to inhibit the PC1- or furin mediated gp160 cleavage. The best inhibitor was decanoyl-Arg-Lys-Arg-Arg-Psi[CH2NH]-Phe-Leu-Gly-Phe-NH2.	CLIN RES INST MONTREAL, BIOCHEM NEUROENDOCRINOL LAB, MONTREAL H2W 1R7, PQ, CANADA; CLIN RES INST MONTREAL, PEPTIDE METAB & STRUCT LAB, MONTREAL H2W 1R7, PQ, CANADA; CLIN RES INST MONTREAL, MOLEC ENDOCRINOL LAB, MONTREAL H2W 1R7, PQ, CANADA; FREE UNIV BRUSSELS, CHIM PHYS MACROMOLEC INTERFACES LAB, B-1050 BRUSSELS, BELGIUM; INST PASTEUR, B-1180 BRUSSELS, BELGIUM; MONSANTO CO, MONSANTO CORP RES, GLYCOSCI, ST LOUIS, MO 63167 USA; WASHINGTON UNIV, SCH MED, CTR MOLEC DESIGN, ST LOUIS, MO 63130 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Monsanto; Washington University (WUSTL)			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; DECROLY, Etienne/0000-0002-6046-024X; Marshall, Garland/0000-0002-3098-0332				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; FAVERO J, 1990, INT J IMMUNOPHARMACO, V12, P769, DOI 10.1016/0192-0561(90)90041-K; FENOUILLET E, 1992, VIROLOGY, V187, P825, DOI 10.1016/0042-6822(92)90487-A; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FTOUHI N, 1994, IN PRESS DNA CELL BI; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GOTOH B, 1992, J VIROL, V66, P6391, DOI 10.1128/JVI.66.11.6391-6397.1992; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KIDO H, 1993, J BIOL CHEM, V268, P13406; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, NEUROSCI LETT, V143, P143, DOI 10.1016/0304-3940(92)90252-3; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; KLENK HD, 1984, EMBO J, V3, P2911, DOI 10.1002/j.1460-2075.1984.tb02231.x; KONINGS PNM, 1993, NEUROPEPTIDES, V25, P19, DOI 10.1016/0143-4179(93)90064-H; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; MORIKAWA Y, 1993, J VIROL, V67, P3601, DOI 10.1128/JVI.67.6.3601-3604.1993; MOULARD M, 1994, FEBS LETT, V338, P281, DOI 10.1016/0014-5793(94)80284-X; ODA K, 1991, BIOCHEM BIOPH RES CO, V179, P1181, DOI 10.1016/0006-291X(91)91696-A; OWENS RJ, 1990, VIROLOGY, V179, P827, DOI 10.1016/0042-6822(90)90151-G; PAL R, 1989, P NATL ACAD SCI USA, V86, P3384, DOI 10.1073/pnas.86.9.3384; PAL R, 1988, P NATL ACAD SCI USA, V85, P9283, DOI 10.1073/pnas.85.23.9283; PHILLIPS DM, 1992, VIROLOGY, V186, P261, DOI 10.1016/0042-6822(92)90080-9; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SASAKI Y, 1987, J MED CHEM, V30, P1162, DOI 10.1021/jm00390a008; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1992, DNA CELL BIOL, V11, P283, DOI 10.1089/dna.1992.11.283; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P7101, DOI 10.1093/nar/17.17.7101; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	57	116	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12240	12247						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163529				2022-12-27	WOS:A1994NG37700086
J	ROCHE, KW; RAYMOND, LA; BLACKSTONE, C; HUGANIR, RL				ROCHE, KW; RAYMOND, LA; BLACKSTONE, C; HUGANIR, RL			TRANSMEMBRANE TOPOLOGY OF THE GLUTAMATE-RECEPTOR SUBUNIT GLUR6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NERVOUS-SYSTEM; KAINATE; DESENSITIZATION; QUISQUALATE; CHANNELS; CLONING; BRAIN; AMPA	Ionotropic glutamate receptors mediate most rapid excitatory synaptic transmission in the mammalian central nervous system. These receptors are divided into alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), kainate, and N-methyl-D-aspartate receptors based on pharmacological and electrophysiological characteristics. Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain. In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent. Examination of the sequences of AMPA and kainate receptors revealed that kainate receptors have several additional consensus sites for N-linked glycosylation; interestingly, one of these is located in the proposed major intracellular loop of the receptor subunits. To test the proposed transmembrane topology model for these receptors, we have used site-specific mutagenesis of the GluR6 subunit to remove the consensus glycosylation site located within the proposed intracellular loop. Mutagenesis of this site demonstrates that it is glycosylated in transiently transfected human embryonic kidney cells, which express functional kainate receptors. Since N-linked glycosylation has only been found to occur on extracellular domains of plasma membrane proteins, these results suggest that the proposed transmembrane topology model for the glutamate receptor subunits is incorrect. Combining these results with other recent data, we have proposed an alternative transmembrane topology model.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROL,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Roche, Katherine/W-9893-2019; Raymond, Lynn A./R-6707-2016; Raymond, Lynn A/A-6664-2010	Raymond, Lynn A./0000-0002-8610-1042; Raymond, Lynn A/0000-0002-8610-1042; Roche, Katherine/0000-0001-7282-6539	NIGMS NIH HHS [GM-07309] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLACKSTONE CD, 1992, ANN NEUROL, V31, P680, DOI 10.1002/ana.410310620; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WONG LA, 1993, MOL PHARMACOL, V44, P504	23	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11679	11682						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163463				2022-12-27	WOS:A1994NG37700002
J	ZHONG, ZY; QUON, D; HIGGINS, LS; HIGAKI, J; CORDELL, B				ZHONG, ZY; QUON, D; HIGGINS, LS; HIGAKI, J; CORDELL, B			INCREASED AMYLOID PRODUCTION FROM ABERRANT BETA-AMYLOID PRECURSOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; TERMINAL FRAGMENTS; CYSTIC-FIBROSIS; CULTURED-CELLS; PROTEASE; MUTATION; PEPTIDE; BRAIN; GENE	The 4-kDa beta-amyloid protein that forms fibrillar deposits in Alzheimer's diseased brains is derived from a large precursor, the beta-amyloid precursor protein (beta-APP). Recently, it has been reported that beta-amyloid is normally produced and secreted by cultured mammalian cells. In our studies involving recombinant expression of beta-APP, increased yields of beta-amyloid were associated with expression of aberrant beta-APP molecules. Deletion mutations within the beta-amyloid domain, incorrect beta-APP isoform expression in fibroblasts or neuronal cells, or excess amounts of beta-APP all led to increases in beta-amyloid production. Aberrant beta-APP appears to be diverted from the secretory pathway and then degraded to beta amyloid.	SCIOS NOVA INC,MT VIEW,CA 94043	Scios								BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; GABUZDA D, 1991, J ACQ IMMUN DEF SYND, V4, P34; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANN DMA, 1989, J NEUROL SCI, V89, P169, DOI 10.1016/0022-510X(89)90019-1; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MOTTE J, 1989, ACTA NEUROPATHOL, V77, P535, DOI 10.1007/BF00687256; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; ZHHONG Z, 1994, J BIOL CHEM, V269, P627	32	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12179	12184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163522				2022-12-27	WOS:A1994NG37700077
J	HAGTING, A; KUNJI, ERS; LEENHOUTS, KJ; POOLMAN, B; KONINGS, WN				HAGTING, A; KUNJI, ERS; LEENHOUTS, KJ; POOLMAN, B; KONINGS, WN			THE DIPEPTIDE AND TRIPEPTIDE TRANSPORT PROTEIN OF LACTOCOCCUS-LACTIS - A NEW-TYPE OF BACTERIAL PEPTIDE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RABBIT SMALL-INTESTINE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; SALMONELLA-TYPHIMURIUM; STREPTOCOCCUS-CREMORIS; OLIGOPEPTIDE PERMEASE; BINDING PROTEIN; GENE FUSIONS; SYSTEM	Lactococcus lactis takes up di- and tripeptides via a proton motive force-dependent carrier protein. The gene (dtpT) encoding the di-tripeptide transport protein of L. lactis was cloned by complementation of a dipeptide transport-deficient and proline auxotrophic Escherichia coli strain. Functional expression of the dipeptide transport gene was demonstrated by uptake studies of alanyl-[C-14]glutamate and other peptides in E. coli cells. The di-tripeptide transport protein catalyzes proton motive force-driven peptide uptake and dipeptide exchange activity. The nucleotide sequence of dtpT was determined and the translated sequence corresponds with a protein of 463 amino acid residues. Hydropathy profiling indicates that the protein could form 12 membrane-spanning segments with the amino and carboxyl termini at the outer surface of the membrane. A secondary structure model is presented which is substantiated by analysis of DtpT-PhoA fusion constructs. Amino acid sequence comparisons showed no significant homology with other bacterial peptide transport systems nor with any other known protein. Flanking regions of the di-tripeptide transport gene were used to delete dtpT from the chromosome of L. lactis. Genetic and biochemical characterization of this mutant indicates that DtpT is the only transport protein in L. lactis for hydrophilic di- and tripeptides.	UNIV GRONINGEN,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS; UNIV GRONINGEN,DEPT GENET,9751 NN HAREN,NETHERLANDS	University of Groningen; University of Groningen			Kunji, Edmund/AAH-2362-2020; Konings, Wilhelmus N./C-7063-2013; Poolman, Bert/D-1882-2012	Kunji, Edmund/0000-0002-0610-4500; 				ADLER HI, 1967, P NATL ACAD SCI USA, V57, P321, DOI 10.1073/pnas.57.2.321; ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; BERTELOOT A, 1981, BIOCHIM BIOPHYS ACTA, V649, P179, DOI 10.1016/0005-2736(81)90405-3; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; DANIEL H, 1992, J BIOL CHEM, V267, P9565; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRANCOIS V, 1987, GENE, V56, P99, DOI 10.1016/0378-1119(87)90162-4; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GASSON MJ, 1983, J BACTERIOL, V154, P1; GIBSON MM, 1987, MOL GEN GENET, V207, P120, DOI 10.1007/BF00331499; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; KASHIWAGI K, 1992, J BACTERIOL, V174, P4331, DOI 10.1128/JB.174.13.4331-4337.1992; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P4658; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; KRAMER W, 1990, BIOCHIM BIOPHYS ACTA, V1028, P174, DOI 10.1016/0005-2736(90)90152-E; KRAMER W, 1987, BIOCHIM BIOPHYS ACTA, V905, P65, DOI 10.1016/0005-2736(87)90009-5; KRAMER W, 1988, BIOCHEM PHARMACOL, V37, P2427, DOI 10.1016/0006-2952(88)90370-X; KUNJI ERS, 1993, J BACTERIOL, V175, P2052, DOI 10.1128/JB.175.7.2052-2059.1993; LAW BA, 1978, J GEN MICROBIOL, V105, P113, DOI 10.1099/00221287-105-1-113; Leenhouts K, 1993, PLASMIDS PRACTICAL A, P65; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; LEENHOUTS KJ, 1991, APPL ENVIRON MICROB, V57, P2562, DOI 10.1128/AEM.57.9.2562-2567.1991; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MAEGHER RB, 1977, CELL, V10, P521; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MANSON MD, 1986, NATURE, V321, P253, DOI 10.1038/321253a0; MATHIOPOULOS C, 1991, MOL MICROBIOL, V5, P1903, DOI 10.1111/j.1365-2958.1991.tb00814.x; MATTHEWS DM, 1980, CURR TOP MEMBR TRANS, V14, P331; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; OKANO T, 1986, J BIOL CHEM, V261, P14130; OLSON ER, 1991, J BACTERIOL, V173, P234, DOI 10.1128/jb.173.1.234-244.1991; Payne J. W., 1980, MICROORGANISMS NITRO, P211; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; POOLMAN B, 1987, J BACTERIOL, V169, P1460, DOI 10.1128/jb.169.4.1460-1468.1987; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SAMBROOK J, 1989, MOL CLONING LABORTOR; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMID EJ, 1989, J BACTERIOL, V171, P6135, DOI 10.1128/jb.171.11.6135-6140.1989; SMID EJ, 1989, J BACTERIOL, V171, P292, DOI 10.1128/jb.171.1.292-298.1989; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TOLNER B, 1992, MOL MICROBIOL, V6, P2845, DOI 10.1111/j.1365-2958.1992.tb01464.x; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7533; VANDEGUCHTE M, 1992, FEMS MICROBIOL LETT, V88, P73, DOI 10.1016/0378-1097(92)90685-H; VANDERVOSSEN JMBM, 1985, APPL ENVIRON MICROB, V50, P540, DOI 10.1128/AEM.50.2.540-542.1985; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VOSMAN B, 1983, J BACTERIOL, V156, P920, DOI 10.1128/JB.156.2.920-921.1983; WILSON D, 1989, BIOCHIM BIOPHYS ACTA, V986, P123, DOI 10.1016/0005-2736(89)90280-0	60	106	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11391	11399						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157671				2022-12-27	WOS:A1994NF96600063
J	LAWRENCE, JC; ZHANG, JN				LAWRENCE, JC; ZHANG, JN			CONTROL OF GLYCOGEN-SYNTHASE AND PHOSPHORYLASE BY AMYLIN IN RAT SKELETAL-MUSCLE - HORMONAL EFFECTS ON THE PHOSPHORYLATION OF PHOSPHORYLASE AND ON THE DISTRIBUTION OF PHOSPHATE IN THE SYNTHASE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; EPITROCHLEARIS MUSCLES; MOLECULAR MECHANISM; INSULIN RESISTANCE; SEQUENCE-ANALYSIS; SOLEUS MUSCLE; INVIVO; GLUCOSE; INVITRO; METABOLISM	The effects of amylin and insulin on the phosphorylation of glycogen synthase and phosphorylase were investigated using rat diaphragms incubated with P-32i. Muscles were incubated with insulin (200 nM) or amylin (200 nM) for 30 min before extracts were prepared. The P-32 contents of the enzymes were determined after immunoprecipitation and SDS-polyacrylamide gel electrophoresis. Amylin increased both the activity ratio (-AMP/+AMP) and the P-32 content of phosphorylase by approximately 2-fold. Insulin alone was without significant effect on phosphorylase, but insulin blocked the effect of amylin on increasing the phosphorylation of phosphorylase. Insulin increased the glycogen synthase activity ratio (low glucose-6-P/high glucose-6-P) by approximately 80%. Amylin decreased this ratio from 0.14 to 0.08 and increased the phosphorylation of synthase by approximately 40%. To investigate changes in phosphorylation of different sites in the synthase, the enzyme was subjected to exhaustive proteolysis with trypsin, and P-32-labeled fragments were separated by reverse phase high performance liquid chromatography. Insulin decreased the P-32 contents of sites 3(a + b + c) and 2(a + b), which appears to account for the increase in synthase activity. Amylin increased phosphorylation of sites 1a, 1b, and 3(a + b + c), but not sites 2(a + b). With insulin plus amylin, phosphorylation of none of the sites was significantly changed. The results indicate that the effects of amylin on glycogen synthase must involve more than activation of cAMP-dependent protein kinase, as this kinase phosphorylates site 2 and does not phosphorylate sites 3(a + b + c).			LAWRENCE, JC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.				NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; Cohen P., 1986, ENZYMES, VXVII, P461; Cooper G J, 1989, Prog Growth Factor Res, V1, P99, DOI 10.1016/0955-2235(89)90004-5; CRYER PE, 1993, AM J PHYSIOL, V264, pE149, DOI 10.1152/ajpendo.1993.264.2.E149; DANIEL PM, 1975, J PHYSIOL-LONDON, V247, P273, DOI 10.1113/jphysiol.1975.sp010931; DEEMS RO, 1991, BIOCHEM BIOPH RES CO, V174, P716, DOI 10.1016/0006-291X(91)91476-S; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fischer E. H., 1971, CURR TOP CELL REGUL, V4, P211; FRONTONI S, 1991, DIABETES, V40, P568, DOI 10.2337/diabetes.40.5.568; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1321, DOI 10.1152/physrev.1984.64.4.1321; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; Goldberg A L, 1975, Methods Enzymol, V39, P82; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JASPERS SR, 1989, ARCH BIOCHEM BIOPHYS, V268, P630, DOI 10.1016/0003-9861(89)90330-5; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KREUTTER DK, 1993, AM J PHYSIOL, V264, pE606, DOI 10.1152/ajpendo.1993.264.4.E606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEIGHTON B, 1990, BIOCHEM J, V269, P19, DOI 10.1042/bj2690019; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LUSKEY KL, 1992, DIABETES CARE, V15, P297, DOI 10.2337/diacare.15.2.297; MAYER SE, 1970, J BIOL CHEM, V245, P3153; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PICTON C, 1982, EUR J BIOCHEM, V124, P37, DOI 10.1111/j.1432-1033.1982.tb05903.x; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; RINK TJ, 1993, TRENDS PHARMACOL SCI, V14, P113, DOI 10.1016/0165-6147(93)90081-T; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROACH PJ, 1993, FASEB J, V7, pA1161; SHEORAIN VS, 1985, J BIOL CHEM, V260, P1567; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1988, J BIOL CHEM, V263, P658; SMITH RL, 1985, J BIOL CHEM, V260, P273; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; WANG YH, 1993, J BIOL CHEM, V268, P23876; YOUNG AA, 1992, AM J PHYSIOL, V263, pE274, DOI 10.1152/ajpendo.1992.263.2.E274; YOUNG AA, 1991, FEBS LETT, V281, P149, DOI 10.1016/0014-5793(91)80380-L; YOUNG DA, 1990, AM J PHYSIOL, V259, pE457, DOI 10.1152/ajpendo.1990.259.3.E457; ZHANG JN, 1989, J BIOL CHEM, V264, P17513	51	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11595	11600						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157693				2022-12-27	WOS:A1994NF96600092
J	MEEZAN, E; ANANTH, S; MANZELLA, S; CAMPBELL, P; SIEGAL, S; PILLION, DJ; RODEN, L				MEEZAN, E; ANANTH, S; MANZELLA, S; CAMPBELL, P; SIEGAL, S; PILLION, DJ; RODEN, L			XYLOSYL TRANSFER TO AN ENDOGENOUS RENAL ACCEPTOR - CHARACTERISTICS OF THE REACTION AND PROPERTIES OF THE PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; BETA-D-XYLOSYLTRANSFERASE; ALPHA-GLUCAN SYNTHESIS; UDP-D-XYLOSE; GLYCOGEN BIOSYNTHESIS; PROTEIN PRIMER; POSSIBLE INTERMEDIATE; RAT-HEART; INITIATION; PROTEOGLYCANS	In the course of a study of UDP-xylose:proteoglycan core protein xylosyltransferase (EC 2.4.2.26), another xylosyltransferase was discovered in the soluble fraction of a rat kidney homogenate. The latter enzyme catalyzed [H-3]xylosyl transfer from UDP-[H-3]xylose to an endogenous acceptor and yielded a product in which the xylose was bound by an alkali-stable linkage. It was therefore concluded that the acceptor was not the core protein of one of the proteoglycans containing a xylose --> serine linkage, since this linkage is cleaved by alkali. The [H-3]xylose-labeled product emerged with the void volume when chromatographed on Sephadex G-50, it was precipitated by trichloroacetic acid, and it had a mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis corresponding to a molecular mass of about 32,000 Da. Digestion with trypsin or alpha-amylase degraded the labeled product to small fragments, as determined by gel chromatography, suggesting that it was a glycoprotein related to glycogen. A product of similar characteristics was formed when UDP-[H-3]glucose was substituted for UDP-[H-3]xylose as the glycosyl donor, and the two nucleotide sugars were mutually competitive in the respective transfer reactions, indicating that they were substrates for the same enzyme. On the basis of these findings, it was tentatively concluded that the xylosyltransferase and its acceptor were the renal form of glycogenin.	UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	MEEZAN, E (corresponding author), UNIV ALABAMA,DEPT PHARMACOL,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027353] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 08252] Funding Source: Medline; NIDDK NIH HHS [DK 39877] Funding Source: Medline; NINDS NIH HHS [NS 27353] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AON MA, 1984, EUR J BIOCHEM, V140, P557, DOI 10.1111/j.1432-1033.1984.tb08138.x; BARENGO R, 1978, BIOCHIM BIOPHYS ACTA, V540, P190, DOI 10.1016/0304-4165(78)90131-9; BARENGO R, 1975, FEBS LETT, V53, P274, DOI 10.1016/0014-5793(75)80035-4; BARTLEY W, 1968, ANAL BIOCHEM, V25, P99, DOI 10.1016/0003-2697(68)90084-5; BLUMENFELD ML, 1985, J BIOL CHEM, V260, P1560; BLUMENFELD ML, 1983, EUR J BIOCHEM, V135, P175, DOI 10.1111/j.1432-1033.1983.tb07634.x; BORDER WA, 1989, SEMIN NEPHROL, V9, P307; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CAMPBELL P, 1984, ANAL BIOCHEM, V137, P505, DOI 10.1016/0003-2697(84)90119-2; FARQUHAR MG, 1985, NEPHROLOGY, V1, P580; FONTANA JD, 1978, BIOCHIM BIOPHYS ACTA, V540, P183, DOI 10.1016/0304-4165(78)90130-7; GREBNER EE, 1966, BIOCHEM BIOPH RES CO, V22, P672, DOI 10.1016/0006-291X(66)90199-9; GREBNER EE, 1966, ARCH BIOCHEM BIOPHYS, V116, P391, DOI 10.1016/0003-9861(66)90045-2; KANWAR YS, 1985, SEMIN NEPHROL, V5, P307; KIMURA JH, 1978, ARCH BIOCHEM BIOPHYS, V191, P687, DOI 10.1016/0003-9861(78)90408-3; KLEIN DJ, 1990, J BIOL CHEM, V265, P9533; KLINGER M, 1986, FASEB J, V45, P1845; KOBAYASHI S, 1983, J BIOL CHEM, V258, P2051; KRISMAN CR, 1973, ANN NY ACAD SCI, V210, P81, DOI 10.1111/j.1749-6632.1973.tb47563.x; KRISMAN CR, 1972, BIOCHEM BIOPH RES CO, V46, P1206, DOI 10.1016/S0006-291X(72)80103-7; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MORENO S, 1987, EUR J BIOCHEM, V162, P609, DOI 10.1111/j.1432-1033.1987.tb10682.x; MORENO S, 1986, EUR J BIOCHEM, V157, P539, DOI 10.1111/j.1432-1033.1986.tb09700.x; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; QUENTMEIER H, 1987, PLANTA, V171, P483, DOI 10.1007/BF00392295; ROBINSON HC, 1966, P NATL ACAD SCI USA, V56, P1859, DOI 10.1073/pnas.56.6.1859; RODEN L, 1985, FED PROC, V44, P373; RODEN L, 1994, J BIOL CHEM, V269, P11509; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; RODRIGUEZ IR, 1986, ICSU SHORT REP, V4, P96; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCHMIDT DD, 1977, NATURWISSENSCHAFTEN, V64, P535, DOI 10.1007/BF00483561; SCHWARTZ NB, 1975, ARCH BIOCHEM BIOPHYS, V171, P136, DOI 10.1016/0003-9861(75)90016-8; SCHWARTZ NB, 1974, CARBOHYD RES, V37, P167, DOI 10.1016/S0008-6215(00)87072-X; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; SMYTHE C, 1990, EUR J BIOCHEM, V289, P199; STOW JL, 1983, ARCH BIOCHEM BIOPHYS, V225, P950, DOI 10.1016/0003-9861(83)90110-8; WHELAN WJ, 1976, TRENDS BIOCHEM SCI, V1, P13, DOI 10.1016/0968-0004(76)90257-7; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	47	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11503	11508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157679				2022-12-27	WOS:A1994NF96600078
J	ROSENTHAL, JA; HSU, SH; SCHNEIDER, D; GENTILE, LN; MESSIER, NJ; VASLET, CA; HAWROT, E				ROSENTHAL, JA; HSU, SH; SCHNEIDER, D; GENTILE, LN; MESSIER, NJ; VASLET, CA; HAWROT, E			FUNCTIONAL EXPRESSION AND SITE-DIRECTED MUTAGENESIS OF A SYNTHETIC GENE FOR ALPHA-BUNGAROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SNAKE; NEUROTOXIN; PROTEIN; SEQUENCE; BINDING; RESOLUTION	In order to explore the structure-function relationships of the curaremimetic alpha-neurotoxins we have constructed and cloned a synthetic gene for Bungarus multicinctus alpha-bungarotoxin which is expressed in Escherichia coli. The recombinant alpha-bungarotoxin is expressed as a fusion protein with alpha-bungarotoxin linked to the COOH-terminal end of the T7 Gene 9-encoded coat protein. After treatment of the fusion protein with Factor Xa protease, a recombinant alpha-bungarotoxin is released that co-migrates with authentic alpha-bungarotoxin upon reverse-phase high performance liquid chromatography and ion-exchange chromatography. Final yields of active recombinant alpha-bungarotoxin were about 0.4 mg/liter of starting bacterial culture. The recombinant alpha-bungarotoxin contains 10 additional residues linked to the NH2-terminal Ile of the alpha-bungarotoxin sequence due apparently to the inaccessibility of the engineered cleavage site to Factor Xa. Nevertheless, the recombinant alpha-bungarotoxin is capable of binding to the nicotinic acetylcholine receptor with an apparent affinity that is only decreased approximately 1.7-fold from that of authentic alpha-bungarotoxin. Alanine substitution of a residue, Asp30, highly conserved among alpha-neurotoxins and previously suggested to play a key role in receptor recognition, resulted in a recombinant alpha-bungarotoxin whose receptor binding activity is indistinguishable from authentic alpha-bungarotoxin.	BROWN UNIV, DIV BIOL & MED, MOLEC & BIOCHEM PHARMACOL SECT, PROVIDENCE, RI 02912 USA	Brown University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629, T32GM007601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07601, GM32629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1982, ACTA CRYSTALLOGR A, V38, P186, DOI 10.1107/S0567739482000436; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; CHANG CC, 1971, BIOCHIM BIOPHYS ACTA, V251, P334, DOI 10.1016/0005-2795(71)90120-6; CHANGEUX JP, 1992, TRENDS PHARMACOL SCI, V13, P299, DOI 10.1016/0165-6147(92)90094-M; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P65; CORRAN PH, 1989, HPLC MACROMOLECULES, P127; CZAJKOWSKI C, 1989, ARCH BIOCHEM BIOPHYS, V272, P412, DOI 10.1016/0003-9861(89)90235-X; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; FIORDALISI JJ, 1991, BIOCHEMISTRY-US, V30, P10337, DOI 10.1021/bi00106a035; FIORDALISI JJ, 1992, PROTEIN EXPRES PURIF, V3, P282, DOI 10.1016/1046-5928(92)90002-E; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; KOSEN PA, 1988, BIOCHEMISTRY-US, V27, P2775, DOI 10.1021/bi00408a018; LENTZ TL, 1991, BIOCHEMISTRY-US, V30, P10949, DOI 10.1021/bi00109a020; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1979, SNAKE VENOMS, P213; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; PILLET L, 1993, J BIOL CHEM, V268, P909; SEELY PJ, 1991, PROTEIN REFOLDING, P206; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSERNOGLOU D, 1978, MOL PHARMACOL, V14, P710; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3	36	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11178	11185						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157645				2022-12-27	WOS:A1994NF96600033
J	CORIN, SJ; JUHASZ, O; ZHU, L; CONLEY, P; KEDES, L; WADE, R				CORIN, SJ; JUHASZ, O; ZHU, L; CONLEY, P; KEDES, L; WADE, R			STRUCTURE AND EXPRESSION OF THE HUMAN SLOW-TWITCH SKELETAL-MUSCLE TROPONIN-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTORS; MESSENGER-RNA; CDNA CLONE; ACTIN GENE; PROMOTER; SEQUENCE; UPSTREAM; ENHANCER; ELEMENTS	The contractile protein troponin I is encoded by a multigene family whose members are expressed differentially in various classes of muscle fibers. In vertebrates, the ''slow'' isoform of troponin I is expressed during early heart and skeletal muscle development but is restricted to slow twitch skeletal muscle in the adult. This diverse expression pattern offers an opportunity to study the regulation of a single gene within different developmental contexts. To initiate such studies, we have cloned the gene encoding the human slow twitch skeletal muscle isoform of troponin I and have identified 5'-flanking sequences required for its expression in skeletal muscle cells. The slow troponin I gene spans 12.5 kilobases and is divided into nine exons. In contrast to many muscle-specific genes, the troponin I promoter does not contain consensus CCAAT or TATA elements. Moreover, the sequence from -9 to +11 resembles an ''initiator element'' previously shown to direct transcription of some tissue-specific genes lacking TATA boxes (Smale, S. T, and Baltimore, D. (1989) Cell 57, 103-113; Brand, N. J., Petkovich, M., and Ghambon, P. (1990) Nucleic Acids Res. 18, 6799-6806; Weis, L., and Reinberg, D. (1992) FASEB J. 6, 3300-3309). A transcriptional fusion construct, comprising 4.2 kilobases of troponin I 5'-flanking DNA linked to the bacterial chloramphenicol acetyltransferase gene, exhibited cell type-specific and developmentally regulated expression. A muscle-specific enhancer regulated slow troponin I promoter activity.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOLEC & CELLULAR BIOL,BALTIMORE,MD 21201; COR THERAPEUT,S SAN FRANCISCO,CA 94080; UNIV SO CALIF,SCH MED,INST MED GENET,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Southern California; University of Southern California; University of Southern California								ARNOTT S, 1980, NATURE, V283, P743, DOI 10.1038/283743a0; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; GREENE JM, 1989, CURRENT PROTOCOLS MO, V1; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HEILIG JS, 1989, CURRENT PROTOCOLS MO, V1; INNIS MA, 1990, PCR PROTOCOLS; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, V1; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LAMINS L, 1982, P NATL ACAD SCI USA, V79, P6453; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SASSONECORSI P, 1985, NATURE, V313, P458, DOI 10.1038/313458a0; SCHIAFFINO S, 1993, TRENDS CARDIOVAS MED, V3, P12, DOI 10.1016/1050-1738(93)90022-X; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	47	67	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10651	10659						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144655				2022-12-27	WOS:A1994NF01700070
J	MORII, H; KOGA, Y				MORII, H; KOGA, Y			ASYMMETRICAL TOPOLOGY OF DIETHER-TYPE AND TETRAETHER-TYPE POLAR LIPIDS IN MEMBRANES OF METHANOBACTERIUM-THERMOAUTOTROPHICUM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHER LIPIDS; ARCHAEBACTERIUM; PHOSPHOLIPIDS; PSEUDOMUREIN; PURIFICATION; WOLFEI; ACID	We investigated the distribution of diether polar lipids between the inner and outer leaflets of the membrane of Methanobacterium thermoautotrophicum comparing the orientation of tetraether polar lipids, which constitute a monolayer in the same membrane. Three kinds of reactions were employed for intact cells or protoplasts and unsealed membrane fragments prepared from the organism: glycosidase digestion for glycolipids, NaIO4 oxidation for glycolipids and inositol lipids, and trinitrophenylation for aminophospholipids. The results indicated that (a) most gentiobiose residues of both diether and tetraether polar lipids were exposed on the outside of the cells; (b) serine and inositol residues of both diether and tetraether polar lipids were mainly oriented to the cytoplasmic surface of the membrane; and (c) approximately 80% of archaetidylethanolamine (diether type) was distributed in the outer leaflet of the membrane bilayer, while only 25% of the ethanolamine residue of gentiobiosyl caldarchaetidylethanolamine (tetraether type) was oriented to the outer surface of the membrane. These results, except for ethanolamine lipids, are consistent with the hypothesis that the tetraether polar lipids are synthesized from the corresponding diether polar lipid precursors that have been already substituted by polar groups in the membrane by head-to-head condensation without rearrangement of lipids.	UNIV OCCUPAT & ENVIRONM HLTH,DEPT CHEM,YAHATANISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Occupational & Environmental Health - Japan								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BISHOP DG, 1977, EUR J BIOCHEM, V80, P381, DOI 10.1111/j.1432-1033.1977.tb11893.x; DEMANT EJF, 1979, EUR J BIOCHEM, V95, P613, DOI 10.1111/j.1432-1033.1979.tb13002.x; DEROSA M, 1983, J MEMBRANE SCI, V16, P287, DOI 10.1016/S0376-7388(00)81316-2; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELFERINK MGL, 1992, J BIOL CHEM, V267, P1375; FUHRHOP JH, 1986, SYST APPL MICROBIOL, V7, P272; GASCARD P, 1991, BIOCHIM BIOPHYS ACTA, V1069, P27, DOI 10.1016/0005-2736(91)90100-M; KIENER A, 1987, J BACTERIOL, V169, P1010, DOI 10.1128/jb.169.3.1010-1016.1987; KONIG H, 1983, H-S Z PHYSIOL CHEM, V364, P627, DOI 10.1515/bchm2.1983.364.1.627; Langworthy T.A., 1985, BACTERIA, V8, P459; LO SL, 1990, BIOCHEM BIOPH RES CO, V167, P238, DOI 10.1016/0006-291X(90)91756-I; MORII H, 1993, FEMS MICROBIOL LETT, V109, P283, DOI 10.1111/j.1574-6968.1993.tb06182.x; MORII H, 1992, J FERMENT BIOENG, V73, P6, DOI 10.1016/0922-338X(92)90222-G; MORII H, 1988, AGR BIOL CHEM TOKYO, V52, P3149, DOI 10.1080/00021369.1988.10869195; NISHIHARA M, 1989, BIOCHEMISTRY-US, V28, P95, DOI 10.1021/bi00427a014; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P1007, DOI 10.1093/oxfordjournals.jbchem.a121942; NISHIHARA M, 1988, J LIPID RES, V29, P384; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P997, DOI 10.1093/oxfordjournals.jbchem.a121969; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PATON JC, 1978, J BACTERIOL, V135, P393, DOI 10.1128/JB.135.2.393-401.1978; ROTHMAN JE, 1977, J MOL BIOL, V110, P603, DOI 10.1016/S0022-2836(77)80114-9	22	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10492	10497						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144633				2022-12-27	WOS:A1994NF01700047
J	SHAINSKAYA, A; KARLISH, SJD				SHAINSKAYA, A; KARLISH, SJD			EVIDENCE THAT THE CATION OCCLUSION DOMAIN OF NA/K-ATPASE CONSISTS OF A COMPLEX OF MEMBRANE-SPANNING SEGMENTS - ANALYSIS OF LIMIT MEMBRANE-EMBEDDED TRYPTIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAIN; PLASMA-MEMBRANE; ALPHA-SUBUNITS; RAPID RELEASE; RB+-OCCLUSION; BETA-SUBUNIT; NA+,K+-ATPASE	Digestion of renal Na/K-ATPase with trypsin, in the presence of rubidium and absence of calcium ions, produces so called ''19-kDa membranes,'' containing a C-terminal 19-kDa and smaller fragments (8-12 kDa) of the alpha chain, and a beta chain either intact or split into two fragments (Karlish, S. J. D., Goldshleger, R., and Stein, W. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4566-4570). Cation occlusion is intact. The cation sites are thought to be located within trans-membrane segments, but the identity and number of segments involved is unknown. Analysis of Ca2+-induced sensitization of 19-kDa membranes to proteolysis, and characterization of the limit membrane-embedded fragments, has provided some insight into this question. Calcium ions have been shown to compete with two rubidium ions for occlusion sites on 19-kDa membranes, with a high affinity (K-D approximate to 2.8 mu M, pH 7.5, 20 degrees C). The kinetics of displacement of rubidium by calcium ions indicate that competition is direct and is not an allosteric antagonism. At 37 degrees C, reversible displacement of rubidium ions by calcium ions is followed by an irreversible thermal inactivation of rubidium occlusion. Calcium ions partially protect rubidium occlusion sites against modification by the carboxyl reagent, N,N'-dicyclohexylcarbodiimide. We propose that calcium ions, like rubidium ions, recognize carboxyl groups at the entrance to the cation sites, but the calcium ions do not become occluded and thus fail to protect 19-kDa membranes against further proteolysis or thermal inactivation. Upon displacement of occluded rubidium, trypsin digests the Ca2+-bound and thermally inactivated 19-kDa membranes, and all of the membrane-embedded fragments are truncated or are split in these conditions. A related finding is that the C-terminal sequence of the 19-kDa fragment (and alpha chain), E-T-Y-Y, is digested by carboxypeptidase Y only when the rubidium occlusion is inactivated. Identification of the limit tryptic fragments indicates that polypeptide loops and the C-terminal tail of the 19-kDa fragment, N and C termini of the smaller fragments of the alpha chain, and both N and C termini of a 16-kDa fragment of the beta chain are split by proteolytic enzymes upon displacement of occluded rubidium. We conclude that all fragments of 19-kDa membranes form a complex, which is stabilized and protected against proteolytic enzymes upon occlusion of rubidium ions, and which relaxes upon displacement of occluded rubidium. The cation occlusion ''cage'' presumably consists of ligating groups from several trans-membrane segments. The interactions between the rubidium occlusion sites and protected segments of the protein are necessarily reciprocal, and so they must also affect properties of rubidium occlusion. These interactions may be either direct or indirect such as those between the 16-kDa fragment of the beta chain and occlusion sites within transmembrane segments of the alpha chain. The arrangement of the limit tryptic fragments in the membrane is discussed within the framework of possible topological models. The results are suggestive of a 10-segment model of the alpha chain but do not exclude certain 8-segment models.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science					NIGMS NIH HHS [GM32286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DAVID P, 1991, J BIOL CHEM, V266, P14896; DAVID P, 1992, J BIOL CHEM, V267, P1141; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P433; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1988, J BIOL CHEM, V263, P7970; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GOLDSHLEGER R, 1993, 7TH P INT C SOD PUMP; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HENAO F, 1992, J BIOL CHEM, V267, P10302; JAISSER F, 1992, J BIOL CHEM, V267, P16895; Jorgensen P L, 1974, Methods Enzymol, V32, P277; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; OR E, 1993, J BIOL CHEM, V268, P16929; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VASSALO PM, 1986, J BIOL CHEM, V261, P16957	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10780	10789						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144667				2022-12-27	WOS:A1994NF01700089
J	FINAZZI, D; CASSEL, D; DONALDSON, JG; KLAUSNER, RD				FINAZZI, D; CASSEL, D; DONALDSON, JG; KLAUSNER, RD			ALUMINUM FLUORIDE ACTS ON THE REVERSIBILITY OF ARF1-DEPENDENT COAT PROTEIN-BINDING TO GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; TRIMERIC-G-PROTEINS; BREFELDIN-A; GUANINE-NUCLEOTIDE; BETA-COP; GTP; TRANSPORT; VESICLES; ARF; RECONSTITUTION	The GTP dependent interaction of ADP ribosylation factor 1 (ARF1) with Golgi membranes is required for the binding of cytosolic coatomer proteins to those membranes. Whereas both GTP and GTP gamma S can support coatomer binding to membranes, by using partially purified components, GTP driven binding is rapidly reversible (t(1/2) of 2 min) while that driven by GTP gamma S is more stable (t(1/2) of over 30 min). In the presence of GTP, aluminum fluoride, an activator of trimeric G proteins, promotes the stable ARF-dependent binding of coatomer to membranes, even though this reagent does not itself activate ARF. Aluminum fluoride appears to act, like GTP gamma S, to make the binding of coatomer relatively irreversible. It acts to inhibit ARF-GTP hydrolysis catalyzed by the membrane and thus makes the ARF-GTP active state persistent. This effect is not dependent on the presence of any cytosolic component, such as the coatomer. The number of molecules of ARF that can be protected from hydrolysis by aluminum fluoride, however, is only a fraction of the total amount of ARF that can bind to membranes in the presence of GTP gamma S. We propose that this population defines a set of binding sites that are sufficient for coat protein assembly onto the membrane.	NIH,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; Technion Israel Institute of Technology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			finazzi, dario/GYV-1567-2022	Finazzi, Dario/0000-0001-5176-2839				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CHABRE M, 1990, TRENDS BIOCHEM SCI, V1, P6; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WEISS O, 1989, J BIOL CHEM, V264, P21066; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	41	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13325	13330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175763				2022-12-27	WOS:A1994NK18400043
J	CARRERAS, CW; COSTI, PM; SANTI, DV				CARRERAS, CW; COSTI, PM; SANTI, DV			HETERODIMERIC THYMIDYLATE SYNTHESES WITH C-TERMINAL DELETION ON ONE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE; SYNTHETASE; MUTANTS; BINDING	We have combined site directed mutagenesis with the technique of reversible unfolding and subunit dissociation to construct heterodimeric thymidylate syntheses that lack the C-terminal valine from only one subunit of the dimer. Removal of this residue either from both subunits of the dimer by mutagenesis (V316Am mutation) or from only one subunit by treatment with carboxypeptidase has been reported to result in an inactive enzyme (Carreras, C. W, Climie, S. C., and Santi, D. V. (1992) Biochemistry 31, 6038-6044; Aull, J. L., Loeble, R. B., and Dunlap, R. B. (1974) J. Biol. Chem. 249, 1167-1172). Arg-178 is an essential active site residue of thymidylate synthese that is donated from the opposing subunit of the dimer. The R178F-V316Am heterodimer was formed by the unfolding and refolding of a mixture of inactive R178F and V316Am mutants. This enzyme has one intact active site and was found to have half of the activity and the same K-m values as wild-type thymidylate synthase that was unfolded and refolded as a control. We have also formed the V316Am-WT heterodimer and report that this heterodimeric enzyme is also active, has a k(cat) value that is approximately half of that of the wild-type thymidylate synthase dimer, and binds substrate and cofactor with K-m values similar to those of the wild-type enzyme.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV MODENA,DIPARTIMENTO SCI FARMACEUT,I-41100 MODENA,ITALY	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universita di Modena e Reggio Emilia			Costi, Maria Paola/F-4747-2015	Costi, Maria Paola/0000-0002-0443-5402	NATIONAL CANCER INSTITUTE [R01CA014394, R37CA014394] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AULL JL, 1974, J BIOL CHEM, V249, P1167; BRUICE TW, 1982, BIOCHEMISTRY-US, V21, P6703, DOI 10.1021/bi00269a014; CARRERAS CW, 1992, BIOCHEMISTRY-US, V31, P6038, DOI 10.1021/bi00141a012; CISNEROS RJ, 1993, J BIOL CHEM, V268, P10102; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; CLIMIE SC, 1992, BIOCHEMISTRY-US, V31, P6032, DOI 10.1021/bi00141a011; FINERMOORE J, 1993, J MOL BIOL, V232, P1101, DOI 10.1006/jmbi.1993.1463; GALIVAN J, 1977, ARCH BIOCHEM BIOPHYS, V184, P346, DOI 10.1016/0003-9861(77)90361-7; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; GREENE PJ, 1993, BIOCHEMISTRY-US, V32, P10283, DOI 10.1021/bi00090a002; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KEALEY JT, 1992, PROTEIN EXPRES PURIF, V3, P380, DOI 10.1016/S1046-5928(05)80039-7; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; PERRY KM, 1992, PROTEIN SCI, V1, P796, DOI 10.1002/pro.5560010611; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; POOKANJANATAVIP M, 1992, BIOCHEMISTRY-US, V31, P10303, DOI 10.1021/bi00157a018	18	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12444	12446						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175650				2022-12-27	WOS:A1994NH71600014
J	HAEBERLE, JR				HAEBERLE, JR			CALPONIN DECREASES THE RATE OF CROSS-BRIDGE CYCLING AND INCREASES MAXIMUM FORCE PRODUCTION BY SMOOTH-MUSCLE MYOSIN IN AN IN-VITRO MOTILITY ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Mammalian smooth muscles, like invertebrate ''catch'' muscles, dynamically regulate the rate of cross-bridge cycling. During sustained contractions, cross-bridge cycling rates may decrease severalfold, whereas tension remains elevated (''latch-state''). Physiologic studies have shown that decreased cycling rate is frequently, but not always, associated with dephosphorylation of the 20,000 dalton light chain of myosin. Tropomyosin, caldesmon, and calponin are actin binding proteins found in mammalian smooth muscles that modulate actin-activated myosin ATPase activity in vitro and may modulate cross-bridge cycling in situ. Using an in vitro motility assay in combination with a new method for estimating relative changes in the force exerted on actin filaments, the present study demonstrates that the effects of calponin on actin filament motility are: increased actin filament binding to thiophosphorylated smooth muscle myosin, decreased filament velocity from 2.0 to 0.74 mu m/s, and a 3-4-fold increase in the force exerted on stationary actin filaments. Taken together, these observations suggest that calponin inhibits the rate of dissociation of the high-affinity actomyosin complex and, consequently, that it may be an integral component of the latch-state in mammalian smooth muscles.			HAEBERLE, JR (corresponding author), UNIV VERMONT, DEPT PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28001] Funding Source: Medline; NIAMS NIH HHS [AR40259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J BIOCHEM-TOKYO, V107, P507, DOI 10.1093/oxfordjournals.jbchem.a123075; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BOREJDO J, 1992, BIOPHYS J, V61, P1267, DOI 10.1016/S0006-3495(92)81935-5; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; ENGANDER SW, 1987, ANAL BIOCHEM, V161, P300; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HAEBERLE JR, 1985, PFLUG ARCH EUR J PHY, V403, P215, DOI 10.1007/BF00584103; HAI CM, 1988, AM J PHYSIOL, V255, pC86, DOI 10.1152/ajpcell.1988.255.1.C86; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KENNEY RE, 1990, J BIOL CHEM, V265, P8642; KERRICK WGL, 1991, J MUSCLE RES CELL M, V12, P53, DOI 10.1007/BF01781174; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MIKI M, 1992, BIOCHEM BIOPH RES CO, V187, P867, DOI 10.1016/0006-291X(92)91277-W; Moreland S, 1986, PFLUEGERS ARCH, V408, P139; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SIEGMAN MJ, 1984, PFLUG ARCH EUR J PHY, V401, P385, DOI 10.1007/BF00584340; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P202, DOI 10.1073/pnas.91.1.202; VANBUREN P, 1993, BIOPHYS J, V64, pA230; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WELLS C, 1985, NATURE, V313, P696, DOI 10.1038/313696a0; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	39	121	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12424	12431						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175648				2022-12-27	WOS:A1994NH71600011
J	RAULO, E; CHERNOUSOV, MA; CAREY, DJ; NOLO, R; RAUVALA, H				RAULO, E; CHERNOUSOV, MA; CAREY, DJ; NOLO, R; RAUVALA, H			ISOLATION OF A NEURONAL CELL-SURFACE RECEPTOR OF HEPARIN-BINDING GROWTH-ASSOCIATED MOLECULE (HB-GAM) - IDENTIFICATION AS N-SYNDECAN (SYNDECAN-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								HB-GAM (heparin binding growth-associated molecule; pleiotrophin) is a secretory, extracellular matrix-associated protein that is strongly expressed in developing nervous tissues and belongs to a novel family of differentiation/growth factors. It promotes axonal growth from perinatal rat brain neurons and is suggested to be mitogenic for some cell types and to display cell-transforming activity. Since the receptors of HB-GAM in cells are unknown, we have started isolation of putative cell surface receptors from brain neurons and from perinatal rat brain. For this purpose, recombinant HB-GAM was produced with the aid of a baculovirus vector and used as an affinity matrix in receptor isolation. A detergent-solubilized component from cultured brain neurons and from brain was identified that binds specifically to HB-GAM and migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a broad smear with an apparent molecular mass of about 200 kDa. This cell surface component was found to contain heparan sulfate chains, which are bound to a core protein with an apparent molecular mass of 120 kDa. Gel electrophoretic characteristics, immunochemical analysis, and partial peptide sequencing revealed that the cell surface component isolated as an HB-GAM receptor is N-syndecan (syndecan-3). In a solid phase binding assay, N-syndecan was found to bind to HB-GAM in a similar manner as to basic fibroblast growth factor (K-D = 0.6 nM). Immunofluorescence microscopy indicated that in brain neurons, N-syndecan occurs at the surface of the cell soma and of the neurites that grow along HB-GAM-coated substrates. Anti-N-syndecan antibodies added to culture media had an inhibitory effect on HB-GAM-induced neurite outgrowth. We suggest that N-syndecan mediates the neurite outgrowth-promoting signal from HB-GAM to the cytoskeleton of growing neurites.	SIGFRIED & JANET WEIS CTR RES, DANVILLE, PA 17822 USA; UNIV HELSINKI, DEPT MED CHEM, SF-00014 HELSINKI, FINLAND	University of Helsinki	RAULO, E (corresponding author), UNIV HELSINKI, INST BIOTECHNOL, MOLEC NEUROBIOL LAB, SF-00014 HELSINKI, FINLAND.			Raulo, Erkki/0000-0001-9113-3770; Rauvala, Heikki/0000-0001-7809-9811	NINDS NIH HHS [NS21925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; FANG WJ, 1992, J BIOL CHEM, V267, P25889; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KUO MD, 1992, BIOCHEM BIOPH RES CO, V182, P188, DOI 10.1016/S0006-291X(05)80129-9; KUO MD, 1990, J BIOL CHEM, V265, P18749; LETOURNEAU PC, 1991, NERVE GROWTH CONE, P535; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VIGNY M, 1989, EUR J BIOCHEM, V186, P733, DOI 10.1111/j.1432-1033.1989.tb15267.x; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582	36	262	268	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12999	13004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175719				2022-12-27	WOS:A1994NH71600095
J	ARCIERO, DM; HOOPER, AB				ARCIERO, DM; HOOPER, AB			A DI-HEME CYTOCHROME-C PEROXIDASE FROM NITROSOMONAS-EUROPAEA CATALYTICALLY ACTIVE IN BOTH THE OXIDIZED AND HALF-REDUCED STATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; PURIFICATION PROCEDURE; COMPOUND-I; BINDING; RES; COMPLEXES; INTENSITY	A di c-heme containing cytochrome (cytochrome c(553) peroxidase) has been isolated from the chemoautotrophic bacterium Nitrosomonas europaea. Sequence analysis of the N terminus and the two heme-containing peptides generated by digestion of the enzyme with trypsin show 40% homology overall to sequences reported for the di-heme peroxidase from Pseudomonas aeruginosa (Ronnberg, M., Kalkkinen, N., and Ellfolk, N. (1989) FEBS Left. 250, 175-178). At room temperature and pH 7.0, one heme is low spin with E(m7) = +450 mV and the other is high spin with E(m7) = -260 mV. EPR spectra show a mixture of high spin and low spin signals at cryogenic temperatures. Anionic ligands (CN-, N-3(-), F-, CNO-) bind so as to perturb the high spin heme when cytochrome c(553) peroxidase is either fully oxidized (Fe-LS(3+):Fe-HS(3+)) or half-reduced (Fe-LS(2+):Fe-HS(3+)). The EPR signal of the high potential, low spin heme in fully oxidized enzyme is unperturbed by the presence of the ligands. Furthermore, each ligand results in similar characteristic EPR signals for either oxidation state of the peroxidase. Both the fully oxidized and half-reduced oxidation states of cytochrome c(553) perocatalytically active as evidenced by the enzyme's ability to oxidize horse heart cytochrome c in the presence of H2O2, as well as by optical changes associated with the addition of H2O2 to the peroxidase. In the presence of stoichiometric amounts of H2O2, the half-reduced enzyme is rapidly oxidized and the fully oxidized enzyme shows a significant decrease in absorbance in the Soret region of the optical spectrum coupled with a lesser increase near 600-650 nm. These latter optical changes are similar to what is observed in the formation of a porphyrin cation radical. This suggests that this di-heme peroxidase may form a compound I intermediate analogous to that formed by horseradish peroxidase.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities								AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; AASA R, 1984, BIOCHIM BIOPHYS ACTA, V670, P170; ARCIERO DM, 1993, J BIOL CHEM, V268, P14645; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; COLLINS MJ, 1993, J BIOL CHEM, V268, P14655; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P334; DISPIRITO AA, 1985, BIOCHIM BIOPHYS ACTA, V827, P320, DOI 10.1016/0167-4838(85)90217-1; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; ELLFOLK N, 1970, ACTA CHEM SCAND, V24, P2126, DOI 10.3891/acta.chem.scand.24-2126; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; ELSTNER EF, 1982, ANNU REV PLANT PHYS, V33, P73, DOI 10.1146/annurev.pp.33.060182.000445; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; FOOTE N, 1985, BIOCHEM J, V230, P227, DOI 10.1042/bj2300227; FOOTE N, 1983, BIOCHEM J, V209, P701, DOI 10.1042/bj2090701; GREENWOOD C, 1988, CHEM SCRIPTA, V28A, P79; HOCHMAN A, 1992, J BACTERIOL, V174, P3386, DOI 10.1128/jb.174.10.3386-3391.1992; HOLLENBERG PF, 1980, J BIOL CHEM, V255, P4801; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LOGAN MSP, 1991, THESIS U MINNESOTA; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; MIGITA CT, 1981, J AM CHEM SOC, V103, P4378, DOI 10.1021/ja00405a015; MILLER DJ, 1983, BIOCHEM J, V211, P503, DOI 10.1042/bj2110503; RONNBERG M, 1985, ARCH BIOCHEM BIOPHYS, V236, P714, DOI 10.1016/0003-9861(85)90677-0; RONNBERG M, 1981, ARCH BIOCHEM BIOPHYS, V207, P197, DOI 10.1016/0003-9861(81)90025-4; RONNBERG M, 1979, BIOCHIM BIOPHYS ACTA, V581, P325, DOI 10.1016/0005-2795(79)90252-6; RONNBERG M, 1989, FEBS LETT, V250, P175, DOI 10.1016/0014-5793(89)80714-8; SALERNO JC, 1984, J AM CHEM SOC, V106, P2156, DOI 10.1021/ja00319a041; VANELLI T, 1990, APPL ENVIRON MICROB, V56, P1169; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WEVER R, 1980, BIOCHIM BIOPHYS ACTA, V612, P178, DOI 10.1016/0005-2744(80)90291-0; YAMAZAKI T, 1986, BIOCHIM BIOPHYS ACTA, V871, P36, DOI 10.1016/0167-4838(86)90130-5; YONETANI T, 1987, J BIOL CHEM, V262, P9547	35	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11878	11886						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163487				2022-12-27	WOS:A1994NG37700034
J	SCHMIDHAUSER, TJ; LAUTER, FR; SCHUMACHER, M; ZHOU, WB; RUSSO, VEA; YANOFSKY, C				SCHMIDHAUSER, TJ; LAUTER, FR; SCHUMACHER, M; ZHOU, WB; RUSSO, VEA; YANOFSKY, C			CHARACTERIZATION OF AL-2, THE PHYTOENE SYNTHASE GENE OF NEUROSPORA-CRASSA - CLONING, SEQUENCE-ANALYSIS, AND PHOTOREGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTENOID BIOSYNTHETIC GENE; WHITE-COLLAR MUTANTS; BLUE-LIGHT; RHODOBACTER-CAPSULATUS; CONIDIATION; PRODUCTS; PROTEIN; PATHWAY; FRAGMENTS; ENCODES	We have cloned the al-2 gene of Neurospora crassa and have analyzed its structure and regulation. The gene encodes a 603-residue polypeptide with a segment homologous to prokaryotic and other eukaryotic phytoene synthases. RNA measurements showed that the level of al-2 mRNA increased over 30-fold in photoinduced mycelia compared with dark-grown mycelia. This observation is consistent with the fact that carotenoid biosynthesis is induced by blue light during growth of N. crassa mycelia. The photoinduced increase in al-2 mRNA levels was not observed in two Neurospora mutants, wc-1 and wc-2, that are defective in all physiological photoresponses.	MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Max Planck Society; Stanford University	SCHMIDHAUSER, TJ (corresponding author), SO ILLINOIS UNIV,SCH MED,CARBONDALE,IL 62901, USA.				NIGMS NIH HHS [GM-45282, GM-41296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041296, R29GM045282] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BARTLEY GE, 1992, J BIOL CHEM, V267, P5036; BARTLEY GE, 1990, J BIOL CHEM, V265, P16020; BERLIN V, 1985, MOL CELL BIOL, V5, P849, DOI 10.1128/MCB.5.4.849; BOLL W, 1986, GENE, V50, P41, DOI 10.1016/0378-1119(86)90308-2; BRAMLEY PM, 1988, CURR TOP CELL REGUL, V29, P291; BUCKLEY KJ, 1985, THESIS U CALIFORNIA; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CHAMBERS JAA, 1985, EMBO J, V4, P3649, DOI 10.1002/j.1460-2075.1985.tb04130.x; CHAMBERS JAA, 1986, FUNGAL GENET NEWSLET, V33, P22; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DEGLIINNOCENTI F, 1984, J BACTERIOL, V159, P757, DOI 10.1128/JB.159.2.757-761.1984; DEGLIINNOCENTI F, 1983, PHOTOCHEM PHOTOBIOL, V37, P49; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDIE AH, 1973, BIOCHEM GENET, V10, P275, DOI 10.1007/BF00485705; HAGER KM, 1990, GENE, V96, P153, DOI 10.1016/0378-1119(90)90247-O; HARDING RW, 1980, ANNU REV PLANT PHYS, V31, P217, DOI 10.1146/annurev.pp.31.060180.001245; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSHINO T, 1993, APPL ENVIRON MICROB, V59, P3150, DOI 10.1128/AEM.59.9.3150-3153.1993; KALDENHOFF R, 1993, CURR GENET, V24, P394, DOI 10.1007/BF00351847; LAUTER FR, 1992, GENE DEV, V6, P2373, DOI 10.1101/gad.6.12a.2373; LAUTER FR, 1993, P NATL ACAD SCI USA, V90, P8249, DOI 10.1073/pnas.90.17.8249; LAUTER FR, 1991, NUCLEIC ACIDS RES, V19, P6883, DOI 10.1093/nar/19.24.6883; LEGERTON TL, 1985, GENE, V39, P129, DOI 10.1016/0378-1119(85)90306-3; Maniatis T., 1982, MOL CLONING; MCCLUNG CR, 1992, MOL CELL BIOL, V12, P1412, DOI 10.1128/MCB.12.4.1412; Metzenberg R.L., 1993, FUNGAL GENET NEWSLET, V40, P130; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MITZKASCHNABEL U, 1981, PHYTOCHEMISTRY, V20, P63, DOI 10.1016/0031-9422(81)85220-X; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; PAYEN A, 1834, ANN CHIM PHYS, V9, P5; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; RAY J, 1987, NUCLEIC ACIDS RES, V15, P10587, DOI 10.1093/nar/15.24.10587; ROBERTS AN, 1989, NUCLEIC ACIDS RES, V17, P197, DOI 10.1093/nar/17.1.197; ROBERTS AN, 1988, MOL CELL BIOL, V8, P2411, DOI 10.1128/MCB.8.6.2411; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; SCHMIDHAUSER TJ, 1990, MOL CELL BIOL, V10, P5064, DOI 10.1128/MCB.10.10.5064; SOKOLOVSKY VY, 1992, J GEN MICROBIOL, V138, P2045, DOI 10.1099/00221287-138-10-2045; SOMMER T, 1989, NUCLEIC ACIDS RES, V17, P5713, DOI 10.1093/nar/17.14.5713; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPURGEON SL, 1979, ARCH BIOCHEM BIOPHYS, V195, P23, DOI 10.1016/0003-9861(79)90323-0; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; WENT FAF, 1904, REC TRAV BOT NEERL, V1, P106; WHITE BT, 1993, DEV BIOL, V160, P254, DOI 10.1006/dbio.1993.1303	50	105	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12060	12066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163509				2022-12-27	WOS:A1994NG37700059
J	YOKOYAMA, K; AKABANE, Y; ISHII, N; YOSHIDA, M				YOKOYAMA, K; AKABANE, Y; ISHII, N; YOSHIDA, M			ISOLATION OF PROKARYOTIC V0V1-ATPASE FROM A THERMOPHILIC EUBACTERIUM THERMUS-THERMOPHILUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; MEMBRANE-BOUND ATPASE; VESICLE PROTON PUMP; V-TYPE ATPASE; METHANOSARCINA-BARKERI; NEUROSPORA-CRASSA; PURIFICATION; SUBUNIT; RECONSTITUTION; PROTEINS	The soluble ATPase purified from an aerobic thermophilic eubacterium, Thermus thermophilus, was not a usual F-1-ATPase but a V-1-ATPase, a peripheral section of plasma membrane V-type ATPase (Yokoyama, K., Oshima, T., and Yoshida, M. (1990) J. Biol. Chem. 265, 21946-21950). Here, we report the purification of V-type ATPase from the same bacterium (V0V1-ATPase) which consists of V-1-ATPase and a membrane-integrated section, V-0. The V0V1-ATPase, either in the Triton X-100-solubilized membrane fraction or in the purified state, migrates as a single band in a non-denaturing polyacrylamide gel electrophoresis for membrane protein complexes, and eight kinds of polypeptides are found when this band is developed in a second dimension denaturing gel electrophoresis in the presence of sodium dodecyl sulfate. The 66-, 56-, 30-, and 12-kDa polypeptides are the subunits of V-1-ATPase and the 100-, 38-, 24-, and 13-kDa polypeptides are candidates for V-0 (or V-0-associated) subunits. The amino-terminal amino acid sequences of the 38- and 24-kDa subunits do not show obvious similarity to any subunits of eukaryotic V0V1-ATPases. The kinetic properties of the purified V0V1-ATPase are very similar to those of V-1-ATPase: a very low ATPase activity, stimulation by bisulfite, inhibition by nitrate, and resistance against inhibitors of eukaryotic V-type ATPases, Bafilomycin A1 and N-ethylmaleimide. The V-0 vesicles prepared from reconstituted V0V1-ATPase vesicles by 6 M urea treatment show the H+ channel activity. This H+ channel activity is abolished either by treatment of vesicles with dicyclohexylcarbodiimide or by the back addition of V-1-ATPase. These results indicate that the coupling ion of this V0V1-ATPase is H+.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 227,JAPAN; LION CORP,SURFACE SCI RES CTR,EDOGAWA KU,TOKYO 132,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	Tokyo Institute of Technology; Lion Corporation; RIKEN			Ishii, Noriyuki/E-5661-2011	Ishii, Noriyuki/0000-0002-4120-6203; Yokoyama, Ken/0000-0002-6813-1096				ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANDA K, 1988, J BIOL CHEM, V263, P17251; DENDA K, 1990, BIOENERGETICS, P341; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; HISABORI T, 1991, J BIOCHEM BIOPH METH, V22, P255; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI K, 1989, BIOCHEM BIOPH RES CO, V162, P1585, DOI 10.1016/0006-291X(89)90856-5; INATOMI K, 1993, J BACTERIOL, V175, P80, DOI 10.1128/JB.175.1.80-84.1993; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KANE PM, 1989, J BIOL CHEM, V264, P19236; KOIDE M, 1987, ANAL BIOCHEM, V164, P150, DOI 10.1016/0003-2697(87)90379-4; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; TAIZ SL, 1991, BOT ACTA, V104, P117, DOI 10.1111/j.1438-8677.1991.tb00206.x; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; XIE XS, 1986, J BIOL CHEM, V261, P2492; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	37	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12248	12253						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163530				2022-12-27	WOS:A1994NG37700087
J	YOO, SH				YOO, SH			PH-DEPENDENT INTERACTION OF CHROMOGRANIN-A WITH INTEGRAL MEMBRANE-PROTEINS OF SECRETORY VESICLE INCLUDING 260-KDA PROTEIN REACTIVE TO INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; CHROMAFFIN GRANULES; NERVOUS-TISSUE; INSP3 RECEPTOR; EXPRESSION; CA-2+; CA2+	Chromogranin A is a high capacity, low affinity Ca2+-binding protein suggested to be responsible for the Ca2+ storage function of the secretory vesicle, which has been identified as a major inositol 1,4,5-trisphosphate (IP3)-sensitive intracellular Ca2+ store of adrenal medullary chromaffin cells. Moreover, chromogranin A has recently been shown to interact with the vesicle membrane at the intravesicular pH of 5.5 and to be released from it at a near physiological pH of 7.5 (Yoo, S. H. (1993) Biochemistry 32, 8213-8219). In the present study, chromogranin A is shown to interact with several integral membrane proteins of secretory vesicles at pH 5.5 but not at pH 7.5. One of the chromogranin A-interacting membrane proteins had a mass of 260 kDa and reacted with the IP3 receptor antibody. This result suggested not only the existence of the IP3 receptor in the vesicle membrane but also the existence of direct communication between chromogranin A and the IP3 receptor. In addition, the pH-dependent interaction of chromogranin A with integral membrane proteins implies an important role for chromogranin A in the sorting process of the vesicle membrane proteins during vesicle biogenesis in the trans-Golgi network.			YOO, SH (corresponding author), NIDOCD,CELLULAR BIOL LAB,BETHESDA,MD 20892, USA.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P760; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HUTTNER WB, 1991, MARKERS NEURAL ENDOC, P93; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MATTER N, 1993, J BIOL CHEM, V268, P732; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SIMON JP, 1989, BIOCHEM J, V262, P1; SNYDER SH, 1988, CELL CALCIUM, V10, P337; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1993, FEBS LETT, V334, P373, DOI 10.1016/0014-5793(93)80715-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023	33	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12001	12006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163503				2022-12-27	WOS:A1994NG37700052
J	KIRSCH, T; WUTHIER, RE				KIRSCH, T; WUTHIER, RE			STIMULATION OF CALCIFICATION OF GROWTH-PLATE CARTILAGE MATRIX VESICLES BY BINDING TO TYPE-II AND TYPE-X COLLAGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN EPIPHYSEAL CARTILAGE; BOUND ALKALINE-PHOSPHATASE; CII ANNEXIN-V; ANCHORIN-CII; CHONDROCYTE MEMBRANES; CALCIUM CHANNELS; PROTEINS; IDENTIFICATION; ASSOCIATION; IMMUNOLOCALIZATION	Matrix vesicles (MV), microstructures which rapidly accumulate Ca2+ and induce mineral formation in vitro, are linked to type II and X collagens and proteoglycans in the hypertrophic cartilage. However, the roles of these matrix proteins on MV function are not known. This led us to investigate the influence of type II and X collagen binding on Ca2+ uptake by MV. MV isolated from chicken growth plate cartilage were treated with pure bacterial collagenase and 1 M NaCl in synthetic cartilage lymph to selectively and completely remove associated type II and X collagens. Uptake of Ca-45(2+) by these collagen-depleted vesicles was markedly reduced. Further treatment with detergent, which disrupted the membrane, restored Ca2+ uptake, indicating that the vesicle membrane structure and the nucleational core inside the vesicle lumen were still intact after the collagenase and 1 M NaCl treatments. Readdition of either native type II or X collagen to the collagenase, 1 M NaCl-treated MV stimulated their Ca2+ uptake to levels similar to those of untreated vesicles. Pepsin-treated type II and X collagens were less effective in stimulating Ca2+ uptake, indicating that non-triple helical domains of these collagens were involved. The pepsin treatment of these collagens also decreased their binding to annexin V (anchorin CII), one of three annexins found in MV, suggesting that annexin V is involved in mediating the binding of type II and X collagens to the MV surface. Furthermore, treatment of collagenase, 1 M NaCl-treated MV with chymotrypsin, which damaged annexin V as well as many other MV proteins, prevented the stimulation of Ca2+ uptake by these collagens. Thus, the interaction between type II and X collagens with MV activates the influx of Ca2+ into MV and may play an important role in calcification of the vesicles.	UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIAMS NIH HHS [AR 18193] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKISAKA T, 1988, CALCIFIED TISSUE INT, V42, P383, DOI 10.1007/BF02556357; ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Anderson H. C., 1990, PATHOLOGY REV, P13, DOI 10.1007/978-1-4612-0485-5_2; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P49, DOI 10.1016/0009-8981(73)90101-0; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; CYBORON GW, 1981, J BIOL CHEM, V256, P7262; GENGE B, 1992, BONE MINER, V17, P202, DOI 10.1016/0169-6009(92)90737-X; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1988, J BIOL CHEM, V263, P18513; HALE JE, 1987, J BIOL CHEM, V262, P1916; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1991, EUR J BIOCHEM, V196, P575, DOI 10.1111/j.1432-1033.1991.tb15852.x; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; SCHMID TM, 1987, STRUCTURE FUNCTION C, P223; SHIMOKOMAKI M, 1980, FEBS LETT, V121, P51, DOI 10.1016/0014-5793(80)81265-8; Von der Mark K., 1986, RHEUMATOLOGY, V10; VONDERMARK K, 1985, ANN NY ACAD SCI, V460, P214; WARNER GP, 1983, CALCIFIED TISSUE INT, V35, P327, DOI 10.1007/BF02405054; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1993, J BIOL CHEM, V268, P25084; WU LNY, 1991, J BIOL CHEM, V266, P1195; WU LNY, 1991, J BIOL CHEM, V266, P1187; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311	42	100	103	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11462	11469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157677				2022-12-27	WOS:A1994NF96600072
J	MICHELSEN, JW; SEWELL, AK; LOUIS, HA; OLSEN, JI; DAVIS, DR; WINGE, DR; BECKERLE, MC				MICHELSEN, JW; SEWELL, AK; LOUIS, HA; OLSEN, JI; DAVIS, DR; WINGE, DR; BECKERLE, MC			MUTATIONAL ANALYSIS OF THE METAL SITES IN AN LIM DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PROTEIN; ZINC-FINGER MOTIF; MAGNETIC-RESONANCE; INSULIN GENE; ZYXIN; SPECTROSCOPY; HOMEODOMAIN; MEMBER	Site-directed mutagenesis was carried out to map the residues that form the two Zn(II) sites within a LIM domain. The C-terminal LIM domain derived from the cysteine-rich protein was utilized for this analysis and is referred to as LIM2. Seven cysteinyl residues and a single histidyl residue in the LIM2 sequence, CX2CX17HX2CX2CX2CX17CX2C, comprise the conserved residues in the LIM consensus that are potential Zn(II) ligands. Two Zn(II) binding sites exhibiting tetrathiolate (S4) and SN3N1 Zn(II) coordination are displayed by LIM2 (Kosa, J. L., Michelsen, J. W., Louis, H. A., Olsen, J. I., Davis, D. R., Beckerle, M. C., and Winge, D. R. (1994) Biochemistry 33, 468-477). Site-directed mutagenesis was employed to generate three mutant LIM2 proteins with conversions of the second conserved cysteine to histidine (C2H), the fifth conserved cysteine to histidine (C5H), and the last conserved cysteine to aspartate (C8D). Metal coordination by the mutant proteins was evaluated by atomic absorption spectroscopy, Co(II) electronic spectroscopy, and Cd-113 NMR spectroscopy. The results permit discrimination between various models of metal ion binding and suggest that the LIM domain is comprised of a S3N1 site generated from the four N-terminal candidate ligands (CX2CX17HX2C) and a S4 site generated from the four C-terminal candidate ligands (CX2CX17CX2C).	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM & MED CHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Sewell, Andrew/GPT-4220-2022	Sewell, Andrew/0000-0003-3194-3135	NHLBI NIH HHS [T35 HL 07744] Funding Source: Medline; NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE IM, 1982, BIOL MAGN RESON, V4, P79; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERTINI I, 1984, ADV INORG BIOCHEM, V6, P72; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ELLIS PD, 1983, SCIENCE, V221, P1141, DOI 10.1126/science.221.4616.1141; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; South T L, 1990, Adv Inorg Biochem, V8, P199; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WANG XK, 1992, J BIOL CHEM, V267, P9176; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	32	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11108	11113						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157637				2022-12-27	WOS:A1994NF96600024
J	SWENDEMAN, SL; SPIELHOLZ, C; JENKINS, NA; GILBERT, DJ; COPELAND, NG; SHEFFERY, M				SWENDEMAN, SL; SPIELHOLZ, C; JENKINS, NA; GILBERT, DJ; COPELAND, NG; SHEFFERY, M			CHARACTERIZATION OF THE GENOMIC STRUCTURE, CHROMOSOMAL LOCATION, PROMOTER, AND DEVELOPMENTAL EXPRESSION OF THE GAMMA-GLOBIN TRANSCRIPTION FACTOR CP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID CELL-PROTEINS; FIREFLY LUCIFERASE GENE; BINDING PROTEINS; MAMMALIAN-CELLS; LINKAGE MAP; DROSOPHILA; HYBRIDIZATION; MOUSE; RNA; ORGANIZATION	We recently cloned murine and human cDNAs that encode CP2, a cellular transcription factor that interacts with the alpha-globin promoter as well as with additional cellular and viral promoter elements. We have now characterized the genomic structure, chromosome location, promoter, and expression pattern of the factor. Genes for the murine and human mRNAs contained 16 and 15 exons, respectively. Both genes spanned approximately 30 kilobases of chromosomal DNA, and among coding exons, all exon/intron boundaries were conserved. The human gene for CP2 was found to reside on chromosome 12 while the murine gene mapped to the distal end of chromosome 15, near Gdc-1, Wnt-1, and Rarg, a region syntenic with human chromosome 12. The murine and human promoters initiated mRNAs at multiple start sites in a conserved region that spanned more than 450 nucleotides. Lastly, a study of the pattern of CP2 gene expression showed that the factor was expressed in all adult and fetal murine tissues examined from at least day 9.5 of development.	CORNELL UNIV,MEM SLOAN KETTERING CANC CTR,GRAD SCH MED SCI,NEW YORK,NY 10021; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Cornell University; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SHEFFERY, M (corresponding author), CORNELL UNIV,MOLEC BIOL PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037513] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, P30-CA-08748] Funding Source: Medline; NIDDK NIH HHS [DK-37513] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BARNHART KM, 1988, MOL CELL BIOL, V8, P3215, DOI 10.1128/MCB.8.8.3215; BRANNAN CI, 1992, GENOMICS, V13, P1075, DOI 10.1016/0888-7543(92)90021-J; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Green EL, 1981, GENETICS PROBABILITY, P77; HAFEN E, 1983, EMBO J, V2, P485; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HAYASHI S, 1978, J HISTOCHEM CYTOCHEM, V26, P677, DOI 10.1177/26.8.99471; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KIM CG, 1988, MOL CELL BIOL, V8, P4270, DOI 10.1128/MCB.8.10.4270; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LI XY, 1992, J BIOL CHEM, V267, P8984; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIM LC, 1993, J BIOL CHEM, V266, P18008; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULRICH MJ, 1990, BLOOD, V75, P990; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WHITELAW E, 1990, MOL CELL BIOL, V10, P3596; ZELLER R, 1991, CURRENT PROTOCOLS MO, V2	39	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11663	11671						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157699				2022-12-27	WOS:A1994NF96600102
J	KITAZUME, S; KITAJIMA, K; INOUE, S; INOUE, Y; TROY, FA				KITAZUME, S; KITAJIMA, K; INOUE, S; INOUE, Y; TROY, FA			DEVELOPMENTAL EXPRESSION OF TROUT EGG POLYSIALOGLYCOPROTEINS AND THE PREREQUISITE ALPHA-2,6-SIALYL, AND ALPHA-2,8-SIALYL AND ALPHA-2,8-POLYSIALYLTRANSFERASE ACTIVITIES REQUIRED FOR THEIR SYNTHESIS DURING OOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; ENDO-N-ACETYLNEURAMINIDASE; RAINBOW-TROUT; SIALIC ACIDS; POLYSIALIC ACID; CARBOHYDRATE UNITS; MASS-SPECTROMETRY; POLY(SIALIC ACID); UNFERTILIZED EGGS	The developmental expression of the alpha 2,6- and alpha 2,8-linked sialic acid (Sia) residues in trout egg polysialoglycoproteins (PSGPs) was studied by correlating the temporal expression of these sugar residues, and the prerequisite sialyltransferases responsible for their synthesis, during oogenesis. The following new findings are reported. 1) Disialylated glycoproteins were identified in ovaries 4-6 months prior to ovulation. Three months prior to ovulation, a second more highly sialylated glycoprotein appeared. Structural studies confirmed that the two glycoproteins were discrete molecular species, designated PSGP(low Sia) and PSGP(high Sia), which differed only in their Sia content. PSGP(low Sia) contained mostly disialyl (Sia alpha 2,8-Sia alpha 2,6-) side chains, whereas PSGP(high Sia) contained alpha 2,8-linked oligo/polySia side chains ranging in length from 2 to over 20 Sia residues. The average degree of polymerization (DP(HV)) was 6. 2) Biosynthetic studies using CMP-[C-14]Neu5Ac indicated that three sialyltransferase activities were responsible for synthesis of the polysialyl residues of PSGPs: (i) alpha-N-acetylgalactosaminide alpha 2,6-sialyltransferase (alpha 2,6-ST), which catalyzed formation of the Sia residues alpha 2,6-linked to the proximal GalNAc residues in asialo-PSGP; (ii) alpha 2,6-sialoside alpha 2,8-sialyltransferase (alpha 2,8-ST or ''initiase''), which catalyzed transfer of the first alpha 2,8-Sia residue to the alpha 2,6-linked Sia residue; and (iii) an alpha 2,8-polysialyltransferase (alpha 2,8-polyST or ''polymerase''), responsible for synthesis of the alpha 2,8-linked poly/oligo Sia chains in PSGP(high Sia). Expression of these enzyme activities increased in accordance with the developmental appearance of each PSGP. 3) Structural characterization of the [C-14]Sia-labeled side chains of each PSGP at different stages of development confirmed that synthesis of the disialyl unit containing a single alpha 2,8-Sia residue occurred before alpha 2,8-polysialylation. 4). In ovaries, 96% of the sialyltransferase activities were found in the Golgi-derived immature cortical vesicles or as soluble enzymes released from the fragile vesicles. Less than 4% of the activities were localized in the membrane (Golgi) fraction. In mature eggs, the sialyltransferases were also detected as soluble enzymes, and within the cortical vesicles.	UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN	University of California System; University of California Davis; University of Tokyo; Showa University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009352] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09352] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRY GT, 1957, NATURE, V179, P206, DOI 10.1038/179206a0; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; Corfield A.P., 1982, Cell Biology Monographs, V10, P5; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DUBOIS M, 1956, ANAL CHEM, V135, P243; FINNE J, 1982, J BIOL CHEM, V257, P1966; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GLICK MC, 1991, ADV NEUROBLASTOMA RE, V3, P267; GROGAN T, 1994, IN PRESS US CAN ACAD; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INOUE S, 1987, DEV BIOL, V123, P442, DOI 10.1016/0012-1606(87)90402-7; INOUE S, 1986, J BIOL CHEM, V261, P5256; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; INOUE S, 1980, BIOCHEM BIOPH RES CO, V93, P162, DOI 10.1016/S0006-291X(80)80260-9; INOUE Y, 1993, POLYSIALIC ACID MICR, P335; IWASAKI M, 1984, BIOCHEM INT, V8, P573; IWASAKI M, 1984, BIOCHEMISTRY-US, V23, P305, DOI 10.1021/bi00297a020; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; Iwasaki M., 1985, GLYCOCONJUGATE J, V2, P209, DOI [10.1007/BF01049269, DOI 10.1007/BF01049269]; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; KITAJIMA K, 1986, J BIOL CHEM, V261, P5262; KITAJIMA K, 1988, DEV BIOL, V129, P270, DOI 10.1016/0012-1606(88)90181-9; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAJIMA K, 1988, BIOCHEMISTRY-US, V27, P741; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KUNDIG FD, 1971, J BIOL CHEM, V246, P2543; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; REGAN CM, 1991, INT J BIOCHH, V23, P515; ROHR TE, 1980, J BIOL CHEM, V255, P2332; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SARFF LD, 1975, LANCET, V1, P1099; SATO C, 1993, J BIOL CHEM, V268, P23675; SCHAEFER HF, 1989, CHIMIA, V43, P1; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHIMAMURA M, 1983, BIOCHEMISTRY-US, V22, P959, DOI 10.1021/bi00273a039; SHIMODA Y, 1994, IN PRESS BIOCHEMISTR, V32; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SORIMACHI H, 1990, J MOL BIOL, V211, P35, DOI 10.1016/0022-2836(90)90009-B; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; TERADA T, 1993, J BIOL CHEM, V268, P2640; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1979, J BIOL CHEM, V254, P7377; TROY FA, 1975, J BIOL CHEM, V250, P156; TROY FA, 1979, ANNU REV MICROBIOL, V33, P529; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357; YANG P, 1992, J CELL BIOL, V116, P487; YE J, 1994, METHOD ENZYMOL, V230, P460; YU S, 1990, ARCH BIOCHEM BIOPHYS, V283, P167; ZUBER C, 1992, J BIOL CHEM, V267, P9965	70	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10330	10340						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144614				2022-12-27	WOS:A1994NF01700026
J	LISZEWSKI, MK; TEDJA, I; ATKINSON, JP				LISZEWSKI, MK; TEDJA, I; ATKINSON, JP			MEMBRANE COFACTOR PROTEIN (CD46) OF COMPLEMENT - PROCESSING DIFFERENCES RELATED TO ALTERNATIVELY SPLICED CYTOPLASMIC DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR VIRUS RECEPTOR; HUMAN LYMPHOCYTES-B; ENDOPLASMIC-RETICULUM; LIGAND-BINDING; GENE-CLUSTER; C3D RECEPTOR; CELL-DAMAGE; SYSTEM; MCP; IDENTIFICATION	Membrane cofactor protein (MCP, CD46), a widely distributed regulatory protein, inhibits complement activation on host cells and serves as a measles virus receptor. Most cells express four isoforms (with one of two cytoplasmic tails, CYT-1 or CYT-2). Previously, we noted that MCP precursors had variable intracellular processing. Therefore, we characterized the intracellular trans port of individual MCP isoforms. Transfectants were used for pulse chase analyses. MCP isoforms bearing CYT-1 chased into their mature, surface forms with a half-life (t(1/2)) of 10-13 min while those with CYT-2 required 35-40 min. The precursor of a tail-less mutant possessed a t(1/2) of 160-165 min. Chimeras were constructed that added both tails in opposite orientation onto the isoform (i.e. CYT 1+2 or CYT 2+1). Chimera 1+2 precursor processed with a t(1/2) of 35-37 min, similar to CYT-2. Chimera 2+1 had a t(1/2) of 15-19 min, more closely resembling CYT-1. Thus, in both cases the carboxyl-terminal tail controlled the processing rate. Deletions were made in the beginning, middle, and carboxyl terminus of CYT-1. Deletion of the first or middle six amino acids had no effect on the processing rate, However, deletion of the terminal tetrapeptide (FTSL) slowed the rate to 30-32 min, suggesting that this sequence facilitates exit from the endoplasmic reticulum.	ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED, DIV RHEUMATOL, ST LOUIS, MO 63110 USA	Saint Louis University				Atkinson, John/0000-0002-2514-3441				ADAMS EM, 1991, J IMMUNOL, V147, P3005; BALLARD LL, 1988, J IMMUNOL, V141, P3923; DINGWALL C, 1992, Current Biology, V2, P503, DOI 10.1016/0960-9822(92)90687-6; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1490, DOI 10.1073/pnas.82.5.1490; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kelley William L., 1992, Current Opinion in Cell Biology, V4, P984, DOI 10.1016/0955-0674(92)90130-5; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LISZEWSKI MK, 1989, BIOTECHNIQUES, V7, P13; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581; SEYA T, 1990, J EXP MED, V172, P1673, DOI 10.1084/jem.172.6.1673	29	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10776	10779						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144666				2022-12-27	WOS:A1994NF01700088
J	ZHANG, L; HIGUCHI, M; TOTPAL, K; CHATURVEDI, MM; AGGARWAL, BB				ZHANG, L; HIGUCHI, M; TOTPAL, K; CHATURVEDI, MM; AGGARWAL, BB			STAUROSPORINE INDUCES THE CELL-SURFACE EXPRESSION OF BOTH FORMS OF HUMAN TUMOR-NECROSIS-FACTOR RECEPTORS ON MYELOID AND EPITHELIAL-CELLS AND MODULATES LIGAND-INDUCED CELLULAR-RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-KINASE INHIBITOR; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; FACTOR-ALPHA; MOLECULAR-CLONING; SOLUBLE RECEPTORS; POTENT INHIBITOR; RESISTANT CELLS; DNA-SYNTHESIS; TNF RECEPTOR	Staurosporine, an inhibitor of protein kinase C, is commonly used to inhibit the growth factor-induced signal transduction pathway at the post-receptor level. In this report, we examined the effect of staurosporine on the constitutive expression of tumor necrosis factor (TNF) receptors in K562, a human erythroblastoid leukemic cell line. Exposure of these cells to staurosporine enhanced cell surface expression of TNF receptors by almost 7-fold in a dose- and time-dependent fashion. Maximum induction occurred at a concentration of 20 nM of the agent for 16 h at 37 degrees C. Induction of the TNF receptor was found to be temperature dependent. No induction was observed at 22 or at 4 degrees C, suggesting the role of cell metabolism. Scatchard analysis indicated an increase in receptor number without any change in receptor affinity. TNF receptors were induced by staurosporine on a wide variety of human cells of both epithelial (primarily p60 receptors) and myeloid (mainly p80 receptor) origin.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGARWALBB, 1986, J BIOL CHEM, V261, P13652; AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1991, TUMOR NECROSIS FACTO, P1; AGGARWAL BB, 1987, J BIOL CHEM, V262; AIYER RA, 1988, CRC HDB CYTOLYTIC LY, P105; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BISHOP WR, 1990, BIOCHEM PHARMACOL, V40, P2129, DOI 10.1016/0006-2952(90)90245-G; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COMBADIERE C, 1993, BIOCHEM J, V289, P695, DOI 10.1042/bj2890695; DAIBATA M, 1991, J IMMUNOL, V147, P292; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DING AH, 1989, J BIOL CHEM, V264, P3924; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; FRIEDMAN BA, 1990, CANCER RES, V50, P533; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; HELLER R, 1992, VANO, V70, P47; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Maniatis T., 1989, MOL CLONING COLD SPR, P11; MIYAMOTO K, 1993, CANCER RES, V53, P1555; MORIOKA H, 1985, AGR BIOL CHEM TOKYO, V49, P1959, DOI 10.1080/00021369.1985.10867017; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; PANG XP, 1989, ENDOCRINOLOGY, V125, P599; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; PENNICA D, 1992, J BIOL CHEM, V267, P21172; POUTEU F, 1990, J EXP MED, V172, P599; ROUBEY RAS, 1991, J IMMUNOL, V146, P3557; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUGGIERO V, 1987, J IMMUNOL, V138, P661; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TOTPAL K, 1991, CANCER RES, V51, P4266; TOTPAL K, 1992, CANCER RES, V52, P2557; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VANOSTADE X, 1993, NATURE, V361, P266; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	62	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10270	10279						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144608				2022-12-27	WOS:A1994NF01700018
J	JUNCOSA, M; PONS, J; DOT, T; QUEROL, E; PLANAS, A				JUNCOSA, M; PONS, J; DOT, T; QUEROL, E; PLANAS, A			IDENTIFICATION OF ACTIVE-SITE CARBOXYLIC RESIDUES IN BACILLUS-LICHENIFORMIS 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCANASE GENE; MOLECULAR-CLONING; ESCHERICHIA-COLI; EXPRESSION; SEQUENCE; SUBTILIS; ENDO-BETA-1,3-1,4-D-GLUCANASE; BETA-1,3-1,4-GLUCANASE; XYLANASE; LYSOZYME	Active site residues of 1,3-1,4-beta-D-glucan 4-glucanohydrolase (EC 3.2.1.73) from Bacillus licheniformis have been identified by site-directed mutagenesis. Previous work revealed that Glu-134 was essential for enzymatic activity, and it was proposed as the catalytic nucleophile by affinity labeling of the highly homologous Bacillus amyloliquefaciens enzyme. To search for the general acid catalyst, the Asp and Glu residues conserved among the Bacillus isozymes have been mutated to Asn and Gln, respectively. Out of the 14 positions studied, only the E138Q mutation yielded an inactive enzyme, whereas the E134Q and and D136N mutants retained less than 0.5% of the wild type activity Based on the three-dimensional structure of a hybrid B. amyloliquefaciens-Bacillus macerans 1,3-1,4-beta-D-glucan 4-glucanohydrolase, Glu-134, Asp-136, and Glu-138 are the only carboxylic acid residues that are properly located into the active site cleft to participate in catalysis. Glu-138 appears as the most Likely candidate to function as the general acid catalyst, while Asp-136 may affect the pK(a) of the catalytic residues.	UNIV AUTONOMA BARCELONA,INST BIOL FONAMENTAL V VILLAR PALASI,E-08193 BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,DEPT BIOQUIM & BIOL MOLEC,E-08193 BARCELONA,SPAIN; UNIV RAMAN LLULL,CETS INST QUIM SARRIA,E-08017 BARCELONA,SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona; Universitat Ramon Llull; Institut Quimic de Sarria			PLANAS, ANTONI/I-4803-2015	PLANAS, ANTONI/0000-0001-7073-3320				ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; [Anonymous], 1983, CARBOHYD POLYM, DOI 10.1016/0144-8617(83)90019-x; BORRIS R, 1988, J BASIC MICROB, V28, P1; BORRISS R, 1990, MOL GEN GENET, V222, P278, DOI 10.1007/BF00633829; BUENO A, 1990, J BACTERIOL, V172, P2160, DOI 10.1128/jb.172.4.2160-2167.1990; BULIGA GS, 1986, CARBOHYD RES, V157, P139, DOI 10.1016/0008-6215(86)85065-0; CANTWELL BA, 1983, GENE, V23, P211, DOI 10.1016/0378-1119(83)90053-7; CHAUVAUX S, 1992, J BIOL CHEM, V267, P4472; CHEN L, 1993, J BIOL CHEM, V268, P13318; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; GOSALBES MJ, 1991, J BACTERIOL, V173, P7705, DOI 10.1128/jb.173.23.7705-7710.1991; HARLOW E, 1988, ANTIBODIES LABORATOR; HINCHLIFFE E, 1984, J GEN MICROBIOL, V130, P1285; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; HOJ PB, 1992, J BIOL CHEM, V267, P25059; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LITTS JC, 1990, EUR J BIOCHEM, V194, P831, DOI 10.1111/j.1432-1033.1990.tb19476.x; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; LOUW ME, 1993, APPL MICROBIOL BIOT, V38, P507, DOI 10.1007/BF00242946; LUTHI E, 1992, APPL MICROBIOL BIOT, V36, P503, DOI 10.1007/BF00170192; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; MURAKI M, 1987, BIOCHIM BIOPHYS ACTA, V916, P66, DOI 10.1016/0167-4838(87)90211-1; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; PLANAS A, 1992, APPL MICROBIOL BIOT, V37, P583; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SIMNOTT ML, 1990, CHEM REV, V90, P1171; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TEATHER RM, 1982, APPL ENVIRON MICROB, V43, P777, DOI 10.1128/AEM.43.4.777-780.1982	37	115	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14530	14535						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182059				2022-12-27	WOS:A1994NM06500036
J	SEKIGUCHI, M; DOI, K; ZHU, WS; WATASE, K; YOKOTANI, N; WADA, K; WENTHOLD, RJ				SEKIGUCHI, M; DOI, K; ZHU, WS; WATASE, K; YOKOTANI, N; WADA, K; WENTHOLD, RJ			A DELETION IN THE 2ND CYTOPLASMIC LOOP OF GLUR3 PRODUCES A DOMINANT-NEGATIVE MUTANT OF ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC-ACID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MUSCLE ACETYLCHOLINE-RECEPTOR; PUTATIVE GLUTAMATE RECEPTOR; KAINATE-BINDING SUBUNIT; CENTRAL NERVOUS-SYSTEM; NMDA RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; STRUCTURAL DETERMINANTS; ENDOPLASMIC-RETICULUM	We have characterized a GluR3 mutant (sGluR3) which has a 33-amino acid deletion in its second cytoplasmic loop (deficit from Tyr-715 to Gly-747 of GluR3-flop). Xenopus oocytes injected with cRNA transcribed from cDNA for this mutant did not respond to kainate and glutamate (each 100 mu M) at a holding potential of -70 mV. In oocytes coinjected with cRNAs for this mutant and for normal alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor subunits, the current response to both kainate and glutamate was much weaker than that observed in oocytes injected with cRNA for the normal subunits alone. This inhibitory action was not accompanied by a significant change of ED(50) value and shape of the I-V curve and was AMPA receptor-specific, A comparable deletion in GluR1 produced a mutant with properties similar to those of sGluR3, while a 33-amino acid deletion elsewhere in the second cytoplasmic loop of GluR3 (Met-674 to Phe-706) gave a mutant with a weaker effect. These results suggest that sGluR3 acts as a dominant negative mutant on the functional expression of normal AMPA receptors in oocytes by assembling with the normal subunits to produce an essentially nonfunctional receptor complex.	NIDOCD, NEUROCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	SEKIGUCHI, M (corresponding author), NATL CTR NEUROL & PSYCHIAT, NATL INST NEUROSCI, DEPT DEGENERAT NEUROL DIS, 4-1-1 OGAWAHIGASHI, KODAIRA, TOKYO 187, JAPAN.							AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; DOI K, 1992, P SENDAI S, V2, P11; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLAUSNER R D, 1989, New Biologist, V1, P3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SEKIGUCHI M, 1992, FEBS LETT, V311, P285, DOI 10.1016/0014-5793(92)81121-2; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	53	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14559	14565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182063				2022-12-27	WOS:A1994NM06500041
J	GE, RW; RHEE, M; MALIK, S; KARATHANASIS, SK				GE, RW; RHEE, M; MALIK, S; KARATHANASIS, SK			TRANSCRIPTIONAL REPRESSION OF APOLIPOPROTEIN AI GENE-EXPRESSION BY ORPHAN RECEPTOR ARP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ENHANCER-BINDING-PROTEIN; ZINC FINGER PROTEIN; E MESSENGER-RNA; I GENE; RETINOIC ACID; LIVER; SUPERFAMILY; CELLS; DIFFERENTIATION	Expression of the apolipoprotein AI (apoAI) gene in the liver is controlled by a liver specific enhancer. The function of this enhancer depends on synergistic interactions between transcription factors bound to at least three sites (designated A, B, and C) located within this enhancer. We have previously shown that an apoAI gene reporter construct containing the entire enhancer is expressed efficiently in a hepatoma cell line and that its activity is repressed by the orphan receptor ARP-1. Moreover, repression by ARP-1 is overcome by the retinoid X receptor RXR alpha in the presence of retinoic acid. In this study, we show that ARP-1 represses the apoAI prometer by binding to site A of the apoAI liver specific enhancer, the repression being a promoter context-specific event. Mapping analysis of ARP-1 indicated that its DNA binding domain is essential but not sufficient for repression. Two separate repression domains located at the amino- and carboxyl terminal halves of ARP-1 were found to individually complement the DNA binding domain for efficient repression. We also demonstrate the reversibility of ARP-1 repression by transcription factors C/EBP and Egr-1, which might also be involved in apoAI gene expression. Significantly, repression by ARP-1 was found to be a prerequisite for C/EBP-mediated transactivation. We interpret our results in terms of a model in which ARP-1 repression via its interaction with site A is an obligatory intermediate step in switching from one activated state of the apoAI gene to another.	AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336; Rhee, Myungchull/0000-0002-4595-7573				BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; ING NH, 1992, J BIOL CHEM, V267, P17617; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	29	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13185	13192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175747				2022-12-27	WOS:A1994NK18400024
J	KOJIMA, M; OHYAMA, Y; MIYAMOTO, K; MINAMINO, N; KANGAWA, K; MATSUO, H				KOJIMA, M; OHYAMA, Y; MIYAMOTO, K; MINAMINO, N; KANGAWA, K; MATSUO, H			CLONING AND CHARACTERIZATION OF A NOVEL NATRIURETIC PEPTIDE IN FROG (RANA-CATESBEIANA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; PORCINE BRAIN; RAT-BRAIN; RECEPTOR; CNP; EXPRESSION; PRECURSOR; FAMILY	C-type natriuretic peptide (CNP) is one of three members of the natriuretic peptide family. In the course of cloning frog CNP precursor cDNA, we found cDNA clones encoding a novel natriuretic peptide precursor. This novel natriuretic peptide precursor is a 118-residue peptide, carrying a 22-residue signal peptide at the N terminus and a 17-residue ring structure characteristic of the natriuretic peptide family at the C terminus. The precursor is highly homologous to mammalian CNP precursors. Its C-terminal Cys codon is directly followed by a termination codon. This feature is characteristic of CNP precursor cDNAs. The cGMP-stimulating activity of the novel natriuretic peptide was at the same level with those of frog CNP and mammalian CNPs, when rat CNP receptor was used in the cGMP assay system. Thus, this novel natriuretic peptide is structurally and functionally a member of the C-type natriuretic peptide. We designated the peptide as frog CNP II, and the previously described CNP as frog CNP I. By Northern blot analysis, expression of this novel CNP mRNA was found in brain, heart, lung, and stomach. On the other hand, frog CNP mRNA was mainly expressed in brain, where mammalian CNP mRNA is exclusively expressed. The distribution of the two frog CNPs suggests a complex system for regulating electrolyte and water balance in frog.	NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan								ARIMURA JJ, 1991, BIOCHEM BIOPH RES CO, V174, P142, DOI 10.1016/0006-291X(91)90497-U; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; MINAMINO N, 1993, BIOCHEM BIOPH RES CO, V197, P326, DOI 10.1006/bbrc.1993.2479; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P336, DOI 10.1016/0006-291X(92)91563-6; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; TALLERICOMELNYK T, 1992, BIOCHEM BIOPH RES CO, V189, P610, DOI 10.1016/0006-291X(92)92244-R; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454; YOSHIHARA A, 1990, BIOCHEM BIOPH RES CO, V173, P591, DOI 10.1016/S0006-291X(05)80076-2	19	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13136	13140						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175740				2022-12-27	WOS:A1994NK18400016
J	BARAGI, VM; FLISZAR, CJ; CONROY, MC; YE, QZ; SHIPLEY, JM; WELGUS, HG				BARAGI, VM; FLISZAR, CJ; CONROY, MC; YE, QZ; SHIPLEY, JM; WELGUS, HG			CONTRIBUTION OF THE C-TERMINAL DOMAIN OF METALLOPROTEINASES TO BINDING BY TISSUE INHIBITOR OF METALLOPROTEINASES - C-TERMINAL TRUNCATED STROMELYSIN AND MATRILYSIN EXHIBIT EQUALLY COMPROMISED BINDING AFFINITIES AS COMPARED TO FULL-LENGTH STROMELYSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; HUMAN 72-KDA GELATINASE; MATRIX METALLOPROTEINASE; IV COLLAGENASE; PURIFICATION; ACTIVATION; EXPRESSION; TIMP-2; PUMP-1; FAMILY	In this study, we have used high resolution gel-filtration chromatography and measurements of K-i to compare the capacity of full-length native stromelysin, C-terminal truncated stromelysin (Phe(100)-Pro(273)), and matrilysin (the only metalloproteinase spontaneously lacking a C-terminal hemopexin-like domain) to bind to the tissue inhibitor of metalloproteinases (TIMP). While prostromelysin failed to bind TIMP, active stromelysin bound to the inhibitor avidly, exhibiting an affinity for TIMP (K-i = 8.3 x 10(-10) M) essentially identical to that of active interstitial collagenase as determined by compe tition experiments. C-terminal truncated stromelysin also formed a higher M(r) complex with TIMP which survived gel filtration. However, when truncated stromelysin was forced to compete with its full-length parent molecule for limiting amounts of TIMP, the full-length enzyme preferentially bound to the inhibitor. Indeed, binding studies indicated a K-i of 5.95 x 10(-9) M for the truncated variant's interaction with TIMP, only 14% as tight as that of full length stromelysin. We also examined the interaction between TIMP and matrilysin, the only metalloproteinase which naturally lacks a C-terminal domain. Promatrilysin failed to bind the inhibitor. However, active matrilysin readily bound TIMP, forming a complex that resisted separation by gel filtration. When active matrilysin was forced to compete with truncated stromelysin for limiting amounts of TIMP, both enzymes appeared to complex the inhibitor with nearly equivalent efficacy. Indeed, active matrilysin exhibited a K-i for TIMP of 4.5 x 10(-9) M, essentially identical to that of truncated stromelysin. These data indicate that, as is true for collagenase, the C-terminal domain of stromelysin contributes significantly to its capacity to bind the physiologic inhibitor, TIMP. Furthermore, since stromelysin readily processes in vitro to a C-terminal truncated form, this enzyme species, as well as the full length metalloproteinase matrilysin, may resist inhibition by TIMP in areas of active inflammation in vivo.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT BIOCHEM,ANN ARBOR,MI 48105; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110	Pfizer; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	BARAGI, VM (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT IMMUNOPATHOL,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.		Ye, Qizhuang/B-3147-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594] Funding Source: Medline; NIAMS NIH HHS [AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI HP, 1992, BIOCHEM J, V285, P899, DOI 10.1042/bj2850899; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RODGERS WH, 1993, AM J OBSTET GYNECOL, V168, P253, DOI 10.1016/S0002-9378(12)90922-9; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SIRES UI, 1993, J BIOL CHEM, V268, P2069; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; TSAO T, 1990, J BIOL CHEM, V265, P5188; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	36	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12692	12697						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175679				2022-12-27	WOS:A1994NH71600051
J	MILLERMARTINI, DM; HUA, S; HOROWITZ, PM				MILLERMARTINI, DM; HUA, S; HOROWITZ, PM			CYSTEINE-254 CAN COOPERATE WITH ACTIVE-SITE CYSTEINE-247 IN REACTIVATION OF 5,5'-DITHIOBIS(2-NITROBENZOIC ACID)-INACTIVATED RHODANESE AS DETERMINED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; ENZYME; CATALYSIS; COVALENT; STATES	Sulfhydryl substitution mutants of rhodanese (thiosulfate:cyanide sulfurtransferase; EC 2.8.1.1) were used to determine whether the 4 cysteine residues in the native structure could cooperate in reactions. The sulfhydryl reactivity of persulfide-containing (ES) rhodanese was not significantly changed when cysteine residues at positions 63, 254, and 263 were replaced by serine, either individually or in combination. However, the sulfhydryl reactivity of persulfide-free (E) rhodanese was enhanced when Cys-254 was mutated. One sulfhydryl group, presumably the active site Cys-247, reacted rapidly in the E forms of these proteins with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) or 4,4'-dipyridyl disulfide (4-PDS). After reaction with DTNB or 4-PDS, proteins with Cys-254 retained >95% of their original activities as compared with Ser-254-containing proteins, which retained <6% of their activities. Cyanide treatment could release thionitrobenzoate from rhodanese-thionitrobenzoate complexes with an approximate 1:1 stoichiometry. After this treatment, only the wild-type and C263S enzymes were fully active. Cyanide-treated rhodanese-thionitrobenzoate complexes of the C254S and C254S/C263S mutants could be fully reactivated using an exogenously added thiol, beta-mercaptoethanol. These results are consistent with the formation of a Cys-247-thiocyano derivative that is inactive but capable of being reactivated by intramolecular transfer of cyanide to Cys-254. In the absence of Cys 254, beta-mercaptoethanol can serve as the transferring sulfhydryl group.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOW SF, 1985, J BIOL CHEM, V260, P2763; CHUNG AE, 1971, BIOCHEMISTRY-US, V10, P2872, DOI 10.1021/bi00791a012; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEINRIKSON RL, 1983, FRONTIERS BIOCH BIOP, P163; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOL WGJ, 1987, BIOL MACROMOL, P483; HOROWITZ P, 1983, J BIOL CHEM, V258, P7894; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1987, J BIOL CHEM, V262, P14544; HOROWITZ PM, 1992, BIOCATALYST DESIGN S, V516, P167; ISLAM TA, 1994, J BIOL CHEM, V269, P7908; JOCELYN PC, 1972, BIOCH SH GROUP, P116; KOHANSKI RA, 1990, J PROTEIN CHEM, V9, P369, DOI 10.1007/BF01024612; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; MINTEL R, 1966, J BIOL CHEM, V241, P3386; OGATA K, 1990, J BIOL CHEM, V265, P8087; OGATA K, 1988, J BIOL CHEM, V264, P2718; PENSA B, 1977, BIOCHIM BIOPHYS ACTA, V484, P368, DOI 10.1016/0005-2744(77)90092-4; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PLOEGMAN JH, 1973, THESIS U GRONINGEN; RUSSELL J, 1978, J BIOL CHEM, V253, P8102; SORBO B, 1973, ACTA CHEM SCAND, V7, P1123; WANG SF, 1968, J BIOL CHEM, V243, P5465; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1983, FUND APPL TOXICOL, V3, P377, DOI 10.1016/S0272-0590(83)80008-6; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; Westley J., 1977, BIOORG CHEM, V1, P371; WOOD JL, 1982, ADV EXP MED BIOL, V148, P327	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12414	12418						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175646				2022-12-27	WOS:A1994NH71600009
J	ZIEGLER, FD; GEMMILL, TR; TRIMBLE, RB				ZIEGLER, FD; GEMMILL, TR; TRIMBLE, RB			GLYCOPROTEIN-SYNTHESIS IN YEAST - EARLY EVENTS IN N-LINKED OLIGOSACCHARIDE PROCESSING IN SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; SACCHAROMYCES-CEREVISIAE; ACETYLGLUCOSAMINIDASE-H; PROTEIN GLYCOSYLATION; H-1-NMR SPECTROSCOPY; PURIFICATION; INVERTASE; BIOSYNTHESIS; MANNOSIDASE; MICROSOMES	Oligosaccharide-lipid precursors and glycoprotein N-linked oligosaccharides isolated from the fission yeast, Schizosaccharomyces pombe, were compared with those from the budding yeast, Saccharomyces cerevisiae. Bio-Gel P-4 chromatography of oligosaccharide intermediates showed that Glc(3)Man(9)GlcNAc(2)-PP-dol synthesis, transfer of glycan to protein, and glucose removal to yield Man(9)GlcNAc(2) proceeded in S. pombe as in S. cerevisiae. Two series of oligosaccharides were released from S. pombe glycoproteins by endo-beta-N-acetylglu cosaminidase H; large ''mannan-like'' structures and smaller precursor or ''core-filling'' species. Unexpectedly, the smallest S. pombe N-linked glycan was Man(9)GlcNAc, confirmed by 500 MHz H-1 NMR spectroscopy to be the lipid-linked isomer. No endoplasmic reticulum Man(9)-alpha 1,2-mannosidase activity was detected in S. pombe, thus identifying Man(9)GlcNAc as the minimum precursor for oligosaccharide elongation in contrast to the Man(8)GlcNA(2), intermediate identified in S. cerevisiae (Byrd, J.C., Tarentino, A.L., Maley, F., Atkinson, P.H., and Trimble, R.B. (1982) J. Biol. Chem. 257, 14657-14666). S. pombe Hex(10)GlcNAc was at least four isomers by high pH anion-exchange chromatography with pulsed amperometric detection. Compositional analyses identified two of the major species as GalMan(9)GlcNac and GlcMan(9)GlcNAc, the latter of which suggests that glycan trimming may be attenuated in the S. pombe endoplasmic reticulum. Hex(13)GlcNAc from S. pombe was homogeneous by mass spectrometry but yielded 12 species by high pH anion-exchange chromatography. Compositional analyses, alpha-galactosidase digestion, and lectin affinity chromatography on Griffonia simplicifolia lectin I-agarose indicated these to be a family of Gal(x) Man(13-x)GlcNAc isomers (X = 1-4 residues). The absence of Man(9)GlcNAc(2), to Man(8)GlcNAc(2), trimming in S. pombe and elongation of the lipid precursor of Man(9)GlcNAc with both Man and Gal to form ''galactomannans'' provides a novel system for N-linked glycoprotein processing studies.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; DIBENEDETTO G, 1972, BIOCHIM BIOPHYS ACTA, V286, P363, DOI 10.1016/0304-4165(72)90272-3; DIBENEDETTO G, 1975, BIOCHEMISTRY-US, V14, P2847, DOI 10.1021/bi00684a009; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MORENO S, 1985, ARCH MICROBIOL, V142, P370, DOI 10.1007/BF00491906; MORENO S, 1990, BIOCHEM J, V267, P697, DOI 10.1042/bj2670697; PARODI AJ, 1982, J BIOL CHEM, V257, P7641; PUCCIA R, 1993, BIOCHEM J, V290, P21, DOI 10.1042/bj2900021; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SCHWEINGRUBER AM, 1986, EUR J BIOCH, V158; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TOWNSEND R R, 1991, Glycobiology, V1, P139, DOI 10.1093/glycob/1.2.139; TOWNSEND RR, 1991, CARBOHYD RES, V215, P211, DOI 10.1016/0008-6215(91)84021-6; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; Verostek M. F., 1992, Glycobiology, V2, P458; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	35	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12527	12535						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175662				2022-12-27	WOS:A1994NH71600027
J	BURKE, J; PETTITT, JM; HUMPHRIS, D; GLEESON, PA				BURKE, J; PETTITT, JM; HUMPHRIS, D; GLEESON, PA			MEDIAL-GOLGI RETENTION OF N-ACETYLGLUCOSAMINYLTRANSFERASE-I - CONTRIBUTION FROM ALL DOMAINS OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; NH2-TERMINAL SIGNAL ANCHOR; MEMBRANE-SPANNING DOMAIN; TRANSMEMBRANE DOMAIN; IMMUNOELECTRON MICROSCOPY; GLYCOPROTEIN-SYNTHESIS; GENOMIC ORGANIZATION; RAT-LIVER; PROTEIN; LOCALIZATION	We have previously shown that the transmembrane domain and flanking residues of beta-1,2-N-acetylglucosaminyltransferase I (GnTI) can localize a hybrid molecule to medial-Golgi cisternae (Burke, J., Pettitt, J. M., Schachter, H., Sarkar, M., and Gleeson, P.A. (1992) J. Biol. Chem. 267, 24433-24440). Here, we have further examined the contribution of the cytoplasmic tail, transmembrane domain, and the catalytically active, luminal domain of GnTI in medial-Golgi localization, by analyzing the localization of hybrid molecules stably expressed in murine cells. In contrast to wild-type GnTI, which was efficiently localized to the medial-Golgi and not detected at the cell surface, hybrid molecules containing any two of the three domains of GnTI were localized to the medial-Golgi and were also present at low levels at the cell surface. Hybrid molecules containing only the transmembrane domain or the luminal domain of GnTI showed partial Golgi retention together with an increased level of cell surface expression compared with molecules containing two GnTI domains. The cytoplasmic tail independently was unable to retain reporter sequences to the Golgi but increased the ability of constructs containing either the luminal or transmembrane domain of GnTI to localize to the Golgi apparatus. Therefore, all three domains of GnTI contribute significantly to medial-Golgi localization. Furthermore, GnTI hybrid molecules showing increased cell surface expression were more readily extracted in a low salt buffer, suggesting that Golgi localized GnTI differs in physicochemical properties from cell surface GnTI. Based on an aggregation model of localization, we propose that Golgi retention of these hybrid molecules is mediated by the interaction of their GnTI domains with the corresponding domains of endogenous glycosyltransferase aggregates within the Golgi membranes of the transfected cell.	MONASH UNIV,ALFRED HOSP,SCH MED,DEPT PATHOL & IMMUNOL,MELBOURNE,VIC 3181,AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Monash University				Gleeson, Paul/0000-0002-5336-6503				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MASIBAY AS, 1992, MOL BIOL REP, V116, P99; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1982, J CELL BIOL, V92, P223; ROTH MG, 1988, INFLUENZA VIRUSES, P219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SLUSAREWICZ P, 1994, IN PRESS J CELL BIOL; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	52	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12049	12059						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163508				2022-12-27	WOS:A1994NG37700058
J	TANG, CSL; BUENO, A; RUSSELL, P				TANG, CSL; BUENO, A; RUSSELL, P			NTF1(+) ENCODES A 6-CYSTEINE ZINC FINGER-CONTAINING TRANSCRIPTION FACTOR THAT REGULATES THE NMT1 PROMOTER IN FISSION YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; CDC25 PROTEIN; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; ACTIVATES P34CDC2; GENE; MITOSIS; KINASE; PHOSPHATASE; DEPHOSPHORYLATION	The nmt1(+) gene of the fission yeast Schizosaccharomyces pombe is subject to transcriptional repression mediated by thiamine. The promoter of nmt1(+) has been used to construct a series of vectors that are now commonly used for the regulated expression of genes in S. pombe. In this report, we describe ntf1(+), a gene involved in regulating nmt1(+) expression. The ntf1(+) gene was cloned in a high copy suppressor screen that utilized a construct, nmt1:wee1(+), in which expression of the mitotic inhibitor Wee1 tyrosine kinase was placed under the control of the nmt1 promoter. ntf1(+) encodes a 706-amino acid protein that shares substantial homology with a family of Cys(6) zinc finger-containing transcription factors typified by GAL4 from Saccharomyces cerevisiae. Increased gene dosage of ntf1(+) greatly increases both the repressed and derepressed activity of the nmt1 promoter. Cells having a disrupted version of ntf1(+) are viable thiamine prototrophs, but basal expression from the nmt1 promoter is greatly reduced. These data demonstrate that Ntf1 plays an important role in regulating nmt1 expression.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Bueno, Avelino/A-9505-2016	Bueno, Avelino/0000-0002-0362-4391; Tang, Carol/0000-0002-1835-5083				AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MOLZ L, 1989, GENETICS, V122, P773; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; RUSSELL PR, 1982, MOL CELL BIOL, V2, P106, DOI 10.1128/MCB.2.2.106; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; WEILGUNY D, 1991, GENE, V99, P47, DOI 10.1016/0378-1119(91)90032-7	33	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11921	11926						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163491				2022-12-27	WOS:A1994NG37700039
J	CHRISTIANSEN, K; KNUDSEN, BR; WESTERGAARD, O				CHRISTIANSEN, K; KNUDSEN, BR; WESTERGAARD, O			THE COVALENT EUKARYOTIC TOPOISOMERASE-I-DNA INTERMEDIATE CATALYZES PH-DEPENDENT HYDROLYSIS AND ALCOHOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ACTIVE-SITE TYROSINE; TYPE-1 TOPOISOMERASE; PHOSPHODIESTER BOND; POLYACRYLAMIDE-GELS; CLEAVAGE; PROTEIN; SPECIFICITY; SEQUENCE; COMPLEX	Eukaryotic topoisomerase I catalysis was characterized by the use of a DNA substrate system, which allows uncoupling of cleavage and ligation half-reactions. Covalent topoisomerase I-DNA intermediates formed by cleavage without concomitant ligation were able to catalyze hydrolysis of the 3'-phosphotyrosyl bond in the pH range 7.5-10, with a broad pH optimum between pH 8.5 and 9.5. In comparison, the DNA cleavage and ligation activity of topoisomerase I were found to be independent of pH in the pH range 7-10 and strongly impaired at higher pH values. Moreover, different polyhydric alcohol compounds were found to function as nucleophiles at pH 9 to facilitate the release of topoisomerase I. The hydrolysis and alcoholysis activities of topoisomerase I were specific for the 3'-phosphotyrosyl bond and blocked by enzyme denaturation or proteolysis. Taken together the data suggest that site-specific hydrolysis or alcoholysis mediated by topoisomerase I-DNA complexes reflects the ability of the enzyme to direct the activation of the 3'-phosphotyrosyl bond or the incoming nucleophile. Analysis of enzyme-directed coupling of non-DNA nucleophiles to the cleaved DNA strand may provide a useful tool for elucidation of the biochemical mechanism of type I DNA topoisomerases.	AARHUS UNIV,DEPT MOLEC BIOL,CF MOLLERS ALLE,BLDG 130,DK-8000 AARHUS,DENMARK	Aarhus University								ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUGHAM MJ, 1986, BIOCHEMISTRY-US, V25, P7362, DOI 10.1021/bi00371a018; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FRANK R, 1979, NUCLEIC ACIDS RES, V6, P2069, DOI 10.1093/nar/6.6.2069; GARABEDIAN PAD, 1991, BIOCHEMISTRY-US, V30, P9940; GARCIADIAZ M, 1993, EUR J BIOCHEM, V213, P1139, DOI 10.1111/j.1432-1033.1993.tb17864.x; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P5808, DOI 10.1021/bi00440a016; PRELL B, 1980, EUR J BIOCHEM, V108, P389, DOI 10.1111/j.1432-1033.1980.tb04734.x; ROTH MJ, 1984, J BIOL CHEM, V259, P556; Saenger W, 1991, CURR OPIN STRUC BIOL, V1, P130, DOI 10.1016/0959-440X(91)90021-K; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TAPPER DP, 1981, NUCLEIC ACIDS RES, V9, P6787, DOI 10.1093/nar/9.24.6787; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	36	35	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11367	11373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157668				2022-12-27	WOS:A1994NF96600060
J	KOGA, T; YOSHIDA, Y; CAI, JQ; ISLAM, MO; IMAI, S				KOGA, T; YOSHIDA, Y; CAI, JQ; ISLAM, MO; IMAI, S			PURIFICATION AND CHARACTERIZATION OF 240-KDA CGMP-DEPENDENT PROTEIN-KINASE SUBSTRATE OF VASCULAR SMOOTH-MUSCLE - CLOSE RESEMBLANCE TO INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; CYCLIC-GMP; PLASMA-MEMBRANE; TRISPHOSPHATE RECEPTOR; SARCOPLASMIC-RETICULUM; INSP3 RECEPTOR; CA-2+ PUMP; PHOSPHORYLATION; CALCIUM; CELLS	The 240-kDa, cGMP-dependent protein kinase substrate protein obtained from porcine aortic smooth muscle, whose phosphorylation was closely associated with stimulation of plasma membrane Ca2+-pump ATPase (Yoshida, Y., Sun, H.-T., Cai, J.-Q., and Imai, S. (1991) J. Biol. Chem. 266, 19819-19825), was purified to near homogeneity by three successive chromatographic runs with calmodulin-, concanavalin A-, and heparin-Sepharose columns from microsomes solubilized with Triton X-100. The purified protein was found to bind inositol 1,4,5-trisphosphate (InsP3) in a specific, heparin-inhibitable manner with a K(d) of 2.0 nM and B(max) 450 pmol/mg protein (the binding of inositol 1,3,4,5-tetrakisphosphate was much weaker). In sedimentation experiments on a linear sucrose density gradient the InsP3 binding activity was always with the 240-kDa protein. Protein kinase G phosphorylated the InsP3 receptor purified from the rat cerebellum as well as the 240-kDa protein. Sialic acid content of the protein measured with Limulus polyphemus agglutinin was not significantly different from that of the cerebellar InsP3 receptor. Thus, 240-kDa protein closely resembles InsP3 receptor and may be a type of InsP3 receptor. The only difference was the behavior on SDS-polyacrylamide gel electrophoresis. The 240-kDa protein presented itself as two polypeptides with similar but slightly differing M(r) values, both of which were phosphorylated by protein kinase G.	NIIGATA UNIV,DEPT PHARMACOL,NIIGATA 951,JAPAN	Niigata University								BALTENSPERGER K, 1988, EUR J BIOCHEM, V172, P7, DOI 10.1111/j.1432-1033.1988.tb13848.x; BALTENSPERGER K, 1990, BIOCHEMISTRY-US, V29, P9753, DOI 10.1021/bi00493a035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CASNELLI.JE, 1974, P NATL ACAD SCI USA, V71, P1891, DOI 10.1073/pnas.71.5.1891; CASNELLIE JE, 1980, J BIOL CHEM, V255, P3770; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; FURUKAWA KI, 1987, J BIOCHEM-TOKYO, V101, P287, DOI 10.1093/oxfordjournals.jbchem.a121904; HINGORANI SR, 1991, ANAL BIOCHEM, V194, P204, DOI 10.1016/0003-2697(91)90169-T; IMAI S, 1990, J BIOCHEM-TOKYO, V107, P755, DOI 10.1093/oxfordjournals.jbchem.a123121; IVES HE, 1980, J BIOL CHEM, V255, P3777; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARKS TP, 1987, ARCH BIOCHEM BIOPHYS, V255, P361, DOI 10.1016/0003-9861(87)90404-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RAPOPORT RM, 1982, P NATL ACAD SCI-BIOL, V79, P6470, DOI 10.1073/pnas.79.21.6470; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WALAAS SI, 1986, J NEUROSCI, V6, P954; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; YOSHIDA Y, 1992, J BIOCHEM-TOKYO, V111, P559, DOI 10.1093/oxfordjournals.jbchem.a123796; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819	50	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11640	11647						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157697				2022-12-27	WOS:A1994NF96600099
J	KREIL, G				KREIL, G			PEPTIDES CONTAINING A D-AMINO-ACID FROM FROGS AND MOLLUSKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DELTA-OPIOID RECEPTORS; AMPHIBIAN SKIN; ACHATINA-FULICA; HIGH-AFFINITY; PHYLLOMEDUSA-BICOLOR; PREPEPTIDE SEQUENCE; RAT-TISSUES; D-ALANINE; DERMORPHIN; RESIDUE				KREIL, G (corresponding author), AUSTRIAN ACAD SCI,INST MOLEC BIOL,BILLROTHSTR 11,A-5020 SALZBURG,AUSTRIA.							BARRA D, 1994, IN PRESS PEPTIDES, V15; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BIERBAUM G, 1993, INT J MICROBIOL VIRO, V278, P1; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BROCCARDO M, 1981, BRIT J PHARMACOL, V73, P625, DOI 10.1111/j.1476-5381.1981.tb16797.x; CSORDAS A, 1970, MONATSH CHEM, V101, P182, DOI 10.1007/BF00907538; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; ERSPAMER V, 1992, INT J DEV NEUROSCI, V10, P3, DOI 10.1016/0736-5748(92)90003-I; ERSPAMER V, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90343-2; ERSPAMER V, 1983, NEUROENDOCRINE PERSP, V2, P37; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V177, P847, DOI 10.1016/0006-291X(91)91867-C; FUJISAWA Y, 1992, COMP BIOCHEM PHYS C, V102, P91, DOI 10.1016/0742-8413(92)90049-D; GEVERS W, 1968, P NATL ACAD SCI USA, V60, P269, DOI 10.1073/pnas.60.1.269; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; GIBSON BW, 1992, 40TH P ASMS C MASS S, P1543; KALETTA C, 1991, EUR J BIOCHEM, V199, P411, DOI 10.1111/j.1432-1033.1991.tb16138.x; KAMATANI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1015, DOI 10.1016/S0006-291X(89)80103-2; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; LAZARUS LH, 1989, J BIOL CHEM, V264, P3047; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MIGNOGNA G, 1992, FEBS LETT, V302, P151, DOI 10.1016/0014-5793(92)80427-I; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P316; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1989, NEUROPEPTIDES, V13, P51, DOI 10.1016/0143-4179(89)90021-8; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; MOR A, 1991, J BIOL CHEM, V266, P6264; MOR A, 1990, BIOCHEM BIOPH RES CO, V170, P30, DOI 10.1016/0006-291X(90)91236-L; NEGRI L, 1981, PEPTIDES, V2, P45, DOI 10.1016/0196-9781(81)90009-7; OHTA N, 1991, BIOCHEM BIOPH RES CO, V178, P486, DOI 10.1016/0006-291X(91)90133-R; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SEETHALER G, 1991, J CELL BIOL, V114, P1125, DOI 10.1083/jcb.114.6.1125; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; TOOYAMA I, 1993, P NATL ACAD SCI USA, V90, P9635, DOI 10.1073/pnas.90.20.9635; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361	40	64	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10967	10970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157620				2022-12-27	WOS:A1994NF96600001
J	LOUNSBURY, KM; BEDDOW, AL; MACARA, IG				LOUNSBURY, KM; BEDDOW, AL; MACARA, IG			A FAMILY OF PROTEINS THAT STABILIZE THE RAN/TC4 GTPASE IN ITS GTP-BOUND CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CYTOSOL; CHROMOSOME CONDENSATION; BINDING PROTEIN; SUBSEQUENT BINDING; RCC1; REGULATOR; MITOSIS; GENES; DNA; COMPLEMENTATION	Ran/TC4, referred to here as Ran1, is a 25-kilodalton nuclear GTP-binding protein with an acidic C terminus that lacks any consensus prenylation sites. Here, we use a nitrocellulose overlay assay to identify potential effector proteins that bind specifically and with high affinity to the GTP-bound form of Ran1. GTP-Ran1 is shown to bind a variety of proteins, present in many eukaryotic tissues and cell extracts. A 28-kDa protein is cytosolic, whereas others, consisting of proteins of 86-300 kDa, are primarily localized in the nucleus. Binding is highly specific and is not detected by other small GTPases, such as c-Ha-Ras or Rab3A. Both deletion of the C-terminal -DEDDDL acidic sequence or alteration of the N terminus of Ran1 inhibits binding. However, these altered forms of Ran1 maintain the capacity to bind guanyl nucleotides and interact with the nucleotide exchange factor. The Ran1-binding proteins potently inhibit release of GTP from Ran1. These proteins can therefore maintain Ran1 in the ''on'' state and are potential down-stream effectors for Ran1-dependent cellular processes.	UNIV VERMONT,COLL MED,VERMONT COMPREHENS CANC CTR,BURLINGTON,VT 05405	University of Vermont	LOUNSBURY, KM (corresponding author), UNIV VERMONT,COLL MED,DEPT PATHOL,MED ALUMNI BLDG,BURLINGTON,VT 05405, USA.				NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA22435] Funding Source: Medline; NIEHS NIH HHS [EST3207122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KORNBERG A, 1959, METHOD ENZYMOL, V1, P451; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; SASAKI T, 1990, J BIOL CHEM, V265, P2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UCHIDA S, 1990, MOL CELL BIOL, V10, P557; UEDA T, 1990, J BIOL CHEM, V265, P9373; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YONEDA Y, 1988, SCIENCE, V242, P276	35	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11285	11290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157660				2022-12-27	WOS:A1994NF96600049
J	MINOWA, T; MINOWA, MT; MOURADIAN, MM				MINOWA, T; MINOWA, MT; MOURADIAN, MM			NEGATIVE MODULATOR OF THE RAT D(2) DOPAMINE-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; MOLECULAR-CLONING; PROMOTER REGION; EXPRESSION; SP1; D1; DNA; AFFINITY; FAMILY; TARGET	The rat D2 dopamine receptor gene is transcribed from a TATA-less promoter that has an initiator-like sequence and several putative Sp1 binding sites. The main activator of this gene is between nucleotides -75 and -29, and a strong negative modulator is located between bases -217 and -76 (Minowa, T., Minowa, M. T., and Mouradian, M. M. (1992) Biochemistry 31, 8389-8396). In the present investigation, a small deletion series within this negative modulator fused with the reporter gene for chloramphenicol acetyltransferase was used to transfect the D2-expressing cells, NB41A3. Two cis-acting functional DNA sequences were identified: a 41-base pair segment between nucleotides -116 and -76 (D2Neg-B), which decreased transcription from the D2 promoter by about 45%, and a 26-base pair segment between nucleotides -160 and -135 (DNeg-A), which, in the presence of the downstream negative modulator, reduced transcription down to the level of a promoterless vector. DNase I footprinting, gel mobility shift, and competitive cotransfection experiments suggested that D2Neg-A functions without trans-acting factors, whereas D2Neg-B interacts with nuclear factors at its Sp1 binding sequences. Gel supershift with anti-Sp1 antibody and UV cross-linking experiments revealed that a novel 130-kDa factor as well as Sp1 interact with D2Neg-B in NB41A3 cells. This novel protein recognizing Sp1 binding sequences in the D2 gene negative modulator is also found in nuclear extract from the rat striatum.	NINCDS,EXPTL THERAPEUT BRANCH,GENET PHARMACOL UNIT,BLDG 10,RM 5C116,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X				Ausubel FM, 1988, MOL REPROD DEV; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CRESS I, 1987, RECEPTOR BIOCH METHO, V8; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE T, 1978, NATURE, V274, P897, DOI 10.1038/274897a0; MAY E, 1992, J VIROL, V66, P3347, DOI 10.1128/JVI.66.6.3347-3354.1992; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MOURADIAN MM, 1988, ANN NEUROL, V24, P372, DOI 10.1002/ana.410240304; PIERCE AJ, 1992, NUCLEIC ACIDS RES, V20, P6583, DOI 10.1093/nar/20.24.6583; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTER M, 1980, NATURE, V286, P157, DOI 10.1038/286157a0; SEEMAN P, 1980, PHARMACOL REV, V32, P229; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	31	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11656	11662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157698				2022-12-27	WOS:A1994NF96600101
J	MOOKHTIAR, KA; KALINOWSKI, SS; ZHANG, DL; POULTER, CD				MOOKHTIAR, KA; KALINOWSKI, SS; ZHANG, DL; POULTER, CD			YEAST SQUALENE SYNTHASE - A MECHANISM FOR ADDITION OF SUBSTRATES AND ACTIVATION BY NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESQUALENE PYROPHOSPHATE; MOLECULAR-CLONING; POTENT INHIBITOR; SYNTHETASE; PURIFICATION; SOLUBILIZATION; LIVER; GENE; BIOSYNTHESIS; DIPHOSPHATE	Squalene synthase catalyzes the condensation of two molecules of farnesyl diphosphate (FPP) to give presqualene diphosphate (PSPP) and the subsequent reductive rearrangement of PSPP to squalene. Previous studies of the mechanism of addition of FPP to the enzyme have led to conflicting interpretations of initial velocity measurements (Beytia, E., Qureshi, A. A., and Porter, J. W. (1973) J. Biol. Chem. 248,1856-1867; Agnew, W. S., and Popjak, G. (1978) J. Biol. Chem. 253,4566-4573). Initial velocities for synthesis of PSPP and squalene were measured over a wider range of FPP and NADPH concentrations than previously reported, using a soluble form of recombinant enzyme. In the absence of NADPH, PSPP formation was activated by FPP at concentrations above approximately 0.5 muM. At fixed levels of NADPH, the dependence of initial rates of PSPP and squalene synthesis on FPP concentrations indicated that the C-15 substrate added by a sequential mechanism. In addition, NADPH stimulated synthesis of PSPP by 40-fold at saturating levels of the cofactor. This stimulation is, at least in part, by reduction of PSPP to squalene.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543	Utah System of Higher Education; University of Utah; Bristol-Myers Squibb					NIGMS NIH HHS [GM 25521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNEW WS, 1978, J BIOL CHEM, V253, P4566; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BEYTIA E, 1973, J BIOL CHEM, V248, P1856; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BILLER SA, 1991, J AM CHEM SOC, V113, P8522, DOI 10.1021/ja00022a050; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DEMONTELLANO PRO, 1976, J AM CHEM SOC, V98, P2018; DEMONTELLANO PRO, 1977, BIOCHEMISTRY-US, V16, P2680; DEMPSEY ME, 1974, ANNU REV BIOCHEM, V43, P967, DOI 10.1146/annurev.bi.43.070174.004535; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FEGUEUR M, 1991, CURR GENET, V20, P365, DOI 10.1007/BF00317063; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1989, J AM CHEM SOC, V111, P3734, DOI 10.1021/ja00192a036; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; RODRIGUEZ CL, 1990, THESIS U UTAH; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHLOSS JV, 1984, BIOCHEMISTRY-US, V23, P4572, DOI 10.1021/bi00315a010; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; WEINSTEIN JD, 1986, ARCH BIOCHEM BIOPHYS, V245, P44, DOI 10.1016/0003-9861(86)90188-8; ZHANG DL, 1993, ARCH BIOCHEM BIOPHYS, V304, P133, DOI 10.1006/abbi.1993.1331	30	29	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11201	11207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157649				2022-12-27	WOS:A1994NF96600037
J	BENEVIDES, JM; WEISS, MA; THOMAS, GJ				BENEVIDES, JM; WEISS, MA; THOMAS, GJ			RAMAN SPECTRAL STUDIES OF NUCLEIC-ACIDS .47. AN ALTERED SPECIFICITY MUTATION IN THE LAMBDA-REPRESSOR INDUCES GLOBAL REORGANIZATION OF THE PROTEIN-DNA INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATOR-BINDING DOMAIN; N-TERMINAL DOMAIN; TURN-HELIX MOTIF; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; WILD-TYPE; RECOGNITION; SPECTROSCOPY; STABILITY; COMPLEX	The lambda repressor exhibits structural characteristics of lock and key complementarity through the helix-turn-helix motif, and of induced fit by virtue of DNA-dependent folding of the N-terminal arm. In both cases, molecular recognition is mediated by direct contacts between amino acids and DNA bases. The extent to which such contacts function as discrete elements in a protein-DNA recognition code is not known. Because of the relevance of protein recognition to the broader issue of protein design, and because the lambda system serves as a prototype for gene regulation, we have employed laser Raman and H-1 NMR spectroscopy to compare free and operator-bound structures of A repressor variants which are known to exhibit altered DNA-binding specificities. Ex perimental design is based upon a previous biochemical study of mutations in the repressor N-terminal arm (K4Q) and helix-turn-helix motif (G48S) (Nelson, H. C, M., and Sauer, R. T. (1986) J. Mol. Biol. 192, 27-38). These mutations, which were originally isolated by loss of function (K4Q) and second-site reversion (G48S), are of particular interest in light of their complex effects on sequence specificity at multiple positions in the operator site (Benson, N., Adams, C., and Youderian, P. (1992) Genetics 130, 17-26). Laser Raman and H-1 NMR spectra of repressor variants carrying one (G48S) or two mutations (K4Q/G48S) are similar to those of the native wild type repressor and are in accord with the x-ray crystal structure. Remarkably, however, the complexes of wild type and mutant repressors exhibit extensive differences both in the global DNA structure and in the environments of key functional groups along the major groove. By demonstrating that single amino acid substitutions can induce global reorganization of a protein-DNA interface, the present results establish that repressor-operator recognition in solution cannot be explained in terms of a simple recognition code.	UNIV MISSOURI,SCH BIOL SCI,DIV CELL BIOL & BIOPHYS,KANSAS CITY,MO 64110; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	University of Missouri System; University of Missouri Kansas City; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018758] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18758] Funding Source: Medline; NICHD NIH HHS [HD26465] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P5955, DOI 10.1021/bi00238a020; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P4381, DOI 10.1021/bi00232a003; BENEVIDES JM, 1984, NUCLEIC ACIDS RES, V12, P5913, DOI 10.1093/nar/12.14.5913; BENSON N, 1992, GENETICS, V130, P17; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DIJKSTRA S, 1991, J MOL STRUCT, V242, P283, DOI 10.1016/0022-2860(91)87142-5; ELIASON JL, 1985, P NATL ACAD SCI USA, V82, P2339, DOI 10.1073/pnas.82.8.2339; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERFURTH SC, 1972, P NATL ACAD SCI USA, V69, P938, DOI 10.1073/pnas.69.4.938; EVERTSZ EM, 1991, BIOCHEMISTRY-US, V30, P1149, DOI 10.1021/bi00218a037; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HECHT MH, 1985, J MOL BIOL, V186, P53, DOI 10.1016/0022-2836(85)90256-6; HECHT MH, 1985, J CELL BIOCHEM, V29, P217, DOI 10.1002/jcb.240290306; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HOCH JC, 1987, J MAG RESON, V72, P324; HOGAN M, 1983, NATURE, V304, P752, DOI 10.1038/304752a0; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; LAW SM, 1993, J MOL BIOL, V230, P161, DOI 10.1006/jmbi.1993.1133; LETELLIER R, 1986, J BIOMOL STRUCT DYN, V3, P671, DOI 10.1080/07391102.1986.10508455; Li Y, 1981, Prog Clin Biol Res, V64, P271; Nelson H C, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P441; NELSON HCM, 1986, J MOL BIOL, V192, P27, DOI 10.1016/0022-2836(86)90461-4; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; REILLY KE, 1992, BIOCHEMISTRY-US, V31, P3118, DOI 10.1021/bi00127a012; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SAUER RT, 1987, NEW FRONTIERS STUDY, P177; SENGUPTA PK, 1987, BIOPOLYMERS, V26, pS99, DOI 10.1002/bip.360260011; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; SIAMWIZA MN, 1975, BIOCHEMISTRY-US, V14, P4870, DOI 10.1021/bi00693a014; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUSI H, 1974, BIOCHIM BIOPHYS ACTA, V312, P311; THOMAS GJ, 1986, BIOCHEMISTRY-US, V25, P6768, DOI 10.1021/bi00370a007; THOMAS GJ, 1988, NUCLEIC ACIDS MOL BI, V2, P1; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P890, DOI 10.1021/bi00377a033; WEISS MA, 1984, BIOCHEMISTRY-US, V23, P5090, DOI 10.1021/bi00317a002; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P897, DOI 10.1021/bi00377a034; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WEISS MA, 1990, J MAGN RESON, V86, P626, DOI 10.1016/0022-2364(90)90041-7	47	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10869	10878						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144673				2022-12-27	WOS:A1994NF01700100
J	CRICK, DC; SCOCCA, JR; RUSH, JS; FRANK, DW; KRAG, SS; WAECHTER, CJ				CRICK, DC; SCOCCA, JR; RUSH, JS; FRANK, DW; KRAG, SS; WAECHTER, CJ			INDUCTION OF DOLICHYL-SACCHARIDE INTERMEDIATE BIOSYNTHESIS CORRESPONDS TO INCREASED LONG-CHAIN CIS-ISOPRENYLTRANSFERASE ACTIVITY DURING THE MITOGENIC RESPONSE IN MOUSE B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; HAMSTER OVARY CELLS; ROUGH ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; SEA-URCHIN; BRAIN; CHOLESTEROL; LYMPHOCYTES; KINASE; DIFFERENTIATION	There are large increases in the rates of Glc(3)-Man(9)GlcNAc(2)-P-P-Dol (Oligo-P-P-Dol) biosynthesis and protein N-glycosylation during the proliferative response of murine B lymphocytes (B cells) to bacterial lipopolysaccharide (LPS). To learn more about the regulation of dolichyl-saccharide biosynthesis, the possible relationships between developmental changes in specific steps in dolichyl phosphate (Dol-P) and N-acetyl-glucosaminylpyrophosphoryldolichol (GlcNAc-P-P-Dol) biosynthesis and the induction of Oligo-P-P-Dol biosynthesis were investigated. These studies describe an impressive induction of long chain cis-isoprenyltransferase (cis-IPTase) activity, an enzyme system required for the chain elongation stage in de novo Dol-P synthesis, which corresponded to the striking increase in the rate of Oligo-P-P-Dol biosynthesis in LPS-activated B cells. The cellular level and specific activity of cis-IPTase increase 15-fold in LPS-treated cells with relatively unaltered affinity for isopentenyl pyrophosphate. The rates of Dol-P and Oligo-P-P-Dol synthesis increased substantially when cis-IPTase activity was induced, suggesting a regulatory relationship between the level of cis-IPTase activity and lipid intermediate synthesis. Distinctly different developmental patterns were observed for cis-IPTase and HMG-CoA reductase activity, and when sterol biosynthesis was drastically inhibited by lovastatin, the rate of synthesis of Dol-P was slightly higher in the presence of the drug. Modest elevations in the cellular levels of dolichol kinase, Dol-P phosphatase, and UDP-GlcNAc:Dol-P N-acetylglucosaminylphosphoryltransferase (L-G1PT) activities were also observed, but these changes were relatively small compared with the increases in cis-IPTase activity and the rates of Dol-P, GlcNAc-P-P-Dol, and Oligo-P-P-Dol synthesis. The expression of the L-G1PT gene is an early event in the developmental program for Oligo-P-P-Dol synthesis, but GlcNAc-P-P-Dol formation is apparently not rate-limiting. In summary, large increases in cis-IPTase activity and the rate of Dol-P biosynthesis appear to play a key regulatory role in the induction of Oligo-P-P-Dol biosynthesis during the proliferative response of B cells to LPS, and the biosynthetic pathways for Dol-P and cholesterol are regulated independently in dividing B cells.	UNIV KENTUCKY,COLL MED,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	University of Kentucky; Johns Hopkins University			Crick, Dean/H-8251-2017	Crick, Dean/0000-0001-9281-7058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036065, R01GM036570] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36570, GM36065] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BHAT NR, 1991, J NEUROCHEM, V56, P339, DOI 10.1111/j.1471-4159.1991.tb02600.x; BURTON WA, 1981, J BIOL CHEM, V256, P632; CARSON DD, 1981, J BIOL CHEM, V256, P1552; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; CRICK DC, 1994, J NEUROCHEM, V62, P247; CRICK DC, 1992, GLYCOBIOLOGY, V2; CRICK DC, 1993, GLYCOBIOLOGY, V3; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; EGGENS I, 1990, J EXP PATHOL, V71, P219; EULLINS, 1991, IN VITRO CELL DEV, V27, pA120; HARFORD JB, 1977, BIOCHEM BIOPH RES CO, V76, P1036, DOI 10.1016/0006-291X(77)90960-3; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; JAMES MJ, 1980, BIOCHIM BIOPHYS ACTA, V619, P432, DOI 10.1016/0005-2760(80)90094-6; KAIDEN A, 1991, SOMAT CELL MOLEC GEN, V17, P15, DOI 10.1007/BF01233202; KAIDEN A, 1991, TRENDS GLYCOSCI GLYC, V3, P275; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLER RK, 1979, J BIOL CHEM, V254, P9966; KRAG SS, 1977, J BIOL CHEM, V252, P2621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LENNARZ WJ, 1985, TRENDS BIOCHEM SCI, V10, P248, DOI 10.1016/0968-0004(85)90144-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; MELCHERS F, 1974, EUR J IMMUNOL, V4, P181, DOI 10.1002/eji.1830040306; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; POTTER JER, 1981, J BIOL CHEM, V256, P2371; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; ROSSIGNOL DP, 1981, J BIOL CHEM, V256, P538; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; RUSH JS, 1988, ARCH BIOCHEM BIOPHYS, V267, P305, DOI 10.1016/0003-9861(88)90036-7; RUSH JS, 1991, ARCH BIOCHEM BIOPHYS, V284, P63, DOI 10.1016/0003-9861(91)90264-J; RUSH JS, 1987, ARCH BIOCHEM BIOPHYS, V259, P567, DOI 10.1016/0003-9861(87)90523-6; SAGAMI H, 1993, J BIOL CHEM, V268, P10109; Sambrook J, 1989, MOL CLONING LABORATO; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHOHAT M, 1973, EUR J IMMUNOL, V3, P680, DOI 10.1002/eji.1830031106; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; SUMBILLA C, 1985, METHOD ENZYMOL, V111, P471; VOLPE JJ, 1987, DEV BRAIN RES, V31, P193, DOI 10.1016/0165-3806(87)90117-9; WAECHTER CJ, 1983, J BIOL CHEM, V258, P5117; WAECHTER CJ, 1989, NEUROBIOLOGY GLYCOCO, P127; WALDMAN BC, 1987, J CELL PHYSIOL, V131, P302, DOI 10.1002/jcp.1041310303; WHITE DA, 1981, ARCH BIOCHEM BIOPHYS, V208, P30, DOI 10.1016/0003-9861(81)90119-3; ZHU JF, 1993, GLYCOBIOLOGY, V3; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895; [No title captured]	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10559	10565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144643				2022-12-27	WOS:A1994NF01700057
J	PANIGRAHI, GB; SADOWSKI, PD				PANIGRAHI, GB; SADOWSKI, PD			INTERACTION OF THE NH2-TERMINAL AND COOH-TERMINAL DOMAINS OF THE FLP RECOMBINASE WITH THE FLP RECOGNITION TARGET SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMID; 2-MU CIRCLE; DNA; PROTEIN; SITE; CONTACTS; BINDING; CLEAVAGE; GROOVES	The FLP protein that is encoded by the 2-mu M plasmid of yeast Saccharomyces cerevisiae is a 45-kDa site-specific recombinase that belongs to the Int family of recombination proteins. FLP catalyzes a recombination event within the plasmid by binding specifically to each of three 13-base pair (bp) symmetry elements of the FLP recognition target (FRT). We have shown previously that partial proteolysis of the FLP protein by proteinase H resulted in a COOH-terminal fragment of size 32 kDa (P32) and an NH2-terminal fragment of 13 kDa (P13). In this study we have used footprinting with dimethyl sulfate to show that P32 binds specifically to the outer 9 bp of the 13 bp symmetry element. Binding of P13 alone to the FRT site was not detectable in this assay. However, when P13 and P32 were incubated together with the FRT site, protection of the remaining 4-bp region of the symmetry element was observed. To confirm these results we used bromodeoxyuridine (BrdU)-dependent UV cross-linking. P32 became crosslinked to the substrate that contained BrdU substitutions in the outer 9 bp of a 13-bp symmetry element, but not to one with the BrdU substitutions in the inner 4 bp. Reciprocally P13 cross-linked to the latter substrate but not the former. Cross-linking was both BrdU and ultraviolet light dependent. This study indicates that the COOH-terminal domain (P32) of FLP recognizes the outer 9 bp of the 13-bp symmetry element, whereas its NH2-terminal domain (P13) is needed for protection of the inner 4 bp of each symmetry element.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto								ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HUTCHINSON F, 1973, Q REV BIOPHYS, V6, P201, DOI 10.1017/S0033583500001141; PAN G, 1991, J BIOL CHEM, V226, P11347; PAN GH, 1993, J BIOL CHEM, V268, P22546; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5927, DOI 10.1093/nar/20.22.5927; PANIGRAHI GB, 1991, BIOCHEMISTRY-US, V30, P9761, DOI 10.1021/bi00104a028; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7	18	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10940	10945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144679				2022-12-27	WOS:A1994NF01700109
J	SALTO, R; BABE, LM; LI, J; ROSE, JR; YU, ZH; BURLINGAME, A; DEVOSS, JJ; SUI, ZH; DEMONTELLANO, PO; CRAIK, CS				SALTO, R; BABE, LM; LI, J; ROSE, JR; YU, ZH; BURLINGAME, A; DEVOSS, JJ; SUI, ZH; DEMONTELLANO, PO; CRAIK, CS			IN-VITRO CHARACTERIZATION OF NONPEPTIDE IRREVERSIBLE INHIBITORS OF HIV PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; TYPE-2; SITE; INACTIVATION; CONSTRUCTION; INFECTIVITY; MATURATION; PROTEINASE; ENZYMES; DESIGN	The irreversible inhibition of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-8) proteases by 1,2-epoxy-3-(p-nitrophenoxy)propane (EPNP) and eight haloperidol derivatives has been studied. EPNP specifically inhibits HIV-1 and HIV-2 proteases with a stoichiometry of one EPNP molecule/dimeric enzyme. The site of modification of HIV-2 protease by EPNP has been unambiguously identified as Asp-25 using high performance tandem mass spectrometry. The haloperidol derivatives assayed consist of epoxides, ynones, and alpha,beta- unsaturated ketones. The K-inact values for these haloperidol derivatives range from 10.7 to 521 mu m for HIV-1 protease and from 8.6 to 283 mu m for the HIV-2 enzyme, being in some cases similar to 1000-fold more potent irreversible inhibitors of HIV proteases than EPNP This potency results from the haloperidol character of the compounds and the chemical reactivity of the groups capable of forming a covalent bond with the enzyme. Covalent modification of HIV-2 protease by a radiolabeled epoxide derivative of haloperidol, UCSF 84, is prevented by EPNP and the peptidomimetic transition state analog U-85548. In similar experiments, incorporation of UCSF 84 into HIV-1 protease is partially prevented by these active-site inhibitors. In contrast, a mutant HIV-1 protease, HIV-1 PR C95M, in which Cys-95 has been replaced by Met, is labeled 50% less than HIV-1 protease and is fully protected by EPNP and U-85548. These results indicate the presence of 2 reactive residues in HTV-1 protease: Cys-95 and another located in the active site of the enzyme. The alpha,beta-unsaturated ketone derivative of halo peridol, UCSF 191, which is stable over a broad pH range, was used to study the pH profile of inactivation of HPV-1 and HIV-2 proteases. Comparison of the profiles of inactivation of wild-type HTV-1 protease, HPV-1 PR C95M, and HIV-1 PR C67L as well as HIV-2 protease (which has no cysteine residues) reveals the contribution of Cys-95 to the reactivity of these irreversible inhibitors. The inhibitors UCSF 70, UCSF 84, UCSF 115, UCSF 142, and UCSF 191 reduce p55(gag) polyprotein processing when assayed in a mammalian cell line that produces HIV-1 viral particles lacking the envelope.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Salto, Rafael/A-6486-2011	Salto, Rafael/0000-0002-7044-3611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039552] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07175, GM39552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BABE LM, 1990, UCLA SYM BI, V110, P71; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DEVOSS J, 1994, IN PRESS J MED CHEM; FRANCHINI G, 1988, AIDS RES HUM RETROV, V4, P243, DOI 10.1089/aid.1988.4.243; GRANT SK, 1992, BIOORG MED CHEM LETT, V2, P1441, DOI 10.1016/S0960-894X(00)80528-4; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; JAMES MNG, 1977, NATURE, V267, P808, DOI 10.1038/267808a0; KARLSTROM AR, 1993, ARCH BIOCHEM BIOPHYS, V304, P163, DOI 10.1006/abbi.1993.1334; KNOWLES JR, 1987, SCIENCE, V236, P1252; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PICHUANTES S, 1990, J BIOL CHEM, V265, P13890; RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003; RICHMAN DD, 1993, ANNU REV PHARMACOL, V33, P149, DOI 10.1146/annurev.pa.33.040193.001053; RITTENHOUSE J, 1990, BIOCHEM BIOPH RES CO, V171, P60, DOI 10.1016/0006-291X(90)91356-W; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROESTORFF P, 1984, J BIOMED MASS SPECTR, V11, P601; ROSE JR, 1993, J BIOL CHEM, V268, P11939; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUI ZH, 1993, SYNTHESIS-STUTTGART, P803; TANG J, 1971, J BIOL CHEM, V246, P4510; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544	35	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10691	10698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144659				2022-12-27	WOS:A1994NF01700075
J	POLOTSKAYA, A; ZHAO, YM; LILLY, MB; KRAFT, AS				POLOTSKAYA, A; ZHAO, YM; LILLY, MB; KRAFT, AS			MAPPING THE INTRACYTOPLASMIC REGIONS OF THE ALPHA-GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR NECESSARY FOR CELL-GROWTH REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GM-CSF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; EXPRESSION CLONING; MOLECULAR-CLONING; INTERLEUKIN-3; RECONSTITUTION; ERYTHROPOIETIN	The granulocyte-macrophage colony-stimulating factor (GM CSF) receptor is composed of an alpha subunit which binds GM-CSF and a beta subunit, which together form the high affinity receptor. By transfecting the human alpha subunit into murine Ba/F3 cells, we have been able to investigate the role of the short 54-amino acid intracytoplasmic portion (amino acid 346-400) of this subunit in mediating cell growth. We have shown that the intracytoplasmic amino acids 346-382 are necessary for GM CSF-mediated cell growth. In contrast, amino acids 382-400 can be removed without effect. The stable transfection of the human beta subunit into the cell lines containing the mutant alpha subunits did not affect the growth characteristics of these cells. The ability of GMCSF to stimulate cell growth of the Ba/F3 cells alpha subunit transfectants was correlated with the ability of this hormone to translocate protein kinase C to the particulate fraction. In contrast, the ability of GM-CSF addition to increase phosphorylation of the human beta subunit did not correlate with cell growth and required the entire intracytoplasmic domain of the alpha subunit. These results demonstrate an important role for the intracytoplasmic portion of the alpha subunit in mediating both signal transduction and cell cycle commitment stimulated by GM-CSF.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV WASHINGTON,DIV MED ONCOL,SEATTLE,WA 98108; VET ADM MED CTR,SEATTLE,WA 98108	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [R55CA045672, R01CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DOMAIN J, 1993, BLOOD, V82, P1445; DURONIO V, 1992, J BIOL CHEM, V267, P21856; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JUBINSKY PT, 1993, BLOOD, V81, P587; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LILLY M, 1992, ONCOGENE, V7, P727; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NISHIMURA M, 1992, BLOOD, V80, P1045; OKUDA K, 1992, BLOOD, V79, P2880; PARK LS, 1986, J BIOL CHEM, V261, P4177; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN PHB, 1989, BLOOD, V73, P406; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	32	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14607	14613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182067				2022-12-27	WOS:A1994NM06500048
J	REDOWICZ, MJ; MARTIN, B; ZOLKIEWSKI, M; GINSBURG, A; KORN, ED				REDOWICZ, MJ; MARTIN, B; ZOLKIEWSKI, M; GINSBURG, A; KORN, ED			EFFECTS OF PHOSPHORYLATION AND NUCLEOTIDES ON THE CONFORMATION OF MYOSIN-II FROM ACANTHAMOEBA-CASTELLANII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-ACTIVATED ATPASE; AMINO-ACID-SEQUENCE; HEAVY-CHAIN; ASPARTATE TRANSCARBAMOYLASE; MG2+-ATPASE ACTIVITY; FILAMENT FORMATION; SITES; SUBFRAGMENT-1; TAIL; PURIFICATION	The actin-activated Mg2+-ATPase activity of filamentous Acanthamoeba myosin II is inactivated by phosphorylation of a short non-helical tailpiece at the C-terminal end of each heavy chain even though the catalytic sites are in the N-terminal globular head. Consistent with this effect, phosphorylation at the tip of the tail alters the conformation of the head as shown by a shift in the principal site of cleavage by endoproteinase Arg-C (Ganguly, C., Martin, B., Bubb, M., and Kern, E. D. (1992) J. Biol. Chem. 267, 20905-20908). We now show that the sedimentation coefficient of monomeric phospho-myosin II is 1.3-4.6% lower than that of dephospho-myosin II, which suggests that phosphorylation produces a less compact conformation with a small increase in frictional coefficient. As shown by changes in papain digestion patterns, bound nucleotide also affects the conformation of the head region of monomeric phospho- and dephospho-myosin II, the conformation of the head region of filamentous phospho- and dephospho-myosin II, and the conformation of the C-terminal region of the tail of filamentous phospho-myosin II, Conformational differences between the dephospho- and phospho-forms of myosin II in the presence of nucleotide, as detected by susceptibility to proteolysis, therefore, appear to be greater in filaments than in monomers. These results provide additional evidence for communication between the N-terminal heads and C-terminal tails of Acanthamoeba myosin II.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Korn, Edward D/F-9929-2012; Redowicz, Maria Jolanta/AAM-8020-2020; Redowicz, Maria Jolanta/R-4083-2016	Redowicz, Maria Jolanta/0000-0001-5834-471X				ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; APPLEGATE D, 1984, BIOCHEMISTRY-US, V23, P4779, DOI 10.1021/bi00315a038; ATKINSON MAL, 1987, J BIOL CHEM, V262, P15809; ATKINSON MAL, 1986, J BIOL CHEM, V261, P1844; ATKINSON MAL, 1986, J BIOL CHEM, V261, P3382; AUDEMARD E, 1988, J MUSCLE RES CELL M, V9, P197, DOI 10.1007/BF01773891; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COLLINS JH, 1981, J BIOL CHEM, V256, P2586; COTE GP, 1984, J BIOL CHEM, V259, P2781; COTE GP, 1981, J BIOL CHEM, V256, P2811; GANGULY C, 1992, J BIOL CHEM, V267, P20905; GANGULY C, 1990, J BIOL CHEM, V265, P9993; GANGULY C, 1992, J BIOL CHEM, V267, P20900; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5077, DOI 10.1021/bi00642a021; HOZUMI T, 1983, BIOCHEMISTRY-US, V22, P799, DOI 10.1021/bi00273a014; KUZNICKI J, 1985, J BIOL CHEM, V260, P1967; MARUTA H, 1977, J BIOL CHEM, V252, P6501; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORNET D, 1985, J MOL BIOL, V183, P479, DOI 10.1016/0022-2836(85)90015-4; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; MUHLRAD A, 1990, EUR J BIOCHEM, V192, P663, DOI 10.1111/j.1432-1033.1990.tb19273.x; MUHLRAD A, 1981, ARCH BIOCHEM BIOPHYS, V209, P304, DOI 10.1016/0003-9861(81)90285-X; OKAMOTO Y, 1980, J BIOCHEM, V88, P361, DOI 10.1093/oxfordjournals.jbchem.a132981; POLLARD TD, 1978, J BIOL CHEM, V253, P4798; RAU DC, 1993, J BIOL CHEM, V268, P4612; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROULET A, 1993, EUR J BIOCHEM, V216, P89, DOI 10.1111/j.1432-1033.1993.tb18120.x; SHRAKE A, 1980, J BIOL CHEM, V255, P581; SINARD JH, 1989, J CELL BIOL, V109, P1537, DOI 10.1083/jcb.109.4.1537; SINARD JH, 1989, J CELL BIOL, V109, P1529, DOI 10.1083/jcb.109.4.1529; UENO H, 1984, J MOL BIOL, V180, P667, DOI 10.1016/0022-2836(84)90032-9; WERNER WE, 1989, J MOL BIOL, V206, P231, DOI 10.1016/0022-2836(89)90536-6; WIJMENGA SS, 1987, J BIOL CHEM, V262, P15803; YAMAMOTO K, 1989, J MOL BIOL, V209, P703, DOI 10.1016/0022-2836(89)90601-3	38	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13558	13563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175791				2022-12-27	WOS:A1994NK18400074
J	LEUNG, T; HOW, BE; MANSER, E; LIM, L				LEUNG, T; HOW, BE; MANSER, E; LIM, L			CEREBELLAR BETA-2-CHIMAERIN, A GTPASE-ACTIVATING PROTEIN FOR P21 RAS-RELATED RAC IS SPECIFICALLY EXPRESSED IN GRANULE CELLS AND HAS A UNIQUE N-TERMINAL SH2 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1; NEURONAL DIFFERENTIATION; MOLECULAR-CLONING; GENE ENCODES; BCR; CHIMAERIN; PRODUCT; RHO	beta-Chimaerin, a 30-kDa GTPase-activating protein (GAP) for the p21 Ras-related Rac, is expressed specifically in late stage spermatocytes (Leung, T., How, B.-E., Manser, E., and Lim, L. (1993) J. Biol. Chem. 268, 3813-3816). Using antibodies raised against beta-chimaerin, we detected a major 46-kDa RacGAP in the rat cerebellum. With beta-chimaerin cDNA as a probe and using polymerase chain reaction, cDNAs from both human and rat cerebellum were isolated. The human and rat cDNAs encoded sequences containing cysteine-rich and GAP domains identical to those of testis beta-chimaerin. The cDNAs also encoded an additional N-terminal SH2 (Src homology 2) domain, probably derived from the beta-chimaerin gene by alternate splicing. This SH2 domain of the predicted 54-kDa protein was strikingly similar to that of alpha 2-chimaerin, including replacement by glutamic acid of the invariant tryptophan present at the start of other SH2 domains. The SH2 domains of alpha- and beta-chimaerin thus represent a subset of SH2 domains. The cerebellar beta-chimaerin (beta 2-) is expressed mainly in granule cells and exhibits postnatal developmental increases. beta 2-Chimaerin was enriched in particulate/synaptosomal fractions. In the mouse weaver mutant lacking mature granule cells, there is a corresponding decrease in beta 2-chimaerin, which could well serve as a marker of granule cell differentiation.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	LEUNG, T (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERNSTEIN G, 1992, CELL, V70, P411; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LEUNG TKC, 1982, J NEUROCHEM, V39, P1496, DOI 10.1111/j.1471-4159.1982.tb12599.x; LEUNG TKC, 1992, GENOMICS, V12, P74, DOI 10.1016/0888-7543(92)90409-L; LI WJ, 1989, ONCOGENE, V4, P127; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHI T, 1991, ONCOGENE, V6, P1555; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1993, ONCOGENE, V8, P655; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	33	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12888	12892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175705				2022-12-27	WOS:A1994NH71600079
J	MACH, L; MORT, JS; GLOSSL, J				MACH, L; MORT, JS; GLOSSL, J			NONCOVALENT COMPLEXES BETWEEN THE LYSOSOMAL PROTEINASE CATHEPSIN-B AND ITS PROPEPTIDE ACCOUNT FOR STABLE, EXTRACELLULAR, HIGH-MOLECULAR-MASS FORMS OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASES; POLYACRYLAMIDE GELS; MAMMARY-GLAND; CYSTATIN-C; SECRETION; INHIBITORS; PROTEOGLYCAN; PURIFICATION; DEGRADATION; FIBROBLASTS	Although the lysosomal cysteine proteinase cathepsin B is alkaline pH-labile, active, stable high molecular mass forms have been reported previously from the culture medium of human and murine mammary tumor explants and the sputum of patients with purulent bronchiectasis. A similar, catalytically active, high molecular mass form of recombinant human cathepsin B produced in yeast has now been found to represent a noncovalent complex between the 30-kDa single chain enzyme and its 6-kDa propeptide formed during autocatalytic maturation of the proenzyme (see accompanying article; Mach, L., Mort, J. S., and Glossl, J. (1994) J. Biol. Chem. 269, 13030-13035). Incubation of the complex under acidic conditions resulted in dissociation and degradation of the inhibitory propeptide leading to increased enzymatic activity, as also observed for partially purified cathepsin B isoenzymes from purulent sputum and mammary tumor explant media. The stabilization of the processed proteinase as a noncovalent complex with its proregion provides an important mechanism whereby extracellular cathepsin B can lie dormant until regional acidification mediates its activity.	AGR UNIV VIENNA,ZENTRUM ANGEW GENET,A-1180 VIENNA,AUSTRIA; SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL H3G 1A6,PQ,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3A 2T6,PQ,CANADA	University of Natural Resources & Life Sciences, Vienna; McGill University; McGill University			Glössl, Josef/H-8208-2013	Glössl, Josef/0000-0002-5042-8828; Mach, Lukas/0000-0001-9013-5408				ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ACHKAR C, 1990, J BIOL CHEM, V265, P13650; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1973, BIOCHEM J, V131, P809, DOI 10.1042/bj1310809; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, BIOCHEM J, V287, P657, DOI 10.1042/bj2870657; BUTTLE DJ, 1988, BIOCHEM J, V254, P693, DOI 10.1042/bj2540693; BUTTLE DJ, 1991, BIOCHEM J, V276, P325, DOI 10.1042/bj2760325; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; KEPPLER D, 1988, CANCER RES, V48, P6855; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARCIC B, 1988, BIOCHEM BIOPH RES CO, V154, P765, DOI 10.1016/0006-291X(88)90206-9; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIL CR, 1982, ELECTROPHORESIS, V3, P17, DOI 10.1002/elps.1150030104; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; QIAN F, 1989, CANCER RES, V49, P4870; RECKLIES AD, 1985, BIOCHEM BIOPH RES CO, V131, P402, DOI 10.1016/0006-291X(85)91816-9; RECKLIES AD, 1982, CANCER RES, V42, P1026; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; RECKLIES AD, 1985, CANCER RES, V45, P2302; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW E, 1980, BIOCHEM J, V186, P385, DOI 10.1042/bj1860385; TOOZE J, 1991, EUR J CELL BIOL, V56, P187; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046	38	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13036	13040						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175724				2022-12-27	WOS:A1994NH71600100
J	SUNG, CK; SANCHEZMARGALET, V; GOLDFINE, ID				SUNG, CK; SANCHEZMARGALET, V; GOLDFINE, ID			ROLE OF P85 SUBUNIT OF PHOSPHATIDYLINOSITOL-3-KINASE AS AN ADAPTER MOLECULE LINKING THE INSULIN-RECEPTOR, P62, AND GTPASE-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								After insulin stimulation of rat HTC hepatoma cells overexpressing normal human insulin receptors (IR), an antiserum to the p85 subunit of phosphatidylinositol-3-kinase (PIK) (alpha-p85) immunoprecipitated three major tyrosine-phosphorylated proteins: IR, insulin receptor substrate-1 (IRS-l), and a new 62-kDa protein (p62). Studies with antibodies to GTPase activating protein (alpha-GAP) and p62 GAP-associated protein suggested that p62 was the same as (or closely related to) p62 GAP-associated protein. In order to understand how p62 interacts with p85, we employed: 1) antibodies to the p110 subunit of PIK (alpha-p110); and 2) antiserum to IRS-1. To determine which subunit of PIK (p110 or p85) p62 associates with, we first immunoprecipitated insulin-treated cell lysates with alpha-p110 and subsequently immunoprecipitated with alpha-p85 followed by Western blotting analysis with anti-phosphotyrosine antibody (alpha-PY). In response to insulin, most of the tyrosine-phosphorylated p62 was complexed to p85 alone rather than with the PIK heterodimer. Moreover, p62 was absent in alpha-IRS-1 immunoprecipitates. These data suggest that: 1) p62 GAP-associated protein is tyrosine phosphorylated after insulin stimulation of cells; 2) p62 and IRS-1 form separate complexes with p85; 3) p62-GAP complex may be linked to p85 that is not bound to p110; 4) p85 may serve as an adaptor molecule in insulin receptor signaling, interacting with and regulating other intracellular proteins via SH2 domains.			SUNG, CK (corresponding author), UNIV CALIF SAN FRANCISCO, MT ZION MED CTR, DEPT MED, DIV DIABET & ENDOCRINE RES, 1600 DIVISADERO ST, SAN FRANCISCO, CA 94120 USA.		Sánchez-Margalet, Victor/AAB-9986-2021	Sánchez-Margalet, Victor/0000-0001-8638-8680	NIDDK NIH HHS [DK44834] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044834] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAHN CR, 1993, 53RD BANT LECT ANN A; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARX J, 1992, SCIENCE, V257, P484, DOI 10.1126/science.1636083; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PORRAS A, 1992, J BIOL CHEM, V267, P21124; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; SUNG CK, 1989, J BIOL CHEM, V264, P18951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; ZHANG B, 1992, J BIOL CHEM, V267, P18320; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12503	12507						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175658				2022-12-27	WOS:A1994NH71600023
J	BRAESCHANDERSEN, S; STAMENKOVIC, I				BRAESCHANDERSEN, S; STAMENKOVIC, I			SIALYLATION OF THE B-LYMPHOCYTE MOLECULE CD22 BY ALPHA-2,6-SIALYLTRANSFERASE IS IMPLICATED IN THE REGULATION OF CD22-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; SURFACE EXPRESSION; ANTIGEN; PROTEIN; SIALYLTRANSFERASE; GLYCOSYLATION; ACTIVATION; RECEPTOR; CLONING; LIVER	The B cell surface receptor CD22 binds several sialoglycoproteins containing sialic acid in alpha 2,6 linkage, on the surface of B and T lymphocytes. Because lymphocytes adhere tightly to fibroblasts transfected with CD22 cDNA, it would appear reasonable to suggest that regulatory mechanisms might have evolved which prevent undesired CD22-mediated leukocyte aggregation. Here we provide evidence for the existence of at least one mechanism that might regulate CD22 interaction with ligands on adjacent cells. We demonstrate that sialylation of CD22 by beta-galactoside alpha 2,6-sialyltransferase abrogates CD22-mediated lymphocyte adhesion, and that adhesion can be restored by removal of alpha 2,6-linked sialic acid residues from the CD22 molecule. Taken together, our results suggest that alpha 2,6-sialyltransferase can both promote and inhibit CD22-ligand interactions. These observations provide the first direct evidence that receptor-ligand interactions mediated by an Ig superfamily molecule are under the control of a specific glycosyltransferase.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP E,DEPT PATHOL RES,BOSTON,MA 02129	Harvard University; Harvard Medical School	BRAESCHANDERSEN, S (corresponding author), MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02129, USA.				NCI NIH HHS [CA55735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PAULSON JC, 1977, J BIOL CHEM, V252, P8624; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; POWELL LD, 1993, J BIOL CHEM, V268, P7019; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	19	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11783	11786						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163475				2022-12-27	WOS:A1994NG37700019
J	LU, Y; HILL, KAW				LU, Y; HILL, KAW			THE INVARIANT ARGININE IN MOTIF 2 OF ESCHERICHIA-COLI ALANYL-TRANSFER-RNA SYNTHETASE IS IMPORTANT FOR CATALYSIS BUT NOT FOR SUBSTRATE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; STRUCTURAL RELATIONSHIPS; CRYSTAL-STRUCTURE; SEQUENCE; CODON; RESOLUTION; SITE	Structural moths 2 and 3, located in the active site of class II aminoacyl-tRNA synthetases, each contain an invariant arginine thought to participate in interactions with ATP. For Escherichia coli alanyl-tRNA synthetase (AlaRS), sequence comparisons indicate that Arg-69 should be aligned with the invariant arginine in motif 2 of other class II synthetases. Site-directed random mutagenesis has been employed to generate a set of proteins containing amino acid substitutions in a portion of motif 2 of AlaRS. In this set, only mutations at position 69 caused the enzyme to lose ability to complement growth of an alaS deletion strain, and proteins containing substitutions at position 69 alone are undetectable in a Western blot assay. A mutant protein containing the transposition of Arg-69 with Gly-71 does not complement growth but does accumulate in vivo and has thus been purified. Michaelis and dissociation constants for the interaction of this protein with ATP are indistinguishable from those of the wild-type enzyme. However, this two-position displacement of the arginine causes a decrease in the k(cat) for the ATP-PPi exchange reaction by 2 orders of magnitude. These data suggest a role for the invariant arginine of motif 2 in stabilization of the transition state during alanyladenylate synthesis.	LOMA LINDA UNIV, SCH MED, DEPT BIOCHEM, LOMA LINDA, CA 92350 USA	Loma Linda University								BONEKAMP F, 1988, NUCLEIC ACIDS RES, V16, P3013, DOI 10.1093/nar/16.7.3013; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CALENDAR R, 1966, PROCEDURES NUCLEIC A, P384; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1993, TRANSLATIONAL APPARATUS, P1; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEPOUPLANA LR, 1993, PROTEIN SCI, V2, P2259; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FILLEY SJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P46, DOI 10.1006/abbi.1993.1558; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; JASIN M, 1983, NATURE, V306, P441, DOI 10.1038/306441a0; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; PUTNEY SD, 1981, SCIENCE, V213, P1497, DOI 10.1126/science.7025207; PUTNEY SD, 1981, J BIOL CHEM, V256, P198; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WUU MX, 1993, ANAL BIOCHEM, V211, P320; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	30	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12137	12141						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163518				2022-12-27	WOS:A1994NG37700070
J	BJORKMAN, AJ; BINNIE, RA; COLE, LB; ZHANG, HD; HERMODSON, MA; MOWBRAY, SL				BJORKMAN, AJ; BINNIE, RA; COLE, LB; ZHANG, HD; HERMODSON, MA; MOWBRAY, SL			IDENTICAL MUTATIONS AT CORRESPONDING POSITIONS IN 2 HOMOLOGOUS PROTEINS WITH NONIDENTICAL EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; FUNCTIONAL-CHANGES; RIBOSE RECEPTOR; GALACTOSE; CHEMOTAXIS; TRANSPORT; TRANSDUCER; SILENT; SYSTEM	The x-ray structure of a mutant (Gly72 to Asp) of the Escherichia coli ribose-binding protein with altered transport function has been solved and refined to 2.2-angstrom resolution with a conventional R-factor (R-factor = SIGMA\\F(obs)\ - \F(calc)\\/SIGMA\F(obs)) of 16.0% and good stereochemistry. Comparison with the wild type ribose-binding protein shows that the structure is disturbed little at the actual mutation site, but quite appreciably in a neighboring loop. Changes in the surface of the protein at the site of mutation, however, seem to explain the functional effects. A corresponding mutation of the related glucose/galactose-binding protein has different structural and functional effects due to the different structural context of the mutation site in that protein. These results are consistent with the concept that these proteins have slightly different ways of interacting with the membrane components in transport and chemotaxis.	SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT MOLEC BIOL,BOX 590,S-75124 UPPSALA,SWEDEN; BIOCRYST PHARMACEUT INC,BIRMINGHAM,AL 35244; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Swedish University of Agricultural Sciences; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Mowbray, Sherry L/D-2141-2013					ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; ARGOS P, 1981, J BIOL CHEM, V256, P4357; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BINNIE RA, 1992, PROTEIN SCI, V1, P1642, DOI 10.1002/pro.5560011212; BOOS W, 1969, EUR J BIOCHEM, V10, P66; BRUNGER AT, 1992, X PLOR SYSTEM XRAY D; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUPLAY P, 1987, J MOL BIOL, V194, P675, DOI 10.1016/0022-2836(87)90244-0; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GALLOWAY DR, 1977, ARCH BIOCHEM BIOPHYS, V184, P496, DOI 10.1016/0003-9861(77)90459-3; HAZELBAUER GL, 1971, NATURE-NEW BIOL, V230, P101, DOI 10.1038/newbio230101a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JONES TA, 1993, O MANUAL; KEHRES DG, 1992, PROTEIN SCI, V1, P1652, DOI 10.1002/pro.5560011213; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Mowbray S L, 1990, Receptor, V1, P41; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; MOWBRAY SL, 1990, RECEPTOR PURIFICATIO, V2, P393; ORDAL GW, 1974, J BACTERIOL, V117, P517, DOI 10.1128/JB.117.2.517-526.1974; PARK C, 1986, J BACTERIOL, V167, P101, DOI 10.1128/jb.167.1.101-109.1986; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; SCHOLLE A, 1987, MOL GEN GENET, V208, P247, DOI 10.1007/BF00330450; STRANGE PG, 1976, P NATL ACAD SCI USA, V73, P762, DOI 10.1073/pnas.73.3.762; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; YAGHMAI R, 1993, EMBO J, V12, P1897, DOI 10.1002/j.1460-2075.1993.tb05838.x; ZHANG YH, 1992, J BIOL CHEM, V267, P22813; ZOU J, 1994, IN PRESS ACTA CRYSTA; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	37	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11196	11200						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157648				2022-12-27	WOS:A1994NF96600036
J	HOJIMA, Y; MORGELIN, MM; ENGEL, J; BOUTILLON, MM; VANDERREST, M; MCKENZIE, J; CHEN, GC; RAFI, N; ROMANIC, AM; PROCKOP, DJ				HOJIMA, Y; MORGELIN, MM; ENGEL, J; BOUTILLON, MM; VANDERREST, M; MCKENZIE, J; CHEN, GC; RAFI, N; ROMANIC, AM; PROCKOP, DJ			CHARACTERIZATION OF TYPE-I PROCOLLAGEN N-PROTEINASE FROM FETAL BOVINE TENDON AND SKIN - PURIFICATION OF THE 500-KILODALTON FORM OF THE ENZYME FROM BOVINE TENDON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; COLLAGEN FIBRILS; C-PROTEINASE; TERMINAL PROPEPTIDE; PC-COLLAGEN; CLEAVAGE; COPOLYMERIZATION; HOMOTRIMER; INHIBITION; PNCOLLAGEN	Procollagen N-proteinase (EC 3.4.24.14) is the enzyme that specifically cleaves the NH2-terminal propeptides from type I procollagen. Two forms of N-proteinase with apparent molecular sizes of 300 and 500 kDa were found in partially purified preparations from fetal bovine tendon extracts. The 500-kDa form of enzyme was purified 16,000-fold with a recovery of 8% from the extracts of the tendons by six purification steps. The purified enzyme was a neutral, Ca2+-dependent proteinase (5-10 mM) that was inhibited by metal chelators. The 500-kDa enzyme contained unreduced polypeptides of 58, 125, 170, and 190 kDa which were separated by polyacrylamide gel electrophoresis in sodium dodecyl sulfate. Electron microscopic study indicated that the enzyme molecules were generally globular and had diameters of 33 +/- 4 m. Other properties of the 500-kDa enzyme were: 1) the K(m) for type I procollagen is 35 nM at pH 7.5 and 35-degrees-C, and the k(cat) is 290 h-1; 2) the activation energy for reaction with type I procollagen is 10,050 cal mol-1; 3) the isoelectric point is 3.8; 4) the enzyme cleaves the NH2-terminal propeptides of type II procollagen as well as type I procollagen but not of type III procollagen; and 5) the enzyme specifically cleaves a -Pro-Gln- bond in the pro(alpha1(I) chain and an -Ala-Gln- bond in the pro-alpha2(I) chain. The bovine N-proteinase with a mass of 300 kDa was found to be similar to the 500-kDa enzyme and appeared to be a degraded form of the 500-kDa enzyme generated during purification. The N-proteinase from fetal bovine skin extracts also contained 300-kDa and 500-kDa enzyme forms.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; UNIV LYON 1,ECOLE NORMALE SUPER LYON,F-69622 VILLEURBANNE,FRANCE	Jefferson University; University of Basel; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1								BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ENGEL J, 1987, METHOD ENZYMOL, V145, P1; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HALILA R, 1986, BIOCHEM J, V239, P47, DOI 10.1042/bj2390047; HALILA R, 1984, BIOCHEMISTRY-US, V23, P1251, DOI 10.1021/bi00301a036; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOJIMA Y, 1992, MATRIX METALLOPROTEI, P97; HORLEIN D, 1978, FEBS LETT, V89, P279, DOI 10.1016/0014-5793(78)80236-1; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KOHN LD, 1974, P NATL ACAD SCI USA, V71, P40, DOI 10.1073/pnas.71.1.40; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; LEUNG MKK, 1979, J BIOL CHEM, V254, P224; MCBRIDE DJ, 1992, MATRIX, V12, P256; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; NAGASE H, 1983, J BIOL CHEM, V258, P7490; NJIEHA FK, 1982, BIOCHEMISTRY-US, V21, P757, DOI 10.1021/bi00533a028; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; RAUTERBERG J, 1972, EUR J BIOCHEM, V27, P231, DOI 10.1111/j.1432-1033.1972.tb01831.x; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; ROMANIC AM, 1992, J BIOL CHEM, V267, P22265; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; TUDERMAN L, 1982, EUR J BIOCHEM, V125, P545, DOI 10.1111/j.1432-1033.1982.tb06716.x; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; Vesterberg O., 1971, METHODS ENZYMOLOGY, V22, P389; WATSON RB, 1992, J BIOL CHEM, V267, P9093; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WOZNEY J, 1981, NATURE, V294, P129, DOI 10.1038/294129a0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	42	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11381	11390						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157670				2022-12-27	WOS:A1994NF96600062
J	LYON, M; DEAKIN, JA; MIZUNO, K; NAKAMURA, T; GALLAGHER, JT				LYON, M; DEAKIN, JA; MIZUNO, K; NAKAMURA, T; GALLAGHER, JT			INTERACTION OF HEPATOCYTE GROWTH-FACTOR WITH HEPARAN-SULFATE - ELUCIDATION OF THE MAJOR HEPARAN-SULFATE STRUCTURAL DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; FIBROBLAST GROWTH; SCATTER FACTOR; C-MET; MOLECULAR-CLONING; CELL-SURFACE; RAT-LIVER; IDENTIFICATION; PURIFICATION; BINDING	We have demonstrated by affinity chromatography that hepatocyte growth factor (HGF) binds strongly to heparan sulfate (HS). This substantiates previous suggestions that cell-surface heparan sulfate proteoglycans constitute the so-called low affinity cellular binding sites for HGF. Using a recombinant human HGF affinity column, we have analyzed the effects of various specific chemical and enzymatic modifications/depolymerizations of HS on its affinity in order to elucidate the polysaccharide structural determinants. Interaction is shown to be only slightly affected by digestion with heparinase I or III or by replacement of N-sulfates with N-acetyl groups. This suggests a specific role for sulfated domains containing nonsulfated IdceA residues, with only a small contribution from N-sulfates and IdceA(2-OSO3) residues. In addition, disaccharide analyses of various HGF-binding oligosaccharides indicate that affinity is more closely associated with 6-O-sulfation of GlcNSO3 residues than with sulfation at any other position. Although interaction can be demonstrated with heparinase III-resistant oligosaccharides as small as hexasaccharides, the highest affinity was found with oligosaccharides containing a minimum of 10-12 monosaccharides. The structural specificity of the HGF-HS interaction is thus shown to be radically different from that previously described for the basic fibroblast growth factor-HS interaction.	UNIV MANCHESTER, CHRISTIE HOSP, DEPT MED ONCOL, MANCHESTER M20 9BX, ENGLAND; KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN; OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT BIOL, SUITA, OSAKA 565, JAPAN	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Kyushu University; Osaka University	LYON, M (corresponding author), CANC RES CAMPAIGN, WILMSLOW RD, MANCHESTER M20 9BX, ENGLAND.		Mizuno, Kensaku/G-8631-2015	Lyon, Malcolm/0000-0001-9575-6879				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; FRANSSON LA, 1989, HEPARIN, P115; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1989, HEPARIN, P135; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; Lindahl U., 1989, HEPARIN, P159; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; LYON M, 1994, J BIOL CHEM, V269, P11208; MASUMOTO A, 1993, BIOCHEM BIOPH RES CO, V191, P1218, DOI 10.1006/bbrc.1993.1347; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; Matsumoto K, 1993, HEPATOCYTE GROWTH FA, P225; MIGUCHI O, 1992, FEBS LETT, V301, P282; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314	38	315	321	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11216	11223						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157651				2022-12-27	WOS:A1994NF96600039
J	CASE, RD; PICCIONE, E; WOLF, G; BENETT, AM; LECHLEIDER, RJ; NEEL, BG; SHOELSON, SE				CASE, RD; PICCIONE, E; WOLF, G; BENETT, AM; LECHLEIDER, RJ; NEEL, BG; SHOELSON, SE			SH-PTP2/SYP SH2 DOMAIN BINDING-SPECIFICITY IS DEFINED BY DIRECT INTERACTIONS WITH PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR, EPIDERMAL GROWTH-FACTOR RECEPTOR, AND INSULIN-RECEPTOR SUBSTRATE-1-DERIVED PHOSPHOPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; AUTOPHOSPHORYLATION SITES; EGF RECEPTOR; PROTEIN; KINASE; IDENTIFICATION; SRC	Signaling by tyrosine kinases involves direct associations between proteins with Src homology 2 (SH2) domains and sites of tyrosine phosphorylation. Specificity in signaling pathways results in part from inherent selectivity in interactions between particular SH2 domains and phosphopeptide sequences. The cytoplasmic phosphotyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) contains two SH2 domains (N and C) which mediate its association with and activation by the platelet-derived growth factor (PDGF) and epidermal growth factor receptors and IRS-1. We have developed a competitive phosphopeptide binding assay to analyze specificity of the SH-PTP2 N-SH2 domain for phosphorylation sites of these phosphoproteins. The sequence surrounding Tyr(1009) bound with greatest affinity (ID50 = 14 mu M) of eight PDGF receptor-derived phosphopeptides tested. No peptides corresponding to known epidermal growth factor receptor phosphorylation sites bound with high affinity. However, an alternative sequence surrounding Tyr(954) bound tightly (ID50 = 21 mu M). Of the 13 IRS-1-related peptides analyzed, sequences surrounding Tyr(546), Tyr(895), and Tyr(1172) bound with highest affinity (ID50 = 11, 4, and 1 mu M, respectively). Alternative phosphopeptides generally bound with much weaker affinity (ID50 > 150 mu M). These findings are consistent with recent mutational analyses of the PDGF receptor and predict site-specific interactions between SH-PTP2 and each of these phosphoproteins. Comparisons between peptide sequences suggest that the N-terminal SH2 domain of SH-PTP2 binds with highest affinity to phosphotyrosine (pY) followed by a beta-branched residue (Val, Ile, Thr) at pY+1 and a hydrophobic residue (Val, Leu, Ile) at pY+3 positions. Peptide truncation studies also indicate that residues outside of the pY-1 to pY+4 motif are required for high affinity interactions.	HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, MOLEC MED UNIT, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KASHISHIAN A, 1992, EMBO J, V11, P1382; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LASZLO B, 1993, CELL, V73, P611; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, IN PRESS MOL CELL BI; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TOBE K, 1993, J BIOL CHEM, V268, P11167; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	132	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10467	10474						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144631				2022-12-27	WOS:A1994NF01700044
J	ERIKSSON, I; SANDBACK, D; EK, B; LINDAHL, U; KJELLEN, L				ERIKSSON, I; SANDBACK, D; EK, B; LINDAHL, U; KJELLEN, L			CDNA CLONING AND SEQUENCING OF MOUSE MASTOCYTOMA GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE, AN ENZYME INVOLVED IN THE BIOSYNTHESIS OF HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE SULFOTRANSFERASE; ESCHERICHIA-COLI; PROTEIN; PURIFICATION; TRANSFERASE; MEMBRANES	A 110-kDa protein involved in heparin biosynthesis in mouse mastocytoma cells was previously shown to express both glucosaminyl N-deacetylase and N-sulfotransferase activity. In this study, the complete nucleotide sequence corresponding to this protein is reported. The mRNA, estimated to contain 3.9 kilobases encodes a protein with an M(r) of 101,092. The predicted domain structure of the protein resembles those of previously characterized Golgi proteins with an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a large catalytic domain linked to the transmembrane domain through a ''stem region.'' Comparison of the deduced amino acid sequence of the mouse mastocytoma protein and a previously cloned similar enzyme from rat liver demonstrated that while large portions of the proteins, corresponding essentially to the putative catalytic domains, were closely related, other portions, in particular in the N-terminal parts, were markedly different. The divergence was not due to species differences since two separate mouse transcripts could be identified that hybridized with probes specific for the two proteins. Also, functional differences were noted since the mastocytoma enzyme, contrary to the liver enzyme, requires a polycation cofactor for expression of N-deacetylase activity. The results are discussed in relation to the structural properties of heparin and heparan sulfate.	SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,S-75007 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT CELL RES,S-75007 UPPSALA,SWEDEN; UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; Uppsala University			Kjellen, Lena/F-1362-2011					BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; DEVREUX J, 1984, NUCLEIC ACIDS RES, V12, P387; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KJELLEN L, 1992, ADV EXP MED BIOL, V313, P107; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; Lindahl U., 1989, HEPARIN, P159; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; NAVIA JL, 1983, ANAL BIOCHEM, V135, P134, DOI 10.1016/0003-2697(83)90741-8; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Sambrook J, 1989, MOL CLONING LABORATO; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	23	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10438	10443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144627				2022-12-27	WOS:A1994NF01700040
J	FRIEDMAN, SL; YAMASAKI, G; WONG, L				FRIEDMAN, SL; YAMASAKI, G; WONG, L			MODULATION OF TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS OF RAT LIPOCYTES DURING THE HEPATIC WOUND-HEALING RESPONSE - ENHANCED BINDING AND REDUCED GENE-EXPRESSION ACCOMPANY CELLULAR ACTIVATION IN CULTURE AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; BASEMENT-MEMBRANE MATRIX; KUPFFER CELLS; LIVER FIBROGENESIS; MESSENGER-RNA; MUSCLE-CELLS; FACTOR-BETA-1; PROLIFERATION; CLONING; PROTEIN	Activation of lipocytes, characterized by increased proliferation and fibrogenesis, is a central feature of the hepatic wound healing response. We have examined whether modulation of receptors for transforming growth factor beta (TGF-beta) contributes to the fibrogenic behavior of activated lipocytes. Isolated lipocytes were maintained in a quiescent state by culturing the cells in suspension, where they displayed minimal specific binding for TGF-beta 1 and only a small amount of type III (betaglycan) receptor by affinity labeling. In contrast, lipocytes activated by growth on uncoated plastic displayed saturable binding of TGF-beta 1 (K-d = 28 pM, 7,730 receptors/ cell), and receptors types I, II, and III. Binding activity in quiescent and activated cells correlated with responsiveness to TGF-beta 1; TGF-beta 1 induced cellular fibronectin mRNA expression only in activated and not quiescent cells. Despite the absence of binding in quiescent cells, type II receptor was detectable by immunoblot. By RNase protection assay, mRNAs for receptor types II and III were greater in quiescent than activated cells. In freshly isolated lipocytes from animals with liver injury caused by the administration of carbon tetrachloride, a rapid but transient increase in mRNA for receptor types I (similar to 3.2 fold), II (similar to 1.5-fold), and III (similar to 3-fold) was observed, with peaks at 12 h for type I receptor, 1 h for type II receptor, and 6 h for type III receptor; mRNA induction was followed by down-regulation for all receptors. The modest changes in mRNAs compared with marked alterations in binding activity during mesenchymal cell activation suggest that TGF-beta receptors may be regulated in vivo in part by a post-translational mechanism.			FRIEDMAN, SL (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,LIVER CTR LAB & MED SERV,BLDG 40,RM 4102,SAN FRANCISCO,CA 94110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM26743] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMENDARIZBORUNDA J, 1989, MATRIX, V9, P150, DOI 10.1016/S0934-8832(89)80034-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BACHEM MG, 1989, FEBS LETT, V257, P134, DOI 10.1016/0014-5793(89)81804-6; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Ben-Ze'ev A, 1985, Cell Muscle Motil, V6, P23; BUTZOW R, 1993, J CELL BIOL, V122, P721, DOI 10.1083/jcb.122.3.721; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FALK LA, 1991, BLOOD, V77, P1248; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, P947; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GEERTS A, 1989, J HEPATOL, V9, P59, DOI 10.1016/0168-8278(89)90076-7; GIRARDI AJ, 1956, VIROLOGY, V2, P532, DOI 10.1016/0042-6822(56)90009-5; GOODMAN LV, 1989, J BIOL CHEM, V264, P5241; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LEMARRE J, 1991, J CLIN INVEST, V87, P39; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAHER JJ, 1988, J CLIN INVEST, V82, P450, DOI 10.1172/JCI113618; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; MILANI S, 1989, HEPATOLOGY, V10, P84, DOI 10.1002/hep.1840100117; MILANI S, 1991, AM J PATHOL, V139, P1221; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; RAMADORI G, 1991, HEPATOLOGY, V14, P875, DOI 10.1002/hep.1840140520; RAMADORI G, 1987, J HEPATOL, V4, P190, DOI 10.1016/S0168-8278(87)80079-X; RAMADORI G, 1992, ROENTEROLOGY, V103, P1313; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; RIZZINO A, 1988, CANCER RES, V48, P4266; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZERBE O, 1988, EXP MOL PATHOL, V49, P87, DOI 10.1016/0014-4800(88)90023-8	61	158	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10551	10558						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144642				2022-12-27	WOS:A1994NF01700056
J	MONTEIRO, PB; LATARO, RC; FERRO, JA; REINACH, FDC				MONTEIRO, PB; LATARO, RC; FERRO, JA; REINACH, FDC			FUNCTIONAL ALPHA-TROPOMYOSIN PRODUCED IN ESCHERICHIA-COLI - A DIPEPTIDE EXTENSION CAN SUBSTITUTE THE AMINO-TERMINAL ACETYL GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; RABBIT SKELETAL-MUSCLE; HELIX DIPOLE MODEL; TROPONIN-TROPOMYOSIN; ACID SEQUENCE; F-ACTIN; BINDING; COMPONENTS; STABILIZATION; ABSENCE	Unlike the muscle protein, alpha-tropomyosin expressed in Escherichia coli does not bind actin, does not exhibit head-to-tail polymerization, and does not inhibit actomyosin ATPase activity in the absence of troponin. The only chemical difference between recombinant and muscle tropomyosins is that the first methionine is not acetylated in the recombinant protein (Hitchcock-DeGregori, S. E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). We expressed three fusion tropomyosins in E. coli with 2, 3, and 17 amino acids fused to its amino terminus. Ah three fusions restored actin binding, head-to-tail polymerization, and the capacity to inhibit the actomyosin ATPase to these unacetylated tropomyosins. Unlike larger fusions, the small fusions of 2 and 3 amino acids do not interfere with regulatory function. Therefore the presence of a fused dipeptide at the amino terminus of unacetylated tropomyosin is sufficient to replace the function of the N-acetyl group present in muscle tropomyosin. A structural interpretation for the function of the acetyl group, based on our results and the coiled coil structure of tropomyosin, is presented.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498 SAO PAULO,SP,BRAZIL; UNIV ESTADUAL PAULISTA,DEPT TECNOL,BR-14870 JABOTICABAL,SP,BRAZIL	Universidade de Sao Paulo; Universidade Estadual Paulista			Ferro, Jesus Aparecido A/C-8251-2013	Ferro, Jesus Aparecido A/0000-0002-3966-1303				CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHO YJ, 1990, J BIOL CHEM, V265, P538; COTE GP, 1981, J BIOL CHEM, V256, P1999; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FARAH CS, 1994, J BIOL CHEM, V269, P4878; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1989, BIOCHEM J, V258, P831, DOI 10.1042/bj2580831; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HODGES RS, 1981, J BIOL CHEM, V256, P1214; ISERHARDT SV, 1988, ARQ BIOL TECNOL, V31, P52; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MAK AS, 1983, J BIOL CHEM, V258, P4330; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MEISTEIR A, 1965, BIOCH AMINO ACIDS, P28; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATO MD, 1981, J BIOL CHEM, V256, P602; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENDER PM, 1971, FEBS LETT, V17, P106, DOI 10.1016/0014-5793(71)80575-6; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SODEK J, 1978, J BIOL CHEM, V253, P1129; STONE D, 1978, J BIOL CHEM, V253, P1137; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; TSAO TC, 1951, BIOCHEM J, V49, P27, DOI 10.1042/bj0490027; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	191	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10461	10466						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144630				2022-12-27	WOS:A1994NF01700043
J	WOLODKO, WT; FRASER, ME; JAMES, MNG; BRIDGER, WA				WOLODKO, WT; FRASER, ME; JAMES, MNG; BRIDGER, WA			THE CRYSTAL-STRUCTURE OF SUCCINYL-COA SYNTHETASE FROM ESCHERICHIA-COLI AT 2.5-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ALPHA-SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; WEISSENBERG CAMERA; PORCINE HEART; CATALYSIS; SEQUENCE; PROTEINS; PRECURSOR; CLONING	The x-ray crystal structure of succinyl-CoA synthetase (SCS) from Escherichia coli has been determined by the method of multiple isomorphous replacement to a resolution of 2.5 Angstrom. Crystals of SCS are tetragonal with a space group of P4(3)22 and unit cell dimensions of a = b = 98.47 Angstrom and c = 400.6 Angstrom. One molecule of SCS (142 kDa) is contained in the asymmetric unit. The current model has been refined to a conventional R factor of 21.6% with root mean square deviations from ideal stereochemistry of 0.022 Angstrom for bond lengths and 3.25 degrees for bond angles. The quaternary organization of the E. coli enzyme is an alpha(2) beta(2) heterotetramer. In this tetramer, the alpha-subunits interact only with the beta-subunits, whereas the beta-subunits interact to form the dimer of alpha beta-dimers. The two active site pockets are located at regions of contact between alpha- and beta subunits. One molecule of coenzyme A is bound to each alpha-subunit at a typical nucleotide-binding motif, and His-246 of each alpha-subunit is phosphorylated. This phosphohistidine, a catalytic intermediate, is stabilized by two helix dipoles (the ''power'' helices), one from each of the two subunit types. A short segment of the beta-subunit from one cup-dimer is in close proximity to the CoA-binding site of the other cup-dimer, providing a possible rationale for the overall tetrameric structure.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA; UNIV ALBERTA, MRC, CANADA GRP PROT STRUCT & FUNCT, EDMONTON T6G 2H7, AB, CANADA	University of Alberta; University of Alberta				Fraser, Marie/0000-0001-8501-1494				ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BEARD LN, 1968, ACTA CRYSTALL B-STRU, VB 24, P1529, DOI 10.1107/S0567740868004590; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; Brtinger A. T., 1990, X PLOR VERSION 2 1; BUCK D, 1989, BIOCHEM J, V260, P737, DOI 10.1042/bj2600737; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; HENNING WD, 1988, P NATL ACAD SCI USA, V85, P1432, DOI 10.1073/pnas.85.5.1432; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KIM YH, 1993, J BIOL CHEM, V268, P18513; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAJUMDAR R, 1990, BIOCHEM CELL BIOL, V68, P292, DOI 10.1139/o90-040; MOFFET FJ, 1972, J BIOL CHEM, V247, P8139; MOFFET FJ, 1973, CAN J BIOCHEM CELL B, V51, P44, DOI 10.1139/o73-007; NISHIMURA JS, 1986, ADV ENZYMOL RAMB, V58, P141; OTWINOWSKI Z, 1990, 1990 AM CRYST ASS AN; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; PHILLIPS GN, 1979, J AM CHEM SOC, V101, P7120, DOI 10.1021/ja00517a081; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REED SI, 1989, J CELL SCI, P29; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; TEHERANI JA, 1975, J BIOL CHEM, V250, P3883; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011; WILLIAMS SP, 1987, BIOCHEMISTRY-US, V26, P4483, DOI 10.1021/bi00388a046; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066; WOLODKO WT, 1987, BIOCHEM CELL BIOL, V65, P452, DOI 10.1139/o87-058; WOLODKO WT, 1981, P NATL ACAD SCI-BIOL, V78, P2140, DOI 10.1073/pnas.78.4.2140; WOLODKO WT, 1984, J BIOL CHEM, V259, P5316; WOLODKO WT, 1986, BIOCHEMISTRY-US, V25, P5420, DOI 10.1021/bi00367a012	41	127	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10883	10890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144675				2022-12-27	WOS:A1994NF01700102
